data_3zeh_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 3zeh _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . 1.635 ' HD2' ' CD1' ' A' ' 5' ' ' PHE . 95.9 m-85 . . . . . 0 N--CA 1.416 -2.126 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 25.9 mttp -94.84 147.49 33.2 Favored Pre-proline 0 C--N 1.291 -1.964 0 CA-C-N 114.583 -1.19 . . . . 0.0 108.783 -173.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -63.19 115.64 3.1 Favored 'Trans proline' 0 N--CA 1.448 -1.157 0 N-CA-C 107.549 -1.751 . . . . 0.0 107.549 170.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 110.07 -8.47 31.3 Favored Glycine 0 N--CA 1.422 -2.253 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.214 -174.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -73.1 154.92 40.19 Favored 'General case' 0 C--O 1.253 1.28 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 -178.214 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 71.1 mt -102.12 122.56 44.37 Favored 'General case' 0 C--N 1.298 -1.665 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.553 -173.064 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -139.97 178.88 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 CA-C-O 122.458 1.123 . . . . 0.0 113.206 -175.154 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 1.624 ' HD1' ' CD2' ' A' ' 12' ' ' PHE . 47.5 m-85 -115.89 127.87 55.35 Favored 'General case' 0 C--N 1.278 -2.516 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 170.422 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.434 ' HB2' HD13 ' A' ' 53' ' ' LEU . . . -108.43 124.68 50.78 Favored 'General case' 0 C--N 1.273 -2.757 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.579 -175.313 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.671 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -105.93 123.39 47.89 Favored 'General case' 0 N--CA 1.404 -2.768 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.34 -177.759 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 68.4 mtm -120.63 158.17 27.97 Favored 'General case' 0 C--N 1.317 -0.847 0 C-N-CA 123.344 0.657 . . . . 0.0 109.231 176.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -67.53 117.07 8.99 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.08 -5.81 57.94 Favored Glycine 0 C--O 1.251 1.195 0 N-CA-C 111.518 -0.633 . . . . 0.0 111.518 178.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . 1.657 ' HE1' ' CE2' ' A' ' 18' ' ' TYR . 94.0 m-85 -124.04 147.25 53.65 Favored Pre-proline 0 N--CA 1.426 -1.666 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 -179.37 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -74.49 170.98 19.03 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 121.805 1.67 . . . . 0.0 109.273 174.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' HIS . . . . . 0.57 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 65.8 m80 -59.97 110.78 1.27 Allowed 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 175.715 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -102.22 137.95 19.59 Favored Pre-proline 0 C--N 1.308 -1.22 0 C-N-CA 124.017 0.927 . . . . 0.0 109.53 -170.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -64.38 118.16 5.15 Favored 'Trans proline' 0 C--O 1.242 0.694 0 C-N-CA 121.869 1.712 . . . . 0.0 110.636 178.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.98 166.12 26.22 Favored 'General case' 0 N--CA 1.415 -2.188 0 CA-C-O 121.181 0.515 . . . . 0.0 110.403 -176.27 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.427 ' HD3' ' O ' ' A' ' 88' ' ' PRO . 11.4 ttp180 -114.63 146.25 41.06 Favored 'General case' 0 C--N 1.282 -2.351 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.496 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.6 t -73.28 117.03 16.37 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 104.098 -2.556 . . . . 0.0 104.098 168.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -92.97 -178.0 4.67 Favored 'General case' 0 C--N 1.281 -2.405 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 -170.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 . . . . . 0 N--CA 1.429 -1.493 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 178.455 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.488 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 47.6 mmtt . . . . . 0 N--CA 1.409 -2.504 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.482 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 79.4 mt -113.25 153.28 45.54 Favored Pre-proline 0 C--N 1.263 -3.186 0 O-C-N 124.812 1.32 . . . . 0.0 108.696 -177.432 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -69.68 123.61 10.3 Favored 'Trans proline' 0 N--CA 1.457 -0.667 0 C-N-CA 121.658 1.572 . . . . 0.0 109.667 174.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.403 ' O ' ' HA ' ' A' ' 50' ' ' THR . 50.7 mm -120.58 122.44 68.04 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 CA-C-O 120.879 0.371 . . . . 0.0 110.454 -176.665 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.513 ' CE1' ' HA ' ' A' ' 48' ' ' HIS . 35.0 t80 -98.05 114.84 27.11 Favored 'General case' 0 C--N 1.285 -2.196 0 C-N-CA 123.441 0.697 . . . . 0.0 109.754 178.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 1.664 ' HD1' ' CD2' ' A' ' 44' ' ' PHE . 81.3 m-85 -79.79 129.93 34.9 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 177.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 73.1 m-85 -82.42 154.85 24.97 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.574 177.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.525 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 74.38 -20.65 1.6 Allowed Glycine 0 C--N 1.31 -0.883 0 CA-C-N 115.442 -0.799 . . . . 0.0 114.411 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 38.1 p -116.41 -22.64 8.68 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 117.911 0.856 . . . . 0.0 109.391 173.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.513 ' HA ' ' CE1' ' A' ' 43' ' ' PHE . 12.5 m-70 68.12 22.61 8.26 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 114.959 -1.019 . . . . 0.0 112.98 177.825 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -79.34 172.3 13.99 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.975 178.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.403 ' HA ' ' O ' ' A' ' 42' ' ' ILE . 3.8 m -140.95 138.18 33.62 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 177.415 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -140.16 -179.0 5.72 Favored 'General case' 0 C--N 1.288 -2.107 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.383 -176.634 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 1.647 ' HE1' ' CE2' ' A' ' 52' ' ' PHE . 62.0 m-85 -129.59 109.94 11.42 Favored 'General case' 0 N--CA 1.445 -0.68 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 177.018 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.434 HD13 ' HB2' ' A' ' 13' ' ' ALA . 94.6 mt -129.08 153.57 47.51 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 -179.565 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.488 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -87.97 171.82 41.32 Favored Glycine 0 CA--C 1.49 -1.492 0 C-N-CA 120.307 -0.949 . . . . 0.0 112.191 -174.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -61.73 -19.0 63.63 Favored 'Trans proline' 0 C--O 1.239 0.532 0 C-N-CA 123.088 2.526 . . . . 0.0 111.982 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -91.86 -19.95 21.97 Favored 'General case' 0 N--CA 1.433 -1.29 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.903 179.473 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.7 m-20 -82.07 -20.86 37.36 Favored 'General case' 0 CA--C 1.493 -1.234 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.298 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.407 ' HA ' ' O ' ' A' ' 12' ' ' PHE . 15.5 pt -110.19 151.56 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.687 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.65 -176.359 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -135.73 137.66 26.18 Favored Pre-proline 0 C--O 1.185 -2.327 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -66.32 127.36 17.27 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 122.486 2.124 . . . . 0.0 113.938 -175.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 1.621 ' HE2' ' CE1' ' A' ' 61' ' ' TYR . 75.3 t80 -57.8 -32.48 67.6 Favored 'General case' 0 C--O 1.205 -1.279 0 CA-C-N 114.713 -1.13 . . . . 0.0 111.694 -175.101 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.59 -57.45 11.04 Favored 'General case' 0 C--N 1.293 -1.889 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -69.42 -34.53 74.6 Favored 'General case' 0 C--O 1.219 -0.518 0 CA-C-O 121.506 0.669 . . . . 0.0 111.555 -177.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . 0.309 0.8 OUTLIER -109.81 23.74 13.98 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 115.32 1.6 . . . . 0.0 115.32 -175.715 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.455 ' HZ3' ' CG ' ' A' ' 85' ' ' ASP . 15.8 ttmm -63.27 -27.38 69.29 Favored 'General case' 0 N--CA 1.481 1.095 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.217 171.742 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.452 ' CD ' ' HG2' ' A' ' 67' ' ' LYS . 1.2 pp20? -77.41 -35.46 54.19 Favored 'General case' 0 N--CA 1.423 -1.796 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.215 176.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.452 ' HG2' ' CD ' ' A' ' 66' ' ' GLU . 0.1 OUTLIER -77.37 -59.74 2.66 Favored 'General case' 0 N--CA 1.439 -0.982 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.119 -174.381 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 1.652 ' HE2' ' CE1' ' A' ' 68' ' ' TYR . 32.7 m-85 -105.82 -4.11 21.17 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.986 -169.603 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . 0.415 ' HA3' ' O ' ' A' ' 65' ' ' LYS . . . -79.7 59.86 4.41 Favored Glycine 0 N--CA 1.436 -1.347 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 176.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 38.7 mmtm -132.34 134.34 24.81 Favored Pre-proline 0 C--N 1.32 -0.679 0 C-N-CA 122.936 0.495 . . . . 0.0 111.259 -179.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.455 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 78.1 Cg_exo -48.31 131.3 22.45 Favored 'Trans proline' 0 C--O 1.273 2.248 0 C-N-CA 123.911 3.074 . . . . 0.0 113.75 178.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.537 ' HB2' ' CD1' ' A' ' 77' ' ' PHE . 1.2 t-20 -113.82 -178.21 3.32 Favored 'General case' 0 N--CA 1.406 -2.633 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.953 -174.146 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . 0.603 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 7.3 mptt -110.81 10.65 22.52 Favored 'General case' 0 N--CA 1.425 -1.696 0 CA-C-O 122.485 1.136 . . . . 0.0 108.375 -178.252 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 31.2 mmt180 -96.45 129.52 43.79 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 114.204 -1.362 . . . . 0.0 108.567 173.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.41 ' HG3' ' OE2' ' A' ' 79' ' ' GLU . 61.9 tttp -69.7 144.35 52.85 Favored 'General case' 0 N--CA 1.446 -0.663 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 174.7 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.525 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 91.47 -25.91 13.83 Favored Glycine 0 C--O 1.208 -1.469 0 N-CA-C 111.761 -0.536 . . . . 0.0 111.761 -177.517 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 0.537 ' CD1' ' HB2' ' A' ' 72' ' ' ASN . 32.5 t80 -69.78 -53.63 17.42 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-O 121.85 0.834 . . . . 0.0 109.423 -178.653 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.455 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 87.5 m-20 -69.93 -32.84 71.33 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.905 -176.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . 0.41 ' OE2' ' HG3' ' A' ' 75' ' ' LYS . 28.1 mt-10 -72.09 -37.68 69.52 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 114.738 -1.119 . . . . 0.0 108.382 178.243 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.04 -31.63 66.58 Favored Glycine 0 N--CA 1.428 -1.86 0 CA-C-N 115.007 -0.997 . . . . 0.0 112.462 177.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 86.0 mt -55.95 -34.74 65.95 Favored 'General case' 0 N--CA 1.474 0.746 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 175.136 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.4 t90 -75.91 -50.71 14.23 Favored 'General case' 0 N--CA 1.426 -1.635 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.457 177.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -54.98 -48.37 73.35 Favored 'General case' 0 C--O 1.2 -1.537 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -178.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.2 tt -67.43 -25.5 33.53 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.172 0 N-CA-C 112.205 0.446 . . . . 0.0 112.205 -175.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.455 ' CG ' ' HZ3' ' A' ' 65' ' ' LYS . 6.7 t0 -94.39 -22.59 18.22 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.261 0.553 . . . . 0.0 110.488 -174.197 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.467 ' N ' HD21 ' A' ' 86' ' ' ASN . 0.8 OUTLIER -106.96 -57.49 2.06 Favored 'General case' 0 CA--C 1.505 -0.777 0 CA-C-O 121.291 0.567 . . . . 0.0 111.366 -179.285 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -127.6 76.02 77.27 Favored Pre-proline 0 C--N 1.313 -1.015 0 C-N-CA 119.849 -0.74 . . . . 0.0 110.413 -179.072 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.427 ' O ' ' HD3' ' A' ' 24' ' ' ARG . 48.6 Cg_endo -69.73 -6.54 18.83 Favored 'Trans proline' 0 N--CA 1.483 0.857 0 C-N-CA 122.722 2.282 . . . . 0.0 113.93 -175.393 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.2 pttm . . . . . 0 C--N 1.301 -1.536 0 CA-C-O 121.19 0.519 . . . . 0.0 109.699 -178.207 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . 0.548 ' CE2' HG13 ' A' ' 58' ' ' ILE . 56.4 m-85 . . . . . 0 N--CA 1.428 -1.554 0 N-CA-C 116.131 1.901 . . . . 0.0 116.131 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.36 149.15 54.32 Favored Pre-proline 0 N--CA 1.423 -1.808 0 CA-C-N 113.166 -1.834 . . . . 0.0 106.71 179.694 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -58.56 130.44 37.31 Favored 'Trans proline' 0 C--O 1.236 0.41 0 C-N-CA 122.008 1.805 . . . . 0.0 109.97 173.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 104.72 -16.58 47.34 Favored Glycine 0 N--CA 1.433 -1.528 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.988 -179.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -79.59 162.31 25.4 Favored 'General case' 0 C--O 1.25 1.099 0 CA-C-N 117.216 0.508 . . . . 0.0 110.156 -175.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.412 HD22 ' HB2' ' A' ' 88' ' ' PRO . 58.0 mt -100.34 122.66 43.48 Favored 'General case' 0 CA--C 1.496 -1.116 0 C-N-CA 122.81 0.444 . . . . 0.0 110.395 -172.676 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -138.37 179.86 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.308 0 CA-C-O 122.5 1.143 . . . . 0.0 113.696 -173.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 1.605 ' HE2' ' CE1' ' A' ' 12' ' ' PHE . 61.0 m-85 -113.76 130.06 56.5 Favored 'General case' 0 C--N 1.283 -2.321 0 CA-C-N 113.775 -1.557 . . . . 0.0 107.684 170.671 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.404 ' HA ' HG23 ' A' ' 58' ' ' ILE . . . -107.7 118.23 36.19 Favored 'General case' 0 N--CA 1.398 -3.042 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -176.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.652 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -105.28 122.72 46.53 Favored 'General case' 0 N--CA 1.399 -2.987 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.192 -176.887 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 70.1 mtm -118.33 158.17 25.72 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.237 177.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 59.3 tttm -65.8 116.58 7.13 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.551 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.15 -2.45 65.81 Favored Glycine 0 C--O 1.251 1.159 0 N-CA-C 111.632 -0.587 . . . . 0.0 111.632 179.335 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 81.5 m-85 -120.9 150.94 54.09 Favored Pre-proline 0 N--CA 1.427 -1.61 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -178.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -77.61 171.09 18.08 Favored 'Trans proline' 0 N--CA 1.44 -1.622 0 C-N-CA 121.815 1.677 . . . . 0.0 109.312 174.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' HIS . . . . . 0.484 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 69.7 m80 -62.01 111.18 1.82 Allowed 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 175.421 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -100.67 137.53 19.88 Favored Pre-proline 0 C--N 1.301 -1.521 0 N-CA-C 109.209 -0.664 . . . . 0.0 109.209 -172.181 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -65.99 118.05 5.17 Favored 'Trans proline' 0 C--O 1.243 0.762 0 C-N-CA 121.561 1.507 . . . . 0.0 110.932 178.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.34 166.85 25.09 Favored 'General case' 0 N--CA 1.419 -1.985 0 CA-C-N 116.223 -0.444 . . . . 0.0 109.815 -176.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.408 ' HB2' ' CE2' ' A' ' 45' ' ' PHE . 14.2 ttp180 -116.58 147.89 41.43 Favored 'General case' 0 C--N 1.28 -2.415 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.342 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 40.6 t -74.14 123.83 30.29 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.199 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 171.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -87.91 169.76 11.73 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 -173.054 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.302 -1.461 0 CA-C-O 121.542 0.687 . . . . 0.0 111.511 -177.394 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.465 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 81.4 mttt . . . . . 0 N--CA 1.424 -1.747 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.447 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 86.8 mt -86.04 144.76 39.43 Favored Pre-proline 0 C--N 1.313 -0.979 0 O-C-N 123.681 0.613 . . . . 0.0 109.863 -176.573 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -73.37 123.97 9.09 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.046 1.831 . . . . 0.0 109.819 175.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 51.1 mm -118.42 125.9 74.68 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.879 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.412 -176.461 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -101.34 113.9 27.4 Favored 'General case' 0 C--N 1.291 -1.971 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 178.03 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 1.667 ' HD2' ' CD1' ' A' ' 44' ' ' PHE . 79.0 m-85 -81.02 130.57 35.08 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-O 121.102 0.477 . . . . 0.0 111.861 178.517 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 1.645 ' HE2' ' CE1' ' A' ' 45' ' ' PHE . 74.1 m-85 -83.73 156.37 22.61 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 176.091 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.45 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 75.59 -20.15 2.31 Favored Glycine 0 C--N 1.314 -0.675 0 CA-C-N 115.922 -0.581 . . . . 0.0 113.957 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 24.7 p -119.08 -23.19 6.92 Favored 'General case' 0 C--N 1.308 -1.232 0 O-C-N 122.383 -0.48 . . . . 0.0 110.084 174.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 61.69 27.98 17.22 Favored 'General case' 0 C--N 1.354 0.788 0 CA-C-O 121.712 0.767 . . . . 0.0 111.536 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -85.35 159.9 19.91 Favored 'General case' 0 CA--C 1.491 -1.317 0 CA-C-N 114.043 -1.435 . . . . 0.0 108.783 176.051 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.5 m -130.05 136.72 49.69 Favored 'General case' 0 C--N 1.268 -2.946 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.126 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -140.08 -179.24 5.85 Favored 'General case' 0 C--N 1.284 -2.243 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.688 -176.15 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.447 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 79.6 m-85 -132.21 110.76 10.87 Favored 'General case' 0 CA--C 1.499 -1.011 0 C-N-CA 123.351 0.66 . . . . 0.0 109.464 177.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 95.9 mt -126.53 151.68 47.54 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.465 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -75.9 162.67 52.99 Favored Glycine 0 N--CA 1.416 -2.648 0 C-N-CA 119.968 -1.111 . . . . 0.0 110.677 -176.192 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.446 ' O ' ' HE2' ' A' ' 5' ' ' PHE . 17.9 Cg_endo -62.42 -19.99 69.08 Favored 'Trans proline' 0 C--O 1.191 -1.874 0 C-N-CA 122.237 1.958 . . . . 0.0 111.162 179.177 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.48 -0.4 40.8 Favored 'General case' 0 C--N 1.286 -2.166 0 O-C-N 121.441 -0.787 . . . . 0.0 111.537 178.278 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -89.57 -20.95 23.15 Favored 'General case' 0 CA--C 1.488 -1.41 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 175.434 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.548 HG13 ' CE2' ' A' ' 5' ' ' PHE . 18.4 pt -110.59 157.24 11.41 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.75 0 CA-C-N 114.174 -1.375 . . . . 0.0 110.223 -175.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -139.36 147.31 52.23 Favored Pre-proline 0 C--N 1.303 -1.432 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 -177.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . 0.407 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 38.6 Cg_endo -64.89 129.68 23.94 Favored 'Trans proline' 0 C--O 1.243 0.728 0 C-N-CA 122.657 2.238 . . . . 0.0 113.081 -175.661 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 1.663 ' HE2' ' CE1' ' A' ' 61' ' ' TYR . 82.2 t80 -60.94 -37.12 81.22 Favored 'General case' 0 C--O 1.205 -1.264 0 CA-C-N 115.447 -0.797 . . . . 0.0 111.983 -177.077 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 22.6 t -63.63 -54.05 41.88 Favored 'General case' 0 C--N 1.307 -1.269 0 CA-C-O 120.946 0.403 . . . . 0.0 110.635 -175.332 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.407 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 4.2 mp0 -71.01 -25.84 62.86 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-O 121.376 0.608 . . . . 0.0 112.304 -178.073 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.456 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 28.0 m-80 -105.48 12.67 31.15 Favored 'General case' 0 C--N 1.293 -1.878 0 C-N-CA 120.536 -0.466 . . . . 0.0 111.917 -176.76 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.3 tttp -63.19 -37.87 88.94 Favored 'General case' 0 N--CA 1.479 1.001 0 CA-C-O 121.153 0.502 . . . . 0.0 110.92 -179.544 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.526 ' CD ' ' HZ1' ' A' ' 70' ' ' LYS . 18.2 mm-40 -71.57 -24.01 61.84 Favored 'General case' 0 CA--C 1.488 -1.417 0 CA-C-O 121.831 0.824 . . . . 0.0 112.151 176.823 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.456 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 35.6 mtpt -85.79 -58.47 2.64 Favored 'General case' 0 C--N 1.266 -3.053 0 CA-C-N 114.135 -1.393 . . . . 0.0 111.426 -176.181 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 1.637 ' HE1' ' CE2' ' A' ' 68' ' ' TYR . 38.3 m-85 -125.17 0.75 7.84 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.995 -0.548 . . . . 0.0 112.006 -172.831 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -94.29 32.11 6.2 Favored Glycine 0 CA--C 1.496 -1.104 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.236 -175.261 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.526 ' HZ1' ' CD ' ' A' ' 66' ' ' GLU . 50.0 mtmt -130.21 153.93 81.28 Favored Pre-proline 0 C--N 1.301 -1.515 0 C-N-CA 122.808 0.443 . . . . 0.0 110.138 178.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_exo -42.68 144.24 1.39 Allowed 'Trans proline' 0 C--N 1.363 1.298 0 C-N-CA 124.583 3.522 . . . . 0.0 117.328 -172.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 -137.13 -166.25 1.89 Allowed 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 105.073 -2.195 . . . . 0.0 105.073 173.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 3.5 mmmp? -116.55 2.26 13.02 Favored 'General case' 0 N--CA 1.416 -2.138 0 C-N-CA 119.019 -1.072 . . . . 0.0 113.28 174.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 14.2 mmt180 -61.39 128.92 38.68 Favored 'General case' 0 C--N 1.324 -0.539 0 O-C-N 124.167 0.917 . . . . 0.0 109.012 175.189 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.8 tmtm? -68.78 123.55 21.24 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.585 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.45 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 105.91 -25.05 25.14 Favored Glycine 0 N--CA 1.428 -1.884 0 N-CA-C 110.164 -1.175 . . . . 0.0 110.164 -177.893 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.6 t80 -76.6 -44.78 32.98 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -60.82 -50.04 75.06 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.61 178.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -68.16 -40.59 82.28 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.314 -178.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -72.24 -30.89 64.37 Favored Glycine 0 CA--C 1.489 -1.531 0 CA-C-N 115.646 -0.707 . . . . 0.0 112.955 -177.204 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 44.0 tp -62.39 -35.51 79.43 Favored 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.086 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.7 t90 -70.57 -48.61 54.47 Favored 'General case' 0 N--CA 1.425 -1.721 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.95 177.416 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -54.82 -51.35 66.1 Favored 'General case' 0 C--O 1.202 -1.447 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -179.382 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.414 ' HB ' ' CD2' ' A' ' 45' ' ' PHE . 17.6 tt -68.13 -24.01 29.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 112.223 0.453 . . . . 0.0 112.223 -175.329 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 6.3 t0 -94.61 -21.21 18.97 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-O 121.252 0.549 . . . . 0.0 110.458 -175.109 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.457 ' N ' HD21 ' A' ' 86' ' ' ASN . 0.8 OUTLIER -109.83 -56.78 2.27 Favored 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 121.268 0.556 . . . . 0.0 111.603 -178.95 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -125.17 71.66 63.84 Favored Pre-proline 0 C--N 1.316 -0.886 0 C-N-CA 120.169 -0.612 . . . . 0.0 110.126 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.412 ' HB2' HD22 ' A' ' 10' ' ' LEU . 60.1 Cg_endo -73.13 -6.12 18.37 Favored 'Trans proline' 0 N--CA 1.475 0.389 0 C-N-CA 122.527 2.151 . . . . 0.0 113.46 -174.643 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.3 pttm . . . . . 0 C--N 1.305 -1.333 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.019 -178.451 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 . . . . . 0 N--CA 1.413 -2.276 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -134.65 154.67 79.68 Favored Pre-proline 0 C--N 1.283 -2.324 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.402 -176.53 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -49.6 123.25 10.14 Favored 'Trans proline' 0 C--N 1.35 0.63 0 C-N-CA 123.365 2.71 . . . . 0.0 111.992 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 112.85 -17.49 22.68 Favored Glycine 0 N--CA 1.424 -2.165 0 CA-C-N 115.656 -0.702 . . . . 0.0 112.24 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -75.44 156.84 34.88 Favored 'General case' 0 C--O 1.249 1.041 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -177.129 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.1 mt -106.92 120.49 42.18 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 -174.525 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.9 pp -137.01 -179.63 3.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 CA-C-O 122.528 1.156 . . . . 0.0 113.42 -174.236 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 1.665 ' HE2' ' CE1' ' A' ' 12' ' ' PHE . 33.2 m-85 -113.57 130.52 56.35 Favored 'General case' 0 C--N 1.275 -2.665 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 170.401 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -107.24 116.39 31.85 Favored 'General case' 0 C--N 1.268 -2.952 0 CA-C-N 115.26 -0.882 . . . . 0.0 108.839 -174.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.626 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -112.87 120.89 43.02 Favored 'General case' 0 N--CA 1.394 -3.256 0 CA-C-N 114.572 -1.194 . . . . 0.0 108.856 -178.888 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 68.1 mtm -105.64 158.48 16.67 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 179.485 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -65.74 116.42 6.93 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -178.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.32 -2.63 63.31 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.726 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . 1.661 ' HE1' ' CE2' ' A' ' 18' ' ' TYR . 97.4 m-85 -125.13 148.27 59.88 Favored Pre-proline 0 N--CA 1.438 -1.04 0 CA-C-O 120.595 0.236 . . . . 0.0 110.593 -178.131 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -72.24 170.53 18.89 Favored 'Trans proline' 0 N--CA 1.455 -0.789 0 C-N-CA 122.444 2.096 . . . . 0.0 111.747 177.424 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' HIS . . . . . 0.456 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 79.4 m80 -67.12 111.69 4.03 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 108.895 -0.779 . . . . 0.0 108.895 178.136 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 13.0 t-105 -109.63 136.03 20.32 Favored Pre-proline 0 C--N 1.314 -0.977 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 -176.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -62.08 120.34 7.88 Favored 'Trans proline' 0 C--O 1.244 0.799 0 C-N-CA 122.536 2.157 . . . . 0.0 112.45 -178.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -148.1 166.07 28.94 Favored 'General case' 0 N--CA 1.431 -1.38 0 CA-C-O 120.932 0.396 . . . . 0.0 110.806 -177.121 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.429 HH21 ' CG ' ' A' ' 26' ' ' ASP . 12.2 ttp180 -109.85 144.53 38.19 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 178.769 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 68.9 t -73.69 107.25 4.15 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.405 0 N-CA-C 102.709 -3.071 . . . . 0.0 102.709 166.489 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . 0.429 ' CG ' HH21 ' A' ' 24' ' ' ARG . 0.4 OUTLIER -88.64 -178.22 5.75 Favored 'General case' 0 C--N 1.271 -2.808 0 C-N-CA 119.654 -0.818 . . . . 0.0 111.957 -168.241 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 . . . . . 0 C--N 1.285 -2.205 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.956 -173.253 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.442 ' HE2' ' N ' ' A' ' 54' ' ' GLY . 31.6 mtpt . . . . . 0 N--CA 1.425 -1.691 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 79.8 mt -85.74 144.2 39.32 Favored Pre-proline 0 C--N 1.302 -1.499 0 O-C-N 123.212 0.32 . . . . 0.0 110.175 -176.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -71.25 123.91 10.0 Favored 'Trans proline' 0 N--CA 1.457 -0.622 0 C-N-CA 122.046 1.83 . . . . 0.0 109.764 175.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 51.4 mm -120.49 122.7 68.77 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 O-C-N 122.165 -0.334 . . . . 0.0 110.265 -176.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 88.0 t80 -104.95 114.48 28.71 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 178.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -74.9 132.7 41.66 Favored 'General case' 0 C--N 1.319 -0.737 0 O-C-N 123.655 0.597 . . . . 0.0 111.335 179.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -90.19 158.1 17.39 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.269 177.586 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.555 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 75.84 -19.9 2.54 Favored Glycine 0 C--N 1.311 -0.852 0 CA-C-N 115.631 -0.713 . . . . 0.0 113.529 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 60.5 p -119.27 -22.68 7.02 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 122.419 -0.46 . . . . 0.0 109.941 175.439 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.1 m170 66.98 25.57 9.3 Favored 'General case' 0 C--N 1.352 0.697 0 C-N-CA 124.12 0.968 . . . . 0.0 111.752 179.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -84.42 178.04 7.9 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.329 178.239 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 8.9 m -144.01 147.42 33.85 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -147.23 -179.79 7.08 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 123.827 0.851 . . . . 0.0 109.776 -178.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -133.06 110.82 10.48 Favored 'General case' 0 C--O 1.252 1.235 0 CA-C-O 121.524 0.678 . . . . 0.0 109.353 177.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.487 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 96.2 mt -127.86 155.76 43.63 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.354 -176.863 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.442 ' N ' ' HE2' ' A' ' 39' ' ' LYS . . . -94.69 174.47 33.24 Favored Glycine 0 N--CA 1.425 -2.053 0 N-CA-C 110.152 -1.179 . . . . 0.0 110.152 -178.342 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -66.31 -11.04 29.73 Favored 'Trans proline' 0 C--O 1.208 -1.024 0 C-N-CA 122.797 2.332 . . . . 0.0 112.799 -177.218 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 20.7 pttp -97.62 -7.96 29.95 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 122.211 1.005 . . . . 0.0 110.245 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.487 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 65.5 m-20 -100.64 -10.24 21.12 Favored 'General case' 0 C--N 1.287 -2.152 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.577 -176.04 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 12.2 pt -125.23 154.97 33.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.42 -175.154 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -142.49 140.74 19.23 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 179.424 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -65.64 127.66 18.44 Favored 'Trans proline' 0 C--O 1.243 0.751 0 C-N-CA 122.774 2.316 . . . . 0.0 114.13 -173.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 65.2 t80 -62.48 -30.61 71.38 Favored 'General case' 0 CA--C 1.505 -0.774 0 C-N-CA 124.105 0.962 . . . . 0.0 109.437 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.8 m -55.02 -35.48 64.47 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-N 114.908 -1.042 . . . . 0.0 111.88 -179.534 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.44 ' C ' ' H ' ' A' ' 65' ' ' LYS 0.284 55.0 mt-10 -85.75 -54.11 4.72 Favored 'General case' 0 CA--C 1.483 -1.618 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 172.048 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 31.6 m-80 -67.96 9.87 0.26 Allowed 'General case' 0 CA--C 1.473 -1.991 0 C-N-CA 127.628 2.371 . . . . 0.0 113.867 -164.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.44 ' H ' ' C ' ' A' ' 63' ' ' GLU . 55.6 tttp -66.85 -33.8 76.4 Favored 'General case' 0 N--CA 1.394 -3.269 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 174.693 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.745 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -80.43 -33.41 36.94 Favored 'General case' 0 N--CA 1.429 -1.525 0 CA-C-N 115.016 -0.993 . . . . 0.0 113.573 172.86 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.745 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 24.5 mtmm -77.54 -59.47 2.77 Favored 'General case' 0 CA--C 1.503 -0.843 0 N-CA-C 113.169 0.803 . . . . 0.0 113.169 -178.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 1.614 ' HD2' ' CD1' ' A' ' 68' ' ' TYR . 89.9 m-85 -120.22 6.77 10.72 Favored 'General case' 0 C--N 1.281 -2.391 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.957 -174.333 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.5 11.99 35.96 Favored Glycine 0 CA--C 1.524 0.636 0 CA-C-N 116.29 -0.413 . . . . 0.0 114.087 -177.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -97.93 127.11 38.13 Favored Pre-proline 0 N--CA 1.441 -0.902 0 CA-C-N 117.162 0.481 . . . . 0.0 110.083 178.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -65.15 128.39 20.44 Favored 'Trans proline' 0 N--CA 1.446 -1.319 0 C-N-CA 122.42 2.08 . . . . 0.0 114.862 -176.05 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -102.35 -157.32 0.6 Allowed 'General case' 0 C--N 1.292 -1.911 0 CA-C-N 113.705 -1.589 . . . . 0.0 108.814 177.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 43.2 mmtm -108.58 15.39 23.82 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 120.444 -0.503 . . . . 0.0 111.359 -179.43 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 39.5 mmt180 -80.02 121.44 25.5 Favored 'General case' 0 CA--C 1.513 -0.476 0 C-N-CA 117.95 -1.5 . . . . 0.0 108.9 171.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 11.0 tppt? -74.06 126.76 31.23 Favored 'General case' 0 N--CA 1.428 -1.551 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.555 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.32 -25.82 18.67 Favored Glycine 0 N--CA 1.424 -2.165 0 N-CA-C 109.114 -1.594 . . . . 0.0 109.114 -173.153 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 1.623 ' HE1' ' CE2' ' A' ' 77' ' ' PHE . 6.8 t80 -76.72 -46.97 23.37 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 179.586 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 11.2 m120 -56.51 -52.53 64.41 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-N 114.944 -1.025 . . . . 0.0 109.009 178.124 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 21.7 mp0 -61.37 -40.91 96.05 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 113.793 -1.549 . . . . 0.0 110.297 -178.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -67.19 -37.66 91.4 Favored Glycine 0 N--CA 1.437 -1.242 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.562 -179.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 90.7 mt -60.82 -34.67 74.89 Favored 'General case' 0 CA--C 1.509 -0.629 0 N-CA-C 110.224 -0.288 . . . . 0.0 110.224 176.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 84.9 t90 -71.7 -50.96 25.57 Favored 'General case' 0 N--CA 1.432 -1.33 0 O-C-N 123.589 0.555 . . . . 0.0 109.557 177.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -56.1 -50.78 70.09 Favored 'General case' 0 C--O 1.202 -1.409 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -178.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.3 tt -66.78 -25.87 35.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 112.486 0.55 . . . . 0.0 112.486 -174.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -93.29 -19.43 21.39 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-O 121.591 0.71 . . . . 0.0 110.621 -173.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.9 m-80 -114.04 -56.29 2.41 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.362 -177.035 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.504 ' OD1' ' HG2' ' A' ' 89' ' ' LYS . 65.3 t30 -128.42 75.51 79.18 Favored Pre-proline 0 C--N 1.311 -1.095 0 C-N-CA 119.831 -0.748 . . . . 0.0 111.22 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -69.73 -6.3 18.25 Favored 'Trans proline' 0 N--CA 1.481 0.736 0 C-N-CA 122.704 2.269 . . . . 0.0 113.481 -176.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . 0.504 ' HG2' ' OD1' ' A' ' 87' ' ' ASN . 9.5 ptpp? . . . . . 0 C--N 1.316 -0.889 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -176.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . 1.659 ' HE2' ' CE1' ' A' ' 5' ' ' PHE . 88.8 m-85 . . . . . 0 N--CA 1.439 -0.987 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 9.2 pttp -135.13 166.72 26.94 Favored Pre-proline 0 N--CA 1.43 -1.455 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 177.31 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -59.44 149.34 82.21 Favored 'Trans proline' 0 C--O 1.265 1.87 0 C-N-CA 122.052 1.834 . . . . 0.0 112.451 175.47 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 98.51 -14.24 62.2 Favored Glycine 0 N--CA 1.434 -1.439 0 CA-C-N 115.683 -0.689 . . . . 0.0 113.36 176.7 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -84.22 154.76 22.85 Favored 'General case' 0 C--O 1.242 0.695 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 -177.217 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.43 ' HB3' HD12 ' A' ' 84' ' ' ILE . 83.2 mt -99.54 128.68 45.66 Favored 'General case' 0 CA--C 1.498 -1.03 0 CA-C-N 114.888 -1.051 . . . . 0.0 109.163 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -141.62 -178.62 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-O 122.131 0.967 . . . . 0.0 112.418 -175.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 48.1 m-85 -112.84 129.77 56.33 Favored 'General case' 0 C--N 1.279 -2.464 0 N-CA-C 106.508 -1.664 . . . . 0.0 106.508 170.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -107.49 132.23 53.45 Favored 'General case' 0 C--N 1.275 -2.658 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -176.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.483 ' HD3' ' C ' ' A' ' 14' ' ' LYS . 7.3 tmtm? -113.79 117.26 30.98 Favored 'General case' 0 N--CA 1.41 -2.434 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.877 -177.103 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 54.9 mtm -114.41 158.69 21.19 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.724 173.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 39.5 ttpt -62.5 118.72 7.94 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 176.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.33 -12.86 68.64 Favored Glycine 0 C--O 1.243 0.716 0 C-N-CA 121.034 -0.603 . . . . 0.0 111.65 -178.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -106.62 151.31 40.39 Favored Pre-proline 0 C--O 1.256 1.446 0 C-N-CA 122.811 0.444 . . . . 0.0 111.137 -179.343 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -82.27 172.41 11.68 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 C-N-CA 123.435 2.757 . . . . 0.0 108.91 173.499 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -65.94 110.47 2.91 Favored 'General case' 0 C--N 1.31 -1.117 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 175.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -104.37 138.24 19.46 Favored Pre-proline 0 C--N 1.303 -1.439 0 CA-C-N 115.318 -0.856 . . . . 0.0 108.909 -171.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -68.01 117.59 5.02 Favored 'Trans proline' 0 N--CA 1.451 -1.003 0 C-N-CA 121.484 1.456 . . . . 0.0 109.867 177.042 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -145.28 167.05 23.78 Favored 'General case' 0 N--CA 1.415 -2.2 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 -176.145 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.555 ' HB3' ' CE2' ' A' ' 45' ' ' PHE . 8.1 ptt85 -123.53 155.89 36.7 Favored 'General case' 0 C--N 1.281 -2.375 0 C-N-CA 119.149 -1.02 . . . . 0.0 109.356 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.7 t -86.32 117.7 31.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 N-CA-C 106.002 -1.851 . . . . 0.0 106.002 174.187 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -91.73 176.08 6.66 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -175.272 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.423 ' CD ' HH22 ' A' ' 24' ' ' ARG . 11.8 mp0 . . . . . 0 N--CA 1.421 -1.912 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.53 ' HE3' ' HA ' ' A' ' 53' ' ' LEU . 22.0 mtpp . . . . . 0 N--CA 1.416 -2.139 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 73.3 mt -99.38 155.12 36.87 Favored Pre-proline 0 C--N 1.299 -1.601 0 C-N-CA 123.189 0.596 . . . . 0.0 109.65 -174.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -74.64 121.92 7.03 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 121.158 1.239 . . . . 0.0 109.399 174.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.45 HG13 ' HB2' ' A' ' 53' ' ' LEU . 49.8 mm -115.39 118.65 59.47 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 CA-C-O 120.898 0.38 . . . . 0.0 110.393 -176.407 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.476 ' CE1' ' HA ' ' A' ' 48' ' ' HIS . 58.3 t80 -97.74 116.27 29.63 Favored 'General case' 0 C--N 1.283 -2.303 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.342 179.147 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -77.75 130.72 37.1 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-O 121.055 0.455 . . . . 0.0 111.669 177.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.555 ' CE2' ' HB3' ' A' ' 24' ' ' ARG . 59.6 m-85 -81.89 150.08 27.95 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.65 176.198 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 82.01 -20.59 7.94 Favored Glycine 0 C--N 1.313 -0.749 0 C-N-CA 123.875 0.75 . . . . 0.0 114.394 177.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 41.3 p -119.56 -22.49 6.93 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 117.521 0.661 . . . . 0.0 110.316 174.331 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.476 ' HA ' ' CE1' ' A' ' 43' ' ' PHE . 11.5 m-70 69.03 19.42 8.11 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 123.655 0.782 . . . . 0.0 111.899 -178.308 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -77.29 177.15 8.15 Favored 'General case' 0 N--CA 1.446 -0.638 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.262 177.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.9 m -142.41 144.83 33.28 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 109.675 -0.491 . . . . 0.0 109.675 -179.031 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -137.98 171.76 13.93 Favored 'General case' 0 C--N 1.29 -1.984 0 CA-C-N 115.397 -0.819 . . . . 0.0 109.516 178.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -124.62 108.4 12.02 Favored 'General case' 0 CA--C 1.482 -1.659 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 174.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.53 ' HA ' ' HE3' ' A' ' 39' ' ' LYS . 94.5 mt -134.85 139.83 45.35 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 -178.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -87.78 177.95 46.8 Favored Glycine 0 N--CA 1.415 -2.717 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -175.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -67.21 -10.94 30.37 Favored 'Trans proline' 0 C--N 1.319 -0.977 0 C-N-CA 122.445 2.096 . . . . 0.0 112.589 -177.161 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 30.7 mmtm -100.07 -8.14 24.13 Favored 'General case' 0 C--N 1.305 -1.361 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 175.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.465 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 4.3 m-20 -98.15 -12.62 21.56 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-O 121.853 0.835 . . . . 0.0 108.771 -178.262 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 15.1 pt -112.63 157.71 13.27 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.231 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.941 -177.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 -130.93 144.87 55.3 Favored Pre-proline 0 C--N 1.298 -1.647 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 -177.267 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . 0.434 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 42.4 Cg_endo -66.04 127.93 18.64 Favored 'Trans proline' 0 CA--C 1.503 -1.034 0 C-N-CA 122.475 2.117 . . . . 0.0 112.949 -177.483 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 1.644 ' HE2' ' CE1' ' A' ' 61' ' ' TYR . 85.3 t80 -61.68 -36.91 82.23 Favored 'General case' 0 C--O 1.206 -1.224 0 CA-C-N 114.816 -1.084 . . . . 0.0 112.149 -176.411 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.416 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 14.0 m -65.85 -50.09 65.82 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-O 121.144 0.497 . . . . 0.0 110.92 -175.707 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.434 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 3.1 mp0 -79.21 -5.25 53.84 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.656 -0.702 . . . . 0.0 112.533 -177.055 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.427 ' OD1' ' HD2' ' A' ' 67' ' ' LYS . 33.3 m-80 -125.45 12.5 8.11 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 120.591 -0.444 . . . . 0.0 112.089 178.364 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.417 ' O ' ' HA3' ' A' ' 69' ' ' GLY . 62.9 tttp -70.92 -32.22 69.08 Favored 'General case' 0 N--CA 1.479 1.02 0 CA-C-O 122.03 0.919 . . . . 0.0 110.25 -179.344 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.617 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -74.82 -30.37 61.36 Favored 'General case' 0 N--CA 1.404 -2.772 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.649 175.981 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.617 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 49.3 mttp -80.14 -56.73 4.02 Favored 'General case' 0 CA--C 1.505 -0.766 0 CA-C-N 115.626 -0.715 . . . . 0.0 112.584 -178.267 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 54.5 m-85 -114.24 7.19 16.46 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.471 0.653 . . . . 0.0 111.837 -172.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . 0.417 ' HA3' ' O ' ' A' ' 65' ' ' LYS . . . -91.46 51.98 3.05 Favored Glycine 0 C--N 1.294 -1.755 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.637 -176.232 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.489 ' HZ3' ' HB3' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -133.64 141.94 41.98 Favored Pre-proline 0 C--N 1.293 -1.866 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 175.509 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -65.67 126.91 16.89 Favored 'Trans proline' 0 N--CA 1.445 -1.345 0 C-N-CA 121.297 1.331 . . . . 0.0 114.425 -173.311 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -83.91 -173.0 4.47 Favored 'General case' 0 CA--C 1.484 -1.589 0 CA-C-N 114.078 -1.419 . . . . 0.0 109.059 178.819 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . 0.535 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 1.1 mptp? -107.4 20.75 18.49 Favored 'General case' 0 C--N 1.282 -2.355 0 CA-C-O 122.664 1.221 . . . . 0.0 108.003 172.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 13.7 mmt180 -87.12 121.09 29.1 Favored 'General case' 0 N--CA 1.436 -1.172 0 CA-C-N 113.504 -1.68 . . . . 0.0 107.174 173.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 28.2 tptp -60.76 124.13 19.52 Favored 'General case' 0 C--N 1.311 -1.087 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 177.307 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.47 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.21 -25.13 21.1 Favored Glycine 0 N--CA 1.437 -1.256 0 N-CA-C 111.452 -0.659 . . . . 0.0 111.452 -179.246 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 15.2 t80 -74.53 -36.02 63.14 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-O 121.337 0.589 . . . . 0.0 109.837 -176.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.502 ' N ' HD21 ' A' ' 78' ' ' ASN . 0.7 OUTLIER -74.77 -41.98 59.03 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -175.836 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -67.9 -34.69 77.13 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 114.336 -1.302 . . . . 0.0 109.452 178.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -66.64 -35.0 89.22 Favored Glycine 0 CA--C 1.493 -1.285 0 CA-C-N 115.659 -0.7 . . . . 0.0 112.167 178.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 87.8 mt -63.65 -35.28 80.01 Favored 'General case' 0 C--O 1.215 -0.723 0 CA-C-O 121.035 0.445 . . . . 0.0 109.845 175.101 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 86.2 t90 -67.43 -49.06 65.36 Favored 'General case' 0 N--CA 1.429 -1.507 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 177.171 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -58.25 -45.44 87.81 Favored 'General case' 0 C--O 1.208 -1.094 0 N-CA-C 113.221 0.822 . . . . 0.0 113.221 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.43 HD12 ' HB3' ' A' ' 10' ' ' LEU . 19.9 tt -73.18 -29.48 28.49 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -173.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -87.23 -18.47 30.22 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 31.8 m-80 -111.63 -54.4 2.61 Favored 'General case' 0 CA--C 1.503 -0.836 0 CA-C-O 121.273 0.559 . . . . 0.0 112.161 -176.344 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.5 t30 -128.56 72.47 80.73 Favored Pre-proline 0 C--N 1.306 -1.316 0 C-N-CA 119.765 -0.774 . . . . 0.0 110.724 -179.218 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -72.85 -5.82 17.89 Favored 'Trans proline' 0 N--CA 1.478 0.582 0 C-N-CA 122.597 2.198 . . . . 0.0 113.447 -175.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.2 pttm . . . . . 0 C--N 1.307 -1.256 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.908 -178.602 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . 1.653 ' HE1' ' CE2' ' A' ' 5' ' ' PHE . 98.4 m-85 . . . . . 0 N--CA 1.433 -1.303 0 CA-C-O 121.327 0.584 . . . . 0.0 110.945 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 24.1 mtmm -119.55 155.97 53.84 Favored Pre-proline 0 C--N 1.291 -1.975 0 CA-C-N 114.703 -1.135 . . . . 0.0 108.013 -178.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -55.04 120.76 8.72 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 121.723 1.615 . . . . 0.0 109.497 174.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 115.94 -24.4 10.15 Favored Glycine 0 N--CA 1.432 -1.573 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.38 -175.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -62.03 123.69 18.79 Favored 'General case' 0 C--O 1.25 1.102 0 CA-C-N 117.494 0.647 . . . . 0.0 110.74 177.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 85.2 mt -79.93 124.26 28.51 Favored 'General case' 0 CA--C 1.483 -1.601 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 177.316 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 9.3 pt -141.07 -175.12 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.036 0 CA-C-O 122.592 1.187 . . . . 0.0 112.792 -172.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 1.623 ' HE2' ' CE1' ' A' ' 12' ' ' PHE . 60.8 m-85 -122.24 130.35 53.09 Favored 'General case' 0 N--CA 1.405 -2.686 0 CA-C-N 113.42 -1.718 . . . . 0.0 106.56 170.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.428 ' HB3' HG22 ' A' ' 42' ' ' ILE . . . -108.8 124.25 50.31 Favored 'General case' 0 C--N 1.275 -2.651 0 O-C-N 123.931 0.769 . . . . 0.0 109.494 -177.711 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.55 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.9 OUTLIER -108.46 126.69 53.18 Favored 'General case' 0 C--N 1.272 -2.781 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.228 -177.462 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 63.5 mtm -125.59 157.75 36.37 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.682 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 1.3 ttpm? -61.34 115.95 4.25 Favored 'General case' 0 C--O 1.247 0.971 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.903 179.134 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.63 -5.68 64.62 Favored Glycine 0 C--O 1.251 1.165 0 O-C-N 123.506 0.504 . . . . 0.0 112.094 178.241 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 88.8 m-85 -120.81 151.02 54.04 Favored Pre-proline 0 N--CA 1.426 -1.656 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -177.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.18 171.09 17.62 Favored 'Trans proline' 0 N--CA 1.443 -1.495 0 C-N-CA 121.676 1.584 . . . . 0.0 109.082 174.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' HIS . . . . . 0.468 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 80.2 m80 -61.22 110.41 1.39 Allowed 'General case' 0 CA--C 1.549 0.941 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 175.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -99.34 138.39 20.51 Favored Pre-proline 0 C--N 1.31 -1.132 0 C-N-CA 123.377 0.671 . . . . 0.0 109.874 -171.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo -60.72 118.2 5.05 Favored 'Trans proline' 0 C--O 1.245 0.861 0 C-N-CA 121.746 1.631 . . . . 0.0 110.709 177.25 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.8 167.19 22.87 Favored 'General case' 0 N--CA 1.413 -2.309 0 CA-C-O 120.898 0.38 . . . . 0.0 110.309 -176.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 24.4 ttp-105 -125.81 147.04 49.54 Favored 'General case' 0 C--N 1.288 -2.083 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 175.346 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 48.1 t -72.78 119.04 18.85 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 N-CA-C 105.714 -1.958 . . . . 0.0 105.714 171.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -90.31 -177.5 5.12 Favored 'General case' 0 C--N 1.307 -1.247 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -175.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 . . . . . 0 C--N 1.282 -2.341 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -175.685 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 90.4 mttt . . . . . 0 N--CA 1.423 -1.81 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 87.9 mt -99.96 141.23 22.38 Favored Pre-proline 0 C--N 1.291 -1.946 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.268 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -71.72 123.4 9.37 Favored 'Trans proline' 0 N--CA 1.454 -0.824 0 C-N-CA 122.037 1.824 . . . . 0.0 109.852 176.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.428 HG22 ' HB3' ' A' ' 13' ' ' ALA . 42.4 mm -118.08 120.76 65.47 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 CA-C-N 116.196 -0.457 . . . . 0.0 109.837 -175.542 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 66.1 t80 -97.92 120.1 37.71 Favored 'General case' 0 C--N 1.281 -2.383 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 1.636 ' HE2' ' CE1' ' A' ' 44' ' ' PHE . 69.6 m-85 -85.2 131.46 34.43 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.257 0.551 . . . . 0.0 111.972 178.28 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -84.96 155.04 21.79 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.712 176.394 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.562 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 79.22 -19.57 5.47 Favored Glycine 0 C--N 1.314 -0.669 0 C-N-CA 123.257 0.456 . . . . 0.0 113.418 179.11 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 16.3 p -118.61 -23.13 7.2 Favored 'General case' 0 C--N 1.307 -1.26 0 O-C-N 122.561 -0.376 . . . . 0.0 110.215 175.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.7 m170 67.46 19.19 10.06 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 123.509 0.724 . . . . 0.0 111.768 -179.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 19.2 mm-40 -87.65 168.27 13.16 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.205 179.59 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.7 m -134.55 142.5 46.99 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 121.067 0.46 . . . . 0.0 109.769 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -139.05 179.66 6.37 Favored 'General case' 0 C--N 1.293 -1.891 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.201 -178.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 1.665 ' HE2' ' CE1' ' A' ' 52' ' ' PHE . 96.6 m-85 -134.13 117.39 16.52 Favored 'General case' 0 C--O 1.262 1.726 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.679 177.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 94.8 mt -129.5 174.56 9.53 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.17 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.37 164.94 21.34 Favored Glycine 0 N--CA 1.417 -2.597 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.16 -5.4 13.62 Favored 'Trans proline' 0 C--O 1.249 1.074 0 C-N-CA 123.752 2.968 . . . . 0.0 112.905 -178.179 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 23.0 pttm -97.57 -19.78 18.12 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.009 178.366 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -96.83 0.37 49.18 Favored 'General case' 0 CA--C 1.5 -0.943 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.598 -173.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.2 pt -123.43 144.78 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.995 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.725 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -130.55 147.13 64.74 Favored Pre-proline 0 C--N 1.289 -2.037 0 CA-C-N 114.631 -1.168 . . . . 0.0 108.006 -177.668 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -66.74 132.49 28.79 Favored 'Trans proline' 0 C--N 1.328 -0.548 0 C-N-CA 122.474 2.116 . . . . 0.0 112.558 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 1.649 ' HE2' ' CE1' ' A' ' 61' ' ' TYR . 53.4 t80 -64.0 -37.79 88.72 Favored 'General case' 0 C--O 1.201 -1.488 0 CA-C-N 114.939 -1.028 . . . . 0.0 112.25 -176.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -62.76 -54.35 40.49 Favored 'General case' 0 C--N 1.292 -1.92 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -176.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 3.6 mp0 -71.58 -26.23 62.52 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-O 121.71 0.766 . . . . 0.0 111.23 -178.266 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.452 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 29.9 m-80 -106.82 10.12 30.79 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -175.45 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -65.44 -31.27 72.26 Favored 'General case' 0 N--CA 1.483 1.195 0 CA-C-O 121.354 0.597 . . . . 0.0 111.898 -178.117 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.507 ' HA ' ' NZ ' ' A' ' 70' ' ' LYS . 55.5 mm-40 -75.97 -28.92 58.05 Favored 'General case' 0 C--N 1.285 -2.211 0 C-N-CA 119.391 -0.924 . . . . 0.0 111.842 178.277 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.452 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 33.2 mtpt -78.04 -59.26 2.85 Favored 'General case' 0 C--N 1.281 -2.407 0 CA-C-N 113.963 -1.471 . . . . 0.0 111.052 -176.769 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 1.655 ' HD2' ' CD1' ' A' ' 68' ' ' TYR . 19.9 m-85 -109.96 -9.47 14.76 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.384 -171.229 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -86.0 47.62 3.81 Favored Glycine 0 C--N 1.311 -0.857 0 N-CA-C 111.291 -0.724 . . . . 0.0 111.291 -178.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.507 ' NZ ' ' HA ' ' A' ' 66' ' ' GLU . 47.7 mmtm -127.91 147.77 64.43 Favored Pre-proline 0 C--N 1.307 -1.263 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.532 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.472 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 77.4 Cg_exo -48.01 128.94 17.4 Favored 'Trans proline' 0 C--N 1.363 1.318 0 C-N-CA 123.662 2.908 . . . . 0.0 114.782 -176.225 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.454 ' HB2' ' CD1' ' A' ' 77' ' ' PHE . 1.9 t-20 -112.22 -165.48 1.0 Allowed 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 114.747 -1.115 . . . . 0.0 109.559 -175.449 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 38.6 mmtm -121.53 12.68 10.82 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 24.2 mmt180 -93.9 128.39 40.17 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 114.874 -1.057 . . . . 0.0 109.712 174.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 28.1 tptp -68.89 122.5 18.75 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 177.18 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.562 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 107.14 -20.83 32.48 Favored Glycine 0 N--CA 1.438 -1.189 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 -179.254 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 0.454 ' CD1' ' HB2' ' A' ' 72' ' ' ASN . 35.6 t80 -75.2 -44.1 48.28 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-O 121.61 0.719 . . . . 0.0 109.701 -177.069 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.472 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 92.8 m-20 -76.38 -35.07 58.85 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 114.893 -1.048 . . . . 0.0 110.63 -174.112 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -70.12 -35.5 74.15 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.183 -1.044 . . . . 0.0 108.183 174.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -65.75 -35.63 91.22 Favored Glycine 0 N--CA 1.435 -1.413 0 CA-C-N 115.112 -0.949 . . . . 0.0 111.968 177.697 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.422 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 95.8 mt -56.16 -38.32 70.73 Favored 'General case' 0 C--O 1.219 -0.52 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 175.589 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 73.0 t90 -74.19 -49.08 25.07 Favored 'General case' 0 N--CA 1.426 -1.635 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.417 178.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -57.0 -46.82 82.02 Favored 'General case' 0 C--O 1.203 -1.343 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.8 tt -70.18 -24.57 26.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 120.628 -0.429 . . . . 0.0 112.033 -175.219 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -93.52 -19.69 20.98 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.058 0.456 . . . . 0.0 110.141 -175.053 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.453 ' N ' HD21 ' A' ' 86' ' ' ASN . 0.8 OUTLIER -111.56 -54.34 2.62 Favored 'General case' 0 N--CA 1.483 1.198 0 CA-C-O 121.351 0.596 . . . . 0.0 111.863 -179.286 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.1 t30 -126.24 71.98 71.12 Favored Pre-proline 0 C--N 1.312 -1.065 0 O-C-N 121.999 -0.438 . . . . 0.0 110.93 -177.715 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -73.2 -6.49 19.0 Favored 'Trans proline' 0 CA--C 1.53 0.309 0 C-N-CA 122.242 1.961 . . . . 0.0 113.232 -175.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.4 pttm . . . . . 0 C--N 1.313 -1.018 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.973 -176.306 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . 1.641 ' HE1' ' CE2' ' A' ' 5' ' ' PHE . 97.3 m-85 . . . . . 0 N--CA 1.439 -0.998 0 CA-C-O 120.753 0.311 . . . . 0.0 110.438 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.511 ' O ' ' HB2' ' A' ' 9' ' ' ASP . 47.9 mmtm -111.51 155.62 42.64 Favored Pre-proline 0 C--N 1.304 -1.392 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 -178.59 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_exo -58.33 121.46 10.02 Favored 'Trans proline' 0 C--O 1.237 0.46 0 C-N-CA 121.78 1.653 . . . . 0.0 108.448 171.105 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . 0.567 ' HA2' ' NH1' ' A' ' 24' ' ' ARG . . . 108.72 -11.95 35.31 Favored Glycine 0 N--CA 1.425 -2.034 0 C-N-CA 120.55 -0.834 . . . . 0.0 112.449 -176.505 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.511 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 0.8 OUTLIER -64.39 133.51 52.73 Favored 'General case' 0 C--O 1.252 1.202 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -178.025 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 78.8 mt -89.27 119.97 30.22 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.403 ' HA ' ' HA ' ' A' ' 60' ' ' PRO . 7.5 pt -139.03 -173.54 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.841 0 CA-C-O 122.753 1.263 . . . . 0.0 112.956 -172.037 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 1.655 ' HD2' ' CD1' ' A' ' 12' ' ' PHE . 84.2 m-85 -127.48 125.41 40.42 Favored 'General case' 0 N--CA 1.403 -2.809 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 171.861 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.419 ' CB ' HG22 ' A' ' 42' ' ' ILE . . . -113.43 134.45 54.65 Favored 'General case' 0 C--N 1.266 -3.024 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.617 -176.573 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.665 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -109.04 121.15 44.53 Favored 'General case' 0 N--CA 1.408 -2.532 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.396 -178.616 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.426 ' HE1' ' CD1' ' A' ' 18' ' ' TYR . 71.5 mtm -112.18 158.88 19.14 Favored 'General case' 0 C--N 1.315 -0.934 0 C-N-CA 123.587 0.755 . . . . 0.0 109.24 176.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 24.9 ttmm -66.18 117.41 8.45 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.106 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.38 -7.07 56.06 Favored Glycine 0 C--O 1.246 0.875 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -178.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . 1.621 ' HE1' ' CE2' ' A' ' 18' ' ' TYR . 65.2 m-85 -123.21 148.15 54.01 Favored Pre-proline 0 N--CA 1.435 -1.222 0 C-N-CA 122.994 0.518 . . . . 0.0 110.684 179.206 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -79.34 171.6 15.81 Favored 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 122.116 1.877 . . . . 0.0 108.28 170.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' HIS . . . . . 0.634 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 78.9 m80 -58.16 111.19 1.11 Allowed 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 175.774 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.426 ' O ' ' HA ' ' A' ' 12' ' ' PHE . 11.5 t-105 -111.74 141.69 25.2 Favored Pre-proline 0 C--N 1.302 -1.46 0 C-N-CA 123.561 0.744 . . . . 0.0 109.343 -170.526 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -57.76 118.71 5.63 Favored 'Trans proline' 0 C--N 1.36 1.14 0 C-N-CA 122.274 1.983 . . . . 0.0 110.994 178.328 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -145.53 167.34 23.25 Favored 'General case' 0 N--CA 1.407 -2.584 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 -177.617 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.567 ' NH1' ' HA2' ' A' ' 8' ' ' GLY . 32.7 ttp85 -123.23 144.52 49.34 Favored 'General case' 0 C--N 1.276 -2.589 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 177.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 58.7 t -74.58 113.74 13.53 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.99 0 N-CA-C 104.793 -2.299 . . . . 0.0 104.793 170.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . 0.43 ' CG ' HH21 ' A' ' 24' ' ' ARG . 1.1 t70 -86.88 -176.01 5.6 Favored 'General case' 0 C--N 1.29 -2.015 0 O-C-N 123.554 0.534 . . . . 0.0 111.084 -172.0 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 33.6 mm-40 . . . . . 0 C--N 1.3 -1.584 0 CA-C-O 121.622 0.725 . . . . 0.0 109.81 -173.209 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.415 ' HB3' ' O ' ' A' ' 53' ' ' LEU . 62.4 mttp . . . . . 0 N--CA 1.433 -1.322 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.424 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 95.8 mt -90.84 139.69 26.14 Favored Pre-proline 0 C--N 1.297 -1.709 0 O-C-N 123.894 0.746 . . . . 0.0 110.134 -177.632 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -71.38 123.22 9.35 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.262 1.974 . . . . 0.0 109.779 176.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.419 HG22 ' CB ' ' A' ' 13' ' ' ALA . 39.7 mm -122.17 121.59 64.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.932 -0.48 . . . . 0.0 109.993 -176.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.668 ' HE2' ' CE1' ' A' ' 43' ' ' PHE . 79.0 t80 -106.35 118.96 38.01 Favored 'General case' 0 C--N 1.29 -2.001 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 178.06 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 73.6 m-85 -82.32 136.07 35.08 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -179.408 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 1.615 ' HE2' ' CE1' ' A' ' 45' ' ' PHE . 78.5 m-85 -85.58 148.85 25.73 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.9 178.334 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.449 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 78.94 -21.08 4.16 Favored Glycine 0 C--N 1.308 -1.019 0 C-N-CA 123.72 0.676 . . . . 0.0 114.168 176.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 30.7 p -119.74 -22.46 6.85 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 117.523 0.662 . . . . 0.0 110.674 174.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.4 m-70 67.01 21.9 10.15 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 123.649 0.779 . . . . 0.0 111.563 -178.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.8 mt-10 -72.42 163.61 27.71 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.064 175.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.7 m -136.87 140.05 42.1 Favored 'General case' 0 C--N 1.275 -2.645 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.346 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -141.05 176.07 9.11 Favored 'General case' 0 C--N 1.286 -2.18 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.273 -179.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.424 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 97.7 m-85 -133.98 111.07 10.11 Favored 'General case' 0 N--CA 1.431 -1.423 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 174.52 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.415 ' O ' ' HB3' ' A' ' 39' ' ' LYS . 85.9 mt -125.69 170.42 11.55 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -177.527 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -95.08 167.17 26.35 Favored Glycine 0 N--CA 1.42 -2.398 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 178.166 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -66.38 -6.85 15.96 Favored 'Trans proline' 0 N--CA 1.484 0.923 0 C-N-CA 123.357 2.705 . . . . 0.0 112.743 -177.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.9 ptmm? -92.37 -19.88 21.64 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.725 178.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -102.45 5.05 39.38 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-O 121.281 0.562 . . . . 0.0 111.623 -174.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.9 pt -125.22 147.53 29.87 Favored 'Isoleucine or valine' 0 C--O 1.266 1.954 0 CA-C-N 114.653 -1.158 . . . . 0.0 110.372 178.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . 1.616 ' HD2' ' CD1' ' A' ' 59' ' ' PHE . 88.8 m-85 -136.37 133.11 19.17 Favored Pre-proline 0 C--N 1.289 -2.035 0 CA-C-N 114.686 -1.143 . . . . 0.0 108.355 -179.543 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . 0.403 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 22.5 Cg_endo -68.3 144.06 60.83 Favored 'Trans proline' 0 CA--C 1.499 -1.264 0 C-N-CA 122.971 2.447 . . . . 0.0 114.04 -177.397 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 1.644 ' HD1' ' CD2' ' A' ' 61' ' ' TYR . 83.9 t80 -58.88 -38.26 78.42 Favored 'General case' 0 C--O 1.203 -1.377 0 CA-C-N 114.305 -1.316 . . . . 0.0 110.579 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.48 -47.57 83.38 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 113.744 1.016 . . . . 0.0 113.744 -175.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -93.33 -8.27 42.46 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-O 121.357 0.599 . . . . 0.0 111.597 -177.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.432 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 24.0 m-80 -124.91 14.12 8.53 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -175.164 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -63.37 -37.78 88.61 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 10.4 mp0 -66.08 -34.68 78.62 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 122.796 1.284 . . . . 0.0 109.326 177.127 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.432 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 35.4 mtpt -75.48 -59.55 2.7 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-N 113.396 -1.729 . . . . 0.0 112.008 -174.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.41 ' CD2' ' HB3' ' A' ' 64' ' ' ASN . 18.5 m-85 -115.11 -15.4 11.7 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.982 -171.068 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.77 10.77 30.19 Favored Glycine 0 N--CA 1.472 1.042 0 CA-C-O 121.213 0.341 . . . . 0.0 113.207 -175.226 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 23.2 pttm -93.04 149.9 38.32 Favored Pre-proline 0 C--N 1.298 -1.671 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -66.91 128.19 18.33 Favored 'Trans proline' 0 N--CA 1.441 -1.56 0 C-N-CA 120.845 1.03 . . . . 0.0 112.287 178.069 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 41.4 m-80 -113.19 -173.41 2.25 Favored 'General case' 0 C--N 1.295 -1.795 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 47.4 mmtm -96.75 15.87 20.72 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-O 121.238 0.542 . . . . 0.0 112.269 -176.066 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -87.94 120.94 29.77 Favored 'General case' 0 C--N 1.309 -1.187 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 174.352 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.4 tppt? -74.71 130.43 39.49 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 177.111 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.449 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.24 -25.78 18.96 Favored Glycine 0 N--CA 1.435 -1.381 0 N-CA-C 108.819 -1.712 . . . . 0.0 108.819 -174.053 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 11.2 t80 -76.79 -44.71 31.71 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 10.0 m120 -60.25 -47.89 84.07 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 22.2 mp0 -63.5 -37.06 85.85 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 113.778 -1.555 . . . . 0.0 110.194 179.341 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -67.55 -34.56 84.5 Favored Glycine 0 N--CA 1.442 -0.924 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.309 177.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 95.5 mt -62.78 -33.95 76.24 Favored 'General case' 0 C--O 1.216 -0.694 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 175.39 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 69.8 t90 -71.62 -49.44 40.12 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.624 175.24 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -60.43 -34.69 74.34 Favored 'General case' 0 C--O 1.21 -0.98 0 N-CA-C 113.882 1.067 . . . . 0.0 113.882 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.6 tt -72.77 -21.41 19.59 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-O 121.214 0.531 . . . . 0.0 110.3 -176.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -89.92 -46.74 8.33 Favored 'General case' 0 N--CA 1.435 -1.211 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.719 -178.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.568 ' N ' HD21 ' A' ' 86' ' ' ASN . 0.8 OUTLIER -86.92 -35.88 18.67 Favored 'General case' 0 C--O 1.252 1.227 0 CA-C-O 121.63 0.728 . . . . 0.0 111.843 -173.766 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -134.08 63.6 62.6 Favored Pre-proline 0 C--N 1.298 -1.669 0 C-N-CA 118.892 -1.123 . . . . 0.0 112.873 -179.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -72.04 -5.74 17.71 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 122.791 2.327 . . . . 0.0 110.838 177.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 16.5 pttp . . . . . 0 C--N 1.302 -1.478 0 C-N-CA 125.378 1.471 . . . . 0.0 110.81 -176.807 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 . . . . . 0 N--CA 1.43 -1.452 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 27.5 mtmm -124.31 156.92 66.21 Favored Pre-proline 0 C--N 1.289 -2.059 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 -176.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo -51.87 117.62 3.72 Favored 'Trans proline' 0 N--CA 1.461 -0.39 0 C-N-CA 122.17 1.913 . . . . 0.0 110.416 173.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.45 -23.55 10.32 Favored Glycine 0 N--CA 1.427 -1.902 0 CA-C-O 119.452 -0.638 . . . . 0.0 112.694 -176.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -64.98 123.68 20.08 Favored 'General case' 0 C--O 1.25 1.11 0 CA-C-N 117.573 0.686 . . . . 0.0 110.115 177.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.8 mt -80.05 129.48 34.53 Favored 'General case' 0 CA--C 1.49 -1.363 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 176.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 8.1 pt -143.17 -172.7 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.421 -1.884 0 CA-C-O 122.479 1.133 . . . . 0.0 112.4 -173.08 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 0.41 ' HB3' ' HB3' ' A' ' 20' ' ' HIS . 31.9 m-85 -128.58 129.07 45.42 Favored 'General case' 0 N--CA 1.402 -2.873 0 CA-C-N 113.288 -1.778 . . . . 0.0 106.55 172.784 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.438 ' HB2' HD13 ' A' ' 53' ' ' LEU . . . -108.78 128.92 55.31 Favored 'General case' 0 C--N 1.271 -2.834 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.446 -174.346 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.674 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -106.39 124.12 49.11 Favored 'General case' 0 N--CA 1.403 -2.782 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.039 -178.697 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 69.1 mtm -121.42 158.38 28.46 Favored 'General case' 0 CA--C 1.508 -0.667 0 C-N-CA 123.219 0.608 . . . . 0.0 109.814 176.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -64.66 116.52 6.32 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 178.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.44 -2.43 65.14 Favored Glycine 0 C--O 1.246 0.868 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -121.93 146.35 45.95 Favored Pre-proline 0 N--CA 1.428 -1.567 0 C-N-CA 122.731 0.412 . . . . 0.0 110.388 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -75.82 171.29 18.45 Favored 'Trans proline' 0 N--CA 1.444 -1.428 0 C-N-CA 121.798 1.665 . . . . 0.0 108.467 172.439 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' HIS . . . . . 0.469 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 69.2 m80 -61.53 111.15 1.69 Allowed 'General case' 0 CA--C 1.548 0.883 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 175.854 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 7.8 t-105 -102.96 139.26 19.96 Favored Pre-proline 0 C--N 1.304 -1.405 0 C-N-CA 123.852 0.861 . . . . 0.0 109.31 -171.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_exo -59.08 118.66 5.59 Favored 'Trans proline' 0 C--N 1.354 0.84 0 C-N-CA 121.875 1.716 . . . . 0.0 110.869 177.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.81 167.05 23.0 Favored 'General case' 0 N--CA 1.414 -2.227 0 CA-C-O 121.227 0.537 . . . . 0.0 110.417 -177.456 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 36.6 ttt-85 -119.05 139.89 50.98 Favored 'General case' 0 C--N 1.285 -2.198 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 177.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 60.2 t -75.34 111.12 11.22 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.951 0 N-CA-C 103.817 -2.66 . . . . 0.0 103.817 168.058 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -89.37 -177.55 5.39 Favored 'General case' 0 C--N 1.289 -2.032 0 C-N-CA 119.535 -0.866 . . . . 0.0 111.451 -170.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 . . . . . 0 C--N 1.293 -1.876 0 CA-C-O 121.875 0.845 . . . . 0.0 113.201 -171.131 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.533 ' HE3' ' HA ' ' A' ' 53' ' ' LEU . 22.5 mtpp . . . . . 0 N--CA 1.418 -2.035 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.404 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 71.2 mt -98.44 153.9 37.8 Favored Pre-proline 0 C--N 1.288 -2.079 0 O-C-N 123.54 0.525 . . . . 0.0 110.356 -173.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -71.4 122.36 8.58 Favored 'Trans proline' 0 C--N 1.354 0.826 0 C-N-CA 121.788 1.659 . . . . 0.0 109.798 176.476 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 43.8 mm -117.84 119.9 62.99 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.943 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 -176.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 86.2 t80 -98.27 117.68 33.2 Favored 'General case' 0 C--N 1.28 -2.437 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 178.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -81.78 129.85 34.87 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 121.419 0.628 . . . . 0.0 112.672 178.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -80.45 151.96 29.03 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.819 177.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.426 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 78.23 -20.68 3.86 Favored Glycine 0 C--N 1.315 -0.628 0 C-N-CA 123.562 0.601 . . . . 0.0 114.306 177.716 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 36.2 p -119.37 -22.59 6.99 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 117.533 0.666 . . . . 0.0 109.849 174.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.0 m-70 67.7 22.74 8.87 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.883 0.873 . . . . 0.0 112.308 179.011 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -78.41 169.3 18.48 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.335 177.596 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 6.3 m -139.36 137.82 36.08 Favored 'General case' 0 C--N 1.289 -2.059 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 177.04 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -138.58 -179.55 5.88 Favored 'General case' 0 C--N 1.28 -2.436 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.614 -176.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.404 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 87.3 m-85 -131.31 109.79 10.62 Favored 'General case' 0 CA--C 1.491 -1.318 0 C-N-CA 123.662 0.785 . . . . 0.0 109.294 177.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.533 ' HA ' ' HE3' ' A' ' 39' ' ' LYS . 96.2 mt -126.77 152.29 47.08 Favored 'General case' 0 C--N 1.295 -1.803 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.076 -178.689 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.421 ' O ' HG12 ' A' ' 58' ' ' ILE . . . -80.43 168.17 51.32 Favored Glycine 0 N--CA 1.429 -1.802 0 N-CA-C 110.564 -1.015 . . . . 0.0 110.564 -177.551 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -65.18 -18.42 61.19 Favored 'Trans proline' 0 C--O 1.209 -0.966 0 C-N-CA 122.337 2.025 . . . . 0.0 112.13 -178.479 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 10.8 mmtm -99.56 2.05 44.34 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 113.206 0.817 . . . . 0.0 113.206 173.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -94.04 -12.02 29.48 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 173.656 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.421 HG12 ' O ' ' A' ' 54' ' ' GLY . 15.9 pt -125.77 151.58 32.01 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.705 0 CA-C-N 114.459 -1.246 . . . . 0.0 109.698 -176.801 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . 1.651 ' HD1' ' CD2' ' A' ' 59' ' ' PHE . 96.4 m-85 -138.23 147.48 55.96 Favored Pre-proline 0 C--N 1.296 -1.754 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 -179.192 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -63.38 140.99 79.51 Favored 'Trans proline' 0 C--O 1.241 0.632 0 C-N-CA 123.19 2.593 . . . . 0.0 114.817 -174.503 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 40.5 t80 -56.03 -33.31 64.81 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 114.32 -1.309 . . . . 0.0 111.841 177.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.8 m -60.05 -41.9 93.3 Favored 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.527 -177.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . 0.301 48.8 mt-10 -75.98 -51.59 12.05 Favored 'General case' 0 CA--C 1.488 -1.426 0 CA-C-O 123.319 1.533 . . . . 0.0 108.656 176.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.409 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 37.0 m-80 -80.66 2.75 24.54 Favored 'General case' 0 N--CA 1.415 -2.211 0 CA-C-N 112.801 -1.999 . . . . 0.0 113.847 -161.439 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -68.92 -37.4 78.89 Favored 'General case' 0 N--CA 1.433 -1.286 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 176.424 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.417 ' CD ' ' HZ2' ' A' ' 70' ' ' LYS . 56.8 mm-40 -80.83 -37.4 30.11 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.104 -0.498 . . . . 0.0 112.159 175.343 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 39.7 mtpt -70.96 -57.37 4.63 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 124.701 1.251 . . . . 0.0 111.171 -173.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 61.8 m-85 -126.97 7.24 6.63 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.213 -174.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -91.98 41.24 2.83 Favored Glycine 0 CA--C 1.496 -1.096 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -178.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.417 ' HZ2' ' CD ' ' A' ' 66' ' ' GLU . 30.4 mmtp -128.77 151.02 76.52 Favored Pre-proline 0 C--N 1.299 -1.616 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 -177.595 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.482 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 52.6 Cg_exo -48.42 148.44 7.81 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 123.642 2.895 . . . . 0.0 114.816 -176.415 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -140.17 -175.73 4.35 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-N 115.087 -0.96 . . . . 0.0 109.933 -178.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.2 mmmm -95.53 -3.26 46.9 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-O 120.804 0.335 . . . . 0.0 110.474 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 18.0 mmt180 -80.25 121.02 25.11 Favored 'General case' 0 C--N 1.309 -1.164 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.064 176.317 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -73.63 135.39 43.8 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 174.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.426 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 103.76 -25.31 27.01 Favored Glycine 0 N--CA 1.436 -1.332 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 -177.123 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 0.411 ' HE1' ' O ' ' A' ' 70' ' ' LYS . 55.7 t80 -74.73 -44.93 47.4 Favored 'General case' 0 N--CA 1.437 -1.077 0 CA-C-N 114.722 -0.739 . . . . 0.0 109.08 -178.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.482 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 89.4 m-20 -76.82 -35.75 57.37 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.062 -176.2 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 8.2 mp0 -67.73 -36.55 80.78 Favored 'General case' 0 N--CA 1.433 -1.311 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 174.376 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.47 -34.38 68.08 Favored Glycine 0 CA--C 1.496 -1.155 0 CA-C-N 115.445 -0.798 . . . . 0.0 112.094 177.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 40.9 tp -60.62 -36.53 78.84 Favored 'General case' 0 N--CA 1.432 -1.331 0 C-N-CA 123.955 0.902 . . . . 0.0 108.947 175.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 76.1 t90 -72.14 -47.39 51.41 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.054 175.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -61.15 -36.87 80.95 Favored 'General case' 0 C--O 1.193 -1.915 0 N-CA-C 114.009 1.114 . . . . 0.0 114.009 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.4 tt -70.67 -26.51 28.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 119.282 -0.967 . . . . 0.0 111.772 -176.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -83.77 -37.06 23.1 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.176 178.238 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 30.8 m-80 -101.86 -31.35 10.76 Favored 'General case' 0 C--O 1.257 1.487 0 CA-C-O 122.063 0.935 . . . . 0.0 112.738 -173.123 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 57.3 t30 -129.06 60.2 49.18 Favored Pre-proline 0 C--N 1.29 -2.014 0 O-C-N 121.628 -0.67 . . . . 0.0 112.539 -177.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -77.77 -5.74 15.57 Favored 'Trans proline' 0 N--CA 1.486 1.076 0 C-N-CA 122.211 1.94 . . . . 0.0 110.747 178.244 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 23.1 pttm . . . . . 0 C--N 1.312 -1.023 0 CA-C-N 113.718 -1.583 . . . . 0.0 111.063 -174.606 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 . . . . . 0 N--CA 1.447 -0.617 0 CA-C-O 120.788 0.328 . . . . 0.0 111.645 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.484 ' HD2' ' N ' ' A' ' 6' ' ' LYS . 7.5 mptt -121.04 147.24 46.02 Favored Pre-proline 0 C--N 1.31 -1.119 0 N-CA-C 108.172 -1.048 . . . . 0.0 108.172 -178.842 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -56.98 121.13 9.53 Favored 'Trans proline' 0 N--CA 1.452 -0.967 0 C-N-CA 121.456 1.438 . . . . 0.0 109.32 172.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.66 -25.33 9.11 Favored Glycine 0 N--CA 1.42 -2.41 0 CA-C-O 118.671 -1.072 . . . . 0.0 114.142 -177.14 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.354 3.7 p30 -79.37 149.71 31.6 Favored 'General case' 0 C--O 1.243 0.748 0 CA-C-N 119.453 1.626 . . . . 0.0 113.557 -179.496 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 78.5 mt -86.74 128.54 35.02 Favored 'General case' 0 C--O 1.253 1.268 0 CA-C-N 114.605 -1.18 . . . . 0.0 110.851 -175.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -141.77 -177.2 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.466 0 CA-C-O 121.785 0.803 . . . . 0.0 112.255 -175.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 1.604 ' HD1' ' CD2' ' A' ' 12' ' ' PHE . 49.1 m-85 -113.65 128.25 56.36 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 107.211 -1.403 . . . . 0.0 107.211 172.531 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.412 ' CB ' HG22 ' A' ' 42' ' ' ILE . . . -108.3 120.31 42.0 Favored 'General case' 0 C--N 1.274 -2.69 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.684 -175.382 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.614 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 1.1 tmmt? -109.72 126.65 53.94 Favored 'General case' 0 C--N 1.27 -2.866 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.619 -177.638 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.402 ' HE1' ' CD1' ' A' ' 18' ' ' TYR . 69.6 mtm -120.48 158.55 27.01 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.489 179.264 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -68.77 117.02 9.94 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 179.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.27 -3.07 61.54 Favored Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -179.655 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . 1.667 ' HE2' ' CE1' ' A' ' 18' ' ' TYR . 59.8 m-85 -122.94 150.3 58.74 Favored Pre-proline 0 N--CA 1.435 -1.195 0 CA-C-O 120.744 0.307 . . . . 0.0 110.855 -179.118 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -74.91 170.74 19.74 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 122.134 1.889 . . . . 0.0 109.498 172.68 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' HIS . . . . . 0.438 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 76.3 m80 -66.77 111.55 3.77 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 177.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 10.6 t-105 -97.06 138.98 21.27 Favored Pre-proline 0 C--N 1.311 -1.093 0 C-N-CA 123.541 0.737 . . . . 0.0 109.689 -174.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_endo -69.05 117.76 5.25 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 121.254 1.303 . . . . 0.0 110.123 175.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.5 167.1 24.52 Favored 'General case' 0 N--CA 1.426 -1.625 0 CA-C-O 121.137 0.494 . . . . 0.0 110.528 -174.619 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.401 HH22 ' CD ' ' A' ' 27' ' ' GLU . 12.7 ttp180 -111.75 145.21 39.76 Favored 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 179.069 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.3 t -68.61 121.32 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.866 0 N-CA-C 104.821 -2.289 . . . . 0.0 104.821 169.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -91.24 175.66 6.86 Favored 'General case' 0 C--N 1.281 -2.395 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 -171.161 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.401 ' CD ' HH22 ' A' ' 24' ' ' ARG . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -1.695 0 CA-C-O 121.385 0.612 . . . . 0.0 110.229 179.453 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 71.6 mttt . . . . . 0 N--CA 1.415 -2.192 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 75.0 mt -100.19 150.42 36.88 Favored Pre-proline 0 C--N 1.291 -1.944 0 O-C-N 124.368 1.042 . . . . 0.0 109.257 -175.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -75.49 133.33 15.75 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 121.684 1.589 . . . . 0.0 109.427 174.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.412 HG22 ' CB ' ' A' ' 13' ' ' ALA . 51.3 mm -124.47 126.74 72.33 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -176.692 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.631 ' HE1' ' CE2' ' A' ' 43' ' ' PHE . 65.2 t80 -105.51 115.02 29.55 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 -179.434 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -79.23 136.18 36.99 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.245 0.545 . . . . 0.0 111.613 179.524 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -87.54 157.08 19.25 Favored 'General case' 0 C--N 1.301 -1.515 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.559 177.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 76.11 -21.27 2.25 Favored Glycine 0 CA--C 1.502 -0.775 0 C-N-CA 124.669 1.128 . . . . 0.0 114.134 179.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 40.4 p -120.01 -23.24 6.42 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 117.294 0.547 . . . . 0.0 110.199 174.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 51.7 m170 67.78 23.3 8.58 Favored 'General case' 0 C--N 1.342 0.25 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.681 178.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -73.78 162.7 28.86 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 175.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.8 m -137.5 142.33 41.48 Favored 'General case' 0 C--N 1.281 -2.371 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -139.65 -179.68 6.06 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.169 -178.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 80.2 m-85 -131.69 109.27 10.06 Favored 'General case' 0 N--CA 1.439 -0.989 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 175.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.429 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 96.0 mt -127.51 152.94 46.95 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.652 -175.171 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.97 171.72 37.71 Favored Glycine 0 N--CA 1.424 -2.164 0 C-N-CA 119.564 -1.303 . . . . 0.0 111.589 -174.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -66.12 -5.65 12.82 Favored 'Trans proline' 0 C--O 1.251 1.131 0 C-N-CA 123.235 2.624 . . . . 0.0 112.172 179.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -98.72 -16.87 18.81 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 114.961 -1.018 . . . . 0.0 111.774 175.062 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.429 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 40.9 m-20 -94.12 -8.7 38.8 Favored 'General case' 0 C--N 1.31 -1.15 0 CA-C-O 121.188 0.518 . . . . 0.0 110.118 -177.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.422 ' HA ' ' O ' ' A' ' 12' ' ' PHE . 14.3 pt -119.59 149.63 22.18 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.607 -176.195 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 57.6 m-85 -132.56 148.54 70.02 Favored Pre-proline 0 C--O 1.192 -1.945 0 N-CA-C 107.428 -1.323 . . . . 0.0 107.428 -177.381 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . 0.448 ' O ' ' HB2' ' A' ' 64' ' ' ASN . 41.4 Cg_endo -66.2 132.32 29.38 Favored 'Trans proline' 0 C--N 1.322 -0.854 0 C-N-CA 121.94 1.76 . . . . 0.0 111.956 -179.236 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.417 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 66.5 t80 -69.38 -38.48 78.05 Favored 'General case' 0 C--O 1.204 -1.327 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -177.338 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 22.7 t -76.31 -33.63 59.03 Favored 'General case' 0 C--N 1.295 -1.8 0 C-N-CA 120.087 -0.645 . . . . 0.0 111.402 -172.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.489 ' C ' HD21 ' A' ' 64' ' ' ASN . 2.8 mp0 -95.69 -1.7 49.51 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.522 -177.778 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.489 HD21 ' C ' ' A' ' 63' ' ' GLU . 0.9 OUTLIER -131.17 15.34 5.12 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 178.232 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -69.75 -32.24 70.65 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.465 0.65 . . . . 0.0 110.1 -179.535 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.527 ' H ' ' CD ' ' A' ' 66' ' ' GLU . 1.5 mp0 -66.1 -31.61 72.58 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 178.103 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.468 ' HD3' ' CG ' ' A' ' 64' ' ' ASN . 37.7 mtpt -82.22 -60.25 2.28 Favored 'General case' 0 N--CA 1.428 -1.567 0 CA-C-N 114.303 -1.317 . . . . 0.0 111.501 -175.594 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -106.71 -1.15 23.01 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.434 -0.803 . . . . 0.0 113.057 -168.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.71 56.91 4.23 Favored Glycine 0 C--N 1.311 -0.827 0 C-N-CA 120.994 -0.622 . . . . 0.0 111.953 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 58.7 mttp -125.86 125.61 24.86 Favored Pre-proline 0 C--N 1.313 -1.021 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.27 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -53.15 128.8 30.51 Favored 'Trans proline' 0 C--O 1.263 1.763 0 C-N-CA 123.451 2.767 . . . . 0.0 114.414 -177.167 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -94.94 -172.43 2.7 Favored 'General case' 0 N--CA 1.407 -2.613 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.636 178.383 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . 0.534 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 2.0 mptp? -106.98 -11.01 15.78 Favored 'General case' 0 N--CA 1.417 -2.118 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -178.506 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.94 118.13 9.3 Favored 'General case' 0 N--CA 1.41 -2.429 0 N-CA-C 106.272 -1.751 . . . . 0.0 106.272 169.71 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 9.3 tptp -69.9 140.25 53.09 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 107.888 -1.152 . . . . 0.0 107.888 179.013 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.93 -24.04 24.25 Favored Glycine 0 N--CA 1.413 -2.889 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 -173.15 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 1.65 ' HE1' ' CE2' ' A' ' 77' ' ' PHE . 11.5 t80 -75.47 -38.79 59.39 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -68.64 -47.33 66.88 Favored 'General case' 0 CA--C 1.506 -0.739 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 -177.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 36.1 mp0 -61.66 -42.34 98.77 Favored 'General case' 0 N--CA 1.426 -1.661 0 CA-C-N 113.152 -1.84 . . . . 0.0 110.068 178.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.1 -37.0 72.6 Favored Glycine 0 CA--C 1.484 -1.846 0 CA-C-N 115.751 -0.659 . . . . 0.0 113.305 -179.243 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 38.3 tp -62.55 -31.1 71.84 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 176.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.0 t90 -74.76 -51.18 14.86 Favored 'General case' 0 N--CA 1.429 -1.501 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.248 175.006 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 -55.06 -45.84 75.34 Favored 'General case' 0 C--O 1.203 -1.346 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 -178.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.2 tt -68.73 -27.89 37.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -176.033 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -93.42 -16.96 24.03 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.252 0.549 . . . . 0.0 110.302 -173.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.432 ' N ' HD21 ' A' ' 86' ' ' ASN . 0.9 OUTLIER -109.91 -56.51 2.31 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-O 121.16 0.505 . . . . 0.0 111.527 179.605 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -128.27 75.19 79.2 Favored Pre-proline 0 C--N 1.313 -0.982 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.199 -177.65 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -73.62 -5.26 16.79 Favored 'Trans proline' 0 C--N 1.332 -0.298 0 C-N-CA 122.699 2.266 . . . . 0.0 112.988 -177.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 26.1 pttm . . . . . 0 C--O 1.249 1.054 0 CA-C-O 121.38 0.609 . . . . 0.0 109.972 -176.393 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . 1.66 ' HD2' ' CD1' ' A' ' 5' ' ' PHE . 91.3 m-85 . . . . . 0 CA--C 1.498 -1.047 0 N-CA-C 117.575 2.435 . . . . 0.0 117.575 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.48 ' HG3' ' OD1' ' A' ' 9' ' ' ASP . 3.8 ptmm? -134.65 156.3 78.8 Favored Pre-proline 0 N--CA 1.413 -2.276 0 CA-C-N 112.076 -2.329 . . . . 0.0 107.684 177.086 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.88 141.1 95.77 Favored 'Trans proline' 0 C--O 1.253 1.234 0 C-N-CA 122.497 2.132 . . . . 0.0 112.455 178.244 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 104.81 -14.17 49.56 Favored Glycine 0 N--CA 1.44 -1.039 0 C-N-CA 121.231 -0.509 . . . . 0.0 113.033 178.18 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.48 ' OD1' ' HG3' ' A' ' 6' ' ' LYS . 1.4 m-20 -79.05 145.87 33.6 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-O 121.087 0.47 . . . . 0.0 111.412 -179.381 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 83.6 mt -95.3 127.43 41.34 Favored 'General case' 0 C--O 1.25 1.116 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.45 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.9 pp -139.54 -178.63 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.205 0 CA-C-O 122.489 1.138 . . . . 0.0 113.761 -173.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 1.621 ' HE2' ' CE1' ' A' ' 12' ' ' PHE . 86.3 m-85 -119.43 128.59 54.17 Favored 'General case' 0 N--CA 1.408 -2.564 0 N-CA-C 105.203 -2.147 . . . . 0.0 105.203 170.766 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.4 ' HB2' HD13 ' A' ' 53' ' ' LEU . . . -108.09 140.84 40.68 Favored 'General case' 0 C--N 1.279 -2.477 0 O-C-N 123.702 0.626 . . . . 0.0 110.045 -173.569 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.466 ' HD3' ' C ' ' A' ' 14' ' ' LYS . 7.6 tmtm? -114.96 115.66 27.24 Favored 'General case' 0 N--CA 1.414 -2.273 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.834 -176.742 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 69.8 mtm -108.12 158.93 16.99 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 172.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 24.4 tptm -62.59 130.04 43.3 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 177.509 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 83.02 -25.5 4.73 Favored Glycine 0 C--O 1.218 -0.888 0 O-C-N 123.539 0.524 . . . . 0.0 112.568 -177.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 53.5 m-85 -93.21 149.85 38.13 Favored Pre-proline 0 C--O 1.257 1.488 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -177.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -75.78 171.7 17.69 Favored 'Trans proline' 0 N--CA 1.449 -1.112 0 C-N-CA 123.395 2.73 . . . . 0.0 109.646 171.251 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 79.8 m80 -69.9 111.53 5.68 Favored 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 178.461 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 8.5 t-105 -100.17 136.39 20.1 Favored Pre-proline 0 C--N 1.309 -1.175 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.961 -173.27 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_endo -65.88 117.79 4.94 Favored 'Trans proline' 0 CA--C 1.542 0.9 0 C-N-CA 121.789 1.66 . . . . 0.0 110.789 176.439 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.44 167.51 23.46 Favored 'General case' 0 N--CA 1.426 -1.645 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -174.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.507 ' HB3' ' CE2' ' A' ' 45' ' ' PHE . 9.2 ptt180 -111.25 160.57 16.86 Favored 'General case' 0 C--N 1.291 -1.965 0 C-N-CA 119.507 -0.877 . . . . 0.0 109.182 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 42.3 t -89.47 116.05 30.24 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.163 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 170.064 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -87.84 173.53 8.89 Favored 'General case' 0 C--N 1.281 -2.407 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.976 -175.013 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.417 -2.1 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 175.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.511 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 34.3 mmtt . . . . . 0 N--CA 1.41 -2.469 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.441 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 74.6 mt -96.63 154.27 38.52 Favored Pre-proline 0 C--N 1.271 -2.814 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 -178.147 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -74.96 126.48 10.02 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 C-N-CA 121.517 1.478 . . . . 0.0 109.276 173.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 50.6 mm -125.3 110.13 23.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-O 121.116 0.484 . . . . 0.0 111.407 -175.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 70.2 t80 -90.26 117.52 29.06 Favored 'General case' 0 C--N 1.279 -2.497 0 C-N-CA 124.46 1.104 . . . . 0.0 109.899 176.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 1.651 ' HD1' ' CD2' ' A' ' 44' ' ' PHE . 88.3 m-85 -78.13 128.83 34.4 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.9 177.616 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.507 ' CE2' ' HB3' ' A' ' 24' ' ' ARG . 58.8 m-85 -78.14 152.04 32.99 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.254 177.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 80.96 -21.05 5.93 Favored Glycine 0 C--N 1.308 -1.027 0 C-N-CA 124.565 1.079 . . . . 0.0 114.592 177.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.434 ' CG2' ' HA3' ' A' ' 76' ' ' GLY . 32.6 p -119.88 -22.73 6.66 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 117.467 0.633 . . . . 0.0 110.349 174.682 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 68.11 23.17 8.09 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.854 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -75.12 169.64 17.63 Favored 'General case' 0 C--N 1.35 0.602 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 175.076 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.4 m -141.47 145.66 35.51 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 121.539 -0.726 . . . . 0.0 110.005 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -139.99 -179.9 6.22 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 123.835 0.854 . . . . 0.0 109.842 178.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.441 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 93.0 m-85 -133.23 109.67 9.58 Favored 'General case' 0 CA--C 1.491 -1.29 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 174.332 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.44 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 79.5 mt -134.13 144.6 48.64 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 -178.867 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.511 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -83.26 177.05 52.97 Favored Glycine 0 N--CA 1.417 -2.596 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 -174.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -66.23 -17.51 54.49 Favored 'Trans proline' 0 C--N 1.319 -0.985 0 C-N-CA 122.112 1.875 . . . . 0.0 112.481 -176.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 16.8 mmmt -98.86 -3.58 35.03 Favored 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 120.204 -0.598 . . . . 0.0 110.923 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.44 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 12.8 m-20 -96.55 -9.2 30.01 Favored 'General case' 0 N--CA 1.481 1.105 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.792 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.484 HG13 ' CE2' ' A' ' 5' ' ' PHE . 12.5 pt -115.63 152.43 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.231 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.428 -176.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -126.05 131.68 24.06 Favored Pre-proline 0 C--N 1.301 -1.542 0 CA-C-N 115.238 -0.892 . . . . 0.0 108.753 -177.612 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . 0.491 ' HG2' ' HB2' ' A' ' 63' ' ' GLU . 34.1 Cg_endo -67.6 131.51 24.67 Favored 'Trans proline' 0 C--N 1.322 -0.821 0 C-N-CA 122.708 2.272 . . . . 0.0 113.202 -175.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 1.608 ' HD1' ' CD2' ' A' ' 61' ' ' TYR . 43.3 t80 -52.37 -42.19 63.74 Favored 'General case' 0 C--O 1.205 -1.257 0 C-N-CA 123.992 0.917 . . . . 0.0 111.337 179.62 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.2 t -64.94 -37.0 86.19 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.476 -175.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.491 ' HB2' ' HG2' ' A' ' 60' ' ' PRO . 29.9 mt-10 -97.03 -7.08 33.78 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.992 0.425 . . . . 0.0 111.949 -175.703 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.466 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 27.2 m-80 -133.53 17.77 3.96 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 112.416 0.525 . . . . 0.0 112.416 -175.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.44 ' HG2' ' OE1' ' A' ' 66' ' ' GLU . 3.6 ptpp? -67.29 -36.13 80.91 Favored 'General case' 0 N--CA 1.498 1.968 0 C-N-CA 120.042 -0.663 . . . . 0.0 110.611 -176.149 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.44 ' OE1' ' HG2' ' A' ' 65' ' ' LYS . 28.8 mp0 -64.94 -35.45 81.21 Favored 'General case' 0 C--O 1.255 1.346 0 CA-C-O 123.241 1.496 . . . . 0.0 108.836 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.466 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 37.6 mtpt -76.38 -59.33 2.81 Favored 'General case' 0 C--N 1.294 -1.834 0 CA-C-N 112.931 -1.94 . . . . 0.0 111.912 -174.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 1.646 ' HD2' ' CD1' ' A' ' 68' ' ' TYR . 23.2 m-85 -112.1 -1.94 15.16 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 -169.084 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -83.85 45.69 3.52 Favored Glycine 0 C--N 1.309 -0.961 0 C-N-CA 120.654 -0.784 . . . . 0.0 113.373 -176.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 17.3 pttm -132.75 143.74 49.98 Favored Pre-proline 0 N--CA 1.43 -1.448 0 O-C-N 122.591 -0.358 . . . . 0.0 111.561 176.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_exo -49.42 158.13 1.83 Allowed 'Trans proline' 0 C--N 1.361 1.236 0 C-N-CA 124.577 3.518 . . . . 0.0 117.06 -173.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -131.48 -178.42 4.85 Favored 'General case' 0 N--CA 1.416 -2.164 0 CA-C-N 113.647 -1.615 . . . . 0.0 108.31 178.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -90.69 -18.51 24.94 Favored 'General case' 0 C--N 1.308 -1.199 0 O-C-N 123.693 0.621 . . . . 0.0 109.659 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.54 115.57 5.9 Favored 'General case' 0 N--CA 1.414 -2.229 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 175.496 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.431 ' HD3' ' H ' ' A' ' 76' ' ' GLY . 14.0 tppt? -64.73 133.42 52.05 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 175.638 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.434 ' HA3' ' CG2' ' A' ' 47' ' ' THR . . . 108.46 -24.75 21.62 Favored Glycine 0 N--CA 1.414 -2.788 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -174.095 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 1.658 ' HE1' ' CE2' ' A' ' 77' ' ' PHE . 11.0 t80 -75.6 -37.91 59.46 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 179.736 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -65.96 -49.55 67.48 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 -178.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 23.5 mp0 -64.58 -39.07 93.07 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 113.202 -1.817 . . . . 0.0 110.522 -179.687 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.64 -35.05 62.63 Favored Glycine 0 CA--C 1.48 -2.145 0 CA-C-N 116.063 -0.517 . . . . 0.0 113.011 -179.41 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 37.7 tp -62.51 -33.31 74.63 Favored 'General case' 0 N--CA 1.423 -1.802 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 176.029 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 70.5 t90 -74.34 -49.11 24.21 Favored 'General case' 0 N--CA 1.426 -1.626 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.602 175.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -55.04 -46.09 75.27 Favored 'General case' 0 C--O 1.188 -2.154 0 N-CA-C 112.644 0.609 . . . . 0.0 112.644 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 17.0 tt -68.56 -23.22 27.73 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-O 121.082 0.468 . . . . 0.0 111.629 -174.054 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -92.34 -41.93 10.09 Favored 'General case' 0 N--CA 1.423 -1.785 0 CA-C-O 121.585 0.707 . . . . 0.0 109.819 -175.443 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.581 ' N ' HD21 ' A' ' 86' ' ' ASN . 0.7 OUTLIER -97.73 -39.73 8.91 Favored 'General case' 0 N--CA 1.48 1.038 0 CA-C-O 121.713 0.768 . . . . 0.0 112.061 -173.838 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 65.2 t30 -134.99 63.33 57.24 Favored Pre-proline 0 C--N 1.296 -1.759 0 C-N-CA 119.797 -0.761 . . . . 0.0 111.673 -178.428 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -68.13 -6.57 17.58 Favored 'Trans proline' 0 C--N 1.371 1.711 0 C-N-CA 122.81 2.34 . . . . 0.0 111.742 -178.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 24.7 pttm . . . . . 0 C--N 1.311 -1.103 0 CA-C-N 114.555 -1.202 . . . . 0.0 109.828 -177.44 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . 1.663 ' HD2' ' CD1' ' A' ' 5' ' ' PHE . 84.3 m-85 . . . . . 0 CA--C 1.496 -1.116 0 CA-C-O 120.959 0.409 . . . . 0.0 110.014 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.502 ' HD2' ' C ' ' A' ' 5' ' ' PHE . 13.4 mmmt -116.81 153.69 49.33 Favored Pre-proline 0 N--CA 1.433 -1.29 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 -178.251 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.6 Cg_exo -52.82 134.45 54.58 Favored 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 122.755 2.303 . . . . 0.0 112.369 177.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 107.58 -25.21 21.97 Favored Glycine 0 N--CA 1.432 -1.613 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.77 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -72.24 150.23 43.85 Favored 'General case' 0 C--O 1.252 1.216 0 CA-C-O 121.582 0.706 . . . . 0.0 112.224 -177.099 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 76.5 mt -100.04 127.96 46.19 Favored 'General case' 0 N--CA 1.423 -1.794 0 CA-C-N 114.352 -1.294 . . . . 0.0 109.754 -177.116 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 8.6 pt -140.12 -173.6 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 CA-C-O 122.348 1.071 . . . . 0.0 111.897 -174.446 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 1.648 ' HD2' ' CD1' ' A' ' 12' ' ' PHE . 66.5 m-85 -126.31 124.31 40.02 Favored 'General case' 0 N--CA 1.412 -2.363 0 N-CA-C 106.174 -1.787 . . . . 0.0 106.174 172.162 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.428 ' CB ' HG22 ' A' ' 42' ' ' ILE . . . -108.89 131.28 55.17 Favored 'General case' 0 C--N 1.28 -2.431 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.343 -174.572 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.686 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -113.54 122.18 46.46 Favored 'General case' 0 N--CA 1.401 -2.911 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.116 -177.76 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 70.2 mtm -110.43 158.03 18.93 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 175.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 60.2 tttm -67.29 116.62 8.26 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 110.145 -0.317 . . . . 0.0 110.145 -179.224 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.81 -2.75 62.26 Favored Glycine 0 C--O 1.248 0.975 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . 1.66 ' HD1' ' CD2' ' A' ' 18' ' ' TYR . 74.3 m-85 -121.86 151.79 58.32 Favored Pre-proline 0 N--CA 1.434 -1.268 0 C-N-CA 122.829 0.452 . . . . 0.0 109.905 -178.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -76.5 171.37 18.18 Favored 'Trans proline' 0 N--CA 1.448 -1.157 0 C-N-CA 122.296 1.997 . . . . 0.0 109.815 175.1 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' HIS . . . . . 0.528 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 76.2 m80 -66.76 110.94 3.46 Favored 'General case' 0 C--N 1.312 -1.061 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 176.269 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -99.88 138.15 20.29 Favored Pre-proline 0 C--N 1.296 -1.718 0 C-N-CA 123.942 0.897 . . . . 0.0 109.324 -171.316 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -63.59 118.28 5.22 Favored 'Trans proline' 0 C--O 1.244 0.808 0 C-N-CA 121.918 1.746 . . . . 0.0 110.043 177.219 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -141.82 167.54 21.91 Favored 'General case' 0 N--CA 1.415 -2.195 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.761 -175.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 56.1 ttt-85 -123.73 141.15 52.29 Favored 'General case' 0 C--N 1.289 -2.03 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 178.191 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 45.6 t -77.64 125.27 37.2 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 175.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -94.2 171.04 9.08 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 120.57 -0.452 . . . . 0.0 109.855 -175.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 . . . . . 0 C--N 1.305 -1.367 0 CA-C-O 121.915 0.864 . . . . 0.0 113.293 -178.116 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 62.6 mttp . . . . . 0 N--CA 1.424 -1.758 0 CA-C-O 120.826 0.346 . . . . 0.0 110.364 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 85.0 mt -112.55 147.29 36.77 Favored Pre-proline 0 C--N 1.286 -2.194 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.487 -176.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -73.73 122.58 7.89 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 121.749 1.632 . . . . 0.0 109.535 176.141 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.428 HG22 ' CB ' ' A' ' 13' ' ' ALA . 45.7 mm -118.22 111.01 32.32 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.251 -174.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.656 ' HD1' ' CD2' ' A' ' 43' ' ' PHE . 91.1 t80 -91.24 118.73 30.72 Favored 'General case' 0 C--N 1.286 -2.153 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.288 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -83.03 133.23 35.1 Favored 'General case' 0 C--O 1.249 1.03 0 CA-C-O 121.107 0.479 . . . . 0.0 112.163 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 72.0 m-85 -81.43 152.34 27.45 Favored 'General case' 0 N--CA 1.433 -1.31 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.154 175.144 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.424 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 81.24 -19.47 8.2 Favored Glycine 0 C--N 1.309 -0.95 0 C-N-CA 123.366 0.507 . . . . 0.0 113.555 178.412 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.471 ' HB ' ' OE1' ' A' ' 49' ' ' GLU . 35.9 p -118.92 -22.78 7.17 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 122.267 -0.549 . . . . 0.0 110.578 176.426 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.439 ' HA ' ' CZ ' ' A' ' 43' ' ' PHE . 13.3 m170 66.43 25.6 10.22 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 123.308 0.643 . . . . 0.0 110.879 -179.729 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.471 ' OE1' ' HB ' ' A' ' 47' ' ' THR . 45.9 mt-10 -97.45 175.47 6.22 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.454 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 10.0 m -143.76 143.85 31.56 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-O 121.172 0.511 . . . . 0.0 109.815 -179.241 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -131.37 178.26 6.85 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 114.814 -1.084 . . . . 0.0 109.675 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 1.606 ' HE1' ' CE2' ' A' ' 52' ' ' PHE . 91.9 m-85 -133.38 109.82 9.6 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 176.598 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 88.9 mt -125.65 163.7 22.2 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 -177.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -85.22 162.8 37.05 Favored Glycine 0 N--CA 1.419 -2.454 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 178.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -63.88 -15.17 47.48 Favored 'Trans proline' 0 C--O 1.208 -0.989 0 C-N-CA 123.006 2.471 . . . . 0.0 112.257 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.527 ' HZ1' ' CG ' ' A' ' 57' ' ' ASP . 0.0 OUTLIER -97.08 4.96 51.1 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 115.648 -0.705 . . . . 0.0 112.75 178.002 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.527 ' CG ' ' HZ1' ' A' ' 56' ' ' LYS . 21.4 m-20 -113.67 1.77 15.02 Favored 'General case' 0 C--N 1.292 -1.911 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.143 177.155 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 17.6 pt -127.13 150.74 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.823 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . 1.6 ' HE2' ' CE1' ' A' ' 59' ' ' PHE . 93.3 m-85 -136.29 142.37 39.45 Favored Pre-proline 0 C--N 1.295 -1.794 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo -65.09 137.88 54.25 Favored 'Trans proline' 0 C--O 1.249 1.046 0 C-N-CA 122.835 2.357 . . . . 0.0 112.922 -177.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 25.4 t80 -56.38 -42.69 78.29 Favored 'General case' 0 C--O 1.208 -1.093 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.172 178.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.6 m -53.87 -43.43 69.59 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 115.677 -0.692 . . . . 0.0 112.509 -175.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -95.62 -17.23 21.51 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.259 0.552 . . . . 0.0 112.031 -176.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.517 ' ND2' ' HB3' ' A' ' 59' ' ' PHE . 28.0 m-80 -116.73 10.54 14.32 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -173.027 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.486 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 19.4 pttp -68.69 -35.44 77.2 Favored 'General case' 0 C--O 1.21 -0.994 0 CA-C-O 121.137 0.494 . . . . 0.0 111.032 -177.296 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.486 ' OE1' ' HG3' ' A' ' 65' ' ' LYS . 2.1 mm-40 -73.01 -22.48 60.66 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 122.177 0.989 . . . . 0.0 108.819 -178.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.433 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 41.5 mtpt -83.42 -59.61 2.4 Favored 'General case' 0 N--CA 1.436 -1.148 0 CA-C-N 114.561 -1.2 . . . . 0.0 110.609 -177.606 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 0.472 ' CD2' ' HB3' ' A' ' 64' ' ' ASN . 27.2 m-85 -105.72 -8.12 18.02 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 115.475 -0.784 . . . . 0.0 112.697 -169.35 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -79.25 52.12 4.01 Favored Glycine 0 C--O 1.219 -0.816 0 C-N-CA 121.583 -0.342 . . . . 0.0 112.781 -177.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.7 ptpp? -132.96 132.9 22.66 Favored Pre-proline 0 C--N 1.301 -1.536 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 176.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -65.49 128.89 21.17 Favored 'Trans proline' 0 N--CA 1.446 -1.316 0 C-N-CA 122.655 2.237 . . . . 0.0 115.531 -172.193 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.44 ' N ' HD21 ' A' ' 72' ' ' ASN . 0.8 OUTLIER -93.92 -170.81 2.41 Favored 'General case' 0 CA--C 1.487 -1.474 0 N-CA-C 106.205 -1.776 . . . . 0.0 106.205 173.829 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . 0.412 ' HD3' ' HA ' ' A' ' 73' ' ' LYS 0.273 70.9 mmtt -110.09 28.93 8.12 Favored 'General case' 0 C--N 1.291 -1.977 0 CA-C-O 122.593 1.187 . . . . 0.0 110.592 171.35 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 14.7 mmt180 -82.51 125.34 31.01 Favored 'General case' 0 C--O 1.25 1.099 0 N-CA-C 106.341 -1.725 . . . . 0.0 106.341 170.511 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -66.73 139.24 57.81 Favored 'General case' 0 C--N 1.318 -0.798 0 C-N-CA 119.83 -0.748 . . . . 0.0 109.882 176.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.424 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 95.87 -25.2 26.28 Favored Glycine 0 N--CA 1.428 -1.895 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -175.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 1.664 ' HD2' ' CD1' ' A' ' 77' ' ' PHE . 31.7 t80 -75.87 -47.06 26.98 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-O 121.196 0.522 . . . . 0.0 109.702 -178.062 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.534 ' N ' HD21 ' A' ' 78' ' ' ASN . 0.7 OUTLIER -67.4 -37.86 83.76 Favored 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.892 0.853 . . . . 0.0 109.142 -179.256 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -72.44 -36.1 68.46 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 114.024 -1.444 . . . . 0.0 109.593 -179.158 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -69.66 -33.89 72.08 Favored Glycine 0 CA--C 1.494 -1.271 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.641 178.455 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 94.7 mt -60.51 -38.79 85.52 Favored 'General case' 0 C--O 1.21 -0.976 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 174.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 85.4 t90 -66.66 -46.07 76.89 Favored 'General case' 0 N--CA 1.429 -1.476 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.695 177.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -61.48 -43.46 98.82 Favored 'General case' 0 C--O 1.204 -1.339 0 N-CA-C 113.076 0.769 . . . . 0.0 113.076 179.564 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.1 tt -70.8 -33.45 52.52 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 120.379 -0.528 . . . . 0.0 112.056 -175.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -88.98 -5.85 57.66 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 112.758 0.651 . . . . 0.0 112.758 -178.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 31.9 m-80 -123.57 -51.12 1.84 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-O 121.388 0.613 . . . . 0.0 112.089 -179.137 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.7 t30 -126.45 67.56 65.59 Favored Pre-proline 0 C--N 1.305 -1.341 0 O-C-N 121.94 -0.475 . . . . 0.0 110.186 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -74.78 -5.95 17.51 Favored 'Trans proline' 0 N--CA 1.48 0.698 0 C-N-CA 122.314 2.009 . . . . 0.0 112.289 -175.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.7 pttp . . . . . 0 C--N 1.3 -1.573 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.083 -178.404 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . 1.642 ' HD2' ' CD1' ' A' ' 5' ' ' PHE . 95.0 m-85 . . . . . 0 N--CA 1.422 -1.851 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.581 ' HG2' ' OD2' ' A' ' 9' ' ' ASP . 1.6 pttm -135.22 152.49 76.96 Favored Pre-proline 0 C--N 1.289 -2.039 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 -175.277 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo -49.09 121.7 7.25 Favored 'Trans proline' 0 C--N 1.352 0.723 0 C-N-CA 122.657 2.238 . . . . 0.0 111.138 176.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.38 -30.48 6.45 Favored Glycine 0 N--CA 1.423 -2.206 0 CA-C-O 118.991 -0.894 . . . . 0.0 113.637 -178.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.581 ' OD2' ' HG2' ' A' ' 6' ' ' LYS 0.335 2.9 p30 -78.71 147.93 33.27 Favored 'General case' 0 C--O 1.248 1.009 0 CA-C-N 118.859 1.329 . . . . 0.0 113.268 -179.161 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 82.3 mt -91.42 129.1 37.45 Favored 'General case' 0 CA--C 1.488 -1.44 0 CA-C-N 114.203 -1.362 . . . . 0.0 110.312 -175.783 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 12.1 pt -140.39 -173.03 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 CA-C-O 122.374 1.083 . . . . 0.0 111.993 -174.118 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 38.4 m-85 -120.71 132.33 55.01 Favored 'General case' 0 N--CA 1.414 -2.236 0 CA-C-N 113.979 -1.464 . . . . 0.0 107.077 171.344 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.426 ' HB3' HG22 ' A' ' 42' ' ' ILE . . . -108.92 124.02 50.0 Favored 'General case' 0 C--N 1.272 -2.788 0 O-C-N 123.947 0.779 . . . . 0.0 109.337 -178.811 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.697 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -109.33 120.27 42.0 Favored 'General case' 0 N--CA 1.398 -3.043 0 CA-C-N 116.184 -0.462 . . . . 0.0 109.916 -179.145 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 66.5 mtm -114.68 157.89 22.52 Favored 'General case' 0 C--N 1.314 -0.977 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 175.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 41.7 ttmt -66.31 117.63 8.85 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 116.712 -0.222 . . . . 0.0 110.429 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.92 -3.88 65.17 Favored Glycine 0 C--O 1.251 1.206 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.651 178.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . 1.646 ' HD1' ' CD2' ' A' ' 18' ' ' TYR . 77.5 m-85 -120.9 151.44 54.85 Favored Pre-proline 0 N--CA 1.428 -1.573 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 -179.211 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -77.58 171.27 17.81 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 122.112 1.875 . . . . 0.0 109.611 175.562 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' HIS . . . . . 0.454 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 70.0 m80 -63.15 110.99 2.03 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 174.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 7.5 t-105 -99.4 137.68 20.37 Favored Pre-proline 0 C--N 1.303 -1.456 0 C-N-CA 123.331 0.653 . . . . 0.0 109.239 -172.535 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -63.97 117.83 4.81 Favored 'Trans proline' 0 C--O 1.245 0.863 0 C-N-CA 121.796 1.664 . . . . 0.0 110.089 176.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.21 167.83 21.21 Favored 'General case' 0 N--CA 1.413 -2.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.143 -175.109 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.416 HH22 ' CD ' ' A' ' 27' ' ' GLU . 10.6 ttp180 -124.7 148.06 48.23 Favored 'General case' 0 C--N 1.282 -2.33 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 176.571 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.7 t -72.41 118.69 17.84 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 N-CA-C 105.275 -2.12 . . . . 0.0 105.275 170.31 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -84.76 172.43 11.49 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -171.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.416 ' CD ' HH22 ' A' ' 24' ' ' ARG . 0.5 OUTLIER . . . . . 0 C--N 1.309 -1.158 0 CA-C-O 121.669 0.747 . . . . 0.0 112.533 -175.465 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 63.0 mttp . . . . . 0 N--CA 1.418 -2.051 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.424 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 92.8 mt -98.89 141.6 23.16 Favored Pre-proline 0 C--N 1.287 -2.148 0 O-C-N 123.977 0.798 . . . . 0.0 109.937 -176.537 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -70.65 123.27 9.65 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.053 1.836 . . . . 0.0 109.429 176.082 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.426 HG22 ' HB3' ' A' ' 13' ' ' ALA . 39.5 mm -116.35 117.05 54.21 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.123 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 -175.775 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 72.7 t80 -94.28 115.89 28.2 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -81.54 129.1 34.54 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 123.425 0.453 . . . . 0.0 111.387 177.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 1.63 ' HE2' ' CE1' ' A' ' 45' ' ' PHE . 86.8 m-85 -80.07 150.64 30.24 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.694 176.249 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.504 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 80.78 -19.91 6.95 Favored Glycine 0 C--N 1.311 -0.827 0 CA-C-N 116.216 -0.447 . . . . 0.0 113.739 179.152 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.4 p -119.33 -23.74 6.61 Favored 'General case' 0 C--N 1.309 -1.16 0 O-C-N 122.074 -0.662 . . . . 0.0 110.556 174.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 68.02 13.66 9.17 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 123.987 0.915 . . . . 0.0 112.231 -178.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.7 mm-40 -76.52 164.11 26.27 Favored 'General case' 0 CA--C 1.493 -1.226 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.263 178.222 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.412 ' HA ' ' O ' ' A' ' 42' ' ' ILE . 4.2 m -133.2 136.85 45.9 Favored 'General case' 0 C--N 1.283 -2.298 0 CA-C-O 121.425 0.631 . . . . 0.0 109.773 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -128.53 178.02 6.6 Favored 'General case' 0 C--N 1.284 -2.256 0 CA-C-N 115.013 -0.994 . . . . 0.0 109.914 -179.302 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.424 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 95.9 m-85 -133.63 110.25 9.75 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 176.527 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 94.9 mt -124.71 160.53 28.36 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 -179.35 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -87.81 167.53 36.73 Favored Glycine 0 N--CA 1.42 -2.383 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 178.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.65 -6.96 16.65 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 123.16 2.573 . . . . 0.0 112.334 -178.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 7.9 ptmm? -97.31 -4.32 38.89 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.415 178.411 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.2 m-20 -115.27 5.66 14.76 Favored 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.891 -176.587 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 14.3 pt -131.38 150.7 34.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.796 0 CA-C-N 114.737 -1.12 . . . . 0.0 108.981 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -141.66 147.19 44.65 Favored Pre-proline 0 C--N 1.295 -1.778 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 -179.371 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -62.06 133.24 43.06 Favored 'Trans proline' 0 CA--C 1.511 -0.667 0 C-N-CA 123.043 2.495 . . . . 0.0 113.256 -177.45 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -64.62 -36.97 85.98 Favored 'General case' 0 C--O 1.207 -1.177 0 CA-C-N 114.88 -1.055 . . . . 0.0 110.7 -177.214 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 10.6 m -63.95 -39.65 94.64 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.239 -178.22 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -89.05 -7.43 55.9 Favored 'General case' 0 C--O 1.218 -0.582 0 N-CA-C 111.879 0.326 . . . . 0.0 111.879 -177.534 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 39.0 m-80 -123.92 13.39 9.16 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -179.476 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.8 ttmm -67.05 -34.36 77.51 Favored 'General case' 0 N--CA 1.473 0.694 0 CA-C-O 121.667 0.746 . . . . 0.0 109.648 -179.669 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.553 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -79.16 -20.25 48.96 Favored 'General case' 0 N--CA 1.408 -2.55 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.347 178.072 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.553 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 8.2 mttm -87.92 -59.28 2.29 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.979 179.529 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 1.668 ' HE1' ' CE2' ' A' ' 68' ' ' TYR . 66.0 m-85 -112.53 1.32 15.81 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.3 -171.789 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.6 55.97 4.15 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 111.601 -0.599 . . . . 0.0 111.601 178.229 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 58.4 mttp -129.54 123.71 21.48 Favored Pre-proline 0 C--N 1.31 -1.131 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 -179.712 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -63.0 128.2 22.35 Favored 'Trans proline' 0 N--CA 1.444 -1.424 0 C-N-CA 121.839 1.693 . . . . 0.0 114.132 -175.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -93.24 -171.84 2.78 Favored 'General case' 0 CA--C 1.482 -1.667 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 176.44 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . 0.268 71.4 mmtt -109.42 27.56 9.42 Favored 'General case' 0 C--N 1.289 -2.045 0 CA-C-O 122.613 1.197 . . . . 0.0 110.361 171.041 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 13.8 mmt180 -80.14 127.64 32.56 Favored 'General case' 0 C--O 1.25 1.11 0 N-CA-C 105.168 -2.16 . . . . 0.0 105.168 169.421 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 42.9 tttm -67.77 141.89 56.41 Favored 'General case' 0 C--N 1.32 -0.699 0 C-N-CA 119.228 -0.989 . . . . 0.0 108.721 179.456 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.504 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 94.17 -25.31 22.83 Favored Glycine 0 N--CA 1.426 -1.985 0 C-N-CA 120.881 -0.676 . . . . 0.0 111.846 -177.08 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 1.636 ' HD1' ' CD2' ' A' ' 77' ' ' PHE . 20.6 t80 -72.87 -44.73 60.98 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.336 0.588 . . . . 0.0 109.585 -177.613 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.556 ' N ' HD21 ' A' ' 78' ' ' ASN . 0.7 OUTLIER -70.34 -42.21 72.18 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 -178.949 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -65.99 -38.48 88.59 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-N 114.447 -1.251 . . . . 0.0 109.451 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -68.51 -34.84 80.07 Favored Glycine 0 N--CA 1.433 -1.505 0 CA-C-N 115.349 -0.842 . . . . 0.0 113.057 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.412 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 94.6 mt -60.61 -35.43 76.12 Favored 'General case' 0 C--O 1.216 -0.668 0 CA-C-O 121.309 0.576 . . . . 0.0 109.782 175.701 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 83.1 t90 -70.78 -48.97 51.46 Favored 'General case' 0 N--CA 1.433 -1.284 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.724 176.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -58.15 -45.33 87.61 Favored 'General case' 0 C--O 1.205 -1.289 0 N-CA-C 113.042 0.756 . . . . 0.0 113.042 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.7 tt -68.82 -31.23 49.86 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -174.021 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -90.58 -10.34 43.77 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -179.027 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 31.7 m-80 -117.78 -53.99 2.37 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-O 121.223 0.535 . . . . 0.0 112.215 -178.373 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -127.86 75.77 77.92 Favored Pre-proline 0 C--N 1.304 -1.396 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.189 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.81 -7.7 21.97 Favored 'Trans proline' 0 N--CA 1.488 1.188 0 C-N-CA 122.87 2.38 . . . . 0.0 112.688 -176.569 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.3 pttp . . . . . 0 C--N 1.302 -1.461 0 C-N-CA 123.982 0.913 . . . . 0.0 109.738 -178.344 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . 1.651 ' HE1' ' CE2' ' A' ' 5' ' ' PHE . 88.9 m-85 . . . . . 0 N--CA 1.432 -1.341 0 CA-C-O 121.758 0.79 . . . . 0.0 113.053 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.621 ' HG2' ' OD2' ' A' ' 9' ' ' ASP . 16.8 pttm -134.6 160.09 69.74 Favored Pre-proline 0 C--N 1.305 -1.35 0 CA-C-N 114.889 -1.05 . . . . 0.0 108.336 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -51.25 122.65 10.46 Favored 'Trans proline' 0 C--N 1.347 0.499 0 C-N-CA 122.496 2.131 . . . . 0.0 111.879 175.328 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.1 -22.59 11.25 Favored Glycine 0 N--CA 1.429 -1.77 0 CA-C-O 119.351 -0.694 . . . . 0.0 113.381 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.621 ' OD2' ' HG2' ' A' ' 6' ' ' LYS . 37.3 m-20 -66.0 128.95 38.09 Favored 'General case' 0 C--O 1.247 0.953 0 CA-C-N 117.659 0.729 . . . . 0.0 112.097 -179.456 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 77.2 mt -83.83 124.43 30.94 Favored 'General case' 0 CA--C 1.485 -1.545 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 176.036 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 10.3 pt -140.24 -174.3 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 CA-C-O 122.367 1.079 . . . . 0.0 112.261 -172.137 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 1.611 ' HE2' ' CE1' ' A' ' 12' ' ' PHE . 45.6 m-85 -119.77 126.96 52.32 Favored 'General case' 0 N--CA 1.404 -2.741 0 CA-C-N 113.181 -1.827 . . . . 0.0 106.973 170.529 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.421 ' CB ' HG22 ' A' ' 42' ' ' ILE . . . -108.98 121.76 45.81 Favored 'General case' 0 C--N 1.27 -2.869 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.312 -178.241 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.68 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -104.77 119.57 39.3 Favored 'General case' 0 N--CA 1.401 -2.887 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.939 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 72.4 mtm -104.07 159.01 16.03 Favored 'General case' 0 C--N 1.312 -1.058 0 C-N-CA 123.172 0.589 . . . . 0.0 110.215 179.406 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.4 tttp -65.37 116.22 6.45 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.553 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.13 -8.04 64.75 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.627 178.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 65.8 m-85 -128.72 147.85 66.09 Favored Pre-proline 0 N--CA 1.444 -0.744 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -178.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -68.7 170.89 14.26 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.845 2.363 . . . . 0.0 111.909 177.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' HIS . . . . . 0.548 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 74.6 m80 -60.83 111.64 1.73 Allowed 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.114 178.229 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 4.0 t-105 -101.85 136.89 19.44 Favored Pre-proline 0 C--N 1.313 -1.002 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -176.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -64.7 117.64 4.7 Favored 'Trans proline' 0 C--O 1.241 0.649 0 C-N-CA 121.779 1.653 . . . . 0.0 110.432 176.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -141.16 167.38 22.32 Favored 'General case' 0 N--CA 1.413 -2.282 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.69 -174.749 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 32.7 ttt180 -109.96 138.35 46.46 Favored 'General case' 0 C--N 1.291 -1.969 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 176.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 64.4 t -74.68 111.68 10.92 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.068 0 N-CA-C 103.501 -2.777 . . . . 0.0 103.501 166.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -86.26 -177.58 6.27 Favored 'General case' 0 C--N 1.282 -2.329 0 C-N-CA 119.543 -0.863 . . . . 0.0 112.105 -169.728 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 . . . . . 0 C--N 1.294 -1.838 0 CA-C-O 121.966 0.889 . . . . 0.0 112.861 -171.776 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 62.5 mttp . . . . . 0 N--CA 1.429 -1.497 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 96.5 mt -97.42 139.93 21.72 Favored Pre-proline 0 C--N 1.293 -1.876 0 O-C-N 123.995 0.809 . . . . 0.0 109.87 -179.333 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -70.29 123.45 9.94 Favored 'Trans proline' 0 N--CA 1.46 -0.475 0 C-N-CA 122.484 2.123 . . . . 0.0 110.247 177.512 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.421 HG22 ' CB ' ' A' ' 13' ' ' ALA . 42.4 mm -117.8 120.52 64.9 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.788 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 -177.072 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.641 ' HD1' ' CD2' ' A' ' 43' ' ' PHE . 93.0 t80 -105.22 117.68 34.63 Favored 'General case' 0 C--N 1.286 -2.194 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 178.733 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 1.625 ' HD1' ' CD2' ' A' ' 44' ' ' PHE . 89.6 m-85 -82.93 135.69 34.82 Favored 'General case' 0 C--N 1.308 -1.212 0 CA-C-O 121.435 0.636 . . . . 0.0 112.332 179.493 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -85.48 151.72 23.75 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.469 178.155 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.422 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 80.84 -20.91 5.96 Favored Glycine 0 C--N 1.309 -0.939 0 C-N-CA 124.553 1.073 . . . . 0.0 114.124 177.657 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.48 ' CG2' ' HA3' ' A' ' 76' ' ' GLY . 37.0 p -119.8 -23.14 6.55 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-N 117.279 0.539 . . . . 0.0 110.201 175.084 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 43.4 m170 67.96 22.37 8.6 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.282 -178.263 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -71.75 164.2 26.41 Favored 'General case' 0 C--N 1.346 0.418 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 176.254 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.4 m -138.37 140.92 39.62 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -179.806 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -141.41 177.68 7.95 Favored 'General case' 0 C--N 1.289 -2.034 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.183 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 1.598 ' HE1' ' CE2' ' A' ' 52' ' ' PHE . 95.7 m-85 -134.36 117.57 16.49 Favored 'General case' 0 N--CA 1.434 -1.238 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 176.755 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 90.7 mt -127.61 169.27 13.94 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.257 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.26 162.8 29.84 Favored Glycine 0 N--CA 1.413 -2.846 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -66.78 -5.98 14.52 Favored 'Trans proline' 0 N--CA 1.487 1.125 0 C-N-CA 123.88 3.053 . . . . 0.0 112.578 -179.476 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.3 ptmm? -97.89 -6.98 31.2 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 114.875 -1.057 . . . . 0.0 111.686 177.186 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -112.52 6.26 18.4 Favored 'General case' 0 C--N 1.294 -1.806 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.995 -175.432 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.447 HG13 ' CE2' ' A' ' 5' ' ' PHE . 14.2 pt -127.28 147.06 32.16 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 CA-C-N 114.853 -1.067 . . . . 0.0 110.396 179.39 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 -140.26 147.62 50.82 Favored Pre-proline 0 C--N 1.302 -1.474 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -177.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -62.09 132.34 38.73 Favored 'Trans proline' 0 N--CA 1.481 0.749 0 C-N-CA 123.315 2.677 . . . . 0.0 113.955 -176.617 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 1.67 ' HE2' ' CE1' ' A' ' 61' ' ' TYR . 77.8 t80 -61.03 -40.7 94.59 Favored 'General case' 0 C--O 1.207 -1.136 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.652 -178.406 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 m -60.45 -40.15 90.11 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.81 -175.583 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -95.25 -4.08 46.39 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 115.763 -0.653 . . . . 0.0 112.193 -174.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.419 ' HA ' ' HE2' ' A' ' 67' ' ' LYS . 29.6 m-80 -125.64 15.36 8.15 Favored 'General case' 0 N--CA 1.446 -0.645 0 CA-C-O 120.427 0.156 . . . . 0.0 111.404 178.589 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 57.2 tttp -69.58 -36.2 76.04 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 121.627 0.727 . . . . 0.0 109.545 -178.355 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.538 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -75.15 -22.42 58.13 Favored 'General case' 0 N--CA 1.416 -2.131 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.964 176.502 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.538 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 7.8 mtmm -84.84 -54.08 4.91 Favored 'General case' 0 N--CA 1.437 -1.09 0 CA-C-N 115.743 -0.662 . . . . 0.0 112.621 179.661 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 1.656 ' HE1' ' CE2' ' A' ' 68' ' ' TYR . 61.4 m-85 -122.0 -4.21 9.07 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -173.116 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.69 52.21 4.38 Favored Glycine 0 N--CA 1.468 0.826 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.103 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.2 ptpt -133.01 156.27 80.24 Favored Pre-proline 0 C--N 1.306 -1.325 0 C-N-CA 123.456 0.703 . . . . 0.0 109.676 -177.464 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.425 ' HB3' ' OD1' ' A' ' 78' ' ' ASN . 85.9 Cg_exo -49.15 153.11 4.52 Favored 'Trans proline' 0 C--N 1.355 0.897 0 C-N-CA 123.781 2.987 . . . . 0.0 115.889 -177.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -136.53 -173.38 3.4 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 114.545 -1.207 . . . . 0.0 109.106 179.634 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 47.5 mmtm -100.8 -14.54 17.97 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 179.222 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 4.1 mmm180 -70.79 123.53 22.17 Favored 'General case' 0 N--CA 1.436 -1.147 0 CA-C-O 121.186 0.517 . . . . 0.0 110.697 175.031 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 16.6 tppt? -68.38 126.4 29.49 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 174.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.48 ' HA3' ' CG2' ' A' ' 47' ' ' THR . . . 108.56 -19.53 31.1 Favored Glycine 0 N--CA 1.416 -2.668 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -177.013 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 0.422 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 16.6 t80 -76.31 -45.49 32.14 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -179.584 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.425 ' OD1' ' HB3' ' A' ' 71' ' ' PRO . 52.7 m-80 -69.91 -39.94 75.89 Favored 'General case' 0 CA--C 1.5 -0.957 0 CA-C-O 121.942 0.877 . . . . 0.0 108.957 -179.624 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 30.4 mp0 -64.87 -36.22 83.66 Favored 'General case' 0 N--CA 1.425 -1.72 0 CA-C-N 114.06 -1.427 . . . . 0.0 109.468 177.317 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.35 -31.48 68.64 Favored Glycine 0 CA--C 1.49 -1.49 0 CA-C-N 115.385 -0.825 . . . . 0.0 112.431 178.756 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.422 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 96.0 mt -58.84 -39.98 82.89 Favored 'General case' 0 C--O 1.212 -0.913 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 174.481 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 83.1 t90 -67.97 -48.7 65.11 Favored 'General case' 0 N--CA 1.432 -1.365 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.283 177.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -59.31 -43.4 92.64 Favored 'General case' 0 C--O 1.207 -1.135 0 N-CA-C 113.5 0.926 . . . . 0.0 113.5 -179.258 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.1 tt -71.98 -28.44 30.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 C-N-CA 120.23 -0.588 . . . . 0.0 112.209 -174.354 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -86.86 -17.37 33.49 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 112.062 0.393 . . . . 0.0 112.062 179.457 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 32.1 m-80 -114.46 -51.19 2.77 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-O 121.366 0.603 . . . . 0.0 112.471 -175.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.8 t30 -127.93 68.16 75.0 Favored Pre-proline 0 C--N 1.305 -1.364 0 O-C-N 121.883 -0.511 . . . . 0.0 110.678 -178.369 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -75.77 -5.83 16.86 Favored 'Trans proline' 0 C--N 1.348 0.508 0 C-N-CA 122.025 1.817 . . . . 0.0 112.208 -177.591 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 19.8 pttp . . . . . 0 C--N 1.299 -1.592 0 CA-C-N 114.737 -1.119 . . . . 0.0 110.429 -178.779 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 . . . . . 0 N--CA 1.42 -1.965 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.1 mttp -105.45 153.53 39.69 Favored Pre-proline 0 C--N 1.298 -1.656 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.638 -172.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -62.44 116.51 3.56 Favored 'Trans proline' 0 N--CA 1.457 -0.667 0 N-CA-C 107.921 -1.607 . . . . 0.0 107.921 170.397 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 108.62 -10.34 35.35 Favored Glycine 0 N--CA 1.426 -1.974 0 C-N-CA 120.833 -0.698 . . . . 0.0 112.172 -175.426 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -73.09 154.96 40.18 Favored 'General case' 0 C--O 1.253 1.245 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 -178.397 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.418 HD22 ' HB2' ' A' ' 88' ' ' PRO . 79.9 mt -105.36 123.67 48.26 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 -173.439 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.9 pp -140.28 177.56 4.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 CA-C-O 122.058 0.932 . . . . 0.0 112.934 -174.14 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 1.609 ' HD2' ' CD1' ' A' ' 12' ' ' PHE . 74.6 m-85 -110.31 129.54 55.72 Favored 'General case' 0 C--N 1.284 -2.263 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 170.662 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -108.0 118.49 36.88 Favored 'General case' 0 C--N 1.277 -2.569 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.136 -176.345 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.685 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -107.14 122.64 46.91 Favored 'General case' 0 N--CA 1.4 -2.957 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.384 -179.092 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 30.2 mtm -127.08 158.25 37.49 Favored 'General case' 0 CA--C 1.493 -1.22 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 176.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -64.17 117.23 6.84 Favored 'General case' 0 C--N 1.307 -1.255 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 178.44 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.05 -16.11 57.47 Favored Glycine 0 C--O 1.249 1.034 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 -178.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . 1.659 ' HD1' ' CD2' ' A' ' 18' ' ' TYR . 8.9 m-85 -105.47 151.04 39.65 Favored Pre-proline 0 N--CA 1.43 -1.466 0 C-N-CA 123.175 0.59 . . . . 0.0 109.623 178.811 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -83.12 171.69 11.3 Favored 'Trans proline' 0 N--CA 1.439 -1.685 0 C-N-CA 122.122 1.882 . . . . 0.0 107.416 169.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' HIS . . . . . 0.484 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 70.6 m80 -61.83 109.97 1.4 Allowed 'General case' 0 CA--C 1.542 0.648 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 174.023 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -105.15 136.79 19.14 Favored Pre-proline 0 C--N 1.305 -1.342 0 C-N-CA 123.131 0.572 . . . . 0.0 109.53 -170.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -65.02 117.84 4.9 Favored 'Trans proline' 0 N--CA 1.455 -0.754 0 C-N-CA 121.321 1.347 . . . . 0.0 110.433 177.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.92 166.61 24.15 Favored 'General case' 0 N--CA 1.413 -2.292 0 CA-C-O 121.279 0.561 . . . . 0.0 110.157 -175.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.46 ' HB2' ' CE2' ' A' ' 45' ' ' PHE . 31.7 ttp85 -116.68 145.83 43.17 Favored 'General case' 0 C--N 1.283 -2.303 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.554 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.6 t -76.49 123.88 33.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 105.302 -2.11 . . . . 0.0 105.302 171.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -90.93 -177.1 4.85 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -173.478 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.411 ' CD ' HH22 ' A' ' 24' ' ' ARG . 15.0 mp0 . . . . . 0 N--CA 1.423 -1.809 0 CA-C-O 121.87 0.843 . . . . 0.0 111.499 -176.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.548 ' HE2' ' N ' ' A' ' 54' ' ' GLY . 30.3 mtpt . . . . . 0 N--CA 1.429 -1.475 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 91.8 mt -88.16 147.05 39.54 Favored Pre-proline 0 C--N 1.304 -1.388 0 C-N-CA 122.721 0.408 . . . . 0.0 110.369 -176.033 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -71.54 123.87 9.84 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.438 2.092 . . . . 0.0 110.295 177.419 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 49.3 mm -119.02 125.17 74.27 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 O-C-N 122.064 -0.398 . . . . 0.0 110.613 -176.344 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.644 ' HE2' ' CE1' ' A' ' 43' ' ' PHE . 59.0 t80 -104.77 114.52 28.79 Favored 'General case' 0 C--N 1.288 -2.104 0 C-N-CA 123.431 0.692 . . . . 0.0 109.144 177.766 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -77.97 137.27 38.22 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.014 0.435 . . . . 0.0 111.681 178.035 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 1.628 ' HD2' ' CD1' ' A' ' 45' ' ' PHE . 70.5 m-85 -89.16 156.44 18.79 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.492 177.168 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.43 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 74.02 -20.78 1.44 Allowed Glycine 0 N--CA 1.469 0.878 0 C-N-CA 124.578 1.085 . . . . 0.0 114.454 178.734 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.2 p -119.15 -22.67 7.08 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 173.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 11.2 m170 65.87 24.7 11.27 Favored 'General case' 0 C--N 1.348 0.519 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.107 179.06 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -73.34 167.39 21.33 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 115.388 -0.824 . . . . 0.0 108.904 176.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.6 m -137.82 140.81 40.71 Favored 'General case' 0 C--N 1.287 -2.122 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -145.37 -179.32 6.58 Favored 'General case' 0 C--N 1.293 -1.859 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.131 -178.202 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 1.653 ' HD2' ' CD1' ' A' ' 52' ' ' PHE . 83.4 m-85 -132.2 110.71 10.84 Favored 'General case' 0 C--O 1.246 0.886 0 CA-C-N 115.217 -0.902 . . . . 0.0 109.427 177.193 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.437 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 93.8 mt -129.48 154.64 46.8 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.656 -177.415 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.548 ' N ' ' HE2' ' A' ' 39' ' ' LYS . . . -95.87 176.34 33.32 Favored Glycine 0 N--CA 1.432 -1.585 0 C-N-CA 120.016 -1.088 . . . . 0.0 111.301 -174.831 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -66.22 -7.53 17.63 Favored 'Trans proline' 0 C--O 1.239 0.566 0 C-N-CA 122.966 2.444 . . . . 0.0 112.311 -178.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.7 mtpp -97.3 -15.16 20.9 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.238 177.054 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.437 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 40.9 m-20 -93.39 -14.38 26.89 Favored 'General case' 0 CA--C 1.49 -1.346 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.084 -178.488 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.461 ' HA ' ' O ' ' A' ' 12' ' ' PHE . 17.9 pt -119.12 148.58 21.96 Favored 'Isoleucine or valine' 0 C--O 1.268 2.04 0 CA-C-O 122.482 1.134 . . . . 0.0 112.849 -171.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 80.8 m-85 -136.08 133.25 19.56 Favored Pre-proline 0 C--N 1.292 -1.895 0 CA-C-N 113.885 -1.507 . . . . 0.0 106.951 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . 0.471 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 35.8 Cg_endo -64.12 127.91 20.45 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.881 2.388 . . . . 0.0 113.147 -177.2 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 1.668 ' HD1' ' CD2' ' A' ' 61' ' ' TYR . 72.0 t80 -58.86 -35.38 72.85 Favored 'General case' 0 C--O 1.197 -1.674 0 CA-C-N 114.062 -1.426 . . . . 0.0 112.915 -174.78 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.421 ' HB3' ' OE1' ' A' ' 63' ' ' GLU . 28.2 t -67.63 -52.19 41.15 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.191 0.52 . . . . 0.0 110.478 -177.808 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.471 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 2.6 mp0 -81.32 -5.67 58.07 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.128 -175.58 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.413 ' HA ' ' HE2' ' A' ' 67' ' ' LYS . 24.2 m-80 -126.59 15.12 7.61 Favored 'General case' 0 C--N 1.311 -1.079 0 C-N-CA 122.893 0.477 . . . . 0.0 111.557 -179.558 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -67.85 -35.89 79.36 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-O 121.722 0.772 . . . . 0.0 110.093 -179.488 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.575 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -72.01 -28.31 63.31 Favored 'General case' 0 N--CA 1.408 -2.566 0 CA-C-N 115.648 -0.705 . . . . 0.0 111.99 176.864 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.575 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 7.0 mtmm -80.2 -58.17 3.27 Favored 'General case' 0 N--CA 1.439 -0.979 0 CA-C-N 115.729 -0.668 . . . . 0.0 112.452 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 1.656 ' HD2' ' CD1' ' A' ' 68' ' ' TYR . 76.4 m-85 -113.67 -10.98 13.02 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -172.368 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.4 56.22 4.09 Favored Glycine 0 C--N 1.314 -0.648 0 C-N-CA 121.332 -0.461 . . . . 0.0 112.834 -177.556 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.424 ' O ' ' HE2' ' A' ' 77' ' ' PHE . 4.5 ptpp? -132.54 147.42 65.53 Favored Pre-proline 0 C--N 1.303 -1.416 0 CA-C-O 119.244 -0.408 . . . . 0.0 110.084 178.702 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.473 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 87.0 Cg_exo -50.2 156.92 3.36 Favored 'Trans proline' 0 C--N 1.355 0.914 0 C-N-CA 124.031 3.154 . . . . 0.0 114.803 -179.413 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -143.04 -173.34 3.88 Favored 'General case' 0 N--CA 1.433 -1.29 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.532 179.189 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . 0.458 ' HB2' ' HZ2' ' A' ' 73' ' ' LYS . 0.1 OUTLIER -93.79 1.11 56.55 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.047 -179.809 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 30.9 mmt180 -82.79 120.6 25.83 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.687 176.72 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.431 ' HD3' ' N ' ' A' ' 76' ' ' GLY . 8.1 tmtt? -70.03 127.15 31.85 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 175.316 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.431 ' N ' ' HD3' ' A' ' 75' ' ' LYS . . . 106.8 -25.41 22.7 Favored Glycine 0 CA--C 1.501 -0.817 0 N-CA-C 110.598 -1.001 . . . . 0.0 110.598 -178.821 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 1.659 ' HE1' ' CE2' ' A' ' 77' ' ' PHE . 54.1 t80 -72.11 -42.06 66.51 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-O 121.74 0.781 . . . . 0.0 109.557 -177.432 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.473 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 87.2 m-20 -79.07 -33.81 44.24 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.668 -173.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -71.55 -33.37 69.06 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 175.111 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.34 -37.26 70.52 Favored Glycine 0 N--CA 1.432 -1.601 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.432 177.395 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 43.9 tp -59.74 -33.58 71.83 Favored 'General case' 0 N--CA 1.434 -1.249 0 C-N-CA 124.007 0.923 . . . . 0.0 108.855 175.03 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 82.0 t90 -72.46 -51.02 21.98 Favored 'General case' 0 N--CA 1.434 -1.236 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.022 175.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 35.6 mt-10 -53.8 -49.76 67.63 Favored 'General case' 0 C--O 1.206 -1.189 0 N-CA-C 112.797 0.666 . . . . 0.0 112.797 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 19.3 tt -67.94 -23.87 29.69 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 N-CA-C 112.573 0.583 . . . . 0.0 112.573 -173.782 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -94.31 -22.67 18.21 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 121.409 0.623 . . . . 0.0 110.686 -176.417 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 28.4 m-80 -105.97 -55.17 2.37 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-O 121.435 0.636 . . . . 0.0 111.785 -176.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 67.4 t30 -127.62 72.61 78.13 Favored Pre-proline 0 C--N 1.312 -1.032 0 C-N-CA 119.969 -0.693 . . . . 0.0 110.228 179.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.418 ' HB2' HD22 ' A' ' 10' ' ' LEU . 57.0 Cg_endo -74.81 -6.76 18.57 Favored 'Trans proline' 0 C--O 1.221 -0.326 0 C-N-CA 122.128 1.886 . . . . 0.0 112.815 -176.223 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.4 pttm . . . . . 0 C--N 1.303 -1.413 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.986 -178.085 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 . . . . . 0 N--CA 1.425 -1.717 0 N-CA-C 107.753 -1.202 . . . . 0.0 107.753 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.453 ' H ' ' HB2' ' A' ' 9' ' ' ASP . 32.3 mttp -104.76 158.36 32.18 Favored Pre-proline 0 C--N 1.298 -1.661 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -174.793 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.46 ' HB3' ' HA ' ' A' ' 27' ' ' GLU . 37.1 Cg_exo -63.46 117.02 3.99 Favored 'Trans proline' 0 N--CA 1.451 -0.986 0 N-CA-C 107.385 -1.813 . . . . 0.0 107.385 167.296 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 101.66 -1.42 52.72 Favored Glycine 0 N--CA 1.435 -1.421 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.458 -175.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.453 ' HB2' ' H ' ' A' ' 6' ' ' LYS . 4.9 t70 -78.11 154.94 30.82 Favored 'General case' 0 C--O 1.254 1.339 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 64.3 mt -102.54 124.83 48.82 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.44 -172.542 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.9 pt -141.39 -177.11 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.825 0 CA-C-O 122.295 1.045 . . . . 0.0 112.82 -174.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 1.611 ' HD1' ' CD2' ' A' ' 12' ' ' PHE . 76.4 m-85 -120.83 126.49 50.2 Favored 'General case' 0 N--CA 1.417 -2.099 0 C-N-CA 126.232 1.813 . . . . 0.0 106.241 170.771 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.408 ' CB ' HG22 ' A' ' 42' ' ' ILE . . . -108.96 128.85 55.3 Favored 'General case' 0 C--N 1.27 -2.859 0 O-C-N 123.625 0.578 . . . . 0.0 109.632 -178.022 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.688 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -114.36 122.13 45.74 Favored 'General case' 0 N--CA 1.407 -2.596 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.707 -179.593 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 63.4 mtm -116.31 158.83 22.8 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 177.218 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -63.94 117.13 6.56 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 174.454 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.54 -5.52 54.73 Favored Glycine 0 C--N 1.315 -0.622 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -176.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . 1.655 ' HE2' ' CE1' ' A' ' 18' ' ' TYR . 21.8 m-85 -126.51 136.57 28.85 Favored Pre-proline 0 N--CA 1.436 -1.164 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -179.782 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_exo -70.21 171.12 15.54 Favored 'Trans proline' 0 N--CA 1.444 -1.399 0 C-N-CA 122.212 1.941 . . . . 0.0 108.628 169.427 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' HIS . . . . . 0.503 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 80.2 m80 -63.55 110.75 2.09 Favored 'General case' 0 C--N 1.312 -1.049 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.722 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . 0.409 ' O ' ' HA ' ' A' ' 12' ' ' PHE . 10.4 t-105 -107.88 136.65 19.7 Favored Pre-proline 0 C--N 1.306 -1.304 0 C-N-CA 123.316 0.646 . . . . 0.0 109.885 -171.91 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -62.97 118.14 5.04 Favored 'Trans proline' 0 C--O 1.244 0.782 0 C-N-CA 122.214 1.943 . . . . 0.0 111.137 178.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -139.7 166.2 25.24 Favored 'General case' 0 N--CA 1.409 -2.5 0 CA-C-O 121.525 0.679 . . . . 0.0 111.285 -176.145 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.534 HH21 ' CD ' ' A' ' 27' ' ' GLU . 17.2 ttt-85 -111.49 139.01 47.27 Favored 'General case' 0 C--N 1.285 -2.204 0 C-N-CA 124.179 0.992 . . . . 0.0 108.404 177.729 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 58.9 t -75.84 121.86 28.6 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 N-CA-C 104.986 -2.228 . . . . 0.0 104.986 170.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -84.02 172.61 11.86 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 -173.275 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.534 ' CD ' HH21 ' A' ' 24' ' ' ARG . 4.4 mp0 . . . . . 0 N--CA 1.411 -2.398 0 CA-C-O 122.256 1.026 . . . . 0.0 112.522 -177.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 86.5 mttt . . . . . 0 N--CA 1.414 -2.266 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 84.4 mt -106.81 146.29 32.79 Favored Pre-proline 0 C--N 1.282 -2.329 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 178.654 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -73.62 128.95 13.1 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 121.888 1.725 . . . . 0.0 109.395 176.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.408 HG22 ' CB ' ' A' ' 13' ' ' ALA . 37.0 mm -118.41 125.73 74.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.987 -0.446 . . . . 0.0 110.799 -174.166 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -109.71 115.34 29.68 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 176.726 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -79.04 139.09 38.22 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-O 121.0 0.429 . . . . 0.0 111.794 179.003 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 1.638 ' HD1' ' CD2' ' A' ' 45' ' ' PHE . 69.3 m-85 -90.26 160.4 16.19 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.385 177.141 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.522 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 73.06 -21.53 1.01 Allowed Glycine 0 C--N 1.311 -0.828 0 C-N-CA 124.932 1.253 . . . . 0.0 114.315 179.228 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.444 HG22 HH21 ' A' ' 74' ' ' ARG . 37.1 p -119.98 -22.3 6.78 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 117.559 0.68 . . . . 0.0 109.685 173.037 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.1 m170 66.88 24.87 9.62 Favored 'General case' 0 C--N 1.35 0.629 0 CA-C-N 115.406 -0.815 . . . . 0.0 111.153 -179.517 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -71.94 167.17 20.65 Favored 'General case' 0 C--N 1.347 0.462 0 CA-C-N 115.179 -0.919 . . . . 0.0 108.728 175.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.9 m -137.45 145.95 43.74 Favored 'General case' 0 C--N 1.289 -2.034 0 O-C-N 121.576 -0.702 . . . . 0.0 109.581 -178.678 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -150.57 178.43 9.08 Favored 'General case' 0 C--N 1.308 -1.197 0 O-C-N 123.533 0.521 . . . . 0.0 111.404 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 1.632 ' HE1' ' CE2' ' A' ' 52' ' ' PHE . 98.2 m-85 -134.26 114.74 13.35 Favored 'General case' 0 C--O 1.262 1.745 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.575 175.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 94.6 mt -130.99 158.75 39.45 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -179.159 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.0 172.55 36.92 Favored Glycine 0 N--CA 1.429 -1.796 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.89 -6.84 15.14 Favored 'Trans proline' 0 C--O 1.21 -0.91 0 C-N-CA 123.046 2.497 . . . . 0.0 112.438 -178.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.2 ptmm? -97.52 -5.02 36.76 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 115.333 -0.849 . . . . 0.0 111.764 179.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -115.86 5.8 14.14 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -177.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.8 pt -126.53 150.63 32.37 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 CA-C-N 115.073 -0.967 . . . . 0.0 110.487 -178.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 -131.94 135.32 26.45 Favored Pre-proline 0 C--O 1.188 -2.167 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 177.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . 0.529 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 37.8 Cg_endo -66.82 131.01 24.53 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 C-N-CA 122.841 2.361 . . . . 0.0 114.007 -177.791 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 1.597 ' HD1' ' CD2' ' A' ' 61' ' ' TYR . 65.4 t80 -63.54 -33.79 76.36 Favored 'General case' 0 C--O 1.204 -1.328 0 CA-C-N 114.889 -1.05 . . . . 0.0 112.159 -174.331 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.15 -54.31 35.81 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -177.121 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.529 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 2.1 pm0 -89.68 1.32 56.2 Favored 'General case' 0 N--CA 1.433 -1.298 0 N-CA-C 114.276 1.213 . . . . 0.0 114.276 -178.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.417 ' HA ' ' HE2' ' A' ' 67' ' ' LYS . 26.8 m-80 -122.8 15.18 10.11 Favored 'General case' 0 C--N 1.314 -0.935 0 C-N-CA 123.327 0.651 . . . . 0.0 111.132 175.613 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.459 ' HZ3' ' CG ' ' A' ' 85' ' ' ASP . 16.5 ttmm -65.13 -33.32 75.75 Favored 'General case' 0 N--CA 1.476 0.855 0 CA-C-O 121.579 0.704 . . . . 0.0 110.189 179.473 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.569 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -80.25 -28.95 38.35 Favored 'General case' 0 N--CA 1.403 -2.819 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.098 177.33 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.569 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 8.3 mttm -76.71 -59.09 2.92 Favored 'General case' 0 CA--C 1.505 -0.778 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.253 -179.24 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 1.629 ' HE1' ' CE2' ' A' ' 68' ' ' TYR . 70.0 m-85 -112.1 -4.28 14.49 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -173.443 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . 0.42 ' HA3' ' O ' ' A' ' 65' ' ' LYS . . . -75.64 51.76 2.68 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 121.715 -0.279 . . . . 0.0 113.11 -179.496 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 4.3 ptpp? -132.44 135.71 26.75 Favored Pre-proline 0 C--N 1.311 -1.09 0 O-C-N 122.459 -0.436 . . . . 0.0 110.161 179.144 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -66.91 128.24 18.42 Favored 'Trans proline' 0 C--O 1.25 1.111 0 C-N-CA 122.787 2.325 . . . . 0.0 116.316 -171.178 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.428 ' N ' HD21 ' A' ' 72' ' ' ASN . 0.9 OUTLIER -84.69 -168.93 2.39 Favored 'General case' 0 CA--C 1.483 -1.633 0 CA-C-N 113.784 -1.553 . . . . 0.0 108.165 175.311 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . 0.408 ' HA ' ' HD3' ' A' ' 73' ' ' LYS . 39.4 mmtm -108.53 10.49 27.19 Favored 'General case' 0 C--N 1.287 -2.146 0 CA-C-O 121.842 0.829 . . . . 0.0 109.475 175.36 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . 0.444 HH21 HG22 ' A' ' 47' ' ' THR . 4.5 mmm-85 -77.45 122.8 25.69 Favored 'General case' 0 N--CA 1.417 -2.099 0 CA-C-N 115.04 -0.982 . . . . 0.0 109.199 170.664 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 15.6 tppt? -65.17 129.54 40.1 Favored 'General case' 0 N--CA 1.429 -1.523 0 N-CA-C 107.551 -1.278 . . . . 0.0 107.551 173.58 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.522 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.21 -25.19 20.9 Favored Glycine 0 N--CA 1.415 -2.742 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -176.142 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -76.63 -41.13 47.03 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-O 121.356 0.598 . . . . 0.0 109.39 -178.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.479 ' N ' HD21 ' A' ' 78' ' ' ASN . 0.7 OUTLIER -71.31 -43.85 66.28 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 -176.289 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 25.2 mp0 -63.11 -41.77 99.42 Favored 'General case' 0 N--CA 1.428 -1.554 0 CA-C-N 113.577 -1.647 . . . . 0.0 109.634 177.712 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -65.38 -37.6 94.02 Favored Glycine 0 N--CA 1.44 -1.052 0 CA-C-N 115.449 -0.796 . . . . 0.0 112.804 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 87.9 mt -59.56 -35.12 73.62 Favored 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 176.094 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.3 t90 -74.29 -50.32 19.38 Favored 'General case' 0 N--CA 1.425 -1.712 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.295 177.501 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 26.8 mt-10 -53.74 -49.94 67.06 Favored 'General case' 0 C--O 1.188 -2.175 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -179.512 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.8 tt -67.99 -23.48 29.09 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 N-CA-C 112.256 0.465 . . . . 0.0 112.256 -173.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . 0.459 ' CG ' ' HZ3' ' A' ' 65' ' ' LYS . 15.2 t70 -94.21 -32.52 13.66 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-O 121.497 0.665 . . . . 0.0 110.05 -175.053 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.514 ' N ' HD21 ' A' ' 86' ' ' ASN . 0.8 OUTLIER -103.43 -44.89 5.02 Favored 'General case' 0 C--O 1.257 1.456 0 CA-C-O 121.911 0.862 . . . . 0.0 111.504 -176.679 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 60.7 t30 -131.76 61.32 57.65 Favored Pre-proline 0 C--N 1.296 -1.73 0 C-N-CA 119.983 -0.687 . . . . 0.0 112.329 -176.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -71.12 -7.68 21.91 Favored 'Trans proline' 0 C--N 1.372 1.789 0 C-N-CA 122.19 1.926 . . . . 0.0 110.465 179.078 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 22.7 pttm . . . . . 0 C--N 1.307 -1.249 0 CA-C-N 113.159 -1.837 . . . . 0.0 109.197 -175.49 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . 1.63 ' HE2' ' CE1' ' A' ' 5' ' ' PHE . 80.5 m-85 . . . . . 0 N--CA 1.397 -3.124 0 CA-C-O 121.514 0.673 . . . . 0.0 109.399 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 25.9 mtmm -120.67 156.65 55.82 Favored Pre-proline 0 C--N 1.274 -2.677 0 CA-C-N 113.886 -1.506 . . . . 0.0 107.695 -172.287 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.41 ' HB3' ' HA ' ' A' ' 27' ' ' GLU . 52.5 Cg_exo -57.4 120.94 9.19 Favored 'Trans proline' 0 N--CA 1.461 -0.436 0 C-N-CA 121.825 1.683 . . . . 0.0 110.566 176.311 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.22 -24.28 10.03 Favored Glycine 0 N--CA 1.426 -2.029 0 CA-C-O 119.138 -0.812 . . . . 0.0 113.452 -178.426 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 32.8 m-20 -63.3 137.31 58.14 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 117.769 0.784 . . . . 0.0 111.725 -179.181 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 95.6 mt -90.18 126.58 35.86 Favored 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 176.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -142.08 -174.97 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-O 122.197 0.998 . . . . 0.0 112.899 -174.497 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 1.65 ' HE1' ' CE2' ' A' ' 12' ' ' PHE . 34.3 m-85 -115.71 130.0 56.69 Favored 'General case' 0 C--N 1.28 -2.431 0 CA-C-N 114.083 -1.417 . . . . 0.0 107.416 170.335 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.423 ' HB2' HD11 ' A' ' 53' ' ' LEU . . . -107.43 114.36 28.31 Favored 'General case' 0 C--N 1.275 -2.654 0 CA-C-N 114.866 -1.061 . . . . 0.0 109.426 -173.372 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.655 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.9 OUTLIER -103.76 128.24 51.16 Favored 'General case' 0 C--N 1.264 -3.129 0 CA-C-N 114.343 -1.299 . . . . 0.0 109.54 -178.597 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 68.2 mtm -113.84 158.25 21.27 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -70.26 116.77 11.0 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 120.607 -0.437 . . . . 0.0 109.879 -178.626 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 93.99 0.11 66.36 Favored Glycine 0 N--CA 1.448 -0.518 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.97 178.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . 1.638 ' HD1' ' CD2' ' A' ' 18' ' ' TYR . 99.5 m-85 -129.75 152.23 79.47 Favored Pre-proline 0 N--CA 1.439 -0.996 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 -177.825 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -68.97 170.33 15.87 Favored 'Trans proline' 0 N--CA 1.457 -0.652 0 C-N-CA 122.4 2.067 . . . . 0.0 112.197 177.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 57.5 m80 -71.5 114.26 9.4 Favored 'General case' 0 CA--C 1.552 1.02 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.605 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 11.1 t-105 -101.35 136.91 19.55 Favored Pre-proline 0 C--N 1.31 -1.127 0 C-N-CA 123.142 0.577 . . . . 0.0 109.468 -176.604 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -64.77 117.87 4.91 Favored 'Trans proline' 0 CA--C 1.542 0.911 0 C-N-CA 121.978 1.786 . . . . 0.0 110.741 177.624 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.55 167.12 24.5 Favored 'General case' 0 N--CA 1.426 -1.66 0 CA-C-O 121.242 0.544 . . . . 0.0 111.214 -174.512 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 41.9 ttt-85 -115.4 143.52 45.17 Favored 'General case' 0 C--N 1.291 -1.965 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 179.552 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 64.9 t -79.21 114.2 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 104.385 -2.45 . . . . 0.0 104.385 168.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -90.74 -179.55 5.55 Favored 'General case' 0 C--N 1.29 -1.985 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.878 -171.45 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.41 ' HA ' ' HB3' ' A' ' 7' ' ' PRO . 32.2 mp0 . . . . . 0 N--CA 1.439 -0.993 0 CA-C-O 121.948 0.88 . . . . 0.0 112.593 -175.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.422 ' HE2' ' N ' ' A' ' 54' ' ' GLY . 8.9 mmpt? . . . . . 0 N--CA 1.429 -1.518 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 87.8 mt -128.41 155.59 78.32 Favored Pre-proline 0 C--N 1.283 -2.298 0 C-N-CA 125.306 1.442 . . . . 0.0 107.253 178.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -71.22 122.8 9.05 Favored 'Trans proline' 0 CA--C 1.536 0.617 0 C-N-CA 121.697 1.598 . . . . 0.0 110.679 177.552 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 49.2 mm -122.51 124.68 71.3 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.083 0 CA-C-O 120.753 0.311 . . . . 0.0 110.355 -176.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 80.9 t80 -106.96 116.41 31.87 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 178.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 1.627 ' HE1' ' CE2' ' A' ' 44' ' ' PHE . 62.2 m-85 -79.27 132.09 36.36 Favored 'General case' 0 C--O 1.244 0.805 0 CA-C-O 121.016 0.436 . . . . 0.0 110.923 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 -82.81 158.6 22.71 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.029 178.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.499 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 74.99 -20.11 1.97 Allowed Glycine 0 C--O 1.256 1.473 0 C-N-CA 124.513 1.054 . . . . 0.0 114.454 178.787 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.407 HG22 ' HA3' ' A' ' 76' ' ' GLY . 31.2 p -119.32 -23.88 6.57 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 122.237 -0.566 . . . . 0.0 109.957 175.273 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 44.8 m170 67.74 23.09 8.71 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.432 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -74.98 166.43 23.67 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 176.352 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.5 m -137.11 145.71 44.21 Favored 'General case' 0 C--N 1.286 -2.192 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 -179.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -146.76 179.52 7.51 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 123.136 0.575 . . . . 0.0 109.71 -179.526 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -131.75 109.29 10.05 Favored 'General case' 0 N--CA 1.432 -1.339 0 N-CA-C 109.003 -0.739 . . . . 0.0 109.003 176.488 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.444 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 88.7 mt -130.26 149.29 52.02 Favored 'General case' 0 C--N 1.287 -2.145 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 -178.826 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.422 ' N ' ' HE2' ' A' ' 39' ' ' LYS . . . -95.37 178.07 35.29 Favored Glycine 0 N--CA 1.417 -2.57 0 C-N-CA 119.707 -1.235 . . . . 0.0 112.104 -174.059 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.1 -9.3 16.6 Favored 'Trans proline' 0 N--CA 1.479 0.667 0 C-N-CA 123.224 2.616 . . . . 0.0 111.831 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 42.6 mtmt -98.29 -1.57 41.5 Favored 'General case' 0 N--CA 1.431 -1.385 0 CA-C-N 114.879 -1.055 . . . . 0.0 110.705 -179.653 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.465 ' O ' ' HB3' ' A' ' 14' ' ' LYS . 36.8 m-20 -115.22 -9.65 12.22 Favored 'General case' 0 CA--C 1.5 -0.957 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.484 -179.436 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 9.5 pt -119.91 152.71 22.65 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.127 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.751 -173.562 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . 1.621 ' HD1' ' CD2' ' A' ' 59' ' ' PHE . 96.8 m-85 -138.99 147.59 54.42 Favored Pre-proline 0 C--N 1.297 -1.68 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -178.416 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . 0.563 ' HG2' ' OE2' ' A' ' 63' ' ' GLU . 11.7 Cg_endo -58.11 139.61 91.1 Favored 'Trans proline' 0 CA--C 1.516 -0.383 0 C-N-CA 122.758 2.305 . . . . 0.0 114.432 -175.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.423 ' O ' ' HB3' ' A' ' 65' ' ' LYS . 16.3 t80 -65.18 -35.84 82.33 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 115.214 -0.903 . . . . 0.0 111.451 177.151 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 10.5 m -48.91 -57.19 6.84 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 112.953 0.723 . . . . 0.0 112.953 -175.319 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.563 ' OE2' ' HG2' ' A' ' 60' ' ' PRO . 0.0 OUTLIER -95.79 -14.43 23.29 Favored 'General case' 0 N--CA 1.432 -1.352 0 N-CA-C 114.903 1.446 . . . . 0.0 114.903 178.867 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.448 ' HB2' ' O ' ' A' ' 60' ' ' PRO . 22.6 m-80 -88.85 -8.0 55.12 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 121.681 -0.637 . . . . 0.0 112.648 179.221 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.447 ' O ' ' HA3' ' A' ' 69' ' ' GLY . 11.6 ptmm? -60.52 -38.28 83.88 Favored 'General case' 0 C--O 1.201 -1.466 0 CA-C-O 121.182 0.515 . . . . 0.0 111.308 -176.89 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 55.9 mm-40 -82.3 -33.85 28.89 Favored 'General case' 0 CA--C 1.477 -1.832 0 C-N-CA 119.453 -0.899 . . . . 0.0 112.426 177.494 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 29.9 mtmm -67.52 -58.92 3.87 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 124.725 1.265 . . . . 0.0 111.526 -176.118 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 84.4 m-85 -111.66 -1.87 15.57 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-O 121.551 0.691 . . . . 0.0 111.447 -175.632 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . 0.447 ' HA3' ' O ' ' A' ' 65' ' ' LYS . . . -91.46 54.68 3.13 Favored Glycine 0 N--CA 1.429 -1.775 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 177.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.431 ' HA ' ' HE3' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -117.93 149.06 44.68 Favored Pre-proline 0 C--N 1.299 -1.623 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 177.709 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.535 ' HB3' ' OD1' ' A' ' 78' ' ' ASN . 70.2 Cg_exo -49.43 146.65 13.8 Favored 'Trans proline' 0 C--O 1.243 0.727 0 C-N-CA 123.338 2.692 . . . . 0.0 114.868 -176.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -131.0 -171.06 2.48 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.829 -178.617 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 45.9 mmtm -104.9 -11.05 16.91 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-O 121.235 0.541 . . . . 0.0 109.618 179.538 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 3.2 mmm180 -73.57 121.64 20.96 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.039 173.176 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.94 127.47 31.54 Favored 'General case' 0 N--CA 1.435 -1.189 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 174.226 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.499 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.86 -21.12 28.15 Favored Glycine 0 N--CA 1.409 -3.132 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.854 -177.61 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 1.669 ' HD2' ' CD1' ' A' ' 77' ' ' PHE . 12.6 t80 -76.26 -43.2 42.91 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 -179.435 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.535 ' OD1' ' HB3' ' A' ' 71' ' ' PRO . 52.5 m-80 -70.66 -43.25 69.51 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.739 -178.808 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -68.36 -33.3 74.04 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 115.362 -0.836 . . . . 0.0 109.771 179.011 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -66.73 -34.94 88.91 Favored Glycine 0 CA--C 1.491 -1.423 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.797 178.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.552 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 98.2 mt -62.26 -41.57 98.56 Favored 'General case' 0 C--O 1.212 -0.915 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 174.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 85.7 t90 -65.5 -45.85 81.97 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.647 178.564 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 54.9 mt-10 -59.72 -47.46 85.56 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 112.837 0.68 . . . . 0.0 112.837 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.8 tt -74.85 -27.48 20.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 C-N-CA 120.248 -0.581 . . . . 0.0 111.959 -175.174 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -84.39 -10.89 57.17 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 122.647 0.379 . . . . 0.0 111.83 178.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 32.3 m-80 -125.32 -56.29 1.53 Allowed 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -175.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -123.62 79.69 55.29 Favored Pre-proline 0 C--N 1.315 -0.932 0 CA-C-O 121.17 0.51 . . . . 0.0 110.479 -177.23 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -68.62 -6.96 19.07 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 123.129 2.552 . . . . 0.0 115.01 -175.155 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 7.3 ptmm? . . . . . 0 C--O 1.263 1.77 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 177.279 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 . . . . . 0 N--CA 1.413 -2.303 0 CA-C-O 121.089 0.471 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.8 mppt? -101.01 151.42 37.62 Favored Pre-proline 0 C--N 1.303 -1.454 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 -174.117 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -59.13 121.85 10.6 Favored 'Trans proline' 0 C--O 1.235 0.328 0 C-N-CA 122.145 1.896 . . . . 0.0 110.278 174.613 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 111.43 -11.37 28.38 Favored Glycine 0 N--CA 1.43 -1.721 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.889 -177.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -79.13 162.41 25.83 Favored 'General case' 0 C--O 1.258 1.532 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 -177.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 99.0 mt -114.56 129.22 56.65 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 123.442 0.697 . . . . 0.0 109.127 -175.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.9 pp -142.75 -177.87 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 CA-C-O 121.856 0.836 . . . . 0.0 112.672 -172.566 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 1.597 ' HD1' ' CD2' ' A' ' 12' ' ' PHE . 66.0 m-85 -119.91 118.86 31.86 Favored 'General case' 0 C--N 1.289 -2.048 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 172.738 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.437 ' HB2' HD13 ' A' ' 53' ' ' LEU . . . -112.67 143.11 44.43 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.46 -173.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.695 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -119.74 123.53 43.97 Favored 'General case' 0 N--CA 1.4 -2.947 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.348 -178.206 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.404 ' HE1' ' CD1' ' A' ' 18' ' ' TYR . 71.2 mtm -113.77 158.53 20.84 Favored 'General case' 0 CA--C 1.5 -0.981 0 N-CA-C 108.52 -0.918 . . . . 0.0 108.52 175.315 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 29.1 tptp -69.61 124.07 22.99 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 120.41 -0.516 . . . . 0.0 109.828 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.97 -12.55 60.7 Favored Glycine 0 C--N 1.303 -1.303 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.086 -176.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . 1.64 ' HE1' ' CE2' ' A' ' 18' ' ' TYR . 72.3 m-85 -117.99 148.87 44.37 Favored Pre-proline 0 N--CA 1.433 -1.315 0 C-N-CA 123.088 0.555 . . . . 0.0 110.501 179.602 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -79.52 171.84 15.27 Favored 'Trans proline' 0 N--CA 1.449 -1.104 0 C-N-CA 122.315 2.01 . . . . 0.0 108.483 170.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' HIS . . . . . 0.524 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 79.7 m80 -57.95 111.86 1.31 Allowed 'General case' 0 CA--C 1.537 0.472 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 175.21 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 10.2 t-105 -112.33 142.27 26.64 Favored Pre-proline 0 C--N 1.294 -1.807 0 C-N-CA 123.983 0.913 . . . . 0.0 108.872 -169.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -62.63 118.49 5.38 Favored 'Trans proline' 0 C--O 1.245 0.847 0 C-N-CA 122.326 2.018 . . . . 0.0 110.57 178.054 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.45 166.98 23.2 Favored 'General case' 0 N--CA 1.41 -2.46 0 CA-C-O 121.702 0.763 . . . . 0.0 111.481 -175.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 36.3 ttt85 -114.38 139.42 49.49 Favored 'General case' 0 C--N 1.276 -2.63 0 C-N-CA 124.255 1.022 . . . . 0.0 110.604 -177.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 50.3 t -82.19 110.15 17.06 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.991 0 N-CA-C 104.025 -2.583 . . . . 0.0 104.025 169.77 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -91.45 168.12 11.77 Favored 'General case' 0 C--N 1.274 -2.707 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.107 -169.387 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.305 -1.361 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 177.509 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 84.1 mttt . . . . . 0 N--CA 1.417 -2.102 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 72.8 mt -118.15 146.98 40.53 Favored Pre-proline 0 C--N 1.285 -2.2 0 O-C-N 124.364 1.04 . . . . 0.0 108.79 -178.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -72.95 123.3 8.8 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 C-N-CA 121.724 1.616 . . . . 0.0 109.524 175.382 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 48.7 mm -115.84 115.6 49.76 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.121 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.21 -175.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.634 ' HD2' ' CD1' ' A' ' 43' ' ' PHE . 74.3 t80 -95.63 115.95 28.16 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 178.58 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 1.639 ' HD1' ' CD2' ' A' ' 44' ' ' PHE . 74.2 m-85 -82.66 133.67 35.16 Favored 'General case' 0 C--N 1.293 -1.86 0 N-CA-C 112.686 0.625 . . . . 0.0 112.686 179.82 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 1.638 ' HE2' ' CE1' ' A' ' 45' ' ' PHE . 71.6 m-85 -84.21 151.0 25.1 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.641 179.523 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.529 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 78.14 -20.45 3.92 Favored Glycine 0 C--N 1.305 -1.188 0 C-N-CA 123.816 0.722 . . . . 0.0 114.109 178.835 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 32.0 p -119.07 -22.66 7.13 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 117.412 0.606 . . . . 0.0 109.939 175.085 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.8 m-70 66.43 22.49 10.71 Favored 'General case' 0 C--N 1.35 0.607 0 C-N-CA 123.667 0.787 . . . . 0.0 112.024 179.393 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -74.31 161.88 29.44 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 176.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.3 m -136.04 135.96 39.85 Favored 'General case' 0 C--N 1.278 -2.503 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 176.749 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -136.28 178.92 6.68 Favored 'General case' 0 C--N 1.277 -2.572 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.151 -177.046 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 1.662 ' HD1' ' CD2' ' A' ' 52' ' ' PHE . 92.9 m-85 -133.49 109.65 9.42 Favored 'General case' 0 C--O 1.262 1.761 0 CA-C-N 115.326 -0.852 . . . . 0.0 108.713 175.066 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.437 HD13 ' HB2' ' A' ' 13' ' ' ALA . 64.8 mt -125.49 161.94 26.01 Favored 'General case' 0 C--N 1.29 -1.999 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 -178.612 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.53 169.58 35.95 Favored Glycine 0 N--CA 1.422 -2.25 0 C-N-CA 119.878 -1.153 . . . . 0.0 110.296 -179.451 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.85 -6.59 14.51 Favored 'Trans proline' 0 C--O 1.212 -0.818 0 C-N-CA 123.087 2.525 . . . . 0.0 112.223 -179.503 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 5.9 ptmm? -97.73 -2.06 42.07 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 115.358 -0.837 . . . . 0.0 111.768 178.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -116.13 6.37 13.96 Favored 'General case' 0 C--N 1.293 -1.875 0 CA-C-O 121.134 0.492 . . . . 0.0 112.158 -179.069 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 11.5 pt -130.55 152.42 37.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.599 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . 1.643 ' HE1' ' CE2' ' A' ' 59' ' ' PHE . 93.7 m-85 -139.28 147.47 53.1 Favored Pre-proline 0 C--N 1.303 -1.434 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -178.84 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -60.55 129.82 31.05 Favored 'Trans proline' 0 N--CA 1.481 0.786 0 C-N-CA 123.2 2.6 . . . . 0.0 112.919 -177.003 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 1.654 ' HE2' ' CE1' ' A' ' 61' ' ' TYR . 3.4 t80 -58.67 -34.28 71.06 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 113.819 1.044 . . . . 0.0 113.819 -177.526 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 30.4 t -60.62 -57.96 10.5 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 123.427 0.455 . . . . 0.0 111.226 -177.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 15.9 mp0 -75.72 -27.36 58.14 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-O 122.059 0.933 . . . . 0.0 110.988 -175.434 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 37.5 m-80 -95.54 5.09 52.42 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 113.484 0.92 . . . . 0.0 113.484 -176.023 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.438 ' HE2' ' CE1' ' A' ' 61' ' ' TYR . 17.6 ttmm -62.69 -39.09 92.9 Favored 'General case' 0 C--O 1.21 -1.024 0 CA-C-O 120.986 0.422 . . . . 0.0 111.295 177.55 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 38.8 mm-40 -80.91 -16.81 52.58 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-O 122.008 0.908 . . . . 0.0 112.205 177.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 19.3 mtpp -85.2 -56.7 3.41 Favored 'General case' 0 C--N 1.268 -2.941 0 CA-C-N 114.462 -1.244 . . . . 0.0 111.733 -178.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 35.1 m-85 -125.4 5.25 7.67 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.08 -174.023 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -99.98 25.41 28.38 Favored Glycine 0 C--N 1.304 -1.201 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 -178.416 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 27.7 mmmt -96.8 153.33 38.69 Favored Pre-proline 0 C--N 1.307 -1.281 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 -179.173 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -58.31 128.2 27.67 Favored 'Trans proline' 0 C--O 1.252 1.18 0 C-N-CA 121.981 1.787 . . . . 0.0 112.974 -179.517 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 16.2 m-80 -114.82 177.64 4.57 Favored 'General case' 0 CA--C 1.47 -2.113 0 CA-C-N 114.955 -1.02 . . . . 0.0 112.226 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . 0.547 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 9.5 mptt -96.03 7.45 46.34 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 113.84 -1.527 . . . . 0.0 108.385 -178.37 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 11.1 mmt180 -88.27 122.79 32.2 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 175.177 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 10.2 tptp -77.04 144.38 38.65 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 177.278 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.529 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 95.13 -26.47 19.0 Favored Glycine 0 C--O 1.21 -1.367 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -173.873 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 1.663 ' HD1' ' CD2' ' A' ' 77' ' ' PHE . 27.0 t80 -76.61 -41.36 46.29 Favored 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 178.153 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 11.6 m120 -61.4 -49.22 77.77 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 177.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 6.1 mp0 -60.85 -40.73 94.0 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 113.711 -1.586 . . . . 0.0 110.352 179.309 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -67.54 -35.75 87.1 Favored Glycine 0 N--CA 1.44 -1.034 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.821 179.432 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.452 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 94.8 mt -61.92 -37.18 83.72 Favored 'General case' 0 C--O 1.218 -0.574 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 175.386 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 85.3 t90 -67.98 -48.34 66.06 Favored 'General case' 0 N--CA 1.427 -1.597 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.46 177.605 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -59.14 -46.7 87.67 Favored 'General case' 0 C--O 1.206 -1.196 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 179.719 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 19.0 tt -71.79 -27.83 28.95 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 C-N-CA 120.619 -0.432 . . . . 0.0 112.164 -174.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -89.57 -11.51 42.53 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 112.262 0.468 . . . . 0.0 112.262 -179.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 32.4 m-80 -120.81 -57.55 1.88 Allowed 'General case' 0 N--CA 1.477 0.912 0 CA-C-O 121.16 0.505 . . . . 0.0 112.052 -176.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -128.59 73.64 80.63 Favored Pre-proline 0 C--N 1.308 -1.214 0 C-N-CA 120.418 -0.513 . . . . 0.0 110.305 -179.386 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -70.13 -6.13 18.06 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 C-N-CA 123.178 2.585 . . . . 0.0 112.431 -176.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.9 pttp . . . . . 0 C--N 1.291 -1.969 0 CA-C-N 114.261 -1.336 . . . . 0.0 110.152 -179.651 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . 1.659 ' HE1' ' CE2' ' A' ' 5' ' ' PHE . 87.0 m-85 . . . . . 0 N--CA 1.43 -1.469 0 N-CA-C 109.138 -0.689 . . . . 0.0 109.138 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -134.07 155.77 79.79 Favored Pre-proline 0 C--N 1.301 -1.538 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.298 179.587 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_exo -45.43 125.52 7.53 Favored 'Trans proline' 0 C--N 1.359 1.086 0 C-N-CA 123.554 2.836 . . . . 0.0 113.05 177.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 115.33 -25.44 9.82 Favored Glycine 0 N--CA 1.428 -1.837 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.871 -179.352 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -74.66 151.57 39.27 Favored 'General case' 0 C--O 1.257 1.466 0 CA-C-O 121.501 0.667 . . . . 0.0 111.564 -177.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 79.3 mt -103.38 124.38 48.58 Favored 'General case' 0 N--CA 1.424 -1.731 0 CA-C-N 114.707 -1.133 . . . . 0.0 110.134 -175.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 8.1 pt -137.11 -173.89 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.896 0 CA-C-O 122.752 1.263 . . . . 0.0 112.2 -173.344 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 0.422 ' CD1' ' HB2' ' A' ' 64' ' ' ASN . 22.0 m-85 -125.49 131.26 52.87 Favored 'General case' 0 N--CA 1.399 -2.99 0 N-CA-C 105.277 -2.12 . . . . 0.0 105.277 170.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -107.47 128.39 54.45 Favored 'General case' 0 C--N 1.265 -3.081 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.011 -174.027 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.636 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -120.02 117.85 29.09 Favored 'General case' 0 N--CA 1.389 -3.524 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 -179.03 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.455 ' HB2' ' HB2' ' A' ' 18' ' ' TYR . 82.1 mtp -97.08 158.39 15.46 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.053 -177.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.6 tttp -67.23 115.8 7.3 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 176.38 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.56 -18.53 55.05 Favored Glycine 0 N--CA 1.446 -0.681 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.429 179.729 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . 0.455 ' HB2' ' HB2' ' A' ' 15' ' ' MET . 88.1 m-85 -119.96 143.86 36.24 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 117.117 0.459 . . . . 0.0 111.173 -177.744 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -68.85 170.95 14.31 Favored 'Trans proline' 0 CA--C 1.539 0.73 0 C-N-CA 123.115 2.543 . . . . 0.0 112.853 179.445 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' HIS . . . . . 0.534 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 77.3 m80 -60.86 122.16 14.17 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.97 179.64 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 15.1 t-105 -121.58 137.48 27.11 Favored Pre-proline 0 C--N 1.304 -1.401 0 N-CA-C 107.497 -1.298 . . . . 0.0 107.497 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -61.09 123.62 13.24 Favored 'Trans proline' 0 C--O 1.243 0.736 0 C-N-CA 122.426 2.084 . . . . 0.0 111.507 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.9 166.71 24.16 Favored 'General case' 0 N--CA 1.422 -1.864 0 CA-C-O 121.39 0.614 . . . . 0.0 111.806 -176.764 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 46.7 ttt85 -114.02 139.94 48.85 Favored 'General case' 0 C--N 1.296 -1.745 0 CA-C-N 115.307 -0.86 . . . . 0.0 109.762 178.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.5 t -85.98 115.53 27.45 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 104.678 -2.342 . . . . 0.0 104.678 169.801 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -99.71 -178.0 3.74 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 119.356 -0.937 . . . . 0.0 110.533 -173.592 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 . . . . . 0 N--CA 1.43 -1.441 0 CA-C-O 121.593 0.711 . . . . 0.0 112.017 -174.102 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.453 ' HA ' ' HA2' ' A' ' 54' ' ' GLY . 56.5 mttm . . . . . 0 N--CA 1.412 -2.333 0 CA-C-O 121.179 0.514 . . . . 0.0 111.274 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 71.0 mt -122.05 157.03 59.03 Favored Pre-proline 0 C--N 1.279 -2.467 0 CA-C-N 113.615 -1.629 . . . . 0.0 108.491 -176.646 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -75.4 122.59 7.11 Favored 'Trans proline' 0 N--CA 1.456 -0.682 0 C-N-CA 121.796 1.664 . . . . 0.0 109.978 174.369 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 41.2 mm -116.8 122.72 70.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -175.73 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 86.0 t80 -103.45 116.05 31.67 Favored 'General case' 0 C--N 1.282 -2.347 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 178.627 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 -76.71 129.66 36.65 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-O 121.047 0.451 . . . . 0.0 112.022 179.448 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 60.3 m-85 -78.96 151.33 31.7 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.258 177.581 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.511 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 77.28 -19.7 3.59 Favored Glycine 0 C--O 1.254 1.38 0 N-CA-C 114.534 0.573 . . . . 0.0 114.534 177.008 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 46.4 p -119.23 -23.04 6.89 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 117.43 0.615 . . . . 0.0 110.248 174.708 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.0 m-70 68.76 21.68 7.67 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.975 0.91 . . . . 0.0 112.546 179.176 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -80.28 164.89 22.85 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.838 178.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 2.2 m -130.29 140.16 50.68 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.241 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -141.24 -179.72 6.28 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 123.641 0.776 . . . . 0.0 109.843 -178.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 1.644 ' HD1' ' CD2' ' A' ' 52' ' ' PHE . 85.8 m-85 -133.19 112.32 11.62 Favored 'General case' 0 C--O 1.249 1.038 0 CA-C-O 121.605 0.717 . . . . 0.0 110.464 178.751 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.448 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 82.0 mt -135.84 147.4 48.24 Favored 'General case' 0 C--N 1.29 -1.993 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.453 ' HA2' ' HA ' ' A' ' 39' ' ' LYS . . . -94.77 177.23 35.54 Favored Glycine 0 CA--C 1.479 -2.169 0 C-N-CA 119.908 -1.139 . . . . 0.0 111.554 -177.196 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -62.25 -17.47 57.19 Favored 'Trans proline' 0 C--O 1.212 -0.821 0 C-N-CA 123.249 2.632 . . . . 0.0 112.096 -177.535 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.55 1.47 48.97 Favored 'General case' 0 N--CA 1.425 -1.708 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.964 178.111 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.448 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 71.9 m-20 -107.92 -16.25 14.35 Favored 'General case' 0 C--N 1.29 -2.021 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.209 176.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.451 HG12 ' O ' ' A' ' 54' ' ' GLY . 12.0 pt -117.55 157.28 18.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.057 -174.059 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . 0.513 ' HB3' HD22 ' A' ' 64' ' ' ASN . 98.0 m-85 -137.92 143.31 39.35 Favored Pre-proline 0 C--N 1.297 -1.711 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -69.29 148.44 68.13 Favored 'Trans proline' 0 C--O 1.245 0.873 0 C-N-CA 122.975 2.45 . . . . 0.0 114.934 -172.516 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 1.634 ' HE1' ' CE2' ' A' ' 61' ' ' TYR . 54.4 t80 -55.82 -34.71 65.6 Favored 'General case' 0 C--O 1.221 -0.434 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.078 177.002 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.1 m -52.86 -44.24 66.67 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.169 -0.923 . . . . 0.0 112.224 -179.028 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -93.3 -26.55 17.26 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 121.644 0.735 . . . . 0.0 111.497 -177.089 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.513 HD22 ' HB3' ' A' ' 59' ' ' PHE . 40.8 m-80 -91.21 0.57 57.5 Favored 'General case' 0 C--O 1.203 -1.377 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -174.446 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.45 ' HB3' ' NZ ' ' A' ' 65' ' ' LYS . 4.5 ttpm? -65.95 -47.68 73.83 Favored 'General case' 0 C--N 1.29 -2.006 0 CA-C-O 121.446 0.641 . . . . 0.0 110.079 179.292 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.438 ' CD ' ' HZ2' ' A' ' 65' ' ' LYS . 12.1 mp0 -68.7 -36.34 78.35 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-O 122.331 1.062 . . . . 0.0 109.65 178.306 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 47.4 mtmt -79.16 -59.75 2.64 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 114.264 -1.335 . . . . 0.0 112.764 -174.34 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 1.643 ' HD2' ' CD1' ' A' ' 68' ' ' TYR . 47.8 m-85 -121.73 4.43 10.04 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 112.394 0.516 . . . . 0.0 112.394 -172.23 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -82.35 34.11 2.69 Favored Glycine 0 CA--C 1.524 0.649 0 C-N-CA 121.28 -0.486 . . . . 0.0 113.211 -177.454 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 2.6 mppt? -122.92 144.37 42.85 Favored Pre-proline 0 N--CA 1.439 -1.017 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.318 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . 0.531 ' HB3' ' OD1' ' A' ' 78' ' ' ASN . 82.8 Cg_exo -46.19 128.67 12.18 Favored 'Trans proline' 0 C--O 1.263 1.772 0 C-N-CA 123.984 3.123 . . . . 0.0 115.142 -176.248 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . 0.505 ' HB2' ' CD1' ' A' ' 77' ' ' PHE . 1.7 t-20 -102.73 -166.96 1.33 Allowed 'General case' 0 C--N 1.269 -2.9 0 CA-C-N 114.516 -1.22 . . . . 0.0 109.356 -178.208 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . 0.459 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 1.9 mptp? -120.61 18.39 12.0 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 178.332 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 37.1 mmt180 -102.75 132.46 48.89 Favored 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 114.343 -1.298 . . . . 0.0 109.269 176.543 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.8 tmtm? -68.37 127.66 33.76 Favored 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 175.477 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.511 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 107.17 -25.67 21.29 Favored Glycine 0 N--CA 1.416 -2.637 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.29 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 1.655 ' HE1' ' CE2' ' A' ' 77' ' ' PHE . 16.0 t80 -76.56 -45.4 30.69 Favored 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 -178.088 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.531 ' OD1' ' HB3' ' A' ' 71' ' ' PRO . 53.6 m-80 -71.61 -41.8 68.46 Favored 'General case' 0 CA--C 1.498 -1.045 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.45 -178.459 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -67.76 -33.64 75.23 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.18 179.487 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.97 -34.71 65.05 Favored Glycine 0 N--CA 1.43 -1.741 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.984 178.342 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.547 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 95.3 mt -61.97 -35.23 77.85 Favored 'General case' 0 C--O 1.215 -0.727 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 174.483 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 71.3 t90 -71.37 -48.78 47.89 Favored 'General case' 0 N--CA 1.431 -1.397 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.326 176.598 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -58.87 -40.53 84.64 Favored 'General case' 0 C--O 1.2 -1.537 0 N-CA-C 112.944 0.72 . . . . 0.0 112.944 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 19.0 tt -71.27 -21.36 21.8 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 CA-C-O 121.128 0.489 . . . . 0.0 110.795 -175.506 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -92.1 -43.78 9.18 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.066 -177.359 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.565 ' N ' HD21 ' A' ' 86' ' ' ASN . 0.8 OUTLIER -92.52 -44.27 8.72 Favored 'General case' 0 N--CA 1.481 1.115 0 CA-C-O 121.327 0.584 . . . . 0.0 112.182 -173.528 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.489 ' OD1' ' HG3' ' A' ' 89' ' ' LYS . 61.5 t30 -133.36 67.91 76.68 Favored Pre-proline 0 C--N 1.299 -1.614 0 C-N-CA 119.809 -0.756 . . . . 0.0 110.786 -178.698 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -68.09 -6.75 17.96 Favored 'Trans proline' 0 C--N 1.369 1.637 0 C-N-CA 123.193 2.595 . . . . 0.0 111.65 -178.227 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . 0.489 ' HG3' ' OD1' ' A' ' 87' ' ' ASN . 5.5 ptmm? . . . . . 0 C--N 1.297 -1.684 0 CA-C-N 113.941 -1.481 . . . . 0.0 110.825 179.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 67.6 m-85 . . . . . 0 N--CA 1.423 -1.805 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.416 ' O ' ' HB2' ' A' ' 9' ' ' ASP . 48.4 mttm -96.35 144.3 27.61 Favored Pre-proline 0 C--N 1.294 -1.831 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.918 -170.364 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -58.0 116.02 2.94 Favored 'Trans proline' 0 N--CA 1.462 -0.369 0 C-N-CA 121.731 1.621 . . . . 0.0 110.002 175.133 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 109.52 -7.4 32.04 Favored Glycine 0 N--CA 1.433 -1.543 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.335 -176.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . 0.416 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 5.2 t70 -69.57 152.57 44.62 Favored 'General case' 0 C--O 1.251 1.175 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -177.86 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.4 mt -104.91 120.91 42.57 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 121.375 0.607 . . . . 0.0 109.85 -175.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.0 pt -140.45 -175.49 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.416 -2.165 0 CA-C-O 122.25 1.024 . . . . 0.0 112.024 -174.734 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -124.62 128.95 49.65 Favored 'General case' 0 N--CA 1.409 -2.497 0 N-CA-C 105.64 -1.985 . . . . 0.0 105.64 171.068 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.404 ' CB ' HG22 ' A' ' 42' ' ' ILE . . . -117.02 141.41 48.29 Favored 'General case' 0 C--N 1.278 -2.513 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.798 -176.62 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.688 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -123.24 124.46 43.07 Favored 'General case' 0 N--CA 1.405 -2.72 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.693 -177.437 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.438 ' HG2' HD22 ' A' ' 53' ' ' LEU . 44.6 mtm -115.87 158.2 23.32 Favored 'General case' 0 CA--C 1.499 -1.017 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 175.574 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.3 tttp -65.45 116.91 7.23 Favored 'General case' 0 C--N 1.311 -1.095 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 178.305 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.33 -12.38 58.49 Favored Glycine 0 C--O 1.247 0.93 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -178.058 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . 1.664 ' HE2' ' CE1' ' A' ' 18' ' ' TYR . 7.8 m-85 -110.59 149.46 40.32 Favored Pre-proline 0 C--N 1.307 -1.279 0 C-N-CA 123.196 0.598 . . . . 0.0 109.872 178.528 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -81.41 171.45 13.61 Favored 'Trans proline' 0 N--CA 1.442 -1.512 0 C-N-CA 122.118 1.879 . . . . 0.0 108.173 171.323 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' HIS . . . . . 0.465 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 80.8 m80 -64.46 111.28 2.61 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 174.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 9.6 t-105 -110.85 141.03 23.29 Favored Pre-proline 0 C--N 1.292 -1.925 0 C-N-CA 123.585 0.754 . . . . 0.0 109.12 -170.001 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -64.49 118.2 5.19 Favored 'Trans proline' 0 C--O 1.245 0.845 0 C-N-CA 122.147 1.898 . . . . 0.0 110.359 177.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -139.92 166.51 24.44 Favored 'General case' 0 N--CA 1.408 -2.526 0 CA-C-O 121.118 0.485 . . . . 0.0 110.311 -175.537 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.472 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 10.7 ttp180 -115.3 145.35 42.56 Favored 'General case' 0 C--N 1.285 -2.237 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.135 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 52.4 t -74.63 119.91 23.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 104.728 -2.323 . . . . 0.0 104.728 170.099 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . 0.405 ' HB3' ' HB2' ' A' ' 41' ' ' PRO . 4.1 t70 -84.78 179.0 7.43 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -172.219 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 . . . . . 0 N--CA 1.429 -1.507 0 C-N-CA 119.278 -0.969 . . . . 0.0 111.72 -175.276 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 62.1 mttp . . . . . 0 N--CA 1.428 -1.551 0 CA-C-O 121.055 0.455 . . . . 0.0 111.12 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . 0.402 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 88.8 mt -116.99 147.17 39.57 Favored Pre-proline 0 C--N 1.287 -2.151 0 CA-C-N 114.33 -1.304 . . . . 0.0 109.246 -178.07 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . 0.405 ' HB2' ' HB3' ' A' ' 26' ' ' ASP . 68.9 Cg_endo -73.06 123.86 9.16 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 122.33 2.02 . . . . 0.0 110.523 177.565 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.404 HG22 ' CB ' ' A' ' 13' ' ' ALA . 43.4 mm -120.86 127.56 75.95 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 -176.753 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.653 ' HD2' ' CD1' ' A' ' 43' ' ' PHE . 87.7 t80 -107.14 120.69 42.8 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 178.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 -86.66 131.7 34.08 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-O 121.254 0.55 . . . . 0.0 112.247 179.028 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.472 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 67.6 m-85 -85.83 158.44 19.97 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.694 179.326 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.524 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 75.31 -20.32 2.1 Favored Glycine 0 C--O 1.248 1.015 0 C-N-CA 123.526 0.584 . . . . 0.0 114.538 179.139 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 18.3 p -119.38 -23.04 6.81 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 122.305 -0.527 . . . . 0.0 109.73 173.005 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.41 ' HA ' ' CZ ' ' A' ' 43' ' ' PHE . 11.5 m-70 67.67 26.18 7.98 Favored 'General case' 0 C--N 1.348 0.507 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.818 179.507 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -79.4 161.89 25.87 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.698 -0.852 . . . . 0.0 108.698 177.373 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 6.9 m -136.12 140.43 43.68 Favored 'General case' 0 C--N 1.284 -2.25 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 176.794 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -142.74 179.35 7.05 Favored 'General case' 0 C--N 1.287 -2.124 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.289 -175.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 1.635 ' HD1' ' CD2' ' A' ' 52' ' ' PHE . 84.8 m-85 -134.0 115.07 13.91 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.305 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.438 HD22 ' HG2' ' A' ' 15' ' ' MET . 87.4 mt -129.44 166.49 19.49 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 -177.67 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -93.03 167.7 29.49 Favored Glycine 0 N--CA 1.423 -2.18 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -67.03 -6.89 17.11 Favored 'Trans proline' 0 N--CA 1.481 0.747 0 C-N-CA 123.303 2.669 . . . . 0.0 112.828 -176.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 20.8 pttp -93.05 -18.17 22.97 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.366 178.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.2 m-20 -99.98 1.25 42.41 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.188 -175.226 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.3 pt -125.94 145.84 32.71 Favored 'Isoleucine or valine' 0 C--O 1.258 1.551 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.754 179.359 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . 0.453 ' HB3' ' ND2' ' A' ' 64' ' ' ASN . 83.0 m-85 -136.32 144.82 49.3 Favored Pre-proline 0 C--N 1.288 -2.087 0 CA-C-N 114.823 -1.081 . . . . 0.0 108.554 -177.131 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -68.34 127.82 16.37 Favored 'Trans proline' 0 N--CA 1.483 0.857 0 C-N-CA 122.746 2.298 . . . . 0.0 113.956 -179.121 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -51.97 -39.34 59.17 Favored 'General case' 0 C--O 1.217 -0.626 0 C-N-CA 123.87 0.868 . . . . 0.0 111.043 -179.536 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.5 m -57.28 -40.33 77.54 Favored 'General case' 0 C--N 1.307 -1.27 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.185 -178.072 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -95.75 -19.19 19.85 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.278 0.561 . . . . 0.0 112.21 -172.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.453 ' ND2' ' HB3' ' A' ' 59' ' ' PHE . 0.5 OUTLIER -124.19 26.88 7.29 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 114.703 1.371 . . . . 0.0 114.703 -178.214 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.482 ' HZ2' ' CD ' ' A' ' 66' ' ' GLU . 17.0 pttm -70.1 -30.91 68.24 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 174.698 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.482 ' CD ' ' HZ2' ' A' ' 65' ' ' LYS . 19.8 mp0 -65.25 -39.06 92.17 Favored 'General case' 0 C--O 1.251 1.151 0 CA-C-O 122.557 1.17 . . . . 0.0 108.617 175.091 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 35.8 mtpt -76.44 -59.96 2.55 Favored 'General case' 0 N--CA 1.427 -1.618 0 CA-C-N 113.918 -1.492 . . . . 0.0 112.029 -175.07 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . 1.66 ' HE1' ' CE2' ' A' ' 68' ' ' TYR . 21.0 m-85 -107.67 -9.75 15.78 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.482 -0.781 . . . . 0.0 112.428 -168.297 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -82.3 41.55 2.8 Favored Glycine 0 C--O 1.22 -0.726 0 C-N-CA 121.245 -0.503 . . . . 0.0 113.21 -176.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 38.4 mtmm -122.96 124.95 26.44 Favored Pre-proline 0 C--N 1.308 -1.202 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 177.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -56.96 127.17 24.72 Favored 'Trans proline' 0 C--O 1.251 1.167 0 C-N-CA 122.23 1.954 . . . . 0.0 114.686 -172.239 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -84.76 -170.46 3.13 Favored 'General case' 0 CA--C 1.484 -1.594 0 CA-C-N 113.875 -1.511 . . . . 0.0 108.304 176.608 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . 0.405 ' HA ' ' HD3' ' A' ' 73' ' ' LYS . 40.0 mmtm -111.46 22.0 15.57 Favored 'General case' 0 C--N 1.285 -2.201 0 CA-C-O 122.592 1.187 . . . . 0.0 107.821 173.88 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -87.06 127.89 35.11 Favored 'General case' 0 C--O 1.251 1.162 0 CA-C-N 113.548 -1.66 . . . . 0.0 107.547 173.279 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -65.29 134.79 54.38 Favored 'General case' 0 N--CA 1.439 -0.997 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 176.47 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.524 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 100.2 -25.73 27.18 Favored Glycine 0 N--CA 1.42 -2.374 0 C-N-CA 121.405 -0.426 . . . . 0.0 112.363 -178.242 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 1.665 ' HD1' ' CD2' ' A' ' 77' ' ' PHE . 23.2 t80 -73.36 -42.61 62.0 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 -177.709 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.473 ' N ' HD21 ' A' ' 78' ' ' ASN . 0.7 OUTLIER -72.87 -41.37 64.79 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 -177.323 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 16.3 mt-10 -65.06 -39.89 93.91 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 114.411 -1.268 . . . . 0.0 109.857 178.464 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -68.63 -32.29 74.47 Favored Glycine 0 CA--C 1.499 -0.936 0 CA-C-N 115.741 -0.663 . . . . 0.0 112.636 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 90.8 mt -62.9 -32.86 74.22 Favored 'General case' 0 C--O 1.214 -0.798 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 174.764 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 73.6 t90 -73.48 -48.27 34.72 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.382 176.541 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -58.3 -41.32 84.19 Favored 'General case' 0 C--O 1.203 -1.384 0 N-CA-C 112.87 0.693 . . . . 0.0 112.87 179.669 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.3 tt -71.29 -21.24 21.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-O 121.145 0.497 . . . . 0.0 110.619 -175.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -90.36 -42.42 10.95 Favored 'General case' 0 N--CA 1.437 -1.112 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.108 -177.196 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.558 ' N ' HD21 ' A' ' 86' ' ' ASN . 0.8 OUTLIER -92.22 -50.16 5.81 Favored 'General case' 0 CA--C 1.494 -1.188 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.136 -174.154 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 64.6 t30 -132.72 75.9 72.17 Favored Pre-proline 0 C--N 1.303 -1.442 0 C-N-CA 119.725 -0.79 . . . . 0.0 110.152 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.471 ' O ' ' HD3' ' A' ' 24' ' ' ARG . 42.5 Cg_endo -68.52 -6.51 17.86 Favored 'Trans proline' 0 N--CA 1.477 0.542 0 C-N-CA 122.795 2.33 . . . . 0.0 114.143 -174.211 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 61.5 pttt . . . . . 0 C--N 1.304 -1.393 0 CA-C-O 120.85 0.357 . . . . 0.0 110.182 -179.053 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . 1.644 ' HD1' ' CD2' ' A' ' 5' ' ' PHE . 76.4 m-85 . . . . . 0 N--CA 1.427 -1.575 0 CA-C-O 120.958 0.408 . . . . 0.0 109.987 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 29.6 mttp -110.27 153.53 43.31 Favored Pre-proline 0 C--N 1.307 -1.281 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 -177.405 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -62.15 115.4 2.82 Favored 'Trans proline' 0 N--CA 1.448 -1.193 0 N-CA-C 107.08 -1.931 . . . . 0.0 107.08 169.02 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 114.93 -19.05 15.94 Favored Glycine 0 N--CA 1.424 -2.152 0 C-N-CA 120.411 -0.899 . . . . 0.0 112.391 -174.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -78.45 152.19 32.26 Favored 'General case' 0 C--O 1.253 1.268 0 CA-C-N 117.397 0.599 . . . . 0.0 109.446 -177.065 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 82.5 mt -98.03 127.32 43.91 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 122.917 0.487 . . . . 0.0 111.211 -171.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -140.08 -178.78 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.046 0 CA-C-O 121.956 0.884 . . . . 0.0 112.555 -174.718 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 1.633 ' HE2' ' CE1' ' A' ' 12' ' ' PHE . 69.0 m-85 -120.98 125.4 47.26 Favored 'General case' 0 C--N 1.291 -1.971 0 N-CA-C 105.429 -2.063 . . . . 0.0 105.429 172.47 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.419 ' HB2' HD13 ' A' ' 53' ' ' LEU . . . -111.22 146.35 37.08 Favored 'General case' 0 C--N 1.277 -2.545 0 O-C-N 123.531 0.519 . . . . 0.0 111.035 -174.54 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.463 ' HD3' ' C ' ' A' ' 14' ' ' LYS . 7.5 tmtm? -117.9 117.66 29.87 Favored 'General case' 0 N--CA 1.419 -1.998 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.707 -177.746 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' MET . . . . . 0.416 ' HE1' ' CD1' ' A' ' 18' ' ' TYR . 70.1 mtm -112.28 159.38 18.69 Favored 'General case' 0 C--O 1.248 0.999 0 CA-C-O 120.962 0.41 . . . . 0.0 111.364 173.384 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 26.2 ttpp -67.71 116.82 8.83 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 176.025 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.52 -4.91 64.43 Favored Glycine 0 C--O 1.239 0.432 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -176.305 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . 1.644 ' HE2' ' CE1' ' A' ' 18' ' ' TYR . 35.3 m-85 -118.13 145.39 36.85 Favored Pre-proline 0 C--O 1.254 1.335 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 179.325 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -79.79 171.93 14.86 Favored 'Trans proline' 0 N--CA 1.445 -1.324 0 C-N-CA 123.16 2.573 . . . . 0.0 108.281 170.093 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 79.1 m80 -63.93 111.51 2.52 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 177.063 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 10.2 t-105 -110.18 140.51 22.47 Favored Pre-proline 0 C--N 1.295 -1.767 0 CA-C-N 114.866 -1.061 . . . . 0.0 109.369 -170.188 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -65.85 118.15 5.24 Favored 'Trans proline' 0 C--O 1.243 0.744 0 C-N-CA 122.008 1.805 . . . . 0.0 110.184 177.233 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -145.94 167.19 23.91 Favored 'General case' 0 N--CA 1.413 -2.307 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 -175.632 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.59 ' HD3' ' O ' ' A' ' 88' ' ' PRO . 10.0 ttp180 -122.29 149.06 44.25 Favored 'General case' 0 C--N 1.272 -2.782 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 51.5 t -72.34 121.07 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 104.647 -2.353 . . . . 0.0 104.647 169.135 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -84.0 172.44 12.03 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 -170.656 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.431 -1.386 0 CA-C-O 121.506 0.669 . . . . 0.0 111.772 -176.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.468 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 88.6 mttt . . . . . 0 N--CA 1.431 -1.407 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 66.6 mt -84.16 140.8 39.71 Favored Pre-proline 0 C--N 1.314 -0.97 0 O-C-N 123.609 0.568 . . . . 0.0 109.574 -177.488 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -72.74 123.93 9.36 Favored 'Trans proline' 0 C--O 1.222 -0.276 0 C-N-CA 122.395 2.064 . . . . 0.0 110.186 178.767 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 47.6 mm -120.85 123.43 70.2 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 0 O-C-N 121.924 -0.485 . . . . 0.0 110.401 -176.495 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.636 ' HD1' ' CD2' ' A' ' 43' ' ' PHE . 77.4 t80 -106.09 119.13 38.4 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 177.889 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 1.611 ' HD1' ' CD2' ' A' ' 44' ' ' PHE . 80.4 m-85 -83.39 131.91 35.02 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-O 121.314 0.578 . . . . 0.0 112.141 179.591 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 46.1 m-85 -85.01 154.5 22.07 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.406 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.544 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 73.44 -21.16 1.17 Allowed Glycine 0 C--N 1.308 -0.981 0 C-N-CA 124.184 0.897 . . . . 0.0 114.977 179.679 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.4 p -115.98 -22.92 8.78 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 117.942 0.871 . . . . 0.0 109.668 173.409 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.402 ' HE2' ' CD ' ' A' ' 83' ' ' GLU . 55.9 m170 69.73 23.17 5.83 Favored 'General case' 0 CA--C 1.518 -0.285 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.595 176.319 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -76.51 160.79 29.17 Favored 'General case' 0 N--CA 1.443 -0.785 0 CA-C-N 115.261 -0.881 . . . . 0.0 108.745 177.035 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.2 m -136.3 138.31 41.6 Favored 'General case' 0 C--N 1.279 -2.473 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.093 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -140.2 -179.62 6.09 Favored 'General case' 0 C--N 1.282 -2.343 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.0 -177.267 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -133.03 111.21 10.8 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 175.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.443 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 87.2 mt -129.25 150.9 50.43 Favored 'General case' 0 C--N 1.288 -2.094 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.293 -176.227 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . 0.468 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -85.17 172.84 47.87 Favored Glycine 0 N--CA 1.424 -2.156 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 -176.54 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -65.04 -16.65 56.35 Favored 'Trans proline' 0 C--O 1.208 -0.992 0 C-N-CA 122.266 1.977 . . . . 0.0 112.407 -177.478 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.75 -1.14 44.04 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-O 121.301 0.572 . . . . 0.0 112.197 177.205 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.443 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 69.4 m-20 -104.22 -4.83 22.54 Favored 'General case' 0 C--N 1.295 -1.791 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 179.513 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.7 pt -128.2 156.58 40.41 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.707 0 CA-C-N 114.898 -1.046 . . . . 0.0 109.1 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . 0.413 ' HB3' ' ND2' ' A' ' 64' ' ' ASN . 88.6 m-85 -136.72 136.76 22.08 Favored Pre-proline 0 C--N 1.287 -2.115 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 -179.625 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . 0.466 ' HG2' ' HB2' ' A' ' 63' ' ' GLU . 20.5 Cg_endo -64.43 132.92 35.19 Favored 'Trans proline' 0 C--N 1.318 -1.079 0 C-N-CA 122.273 1.982 . . . . 0.0 112.416 -177.621 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.42 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 60.7 t80 -58.63 -39.76 81.41 Favored 'General case' 0 C--O 1.206 -1.214 0 C-N-CA 123.695 0.798 . . . . 0.0 110.839 -178.331 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 29.5 t -62.06 -36.09 80.58 Favored 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.484 -176.009 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . 0.466 ' HB2' ' HG2' ' A' ' 60' ' ' PRO . 1.3 mp0 -95.05 -18.0 21.39 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 113.172 0.805 . . . . 0.0 113.172 -175.2 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.413 ' ND2' ' HB3' ' A' ' 59' ' ' PHE . 37.3 m-80 -123.55 16.07 9.6 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 112.778 0.658 . . . . 0.0 112.778 -175.814 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.49 ' HG2' ' OE2' ' A' ' 66' ' ' GLU . 21.4 pttm -66.8 -32.19 73.3 Favored 'General case' 0 N--CA 1.484 1.268 0 CA-C-O 121.273 0.559 . . . . 0.0 110.703 -178.062 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.49 ' OE2' ' HG2' ' A' ' 65' ' ' LYS . 2.7 mp0 -70.36 -25.39 63.25 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 -179.537 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 43.6 mttp -91.05 -59.66 2.11 Favored 'General case' 0 N--CA 1.422 -1.826 0 CA-C-N 114.271 -1.331 . . . . 0.0 111.297 -171.01 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 56.1 m-85 -105.76 -0.62 25.24 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.806 -172.254 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.9 56.43 4.81 Favored Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.74 179.292 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -128.61 128.53 23.54 Favored Pre-proline 0 C--N 1.317 -0.845 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.806 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_exo -54.57 137.9 74.01 Favored 'Trans proline' 0 C--N 1.349 0.575 0 C-N-CA 122.969 2.446 . . . . 0.0 112.169 177.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 15.9 m-80 -116.04 -179.34 3.63 Favored 'General case' 0 CA--C 1.472 -2.049 0 N-CA-C 113.845 1.054 . . . . 0.0 113.845 -178.633 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . 0.462 ' HD3' ' N ' ' A' ' 73' ' ' LYS . 2.8 mppt? -93.27 1.9 56.83 Favored 'General case' 0 N--CA 1.429 -1.494 0 CA-C-N 112.921 -1.945 . . . . 0.0 108.247 -178.516 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 5.6 mmt180 -84.54 116.34 23.08 Favored 'General case' 0 N--CA 1.426 -1.645 0 CA-C-N 114.889 -1.051 . . . . 0.0 109.783 176.43 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.521 ' HZ2' ' CD ' ' A' ' 79' ' ' GLU . 8.7 tmtt? -56.5 125.92 24.22 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 175.632 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.544 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.03 -25.44 20.42 Favored Glycine 0 N--CA 1.434 -1.451 0 C-N-CA 121.222 -0.514 . . . . 0.0 112.081 -179.363 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 1.665 ' HE1' ' CE2' ' A' ' 77' ' ' PHE . 14.1 t80 -70.29 -40.28 74.39 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 122.068 0.937 . . . . 0.0 108.738 -176.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -68.47 -43.64 76.55 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 114.198 -1.364 . . . . 0.0 108.986 -176.808 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . 0.521 ' CD ' ' HZ2' ' A' ' 75' ' ' LYS . 23.5 mt-10 -68.49 -35.57 77.72 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 114.39 -1.277 . . . . 0.0 109.964 179.765 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -68.45 -33.66 77.65 Favored Glycine 0 N--CA 1.438 -1.186 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.24 177.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.409 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 95.4 mt -62.76 -33.83 75.98 Favored 'General case' 0 C--O 1.213 -0.818 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 174.596 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 72.8 t90 -71.92 -49.54 36.84 Favored 'General case' 0 N--CA 1.441 -0.901 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.778 176.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . 0.402 ' CD ' ' HE2' ' A' ' 48' ' ' HIS . 46.7 mt-10 -58.25 -40.35 81.53 Favored 'General case' 0 C--O 1.204 -1.335 0 N-CA-C 112.895 0.702 . . . . 0.0 112.895 179.503 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.0 tt -71.18 -21.21 21.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.179 0.514 . . . . 0.0 110.583 -176.571 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -89.03 -42.9 11.48 Favored 'General case' 0 N--CA 1.439 -1.011 0 CA-C-N 115.47 -0.787 . . . . 0.0 110.019 -177.856 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.547 ' N ' HD21 ' A' ' 86' ' ' ASN . 0.8 OUTLIER -89.49 -48.66 7.17 Favored 'General case' 0 CA--C 1.493 -1.225 0 CA-C-N 115.92 -0.582 . . . . 0.0 112.077 -174.295 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -132.29 76.87 71.84 Favored Pre-proline 0 C--N 1.302 -1.481 0 C-N-CA 120.17 -0.612 . . . . 0.0 109.761 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . 0.59 ' O ' ' HD3' ' A' ' 24' ' ' ARG . 28.8 Cg_endo -62.97 -16.96 57.61 Favored 'Trans proline' 0 C--O 1.218 -0.515 0 C-N-CA 122.808 2.339 . . . . 0.0 115.719 -171.399 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 8.5 ptmm? . . . . . 0 C--O 1.259 1.573 0 C-N-CA 119.317 -0.953 . . . . 0.0 111.323 -179.213 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 . . . . . 0 N--CA 1.427 -1.618 0 CA-C-O 121.452 0.644 . . . . 0.0 110.152 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.532 ' HB2' ' HZ1' ' A' ' 6' ' ' LYS . 0.1 OUTLIER -94.36 145.98 30.7 Favored Pre-proline 0 C--N 1.304 -1.39 0 CA-C-N 114.913 -1.039 . . . . 0.0 109.326 -177.079 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -53.28 122.23 10.83 Favored 'Trans proline' 0 C--O 1.238 0.523 0 C-N-CA 122.336 2.024 . . . . 0.0 109.579 172.118 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 109.58 -9.91 32.72 Favored Glycine 0 N--CA 1.427 -1.904 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.051 -177.258 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -79.9 153.51 28.96 Favored 'General case' 0 C--O 1.251 1.166 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -179.297 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.0 mt -105.64 126.39 52.09 Favored 'General case' 0 C--N 1.291 -1.97 0 CA-C-O 121.251 0.548 . . . . 0.0 109.892 -175.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 9.3 pt -140.84 -172.66 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.832 0 CA-C-O 122.256 1.027 . . . . 0.0 111.813 -174.616 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 0.55 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 72.8 m-85 -126.15 134.44 51.3 Favored 'General case' 0 N--CA 1.411 -2.377 0 N-CA-C 105.894 -1.891 . . . . 0.0 105.894 172.342 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . 0.441 ' HB2' ' CD1' ' A' ' 53' ' ' LEU . . . -113.44 141.92 46.52 Favored 'General case' 0 C--N 1.273 -2.72 0 O-C-N 123.776 0.673 . . . . 0.0 110.235 -176.28 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' LYS . . . . . 0.472 ' HD3' ' C ' ' A' ' 14' ' ' LYS . 7.5 tmtm? -113.15 117.72 32.73 Favored 'General case' 0 N--CA 1.422 -1.837 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.834 -177.441 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 72.1 mtm -109.54 158.48 17.96 Favored 'General case' 0 C--O 1.254 1.331 0 CA-C-O 121.26 0.552 . . . . 0.0 111.056 173.241 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 61.4 tttm -68.46 117.26 9.99 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.682 178.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.3 -1.55 76.85 Favored Glycine 0 C--O 1.238 0.361 0 C-N-CA 121.0 -0.619 . . . . 0.0 111.768 -178.746 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -120.39 150.68 52.37 Favored Pre-proline 0 C--O 1.258 1.52 0 CA-C-N 115.636 -0.282 . . . . 0.0 111.061 -179.202 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -74.97 171.97 17.26 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 123.286 2.657 . . . . 0.0 109.691 172.513 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -67.3 110.97 3.75 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 176.788 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 3.9 t-105 -98.78 137.48 20.57 Favored Pre-proline 0 C--N 1.297 -1.681 0 CA-C-N 114.801 -1.091 . . . . 0.0 108.542 -171.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -64.49 118.13 5.13 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 121.763 1.642 . . . . 0.0 110.148 177.72 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -135.85 166.79 22.48 Favored 'General case' 0 N--CA 1.411 -2.398 0 CA-C-O 121.519 0.676 . . . . 0.0 110.975 -175.181 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.497 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 64.4 ttt-85 -115.66 141.76 47.65 Favored 'General case' 0 C--N 1.28 -2.423 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.455 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 48.1 t -77.65 119.92 27.26 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.249 0 N-CA-C 103.957 -2.608 . . . . 0.0 103.957 169.816 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -102.33 -179.58 4.03 Favored 'General case' 0 C--N 1.283 -2.294 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.858 -170.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLU . . . . . 0.405 ' CD ' HH12 ' A' ' 24' ' ' ARG . 30.5 mp0 . . . . . 0 N--CA 1.424 -1.731 0 CA-C-O 121.622 0.725 . . . . 0.0 110.504 -178.684 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' LYS . . . . . 0.532 ' HE3' ' HA ' ' A' ' 53' ' ' LEU . 22.5 mtpp . . . . . 0 N--CA 1.415 -2.209 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 80.7 mt -103.55 154.62 37.73 Favored Pre-proline 0 C--N 1.29 -2.002 0 O-C-N 124.023 0.827 . . . . 0.0 109.772 -175.605 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -71.15 122.32 8.62 Favored 'Trans proline' 0 N--CA 1.451 -0.991 0 C-N-CA 121.521 1.481 . . . . 0.0 109.734 174.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' ILE . . . . . 0.406 HG13 ' HB2' ' A' ' 53' ' ' LEU . 44.9 mm -118.53 116.81 52.48 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.935 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -176.585 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 1.669 ' HE1' ' CE2' ' A' ' 43' ' ' PHE . 79.0 t80 -93.33 122.34 35.64 Favored 'General case' 0 C--N 1.268 -2.972 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 179.718 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . 1.651 ' HD1' ' CD2' ' A' ' 44' ' ' PHE . 71.7 m-85 -88.51 124.91 34.47 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.347 0.594 . . . . 0.0 112.542 178.434 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.497 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 78.2 m-85 -74.64 152.53 39.19 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.536 176.053 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' GLY . . . . . 0.542 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 79.78 -19.97 5.79 Favored Glycine 0 C--N 1.308 -1.02 0 CA-C-N 116.289 -0.414 . . . . 0.0 113.701 178.786 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.0 p -116.62 -22.79 8.48 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 117.166 0.483 . . . . 0.0 110.149 175.48 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.402 ' HA ' ' CZ ' ' A' ' 43' ' ' PHE . 49.7 m170 70.22 14.23 7.63 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 124.321 1.048 . . . . 0.0 112.017 177.123 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 57.4 mm-40 -92.4 168.15 11.49 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.873 -179.113 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.0 m -129.48 142.15 50.85 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-O 121.2 0.524 . . . . 0.0 109.908 179.606 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -137.89 -178.9 5.46 Favored 'General case' 0 C--N 1.295 -1.791 0 C-N-CA 124.096 0.958 . . . . 0.0 110.023 -177.499 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -128.53 116.0 18.99 Favored 'General case' 0 CA--C 1.5 -0.975 0 CA-C-O 120.851 0.357 . . . . 0.0 110.637 179.141 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.532 ' HA ' ' HE3' ' A' ' 39' ' ' LYS . 89.0 mt -131.59 151.32 51.7 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.793 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -85.69 174.38 48.19 Favored Glycine 0 N--CA 1.433 -1.514 0 C-N-CA 120.564 -0.827 . . . . 0.0 111.192 -176.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 -6.87 19.67 Favored 'Trans proline' 0 C--O 1.212 -0.794 0 C-N-CA 122.591 2.194 . . . . 0.0 112.98 -176.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.528 ' NZ ' ' HB2' ' A' ' 56' ' ' LYS . 5.8 mtmp? -97.99 -15.59 20.02 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 177.317 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.434 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 9.7 m-20 -99.72 1.78 43.65 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 114.585 -1.189 . . . . 0.0 108.58 -168.121 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.2 pt -132.06 152.11 36.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 114.19 -1.368 . . . . 0.0 110.187 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' PHE . . . . . 1.644 ' HD1' ' CD2' ' A' ' 59' ' ' PHE . 85.5 m-85 -135.29 141.31 37.3 Favored Pre-proline 0 C--N 1.302 -1.457 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 179.543 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -66.11 132.23 29.28 Favored 'Trans proline' 0 C--N 1.33 -0.432 0 C-N-CA 122.801 2.334 . . . . 0.0 113.36 -177.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' TYR . . . . . 0.55 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 50.3 t80 -59.48 -41.1 89.02 Favored 'General case' 0 C--O 1.208 -1.116 0 C-N-CA 123.639 0.776 . . . . 0.0 110.209 -179.496 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.1 p -59.41 -42.67 92.36 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 115.171 -0.922 . . . . 0.0 112.99 -176.19 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -96.48 -2.88 44.38 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 112.886 0.698 . . . . 0.0 112.886 -179.094 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 36.8 m-80 -132.14 15.04 4.67 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 113.185 0.809 . . . . 0.0 113.185 -176.317 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' LYS . . . . . 0.492 ' HG2' ' OE2' ' A' ' 66' ' ' GLU . 20.5 pttm -66.02 -29.16 69.47 Favored 'General case' 0 N--CA 1.487 1.415 0 CA-C-O 121.735 0.778 . . . . 0.0 110.831 -179.18 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' GLU . . . . . 0.492 ' OE2' ' HG2' ' A' ' 65' ' ' LYS . 2.9 mp0 -68.21 -36.78 80.07 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 179.476 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 40.9 mttp -84.19 -59.78 2.29 Favored 'General case' 0 N--CA 1.428 -1.542 0 CA-C-N 113.405 -1.725 . . . . 0.0 111.583 -170.42 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 36.2 m-85 -105.51 -4.91 20.71 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.386 -170.807 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -81.7 56.45 4.92 Favored Glycine 0 N--CA 1.444 -0.805 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 177.748 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.534 ' O ' ' HE1' ' A' ' 77' ' ' PHE . 0.0 OUTLIER -119.33 158.55 48.44 Favored Pre-proline 0 C--N 1.305 -1.352 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 -177.55 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -73.36 167.24 27.81 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 121.883 1.722 . . . . 0.0 111.926 175.14 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -152.65 -177.63 6.36 Favored 'General case' 0 C--N 1.308 -1.23 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.226 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 30.9 mmmt -97.08 -10.56 25.81 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 122.243 0.217 . . . . 0.0 110.795 178.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 27.4 mmt180 -67.17 124.38 22.93 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 177.456 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.61 137.22 40.62 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 176.345 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . 0.542 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 100.97 -26.14 25.77 Favored Glycine 0 N--CA 1.426 -2.013 0 N-CA-C 108.926 -1.67 . . . . 0.0 108.926 -174.53 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' PHE . . . . . 0.534 ' HE1' ' O ' ' A' ' 70' ' ' LYS . 20.6 t80 -77.04 -46.52 23.48 Favored 'General case' 0 N--CA 1.44 -0.939 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.473 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -60.37 -50.29 74.19 Favored 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 115.164 -0.925 . . . . 0.0 108.597 177.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 20.5 mp0 -61.09 -41.7 97.15 Favored 'General case' 0 N--CA 1.435 -1.207 0 CA-C-N 113.797 -1.547 . . . . 0.0 110.513 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.06 -34.55 64.76 Favored Glycine 0 CA--C 1.496 -1.11 0 CA-C-N 115.879 -0.601 . . . . 0.0 113.403 -178.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 32.3 tp -63.62 -30.62 71.71 Favored 'General case' 0 C--O 1.204 -1.325 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 176.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 79.1 t90 -77.04 -47.12 21.48 Favored 'General case' 0 N--CA 1.437 -1.109 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.031 175.237 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 39.0 mt-10 -58.93 -42.28 89.37 Favored 'General case' 0 C--O 1.196 -1.711 0 N-CA-C 113.202 0.816 . . . . 0.0 113.202 -178.723 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 21.1 tt -63.33 -33.18 59.63 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -175.631 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -81.61 -34.24 31.04 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.126 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.7 m-80 -100.52 -46.54 5.18 Favored 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 112.94 0.719 . . . . 0.0 112.94 -172.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 64.9 t30 -133.58 73.64 72.28 Favored Pre-proline 0 C--N 1.3 -1.565 0 CA-C-O 121.058 0.456 . . . . 0.0 110.686 -178.166 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -73.61 -5.61 17.37 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 122.978 2.452 . . . . 0.0 112.791 -176.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 61.5 pttt . . . . . 0 C--N 1.308 -1.2 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.874 -177.982 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.0 mmt . . . . . 0 CA--C 1.497 -1.075 0 N-CA-C 110.203 -0.295 . . . . 0.0 110.203 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -121.61 75.37 1.18 Allowed 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 175.324 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . 0.408 ' HG3' ' O ' ' A' ' 4' ' ' ASP . 8.0 ptt180 -147.22 -172.91 4.12 Favored 'General case' 0 C--N 1.297 -1.674 0 N-CA-C 106.286 -1.746 . . . . 0.0 106.286 176.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . 0.408 ' O ' ' HG3' ' A' ' 3' ' ' ARG . 3.6 p-10 -89.55 155.37 19.32 Favored 'General case' 0 C--O 1.257 1.457 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 179.388 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 1.635 ' HD2' ' CD1' ' A' ' 5' ' ' PHE . 95.9 m-85 -133.51 118.35 18.21 Favored 'General case' 0 N--CA 1.416 -2.126 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 178.515 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 25.9 mttp -94.84 147.49 33.2 Favored Pre-proline 0 C--N 1.291 -1.964 0 CA-C-N 114.583 -1.19 . . . . 0.0 108.783 -173.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -63.19 115.64 3.1 Favored 'Trans proline' 0 N--CA 1.448 -1.157 0 N-CA-C 107.549 -1.751 . . . . 0.0 107.549 170.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 110.07 -8.47 31.3 Favored Glycine 0 N--CA 1.422 -2.253 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.214 -174.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -73.1 154.92 40.19 Favored 'General case' 0 C--O 1.253 1.28 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 -178.214 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 71.1 mt -102.12 122.56 44.37 Favored 'General case' 0 C--N 1.298 -1.665 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.553 -173.064 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -139.97 178.88 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 CA-C-O 122.458 1.123 . . . . 0.0 113.206 -175.154 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 1.624 ' HD1' ' CD2' ' A' ' 12' ' ' PHE . 47.5 m-85 -115.89 127.87 55.35 Favored 'General case' 0 C--N 1.278 -2.516 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 170.422 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.434 ' HB2' HD13 ' A' ' 53' ' ' LEU . . . -108.43 124.68 50.78 Favored 'General case' 0 C--N 1.273 -2.757 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.579 -175.313 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.671 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -105.93 123.39 47.89 Favored 'General case' 0 N--CA 1.404 -2.768 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.34 -177.759 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 68.4 mtm -120.63 158.17 27.97 Favored 'General case' 0 C--N 1.317 -0.847 0 C-N-CA 123.344 0.657 . . . . 0.0 109.231 176.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -67.53 117.07 8.99 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.08 -5.81 57.94 Favored Glycine 0 C--O 1.251 1.195 0 N-CA-C 111.518 -0.633 . . . . 0.0 111.518 178.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 1.657 ' HE1' ' CE2' ' A' ' 18' ' ' TYR . 94.0 m-85 -124.04 147.25 53.65 Favored Pre-proline 0 N--CA 1.426 -1.666 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 -179.37 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -74.49 170.98 19.03 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 121.805 1.67 . . . . 0.0 109.273 174.249 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.57 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 65.8 m80 -59.97 110.78 1.27 Allowed 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 175.715 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -102.22 137.95 19.59 Favored Pre-proline 0 C--N 1.308 -1.22 0 C-N-CA 124.017 0.927 . . . . 0.0 109.53 -170.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -64.38 118.16 5.15 Favored 'Trans proline' 0 C--O 1.242 0.694 0 C-N-CA 121.869 1.712 . . . . 0.0 110.636 178.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.98 166.12 26.22 Favored 'General case' 0 N--CA 1.415 -2.188 0 CA-C-O 121.181 0.515 . . . . 0.0 110.403 -176.27 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.427 ' HD3' ' O ' ' A' ' 88' ' ' PRO . 11.4 ttp180 -114.63 146.25 41.06 Favored 'General case' 0 C--N 1.282 -2.351 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.496 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.6 t -73.28 117.03 16.37 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 104.098 -2.556 . . . . 0.0 104.098 168.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.495 ' CG ' ' HZ2' ' A' ' 91' ' ' LYS . 4.6 t70 -92.97 -178.0 4.67 Favored 'General case' 0 C--N 1.281 -2.405 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 -170.334 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -100.51 169.78 8.84 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 178.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 52.3 t -67.3 119.89 68.46 Favored Pre-proline 0 C--N 1.311 -1.081 0 C-N-CA 120.766 -0.374 . . . . 0.0 110.209 -177.155 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -74.65 152.02 42.11 Favored 'Trans proline' 0 N--CA 1.421 -2.744 0 C-N-CA 121.877 1.718 . . . . 0.0 112.468 -179.087 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -68.45 129.21 39.24 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-N 115.42 -0.809 . . . . 0.0 108.947 179.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.17 -18.57 45.38 Favored Glycine 0 N--CA 1.434 -1.454 0 CA-C-N 115.461 -0.791 . . . . 0.0 111.439 -178.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -79.05 94.42 5.31 Favored 'General case' 0 N--CA 1.441 -0.924 0 CA-C-O 121.406 0.622 . . . . 0.0 110.819 179.2 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.2 m -89.31 6.09 4.35 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.158 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.934 178.538 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -82.43 128.23 67.85 Favored Pre-proline 0 N--CA 1.427 -1.597 0 CA-C-N 115.429 -0.805 . . . . 0.0 112.903 -179.207 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 13.7 Cg_exo -70.99 170.27 18.44 Favored 'Trans proline' 0 C--O 1.265 1.833 0 C-N-CA 122.474 2.116 . . . . 0.0 110.431 175.007 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -52.24 127.89 25.38 Favored 'Trans proline' 0 C--N 1.359 1.112 0 C-N-CA 122.735 2.29 . . . . 0.0 110.787 177.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.2 m -105.94 9.0 32.79 Favored 'General case' 0 C--N 1.287 -2.121 0 CA-C-N 114.712 -1.131 . . . . 0.0 108.97 -173.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 46.9 m-80 78.92 8.53 1.95 Allowed 'General case' 0 N--CA 1.492 1.653 0 C-N-CA 125.969 1.708 . . . . 0.0 108.155 -170.478 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.488 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 47.6 mmtt -118.63 149.52 41.25 Favored 'General case' 0 N--CA 1.409 -2.504 0 CA-C-N 113.346 -1.752 . . . . 0.0 107.444 174.292 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.482 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 79.4 mt -113.25 153.28 45.54 Favored Pre-proline 0 C--N 1.263 -3.186 0 O-C-N 124.812 1.32 . . . . 0.0 108.696 -177.432 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -69.68 123.61 10.3 Favored 'Trans proline' 0 N--CA 1.457 -0.667 0 C-N-CA 121.658 1.572 . . . . 0.0 109.667 174.794 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.403 ' O ' ' HA ' ' A' ' 50' ' ' THR . 50.7 mm -120.58 122.44 68.04 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 CA-C-O 120.879 0.371 . . . . 0.0 110.454 -176.665 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.513 ' CE1' ' HA ' ' A' ' 48' ' ' HIS . 35.0 t80 -98.05 114.84 27.11 Favored 'General case' 0 C--N 1.285 -2.196 0 C-N-CA 123.441 0.697 . . . . 0.0 109.754 178.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 1.664 ' HD1' ' CD2' ' A' ' 44' ' ' PHE . 81.3 m-85 -79.79 129.93 34.9 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 177.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 73.1 m-85 -82.42 154.85 24.97 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.574 177.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.525 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 74.38 -20.65 1.6 Allowed Glycine 0 C--N 1.31 -0.883 0 CA-C-N 115.442 -0.799 . . . . 0.0 114.411 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 38.1 p -116.41 -22.64 8.68 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 117.911 0.856 . . . . 0.0 109.391 173.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.513 ' HA ' ' CE1' ' A' ' 43' ' ' PHE . 12.5 m-70 68.12 22.61 8.26 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 114.959 -1.019 . . . . 0.0 112.98 177.825 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -79.34 172.3 13.99 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.975 178.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.403 ' HA ' ' O ' ' A' ' 42' ' ' ILE . 3.8 m -140.95 138.18 33.62 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 177.415 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -140.16 -179.0 5.72 Favored 'General case' 0 C--N 1.288 -2.107 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.383 -176.634 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 1.647 ' HE1' ' CE2' ' A' ' 52' ' ' PHE . 62.0 m-85 -129.59 109.94 11.42 Favored 'General case' 0 N--CA 1.445 -0.68 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 177.018 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.434 HD13 ' HB2' ' A' ' 13' ' ' ALA . 94.6 mt -129.08 153.57 47.51 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 -179.565 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.488 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -87.97 171.82 41.32 Favored Glycine 0 CA--C 1.49 -1.492 0 C-N-CA 120.307 -0.949 . . . . 0.0 112.191 -174.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -61.73 -19.0 63.63 Favored 'Trans proline' 0 C--O 1.239 0.532 0 C-N-CA 123.088 2.526 . . . . 0.0 111.982 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -91.86 -19.95 21.97 Favored 'General case' 0 N--CA 1.433 -1.29 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.903 179.473 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.7 m-20 -82.07 -20.86 37.36 Favored 'General case' 0 CA--C 1.493 -1.234 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.298 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.407 ' HA ' ' O ' ' A' ' 12' ' ' PHE . 15.5 pt -110.19 151.56 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.687 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.65 -176.359 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -135.73 137.66 26.18 Favored Pre-proline 0 C--O 1.185 -2.327 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -66.32 127.36 17.27 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 122.486 2.124 . . . . 0.0 113.938 -175.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 1.621 ' HE2' ' CE1' ' A' ' 61' ' ' TYR . 75.3 t80 -57.8 -32.48 67.6 Favored 'General case' 0 C--O 1.205 -1.279 0 CA-C-N 114.713 -1.13 . . . . 0.0 111.694 -175.101 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.59 -57.45 11.04 Favored 'General case' 0 C--N 1.293 -1.889 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -69.42 -34.53 74.6 Favored 'General case' 0 C--O 1.219 -0.518 0 CA-C-O 121.506 0.669 . . . . 0.0 111.555 -177.513 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . 0.309 0.8 OUTLIER -109.81 23.74 13.98 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 115.32 1.6 . . . . 0.0 115.32 -175.715 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.455 ' HZ3' ' CG ' ' A' ' 85' ' ' ASP . 15.8 ttmm -63.27 -27.38 69.29 Favored 'General case' 0 N--CA 1.481 1.095 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.217 171.742 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.452 ' CD ' ' HG2' ' A' ' 67' ' ' LYS . 1.2 pp20? -77.41 -35.46 54.19 Favored 'General case' 0 N--CA 1.423 -1.796 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.215 176.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.452 ' HG2' ' CD ' ' A' ' 66' ' ' GLU . 0.1 OUTLIER -77.37 -59.74 2.66 Favored 'General case' 0 N--CA 1.439 -0.982 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.119 -174.381 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 1.652 ' HE2' ' CE1' ' A' ' 68' ' ' TYR . 32.7 m-85 -105.82 -4.11 21.17 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.986 -169.603 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . 0.415 ' HA3' ' O ' ' A' ' 65' ' ' LYS . . . -79.7 59.86 4.41 Favored Glycine 0 N--CA 1.436 -1.347 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 176.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 38.7 mmtm -132.34 134.34 24.81 Favored Pre-proline 0 C--N 1.32 -0.679 0 C-N-CA 122.936 0.495 . . . . 0.0 111.259 -179.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.455 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 78.1 Cg_exo -48.31 131.3 22.45 Favored 'Trans proline' 0 C--O 1.273 2.248 0 C-N-CA 123.911 3.074 . . . . 0.0 113.75 178.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.537 ' HB2' ' CD1' ' A' ' 77' ' ' PHE . 1.2 t-20 -113.82 -178.21 3.32 Favored 'General case' 0 N--CA 1.406 -2.633 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.953 -174.146 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . 0.603 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 7.3 mptt -110.81 10.65 22.52 Favored 'General case' 0 N--CA 1.425 -1.696 0 CA-C-O 122.485 1.136 . . . . 0.0 108.375 -178.252 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 31.2 mmt180 -96.45 129.52 43.79 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 114.204 -1.362 . . . . 0.0 108.567 173.81 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.41 ' HG3' ' OE2' ' A' ' 79' ' ' GLU . 61.9 tttp -69.7 144.35 52.85 Favored 'General case' 0 N--CA 1.446 -0.663 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 174.7 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.525 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 91.47 -25.91 13.83 Favored Glycine 0 C--O 1.208 -1.469 0 N-CA-C 111.761 -0.536 . . . . 0.0 111.761 -177.517 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.537 ' CD1' ' HB2' ' A' ' 72' ' ' ASN . 32.5 t80 -69.78 -53.63 17.42 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-O 121.85 0.834 . . . . 0.0 109.423 -178.653 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.455 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 87.5 m-20 -69.93 -32.84 71.33 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.905 -176.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . 0.41 ' OE2' ' HG3' ' A' ' 75' ' ' LYS . 28.1 mt-10 -72.09 -37.68 69.52 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 114.738 -1.119 . . . . 0.0 108.382 178.243 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.04 -31.63 66.58 Favored Glycine 0 N--CA 1.428 -1.86 0 CA-C-N 115.007 -0.997 . . . . 0.0 112.462 177.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 86.0 mt -55.95 -34.74 65.95 Favored 'General case' 0 N--CA 1.474 0.746 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 175.136 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.4 t90 -75.91 -50.71 14.23 Favored 'General case' 0 N--CA 1.426 -1.635 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.457 177.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -54.98 -48.37 73.35 Favored 'General case' 0 C--O 1.2 -1.537 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -178.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.2 tt -67.43 -25.5 33.53 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.172 0 N-CA-C 112.205 0.446 . . . . 0.0 112.205 -175.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.455 ' CG ' ' HZ3' ' A' ' 65' ' ' LYS . 6.7 t0 -94.39 -22.59 18.22 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.261 0.553 . . . . 0.0 110.488 -174.197 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.467 ' N ' HD21 ' A' ' 86' ' ' ASN . 0.8 OUTLIER -106.96 -57.49 2.06 Favored 'General case' 0 CA--C 1.505 -0.777 0 CA-C-O 121.291 0.567 . . . . 0.0 111.366 -179.285 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -127.6 76.02 77.27 Favored Pre-proline 0 C--N 1.313 -1.015 0 C-N-CA 119.849 -0.74 . . . . 0.0 110.413 -179.072 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.427 ' O ' ' HD3' ' A' ' 24' ' ' ARG . 48.6 Cg_endo -69.73 -6.54 18.83 Favored 'Trans proline' 0 N--CA 1.483 0.857 0 C-N-CA 122.722 2.282 . . . . 0.0 113.93 -175.393 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.2 pttm -103.22 20.3 17.96 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 121.19 0.519 . . . . 0.0 109.699 -178.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 14.7 p -78.6 119.19 27.21 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.006 0 CA-C-O 122.193 0.997 . . . . 0.0 113.173 -176.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.495 ' HZ2' ' CG ' ' A' ' 26' ' ' ASP . 18.2 ptpt -162.1 171.97 16.62 Favored 'General case' 0 N--CA 1.419 -2.002 0 CA-C-N 114.757 -1.11 . . . . 0.0 108.275 172.582 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -88.4 -174.61 4.68 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 123.553 0.533 . . . . 0.0 109.656 -179.106 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.9 p . . . . . 0 N--CA 1.434 -1.228 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 179.353 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 98.0 mmm . . . . . 0 CA--C 1.49 -1.352 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -94.86 69.92 3.37 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 178.258 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 15.5 ptt180 -121.96 160.58 24.56 Favored 'General case' 0 C--N 1.286 -2.156 0 CA-C-N 113.61 -1.632 . . . . 0.0 109.729 -179.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -114.75 -170.12 1.68 Allowed 'General case' 0 C--O 1.261 1.673 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 174.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 0.548 ' CE2' HG13 ' A' ' 58' ' ' ILE . 56.4 m-85 -109.01 145.52 35.41 Favored 'General case' 0 C--N 1.288 -2.078 0 N-CA-C 116.131 1.901 . . . . 0.0 116.131 -165.496 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.36 149.15 54.32 Favored Pre-proline 0 N--CA 1.423 -1.808 0 CA-C-N 113.166 -1.834 . . . . 0.0 106.71 179.694 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -58.56 130.44 37.31 Favored 'Trans proline' 0 C--O 1.236 0.41 0 C-N-CA 122.008 1.805 . . . . 0.0 109.97 173.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 104.72 -16.58 47.34 Favored Glycine 0 N--CA 1.433 -1.528 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.988 -179.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -79.59 162.31 25.4 Favored 'General case' 0 C--O 1.25 1.099 0 CA-C-N 117.216 0.508 . . . . 0.0 110.156 -175.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.412 HD22 ' HB2' ' A' ' 88' ' ' PRO . 58.0 mt -100.34 122.66 43.48 Favored 'General case' 0 CA--C 1.496 -1.116 0 C-N-CA 122.81 0.444 . . . . 0.0 110.395 -172.676 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -138.37 179.86 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.308 0 CA-C-O 122.5 1.143 . . . . 0.0 113.696 -173.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 1.605 ' HE2' ' CE1' ' A' ' 12' ' ' PHE . 61.0 m-85 -113.76 130.06 56.5 Favored 'General case' 0 C--N 1.283 -2.321 0 CA-C-N 113.775 -1.557 . . . . 0.0 107.684 170.671 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.404 ' HA ' HG23 ' A' ' 58' ' ' ILE . . . -107.7 118.23 36.19 Favored 'General case' 0 N--CA 1.398 -3.042 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -176.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.652 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -105.28 122.72 46.53 Favored 'General case' 0 N--CA 1.399 -2.987 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.192 -176.887 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 70.1 mtm -118.33 158.17 25.72 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.237 177.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 59.3 tttm -65.8 116.58 7.13 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.551 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.15 -2.45 65.81 Favored Glycine 0 C--O 1.251 1.159 0 N-CA-C 111.632 -0.587 . . . . 0.0 111.632 179.335 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 81.5 m-85 -120.9 150.94 54.09 Favored Pre-proline 0 N--CA 1.427 -1.61 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -178.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -77.61 171.09 18.08 Favored 'Trans proline' 0 N--CA 1.44 -1.622 0 C-N-CA 121.815 1.677 . . . . 0.0 109.312 174.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.484 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 69.7 m80 -62.01 111.18 1.82 Allowed 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 175.421 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -100.67 137.53 19.88 Favored Pre-proline 0 C--N 1.301 -1.521 0 N-CA-C 109.209 -0.664 . . . . 0.0 109.209 -172.181 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -65.99 118.05 5.17 Favored 'Trans proline' 0 C--O 1.243 0.762 0 C-N-CA 121.561 1.507 . . . . 0.0 110.932 178.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.34 166.85 25.09 Favored 'General case' 0 N--CA 1.419 -1.985 0 CA-C-N 116.223 -0.444 . . . . 0.0 109.815 -176.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.408 ' HB2' ' CE2' ' A' ' 45' ' ' PHE . 14.2 ttp180 -116.58 147.89 41.43 Favored 'General case' 0 C--N 1.28 -2.415 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.342 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 40.6 t -74.14 123.83 30.29 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.199 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 171.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -87.91 169.76 11.73 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 -173.054 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -113.44 132.21 55.73 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-O 121.542 0.687 . . . . 0.0 111.511 -177.394 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.4 p -87.13 124.8 67.94 Favored Pre-proline 0 N--CA 1.432 -1.335 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.313 -179.247 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -76.48 158.49 36.36 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.453 2.102 . . . . 0.0 112.474 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 20.1 t0 -70.82 149.13 47.14 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 174.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.97 -23.49 35.44 Favored Glycine 0 C--N 1.29 -1.995 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 -174.143 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -93.84 38.94 1.07 Allowed 'General case' 0 C--O 1.201 -1.449 0 CA-C-O 121.819 0.819 . . . . 0.0 109.753 176.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.5 m -73.72 8.47 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 113.422 -1.717 . . . . 0.0 113.756 -175.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 3.5 mppt? -72.93 142.86 83.49 Favored Pre-proline 0 C--N 1.3 -1.576 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 176.254 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -59.4 133.86 54.92 Favored 'Trans proline' 0 CA--C 1.537 0.66 0 C-N-CA 122.039 1.826 . . . . 0.0 113.111 -176.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.438 ' C ' ' H ' ' A' ' 38' ' ' ASN . 89.4 Cg_endo -87.1 172.43 6.23 Favored 'Trans proline' 0 N--CA 1.439 -1.702 0 C-N-CA 122.984 2.456 . . . . 0.0 111.85 179.332 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.406 ' O ' ' HB3' ' A' ' 38' ' ' ASN . 4.8 m -60.2 8.79 0.02 OUTLIER 'General case' 0 CA--C 1.58 2.099 0 C-N-CA 126.548 1.939 . . . . 0.0 113.735 179.448 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.438 ' H ' ' C ' ' A' ' 36' ' ' PRO . 0.5 OUTLIER 74.66 9.79 4.14 Favored 'General case' 0 N--CA 1.481 1.105 0 CA-C-O 123.479 1.609 . . . . 0.0 110.05 -177.215 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.465 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 81.4 mttt -127.74 169.99 13.23 Favored 'General case' 0 N--CA 1.424 -1.747 0 CA-C-N 114.244 -1.343 . . . . 0.0 110.134 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.447 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 86.8 mt -86.04 144.76 39.43 Favored Pre-proline 0 C--N 1.313 -0.979 0 O-C-N 123.681 0.613 . . . . 0.0 109.863 -176.573 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -73.37 123.97 9.09 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.046 1.831 . . . . 0.0 109.819 175.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 51.1 mm -118.42 125.9 74.68 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.879 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.412 -176.461 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -101.34 113.9 27.4 Favored 'General case' 0 C--N 1.291 -1.971 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 178.03 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 1.667 ' HD2' ' CD1' ' A' ' 44' ' ' PHE . 79.0 m-85 -81.02 130.57 35.08 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-O 121.102 0.477 . . . . 0.0 111.861 178.517 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 1.645 ' HE2' ' CE1' ' A' ' 45' ' ' PHE . 74.1 m-85 -83.73 156.37 22.61 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 176.091 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.45 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 75.59 -20.15 2.31 Favored Glycine 0 C--N 1.314 -0.675 0 CA-C-N 115.922 -0.581 . . . . 0.0 113.957 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 24.7 p -119.08 -23.19 6.92 Favored 'General case' 0 C--N 1.308 -1.232 0 O-C-N 122.383 -0.48 . . . . 0.0 110.084 174.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 61.69 27.98 17.22 Favored 'General case' 0 C--N 1.354 0.788 0 CA-C-O 121.712 0.767 . . . . 0.0 111.536 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -85.35 159.9 19.91 Favored 'General case' 0 CA--C 1.491 -1.317 0 CA-C-N 114.043 -1.435 . . . . 0.0 108.783 176.051 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.5 m -130.05 136.72 49.69 Favored 'General case' 0 C--N 1.268 -2.946 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.126 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -140.08 -179.24 5.85 Favored 'General case' 0 C--N 1.284 -2.243 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.688 -176.15 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.447 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 79.6 m-85 -132.21 110.76 10.87 Favored 'General case' 0 CA--C 1.499 -1.011 0 C-N-CA 123.351 0.66 . . . . 0.0 109.464 177.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 95.9 mt -126.53 151.68 47.54 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.465 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -75.9 162.67 52.99 Favored Glycine 0 N--CA 1.416 -2.648 0 C-N-CA 119.968 -1.111 . . . . 0.0 110.677 -176.192 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.446 ' O ' ' HE2' ' A' ' 5' ' ' PHE . 17.9 Cg_endo -62.42 -19.99 69.08 Favored 'Trans proline' 0 C--O 1.191 -1.874 0 C-N-CA 122.237 1.958 . . . . 0.0 111.162 179.177 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.48 -0.4 40.8 Favored 'General case' 0 C--N 1.286 -2.166 0 O-C-N 121.441 -0.787 . . . . 0.0 111.537 178.278 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -89.57 -20.95 23.15 Favored 'General case' 0 CA--C 1.488 -1.41 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 175.434 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.548 HG13 ' CE2' ' A' ' 5' ' ' PHE . 18.4 pt -110.59 157.24 11.41 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.75 0 CA-C-N 114.174 -1.375 . . . . 0.0 110.223 -175.872 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -139.36 147.31 52.23 Favored Pre-proline 0 C--N 1.303 -1.432 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 -177.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . 0.407 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 38.6 Cg_endo -64.89 129.68 23.94 Favored 'Trans proline' 0 C--O 1.243 0.728 0 C-N-CA 122.657 2.238 . . . . 0.0 113.081 -175.661 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 1.663 ' HE2' ' CE1' ' A' ' 61' ' ' TYR . 82.2 t80 -60.94 -37.12 81.22 Favored 'General case' 0 C--O 1.205 -1.264 0 CA-C-N 115.447 -0.797 . . . . 0.0 111.983 -177.077 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 22.6 t -63.63 -54.05 41.88 Favored 'General case' 0 C--N 1.307 -1.269 0 CA-C-O 120.946 0.403 . . . . 0.0 110.635 -175.332 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.407 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 4.2 mp0 -71.01 -25.84 62.86 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-O 121.376 0.608 . . . . 0.0 112.304 -178.073 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.456 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 28.0 m-80 -105.48 12.67 31.15 Favored 'General case' 0 C--N 1.293 -1.878 0 C-N-CA 120.536 -0.466 . . . . 0.0 111.917 -176.76 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.3 tttp -63.19 -37.87 88.94 Favored 'General case' 0 N--CA 1.479 1.001 0 CA-C-O 121.153 0.502 . . . . 0.0 110.92 -179.544 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.526 ' CD ' ' HZ1' ' A' ' 70' ' ' LYS . 18.2 mm-40 -71.57 -24.01 61.84 Favored 'General case' 0 CA--C 1.488 -1.417 0 CA-C-O 121.831 0.824 . . . . 0.0 112.151 176.823 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.456 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 35.6 mtpt -85.79 -58.47 2.64 Favored 'General case' 0 C--N 1.266 -3.053 0 CA-C-N 114.135 -1.393 . . . . 0.0 111.426 -176.181 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 1.637 ' HE1' ' CE2' ' A' ' 68' ' ' TYR . 38.3 m-85 -125.17 0.75 7.84 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.995 -0.548 . . . . 0.0 112.006 -172.831 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -94.29 32.11 6.2 Favored Glycine 0 CA--C 1.496 -1.104 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.236 -175.261 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.526 ' HZ1' ' CD ' ' A' ' 66' ' ' GLU . 50.0 mtmt -130.21 153.93 81.28 Favored Pre-proline 0 C--N 1.301 -1.515 0 C-N-CA 122.808 0.443 . . . . 0.0 110.138 178.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_exo -42.68 144.24 1.39 Allowed 'Trans proline' 0 C--N 1.363 1.298 0 C-N-CA 124.583 3.522 . . . . 0.0 117.328 -172.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 -137.13 -166.25 1.89 Allowed 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 105.073 -2.195 . . . . 0.0 105.073 173.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 3.5 mmmp? -116.55 2.26 13.02 Favored 'General case' 0 N--CA 1.416 -2.138 0 C-N-CA 119.019 -1.072 . . . . 0.0 113.28 174.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 14.2 mmt180 -61.39 128.92 38.68 Favored 'General case' 0 C--N 1.324 -0.539 0 O-C-N 124.167 0.917 . . . . 0.0 109.012 175.189 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.8 tmtm? -68.78 123.55 21.24 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.585 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.45 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 105.91 -25.05 25.14 Favored Glycine 0 N--CA 1.428 -1.884 0 N-CA-C 110.164 -1.175 . . . . 0.0 110.164 -177.893 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.6 t80 -76.6 -44.78 32.98 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -60.82 -50.04 75.06 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.61 178.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -68.16 -40.59 82.28 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.314 -178.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -72.24 -30.89 64.37 Favored Glycine 0 CA--C 1.489 -1.531 0 CA-C-N 115.646 -0.707 . . . . 0.0 112.955 -177.204 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 44.0 tp -62.39 -35.51 79.43 Favored 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.086 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.7 t90 -70.57 -48.61 54.47 Favored 'General case' 0 N--CA 1.425 -1.721 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.95 177.416 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -54.82 -51.35 66.1 Favored 'General case' 0 C--O 1.202 -1.447 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -179.382 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.414 ' HB ' ' CD2' ' A' ' 45' ' ' PHE . 17.6 tt -68.13 -24.01 29.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 112.223 0.453 . . . . 0.0 112.223 -175.329 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 6.3 t0 -94.61 -21.21 18.97 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-O 121.252 0.549 . . . . 0.0 110.458 -175.109 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.457 ' N ' HD21 ' A' ' 86' ' ' ASN . 0.8 OUTLIER -109.83 -56.78 2.27 Favored 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 121.268 0.556 . . . . 0.0 111.603 -178.95 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -125.17 71.66 63.84 Favored Pre-proline 0 C--N 1.316 -0.886 0 C-N-CA 120.169 -0.612 . . . . 0.0 110.126 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.412 ' HB2' HD22 ' A' ' 10' ' ' LEU . 60.1 Cg_endo -73.13 -6.12 18.37 Favored 'Trans proline' 0 N--CA 1.475 0.389 0 C-N-CA 122.527 2.151 . . . . 0.0 113.46 -174.643 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.3 pttm -95.1 13.81 24.03 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.019 -178.451 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 9.8 p -86.3 141.79 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.328 0 CA-C-O 121.052 0.453 . . . . 0.0 110.639 -179.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 30.5 mtpp -128.25 -70.13 0.7 Allowed 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 175.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 1.654 ' HD2' ' CD1' ' A' ' 92' ' ' PHE . 87.8 t80 -97.92 115.63 28.5 Favored 'General case' 0 C--N 1.29 -2.003 0 CA-C-N 114.83 -1.077 . . . . 0.0 111.272 -178.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 25.7 p . . . . . 0 C--N 1.277 -2.585 0 N-CA-C 105.087 -2.19 . . . . 0.0 105.087 173.761 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.489 ' H2 ' ' CG ' ' A' ' 4' ' ' ASP . 64.5 mtt . . . . . 0 N--CA 1.477 0.903 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -100.01 -5.49 28.04 Favored 'General case' 0 C--O 1.207 -1.16 0 CA-C-O 121.226 0.536 . . . . 0.0 110.613 176.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -83.87 -20.23 33.45 Favored 'General case' 0 N--CA 1.479 1.014 0 CA-C-O 122.892 1.33 . . . . 0.0 109.722 178.833 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . 0.489 ' CG ' ' H2 ' ' A' ' 1' ' ' MET . 1.7 p30 -108.61 132.36 53.96 Favored 'General case' 0 C--N 1.258 -3.411 0 CA-C-N 112.252 -2.249 . . . . 0.0 109.783 178.676 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -110.2 124.95 52.52 Favored 'General case' 0 N--CA 1.413 -2.276 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.401 -174.405 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -134.65 154.67 79.68 Favored Pre-proline 0 C--N 1.283 -2.324 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.402 -176.53 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -49.6 123.25 10.14 Favored 'Trans proline' 0 C--N 1.35 0.63 0 C-N-CA 123.365 2.71 . . . . 0.0 111.992 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 112.85 -17.49 22.68 Favored Glycine 0 N--CA 1.424 -2.165 0 CA-C-N 115.656 -0.702 . . . . 0.0 112.24 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -75.44 156.84 34.88 Favored 'General case' 0 C--O 1.249 1.041 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -177.129 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.1 mt -106.92 120.49 42.18 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 -174.525 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.9 pp -137.01 -179.63 3.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 CA-C-O 122.528 1.156 . . . . 0.0 113.42 -174.236 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 1.665 ' HE2' ' CE1' ' A' ' 12' ' ' PHE . 33.2 m-85 -113.57 130.52 56.35 Favored 'General case' 0 C--N 1.275 -2.665 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 170.401 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -107.24 116.39 31.85 Favored 'General case' 0 C--N 1.268 -2.952 0 CA-C-N 115.26 -0.882 . . . . 0.0 108.839 -174.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.626 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -112.87 120.89 43.02 Favored 'General case' 0 N--CA 1.394 -3.256 0 CA-C-N 114.572 -1.194 . . . . 0.0 108.856 -178.888 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 68.1 mtm -105.64 158.48 16.67 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 179.485 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -65.74 116.42 6.93 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -178.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.32 -2.63 63.31 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.726 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 1.661 ' HE1' ' CE2' ' A' ' 18' ' ' TYR . 97.4 m-85 -125.13 148.27 59.88 Favored Pre-proline 0 N--CA 1.438 -1.04 0 CA-C-O 120.595 0.236 . . . . 0.0 110.593 -178.131 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -72.24 170.53 18.89 Favored 'Trans proline' 0 N--CA 1.455 -0.789 0 C-N-CA 122.444 2.096 . . . . 0.0 111.747 177.424 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.456 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 79.4 m80 -67.12 111.69 4.03 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 108.895 -0.779 . . . . 0.0 108.895 178.136 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 13.0 t-105 -109.63 136.03 20.32 Favored Pre-proline 0 C--N 1.314 -0.977 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 -176.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -62.08 120.34 7.88 Favored 'Trans proline' 0 C--O 1.244 0.799 0 C-N-CA 122.536 2.157 . . . . 0.0 112.45 -178.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -148.1 166.07 28.94 Favored 'General case' 0 N--CA 1.431 -1.38 0 CA-C-O 120.932 0.396 . . . . 0.0 110.806 -177.121 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.429 HH21 ' CG ' ' A' ' 26' ' ' ASP . 12.2 ttp180 -109.85 144.53 38.19 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 178.769 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 68.9 t -73.69 107.25 4.15 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.405 0 N-CA-C 102.709 -3.071 . . . . 0.0 102.709 166.489 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.429 ' CG ' HH21 ' A' ' 24' ' ' ARG . 0.4 OUTLIER -88.64 -178.22 5.75 Favored 'General case' 0 C--N 1.271 -2.808 0 C-N-CA 119.654 -0.818 . . . . 0.0 111.957 -168.241 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 -103.69 152.06 22.26 Favored 'General case' 0 C--N 1.285 -2.205 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.956 -173.253 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 39.9 t -90.48 121.56 68.26 Favored Pre-proline 0 C--N 1.312 -1.049 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 179.604 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -78.81 144.05 19.0 Favored 'Trans proline' 0 N--CA 1.438 -1.755 0 C-N-CA 121.771 1.648 . . . . 0.0 113.598 -178.041 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -54.17 130.47 38.49 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.079 173.053 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 110.36 -27.09 11.98 Favored Glycine 0 C--N 1.295 -1.722 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 -177.399 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -78.69 80.81 5.04 Favored 'General case' 0 N--CA 1.439 -0.976 0 CA-C-O 121.988 0.899 . . . . 0.0 109.917 175.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.2 m -95.86 4.04 9.19 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 CA-C-N 114.406 -1.27 . . . . 0.0 110.532 179.315 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 31.0 mmtp -84.26 129.43 58.15 Favored Pre-proline 0 C--N 1.299 -1.62 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 178.05 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -64.09 134.95 45.03 Favored 'Trans proline' 0 N--CA 1.455 -0.753 0 C-N-CA 122.029 1.819 . . . . 0.0 112.543 -178.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.451 ' C ' ' H ' ' A' ' 38' ' ' ASN . 69.7 Cg_endo -78.41 172.05 15.91 Favored 'Trans proline' 0 N--CA 1.443 -1.481 0 C-N-CA 122.695 2.263 . . . . 0.0 111.888 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.6 m -70.31 8.14 0.86 Allowed 'General case' 0 CA--C 1.565 1.551 0 C-N-CA 125.178 1.391 . . . . 0.0 111.552 -179.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.451 ' H ' ' C ' ' A' ' 36' ' ' PRO . 47.9 m-80 75.8 14.11 2.74 Favored 'General case' 0 N--CA 1.481 1.119 0 C-N-CA 125.333 1.453 . . . . 0.0 110.527 -177.494 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.442 ' HE2' ' N ' ' A' ' 54' ' ' GLY . 31.6 mtpt -113.09 166.74 11.14 Favored 'General case' 0 N--CA 1.425 -1.691 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 177.754 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 79.8 mt -85.74 144.2 39.32 Favored Pre-proline 0 C--N 1.302 -1.499 0 O-C-N 123.212 0.32 . . . . 0.0 110.175 -176.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -71.25 123.91 10.0 Favored 'Trans proline' 0 N--CA 1.457 -0.622 0 C-N-CA 122.046 1.83 . . . . 0.0 109.764 175.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 51.4 mm -120.49 122.7 68.77 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 O-C-N 122.165 -0.334 . . . . 0.0 110.265 -176.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 88.0 t80 -104.95 114.48 28.71 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 178.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -74.9 132.7 41.66 Favored 'General case' 0 C--N 1.319 -0.737 0 O-C-N 123.655 0.597 . . . . 0.0 111.335 179.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -90.19 158.1 17.39 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.269 177.586 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.555 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 75.84 -19.9 2.54 Favored Glycine 0 C--N 1.311 -0.852 0 CA-C-N 115.631 -0.713 . . . . 0.0 113.529 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 60.5 p -119.27 -22.68 7.02 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 122.419 -0.46 . . . . 0.0 109.941 175.439 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.1 m170 66.98 25.57 9.3 Favored 'General case' 0 C--N 1.352 0.697 0 C-N-CA 124.12 0.968 . . . . 0.0 111.752 179.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -84.42 178.04 7.9 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.329 178.239 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 8.9 m -144.01 147.42 33.85 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -147.23 -179.79 7.08 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 123.827 0.851 . . . . 0.0 109.776 -178.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -133.06 110.82 10.48 Favored 'General case' 0 C--O 1.252 1.235 0 CA-C-O 121.524 0.678 . . . . 0.0 109.353 177.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.487 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 96.2 mt -127.86 155.76 43.63 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.354 -176.863 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.442 ' N ' ' HE2' ' A' ' 39' ' ' LYS . . . -94.69 174.47 33.24 Favored Glycine 0 N--CA 1.425 -2.053 0 N-CA-C 110.152 -1.179 . . . . 0.0 110.152 -178.342 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -66.31 -11.04 29.73 Favored 'Trans proline' 0 C--O 1.208 -1.024 0 C-N-CA 122.797 2.332 . . . . 0.0 112.799 -177.218 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 20.7 pttp -97.62 -7.96 29.95 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 122.211 1.005 . . . . 0.0 110.245 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.487 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 65.5 m-20 -100.64 -10.24 21.12 Favored 'General case' 0 C--N 1.287 -2.152 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.577 -176.04 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 12.2 pt -125.23 154.97 33.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.42 -175.154 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -142.49 140.74 19.23 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 179.424 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -65.64 127.66 18.44 Favored 'Trans proline' 0 C--O 1.243 0.751 0 C-N-CA 122.774 2.316 . . . . 0.0 114.13 -173.73 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 65.2 t80 -62.48 -30.61 71.38 Favored 'General case' 0 CA--C 1.505 -0.774 0 C-N-CA 124.105 0.962 . . . . 0.0 109.437 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.8 m -55.02 -35.48 64.47 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-N 114.908 -1.042 . . . . 0.0 111.88 -179.534 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.44 ' C ' ' H ' ' A' ' 65' ' ' LYS 0.284 55.0 mt-10 -85.75 -54.11 4.72 Favored 'General case' 0 CA--C 1.483 -1.618 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 172.048 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 31.6 m-80 -67.96 9.87 0.26 Allowed 'General case' 0 CA--C 1.473 -1.991 0 C-N-CA 127.628 2.371 . . . . 0.0 113.867 -164.238 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.44 ' H ' ' C ' ' A' ' 63' ' ' GLU . 55.6 tttp -66.85 -33.8 76.4 Favored 'General case' 0 N--CA 1.394 -3.269 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 174.693 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.745 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -80.43 -33.41 36.94 Favored 'General case' 0 N--CA 1.429 -1.525 0 CA-C-N 115.016 -0.993 . . . . 0.0 113.573 172.86 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.745 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 24.5 mtmm -77.54 -59.47 2.77 Favored 'General case' 0 CA--C 1.503 -0.843 0 N-CA-C 113.169 0.803 . . . . 0.0 113.169 -178.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 1.614 ' HD2' ' CD1' ' A' ' 68' ' ' TYR . 89.9 m-85 -120.22 6.77 10.72 Favored 'General case' 0 C--N 1.281 -2.391 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.957 -174.333 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.5 11.99 35.96 Favored Glycine 0 CA--C 1.524 0.636 0 CA-C-N 116.29 -0.413 . . . . 0.0 114.087 -177.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -97.93 127.11 38.13 Favored Pre-proline 0 N--CA 1.441 -0.902 0 CA-C-N 117.162 0.481 . . . . 0.0 110.083 178.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -65.15 128.39 20.44 Favored 'Trans proline' 0 N--CA 1.446 -1.319 0 C-N-CA 122.42 2.08 . . . . 0.0 114.862 -176.05 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -102.35 -157.32 0.6 Allowed 'General case' 0 C--N 1.292 -1.911 0 CA-C-N 113.705 -1.589 . . . . 0.0 108.814 177.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 43.2 mmtm -108.58 15.39 23.82 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 120.444 -0.503 . . . . 0.0 111.359 -179.43 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 39.5 mmt180 -80.02 121.44 25.5 Favored 'General case' 0 CA--C 1.513 -0.476 0 C-N-CA 117.95 -1.5 . . . . 0.0 108.9 171.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 11.0 tppt? -74.06 126.76 31.23 Favored 'General case' 0 N--CA 1.428 -1.551 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.555 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.32 -25.82 18.67 Favored Glycine 0 N--CA 1.424 -2.165 0 N-CA-C 109.114 -1.594 . . . . 0.0 109.114 -173.153 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 1.623 ' HE1' ' CE2' ' A' ' 77' ' ' PHE . 6.8 t80 -76.72 -46.97 23.37 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 179.586 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 11.2 m120 -56.51 -52.53 64.41 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-N 114.944 -1.025 . . . . 0.0 109.009 178.124 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 21.7 mp0 -61.37 -40.91 96.05 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 113.793 -1.549 . . . . 0.0 110.297 -178.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -67.19 -37.66 91.4 Favored Glycine 0 N--CA 1.437 -1.242 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.562 -179.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 90.7 mt -60.82 -34.67 74.89 Favored 'General case' 0 CA--C 1.509 -0.629 0 N-CA-C 110.224 -0.288 . . . . 0.0 110.224 176.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 84.9 t90 -71.7 -50.96 25.57 Favored 'General case' 0 N--CA 1.432 -1.33 0 O-C-N 123.589 0.555 . . . . 0.0 109.557 177.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -56.1 -50.78 70.09 Favored 'General case' 0 C--O 1.202 -1.409 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -178.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.3 tt -66.78 -25.87 35.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 112.486 0.55 . . . . 0.0 112.486 -174.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -93.29 -19.43 21.39 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-O 121.591 0.71 . . . . 0.0 110.621 -173.896 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.9 m-80 -114.04 -56.29 2.41 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.362 -177.035 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.504 ' OD1' ' HG2' ' A' ' 89' ' ' LYS . 65.3 t30 -128.42 75.51 79.18 Favored Pre-proline 0 C--N 1.311 -1.095 0 C-N-CA 119.831 -0.748 . . . . 0.0 111.22 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -69.73 -6.3 18.25 Favored 'Trans proline' 0 N--CA 1.481 0.736 0 C-N-CA 122.704 2.269 . . . . 0.0 113.481 -176.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . 0.504 ' HG2' ' OD1' ' A' ' 87' ' ' ASN . 9.5 ptpp? -97.55 6.26 48.36 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -176.776 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 10.2 p -68.35 148.08 11.99 Favored 'Isoleucine or valine' 0 C--O 1.246 0.909 0 CA-C-O 121.732 0.777 . . . . 0.0 111.818 -175.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 39.1 mmtm -144.66 -49.78 0.27 Allowed 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 177.328 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 1.657 ' HD2' ' CD1' ' A' ' 92' ' ' PHE . 62.9 t80 -134.88 168.65 18.68 Favored 'General case' 0 C--N 1.286 -2.165 0 N-CA-C 104.757 -2.312 . . . . 0.0 104.757 176.072 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 25.0 m . . . . . 0 C--N 1.324 -0.543 0 O-C-N 124.318 1.011 . . . . 0.0 111.569 -177.934 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.8 mtt . . . . . 0 CA--C 1.5 -0.957 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -127.83 79.78 1.92 Allowed 'General case' 0 N--CA 1.436 -1.163 0 N-CA-C 106.857 -1.535 . . . . 0.0 106.857 175.258 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 11.5 ptm180 -137.69 176.31 8.82 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-N 114.442 -1.254 . . . . 0.0 110.321 -177.282 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -115.08 -176.58 2.94 Favored 'General case' 0 C--O 1.252 1.199 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 174.18 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 1.659 ' HE2' ' CE1' ' A' ' 5' ' ' PHE . 88.8 m-85 -114.27 150.41 34.45 Favored 'General case' 0 C--N 1.29 -1.998 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 -169.516 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 9.2 pttp -135.13 166.72 26.94 Favored Pre-proline 0 N--CA 1.43 -1.455 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 177.31 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -59.44 149.34 82.21 Favored 'Trans proline' 0 C--O 1.265 1.87 0 C-N-CA 122.052 1.834 . . . . 0.0 112.451 175.47 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 98.51 -14.24 62.2 Favored Glycine 0 N--CA 1.434 -1.439 0 CA-C-N 115.683 -0.689 . . . . 0.0 113.36 176.7 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -84.22 154.76 22.85 Favored 'General case' 0 C--O 1.242 0.695 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 -177.217 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.43 ' HB3' HD12 ' A' ' 84' ' ' ILE . 83.2 mt -99.54 128.68 45.66 Favored 'General case' 0 CA--C 1.498 -1.03 0 CA-C-N 114.888 -1.051 . . . . 0.0 109.163 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -141.62 -178.62 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-O 122.131 0.967 . . . . 0.0 112.418 -175.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 48.1 m-85 -112.84 129.77 56.33 Favored 'General case' 0 C--N 1.279 -2.464 0 N-CA-C 106.508 -1.664 . . . . 0.0 106.508 170.836 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -107.49 132.23 53.45 Favored 'General case' 0 C--N 1.275 -2.658 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -176.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.483 ' HD3' ' C ' ' A' ' 14' ' ' LYS . 7.3 tmtm? -113.79 117.26 30.98 Favored 'General case' 0 N--CA 1.41 -2.434 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.877 -177.103 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 54.9 mtm -114.41 158.69 21.19 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.724 173.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 39.5 ttpt -62.5 118.72 7.94 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 176.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.33 -12.86 68.64 Favored Glycine 0 C--O 1.243 0.716 0 C-N-CA 121.034 -0.603 . . . . 0.0 111.65 -178.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -106.62 151.31 40.39 Favored Pre-proline 0 C--O 1.256 1.446 0 C-N-CA 122.811 0.444 . . . . 0.0 111.137 -179.343 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -82.27 172.41 11.68 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 C-N-CA 123.435 2.757 . . . . 0.0 108.91 173.499 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -65.94 110.47 2.91 Favored 'General case' 0 C--N 1.31 -1.117 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 175.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -104.37 138.24 19.46 Favored Pre-proline 0 C--N 1.303 -1.439 0 CA-C-N 115.318 -0.856 . . . . 0.0 108.909 -171.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -68.01 117.59 5.02 Favored 'Trans proline' 0 N--CA 1.451 -1.003 0 C-N-CA 121.484 1.456 . . . . 0.0 109.867 177.042 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -145.28 167.05 23.78 Favored 'General case' 0 N--CA 1.415 -2.2 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 -176.145 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.555 ' HB3' ' CE2' ' A' ' 45' ' ' PHE . 8.1 ptt85 -123.53 155.89 36.7 Favored 'General case' 0 C--N 1.281 -2.375 0 C-N-CA 119.149 -1.02 . . . . 0.0 109.356 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.7 t -86.32 117.7 31.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 N-CA-C 106.002 -1.851 . . . . 0.0 106.002 174.187 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -91.73 176.08 6.66 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -175.272 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.423 ' CD ' HH22 ' A' ' 24' ' ' ARG . 11.8 mp0 -92.7 162.5 14.12 Favored 'General case' 0 N--CA 1.421 -1.912 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 45.3 t -77.52 123.47 86.74 Favored Pre-proline 0 C--N 1.304 -1.385 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 175.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -76.57 148.15 29.09 Favored 'Trans proline' 0 N--CA 1.431 -2.162 0 C-N-CA 121.481 1.454 . . . . 0.0 112.611 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -60.1 134.22 56.84 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 175.376 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 110.06 -31.76 7.22 Favored Glycine 0 C--N 1.278 -2.648 0 N-CA-C 109.456 -1.457 . . . . 0.0 109.456 -175.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -83.01 82.72 8.12 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-O 121.926 0.87 . . . . 0.0 109.551 176.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.6 m -90.24 6.83 4.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 CA-C-N 114.475 -1.239 . . . . 0.0 110.858 179.475 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 30.8 mmtp -86.53 130.32 49.66 Favored Pre-proline 0 C--N 1.296 -1.75 0 CA-C-N 114.943 -1.026 . . . . 0.0 108.831 179.02 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -64.43 150.18 88.71 Favored 'Trans proline' 0 C--O 1.243 0.736 0 C-N-CA 122.213 1.942 . . . . 0.0 112.105 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.431 ' C ' ' H ' ' A' ' 38' ' ' ASN . 20.5 Cg_endo -62.6 144.48 94.37 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 122.468 2.112 . . . . 0.0 112.407 -179.289 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.8 m -71.45 8.74 0.97 Allowed 'General case' 0 CA--C 1.566 1.575 0 C-N-CA 125.69 1.596 . . . . 0.0 112.284 -178.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.431 ' H ' ' C ' ' A' ' 36' ' ' PRO . 0.1 OUTLIER 85.85 7.69 0.35 Allowed 'General case' 0 N--CA 1.501 2.117 0 C-N-CA 127.551 2.341 . . . . 0.0 108.849 -173.092 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.53 ' HE3' ' HA ' ' A' ' 53' ' ' LEU . 22.0 mtpp -122.13 155.82 34.93 Favored 'General case' 0 N--CA 1.416 -2.139 0 CA-C-N 113.657 -1.611 . . . . 0.0 107.321 176.27 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 73.3 mt -99.38 155.12 36.87 Favored Pre-proline 0 C--N 1.299 -1.601 0 C-N-CA 123.189 0.596 . . . . 0.0 109.65 -174.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -74.64 121.92 7.03 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 121.158 1.239 . . . . 0.0 109.399 174.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.45 HG13 ' HB2' ' A' ' 53' ' ' LEU . 49.8 mm -115.39 118.65 59.47 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 CA-C-O 120.898 0.38 . . . . 0.0 110.393 -176.407 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.476 ' CE1' ' HA ' ' A' ' 48' ' ' HIS . 58.3 t80 -97.74 116.27 29.63 Favored 'General case' 0 C--N 1.283 -2.303 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.342 179.147 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -77.75 130.72 37.1 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-O 121.055 0.455 . . . . 0.0 111.669 177.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.555 ' CE2' ' HB3' ' A' ' 24' ' ' ARG . 59.6 m-85 -81.89 150.08 27.95 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.65 176.198 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 82.01 -20.59 7.94 Favored Glycine 0 C--N 1.313 -0.749 0 C-N-CA 123.875 0.75 . . . . 0.0 114.394 177.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 41.3 p -119.56 -22.49 6.93 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 117.521 0.661 . . . . 0.0 110.316 174.331 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.476 ' HA ' ' CE1' ' A' ' 43' ' ' PHE . 11.5 m-70 69.03 19.42 8.11 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 123.655 0.782 . . . . 0.0 111.899 -178.308 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -77.29 177.15 8.15 Favored 'General case' 0 N--CA 1.446 -0.638 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.262 177.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.9 m -142.41 144.83 33.28 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 109.675 -0.491 . . . . 0.0 109.675 -179.031 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -137.98 171.76 13.93 Favored 'General case' 0 C--N 1.29 -1.984 0 CA-C-N 115.397 -0.819 . . . . 0.0 109.516 178.536 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -124.62 108.4 12.02 Favored 'General case' 0 CA--C 1.482 -1.659 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 174.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.53 ' HA ' ' HE3' ' A' ' 39' ' ' LYS . 94.5 mt -134.85 139.83 45.35 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 -178.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -87.78 177.95 46.8 Favored Glycine 0 N--CA 1.415 -2.717 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -175.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -67.21 -10.94 30.37 Favored 'Trans proline' 0 C--N 1.319 -0.977 0 C-N-CA 122.445 2.096 . . . . 0.0 112.589 -177.161 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 30.7 mmtm -100.07 -8.14 24.13 Favored 'General case' 0 C--N 1.305 -1.361 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 175.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.465 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 4.3 m-20 -98.15 -12.62 21.56 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-O 121.853 0.835 . . . . 0.0 108.771 -178.262 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 15.1 pt -112.63 157.71 13.27 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.231 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.941 -177.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 -130.93 144.87 55.3 Favored Pre-proline 0 C--N 1.298 -1.647 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 -177.267 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . 0.434 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 42.4 Cg_endo -66.04 127.93 18.64 Favored 'Trans proline' 0 CA--C 1.503 -1.034 0 C-N-CA 122.475 2.117 . . . . 0.0 112.949 -177.483 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 1.644 ' HE2' ' CE1' ' A' ' 61' ' ' TYR . 85.3 t80 -61.68 -36.91 82.23 Favored 'General case' 0 C--O 1.206 -1.224 0 CA-C-N 114.816 -1.084 . . . . 0.0 112.149 -176.411 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.416 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 14.0 m -65.85 -50.09 65.82 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-O 121.144 0.497 . . . . 0.0 110.92 -175.707 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.434 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 3.1 mp0 -79.21 -5.25 53.84 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.656 -0.702 . . . . 0.0 112.533 -177.055 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.427 ' OD1' ' HD2' ' A' ' 67' ' ' LYS . 33.3 m-80 -125.45 12.5 8.11 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 120.591 -0.444 . . . . 0.0 112.089 178.364 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.417 ' O ' ' HA3' ' A' ' 69' ' ' GLY . 62.9 tttp -70.92 -32.22 69.08 Favored 'General case' 0 N--CA 1.479 1.02 0 CA-C-O 122.03 0.919 . . . . 0.0 110.25 -179.344 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.617 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -74.82 -30.37 61.36 Favored 'General case' 0 N--CA 1.404 -2.772 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.649 175.981 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.617 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 49.3 mttp -80.14 -56.73 4.02 Favored 'General case' 0 CA--C 1.505 -0.766 0 CA-C-N 115.626 -0.715 . . . . 0.0 112.584 -178.267 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 54.5 m-85 -114.24 7.19 16.46 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.471 0.653 . . . . 0.0 111.837 -172.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . 0.417 ' HA3' ' O ' ' A' ' 65' ' ' LYS . . . -91.46 51.98 3.05 Favored Glycine 0 C--N 1.294 -1.755 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.637 -176.232 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.489 ' HZ3' ' HB3' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -133.64 141.94 41.98 Favored Pre-proline 0 C--N 1.293 -1.866 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 175.509 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -65.67 126.91 16.89 Favored 'Trans proline' 0 N--CA 1.445 -1.345 0 C-N-CA 121.297 1.331 . . . . 0.0 114.425 -173.311 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -83.91 -173.0 4.47 Favored 'General case' 0 CA--C 1.484 -1.589 0 CA-C-N 114.078 -1.419 . . . . 0.0 109.059 178.819 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . 0.535 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 1.1 mptp? -107.4 20.75 18.49 Favored 'General case' 0 C--N 1.282 -2.355 0 CA-C-O 122.664 1.221 . . . . 0.0 108.003 172.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 13.7 mmt180 -87.12 121.09 29.1 Favored 'General case' 0 N--CA 1.436 -1.172 0 CA-C-N 113.504 -1.68 . . . . 0.0 107.174 173.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 28.2 tptp -60.76 124.13 19.52 Favored 'General case' 0 C--N 1.311 -1.087 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 177.307 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.47 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.21 -25.13 21.1 Favored Glycine 0 N--CA 1.437 -1.256 0 N-CA-C 111.452 -0.659 . . . . 0.0 111.452 -179.246 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 15.2 t80 -74.53 -36.02 63.14 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-O 121.337 0.589 . . . . 0.0 109.837 -176.687 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.502 ' N ' HD21 ' A' ' 78' ' ' ASN . 0.7 OUTLIER -74.77 -41.98 59.03 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -175.836 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -67.9 -34.69 77.13 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 114.336 -1.302 . . . . 0.0 109.452 178.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -66.64 -35.0 89.22 Favored Glycine 0 CA--C 1.493 -1.285 0 CA-C-N 115.659 -0.7 . . . . 0.0 112.167 178.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 87.8 mt -63.65 -35.28 80.01 Favored 'General case' 0 C--O 1.215 -0.723 0 CA-C-O 121.035 0.445 . . . . 0.0 109.845 175.101 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 86.2 t90 -67.43 -49.06 65.36 Favored 'General case' 0 N--CA 1.429 -1.507 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 177.171 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -58.25 -45.44 87.81 Favored 'General case' 0 C--O 1.208 -1.094 0 N-CA-C 113.221 0.822 . . . . 0.0 113.221 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.43 HD12 ' HB3' ' A' ' 10' ' ' LEU . 19.9 tt -73.18 -29.48 28.49 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -173.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -87.23 -18.47 30.22 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 31.8 m-80 -111.63 -54.4 2.61 Favored 'General case' 0 CA--C 1.503 -0.836 0 CA-C-O 121.273 0.559 . . . . 0.0 112.161 -176.344 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.5 t30 -128.56 72.47 80.73 Favored Pre-proline 0 C--N 1.306 -1.316 0 C-N-CA 119.765 -0.774 . . . . 0.0 110.724 -179.218 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -72.85 -5.82 17.89 Favored 'Trans proline' 0 N--CA 1.478 0.582 0 C-N-CA 122.597 2.198 . . . . 0.0 113.447 -175.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.2 pttm -95.87 12.65 29.47 Favored 'General case' 0 C--N 1.307 -1.256 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.908 -178.602 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 9.4 p -87.55 152.32 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.26 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 178.385 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 16.9 ptpt -141.13 -165.26 1.92 Allowed 'General case' 0 N--CA 1.433 -1.311 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 177.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 1.637 ' HE1' ' CE2' ' A' ' 92' ' ' PHE . 13.3 m-85 -34.99 -71.4 0.07 Allowed 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 126.602 1.961 . . . . 0.0 112.174 -175.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 50.1 m . . . . . 0 C--N 1.299 -1.618 0 N-CA-C 106.556 -1.646 . . . . 0.0 106.556 179.27 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.503 -0.833 0 N-CA-C 103.999 -2.593 . . . . 0.0 103.999 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.58 -30.62 71.71 Favored 'General case' 0 C--N 1.307 -1.259 0 O-C-N 123.694 0.621 . . . . 0.0 110.477 176.479 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 10.1 ptp180 -102.53 165.81 10.88 Favored 'General case' 0 C--O 1.266 1.97 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 176.435 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 9.6 p-10 -90.05 173.77 8.01 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 106.976 -1.491 . . . . 0.0 106.976 175.068 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 1.653 ' HE1' ' CE2' ' A' ' 5' ' ' PHE . 98.4 m-85 -133.86 119.93 19.78 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 120.22 -0.592 . . . . 0.0 110.945 -175.721 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 24.1 mtmm -119.55 155.97 53.84 Favored Pre-proline 0 C--N 1.291 -1.975 0 CA-C-N 114.703 -1.135 . . . . 0.0 108.013 -178.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -55.04 120.76 8.72 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 121.723 1.615 . . . . 0.0 109.497 174.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 115.94 -24.4 10.15 Favored Glycine 0 N--CA 1.432 -1.573 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.38 -175.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -62.03 123.69 18.79 Favored 'General case' 0 C--O 1.25 1.102 0 CA-C-N 117.494 0.647 . . . . 0.0 110.74 177.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 85.2 mt -79.93 124.26 28.51 Favored 'General case' 0 CA--C 1.483 -1.601 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 177.316 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 9.3 pt -141.07 -175.12 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.036 0 CA-C-O 122.592 1.187 . . . . 0.0 112.792 -172.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 1.623 ' HE2' ' CE1' ' A' ' 12' ' ' PHE . 60.8 m-85 -122.24 130.35 53.09 Favored 'General case' 0 N--CA 1.405 -2.686 0 CA-C-N 113.42 -1.718 . . . . 0.0 106.56 170.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.428 ' HB3' HG22 ' A' ' 42' ' ' ILE . . . -108.8 124.25 50.31 Favored 'General case' 0 C--N 1.275 -2.651 0 O-C-N 123.931 0.769 . . . . 0.0 109.494 -177.711 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.55 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.9 OUTLIER -108.46 126.69 53.18 Favored 'General case' 0 C--N 1.272 -2.781 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.228 -177.462 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 63.5 mtm -125.59 157.75 36.37 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.682 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 1.3 ttpm? -61.34 115.95 4.25 Favored 'General case' 0 C--O 1.247 0.971 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.903 179.134 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.63 -5.68 64.62 Favored Glycine 0 C--O 1.251 1.165 0 O-C-N 123.506 0.504 . . . . 0.0 112.094 178.241 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 88.8 m-85 -120.81 151.02 54.04 Favored Pre-proline 0 N--CA 1.426 -1.656 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -177.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.18 171.09 17.62 Favored 'Trans proline' 0 N--CA 1.443 -1.495 0 C-N-CA 121.676 1.584 . . . . 0.0 109.082 174.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.468 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 80.2 m80 -61.22 110.41 1.39 Allowed 'General case' 0 CA--C 1.549 0.941 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 175.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -99.34 138.39 20.51 Favored Pre-proline 0 C--N 1.31 -1.132 0 C-N-CA 123.377 0.671 . . . . 0.0 109.874 -171.071 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo -60.72 118.2 5.05 Favored 'Trans proline' 0 C--O 1.245 0.861 0 C-N-CA 121.746 1.631 . . . . 0.0 110.709 177.25 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.8 167.19 22.87 Favored 'General case' 0 N--CA 1.413 -2.309 0 CA-C-O 120.898 0.38 . . . . 0.0 110.309 -176.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 24.4 ttp-105 -125.81 147.04 49.54 Favored 'General case' 0 C--N 1.288 -2.083 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 175.346 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 48.1 t -72.78 119.04 18.85 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 N-CA-C 105.714 -1.958 . . . . 0.0 105.714 171.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.454 ' CG ' ' HZ1' ' A' ' 91' ' ' LYS . 9.7 t70 -90.31 -177.5 5.12 Favored 'General case' 0 C--N 1.307 -1.247 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -175.754 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -101.26 168.68 9.4 Favored 'General case' 0 C--N 1.282 -2.341 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -175.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 48.4 t -83.43 124.07 76.11 Favored Pre-proline 0 C--N 1.309 -1.178 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 177.294 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -72.18 138.0 29.77 Favored 'Trans proline' 0 N--CA 1.43 -2.229 0 C-N-CA 121.429 1.42 . . . . 0.0 112.615 -179.476 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -71.0 148.99 47.09 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 174.306 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.03 -16.43 61.35 Favored Glycine 0 N--CA 1.429 -1.788 0 C-N-CA 120.726 -0.749 . . . . 0.0 111.299 -176.132 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.82 92.92 1.63 Allowed 'General case' 0 N--CA 1.442 -0.848 0 CA-C-O 121.451 0.644 . . . . 0.0 110.554 177.183 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.9 m -78.2 -8.13 11.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.373 178.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 25.6 mmmt -108.05 119.89 48.58 Favored Pre-proline 0 N--CA 1.416 -2.157 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 174.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_exo -70.58 155.13 63.85 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 121.978 1.785 . . . . 0.0 110.639 177.146 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -71.62 168.59 23.24 Favored 'Trans proline' 0 N--CA 1.449 -1.14 0 C-N-CA 121.907 1.738 . . . . 0.0 112.545 -179.17 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.53 ' O ' ' HB3' ' A' ' 38' ' ' ASN . 4.7 m -64.62 10.23 0.07 Allowed 'General case' 0 CA--C 1.571 1.777 0 C-N-CA 126.603 1.961 . . . . 0.0 113.465 -178.469 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.53 ' HB3' ' O ' ' A' ' 37' ' ' THR . 0.7 OUTLIER 81.32 10.96 0.83 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-O 124.172 1.939 . . . . 0.0 108.701 -172.139 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -95.79 166.6 11.73 Favored 'General case' 0 N--CA 1.423 -1.81 0 CA-C-N 112.825 -1.989 . . . . 0.0 108.712 175.066 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 87.9 mt -99.96 141.23 22.38 Favored Pre-proline 0 C--N 1.291 -1.946 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.268 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -71.72 123.4 9.37 Favored 'Trans proline' 0 N--CA 1.454 -0.824 0 C-N-CA 122.037 1.824 . . . . 0.0 109.852 176.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.428 HG22 ' HB3' ' A' ' 13' ' ' ALA . 42.4 mm -118.08 120.76 65.47 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 CA-C-N 116.196 -0.457 . . . . 0.0 109.837 -175.542 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 66.1 t80 -97.92 120.1 37.71 Favored 'General case' 0 C--N 1.281 -2.383 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 1.636 ' HE2' ' CE1' ' A' ' 44' ' ' PHE . 69.6 m-85 -85.2 131.46 34.43 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.257 0.551 . . . . 0.0 111.972 178.28 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -84.96 155.04 21.79 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.712 176.394 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.562 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 79.22 -19.57 5.47 Favored Glycine 0 C--N 1.314 -0.669 0 C-N-CA 123.257 0.456 . . . . 0.0 113.418 179.11 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 16.3 p -118.61 -23.13 7.2 Favored 'General case' 0 C--N 1.307 -1.26 0 O-C-N 122.561 -0.376 . . . . 0.0 110.215 175.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.7 m170 67.46 19.19 10.06 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 123.509 0.724 . . . . 0.0 111.768 -179.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 19.2 mm-40 -87.65 168.27 13.16 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.205 179.59 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.7 m -134.55 142.5 46.99 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 121.067 0.46 . . . . 0.0 109.769 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -139.05 179.66 6.37 Favored 'General case' 0 C--N 1.293 -1.891 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.201 -178.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 1.665 ' HE2' ' CE1' ' A' ' 52' ' ' PHE . 96.6 m-85 -134.13 117.39 16.52 Favored 'General case' 0 C--O 1.262 1.726 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.679 177.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 94.8 mt -129.5 174.56 9.53 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.17 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.37 164.94 21.34 Favored Glycine 0 N--CA 1.417 -2.597 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.16 -5.4 13.62 Favored 'Trans proline' 0 C--O 1.249 1.074 0 C-N-CA 123.752 2.968 . . . . 0.0 112.905 -178.179 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 23.0 pttm -97.57 -19.78 18.12 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.009 178.366 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -96.83 0.37 49.18 Favored 'General case' 0 CA--C 1.5 -0.943 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.598 -173.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.2 pt -123.43 144.78 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.995 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.725 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -130.55 147.13 64.74 Favored Pre-proline 0 C--N 1.289 -2.037 0 CA-C-N 114.631 -1.168 . . . . 0.0 108.006 -177.668 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -66.74 132.49 28.79 Favored 'Trans proline' 0 C--N 1.328 -0.548 0 C-N-CA 122.474 2.116 . . . . 0.0 112.558 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 1.649 ' HE2' ' CE1' ' A' ' 61' ' ' TYR . 53.4 t80 -64.0 -37.79 88.72 Favored 'General case' 0 C--O 1.201 -1.488 0 CA-C-N 114.939 -1.028 . . . . 0.0 112.25 -176.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -62.76 -54.35 40.49 Favored 'General case' 0 C--N 1.292 -1.92 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -176.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 3.6 mp0 -71.58 -26.23 62.52 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-O 121.71 0.766 . . . . 0.0 111.23 -178.266 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.452 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 29.9 m-80 -106.82 10.12 30.79 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -175.45 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -65.44 -31.27 72.26 Favored 'General case' 0 N--CA 1.483 1.195 0 CA-C-O 121.354 0.597 . . . . 0.0 111.898 -178.117 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.507 ' HA ' ' NZ ' ' A' ' 70' ' ' LYS . 55.5 mm-40 -75.97 -28.92 58.05 Favored 'General case' 0 C--N 1.285 -2.211 0 C-N-CA 119.391 -0.924 . . . . 0.0 111.842 178.277 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.452 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 33.2 mtpt -78.04 -59.26 2.85 Favored 'General case' 0 C--N 1.281 -2.407 0 CA-C-N 113.963 -1.471 . . . . 0.0 111.052 -176.769 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 1.655 ' HD2' ' CD1' ' A' ' 68' ' ' TYR . 19.9 m-85 -109.96 -9.47 14.76 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.384 -171.229 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -86.0 47.62 3.81 Favored Glycine 0 C--N 1.311 -0.857 0 N-CA-C 111.291 -0.724 . . . . 0.0 111.291 -178.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.507 ' NZ ' ' HA ' ' A' ' 66' ' ' GLU . 47.7 mmtm -127.91 147.77 64.43 Favored Pre-proline 0 C--N 1.307 -1.263 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.532 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.472 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 77.4 Cg_exo -48.01 128.94 17.4 Favored 'Trans proline' 0 C--N 1.363 1.318 0 C-N-CA 123.662 2.908 . . . . 0.0 114.782 -176.225 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.454 ' HB2' ' CD1' ' A' ' 77' ' ' PHE . 1.9 t-20 -112.22 -165.48 1.0 Allowed 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 114.747 -1.115 . . . . 0.0 109.559 -175.449 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 38.6 mmtm -121.53 12.68 10.82 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.686 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 24.2 mmt180 -93.9 128.39 40.17 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 114.874 -1.057 . . . . 0.0 109.712 174.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 28.1 tptp -68.89 122.5 18.75 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 177.18 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.562 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 107.14 -20.83 32.48 Favored Glycine 0 N--CA 1.438 -1.189 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 -179.254 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.454 ' CD1' ' HB2' ' A' ' 72' ' ' ASN . 35.6 t80 -75.2 -44.1 48.28 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-O 121.61 0.719 . . . . 0.0 109.701 -177.069 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.472 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 92.8 m-20 -76.38 -35.07 58.85 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 114.893 -1.048 . . . . 0.0 110.63 -174.112 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -70.12 -35.5 74.15 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.183 -1.044 . . . . 0.0 108.183 174.913 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -65.75 -35.63 91.22 Favored Glycine 0 N--CA 1.435 -1.413 0 CA-C-N 115.112 -0.949 . . . . 0.0 111.968 177.697 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.422 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 95.8 mt -56.16 -38.32 70.73 Favored 'General case' 0 C--O 1.219 -0.52 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 175.589 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 73.0 t90 -74.19 -49.08 25.07 Favored 'General case' 0 N--CA 1.426 -1.635 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.417 178.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -57.0 -46.82 82.02 Favored 'General case' 0 C--O 1.203 -1.343 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.8 tt -70.18 -24.57 26.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 120.628 -0.429 . . . . 0.0 112.033 -175.219 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -93.52 -19.69 20.98 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.058 0.456 . . . . 0.0 110.141 -175.053 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.453 ' N ' HD21 ' A' ' 86' ' ' ASN . 0.8 OUTLIER -111.56 -54.34 2.62 Favored 'General case' 0 N--CA 1.483 1.198 0 CA-C-O 121.351 0.596 . . . . 0.0 111.863 -179.286 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.1 t30 -126.24 71.98 71.12 Favored Pre-proline 0 C--N 1.312 -1.065 0 O-C-N 121.999 -0.438 . . . . 0.0 110.93 -177.715 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -73.2 -6.49 19.0 Favored 'Trans proline' 0 CA--C 1.53 0.309 0 C-N-CA 122.242 1.961 . . . . 0.0 113.232 -175.819 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.4 pttm -95.91 12.55 29.87 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.973 -176.306 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 8.4 p -72.78 158.73 6.04 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.303 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 178.199 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.454 ' HZ1' ' CG ' ' A' ' 26' ' ' ASP . 65.8 mmtt -119.36 171.52 8.27 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 112.618 0.599 . . . . 0.0 112.618 -175.716 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 1.654 ' HE2' ' CE1' ' A' ' 92' ' ' PHE . 7.4 p90 -66.41 128.42 36.09 Favored 'General case' 0 N--CA 1.441 -0.89 0 CA-C-N 114.239 -1.346 . . . . 0.0 111.08 177.883 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 22.6 p . . . . . 0 N--CA 1.432 -1.352 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.734 -175.175 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.477 0.884 0 N-CA-C 105.462 -2.051 . . . . 0.0 105.462 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -79.21 -25.55 42.69 Favored 'General case' 0 C--N 1.313 -0.992 0 O-C-N 123.585 0.553 . . . . 0.0 110.266 177.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 47.2 ptt85 -93.75 170.16 9.78 Favored 'General case' 0 C--O 1.253 1.26 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 177.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . 0.404 ' CG ' ' HZ3' ' A' ' 6' ' ' LYS . 3.2 p-10 -91.02 179.44 5.74 Favored 'General case' 0 N--CA 1.433 -1.317 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.464 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 1.641 ' HE1' ' CE2' ' A' ' 5' ' ' PHE . 97.3 m-85 -130.26 143.05 50.54 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-O 120.753 0.311 . . . . 0.0 110.438 -173.248 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.511 ' O ' ' HB2' ' A' ' 9' ' ' ASP . 47.9 mmtm -111.51 155.62 42.64 Favored Pre-proline 0 C--N 1.304 -1.392 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 -178.59 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_exo -58.33 121.46 10.02 Favored 'Trans proline' 0 C--O 1.237 0.46 0 C-N-CA 121.78 1.653 . . . . 0.0 108.448 171.105 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . 0.567 ' HA2' ' NH1' ' A' ' 24' ' ' ARG . . . 108.72 -11.95 35.31 Favored Glycine 0 N--CA 1.425 -2.034 0 C-N-CA 120.55 -0.834 . . . . 0.0 112.449 -176.505 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.511 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 0.8 OUTLIER -64.39 133.51 52.73 Favored 'General case' 0 C--O 1.252 1.202 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -178.025 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 78.8 mt -89.27 119.97 30.22 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.403 ' HA ' ' HA ' ' A' ' 60' ' ' PRO . 7.5 pt -139.03 -173.54 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.841 0 CA-C-O 122.753 1.263 . . . . 0.0 112.956 -172.037 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 1.655 ' HD2' ' CD1' ' A' ' 12' ' ' PHE . 84.2 m-85 -127.48 125.41 40.42 Favored 'General case' 0 N--CA 1.403 -2.809 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 171.861 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.419 ' CB ' HG22 ' A' ' 42' ' ' ILE . . . -113.43 134.45 54.65 Favored 'General case' 0 C--N 1.266 -3.024 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.617 -176.573 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.665 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -109.04 121.15 44.53 Favored 'General case' 0 N--CA 1.408 -2.532 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.396 -178.616 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.426 ' HE1' ' CD1' ' A' ' 18' ' ' TYR . 71.5 mtm -112.18 158.88 19.14 Favored 'General case' 0 C--N 1.315 -0.934 0 C-N-CA 123.587 0.755 . . . . 0.0 109.24 176.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 24.9 ttmm -66.18 117.41 8.45 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.106 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.38 -7.07 56.06 Favored Glycine 0 C--O 1.246 0.875 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -178.639 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 1.621 ' HE1' ' CE2' ' A' ' 18' ' ' TYR . 65.2 m-85 -123.21 148.15 54.01 Favored Pre-proline 0 N--CA 1.435 -1.222 0 C-N-CA 122.994 0.518 . . . . 0.0 110.684 179.206 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -79.34 171.6 15.81 Favored 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 122.116 1.877 . . . . 0.0 108.28 170.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.634 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 78.9 m80 -58.16 111.19 1.11 Allowed 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 175.774 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.426 ' O ' ' HA ' ' A' ' 12' ' ' PHE . 11.5 t-105 -111.74 141.69 25.2 Favored Pre-proline 0 C--N 1.302 -1.46 0 C-N-CA 123.561 0.744 . . . . 0.0 109.343 -170.526 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_exo -57.76 118.71 5.63 Favored 'Trans proline' 0 C--N 1.36 1.14 0 C-N-CA 122.274 1.983 . . . . 0.0 110.994 178.328 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -145.53 167.34 23.25 Favored 'General case' 0 N--CA 1.407 -2.584 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 -177.617 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.567 ' NH1' ' HA2' ' A' ' 8' ' ' GLY . 32.7 ttp85 -123.23 144.52 49.34 Favored 'General case' 0 C--N 1.276 -2.589 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 177.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 58.7 t -74.58 113.74 13.53 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.99 0 N-CA-C 104.793 -2.299 . . . . 0.0 104.793 170.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.545 ' OD1' ' HA ' ' A' ' 91' ' ' LYS . 1.1 t70 -86.88 -176.01 5.6 Favored 'General case' 0 C--N 1.29 -2.015 0 O-C-N 123.554 0.534 . . . . 0.0 111.084 -172.0 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 33.6 mm-40 -91.56 164.28 13.83 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 121.622 0.725 . . . . 0.0 109.81 -173.209 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.7 t -93.8 120.9 65.52 Favored Pre-proline 0 C--N 1.301 -1.522 0 N-CA-C 107.197 -1.408 . . . . 0.0 107.197 172.261 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -71.99 142.88 39.49 Favored 'Trans proline' 0 N--CA 1.431 -2.155 0 C-N-CA 121.57 1.513 . . . . 0.0 113.365 -178.019 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 18.1 t0 -71.11 152.84 43.05 Favored 'General case' 0 C--O 1.251 1.161 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 170.585 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 85.48 0.39 88.19 Favored Glycine 0 N--CA 1.421 -2.31 0 C-N-CA 120.087 -1.054 . . . . 0.0 110.882 -174.363 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.29 76.36 1.84 Allowed 'General case' 0 C--O 1.208 -1.106 0 CA-C-O 122.163 0.982 . . . . 0.0 110.98 173.013 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 26.8 m -96.31 6.39 8.08 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 CA-C-N 114.154 -1.384 . . . . 0.0 109.767 177.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.494 ' H ' ' HD2' ' A' ' 34' ' ' LYS . 0.0 OUTLIER -107.79 141.39 22.98 Favored Pre-proline 0 N--CA 1.409 -2.499 0 N-CA-C 106.584 -1.635 . . . . 0.0 106.584 178.524 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 20.8 Cg_endo -62.19 134.13 47.37 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 121.969 1.779 . . . . 0.0 112.58 -178.096 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.402 ' C ' ' H ' ' A' ' 38' ' ' ASN . 3.3 Cg_exo -76.64 171.76 17.44 Favored 'Trans proline' 0 N--CA 1.447 -1.208 0 C-N-CA 122.438 2.092 . . . . 0.0 111.49 176.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 5.9 m -71.26 6.96 1.45 Allowed 'General case' 0 C--O 1.265 1.882 0 C-N-CA 124.413 1.085 . . . . 0.0 111.92 -178.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.402 ' H ' ' C ' ' A' ' 36' ' ' PRO . 40.1 m-80 63.74 28.07 14.81 Favored 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 124.359 1.064 . . . . 0.0 109.65 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.415 ' HB3' ' O ' ' A' ' 53' ' ' LEU . 62.4 mttp -139.91 -179.55 6.01 Favored 'General case' 0 N--CA 1.433 -1.322 0 CA-C-N 114.748 -1.115 . . . . 0.0 109.237 -178.422 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.424 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 95.8 mt -90.84 139.69 26.14 Favored Pre-proline 0 C--N 1.297 -1.709 0 O-C-N 123.894 0.746 . . . . 0.0 110.134 -177.632 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -71.38 123.22 9.35 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.262 1.974 . . . . 0.0 109.779 176.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.419 HG22 ' CB ' ' A' ' 13' ' ' ALA . 39.7 mm -122.17 121.59 64.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.932 -0.48 . . . . 0.0 109.993 -176.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.668 ' HE2' ' CE1' ' A' ' 43' ' ' PHE . 79.0 t80 -106.35 118.96 38.01 Favored 'General case' 0 C--N 1.29 -2.001 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 178.06 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 73.6 m-85 -82.32 136.07 35.08 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -179.408 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 1.615 ' HE2' ' CE1' ' A' ' 45' ' ' PHE . 78.5 m-85 -85.58 148.85 25.73 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.9 178.334 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.449 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 78.94 -21.08 4.16 Favored Glycine 0 C--N 1.308 -1.019 0 C-N-CA 123.72 0.676 . . . . 0.0 114.168 176.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 30.7 p -119.74 -22.46 6.85 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 117.523 0.662 . . . . 0.0 110.674 174.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.4 m-70 67.01 21.9 10.15 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 123.649 0.779 . . . . 0.0 111.563 -178.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.8 mt-10 -72.42 163.61 27.71 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.064 175.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.7 m -136.87 140.05 42.1 Favored 'General case' 0 C--N 1.275 -2.645 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.346 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -141.05 176.07 9.11 Favored 'General case' 0 C--N 1.286 -2.18 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.273 -179.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.424 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 97.7 m-85 -133.98 111.07 10.11 Favored 'General case' 0 N--CA 1.431 -1.423 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 174.52 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.415 ' O ' ' HB3' ' A' ' 39' ' ' LYS . 85.9 mt -125.69 170.42 11.55 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -177.527 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -95.08 167.17 26.35 Favored Glycine 0 N--CA 1.42 -2.398 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 178.166 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -66.38 -6.85 15.96 Favored 'Trans proline' 0 N--CA 1.484 0.923 0 C-N-CA 123.357 2.705 . . . . 0.0 112.743 -177.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.9 ptmm? -92.37 -19.88 21.64 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.725 178.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -102.45 5.05 39.38 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-O 121.281 0.562 . . . . 0.0 111.623 -174.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.9 pt -125.22 147.53 29.87 Favored 'Isoleucine or valine' 0 C--O 1.266 1.954 0 CA-C-N 114.653 -1.158 . . . . 0.0 110.372 178.791 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 1.616 ' HD2' ' CD1' ' A' ' 59' ' ' PHE . 88.8 m-85 -136.37 133.11 19.17 Favored Pre-proline 0 C--N 1.289 -2.035 0 CA-C-N 114.686 -1.143 . . . . 0.0 108.355 -179.543 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . 0.403 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 22.5 Cg_endo -68.3 144.06 60.83 Favored 'Trans proline' 0 CA--C 1.499 -1.264 0 C-N-CA 122.971 2.447 . . . . 0.0 114.04 -177.397 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 1.644 ' HD1' ' CD2' ' A' ' 61' ' ' TYR . 83.9 t80 -58.88 -38.26 78.42 Favored 'General case' 0 C--O 1.203 -1.377 0 CA-C-N 114.305 -1.316 . . . . 0.0 110.579 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.48 -47.57 83.38 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 113.744 1.016 . . . . 0.0 113.744 -175.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -93.33 -8.27 42.46 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-O 121.357 0.599 . . . . 0.0 111.597 -177.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.432 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 24.0 m-80 -124.91 14.12 8.53 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -175.164 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -63.37 -37.78 88.61 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 10.4 mp0 -66.08 -34.68 78.62 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 122.796 1.284 . . . . 0.0 109.326 177.127 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.432 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 35.4 mtpt -75.48 -59.55 2.7 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-N 113.396 -1.729 . . . . 0.0 112.008 -174.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.41 ' CD2' ' HB3' ' A' ' 64' ' ' ASN . 18.5 m-85 -115.11 -15.4 11.7 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.982 -171.068 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.77 10.77 30.19 Favored Glycine 0 N--CA 1.472 1.042 0 CA-C-O 121.213 0.341 . . . . 0.0 113.207 -175.226 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 23.2 pttm -93.04 149.9 38.32 Favored Pre-proline 0 C--N 1.298 -1.671 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -66.91 128.19 18.33 Favored 'Trans proline' 0 N--CA 1.441 -1.56 0 C-N-CA 120.845 1.03 . . . . 0.0 112.287 178.069 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 41.4 m-80 -113.19 -173.41 2.25 Favored 'General case' 0 C--N 1.295 -1.795 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 47.4 mmtm -96.75 15.87 20.72 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-O 121.238 0.542 . . . . 0.0 112.269 -176.066 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -87.94 120.94 29.77 Favored 'General case' 0 C--N 1.309 -1.187 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 174.352 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.4 tppt? -74.71 130.43 39.49 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 177.111 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.449 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.24 -25.78 18.96 Favored Glycine 0 N--CA 1.435 -1.381 0 N-CA-C 108.819 -1.712 . . . . 0.0 108.819 -174.053 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 11.2 t80 -76.79 -44.71 31.71 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 10.0 m120 -60.25 -47.89 84.07 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 22.2 mp0 -63.5 -37.06 85.85 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 113.778 -1.555 . . . . 0.0 110.194 179.341 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -67.55 -34.56 84.5 Favored Glycine 0 N--CA 1.442 -0.924 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.309 177.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 95.5 mt -62.78 -33.95 76.24 Favored 'General case' 0 C--O 1.216 -0.694 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 175.39 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 69.8 t90 -71.62 -49.44 40.12 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.624 175.24 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -60.43 -34.69 74.34 Favored 'General case' 0 C--O 1.21 -0.98 0 N-CA-C 113.882 1.067 . . . . 0.0 113.882 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.6 tt -72.77 -21.41 19.59 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-O 121.214 0.531 . . . . 0.0 110.3 -176.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -89.92 -46.74 8.33 Favored 'General case' 0 N--CA 1.435 -1.211 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.719 -178.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.568 ' N ' HD21 ' A' ' 86' ' ' ASN . 0.8 OUTLIER -86.92 -35.88 18.67 Favored 'General case' 0 C--O 1.252 1.227 0 CA-C-O 121.63 0.728 . . . . 0.0 111.843 -173.766 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -134.08 63.6 62.6 Favored Pre-proline 0 C--N 1.298 -1.669 0 C-N-CA 118.892 -1.123 . . . . 0.0 112.873 -179.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -72.04 -5.74 17.71 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 122.791 2.327 . . . . 0.0 110.838 177.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 16.5 pttp -99.09 17.08 20.69 Favored 'General case' 0 C--N 1.302 -1.478 0 C-N-CA 125.378 1.471 . . . . 0.0 110.81 -176.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 9.6 p -81.2 166.02 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.849 0 N-CA-C 107.969 -1.122 . . . . 0.0 107.969 175.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.545 ' HA ' ' OD1' ' A' ' 26' ' ' ASP . 2.4 mtmp? -147.55 -176.07 5.1 Favored 'General case' 0 C--O 1.252 1.225 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -178.335 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -43.34 -53.86 5.02 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 124.972 1.42 . . . . 0.0 108.682 175.53 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 4.1 p . . . . . 0 N--CA 1.4 -2.957 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 173.074 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.3 mtt . . . . . 0 C--O 1.194 -1.823 0 N-CA-C 106.956 -1.498 . . . . 0.0 106.956 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -79.22 -30.2 43.16 Favored 'General case' 0 C--O 1.251 1.161 0 CA-C-N 118.639 0.654 . . . . 0.0 111.356 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . 0.536 ' HG3' ' N ' ' A' ' 4' ' ' ASP . 23.3 ptt180 -89.02 -49.61 6.67 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.594 -177.625 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . 0.536 ' N ' ' HG3' ' A' ' 3' ' ' ARG . 5.8 p-10 -117.58 147.15 43.1 Favored 'General case' 0 C--N 1.274 -2.681 0 CA-C-N 114.273 -1.33 . . . . 0.0 109.462 -174.201 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -137.02 121.45 18.23 Favored 'General case' 0 C--N 1.298 -1.638 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 27.5 mtmm -124.31 156.92 66.21 Favored Pre-proline 0 C--N 1.289 -2.059 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 -176.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo -51.87 117.62 3.72 Favored 'Trans proline' 0 N--CA 1.461 -0.39 0 C-N-CA 122.17 1.913 . . . . 0.0 110.416 173.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.45 -23.55 10.32 Favored Glycine 0 N--CA 1.427 -1.902 0 CA-C-O 119.452 -0.638 . . . . 0.0 112.694 -176.475 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -64.98 123.68 20.08 Favored 'General case' 0 C--O 1.25 1.11 0 CA-C-N 117.573 0.686 . . . . 0.0 110.115 177.213 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.8 mt -80.05 129.48 34.53 Favored 'General case' 0 CA--C 1.49 -1.363 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 176.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 8.1 pt -143.17 -172.7 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.421 -1.884 0 CA-C-O 122.479 1.133 . . . . 0.0 112.4 -173.08 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.41 ' HB3' ' HB3' ' A' ' 20' ' ' HIS . 31.9 m-85 -128.58 129.07 45.42 Favored 'General case' 0 N--CA 1.402 -2.873 0 CA-C-N 113.288 -1.778 . . . . 0.0 106.55 172.784 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.438 ' HB2' HD13 ' A' ' 53' ' ' LEU . . . -108.78 128.92 55.31 Favored 'General case' 0 C--N 1.271 -2.834 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.446 -174.346 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.674 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -106.39 124.12 49.11 Favored 'General case' 0 N--CA 1.403 -2.782 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.039 -178.697 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 69.1 mtm -121.42 158.38 28.46 Favored 'General case' 0 CA--C 1.508 -0.667 0 C-N-CA 123.219 0.608 . . . . 0.0 109.814 176.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -64.66 116.52 6.32 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 178.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.44 -2.43 65.14 Favored Glycine 0 C--O 1.246 0.868 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -121.93 146.35 45.95 Favored Pre-proline 0 N--CA 1.428 -1.567 0 C-N-CA 122.731 0.412 . . . . 0.0 110.388 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -75.82 171.29 18.45 Favored 'Trans proline' 0 N--CA 1.444 -1.428 0 C-N-CA 121.798 1.665 . . . . 0.0 108.467 172.439 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.469 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 69.2 m80 -61.53 111.15 1.69 Allowed 'General case' 0 CA--C 1.548 0.883 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 175.854 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 7.8 t-105 -102.96 139.26 19.96 Favored Pre-proline 0 C--N 1.304 -1.405 0 C-N-CA 123.852 0.861 . . . . 0.0 109.31 -171.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_exo -59.08 118.66 5.59 Favored 'Trans proline' 0 C--N 1.354 0.84 0 C-N-CA 121.875 1.716 . . . . 0.0 110.869 177.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.81 167.05 23.0 Favored 'General case' 0 N--CA 1.414 -2.227 0 CA-C-O 121.227 0.537 . . . . 0.0 110.417 -177.456 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 36.6 ttt-85 -119.05 139.89 50.98 Favored 'General case' 0 C--N 1.285 -2.198 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 177.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 60.2 t -75.34 111.12 11.22 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.951 0 N-CA-C 103.817 -2.66 . . . . 0.0 103.817 168.058 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -89.37 -177.55 5.39 Favored 'General case' 0 C--N 1.289 -2.032 0 C-N-CA 119.535 -0.866 . . . . 0.0 111.451 -170.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.483 ' CD ' ' HZ3' ' A' ' 91' ' ' LYS . 4.7 pt-20 -104.99 141.94 35.67 Favored 'General case' 0 C--N 1.293 -1.876 0 CA-C-O 121.875 0.845 . . . . 0.0 113.201 -171.131 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.1 t -88.86 128.56 51.75 Favored Pre-proline 0 C--N 1.312 -1.056 0 CA-C-N 114.59 -1.186 . . . . 0.0 109.828 -176.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -71.93 149.08 52.74 Favored 'Trans proline' 0 N--CA 1.434 -1.983 0 C-N-CA 121.623 1.549 . . . . 0.0 112.477 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -68.08 146.78 53.15 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 174.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.43 -27.5 20.05 Favored Glycine 0 C--N 1.292 -1.865 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 -174.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -79.18 78.47 5.64 Favored 'General case' 0 N--CA 1.434 -1.233 0 CA-C-O 122.1 0.952 . . . . 0.0 110.004 175.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.0 m -94.19 6.92 6.61 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 114.383 -1.281 . . . . 0.0 111.035 -179.798 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 31.3 mmtp -81.56 126.89 74.91 Favored Pre-proline 0 C--N 1.297 -1.705 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.048 179.297 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_endo -65.54 135.21 41.36 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 122.053 1.835 . . . . 0.0 112.263 -179.543 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.414 ' C ' ' H ' ' A' ' 38' ' ' ASN . 73.2 Cg_endo -80.07 171.47 15.17 Favored 'Trans proline' 0 N--CA 1.443 -1.485 0 C-N-CA 122.445 2.096 . . . . 0.0 112.512 -179.07 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.3 m -72.86 8.94 1.29 Allowed 'General case' 0 CA--C 1.563 1.449 0 C-N-CA 125.576 1.55 . . . . 0.0 111.44 -179.024 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.414 ' H ' ' C ' ' A' ' 36' ' ' PRO . 49.0 m-80 78.42 13.41 1.48 Allowed 'General case' 0 N--CA 1.485 1.301 0 C-N-CA 125.209 1.404 . . . . 0.0 109.758 -174.789 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.533 ' HE3' ' HA ' ' A' ' 53' ' ' LEU . 22.5 mtpp -111.46 152.14 27.77 Favored 'General case' 0 N--CA 1.418 -2.035 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 175.275 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.404 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 71.2 mt -98.44 153.9 37.8 Favored Pre-proline 0 C--N 1.288 -2.079 0 O-C-N 123.54 0.525 . . . . 0.0 110.356 -173.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -71.4 122.36 8.58 Favored 'Trans proline' 0 C--N 1.354 0.826 0 C-N-CA 121.788 1.659 . . . . 0.0 109.798 176.476 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 43.8 mm -117.84 119.9 62.99 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.943 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 -176.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 86.2 t80 -98.27 117.68 33.2 Favored 'General case' 0 C--N 1.28 -2.437 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 178.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -81.78 129.85 34.87 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 121.419 0.628 . . . . 0.0 112.672 178.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -80.45 151.96 29.03 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.819 177.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.426 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 78.23 -20.68 3.86 Favored Glycine 0 C--N 1.315 -0.628 0 C-N-CA 123.562 0.601 . . . . 0.0 114.306 177.716 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 36.2 p -119.37 -22.59 6.99 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 117.533 0.666 . . . . 0.0 109.849 174.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.0 m-70 67.7 22.74 8.87 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.883 0.873 . . . . 0.0 112.308 179.011 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -78.41 169.3 18.48 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.335 177.596 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 6.3 m -139.36 137.82 36.08 Favored 'General case' 0 C--N 1.289 -2.059 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 177.04 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -138.58 -179.55 5.88 Favored 'General case' 0 C--N 1.28 -2.436 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.614 -176.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.404 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 87.3 m-85 -131.31 109.79 10.62 Favored 'General case' 0 CA--C 1.491 -1.318 0 C-N-CA 123.662 0.785 . . . . 0.0 109.294 177.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.533 ' HA ' ' HE3' ' A' ' 39' ' ' LYS . 96.2 mt -126.77 152.29 47.08 Favored 'General case' 0 C--N 1.295 -1.803 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.076 -178.689 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.421 ' O ' HG12 ' A' ' 58' ' ' ILE . . . -80.43 168.17 51.32 Favored Glycine 0 N--CA 1.429 -1.802 0 N-CA-C 110.564 -1.015 . . . . 0.0 110.564 -177.551 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -65.18 -18.42 61.19 Favored 'Trans proline' 0 C--O 1.209 -0.966 0 C-N-CA 122.337 2.025 . . . . 0.0 112.13 -178.479 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 10.8 mmtm -99.56 2.05 44.34 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 113.206 0.817 . . . . 0.0 113.206 173.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -94.04 -12.02 29.48 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 173.656 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.421 HG12 ' O ' ' A' ' 54' ' ' GLY . 15.9 pt -125.77 151.58 32.01 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.705 0 CA-C-N 114.459 -1.246 . . . . 0.0 109.698 -176.801 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 1.651 ' HD1' ' CD2' ' A' ' 59' ' ' PHE . 96.4 m-85 -138.23 147.48 55.96 Favored Pre-proline 0 C--N 1.296 -1.754 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 -179.192 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -63.38 140.99 79.51 Favored 'Trans proline' 0 C--O 1.241 0.632 0 C-N-CA 123.19 2.593 . . . . 0.0 114.817 -174.503 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 40.5 t80 -56.03 -33.31 64.81 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 114.32 -1.309 . . . . 0.0 111.841 177.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.8 m -60.05 -41.9 93.3 Favored 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.527 -177.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . 0.301 48.8 mt-10 -75.98 -51.59 12.05 Favored 'General case' 0 CA--C 1.488 -1.426 0 CA-C-O 123.319 1.533 . . . . 0.0 108.656 176.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.409 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 37.0 m-80 -80.66 2.75 24.54 Favored 'General case' 0 N--CA 1.415 -2.211 0 CA-C-N 112.801 -1.999 . . . . 0.0 113.847 -161.439 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -68.92 -37.4 78.89 Favored 'General case' 0 N--CA 1.433 -1.286 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 176.424 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.417 ' CD ' ' HZ2' ' A' ' 70' ' ' LYS . 56.8 mm-40 -80.83 -37.4 30.11 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.104 -0.498 . . . . 0.0 112.159 175.343 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 39.7 mtpt -70.96 -57.37 4.63 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 124.701 1.251 . . . . 0.0 111.171 -173.964 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 61.8 m-85 -126.97 7.24 6.63 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.213 -174.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -91.98 41.24 2.83 Favored Glycine 0 CA--C 1.496 -1.096 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -178.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.417 ' HZ2' ' CD ' ' A' ' 66' ' ' GLU . 30.4 mmtp -128.77 151.02 76.52 Favored Pre-proline 0 C--N 1.299 -1.616 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 -177.595 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.482 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 52.6 Cg_exo -48.42 148.44 7.81 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 123.642 2.895 . . . . 0.0 114.816 -176.415 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -140.17 -175.73 4.35 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-N 115.087 -0.96 . . . . 0.0 109.933 -178.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.2 mmmm -95.53 -3.26 46.9 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-O 120.804 0.335 . . . . 0.0 110.474 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 18.0 mmt180 -80.25 121.02 25.11 Favored 'General case' 0 C--N 1.309 -1.164 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.064 176.317 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -73.63 135.39 43.8 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 174.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.426 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 103.76 -25.31 27.01 Favored Glycine 0 N--CA 1.436 -1.332 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 -177.123 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.411 ' HE1' ' O ' ' A' ' 70' ' ' LYS . 55.7 t80 -74.73 -44.93 47.4 Favored 'General case' 0 N--CA 1.437 -1.077 0 CA-C-N 114.722 -0.739 . . . . 0.0 109.08 -178.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.482 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 89.4 m-20 -76.82 -35.75 57.37 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.062 -176.2 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 8.2 mp0 -67.73 -36.55 80.78 Favored 'General case' 0 N--CA 1.433 -1.311 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 174.376 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.47 -34.38 68.08 Favored Glycine 0 CA--C 1.496 -1.155 0 CA-C-N 115.445 -0.798 . . . . 0.0 112.094 177.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 40.9 tp -60.62 -36.53 78.84 Favored 'General case' 0 N--CA 1.432 -1.331 0 C-N-CA 123.955 0.902 . . . . 0.0 108.947 175.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 76.1 t90 -72.14 -47.39 51.41 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.054 175.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -61.15 -36.87 80.95 Favored 'General case' 0 C--O 1.193 -1.915 0 N-CA-C 114.009 1.114 . . . . 0.0 114.009 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.4 tt -70.67 -26.51 28.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 119.282 -0.967 . . . . 0.0 111.772 -176.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -83.77 -37.06 23.1 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.176 178.238 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 30.8 m-80 -101.86 -31.35 10.76 Favored 'General case' 0 C--O 1.257 1.487 0 CA-C-O 122.063 0.935 . . . . 0.0 112.738 -173.123 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 57.3 t30 -129.06 60.2 49.18 Favored Pre-proline 0 C--N 1.29 -2.014 0 O-C-N 121.628 -0.67 . . . . 0.0 112.539 -177.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -77.77 -5.74 15.57 Favored 'Trans proline' 0 N--CA 1.486 1.076 0 C-N-CA 122.211 1.94 . . . . 0.0 110.747 178.244 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 23.1 pttm -93.09 4.31 54.22 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 113.718 -1.583 . . . . 0.0 111.063 -174.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 9.9 p -73.49 162.63 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.008 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 179.61 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.483 ' HZ3' ' CD ' ' A' ' 27' ' ' GLU . 3.6 mptp? -127.99 179.64 5.47 Favored 'General case' 0 C--O 1.262 1.731 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 176.782 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 41.4 p90 -49.93 133.22 22.59 Favored 'General case' 0 C--O 1.241 0.617 0 O-C-N 124.142 0.901 . . . . 0.0 109.097 170.416 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 41.5 m . . . . . 0 C--N 1.304 -1.382 0 N-CA-C 115.039 1.496 . . . . 0.0 115.039 -170.657 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 18.5 mmt . . . . . 0 CA--C 1.484 -1.588 0 CA-C-O 118.646 -0.692 . . . . 0.0 109.354 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -53.12 -40.59 64.31 Favored 'General case' 0 C--O 1.213 -0.868 0 O-C-N 124.603 1.19 . . . . 0.0 111.305 178.404 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . 0.401 ' NE ' ' HB3' ' A' ' 60' ' ' PRO . 4.8 ptp180 -98.73 158.93 15.3 Favored 'General case' 0 C--O 1.262 1.713 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 175.805 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . 0.437 ' OD2' ' HE3' ' A' ' 6' ' ' LYS . 13.7 p-10 -93.21 157.51 16.23 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 105.487 -2.042 . . . . 0.0 105.487 170.06 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -117.97 139.31 51.35 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.645 -170.007 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.484 ' HD2' ' N ' ' A' ' 6' ' ' LYS . 7.5 mptt -121.04 147.24 46.02 Favored Pre-proline 0 C--N 1.31 -1.119 0 N-CA-C 108.172 -1.048 . . . . 0.0 108.172 -178.842 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -56.98 121.13 9.53 Favored 'Trans proline' 0 N--CA 1.452 -0.967 0 C-N-CA 121.456 1.438 . . . . 0.0 109.32 172.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.66 -25.33 9.11 Favored Glycine 0 N--CA 1.42 -2.41 0 CA-C-O 118.671 -1.072 . . . . 0.0 114.142 -177.14 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.354 3.7 p30 -79.37 149.71 31.6 Favored 'General case' 0 C--O 1.243 0.748 0 CA-C-N 119.453 1.626 . . . . 0.0 113.557 -179.496 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 78.5 mt -86.74 128.54 35.02 Favored 'General case' 0 C--O 1.253 1.268 0 CA-C-N 114.605 -1.18 . . . . 0.0 110.851 -175.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -141.77 -177.2 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.466 0 CA-C-O 121.785 0.803 . . . . 0.0 112.255 -175.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 1.604 ' HD1' ' CD2' ' A' ' 12' ' ' PHE . 49.1 m-85 -113.65 128.25 56.36 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 107.211 -1.403 . . . . 0.0 107.211 172.531 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.412 ' CB ' HG22 ' A' ' 42' ' ' ILE . . . -108.3 120.31 42.0 Favored 'General case' 0 C--N 1.274 -2.69 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.684 -175.382 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.614 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 1.1 tmmt? -109.72 126.65 53.94 Favored 'General case' 0 C--N 1.27 -2.866 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.619 -177.638 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.402 ' HE1' ' CD1' ' A' ' 18' ' ' TYR . 69.6 mtm -120.48 158.55 27.01 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.489 179.264 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -68.77 117.02 9.94 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 179.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.27 -3.07 61.54 Favored Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -179.655 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 1.667 ' HE2' ' CE1' ' A' ' 18' ' ' TYR . 59.8 m-85 -122.94 150.3 58.74 Favored Pre-proline 0 N--CA 1.435 -1.195 0 CA-C-O 120.744 0.307 . . . . 0.0 110.855 -179.118 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -74.91 170.74 19.74 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 122.134 1.889 . . . . 0.0 109.498 172.68 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.438 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 76.3 m80 -66.77 111.55 3.77 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 177.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 10.6 t-105 -97.06 138.98 21.27 Favored Pre-proline 0 C--N 1.311 -1.093 0 C-N-CA 123.541 0.737 . . . . 0.0 109.689 -174.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_endo -69.05 117.76 5.25 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 121.254 1.303 . . . . 0.0 110.123 175.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.5 167.1 24.52 Favored 'General case' 0 N--CA 1.426 -1.625 0 CA-C-O 121.137 0.494 . . . . 0.0 110.528 -174.619 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.408 ' NH2' ' HG2' ' A' ' 91' ' ' LYS . 12.7 ttp180 -111.75 145.21 39.76 Favored 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 179.069 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.3 t -68.61 121.32 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.866 0 N-CA-C 104.821 -2.289 . . . . 0.0 104.821 169.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.553 ' CG ' ' HZ1' ' A' ' 91' ' ' LYS . 15.4 t70 -91.24 175.66 6.86 Favored 'General case' 0 C--N 1.281 -2.395 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 -171.161 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.401 ' CD ' HH22 ' A' ' 24' ' ' ARG . 0.3 OUTLIER -118.22 123.83 46.41 Favored 'General case' 0 N--CA 1.425 -1.695 0 CA-C-O 121.385 0.612 . . . . 0.0 110.229 179.453 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.1 p -83.02 124.62 76.42 Favored Pre-proline 0 N--CA 1.433 -1.282 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.089 -178.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -80.89 165.05 19.99 Favored 'Trans proline' 0 C--O 1.247 0.928 0 C-N-CA 122.482 2.121 . . . . 0.0 112.276 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 9.6 p-10 -79.05 154.31 29.53 Favored 'General case' 0 N--CA 1.426 -1.671 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 173.078 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 92.23 -19.89 46.91 Favored Glycine 0 C--N 1.296 -1.64 0 C-N-CA 119.764 -1.208 . . . . 0.0 110.951 -177.031 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.58 130.63 47.78 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 174.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 26.8 m -71.14 -10.62 14.18 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 N-CA-C 113.915 1.08 . . . . 0.0 113.915 -175.687 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.418 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 0.1 OUTLIER -108.15 122.73 39.72 Favored Pre-proline 0 N--CA 1.412 -2.326 0 C-N-CA 119.86 -0.736 . . . . 0.0 112.905 179.82 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 34' ' ' LYS . 9.8 Cg_exo -72.81 172.12 15.96 Favored 'Trans proline' 0 C--O 1.264 1.803 0 C-N-CA 122.587 2.192 . . . . 0.0 110.587 174.718 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_endo -50.5 128.04 22.29 Favored 'Trans proline' 0 C--N 1.363 1.311 0 C-N-CA 122.858 2.372 . . . . 0.0 110.431 176.232 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.6 m -102.03 8.49 40.91 Favored 'General case' 0 C--N 1.286 -2.158 0 CA-C-N 115.027 -0.988 . . . . 0.0 110.005 -172.279 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 44.7 m-80 75.52 9.98 3.55 Favored 'General case' 0 N--CA 1.493 1.697 0 C-N-CA 124.843 1.257 . . . . 0.0 109.29 -173.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 71.6 mttt -132.28 162.0 32.09 Favored 'General case' 0 N--CA 1.415 -2.192 0 CA-C-N 113.88 -1.509 . . . . 0.0 108.609 177.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 75.0 mt -100.19 150.42 36.88 Favored Pre-proline 0 C--N 1.291 -1.944 0 O-C-N 124.368 1.042 . . . . 0.0 109.257 -175.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -75.49 133.33 15.75 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 121.684 1.589 . . . . 0.0 109.427 174.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.412 HG22 ' CB ' ' A' ' 13' ' ' ALA . 51.3 mm -124.47 126.74 72.33 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -176.692 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.631 ' HE1' ' CE2' ' A' ' 43' ' ' PHE . 65.2 t80 -105.51 115.02 29.55 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 -179.434 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -79.23 136.18 36.99 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.245 0.545 . . . . 0.0 111.613 179.524 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -87.54 157.08 19.25 Favored 'General case' 0 C--N 1.301 -1.515 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.559 177.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 76.11 -21.27 2.25 Favored Glycine 0 CA--C 1.502 -0.775 0 C-N-CA 124.669 1.128 . . . . 0.0 114.134 179.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 40.4 p -120.01 -23.24 6.42 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 117.294 0.547 . . . . 0.0 110.199 174.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 51.7 m170 67.78 23.3 8.58 Favored 'General case' 0 C--N 1.342 0.25 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.681 178.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -73.78 162.7 28.86 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 175.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.8 m -137.5 142.33 41.48 Favored 'General case' 0 C--N 1.281 -2.371 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -139.65 -179.68 6.06 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.169 -178.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 80.2 m-85 -131.69 109.27 10.06 Favored 'General case' 0 N--CA 1.439 -0.989 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 175.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.429 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 96.0 mt -127.51 152.94 46.95 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.652 -175.171 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.97 171.72 37.71 Favored Glycine 0 N--CA 1.424 -2.164 0 C-N-CA 119.564 -1.303 . . . . 0.0 111.589 -174.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -66.12 -5.65 12.82 Favored 'Trans proline' 0 C--O 1.251 1.131 0 C-N-CA 123.235 2.624 . . . . 0.0 112.172 179.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -98.72 -16.87 18.81 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 114.961 -1.018 . . . . 0.0 111.774 175.062 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.429 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 40.9 m-20 -94.12 -8.7 38.8 Favored 'General case' 0 C--N 1.31 -1.15 0 CA-C-O 121.188 0.518 . . . . 0.0 110.118 -177.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.422 ' HA ' ' O ' ' A' ' 12' ' ' PHE . 14.3 pt -119.59 149.63 22.18 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.607 -176.195 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 57.6 m-85 -132.56 148.54 70.02 Favored Pre-proline 0 C--O 1.192 -1.945 0 N-CA-C 107.428 -1.323 . . . . 0.0 107.428 -177.381 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . 0.448 ' O ' ' HB2' ' A' ' 64' ' ' ASN . 41.4 Cg_endo -66.2 132.32 29.38 Favored 'Trans proline' 0 C--N 1.322 -0.854 0 C-N-CA 121.94 1.76 . . . . 0.0 111.956 -179.236 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.417 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 66.5 t80 -69.38 -38.48 78.05 Favored 'General case' 0 C--O 1.204 -1.327 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -177.338 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 22.7 t -76.31 -33.63 59.03 Favored 'General case' 0 C--N 1.295 -1.8 0 C-N-CA 120.087 -0.645 . . . . 0.0 111.402 -172.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.489 ' C ' HD21 ' A' ' 64' ' ' ASN . 2.8 mp0 -95.69 -1.7 49.51 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.522 -177.778 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.489 HD21 ' C ' ' A' ' 63' ' ' GLU . 0.9 OUTLIER -131.17 15.34 5.12 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 178.232 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -69.75 -32.24 70.65 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.465 0.65 . . . . 0.0 110.1 -179.535 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.527 ' H ' ' CD ' ' A' ' 66' ' ' GLU . 1.5 mp0 -66.1 -31.61 72.58 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 178.103 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.468 ' HD3' ' CG ' ' A' ' 64' ' ' ASN . 37.7 mtpt -82.22 -60.25 2.28 Favored 'General case' 0 N--CA 1.428 -1.567 0 CA-C-N 114.303 -1.317 . . . . 0.0 111.501 -175.594 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -106.71 -1.15 23.01 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.434 -0.803 . . . . 0.0 113.057 -168.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.71 56.91 4.23 Favored Glycine 0 C--N 1.311 -0.827 0 C-N-CA 120.994 -0.622 . . . . 0.0 111.953 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 58.7 mttp -125.86 125.61 24.86 Favored Pre-proline 0 C--N 1.313 -1.021 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.27 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -53.15 128.8 30.51 Favored 'Trans proline' 0 C--O 1.263 1.763 0 C-N-CA 123.451 2.767 . . . . 0.0 114.414 -177.167 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -94.94 -172.43 2.7 Favored 'General case' 0 N--CA 1.407 -2.613 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.636 178.383 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . 0.534 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 2.0 mptp? -106.98 -11.01 15.78 Favored 'General case' 0 N--CA 1.417 -2.118 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -178.506 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.94 118.13 9.3 Favored 'General case' 0 N--CA 1.41 -2.429 0 N-CA-C 106.272 -1.751 . . . . 0.0 106.272 169.71 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 9.3 tptp -69.9 140.25 53.09 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 107.888 -1.152 . . . . 0.0 107.888 179.013 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 107.93 -24.04 24.25 Favored Glycine 0 N--CA 1.413 -2.889 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 -173.15 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 1.65 ' HE1' ' CE2' ' A' ' 77' ' ' PHE . 11.5 t80 -75.47 -38.79 59.39 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -68.64 -47.33 66.88 Favored 'General case' 0 CA--C 1.506 -0.739 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 -177.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 36.1 mp0 -61.66 -42.34 98.77 Favored 'General case' 0 N--CA 1.426 -1.661 0 CA-C-N 113.152 -1.84 . . . . 0.0 110.068 178.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.1 -37.0 72.6 Favored Glycine 0 CA--C 1.484 -1.846 0 CA-C-N 115.751 -0.659 . . . . 0.0 113.305 -179.243 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 38.3 tp -62.55 -31.1 71.84 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 176.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.0 t90 -74.76 -51.18 14.86 Favored 'General case' 0 N--CA 1.429 -1.501 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.248 175.006 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 -55.06 -45.84 75.34 Favored 'General case' 0 C--O 1.203 -1.346 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 -178.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.2 tt -68.73 -27.89 37.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -176.033 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -93.42 -16.96 24.03 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.252 0.549 . . . . 0.0 110.302 -173.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.432 ' N ' HD21 ' A' ' 86' ' ' ASN . 0.9 OUTLIER -109.91 -56.51 2.31 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-O 121.16 0.505 . . . . 0.0 111.527 179.605 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.412 HD21 ' HB ' ' A' ' 90' ' ' VAL . 6.8 t30 -128.27 75.19 79.2 Favored Pre-proline 0 C--N 1.313 -0.982 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.199 -177.65 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -73.62 -5.26 16.79 Favored 'Trans proline' 0 C--N 1.332 -0.298 0 C-N-CA 122.699 2.266 . . . . 0.0 112.988 -177.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 26.1 pttm -87.46 8.73 23.46 Favored 'General case' 0 C--O 1.249 1.054 0 CA-C-O 121.38 0.609 . . . . 0.0 109.972 -176.393 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.412 ' HB ' HD21 ' A' ' 87' ' ' ASN 0.252 11.2 p -75.54 105.89 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.509 0 CA-C-O 122.475 1.131 . . . . 0.0 112.237 179.741 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.553 ' HZ1' ' CG ' ' A' ' 26' ' ' ASP . 20.2 tptm 173.13 -53.73 0.01 OUTLIER 'General case' 0 N--CA 1.431 -1.412 0 CA-C-N 112.437 -2.165 . . . . 0.0 107.326 -177.309 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 85.8 t80 -120.18 -63.23 1.39 Allowed 'General case' 0 C--N 1.299 -1.611 0 CA-C-N 114.53 -1.214 . . . . 0.0 109.719 -178.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.7 m . . . . . 0 C--N 1.316 -0.858 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.788 -179.813 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.0 mpp? . . . . . 0 CA--C 1.499 -1.002 0 CA-C-O 120.651 0.263 . . . . 0.0 111.03 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -99.81 70.25 1.62 Allowed 'General case' 0 N--CA 1.435 -1.182 0 N-CA-C 107.71 -1.218 . . . . 0.0 107.71 178.191 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 2.2 ptp180 -91.79 -176.05 4.34 Favored 'General case' 0 C--N 1.29 -2.021 0 CA-C-N 113.983 -1.462 . . . . 0.0 111.233 -178.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -143.42 -173.03 3.83 Favored 'General case' 0 N--CA 1.428 -1.553 0 N-CA-C 105.366 -2.087 . . . . 0.0 105.366 174.115 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 1.66 ' HD2' ' CD1' ' A' ' 5' ' ' PHE . 91.3 m-85 -125.37 149.1 48.44 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 117.575 2.435 . . . . 0.0 117.575 -170.771 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.48 ' HG3' ' OD1' ' A' ' 9' ' ' ASP . 3.8 ptmm? -134.65 156.3 78.8 Favored Pre-proline 0 N--CA 1.413 -2.276 0 CA-C-N 112.076 -2.329 . . . . 0.0 107.684 177.086 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.88 141.1 95.77 Favored 'Trans proline' 0 C--O 1.253 1.234 0 C-N-CA 122.497 2.132 . . . . 0.0 112.455 178.244 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 104.81 -14.17 49.56 Favored Glycine 0 N--CA 1.44 -1.039 0 C-N-CA 121.231 -0.509 . . . . 0.0 113.033 178.18 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.48 ' OD1' ' HG3' ' A' ' 6' ' ' LYS . 1.4 m-20 -79.05 145.87 33.6 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-O 121.087 0.47 . . . . 0.0 111.412 -179.381 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 83.6 mt -95.3 127.43 41.34 Favored 'General case' 0 C--O 1.25 1.116 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.45 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.9 pp -139.54 -178.63 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.205 0 CA-C-O 122.489 1.138 . . . . 0.0 113.761 -173.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 1.621 ' HE2' ' CE1' ' A' ' 12' ' ' PHE . 86.3 m-85 -119.43 128.59 54.17 Favored 'General case' 0 N--CA 1.408 -2.564 0 N-CA-C 105.203 -2.147 . . . . 0.0 105.203 170.766 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.4 ' HB2' HD13 ' A' ' 53' ' ' LEU . . . -108.09 140.84 40.68 Favored 'General case' 0 C--N 1.279 -2.477 0 O-C-N 123.702 0.626 . . . . 0.0 110.045 -173.569 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.466 ' HD3' ' C ' ' A' ' 14' ' ' LYS . 7.6 tmtm? -114.96 115.66 27.24 Favored 'General case' 0 N--CA 1.414 -2.273 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.834 -176.742 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 69.8 mtm -108.12 158.93 16.99 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 172.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 24.4 tptm -62.59 130.04 43.3 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 177.509 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 83.02 -25.5 4.73 Favored Glycine 0 C--O 1.218 -0.888 0 O-C-N 123.539 0.524 . . . . 0.0 112.568 -177.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 53.5 m-85 -93.21 149.85 38.13 Favored Pre-proline 0 C--O 1.257 1.488 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -177.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -75.78 171.7 17.69 Favored 'Trans proline' 0 N--CA 1.449 -1.112 0 C-N-CA 123.395 2.73 . . . . 0.0 109.646 171.251 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 79.8 m80 -69.9 111.53 5.68 Favored 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 178.461 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 8.5 t-105 -100.17 136.39 20.1 Favored Pre-proline 0 C--N 1.309 -1.175 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.961 -173.27 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_endo -65.88 117.79 4.94 Favored 'Trans proline' 0 CA--C 1.542 0.9 0 C-N-CA 121.789 1.66 . . . . 0.0 110.789 176.439 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.44 167.51 23.46 Favored 'General case' 0 N--CA 1.426 -1.645 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -174.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.507 ' HB3' ' CE2' ' A' ' 45' ' ' PHE . 9.2 ptt180 -111.25 160.57 16.86 Favored 'General case' 0 C--N 1.291 -1.965 0 C-N-CA 119.507 -0.877 . . . . 0.0 109.182 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 42.3 t -89.47 116.05 30.24 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.163 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 170.064 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -87.84 173.53 8.89 Favored 'General case' 0 C--N 1.281 -2.407 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.976 -175.013 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.02 166.22 11.11 Favored 'General case' 0 N--CA 1.417 -2.1 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 175.613 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.2 p -98.56 115.47 65.76 Favored Pre-proline 0 C--N 1.294 -1.833 0 C-N-CA 120.05 -0.66 . . . . 0.0 110.931 -177.523 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_endo -88.59 164.3 6.45 Favored 'Trans proline' 0 N--CA 1.448 -1.156 0 C-N-CA 123.058 2.505 . . . . 0.0 113.108 -178.187 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -73.15 142.01 47.45 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 106.416 -1.698 . . . . 0.0 106.416 172.236 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.92 -17.88 51.33 Favored Glycine 0 C--N 1.291 -1.917 0 C-N-CA 119.797 -1.192 . . . . 0.0 111.078 -177.792 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -65.51 103.64 0.87 Allowed 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 173.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 31.9 m -69.74 -19.91 23.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 N-CA-C 114.082 1.141 . . . . 0.0 114.082 -174.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.575 ' HD3' ' O ' ' A' ' 34' ' ' LYS . 0.0 OUTLIER -108.25 129.49 24.0 Favored Pre-proline 0 N--CA 1.41 -2.437 0 C-N-CA 119.736 -0.786 . . . . 0.0 111.515 -179.458 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -68.9 171.49 13.42 Favored 'Trans proline' 0 C--O 1.265 1.831 0 C-N-CA 123.401 2.734 . . . . 0.0 113.701 -176.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -55.83 133.28 57.08 Favored 'Trans proline' 0 C--N 1.364 1.374 0 C-N-CA 123.127 2.552 . . . . 0.0 110.757 174.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.7 m -110.02 8.95 24.27 Favored 'General case' 0 C--N 1.291 -1.961 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.186 -174.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 45.2 m-80 78.98 8.6 1.91 Allowed 'General case' 0 N--CA 1.496 1.87 0 C-N-CA 126.027 1.731 . . . . 0.0 108.747 -172.057 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.511 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 34.3 mmtt -113.1 153.39 28.29 Favored 'General case' 0 N--CA 1.41 -2.469 0 CA-C-N 113.278 -1.783 . . . . 0.0 107.075 174.238 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.441 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 74.6 mt -96.63 154.27 38.52 Favored Pre-proline 0 C--N 1.271 -2.814 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 -178.147 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -74.96 126.48 10.02 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 C-N-CA 121.517 1.478 . . . . 0.0 109.276 173.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 50.6 mm -125.3 110.13 23.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-O 121.116 0.484 . . . . 0.0 111.407 -175.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 70.2 t80 -90.26 117.52 29.06 Favored 'General case' 0 C--N 1.279 -2.497 0 C-N-CA 124.46 1.104 . . . . 0.0 109.899 176.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 1.651 ' HD1' ' CD2' ' A' ' 44' ' ' PHE . 88.3 m-85 -78.13 128.83 34.4 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.9 177.616 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.507 ' CE2' ' HB3' ' A' ' 24' ' ' ARG . 58.8 m-85 -78.14 152.04 32.99 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.254 177.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 80.96 -21.05 5.93 Favored Glycine 0 C--N 1.308 -1.027 0 C-N-CA 124.565 1.079 . . . . 0.0 114.592 177.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.434 ' CG2' ' HA3' ' A' ' 76' ' ' GLY . 32.6 p -119.88 -22.73 6.66 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 117.467 0.633 . . . . 0.0 110.349 174.682 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 68.11 23.17 8.09 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.854 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -75.12 169.64 17.63 Favored 'General case' 0 C--N 1.35 0.602 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 175.076 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.4 m -141.47 145.66 35.51 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 121.539 -0.726 . . . . 0.0 110.005 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -139.99 -179.9 6.22 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 123.835 0.854 . . . . 0.0 109.842 178.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.441 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 93.0 m-85 -133.23 109.67 9.58 Favored 'General case' 0 CA--C 1.491 -1.29 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 174.332 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.44 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 79.5 mt -134.13 144.6 48.64 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 -178.867 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.511 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -83.26 177.05 52.97 Favored Glycine 0 N--CA 1.417 -2.596 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 -174.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -66.23 -17.51 54.49 Favored 'Trans proline' 0 C--N 1.319 -0.985 0 C-N-CA 122.112 1.875 . . . . 0.0 112.481 -176.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 16.8 mmmt -98.86 -3.58 35.03 Favored 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 120.204 -0.598 . . . . 0.0 110.923 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.44 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 12.8 m-20 -96.55 -9.2 30.01 Favored 'General case' 0 N--CA 1.481 1.105 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.792 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.484 HG13 ' CE2' ' A' ' 5' ' ' PHE . 12.5 pt -115.63 152.43 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.231 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.428 -176.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -126.05 131.68 24.06 Favored Pre-proline 0 C--N 1.301 -1.542 0 CA-C-N 115.238 -0.892 . . . . 0.0 108.753 -177.612 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . 0.491 ' HG2' ' HB2' ' A' ' 63' ' ' GLU . 34.1 Cg_endo -67.6 131.51 24.67 Favored 'Trans proline' 0 C--N 1.322 -0.821 0 C-N-CA 122.708 2.272 . . . . 0.0 113.202 -175.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 1.608 ' HD1' ' CD2' ' A' ' 61' ' ' TYR . 43.3 t80 -52.37 -42.19 63.74 Favored 'General case' 0 C--O 1.205 -1.257 0 C-N-CA 123.992 0.917 . . . . 0.0 111.337 179.62 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.2 t -64.94 -37.0 86.19 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.476 -175.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.491 ' HB2' ' HG2' ' A' ' 60' ' ' PRO . 29.9 mt-10 -97.03 -7.08 33.78 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.992 0.425 . . . . 0.0 111.949 -175.703 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.466 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 27.2 m-80 -133.53 17.77 3.96 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 112.416 0.525 . . . . 0.0 112.416 -175.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.44 ' HG2' ' OE1' ' A' ' 66' ' ' GLU . 3.6 ptpp? -67.29 -36.13 80.91 Favored 'General case' 0 N--CA 1.498 1.968 0 C-N-CA 120.042 -0.663 . . . . 0.0 110.611 -176.149 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.44 ' OE1' ' HG2' ' A' ' 65' ' ' LYS . 28.8 mp0 -64.94 -35.45 81.21 Favored 'General case' 0 C--O 1.255 1.346 0 CA-C-O 123.241 1.496 . . . . 0.0 108.836 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.466 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 37.6 mtpt -76.38 -59.33 2.81 Favored 'General case' 0 C--N 1.294 -1.834 0 CA-C-N 112.931 -1.94 . . . . 0.0 111.912 -174.744 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 1.646 ' HD2' ' CD1' ' A' ' 68' ' ' TYR . 23.2 m-85 -112.1 -1.94 15.16 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 -169.084 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -83.85 45.69 3.52 Favored Glycine 0 C--N 1.309 -0.961 0 C-N-CA 120.654 -0.784 . . . . 0.0 113.373 -176.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 17.3 pttm -132.75 143.74 49.98 Favored Pre-proline 0 N--CA 1.43 -1.448 0 O-C-N 122.591 -0.358 . . . . 0.0 111.561 176.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_exo -49.42 158.13 1.83 Allowed 'Trans proline' 0 C--N 1.361 1.236 0 C-N-CA 124.577 3.518 . . . . 0.0 117.06 -173.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -131.48 -178.42 4.85 Favored 'General case' 0 N--CA 1.416 -2.164 0 CA-C-N 113.647 -1.615 . . . . 0.0 108.31 178.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -90.69 -18.51 24.94 Favored 'General case' 0 C--N 1.308 -1.199 0 O-C-N 123.693 0.621 . . . . 0.0 109.659 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.54 115.57 5.9 Favored 'General case' 0 N--CA 1.414 -2.229 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 175.496 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.431 ' HD3' ' H ' ' A' ' 76' ' ' GLY . 14.0 tppt? -64.73 133.42 52.05 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 175.638 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.434 ' HA3' ' CG2' ' A' ' 47' ' ' THR . . . 108.46 -24.75 21.62 Favored Glycine 0 N--CA 1.414 -2.788 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -174.095 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 1.658 ' HE1' ' CE2' ' A' ' 77' ' ' PHE . 11.0 t80 -75.6 -37.91 59.46 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 179.736 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -65.96 -49.55 67.48 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 -178.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 23.5 mp0 -64.58 -39.07 93.07 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 113.202 -1.817 . . . . 0.0 110.522 -179.687 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.64 -35.05 62.63 Favored Glycine 0 CA--C 1.48 -2.145 0 CA-C-N 116.063 -0.517 . . . . 0.0 113.011 -179.41 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 37.7 tp -62.51 -33.31 74.63 Favored 'General case' 0 N--CA 1.423 -1.802 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 176.029 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 70.5 t90 -74.34 -49.11 24.21 Favored 'General case' 0 N--CA 1.426 -1.626 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.602 175.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -55.04 -46.09 75.27 Favored 'General case' 0 C--O 1.188 -2.154 0 N-CA-C 112.644 0.609 . . . . 0.0 112.644 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 17.0 tt -68.56 -23.22 27.73 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-O 121.082 0.468 . . . . 0.0 111.629 -174.054 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -92.34 -41.93 10.09 Favored 'General case' 0 N--CA 1.423 -1.785 0 CA-C-O 121.585 0.707 . . . . 0.0 109.819 -175.443 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.581 ' N ' HD21 ' A' ' 86' ' ' ASN . 0.7 OUTLIER -97.73 -39.73 8.91 Favored 'General case' 0 N--CA 1.48 1.038 0 CA-C-O 121.713 0.768 . . . . 0.0 112.061 -173.838 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 65.2 t30 -134.99 63.33 57.24 Favored Pre-proline 0 C--N 1.296 -1.759 0 C-N-CA 119.797 -0.761 . . . . 0.0 111.673 -178.428 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -68.13 -6.57 17.58 Favored 'Trans proline' 0 C--N 1.371 1.711 0 C-N-CA 122.81 2.34 . . . . 0.0 111.742 -178.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 24.7 pttm -102.12 19.94 17.61 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 114.555 -1.202 . . . . 0.0 109.828 -177.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 14.6 p -71.7 141.33 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 CA-C-O 121.447 0.641 . . . . 0.0 110.242 179.301 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.655 ' HE2' ' O ' ' A' ' 93' ' ' SER . 19.6 ptmt -74.4 146.56 42.85 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.584 -178.881 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 1.616 ' HD2' ' CD1' ' A' ' 92' ' ' PHE . 65.9 t80 -46.6 -64.98 0.63 Allowed 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 125.425 1.49 . . . . 0.0 111.652 -178.656 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' SER . . . . . 0.655 ' O ' ' HE2' ' A' ' 91' ' ' LYS . 46.6 t . . . . . 0 C--N 1.292 -1.931 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 178.255 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.9 mtt . . . . . 0 CA--C 1.503 -0.85 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -97.32 72.33 2.4 Favored 'General case' 0 N--CA 1.44 -0.974 0 N-CA-C 105.846 -1.909 . . . . 0.0 105.846 175.377 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -117.55 175.86 5.44 Favored 'General case' 0 C--N 1.286 -2.156 0 CA-C-N 113.412 -1.722 . . . . 0.0 111.697 -174.161 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -127.33 162.42 26.31 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 105.8 -1.926 . . . . 0.0 105.8 176.067 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 1.663 ' HD2' ' CD1' ' A' ' 5' ' ' PHE . 84.3 m-85 -105.37 121.24 43.5 Favored 'General case' 0 C--N 1.293 -1.857 0 CA-C-O 120.959 0.409 . . . . 0.0 110.014 -172.466 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.502 ' HD2' ' C ' ' A' ' 5' ' ' PHE . 13.4 mmmt -116.81 153.69 49.33 Favored Pre-proline 0 N--CA 1.433 -1.29 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 -178.251 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.6 Cg_exo -52.82 134.45 54.58 Favored 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 122.755 2.303 . . . . 0.0 112.369 177.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 107.58 -25.21 21.97 Favored Glycine 0 N--CA 1.432 -1.613 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.77 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -72.24 150.23 43.85 Favored 'General case' 0 C--O 1.252 1.216 0 CA-C-O 121.582 0.706 . . . . 0.0 112.224 -177.099 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 76.5 mt -100.04 127.96 46.19 Favored 'General case' 0 N--CA 1.423 -1.794 0 CA-C-N 114.352 -1.294 . . . . 0.0 109.754 -177.116 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 8.6 pt -140.12 -173.6 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 CA-C-O 122.348 1.071 . . . . 0.0 111.897 -174.446 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 1.648 ' HD2' ' CD1' ' A' ' 12' ' ' PHE . 66.5 m-85 -126.31 124.31 40.02 Favored 'General case' 0 N--CA 1.412 -2.363 0 N-CA-C 106.174 -1.787 . . . . 0.0 106.174 172.162 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.428 ' CB ' HG22 ' A' ' 42' ' ' ILE . . . -108.89 131.28 55.17 Favored 'General case' 0 C--N 1.28 -2.431 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.343 -174.572 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.686 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -113.54 122.18 46.46 Favored 'General case' 0 N--CA 1.401 -2.911 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.116 -177.76 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 70.2 mtm -110.43 158.03 18.93 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 175.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 60.2 tttm -67.29 116.62 8.26 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 110.145 -0.317 . . . . 0.0 110.145 -179.224 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.81 -2.75 62.26 Favored Glycine 0 C--O 1.248 0.975 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 1.66 ' HD1' ' CD2' ' A' ' 18' ' ' TYR . 74.3 m-85 -121.86 151.79 58.32 Favored Pre-proline 0 N--CA 1.434 -1.268 0 C-N-CA 122.829 0.452 . . . . 0.0 109.905 -178.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -76.5 171.37 18.18 Favored 'Trans proline' 0 N--CA 1.448 -1.157 0 C-N-CA 122.296 1.997 . . . . 0.0 109.815 175.1 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.528 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 76.2 m80 -66.76 110.94 3.46 Favored 'General case' 0 C--N 1.312 -1.061 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 176.269 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -99.88 138.15 20.29 Favored Pre-proline 0 C--N 1.296 -1.718 0 C-N-CA 123.942 0.897 . . . . 0.0 109.324 -171.316 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -63.59 118.28 5.22 Favored 'Trans proline' 0 C--O 1.244 0.808 0 C-N-CA 121.918 1.746 . . . . 0.0 110.043 177.219 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -141.82 167.54 21.91 Favored 'General case' 0 N--CA 1.415 -2.195 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.761 -175.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 56.1 ttt-85 -123.73 141.15 52.29 Favored 'General case' 0 C--N 1.289 -2.03 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 178.191 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 45.6 t -77.64 125.27 37.2 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 175.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.467 ' OD1' ' HE3' ' A' ' 91' ' ' LYS . 5.4 t70 -94.2 171.04 9.08 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 120.57 -0.452 . . . . 0.0 109.855 -175.741 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -100.88 124.43 46.56 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-O 121.915 0.864 . . . . 0.0 113.293 -178.116 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.2 p -81.51 133.51 52.85 Favored Pre-proline 0 N--CA 1.437 -1.122 0 CA-C-N 114.357 -1.292 . . . . 0.0 108.297 177.254 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -70.67 141.09 40.7 Favored 'Trans proline' 0 N--CA 1.456 -0.7 0 C-N-CA 122.051 1.834 . . . . 0.0 112.763 -179.306 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -74.25 149.31 40.83 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 172.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 89.11 -3.83 84.48 Favored Glycine 0 C--N 1.291 -1.93 0 C-N-CA 120.508 -0.854 . . . . 0.0 111.725 -175.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -57.34 116.64 3.43 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-O 121.117 0.484 . . . . 0.0 110.381 175.36 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.6 m -63.62 -21.35 28.35 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 CA-C-N 115.558 -0.746 . . . . 0.0 112.754 -178.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 44.7 mmtm -107.94 118.87 51.79 Favored Pre-proline 0 N--CA 1.424 -1.739 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 171.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.94 166.79 28.79 Favored 'Trans proline' 0 C--O 1.246 0.879 0 C-N-CA 122.446 2.097 . . . . 0.0 111.33 178.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -54.52 129.52 35.25 Favored 'Trans proline' 0 C--N 1.358 1.062 0 C-N-CA 122.679 2.253 . . . . 0.0 111.953 179.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.483 HG23 ' O ' ' A' ' 37' ' ' THR . 4.9 m -73.64 9.48 1.41 Allowed 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 125.661 1.584 . . . . 0.0 112.722 -174.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 5.1 p30 87.44 9.16 0.17 Allowed 'General case' 0 N--CA 1.502 2.169 0 C-N-CA 126.853 2.061 . . . . 0.0 109.752 -173.554 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 62.6 mttp -126.18 162.23 25.87 Favored 'General case' 0 C--N 1.294 -1.845 0 CA-C-N 113.283 -1.78 . . . . 0.0 110.364 178.16 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 85.0 mt -112.55 147.29 36.77 Favored Pre-proline 0 C--N 1.286 -2.194 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.487 -176.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -73.73 122.58 7.89 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 121.749 1.632 . . . . 0.0 109.535 176.141 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.428 HG22 ' CB ' ' A' ' 13' ' ' ALA . 45.7 mm -118.22 111.01 32.32 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.251 -174.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.656 ' HD1' ' CD2' ' A' ' 43' ' ' PHE . 91.1 t80 -91.24 118.73 30.72 Favored 'General case' 0 C--N 1.286 -2.153 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.288 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -83.03 133.23 35.1 Favored 'General case' 0 C--O 1.249 1.03 0 CA-C-O 121.107 0.479 . . . . 0.0 112.163 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 72.0 m-85 -81.43 152.34 27.45 Favored 'General case' 0 N--CA 1.433 -1.31 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.154 175.144 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.424 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 81.24 -19.47 8.2 Favored Glycine 0 C--N 1.309 -0.95 0 C-N-CA 123.366 0.507 . . . . 0.0 113.555 178.412 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.471 ' HB ' ' OE1' ' A' ' 49' ' ' GLU . 35.9 p -118.92 -22.78 7.17 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 122.267 -0.549 . . . . 0.0 110.578 176.426 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.439 ' HA ' ' CZ ' ' A' ' 43' ' ' PHE . 13.3 m170 66.43 25.6 10.22 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 123.308 0.643 . . . . 0.0 110.879 -179.729 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.471 ' OE1' ' HB ' ' A' ' 47' ' ' THR . 45.9 mt-10 -97.45 175.47 6.22 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.454 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 10.0 m -143.76 143.85 31.56 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-O 121.172 0.511 . . . . 0.0 109.815 -179.241 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -131.37 178.26 6.85 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 114.814 -1.084 . . . . 0.0 109.675 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 1.606 ' HE1' ' CE2' ' A' ' 52' ' ' PHE . 91.9 m-85 -133.38 109.82 9.6 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 176.598 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 88.9 mt -125.65 163.7 22.2 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 -177.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -85.22 162.8 37.05 Favored Glycine 0 N--CA 1.419 -2.454 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 178.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -63.88 -15.17 47.48 Favored 'Trans proline' 0 C--O 1.208 -0.989 0 C-N-CA 123.006 2.471 . . . . 0.0 112.257 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.527 ' HZ1' ' CG ' ' A' ' 57' ' ' ASP . 0.0 OUTLIER -97.08 4.96 51.1 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 115.648 -0.705 . . . . 0.0 112.75 178.002 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.527 ' CG ' ' HZ1' ' A' ' 56' ' ' LYS . 21.4 m-20 -113.67 1.77 15.02 Favored 'General case' 0 C--N 1.292 -1.911 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.143 177.155 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 17.6 pt -127.13 150.74 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.823 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 1.6 ' HE2' ' CE1' ' A' ' 59' ' ' PHE . 93.3 m-85 -136.29 142.37 39.45 Favored Pre-proline 0 C--N 1.295 -1.794 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo -65.09 137.88 54.25 Favored 'Trans proline' 0 C--O 1.249 1.046 0 C-N-CA 122.835 2.357 . . . . 0.0 112.922 -177.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 25.4 t80 -56.38 -42.69 78.29 Favored 'General case' 0 C--O 1.208 -1.093 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.172 178.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.6 m -53.87 -43.43 69.59 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 115.677 -0.692 . . . . 0.0 112.509 -175.259 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -95.62 -17.23 21.51 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.259 0.552 . . . . 0.0 112.031 -176.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.517 ' ND2' ' HB3' ' A' ' 59' ' ' PHE . 28.0 m-80 -116.73 10.54 14.32 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -173.027 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.486 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 19.4 pttp -68.69 -35.44 77.2 Favored 'General case' 0 C--O 1.21 -0.994 0 CA-C-O 121.137 0.494 . . . . 0.0 111.032 -177.296 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.486 ' OE1' ' HG3' ' A' ' 65' ' ' LYS . 2.1 mm-40 -73.01 -22.48 60.66 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 122.177 0.989 . . . . 0.0 108.819 -178.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.433 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 41.5 mtpt -83.42 -59.61 2.4 Favored 'General case' 0 N--CA 1.436 -1.148 0 CA-C-N 114.561 -1.2 . . . . 0.0 110.609 -177.606 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 0.472 ' CD2' ' HB3' ' A' ' 64' ' ' ASN . 27.2 m-85 -105.72 -8.12 18.02 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 115.475 -0.784 . . . . 0.0 112.697 -169.35 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -79.25 52.12 4.01 Favored Glycine 0 C--O 1.219 -0.816 0 C-N-CA 121.583 -0.342 . . . . 0.0 112.781 -177.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.7 ptpp? -132.96 132.9 22.66 Favored Pre-proline 0 C--N 1.301 -1.536 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 176.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -65.49 128.89 21.17 Favored 'Trans proline' 0 N--CA 1.446 -1.316 0 C-N-CA 122.655 2.237 . . . . 0.0 115.531 -172.193 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.44 ' N ' HD21 ' A' ' 72' ' ' ASN . 0.8 OUTLIER -93.92 -170.81 2.41 Favored 'General case' 0 CA--C 1.487 -1.474 0 N-CA-C 106.205 -1.776 . . . . 0.0 106.205 173.829 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . 0.412 ' HD3' ' HA ' ' A' ' 73' ' ' LYS 0.273 70.9 mmtt -110.09 28.93 8.12 Favored 'General case' 0 C--N 1.291 -1.977 0 CA-C-O 122.593 1.187 . . . . 0.0 110.592 171.35 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 14.7 mmt180 -82.51 125.34 31.01 Favored 'General case' 0 C--O 1.25 1.099 0 N-CA-C 106.341 -1.725 . . . . 0.0 106.341 170.511 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -66.73 139.24 57.81 Favored 'General case' 0 C--N 1.318 -0.798 0 C-N-CA 119.83 -0.748 . . . . 0.0 109.882 176.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.424 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 95.87 -25.2 26.28 Favored Glycine 0 N--CA 1.428 -1.895 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -175.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 1.664 ' HD2' ' CD1' ' A' ' 77' ' ' PHE . 31.7 t80 -75.87 -47.06 26.98 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-O 121.196 0.522 . . . . 0.0 109.702 -178.062 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.534 ' N ' HD21 ' A' ' 78' ' ' ASN . 0.7 OUTLIER -67.4 -37.86 83.76 Favored 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.892 0.853 . . . . 0.0 109.142 -179.256 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 26.1 mt-10 -72.44 -36.1 68.46 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 114.024 -1.444 . . . . 0.0 109.593 -179.158 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -69.66 -33.89 72.08 Favored Glycine 0 CA--C 1.494 -1.271 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.641 178.455 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 94.7 mt -60.51 -38.79 85.52 Favored 'General case' 0 C--O 1.21 -0.976 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 174.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 85.4 t90 -66.66 -46.07 76.89 Favored 'General case' 0 N--CA 1.429 -1.476 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.695 177.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -61.48 -43.46 98.82 Favored 'General case' 0 C--O 1.204 -1.339 0 N-CA-C 113.076 0.769 . . . . 0.0 113.076 179.564 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.1 tt -70.8 -33.45 52.52 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 120.379 -0.528 . . . . 0.0 112.056 -175.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -88.98 -5.85 57.66 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 112.758 0.651 . . . . 0.0 112.758 -178.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 31.9 m-80 -123.57 -51.12 1.84 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-O 121.388 0.613 . . . . 0.0 112.089 -179.137 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.7 t30 -126.45 67.56 65.59 Favored Pre-proline 0 C--N 1.305 -1.341 0 O-C-N 121.94 -0.475 . . . . 0.0 110.186 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -74.78 -5.95 17.51 Favored 'Trans proline' 0 N--CA 1.48 0.698 0 C-N-CA 122.314 2.009 . . . . 0.0 112.289 -175.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.7 pttp -93.86 15.19 17.25 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.083 -178.404 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 10.0 p -89.9 147.7 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.583 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 176.172 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.467 ' HE3' ' OD1' ' A' ' 26' ' ' ASP . 18.2 ptmt -144.67 -163.17 1.64 Allowed 'General case' 0 C--N 1.309 -1.181 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 177.142 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 1.667 ' HD2' ' CD1' ' A' ' 92' ' ' PHE . 87.6 m-85 -29.56 104.03 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 C-N-CA 125.352 1.461 . . . . 0.0 113.737 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 22.8 t . . . . . 0 N--CA 1.425 -1.696 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 178.535 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.7 mtt . . . . . 0 CA--C 1.501 -0.908 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -130.5 82.76 2.08 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 104.098 -2.556 . . . . 0.0 104.098 172.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 14.2 ptm180 -122.09 -152.14 0.5 Allowed 'General case' 0 C--N 1.293 -1.862 0 CA-C-N 114.252 -1.34 . . . . 0.0 112.251 -171.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -82.02 156.32 24.69 Favored 'General case' 0 N--CA 1.435 -1.202 0 C-N-CA 124.509 1.124 . . . . 0.0 109.948 -179.104 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 1.642 ' HD2' ' CD1' ' A' ' 5' ' ' PHE . 95.0 m-85 -134.79 131.75 37.87 Favored 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 178.692 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.581 ' HG2' ' OD2' ' A' ' 9' ' ' ASP . 1.6 pttm -135.22 152.49 76.96 Favored Pre-proline 0 C--N 1.289 -2.039 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 -175.277 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo -49.09 121.7 7.25 Favored 'Trans proline' 0 C--N 1.352 0.723 0 C-N-CA 122.657 2.238 . . . . 0.0 111.138 176.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.38 -30.48 6.45 Favored Glycine 0 N--CA 1.423 -2.206 0 CA-C-O 118.991 -0.894 . . . . 0.0 113.637 -178.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.581 ' OD2' ' HG2' ' A' ' 6' ' ' LYS 0.335 2.9 p30 -78.71 147.93 33.27 Favored 'General case' 0 C--O 1.248 1.009 0 CA-C-N 118.859 1.329 . . . . 0.0 113.268 -179.161 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 82.3 mt -91.42 129.1 37.45 Favored 'General case' 0 CA--C 1.488 -1.44 0 CA-C-N 114.203 -1.362 . . . . 0.0 110.312 -175.783 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 12.1 pt -140.39 -173.03 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 CA-C-O 122.374 1.083 . . . . 0.0 111.993 -174.118 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 38.4 m-85 -120.71 132.33 55.01 Favored 'General case' 0 N--CA 1.414 -2.236 0 CA-C-N 113.979 -1.464 . . . . 0.0 107.077 171.344 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.426 ' HB3' HG22 ' A' ' 42' ' ' ILE . . . -108.92 124.02 50.0 Favored 'General case' 0 C--N 1.272 -2.788 0 O-C-N 123.947 0.779 . . . . 0.0 109.337 -178.811 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.697 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -109.33 120.27 42.0 Favored 'General case' 0 N--CA 1.398 -3.043 0 CA-C-N 116.184 -0.462 . . . . 0.0 109.916 -179.145 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 66.5 mtm -114.68 157.89 22.52 Favored 'General case' 0 C--N 1.314 -0.977 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 175.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 41.7 ttmt -66.31 117.63 8.85 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 116.712 -0.222 . . . . 0.0 110.429 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.92 -3.88 65.17 Favored Glycine 0 C--O 1.251 1.206 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.651 178.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 1.646 ' HD1' ' CD2' ' A' ' 18' ' ' TYR . 77.5 m-85 -120.9 151.44 54.85 Favored Pre-proline 0 N--CA 1.428 -1.573 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 -179.211 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -77.58 171.27 17.81 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 122.112 1.875 . . . . 0.0 109.611 175.562 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.454 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 70.0 m80 -63.15 110.99 2.03 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 174.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 7.5 t-105 -99.4 137.68 20.37 Favored Pre-proline 0 C--N 1.303 -1.456 0 C-N-CA 123.331 0.653 . . . . 0.0 109.239 -172.535 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -63.97 117.83 4.81 Favored 'Trans proline' 0 C--O 1.245 0.863 0 C-N-CA 121.796 1.664 . . . . 0.0 110.089 176.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.21 167.83 21.21 Favored 'General case' 0 N--CA 1.413 -2.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.143 -175.109 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.416 HH22 ' CD ' ' A' ' 27' ' ' GLU . 10.6 ttp180 -124.7 148.06 48.23 Favored 'General case' 0 C--N 1.282 -2.33 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 176.571 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.7 t -72.41 118.69 17.84 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 N-CA-C 105.275 -2.12 . . . . 0.0 105.275 170.31 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -84.76 172.43 11.49 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -171.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.416 ' CD ' HH22 ' A' ' 24' ' ' ARG . 0.5 OUTLIER -108.76 135.74 49.48 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-O 121.669 0.747 . . . . 0.0 112.533 -175.465 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 45.6 t -86.44 124.9 69.11 Favored Pre-proline 0 C--N 1.31 -1.143 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 178.639 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -72.72 140.9 33.11 Favored 'Trans proline' 0 N--CA 1.43 -2.264 0 C-N-CA 121.356 1.371 . . . . 0.0 112.566 -179.564 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -69.6 147.88 50.12 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 174.66 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.38 -16.08 61.46 Favored Glycine 0 C--N 1.296 -1.677 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.692 -176.119 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -67.25 118.71 11.01 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-O 121.308 0.575 . . . . 0.0 110.593 177.379 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.7 m -79.38 -0.01 3.46 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 115.703 -0.681 . . . . 0.0 112.273 -179.497 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 69.7 mmtt -103.17 118.35 58.15 Favored Pre-proline 0 N--CA 1.428 -1.556 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 175.312 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -82.63 166.43 15.48 Favored 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 122.454 2.103 . . . . 0.0 111.505 178.745 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 14.2 Cg_endo -59.63 144.07 99.51 Favored 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 122.204 1.936 . . . . 0.0 111.942 178.326 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.498 ' O ' HG21 ' A' ' 37' ' ' THR . 5.6 m -73.54 9.08 1.5 Allowed 'General case' 0 C--N 1.309 -1.173 0 C-N-CA 125.185 1.394 . . . . 0.0 112.644 -175.882 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 4.6 p30 87.11 9.43 0.18 Allowed 'General case' 0 N--CA 1.503 2.189 0 C-N-CA 126.829 2.051 . . . . 0.0 109.314 -173.489 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -131.47 170.06 15.21 Favored 'General case' 0 N--CA 1.418 -2.051 0 CA-C-N 112.74 -2.027 . . . . 0.0 109.192 178.591 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.424 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 92.8 mt -98.89 141.6 23.16 Favored Pre-proline 0 C--N 1.287 -2.148 0 O-C-N 123.977 0.798 . . . . 0.0 109.937 -176.537 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -70.65 123.27 9.65 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.053 1.836 . . . . 0.0 109.429 176.082 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.426 HG22 ' HB3' ' A' ' 13' ' ' ALA . 39.5 mm -116.35 117.05 54.21 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.123 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 -175.775 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 72.7 t80 -94.28 115.89 28.2 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -81.54 129.1 34.54 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 123.425 0.453 . . . . 0.0 111.387 177.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 1.63 ' HE2' ' CE1' ' A' ' 45' ' ' PHE . 86.8 m-85 -80.07 150.64 30.24 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.694 176.249 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.504 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 80.78 -19.91 6.95 Favored Glycine 0 C--N 1.311 -0.827 0 CA-C-N 116.216 -0.447 . . . . 0.0 113.739 179.152 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.4 p -119.33 -23.74 6.61 Favored 'General case' 0 C--N 1.309 -1.16 0 O-C-N 122.074 -0.662 . . . . 0.0 110.556 174.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 68.02 13.66 9.17 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 123.987 0.915 . . . . 0.0 112.231 -178.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.7 mm-40 -76.52 164.11 26.27 Favored 'General case' 0 CA--C 1.493 -1.226 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.263 178.222 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.412 ' HA ' ' O ' ' A' ' 42' ' ' ILE . 4.2 m -133.2 136.85 45.9 Favored 'General case' 0 C--N 1.283 -2.298 0 CA-C-O 121.425 0.631 . . . . 0.0 109.773 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -128.53 178.02 6.6 Favored 'General case' 0 C--N 1.284 -2.256 0 CA-C-N 115.013 -0.994 . . . . 0.0 109.914 -179.302 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.424 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 95.9 m-85 -133.63 110.25 9.75 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 176.527 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 94.9 mt -124.71 160.53 28.36 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 -179.35 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -87.81 167.53 36.73 Favored Glycine 0 N--CA 1.42 -2.383 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 178.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.65 -6.96 16.65 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 123.16 2.573 . . . . 0.0 112.334 -178.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 7.9 ptmm? -97.31 -4.32 38.89 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.415 178.411 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.2 m-20 -115.27 5.66 14.76 Favored 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.891 -176.587 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 14.3 pt -131.38 150.7 34.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.796 0 CA-C-N 114.737 -1.12 . . . . 0.0 108.981 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -141.66 147.19 44.65 Favored Pre-proline 0 C--N 1.295 -1.778 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 -179.371 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -62.06 133.24 43.06 Favored 'Trans proline' 0 CA--C 1.511 -0.667 0 C-N-CA 123.043 2.495 . . . . 0.0 113.256 -177.45 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -64.62 -36.97 85.98 Favored 'General case' 0 C--O 1.207 -1.177 0 CA-C-N 114.88 -1.055 . . . . 0.0 110.7 -177.214 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 10.6 m -63.95 -39.65 94.64 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.239 -178.22 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -89.05 -7.43 55.9 Favored 'General case' 0 C--O 1.218 -0.582 0 N-CA-C 111.879 0.326 . . . . 0.0 111.879 -177.534 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 39.0 m-80 -123.92 13.39 9.16 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -179.476 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.8 ttmm -67.05 -34.36 77.51 Favored 'General case' 0 N--CA 1.473 0.694 0 CA-C-O 121.667 0.746 . . . . 0.0 109.648 -179.669 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.553 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -79.16 -20.25 48.96 Favored 'General case' 0 N--CA 1.408 -2.55 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.347 178.072 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.553 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 8.2 mttm -87.92 -59.28 2.29 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.979 179.529 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 1.668 ' HE1' ' CE2' ' A' ' 68' ' ' TYR . 66.0 m-85 -112.53 1.32 15.81 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.3 -171.789 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.6 55.97 4.15 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 111.601 -0.599 . . . . 0.0 111.601 178.229 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 58.4 mttp -129.54 123.71 21.48 Favored Pre-proline 0 C--N 1.31 -1.131 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 -179.712 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -63.0 128.2 22.35 Favored 'Trans proline' 0 N--CA 1.444 -1.424 0 C-N-CA 121.839 1.693 . . . . 0.0 114.132 -175.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -93.24 -171.84 2.78 Favored 'General case' 0 CA--C 1.482 -1.667 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 176.44 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . 0.268 71.4 mmtt -109.42 27.56 9.42 Favored 'General case' 0 C--N 1.289 -2.045 0 CA-C-O 122.613 1.197 . . . . 0.0 110.361 171.041 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 13.8 mmt180 -80.14 127.64 32.56 Favored 'General case' 0 C--O 1.25 1.11 0 N-CA-C 105.168 -2.16 . . . . 0.0 105.168 169.421 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 42.9 tttm -67.77 141.89 56.41 Favored 'General case' 0 C--N 1.32 -0.699 0 C-N-CA 119.228 -0.989 . . . . 0.0 108.721 179.456 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.504 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 94.17 -25.31 22.83 Favored Glycine 0 N--CA 1.426 -1.985 0 C-N-CA 120.881 -0.676 . . . . 0.0 111.846 -177.08 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 1.636 ' HD1' ' CD2' ' A' ' 77' ' ' PHE . 20.6 t80 -72.87 -44.73 60.98 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.336 0.588 . . . . 0.0 109.585 -177.613 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.556 ' N ' HD21 ' A' ' 78' ' ' ASN . 0.7 OUTLIER -70.34 -42.21 72.18 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 -178.949 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -65.99 -38.48 88.59 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-N 114.447 -1.251 . . . . 0.0 109.451 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -68.51 -34.84 80.07 Favored Glycine 0 N--CA 1.433 -1.505 0 CA-C-N 115.349 -0.842 . . . . 0.0 113.057 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.412 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 94.6 mt -60.61 -35.43 76.12 Favored 'General case' 0 C--O 1.216 -0.668 0 CA-C-O 121.309 0.576 . . . . 0.0 109.782 175.701 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 83.1 t90 -70.78 -48.97 51.46 Favored 'General case' 0 N--CA 1.433 -1.284 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.724 176.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -58.15 -45.33 87.61 Favored 'General case' 0 C--O 1.205 -1.289 0 N-CA-C 113.042 0.756 . . . . 0.0 113.042 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.7 tt -68.82 -31.23 49.86 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -174.021 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -90.58 -10.34 43.77 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -179.027 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 31.7 m-80 -117.78 -53.99 2.37 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-O 121.223 0.535 . . . . 0.0 112.215 -178.373 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -127.86 75.77 77.92 Favored Pre-proline 0 C--N 1.304 -1.396 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.189 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.81 -7.7 21.97 Favored 'Trans proline' 0 N--CA 1.488 1.188 0 C-N-CA 122.87 2.38 . . . . 0.0 112.688 -176.569 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.3 pttp -105.36 21.08 17.78 Favored 'General case' 0 C--N 1.302 -1.461 0 C-N-CA 123.982 0.913 . . . . 0.0 109.738 -178.344 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 11.5 p -66.61 78.42 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.558 1.275 0 N-CA-C 115.64 1.719 . . . . 0.0 115.64 -175.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 9.1 mmpt? -75.34 -46.64 31.97 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 103.413 -2.81 . . . . 0.0 103.413 166.303 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -132.35 149.49 52.34 Favored 'General case' 0 N--CA 1.423 -1.781 0 N-CA-C 104.23 -2.507 . . . . 0.0 104.23 173.187 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 8.1 t . . . . . 0 C--N 1.294 -1.81 0 C-N-CA 119.229 -0.988 . . . . 0.0 109.423 -177.492 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.615 ' HB3' ' O ' ' A' ' 3' ' ' ARG . 10.2 tpt . . . . . 0 C--O 1.214 -0.797 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.433 ' H ' ' HG3' ' A' ' 1' ' ' MET . . . -66.79 -13.19 61.2 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-O 121.979 0.895 . . . . 0.0 110.301 174.309 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . 0.615 ' O ' ' HB3' ' A' ' 1' ' ' MET . 6.0 ptp180 -135.48 158.28 44.77 Favored 'General case' 0 N--CA 1.426 -1.658 0 N-CA-C 101.41 -3.552 . . . . 0.0 101.41 173.114 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . 0.326 0.2 OUTLIER -120.56 175.8 5.81 Favored 'General case' 0 C--N 1.286 -2.166 0 C-N-CA 115.105 -2.638 . . . . 0.0 114.329 179.59 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 1.651 ' HE1' ' CE2' ' A' ' 5' ' ' PHE . 88.9 m-85 -106.37 152.5 23.5 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 124.045 0.841 . . . . 0.0 113.053 -167.331 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.621 ' HG2' ' OD2' ' A' ' 9' ' ' ASP . 16.8 pttm -134.6 160.09 69.74 Favored Pre-proline 0 C--N 1.305 -1.35 0 CA-C-N 114.889 -1.05 . . . . 0.0 108.336 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -51.25 122.65 10.46 Favored 'Trans proline' 0 C--N 1.347 0.499 0 C-N-CA 122.496 2.131 . . . . 0.0 111.879 175.328 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.1 -22.59 11.25 Favored Glycine 0 N--CA 1.429 -1.77 0 CA-C-O 119.351 -0.694 . . . . 0.0 113.381 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.621 ' OD2' ' HG2' ' A' ' 6' ' ' LYS . 37.3 m-20 -66.0 128.95 38.09 Favored 'General case' 0 C--O 1.247 0.953 0 CA-C-N 117.659 0.729 . . . . 0.0 112.097 -179.456 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 77.2 mt -83.83 124.43 30.94 Favored 'General case' 0 CA--C 1.485 -1.545 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 176.036 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 10.3 pt -140.24 -174.3 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 CA-C-O 122.367 1.079 . . . . 0.0 112.261 -172.137 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 1.611 ' HE2' ' CE1' ' A' ' 12' ' ' PHE . 45.6 m-85 -119.77 126.96 52.32 Favored 'General case' 0 N--CA 1.404 -2.741 0 CA-C-N 113.181 -1.827 . . . . 0.0 106.973 170.529 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.421 ' CB ' HG22 ' A' ' 42' ' ' ILE . . . -108.98 121.76 45.81 Favored 'General case' 0 C--N 1.27 -2.869 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.312 -178.241 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.68 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -104.77 119.57 39.3 Favored 'General case' 0 N--CA 1.401 -2.887 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.939 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 72.4 mtm -104.07 159.01 16.03 Favored 'General case' 0 C--N 1.312 -1.058 0 C-N-CA 123.172 0.589 . . . . 0.0 110.215 179.406 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.4 tttp -65.37 116.22 6.45 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.553 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.13 -8.04 64.75 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.627 178.755 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 65.8 m-85 -128.72 147.85 66.09 Favored Pre-proline 0 N--CA 1.444 -0.744 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -178.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -68.7 170.89 14.26 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.845 2.363 . . . . 0.0 111.909 177.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.548 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 74.6 m80 -60.83 111.64 1.73 Allowed 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.114 178.229 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 4.0 t-105 -101.85 136.89 19.44 Favored Pre-proline 0 C--N 1.313 -1.002 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -176.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -64.7 117.64 4.7 Favored 'Trans proline' 0 C--O 1.241 0.649 0 C-N-CA 121.779 1.653 . . . . 0.0 110.432 176.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -141.16 167.38 22.32 Favored 'General case' 0 N--CA 1.413 -2.282 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.69 -174.749 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 32.7 ttt180 -109.96 138.35 46.46 Favored 'General case' 0 C--N 1.291 -1.969 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 176.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 64.4 t -74.68 111.68 10.92 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.068 0 N-CA-C 103.501 -2.777 . . . . 0.0 103.501 166.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -86.26 -177.58 6.27 Favored 'General case' 0 C--N 1.282 -2.329 0 C-N-CA 119.543 -0.863 . . . . 0.0 112.105 -169.728 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -104.24 143.56 32.78 Favored 'General case' 0 C--N 1.294 -1.838 0 CA-C-O 121.966 0.889 . . . . 0.0 112.861 -171.776 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.3 t -105.09 126.92 29.77 Favored Pre-proline 0 C--N 1.31 -1.136 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 178.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -71.04 137.84 32.56 Favored 'Trans proline' 0 N--CA 1.433 -2.087 0 C-N-CA 121.319 1.346 . . . . 0.0 112.605 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -71.65 149.69 45.31 Favored 'General case' 0 C--N 1.31 -1.13 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 173.756 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 92.43 -10.89 73.35 Favored Glycine 0 C--N 1.294 -1.759 0 C-N-CA 120.553 -0.832 . . . . 0.0 111.793 -176.097 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -65.71 101.68 0.66 Allowed 'General case' 0 C--O 1.219 -0.537 0 CA-C-O 121.439 0.638 . . . . 0.0 110.929 176.485 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 26.0 m -85.11 7.95 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.79 0.805 . . . . 0.0 111.804 179.741 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 26.7 mmmt -97.59 128.93 32.86 Favored Pre-proline 0 C--N 1.291 -1.969 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 176.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -64.18 141.98 78.24 Favored 'Trans proline' 0 CA--C 1.534 0.499 0 C-N-CA 122.012 1.808 . . . . 0.0 112.039 179.666 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.401 ' C ' ' H ' ' A' ' 38' ' ' ASN . 68.6 Cg_endo -75.55 171.25 18.58 Favored 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 122.369 2.046 . . . . 0.0 112.238 -179.339 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.2 m -73.03 7.46 2.07 Favored 'General case' 0 C--O 1.262 1.745 0 C-N-CA 124.548 1.139 . . . . 0.0 111.562 -178.753 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.401 ' H ' ' C ' ' A' ' 36' ' ' PRO . 39.8 m-80 65.53 25.16 11.79 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 124.499 1.12 . . . . 0.0 108.98 -177.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 62.5 mttp -142.99 179.72 6.87 Favored 'General case' 0 N--CA 1.429 -1.497 0 CA-C-N 114.255 -1.339 . . . . 0.0 108.644 -178.173 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 96.5 mt -97.42 139.93 21.72 Favored Pre-proline 0 C--N 1.293 -1.876 0 O-C-N 123.995 0.809 . . . . 0.0 109.87 -179.333 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -70.29 123.45 9.94 Favored 'Trans proline' 0 N--CA 1.46 -0.475 0 C-N-CA 122.484 2.123 . . . . 0.0 110.247 177.512 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.421 HG22 ' CB ' ' A' ' 13' ' ' ALA . 42.4 mm -117.8 120.52 64.9 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.788 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 -177.072 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.641 ' HD1' ' CD2' ' A' ' 43' ' ' PHE . 93.0 t80 -105.22 117.68 34.63 Favored 'General case' 0 C--N 1.286 -2.194 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 178.733 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 1.625 ' HD1' ' CD2' ' A' ' 44' ' ' PHE . 89.6 m-85 -82.93 135.69 34.82 Favored 'General case' 0 C--N 1.308 -1.212 0 CA-C-O 121.435 0.636 . . . . 0.0 112.332 179.493 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -85.48 151.72 23.75 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.469 178.155 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.422 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 80.84 -20.91 5.96 Favored Glycine 0 C--N 1.309 -0.939 0 C-N-CA 124.553 1.073 . . . . 0.0 114.124 177.657 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.48 ' CG2' ' HA3' ' A' ' 76' ' ' GLY . 37.0 p -119.8 -23.14 6.55 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-N 117.279 0.539 . . . . 0.0 110.201 175.084 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 43.4 m170 67.96 22.37 8.6 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.282 -178.263 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -71.75 164.2 26.41 Favored 'General case' 0 C--N 1.346 0.418 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 176.254 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.4 m -138.37 140.92 39.62 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -179.806 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -141.41 177.68 7.95 Favored 'General case' 0 C--N 1.289 -2.034 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.183 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 1.598 ' HE1' ' CE2' ' A' ' 52' ' ' PHE . 95.7 m-85 -134.36 117.57 16.49 Favored 'General case' 0 N--CA 1.434 -1.238 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 176.755 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 90.7 mt -127.61 169.27 13.94 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.257 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.26 162.8 29.84 Favored Glycine 0 N--CA 1.413 -2.846 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -66.78 -5.98 14.52 Favored 'Trans proline' 0 N--CA 1.487 1.125 0 C-N-CA 123.88 3.053 . . . . 0.0 112.578 -179.476 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.3 ptmm? -97.89 -6.98 31.2 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 114.875 -1.057 . . . . 0.0 111.686 177.186 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -112.52 6.26 18.4 Favored 'General case' 0 C--N 1.294 -1.806 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.995 -175.432 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.447 HG13 ' CE2' ' A' ' 5' ' ' PHE . 14.2 pt -127.28 147.06 32.16 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 CA-C-N 114.853 -1.067 . . . . 0.0 110.396 179.39 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 -140.26 147.62 50.82 Favored Pre-proline 0 C--N 1.302 -1.474 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -177.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -62.09 132.34 38.73 Favored 'Trans proline' 0 N--CA 1.481 0.749 0 C-N-CA 123.315 2.677 . . . . 0.0 113.955 -176.617 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 1.67 ' HE2' ' CE1' ' A' ' 61' ' ' TYR . 77.8 t80 -61.03 -40.7 94.59 Favored 'General case' 0 C--O 1.207 -1.136 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.652 -178.406 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 m -60.45 -40.15 90.11 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.81 -175.583 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -95.25 -4.08 46.39 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 115.763 -0.653 . . . . 0.0 112.193 -174.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.419 ' HA ' ' HE2' ' A' ' 67' ' ' LYS . 29.6 m-80 -125.64 15.36 8.15 Favored 'General case' 0 N--CA 1.446 -0.645 0 CA-C-O 120.427 0.156 . . . . 0.0 111.404 178.589 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 57.2 tttp -69.58 -36.2 76.04 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 121.627 0.727 . . . . 0.0 109.545 -178.355 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.538 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -75.15 -22.42 58.13 Favored 'General case' 0 N--CA 1.416 -2.131 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.964 176.502 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.538 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 7.8 mtmm -84.84 -54.08 4.91 Favored 'General case' 0 N--CA 1.437 -1.09 0 CA-C-N 115.743 -0.662 . . . . 0.0 112.621 179.661 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 1.656 ' HE1' ' CE2' ' A' ' 68' ' ' TYR . 61.4 m-85 -122.0 -4.21 9.07 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -173.116 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.69 52.21 4.38 Favored Glycine 0 N--CA 1.468 0.826 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.103 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.2 ptpt -133.01 156.27 80.24 Favored Pre-proline 0 C--N 1.306 -1.325 0 C-N-CA 123.456 0.703 . . . . 0.0 109.676 -177.464 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.425 ' HB3' ' OD1' ' A' ' 78' ' ' ASN . 85.9 Cg_exo -49.15 153.11 4.52 Favored 'Trans proline' 0 C--N 1.355 0.897 0 C-N-CA 123.781 2.987 . . . . 0.0 115.889 -177.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -136.53 -173.38 3.4 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 114.545 -1.207 . . . . 0.0 109.106 179.634 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 47.5 mmtm -100.8 -14.54 17.97 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 179.222 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 4.1 mmm180 -70.79 123.53 22.17 Favored 'General case' 0 N--CA 1.436 -1.147 0 CA-C-O 121.186 0.517 . . . . 0.0 110.697 175.031 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 16.6 tppt? -68.38 126.4 29.49 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 174.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.48 ' HA3' ' CG2' ' A' ' 47' ' ' THR . . . 108.56 -19.53 31.1 Favored Glycine 0 N--CA 1.416 -2.668 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -177.013 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.422 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 16.6 t80 -76.31 -45.49 32.14 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -179.584 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.425 ' OD1' ' HB3' ' A' ' 71' ' ' PRO . 52.7 m-80 -69.91 -39.94 75.89 Favored 'General case' 0 CA--C 1.5 -0.957 0 CA-C-O 121.942 0.877 . . . . 0.0 108.957 -179.624 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 30.4 mp0 -64.87 -36.22 83.66 Favored 'General case' 0 N--CA 1.425 -1.72 0 CA-C-N 114.06 -1.427 . . . . 0.0 109.468 177.317 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.35 -31.48 68.64 Favored Glycine 0 CA--C 1.49 -1.49 0 CA-C-N 115.385 -0.825 . . . . 0.0 112.431 178.756 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.422 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 96.0 mt -58.84 -39.98 82.89 Favored 'General case' 0 C--O 1.212 -0.913 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 174.481 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 83.1 t90 -67.97 -48.7 65.11 Favored 'General case' 0 N--CA 1.432 -1.365 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.283 177.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -59.31 -43.4 92.64 Favored 'General case' 0 C--O 1.207 -1.135 0 N-CA-C 113.5 0.926 . . . . 0.0 113.5 -179.258 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.1 tt -71.98 -28.44 30.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 C-N-CA 120.23 -0.588 . . . . 0.0 112.209 -174.354 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -86.86 -17.37 33.49 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 112.062 0.393 . . . . 0.0 112.062 179.457 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 32.1 m-80 -114.46 -51.19 2.77 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-O 121.366 0.603 . . . . 0.0 112.471 -175.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.458 ' ND2' ' HB ' ' A' ' 90' ' ' VAL . 66.8 t30 -127.93 68.16 75.0 Favored Pre-proline 0 C--N 1.305 -1.364 0 O-C-N 121.883 -0.511 . . . . 0.0 110.678 -178.369 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_endo -75.77 -5.83 16.86 Favored 'Trans proline' 0 C--N 1.348 0.508 0 C-N-CA 122.025 1.817 . . . . 0.0 112.208 -177.591 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 19.8 pttp -93.4 14.67 17.82 Favored 'General case' 0 C--N 1.299 -1.592 0 CA-C-N 114.737 -1.119 . . . . 0.0 110.429 -178.779 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.458 ' HB ' ' ND2' ' A' ' 87' ' ' ASN . 13.4 p -80.8 83.48 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.117 0 CA-C-O 122.581 1.181 . . . . 0.0 111.896 178.869 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -109.28 21.53 16.99 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-O 122.475 1.131 . . . . 0.0 111.465 -178.419 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 -93.45 -0.13 56.55 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 114.617 -1.174 . . . . 0.0 109.028 179.005 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 14.3 m . . . . . 0 N--CA 1.444 -0.751 0 C-N-CA 124.948 1.299 . . . . 0.0 111.522 -177.176 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.7 mmm . . . . . 0 C--O 1.21 -1.017 0 CA-C-O 119.44 -0.314 . . . . 0.0 110.28 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -81.23 -7.17 59.52 Favored 'General case' 0 C--O 1.218 -0.595 0 O-C-N 124.203 0.939 . . . . 0.0 113.404 -176.387 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 47.7 ptt85 -95.77 177.29 5.83 Favored 'General case' 0 CA--C 1.511 -0.542 0 C-N-CA 118.954 -1.098 . . . . 0.0 109.587 177.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -84.45 165.75 17.87 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -177.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -131.35 125.73 33.45 Favored 'General case' 0 N--CA 1.42 -1.965 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.1 mttp -105.45 153.53 39.69 Favored Pre-proline 0 C--N 1.298 -1.656 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.638 -172.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -62.44 116.51 3.56 Favored 'Trans proline' 0 N--CA 1.457 -0.667 0 N-CA-C 107.921 -1.607 . . . . 0.0 107.921 170.397 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 108.62 -10.34 35.35 Favored Glycine 0 N--CA 1.426 -1.974 0 C-N-CA 120.833 -0.698 . . . . 0.0 112.172 -175.426 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -73.09 154.96 40.18 Favored 'General case' 0 C--O 1.253 1.245 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 -178.397 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.418 HD22 ' HB2' ' A' ' 88' ' ' PRO . 79.9 mt -105.36 123.67 48.26 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 -173.439 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.9 pp -140.28 177.56 4.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 CA-C-O 122.058 0.932 . . . . 0.0 112.934 -174.14 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 1.609 ' HD2' ' CD1' ' A' ' 12' ' ' PHE . 74.6 m-85 -110.31 129.54 55.72 Favored 'General case' 0 C--N 1.284 -2.263 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 170.662 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -108.0 118.49 36.88 Favored 'General case' 0 C--N 1.277 -2.569 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.136 -176.345 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.685 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -107.14 122.64 46.91 Favored 'General case' 0 N--CA 1.4 -2.957 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.384 -179.092 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 30.2 mtm -127.08 158.25 37.49 Favored 'General case' 0 CA--C 1.493 -1.22 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 176.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -64.17 117.23 6.84 Favored 'General case' 0 C--N 1.307 -1.255 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 178.44 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.05 -16.11 57.47 Favored Glycine 0 C--O 1.249 1.034 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 -178.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 1.659 ' HD1' ' CD2' ' A' ' 18' ' ' TYR . 8.9 m-85 -105.47 151.04 39.65 Favored Pre-proline 0 N--CA 1.43 -1.466 0 C-N-CA 123.175 0.59 . . . . 0.0 109.623 178.811 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -83.12 171.69 11.3 Favored 'Trans proline' 0 N--CA 1.439 -1.685 0 C-N-CA 122.122 1.882 . . . . 0.0 107.416 169.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.484 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 70.6 m80 -61.83 109.97 1.4 Allowed 'General case' 0 CA--C 1.542 0.648 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 174.023 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -105.15 136.79 19.14 Favored Pre-proline 0 C--N 1.305 -1.342 0 C-N-CA 123.131 0.572 . . . . 0.0 109.53 -170.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -65.02 117.84 4.9 Favored 'Trans proline' 0 N--CA 1.455 -0.754 0 C-N-CA 121.321 1.347 . . . . 0.0 110.433 177.497 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.92 166.61 24.15 Favored 'General case' 0 N--CA 1.413 -2.292 0 CA-C-O 121.279 0.561 . . . . 0.0 110.157 -175.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.46 ' HB2' ' CE2' ' A' ' 45' ' ' PHE . 31.7 ttp85 -116.68 145.83 43.17 Favored 'General case' 0 C--N 1.283 -2.303 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.554 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.6 t -76.49 123.88 33.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 105.302 -2.11 . . . . 0.0 105.302 171.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -90.93 -177.1 4.85 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -173.478 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.411 ' CD ' HH22 ' A' ' 24' ' ' ARG . 15.0 mp0 -91.09 156.68 17.72 Favored 'General case' 0 N--CA 1.423 -1.809 0 CA-C-O 121.87 0.843 . . . . 0.0 111.499 -176.867 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 61.5 t -112.26 126.74 27.89 Favored Pre-proline 0 C--N 1.313 -1.012 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 175.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_endo -73.0 136.34 24.71 Favored 'Trans proline' 0 N--CA 1.431 -2.201 0 C-N-CA 121.131 1.221 . . . . 0.0 112.182 178.293 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -74.83 150.24 39.33 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 174.178 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 88.15 -4.71 85.41 Favored Glycine 0 N--CA 1.428 -1.869 0 C-N-CA 120.452 -0.88 . . . . 0.0 111.909 -175.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -67.36 94.66 0.4 Allowed 'General case' 0 N--CA 1.448 -0.528 0 CA-C-O 121.409 0.624 . . . . 0.0 111.074 176.511 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 31.3 m -83.82 1.87 3.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.691 178.554 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 31.1 mmtp -86.41 124.83 69.28 Favored Pre-proline 0 C--N 1.304 -1.408 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 177.086 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -65.07 134.5 39.89 Favored 'Trans proline' 0 N--CA 1.453 -0.88 0 C-N-CA 121.862 1.708 . . . . 0.0 111.976 -179.091 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -82.43 171.17 12.58 Favored 'Trans proline' 0 N--CA 1.441 -1.573 0 C-N-CA 122.176 1.917 . . . . 0.0 111.638 -179.702 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.4 m -78.12 7.23 6.51 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 123.316 0.646 . . . . 0.0 110.511 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 41.8 m-80 70.69 18.06 6.42 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 124.819 1.248 . . . . 0.0 110.213 -177.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.548 ' HE2' ' N ' ' A' ' 54' ' ' GLY . 30.3 mtpt -122.87 166.67 14.64 Favored 'General case' 0 N--CA 1.429 -1.475 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 -179.746 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 91.8 mt -88.16 147.05 39.54 Favored Pre-proline 0 C--N 1.304 -1.388 0 C-N-CA 122.721 0.408 . . . . 0.0 110.369 -176.033 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -71.54 123.87 9.84 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.438 2.092 . . . . 0.0 110.295 177.419 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 49.3 mm -119.02 125.17 74.27 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 O-C-N 122.064 -0.398 . . . . 0.0 110.613 -176.344 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.644 ' HE2' ' CE1' ' A' ' 43' ' ' PHE . 59.0 t80 -104.77 114.52 28.79 Favored 'General case' 0 C--N 1.288 -2.104 0 C-N-CA 123.431 0.692 . . . . 0.0 109.144 177.766 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -77.97 137.27 38.22 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.014 0.435 . . . . 0.0 111.681 178.035 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 1.628 ' HD2' ' CD1' ' A' ' 45' ' ' PHE . 70.5 m-85 -89.16 156.44 18.79 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.492 177.168 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.43 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 74.02 -20.78 1.44 Allowed Glycine 0 N--CA 1.469 0.878 0 C-N-CA 124.578 1.085 . . . . 0.0 114.454 178.734 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.2 p -119.15 -22.67 7.08 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 173.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 11.2 m170 65.87 24.7 11.27 Favored 'General case' 0 C--N 1.348 0.519 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.107 179.06 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -73.34 167.39 21.33 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 115.388 -0.824 . . . . 0.0 108.904 176.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.6 m -137.82 140.81 40.71 Favored 'General case' 0 C--N 1.287 -2.122 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -145.37 -179.32 6.58 Favored 'General case' 0 C--N 1.293 -1.859 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.131 -178.202 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 1.653 ' HD2' ' CD1' ' A' ' 52' ' ' PHE . 83.4 m-85 -132.2 110.71 10.84 Favored 'General case' 0 C--O 1.246 0.886 0 CA-C-N 115.217 -0.902 . . . . 0.0 109.427 177.193 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.437 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 93.8 mt -129.48 154.64 46.8 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.656 -177.415 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.548 ' N ' ' HE2' ' A' ' 39' ' ' LYS . . . -95.87 176.34 33.32 Favored Glycine 0 N--CA 1.432 -1.585 0 C-N-CA 120.016 -1.088 . . . . 0.0 111.301 -174.831 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -66.22 -7.53 17.63 Favored 'Trans proline' 0 C--O 1.239 0.566 0 C-N-CA 122.966 2.444 . . . . 0.0 112.311 -178.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.7 mtpp -97.3 -15.16 20.9 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.238 177.054 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.437 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 40.9 m-20 -93.39 -14.38 26.89 Favored 'General case' 0 CA--C 1.49 -1.346 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.084 -178.488 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.461 ' HA ' ' O ' ' A' ' 12' ' ' PHE . 17.9 pt -119.12 148.58 21.96 Favored 'Isoleucine or valine' 0 C--O 1.268 2.04 0 CA-C-O 122.482 1.134 . . . . 0.0 112.849 -171.947 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 80.8 m-85 -136.08 133.25 19.56 Favored Pre-proline 0 C--N 1.292 -1.895 0 CA-C-N 113.885 -1.507 . . . . 0.0 106.951 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . 0.471 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 35.8 Cg_endo -64.12 127.91 20.45 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.881 2.388 . . . . 0.0 113.147 -177.2 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 1.668 ' HD1' ' CD2' ' A' ' 61' ' ' TYR . 72.0 t80 -58.86 -35.38 72.85 Favored 'General case' 0 C--O 1.197 -1.674 0 CA-C-N 114.062 -1.426 . . . . 0.0 112.915 -174.78 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.421 ' HB3' ' OE1' ' A' ' 63' ' ' GLU . 28.2 t -67.63 -52.19 41.15 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.191 0.52 . . . . 0.0 110.478 -177.808 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.471 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 2.6 mp0 -81.32 -5.67 58.07 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.128 -175.58 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.413 ' HA ' ' HE2' ' A' ' 67' ' ' LYS . 24.2 m-80 -126.59 15.12 7.61 Favored 'General case' 0 C--N 1.311 -1.079 0 C-N-CA 122.893 0.477 . . . . 0.0 111.557 -179.558 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -67.85 -35.89 79.36 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-O 121.722 0.772 . . . . 0.0 110.093 -179.488 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.575 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -72.01 -28.31 63.31 Favored 'General case' 0 N--CA 1.408 -2.566 0 CA-C-N 115.648 -0.705 . . . . 0.0 111.99 176.864 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.575 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 7.0 mtmm -80.2 -58.17 3.27 Favored 'General case' 0 N--CA 1.439 -0.979 0 CA-C-N 115.729 -0.668 . . . . 0.0 112.452 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 1.656 ' HD2' ' CD1' ' A' ' 68' ' ' TYR . 76.4 m-85 -113.67 -10.98 13.02 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -172.368 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.4 56.22 4.09 Favored Glycine 0 C--N 1.314 -0.648 0 C-N-CA 121.332 -0.461 . . . . 0.0 112.834 -177.556 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.424 ' O ' ' HE2' ' A' ' 77' ' ' PHE . 4.5 ptpp? -132.54 147.42 65.53 Favored Pre-proline 0 C--N 1.303 -1.416 0 CA-C-O 119.244 -0.408 . . . . 0.0 110.084 178.702 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.473 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 87.0 Cg_exo -50.2 156.92 3.36 Favored 'Trans proline' 0 C--N 1.355 0.914 0 C-N-CA 124.031 3.154 . . . . 0.0 114.803 -179.413 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -143.04 -173.34 3.88 Favored 'General case' 0 N--CA 1.433 -1.29 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.532 179.189 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . 0.458 ' HB2' ' HZ2' ' A' ' 73' ' ' LYS . 0.1 OUTLIER -93.79 1.11 56.55 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.047 -179.809 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 30.9 mmt180 -82.79 120.6 25.83 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.687 176.72 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.431 ' HD3' ' N ' ' A' ' 76' ' ' GLY . 8.1 tmtt? -70.03 127.15 31.85 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 175.316 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.431 ' N ' ' HD3' ' A' ' 75' ' ' LYS . . . 106.8 -25.41 22.7 Favored Glycine 0 CA--C 1.501 -0.817 0 N-CA-C 110.598 -1.001 . . . . 0.0 110.598 -178.821 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 1.659 ' HE1' ' CE2' ' A' ' 77' ' ' PHE . 54.1 t80 -72.11 -42.06 66.51 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-O 121.74 0.781 . . . . 0.0 109.557 -177.432 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.473 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 87.2 m-20 -79.07 -33.81 44.24 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.668 -173.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -71.55 -33.37 69.06 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 175.111 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.34 -37.26 70.52 Favored Glycine 0 N--CA 1.432 -1.601 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.432 177.395 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 43.9 tp -59.74 -33.58 71.83 Favored 'General case' 0 N--CA 1.434 -1.249 0 C-N-CA 124.007 0.923 . . . . 0.0 108.855 175.03 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 82.0 t90 -72.46 -51.02 21.98 Favored 'General case' 0 N--CA 1.434 -1.236 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.022 175.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 35.6 mt-10 -53.8 -49.76 67.63 Favored 'General case' 0 C--O 1.206 -1.189 0 N-CA-C 112.797 0.666 . . . . 0.0 112.797 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 19.3 tt -67.94 -23.87 29.69 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 N-CA-C 112.573 0.583 . . . . 0.0 112.573 -173.782 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -94.31 -22.67 18.21 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 121.409 0.623 . . . . 0.0 110.686 -176.417 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 28.4 m-80 -105.97 -55.17 2.37 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-O 121.435 0.636 . . . . 0.0 111.785 -176.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 67.4 t30 -127.62 72.61 78.13 Favored Pre-proline 0 C--N 1.312 -1.032 0 C-N-CA 119.969 -0.693 . . . . 0.0 110.228 179.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.418 ' HB2' HD22 ' A' ' 10' ' ' LEU . 57.0 Cg_endo -74.81 -6.76 18.57 Favored 'Trans proline' 0 C--O 1.221 -0.326 0 C-N-CA 122.128 1.886 . . . . 0.0 112.815 -176.223 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.4 pttm -97.6 17.75 17.06 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.986 -178.085 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 14.9 p -75.52 113.68 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.996 0 CA-C-O 122.575 1.179 . . . . 0.0 112.947 -178.296 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -113.5 143.89 43.77 Favored 'General case' 0 N--CA 1.423 -1.817 0 N-CA-C 105.082 -2.192 . . . . 0.0 105.082 174.019 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 24.5 p90 -114.76 161.48 18.12 Favored 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.007 -177.689 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 20.4 m . . . . . 0 N--CA 1.471 0.625 0 C-N-CA 125.767 1.627 . . . . 0.0 110.902 -179.612 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.3 mtt . . . . . 0 CA--C 1.506 -0.746 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -68.31 -15.66 63.65 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 112.767 0.655 . . . . 0.0 112.767 -179.08 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . 0.542 ' HG3' ' OD1' ' A' ' 4' ' ' ASP . 8.2 ptm180 -95.86 -39.67 9.7 Favored 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 113.037 0.754 . . . . 0.0 113.037 -179.344 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . 0.542 ' OD1' ' HG3' ' A' ' 3' ' ' ARG . 4.9 p-10 -152.69 162.4 41.3 Favored 'General case' 0 C--N 1.275 -2.673 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.383 -177.46 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -125.76 120.37 30.43 Favored 'General case' 0 N--CA 1.425 -1.717 0 N-CA-C 107.753 -1.202 . . . . 0.0 107.753 178.23 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.453 ' H ' ' HB2' ' A' ' 9' ' ' ASP . 32.3 mttp -104.76 158.36 32.18 Favored Pre-proline 0 C--N 1.298 -1.661 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -174.793 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.46 ' HB3' ' HA ' ' A' ' 27' ' ' GLU . 37.1 Cg_exo -63.46 117.02 3.99 Favored 'Trans proline' 0 N--CA 1.451 -0.986 0 N-CA-C 107.385 -1.813 . . . . 0.0 107.385 167.296 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 101.66 -1.42 52.72 Favored Glycine 0 N--CA 1.435 -1.421 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.458 -175.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.453 ' HB2' ' H ' ' A' ' 6' ' ' LYS . 4.9 t70 -78.11 154.94 30.82 Favored 'General case' 0 C--O 1.254 1.339 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 64.3 mt -102.54 124.83 48.82 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.44 -172.542 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.9 pt -141.39 -177.11 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.825 0 CA-C-O 122.295 1.045 . . . . 0.0 112.82 -174.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 1.611 ' HD1' ' CD2' ' A' ' 12' ' ' PHE . 76.4 m-85 -120.83 126.49 50.2 Favored 'General case' 0 N--CA 1.417 -2.099 0 C-N-CA 126.232 1.813 . . . . 0.0 106.241 170.771 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.408 ' CB ' HG22 ' A' ' 42' ' ' ILE . . . -108.96 128.85 55.3 Favored 'General case' 0 C--N 1.27 -2.859 0 O-C-N 123.625 0.578 . . . . 0.0 109.632 -178.022 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.688 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -114.36 122.13 45.74 Favored 'General case' 0 N--CA 1.407 -2.596 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.707 -179.593 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 63.4 mtm -116.31 158.83 22.8 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 177.218 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -63.94 117.13 6.56 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 174.454 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.54 -5.52 54.73 Favored Glycine 0 C--N 1.315 -0.622 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -176.858 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 1.655 ' HE2' ' CE1' ' A' ' 18' ' ' TYR . 21.8 m-85 -126.51 136.57 28.85 Favored Pre-proline 0 N--CA 1.436 -1.164 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -179.782 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_exo -70.21 171.12 15.54 Favored 'Trans proline' 0 N--CA 1.444 -1.399 0 C-N-CA 122.212 1.941 . . . . 0.0 108.628 169.427 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.503 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 80.2 m80 -63.55 110.75 2.09 Favored 'General case' 0 C--N 1.312 -1.049 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.722 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . 0.409 ' O ' ' HA ' ' A' ' 12' ' ' PHE . 10.4 t-105 -107.88 136.65 19.7 Favored Pre-proline 0 C--N 1.306 -1.304 0 C-N-CA 123.316 0.646 . . . . 0.0 109.885 -171.91 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -62.97 118.14 5.04 Favored 'Trans proline' 0 C--O 1.244 0.782 0 C-N-CA 122.214 1.943 . . . . 0.0 111.137 178.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -139.7 166.2 25.24 Favored 'General case' 0 N--CA 1.409 -2.5 0 CA-C-O 121.525 0.679 . . . . 0.0 111.285 -176.145 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.534 HH21 ' CD ' ' A' ' 27' ' ' GLU . 17.2 ttt-85 -111.49 139.01 47.27 Favored 'General case' 0 C--N 1.285 -2.204 0 C-N-CA 124.179 0.992 . . . . 0.0 108.404 177.729 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 58.9 t -75.84 121.86 28.6 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 N-CA-C 104.986 -2.228 . . . . 0.0 104.986 170.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -84.02 172.61 11.86 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 -173.275 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.534 ' CD ' HH21 ' A' ' 24' ' ' ARG . 4.4 mp0 -92.62 123.23 35.76 Favored 'General case' 0 N--CA 1.411 -2.398 0 CA-C-O 122.256 1.026 . . . . 0.0 112.522 -177.555 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.7 p -106.1 126.67 30.01 Favored Pre-proline 0 N--CA 1.425 -1.71 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 174.105 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_endo -73.67 136.11 22.85 Favored 'Trans proline' 0 N--CA 1.445 -1.35 0 C-N-CA 121.481 1.454 . . . . 0.0 111.718 178.478 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -77.83 147.82 35.0 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 174.369 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 83.49 5.5 88.45 Favored Glycine 0 N--CA 1.427 -1.924 0 C-N-CA 120.557 -0.83 . . . . 0.0 111.678 -175.32 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -60.67 138.32 58.09 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-O 121.117 0.484 . . . . 0.0 110.59 176.263 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.7 m -62.91 -22.09 29.6 Favored 'Isoleucine or valine' 0 C--O 1.243 0.725 0 CA-C-N 115.476 -0.784 . . . . 0.0 111.986 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 23.5 mmmt -108.48 118.06 52.99 Favored Pre-proline 0 N--CA 1.416 -2.167 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 172.142 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -78.58 155.98 28.04 Favored 'Trans proline' 0 N--CA 1.453 -0.887 0 C-N-CA 121.785 1.657 . . . . 0.0 111.957 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . 0.409 ' C ' ' H ' ' A' ' 38' ' ' ASN . 27.8 Cg_endo -64.82 136.9 51.17 Favored 'Trans proline' 0 N--CA 1.451 -1.022 0 C-N-CA 122.18 1.92 . . . . 0.0 111.857 179.239 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.0 m -72.34 9.05 1.11 Allowed 'General case' 0 CA--C 1.567 1.6 0 C-N-CA 125.399 1.479 . . . . 0.0 112.392 -177.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.409 ' H ' ' C ' ' A' ' 36' ' ' PRO . 0.0 OUTLIER 84.27 8.12 0.53 Allowed 'General case' 0 N--CA 1.503 2.211 0 C-N-CA 126.986 2.114 . . . . 0.0 108.221 -171.814 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 86.5 mttt -109.08 162.24 14.43 Favored 'General case' 0 N--CA 1.414 -2.266 0 CA-C-N 113.036 -1.893 . . . . 0.0 109.637 176.268 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 84.4 mt -106.81 146.29 32.79 Favored Pre-proline 0 C--N 1.282 -2.329 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 178.654 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -73.62 128.95 13.1 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 121.888 1.725 . . . . 0.0 109.395 176.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.408 HG22 ' CB ' ' A' ' 13' ' ' ALA . 37.0 mm -118.41 125.73 74.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.987 -0.446 . . . . 0.0 110.799 -174.166 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -109.71 115.34 29.68 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 176.726 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -79.04 139.09 38.22 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-O 121.0 0.429 . . . . 0.0 111.794 179.003 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 1.638 ' HD1' ' CD2' ' A' ' 45' ' ' PHE . 69.3 m-85 -90.26 160.4 16.19 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.385 177.141 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.522 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 73.06 -21.53 1.01 Allowed Glycine 0 C--N 1.311 -0.828 0 C-N-CA 124.932 1.253 . . . . 0.0 114.315 179.228 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.444 HG22 HH21 ' A' ' 74' ' ' ARG . 37.1 p -119.98 -22.3 6.78 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 117.559 0.68 . . . . 0.0 109.685 173.037 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.1 m170 66.88 24.87 9.62 Favored 'General case' 0 C--N 1.35 0.629 0 CA-C-N 115.406 -0.815 . . . . 0.0 111.153 -179.517 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -71.94 167.17 20.65 Favored 'General case' 0 C--N 1.347 0.462 0 CA-C-N 115.179 -0.919 . . . . 0.0 108.728 175.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.9 m -137.45 145.95 43.74 Favored 'General case' 0 C--N 1.289 -2.034 0 O-C-N 121.576 -0.702 . . . . 0.0 109.581 -178.678 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -150.57 178.43 9.08 Favored 'General case' 0 C--N 1.308 -1.197 0 O-C-N 123.533 0.521 . . . . 0.0 111.404 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 1.632 ' HE1' ' CE2' ' A' ' 52' ' ' PHE . 98.2 m-85 -134.26 114.74 13.35 Favored 'General case' 0 C--O 1.262 1.745 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.575 175.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 94.6 mt -130.99 158.75 39.45 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -179.159 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.0 172.55 36.92 Favored Glycine 0 N--CA 1.429 -1.796 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -65.89 -6.84 15.14 Favored 'Trans proline' 0 C--O 1.21 -0.91 0 C-N-CA 123.046 2.497 . . . . 0.0 112.438 -178.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.2 ptmm? -97.52 -5.02 36.76 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 115.333 -0.849 . . . . 0.0 111.764 179.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -115.86 5.8 14.14 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -177.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.8 pt -126.53 150.63 32.37 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 CA-C-N 115.073 -0.967 . . . . 0.0 110.487 -178.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 -131.94 135.32 26.45 Favored Pre-proline 0 C--O 1.188 -2.167 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 177.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . 0.529 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 37.8 Cg_endo -66.82 131.01 24.53 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 C-N-CA 122.841 2.361 . . . . 0.0 114.007 -177.791 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 1.597 ' HD1' ' CD2' ' A' ' 61' ' ' TYR . 65.4 t80 -63.54 -33.79 76.36 Favored 'General case' 0 C--O 1.204 -1.328 0 CA-C-N 114.889 -1.05 . . . . 0.0 112.159 -174.331 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.15 -54.31 35.81 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -177.121 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.529 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 2.1 pm0 -89.68 1.32 56.2 Favored 'General case' 0 N--CA 1.433 -1.298 0 N-CA-C 114.276 1.213 . . . . 0.0 114.276 -178.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.417 ' HA ' ' HE2' ' A' ' 67' ' ' LYS . 26.8 m-80 -122.8 15.18 10.11 Favored 'General case' 0 C--N 1.314 -0.935 0 C-N-CA 123.327 0.651 . . . . 0.0 111.132 175.613 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.459 ' HZ3' ' CG ' ' A' ' 85' ' ' ASP . 16.5 ttmm -65.13 -33.32 75.75 Favored 'General case' 0 N--CA 1.476 0.855 0 CA-C-O 121.579 0.704 . . . . 0.0 110.189 179.473 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.569 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -80.25 -28.95 38.35 Favored 'General case' 0 N--CA 1.403 -2.819 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.098 177.33 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.569 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 8.3 mttm -76.71 -59.09 2.92 Favored 'General case' 0 CA--C 1.505 -0.778 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.253 -179.24 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 1.629 ' HE1' ' CE2' ' A' ' 68' ' ' TYR . 70.0 m-85 -112.1 -4.28 14.49 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -173.443 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . 0.42 ' HA3' ' O ' ' A' ' 65' ' ' LYS . . . -75.64 51.76 2.68 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 121.715 -0.279 . . . . 0.0 113.11 -179.496 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 4.3 ptpp? -132.44 135.71 26.75 Favored Pre-proline 0 C--N 1.311 -1.09 0 O-C-N 122.459 -0.436 . . . . 0.0 110.161 179.144 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -66.91 128.24 18.42 Favored 'Trans proline' 0 C--O 1.25 1.111 0 C-N-CA 122.787 2.325 . . . . 0.0 116.316 -171.178 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.428 ' N ' HD21 ' A' ' 72' ' ' ASN . 0.9 OUTLIER -84.69 -168.93 2.39 Favored 'General case' 0 CA--C 1.483 -1.633 0 CA-C-N 113.784 -1.553 . . . . 0.0 108.165 175.311 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . 0.408 ' HA ' ' HD3' ' A' ' 73' ' ' LYS . 39.4 mmtm -108.53 10.49 27.19 Favored 'General case' 0 C--N 1.287 -2.146 0 CA-C-O 121.842 0.829 . . . . 0.0 109.475 175.36 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . 0.444 HH21 HG22 ' A' ' 47' ' ' THR . 4.5 mmm-85 -77.45 122.8 25.69 Favored 'General case' 0 N--CA 1.417 -2.099 0 CA-C-N 115.04 -0.982 . . . . 0.0 109.199 170.664 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 15.6 tppt? -65.17 129.54 40.1 Favored 'General case' 0 N--CA 1.429 -1.523 0 N-CA-C 107.551 -1.278 . . . . 0.0 107.551 173.58 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.522 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.21 -25.19 20.9 Favored Glycine 0 N--CA 1.415 -2.742 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -176.142 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -76.63 -41.13 47.03 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-O 121.356 0.598 . . . . 0.0 109.39 -178.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.479 ' N ' HD21 ' A' ' 78' ' ' ASN . 0.7 OUTLIER -71.31 -43.85 66.28 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 -176.289 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 25.2 mp0 -63.11 -41.77 99.42 Favored 'General case' 0 N--CA 1.428 -1.554 0 CA-C-N 113.577 -1.647 . . . . 0.0 109.634 177.712 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -65.38 -37.6 94.02 Favored Glycine 0 N--CA 1.44 -1.052 0 CA-C-N 115.449 -0.796 . . . . 0.0 112.804 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 87.9 mt -59.56 -35.12 73.62 Favored 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 176.094 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.3 t90 -74.29 -50.32 19.38 Favored 'General case' 0 N--CA 1.425 -1.712 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.295 177.501 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 26.8 mt-10 -53.74 -49.94 67.06 Favored 'General case' 0 C--O 1.188 -2.175 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -179.512 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.8 tt -67.99 -23.48 29.09 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 N-CA-C 112.256 0.465 . . . . 0.0 112.256 -173.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . 0.459 ' CG ' ' HZ3' ' A' ' 65' ' ' LYS . 15.2 t70 -94.21 -32.52 13.66 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-O 121.497 0.665 . . . . 0.0 110.05 -175.053 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.514 ' N ' HD21 ' A' ' 86' ' ' ASN . 0.8 OUTLIER -103.43 -44.89 5.02 Favored 'General case' 0 C--O 1.257 1.456 0 CA-C-O 121.911 0.862 . . . . 0.0 111.504 -176.679 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 60.7 t30 -131.76 61.32 57.65 Favored Pre-proline 0 C--N 1.296 -1.73 0 C-N-CA 119.983 -0.687 . . . . 0.0 112.329 -176.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -71.12 -7.68 21.91 Favored 'Trans proline' 0 C--N 1.372 1.789 0 C-N-CA 122.19 1.926 . . . . 0.0 110.465 179.078 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 22.7 pttm -102.88 20.52 17.27 Favored 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 113.159 -1.837 . . . . 0.0 109.197 -175.49 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 7.4 p -53.56 108.17 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.847 0 CA-C-O 122.15 0.976 . . . . 0.0 112.452 -179.107 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.9 mmmp? 74.65 -66.87 0.28 Allowed 'General case' 0 CA--C 1.492 -1.282 0 CA-C-N 114.218 -1.356 . . . . 0.0 114.418 -179.089 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 46.2 t80 61.68 177.65 0.12 Allowed 'General case' 0 C--O 1.265 1.869 0 O-C-N 124.382 1.051 . . . . 0.0 110.02 -174.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 23.0 m . . . . . 0 C--N 1.309 -1.156 0 N-CA-C 112.241 0.46 . . . . 0.0 112.241 -177.865 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.0 mmt . . . . . 0 CA--C 1.495 -1.158 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . 0.536 ' O ' ' HB3' ' A' ' 3' ' ' ARG . . . -84.32 55.39 3.34 Favored 'General case' 0 C--O 1.248 1.012 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 173.2 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . 0.536 ' HB3' ' O ' ' A' ' 2' ' ' ALA . 14.0 ptp180 168.71 -164.92 0.01 OUTLIER 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 130.398 3.479 . . . . 0.0 104.451 -178.566 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . 0.291 3.6 p30 58.55 105.04 0.02 OUTLIER 'General case' 0 CA--C 1.495 -1.136 0 C-N-CA 125.061 1.344 . . . . 0.0 112.786 -178.46 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 1.63 ' HE2' ' CE1' ' A' ' 5' ' ' PHE . 80.5 m-85 -113.45 123.46 50.1 Favored 'General case' 0 N--CA 1.397 -3.124 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.399 -172.113 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 25.9 mtmm -120.67 156.65 55.82 Favored Pre-proline 0 C--N 1.274 -2.677 0 CA-C-N 113.886 -1.506 . . . . 0.0 107.695 -172.287 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.41 ' HB3' ' HA ' ' A' ' 27' ' ' GLU . 52.5 Cg_exo -57.4 120.94 9.19 Favored 'Trans proline' 0 N--CA 1.461 -0.436 0 C-N-CA 121.825 1.683 . . . . 0.0 110.566 176.311 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.22 -24.28 10.03 Favored Glycine 0 N--CA 1.426 -2.029 0 CA-C-O 119.138 -0.812 . . . . 0.0 113.452 -178.426 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 32.8 m-20 -63.3 137.31 58.14 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 117.769 0.784 . . . . 0.0 111.725 -179.181 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 95.6 mt -90.18 126.58 35.86 Favored 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 176.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -142.08 -174.97 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-O 122.197 0.998 . . . . 0.0 112.899 -174.497 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 1.65 ' HE1' ' CE2' ' A' ' 12' ' ' PHE . 34.3 m-85 -115.71 130.0 56.69 Favored 'General case' 0 C--N 1.28 -2.431 0 CA-C-N 114.083 -1.417 . . . . 0.0 107.416 170.335 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.423 ' HB2' HD11 ' A' ' 53' ' ' LEU . . . -107.43 114.36 28.31 Favored 'General case' 0 C--N 1.275 -2.654 0 CA-C-N 114.866 -1.061 . . . . 0.0 109.426 -173.372 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.655 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.9 OUTLIER -103.76 128.24 51.16 Favored 'General case' 0 C--N 1.264 -3.129 0 CA-C-N 114.343 -1.299 . . . . 0.0 109.54 -178.597 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 68.2 mtm -113.84 158.25 21.27 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -70.26 116.77 11.0 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 120.607 -0.437 . . . . 0.0 109.879 -178.626 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 93.99 0.11 66.36 Favored Glycine 0 N--CA 1.448 -0.518 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.97 178.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 1.638 ' HD1' ' CD2' ' A' ' 18' ' ' TYR . 99.5 m-85 -129.75 152.23 79.47 Favored Pre-proline 0 N--CA 1.439 -0.996 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 -177.825 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -68.97 170.33 15.87 Favored 'Trans proline' 0 N--CA 1.457 -0.652 0 C-N-CA 122.4 2.067 . . . . 0.0 112.197 177.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 57.5 m80 -71.5 114.26 9.4 Favored 'General case' 0 CA--C 1.552 1.02 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.605 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 11.1 t-105 -101.35 136.91 19.55 Favored Pre-proline 0 C--N 1.31 -1.127 0 C-N-CA 123.142 0.577 . . . . 0.0 109.468 -176.604 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -64.77 117.87 4.91 Favored 'Trans proline' 0 CA--C 1.542 0.911 0 C-N-CA 121.978 1.786 . . . . 0.0 110.741 177.624 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.55 167.12 24.5 Favored 'General case' 0 N--CA 1.426 -1.66 0 CA-C-O 121.242 0.544 . . . . 0.0 111.214 -174.512 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 41.9 ttt-85 -115.4 143.52 45.17 Favored 'General case' 0 C--N 1.291 -1.965 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 179.552 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 64.9 t -79.21 114.2 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 104.385 -2.45 . . . . 0.0 104.385 168.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.504 ' CG ' ' HZ1' ' A' ' 91' ' ' LYS . 4.3 t70 -90.74 -179.55 5.55 Favored 'General case' 0 C--N 1.29 -1.985 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.878 -171.45 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.41 ' HA ' ' HB3' ' A' ' 7' ' ' PRO . 32.2 mp0 -92.61 151.23 20.24 Favored 'General case' 0 N--CA 1.439 -0.993 0 CA-C-O 121.948 0.88 . . . . 0.0 112.593 -175.9 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 8.1 p -113.74 130.74 23.52 Favored Pre-proline 0 N--CA 1.43 -1.454 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 176.209 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -66.2 139.12 54.07 Favored 'Trans proline' 0 C--O 1.248 0.996 0 C-N-CA 122.41 2.073 . . . . 0.0 114.108 -177.167 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -59.17 129.87 44.19 Favored 'General case' 0 CA--C 1.505 -0.762 0 CA-C-N 115.3 -0.864 . . . . 0.0 108.86 174.2 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 110.4 -17.33 28.75 Favored Glycine 0 C--N 1.297 -1.612 0 C-N-CA 120.364 -0.922 . . . . 0.0 111.181 -178.235 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -66.3 108.54 2.36 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-O 121.087 0.47 . . . . 0.0 109.766 175.011 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.9 m -79.01 6.42 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 115.51 -0.768 . . . . 0.0 113.005 -178.323 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 31.5 mmtp -83.59 118.32 71.15 Favored Pre-proline 0 C--N 1.301 -1.507 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.203 178.51 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -80.58 163.71 21.35 Favored 'Trans proline' 0 C--O 1.249 1.065 0 C-N-CA 122.186 1.924 . . . . 0.0 111.146 177.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -59.88 127.56 23.82 Favored 'Trans proline' 0 N--CA 1.452 -0.96 0 C-N-CA 121.825 1.683 . . . . 0.0 111.193 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.501 ' O ' ' HB2' ' A' ' 38' ' ' ASN . 3.2 m -95.53 8.94 41.86 Favored 'General case' 0 C--N 1.293 -1.857 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.424 -175.12 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . 0.501 ' HB2' ' O ' ' A' ' 37' ' ' THR . 25.4 m-80 86.33 8.98 0.26 Allowed 'General case' 0 N--CA 1.493 1.725 0 C-N-CA 125.57 1.548 . . . . 0.0 109.065 -169.54 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.422 ' HE2' ' N ' ' A' ' 54' ' ' GLY . 8.9 mmpt? -124.12 155.94 37.54 Favored 'General case' 0 N--CA 1.429 -1.518 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 175.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 87.8 mt -128.41 155.59 78.32 Favored Pre-proline 0 C--N 1.283 -2.298 0 C-N-CA 125.306 1.442 . . . . 0.0 107.253 178.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -71.22 122.8 9.05 Favored 'Trans proline' 0 CA--C 1.536 0.617 0 C-N-CA 121.697 1.598 . . . . 0.0 110.679 177.552 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 49.2 mm -122.51 124.68 71.3 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.083 0 CA-C-O 120.753 0.311 . . . . 0.0 110.355 -176.377 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 80.9 t80 -106.96 116.41 31.87 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 178.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 1.627 ' HE1' ' CE2' ' A' ' 44' ' ' PHE . 62.2 m-85 -79.27 132.09 36.36 Favored 'General case' 0 C--O 1.244 0.805 0 CA-C-O 121.016 0.436 . . . . 0.0 110.923 179.746 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 -82.81 158.6 22.71 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.029 178.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.499 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 74.99 -20.11 1.97 Allowed Glycine 0 C--O 1.256 1.473 0 C-N-CA 124.513 1.054 . . . . 0.0 114.454 178.787 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.407 HG22 ' HA3' ' A' ' 76' ' ' GLY . 31.2 p -119.32 -23.88 6.57 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 122.237 -0.566 . . . . 0.0 109.957 175.273 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 44.8 m170 67.74 23.09 8.71 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.432 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -74.98 166.43 23.67 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 176.352 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.5 m -137.11 145.71 44.21 Favored 'General case' 0 C--N 1.286 -2.192 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 -179.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -146.76 179.52 7.51 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 123.136 0.575 . . . . 0.0 109.71 -179.526 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -131.75 109.29 10.05 Favored 'General case' 0 N--CA 1.432 -1.339 0 N-CA-C 109.003 -0.739 . . . . 0.0 109.003 176.488 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.444 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 88.7 mt -130.26 149.29 52.02 Favored 'General case' 0 C--N 1.287 -2.145 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 -178.826 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.467 ' HA3' ' O ' ' A' ' 38' ' ' ASN . . . -95.37 178.07 35.29 Favored Glycine 0 N--CA 1.417 -2.57 0 C-N-CA 119.707 -1.235 . . . . 0.0 112.104 -174.059 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.1 -9.3 16.6 Favored 'Trans proline' 0 N--CA 1.479 0.667 0 C-N-CA 123.224 2.616 . . . . 0.0 111.831 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 42.6 mtmt -98.29 -1.57 41.5 Favored 'General case' 0 N--CA 1.431 -1.385 0 CA-C-N 114.879 -1.055 . . . . 0.0 110.705 -179.653 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.465 ' O ' ' HB3' ' A' ' 14' ' ' LYS . 36.8 m-20 -115.22 -9.65 12.22 Favored 'General case' 0 CA--C 1.5 -0.957 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.484 -179.436 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 9.5 pt -119.91 152.71 22.65 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.127 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.751 -173.562 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 1.621 ' HD1' ' CD2' ' A' ' 59' ' ' PHE . 96.8 m-85 -138.99 147.59 54.42 Favored Pre-proline 0 C--N 1.297 -1.68 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -178.416 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . 0.563 ' HG2' ' OE2' ' A' ' 63' ' ' GLU . 11.7 Cg_endo -58.11 139.61 91.1 Favored 'Trans proline' 0 CA--C 1.516 -0.383 0 C-N-CA 122.758 2.305 . . . . 0.0 114.432 -175.991 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.423 ' O ' ' HB3' ' A' ' 65' ' ' LYS . 16.3 t80 -65.18 -35.84 82.33 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 115.214 -0.903 . . . . 0.0 111.451 177.151 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 10.5 m -48.91 -57.19 6.84 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 112.953 0.723 . . . . 0.0 112.953 -175.319 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.563 ' OE2' ' HG2' ' A' ' 60' ' ' PRO . 0.0 OUTLIER -95.79 -14.43 23.29 Favored 'General case' 0 N--CA 1.432 -1.352 0 N-CA-C 114.903 1.446 . . . . 0.0 114.903 178.867 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.448 ' HB2' ' O ' ' A' ' 60' ' ' PRO . 22.6 m-80 -88.85 -8.0 55.12 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 121.681 -0.637 . . . . 0.0 112.648 179.221 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.447 ' O ' ' HA3' ' A' ' 69' ' ' GLY . 11.6 ptmm? -60.52 -38.28 83.88 Favored 'General case' 0 C--O 1.201 -1.466 0 CA-C-O 121.182 0.515 . . . . 0.0 111.308 -176.89 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 55.9 mm-40 -82.3 -33.85 28.89 Favored 'General case' 0 CA--C 1.477 -1.832 0 C-N-CA 119.453 -0.899 . . . . 0.0 112.426 177.494 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 29.9 mtmm -67.52 -58.92 3.87 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 124.725 1.265 . . . . 0.0 111.526 -176.118 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 84.4 m-85 -111.66 -1.87 15.57 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-O 121.551 0.691 . . . . 0.0 111.447 -175.632 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . 0.447 ' HA3' ' O ' ' A' ' 65' ' ' LYS . . . -91.46 54.68 3.13 Favored Glycine 0 N--CA 1.429 -1.775 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 177.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.431 ' HA ' ' HE3' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -117.93 149.06 44.68 Favored Pre-proline 0 C--N 1.299 -1.623 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 177.709 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.535 ' HB3' ' OD1' ' A' ' 78' ' ' ASN . 70.2 Cg_exo -49.43 146.65 13.8 Favored 'Trans proline' 0 C--O 1.243 0.727 0 C-N-CA 123.338 2.692 . . . . 0.0 114.868 -176.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -131.0 -171.06 2.48 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.829 -178.617 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 45.9 mmtm -104.9 -11.05 16.91 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-O 121.235 0.541 . . . . 0.0 109.618 179.538 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 3.2 mmm180 -73.57 121.64 20.96 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.039 173.176 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.94 127.47 31.54 Favored 'General case' 0 N--CA 1.435 -1.189 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 174.226 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.499 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.86 -21.12 28.15 Favored Glycine 0 N--CA 1.409 -3.132 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.854 -177.61 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 1.669 ' HD2' ' CD1' ' A' ' 77' ' ' PHE . 12.6 t80 -76.26 -43.2 42.91 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 -179.435 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.535 ' OD1' ' HB3' ' A' ' 71' ' ' PRO . 52.5 m-80 -70.66 -43.25 69.51 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.739 -178.808 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -68.36 -33.3 74.04 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 115.362 -0.836 . . . . 0.0 109.771 179.011 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -66.73 -34.94 88.91 Favored Glycine 0 CA--C 1.491 -1.423 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.797 178.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.552 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 98.2 mt -62.26 -41.57 98.56 Favored 'General case' 0 C--O 1.212 -0.915 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 174.922 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 85.7 t90 -65.5 -45.85 81.97 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.647 178.564 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 54.9 mt-10 -59.72 -47.46 85.56 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 112.837 0.68 . . . . 0.0 112.837 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.8 tt -74.85 -27.48 20.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 C-N-CA 120.248 -0.581 . . . . 0.0 111.959 -175.174 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -84.39 -10.89 57.17 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 122.647 0.379 . . . . 0.0 111.83 178.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 32.3 m-80 -125.32 -56.29 1.53 Allowed 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -175.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -123.62 79.69 55.29 Favored Pre-proline 0 C--N 1.315 -0.932 0 CA-C-O 121.17 0.51 . . . . 0.0 110.479 -177.23 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -68.62 -6.96 19.07 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 123.129 2.552 . . . . 0.0 115.01 -175.155 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 7.3 ptmm? -103.69 18.67 21.41 Favored 'General case' 0 C--O 1.263 1.77 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 177.279 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 7.3 p -72.87 121.89 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.866 0 CA-C-O 122.726 1.251 . . . . 0.0 112.244 -177.343 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.504 ' HZ1' ' CG ' ' A' ' 26' ' ' ASP . 60.8 pttt -173.36 172.25 3.8 Favored 'General case' 0 N--CA 1.405 -2.717 0 N-CA-C 103.511 -2.774 . . . . 0.0 103.511 174.862 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 1.664 ' HD2' ' CD1' ' A' ' 92' ' ' PHE . 89.7 m-85 -44.91 -51.3 9.84 Favored 'General case' 0 C--N 1.312 -1.057 0 O-C-N 124.803 1.315 . . . . 0.0 112.779 -174.326 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 17.1 m . . . . . 0 N--CA 1.478 0.974 0 C-N-CA 124.651 1.181 . . . . 0.0 110.539 179.41 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.8 mtt . . . . . 0 CA--C 1.507 -0.711 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.91 -36.68 84.07 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 107.816 -1.179 . . . . 0.0 107.816 172.06 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 19.1 ptt180 -92.09 -175.31 4.04 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 105.634 -1.988 . . . . 0.0 105.634 172.015 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . 0.431 2.6 p30 58.73 -105.35 0.25 Allowed 'General case' 0 N--CA 1.412 -2.328 0 N-CA-C 114.377 1.251 . . . . 0.0 114.377 174.733 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -109.38 119.34 39.17 Favored 'General case' 1 C--N 1.209 -5.524 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.628 -178.987 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.8 mppt? -101.01 151.42 37.62 Favored Pre-proline 0 C--N 1.303 -1.454 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 -174.117 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -59.13 121.85 10.6 Favored 'Trans proline' 0 C--O 1.235 0.328 0 C-N-CA 122.145 1.896 . . . . 0.0 110.278 174.613 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 111.43 -11.37 28.38 Favored Glycine 0 N--CA 1.43 -1.721 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.889 -177.963 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -79.13 162.41 25.83 Favored 'General case' 0 C--O 1.258 1.532 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 -177.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 99.0 mt -114.56 129.22 56.65 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 123.442 0.697 . . . . 0.0 109.127 -175.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.9 pp -142.75 -177.87 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 CA-C-O 121.856 0.836 . . . . 0.0 112.672 -172.566 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 1.597 ' HD1' ' CD2' ' A' ' 12' ' ' PHE . 66.0 m-85 -119.91 118.86 31.86 Favored 'General case' 0 C--N 1.289 -2.048 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 172.738 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.437 ' HB2' HD13 ' A' ' 53' ' ' LEU . . . -112.67 143.11 44.43 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.46 -173.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.695 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -119.74 123.53 43.97 Favored 'General case' 0 N--CA 1.4 -2.947 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.348 -178.206 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.404 ' HE1' ' CD1' ' A' ' 18' ' ' TYR . 71.2 mtm -113.77 158.53 20.84 Favored 'General case' 0 CA--C 1.5 -0.981 0 N-CA-C 108.52 -0.918 . . . . 0.0 108.52 175.315 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 29.1 tptp -69.61 124.07 22.99 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 120.41 -0.516 . . . . 0.0 109.828 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.97 -12.55 60.7 Favored Glycine 0 C--N 1.303 -1.303 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.086 -176.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 1.64 ' HE1' ' CE2' ' A' ' 18' ' ' TYR . 72.3 m-85 -117.99 148.87 44.37 Favored Pre-proline 0 N--CA 1.433 -1.315 0 C-N-CA 123.088 0.555 . . . . 0.0 110.501 179.602 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -79.52 171.84 15.27 Favored 'Trans proline' 0 N--CA 1.449 -1.104 0 C-N-CA 122.315 2.01 . . . . 0.0 108.483 170.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.524 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 79.7 m80 -57.95 111.86 1.31 Allowed 'General case' 0 CA--C 1.537 0.472 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 175.21 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 10.2 t-105 -112.33 142.27 26.64 Favored Pre-proline 0 C--N 1.294 -1.807 0 C-N-CA 123.983 0.913 . . . . 0.0 108.872 -169.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -62.63 118.49 5.38 Favored 'Trans proline' 0 C--O 1.245 0.847 0 C-N-CA 122.326 2.018 . . . . 0.0 110.57 178.054 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.45 166.98 23.2 Favored 'General case' 0 N--CA 1.41 -2.46 0 CA-C-O 121.702 0.763 . . . . 0.0 111.481 -175.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 36.3 ttt85 -114.38 139.42 49.49 Favored 'General case' 0 C--N 1.276 -2.63 0 C-N-CA 124.255 1.022 . . . . 0.0 110.604 -177.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 50.3 t -82.19 110.15 17.06 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.991 0 N-CA-C 104.025 -2.583 . . . . 0.0 104.025 169.77 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.473 ' CG ' ' HZ3' ' A' ' 91' ' ' LYS . 10.3 t70 -91.45 168.12 11.77 Favored 'General case' 0 C--N 1.274 -2.707 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.107 -169.387 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -102.16 138.17 39.46 Favored 'General case' 0 C--N 1.305 -1.361 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 177.509 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 47.4 t -71.03 125.07 91.97 Favored Pre-proline 0 C--N 1.316 -0.868 0 CA-C-N 115.526 -0.761 . . . . 0.0 111.002 -175.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -83.19 161.54 15.38 Favored 'Trans proline' 0 N--CA 1.431 -2.17 0 C-N-CA 122.023 1.815 . . . . 0.0 111.8 177.27 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -69.54 145.85 52.29 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 175.402 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.92 -34.15 5.93 Favored Glycine 0 C--N 1.291 -1.946 0 N-CA-C 108.57 -1.812 . . . . 0.0 108.57 -174.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . 0.407 ' C ' ' H ' ' A' ' 34' ' ' LYS . . . -95.22 43.82 1.09 Allowed 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 177.901 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.7 m -64.8 15.68 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.218 0 C-N-CA 127.475 2.31 . . . . 0.0 115.617 -172.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.407 ' H ' ' C ' ' A' ' 32' ' ' ALA . 0.1 OUTLIER -64.1 135.45 96.32 Favored Pre-proline 0 C--N 1.292 -1.927 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 178.258 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_exo -67.24 164.56 29.91 Favored 'Trans proline' 0 C--O 1.262 1.708 0 C-N-CA 122.235 1.956 . . . . 0.0 111.822 179.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_endo -55.48 128.22 29.51 Favored 'Trans proline' 0 C--N 1.36 1.149 0 C-N-CA 122.678 2.252 . . . . 0.0 111.391 -179.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 7.5 m -101.45 8.8 41.94 Favored 'General case' 0 C--N 1.291 -1.944 0 CA-C-N 114.927 -1.033 . . . . 0.0 109.605 -175.134 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 73.59 8.97 5.01 Favored 'General case' 0 N--CA 1.482 1.156 0 CA-C-O 123.726 1.727 . . . . 0.0 109.202 -173.841 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 84.1 mttt -124.37 163.04 22.57 Favored 'General case' 0 N--CA 1.417 -2.102 0 CA-C-N 113.296 -1.775 . . . . 0.0 108.832 177.349 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 72.8 mt -118.15 146.98 40.53 Favored Pre-proline 0 C--N 1.285 -2.2 0 O-C-N 124.364 1.04 . . . . 0.0 108.79 -178.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -72.95 123.3 8.8 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 C-N-CA 121.724 1.616 . . . . 0.0 109.524 175.382 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 48.7 mm -115.84 115.6 49.76 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.121 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.21 -175.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.634 ' HD2' ' CD1' ' A' ' 43' ' ' PHE . 74.3 t80 -95.63 115.95 28.16 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 178.58 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 1.639 ' HD1' ' CD2' ' A' ' 44' ' ' PHE . 74.2 m-85 -82.66 133.67 35.16 Favored 'General case' 0 C--N 1.293 -1.86 0 N-CA-C 112.686 0.625 . . . . 0.0 112.686 179.82 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 1.638 ' HE2' ' CE1' ' A' ' 45' ' ' PHE . 71.6 m-85 -84.21 151.0 25.1 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.641 179.523 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.529 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 78.14 -20.45 3.92 Favored Glycine 0 C--N 1.305 -1.188 0 C-N-CA 123.816 0.722 . . . . 0.0 114.109 178.835 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 32.0 p -119.07 -22.66 7.13 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 117.412 0.606 . . . . 0.0 109.939 175.085 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.8 m-70 66.43 22.49 10.71 Favored 'General case' 0 C--N 1.35 0.607 0 C-N-CA 123.667 0.787 . . . . 0.0 112.024 179.393 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -74.31 161.88 29.44 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 176.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.3 m -136.04 135.96 39.85 Favored 'General case' 0 C--N 1.278 -2.503 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 176.749 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -136.28 178.92 6.68 Favored 'General case' 0 C--N 1.277 -2.572 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.151 -177.046 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 1.662 ' HD1' ' CD2' ' A' ' 52' ' ' PHE . 92.9 m-85 -133.49 109.65 9.42 Favored 'General case' 0 C--O 1.262 1.761 0 CA-C-N 115.326 -0.852 . . . . 0.0 108.713 175.066 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.437 HD13 ' HB2' ' A' ' 13' ' ' ALA . 64.8 mt -125.49 161.94 26.01 Favored 'General case' 0 C--N 1.29 -1.999 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 -178.612 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.53 169.58 35.95 Favored Glycine 0 N--CA 1.422 -2.25 0 C-N-CA 119.878 -1.153 . . . . 0.0 110.296 -179.451 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.85 -6.59 14.51 Favored 'Trans proline' 0 C--O 1.212 -0.818 0 C-N-CA 123.087 2.525 . . . . 0.0 112.223 -179.503 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 5.9 ptmm? -97.73 -2.06 42.07 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 115.358 -0.837 . . . . 0.0 111.768 178.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -116.13 6.37 13.96 Favored 'General case' 0 C--N 1.293 -1.875 0 CA-C-O 121.134 0.492 . . . . 0.0 112.158 -179.069 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 11.5 pt -130.55 152.42 37.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.599 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 1.643 ' HE1' ' CE2' ' A' ' 59' ' ' PHE . 93.7 m-85 -139.28 147.47 53.1 Favored Pre-proline 0 C--N 1.303 -1.434 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -178.84 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -60.55 129.82 31.05 Favored 'Trans proline' 0 N--CA 1.481 0.786 0 C-N-CA 123.2 2.6 . . . . 0.0 112.919 -177.003 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 1.654 ' HE2' ' CE1' ' A' ' 61' ' ' TYR . 3.4 t80 -58.67 -34.28 71.06 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 113.819 1.044 . . . . 0.0 113.819 -177.526 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 30.4 t -60.62 -57.96 10.5 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 123.427 0.455 . . . . 0.0 111.226 -177.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 15.9 mp0 -75.72 -27.36 58.14 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-O 122.059 0.933 . . . . 0.0 110.988 -175.434 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 37.5 m-80 -95.54 5.09 52.42 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 113.484 0.92 . . . . 0.0 113.484 -176.023 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.438 ' HE2' ' CE1' ' A' ' 61' ' ' TYR . 17.6 ttmm -62.69 -39.09 92.9 Favored 'General case' 0 C--O 1.21 -1.024 0 CA-C-O 120.986 0.422 . . . . 0.0 111.295 177.55 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 38.8 mm-40 -80.91 -16.81 52.58 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-O 122.008 0.908 . . . . 0.0 112.205 177.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 19.3 mtpp -85.2 -56.7 3.41 Favored 'General case' 0 C--N 1.268 -2.941 0 CA-C-N 114.462 -1.244 . . . . 0.0 111.733 -178.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 35.1 m-85 -125.4 5.25 7.67 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.08 -174.023 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -99.98 25.41 28.38 Favored Glycine 0 C--N 1.304 -1.201 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 -178.416 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 27.7 mmmt -96.8 153.33 38.69 Favored Pre-proline 0 C--N 1.307 -1.281 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 -179.173 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -58.31 128.2 27.67 Favored 'Trans proline' 0 C--O 1.252 1.18 0 C-N-CA 121.981 1.787 . . . . 0.0 112.974 -179.517 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 16.2 m-80 -114.82 177.64 4.57 Favored 'General case' 0 CA--C 1.47 -2.113 0 CA-C-N 114.955 -1.02 . . . . 0.0 112.226 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . 0.547 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 9.5 mptt -96.03 7.45 46.34 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 113.84 -1.527 . . . . 0.0 108.385 -178.37 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 11.1 mmt180 -88.27 122.79 32.2 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 175.177 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 10.2 tptp -77.04 144.38 38.65 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 177.278 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.529 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 95.13 -26.47 19.0 Favored Glycine 0 C--O 1.21 -1.367 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -173.873 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 1.663 ' HD1' ' CD2' ' A' ' 77' ' ' PHE . 27.0 t80 -76.61 -41.36 46.29 Favored 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 178.153 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 11.6 m120 -61.4 -49.22 77.77 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 177.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 6.1 mp0 -60.85 -40.73 94.0 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 113.711 -1.586 . . . . 0.0 110.352 179.309 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -67.54 -35.75 87.1 Favored Glycine 0 N--CA 1.44 -1.034 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.821 179.432 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.452 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 94.8 mt -61.92 -37.18 83.72 Favored 'General case' 0 C--O 1.218 -0.574 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 175.386 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 85.3 t90 -67.98 -48.34 66.06 Favored 'General case' 0 N--CA 1.427 -1.597 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.46 177.605 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -59.14 -46.7 87.67 Favored 'General case' 0 C--O 1.206 -1.196 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 179.719 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 19.0 tt -71.79 -27.83 28.95 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 C-N-CA 120.619 -0.432 . . . . 0.0 112.164 -174.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -89.57 -11.51 42.53 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 112.262 0.468 . . . . 0.0 112.262 -179.939 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 32.4 m-80 -120.81 -57.55 1.88 Allowed 'General case' 0 N--CA 1.477 0.912 0 CA-C-O 121.16 0.505 . . . . 0.0 112.052 -176.813 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -128.59 73.64 80.63 Favored Pre-proline 0 C--N 1.308 -1.214 0 C-N-CA 120.418 -0.513 . . . . 0.0 110.305 -179.386 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -70.13 -6.13 18.06 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 C-N-CA 123.178 2.585 . . . . 0.0 112.431 -176.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.9 pttp -106.52 21.69 17.04 Favored 'General case' 0 C--N 1.291 -1.969 0 CA-C-N 114.261 -1.336 . . . . 0.0 110.152 -179.651 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 8.4 p -61.51 81.32 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.55 0.952 0 CA-C-O 123.753 1.739 . . . . 0.0 113.802 -178.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.473 ' HZ3' ' CG ' ' A' ' 26' ' ' ASP . 59.9 mtpt -155.87 -38.75 0.08 Allowed 'General case' 0 C--N 1.281 -2.398 0 N-CA-C 102.541 -3.133 . . . . 0.0 102.541 179.044 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -78.16 141.77 38.46 Favored 'General case' 0 N--CA 1.428 -1.549 0 CA-C-N 112.714 -2.039 . . . . 0.0 106.363 168.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 14.6 m . . . . . 0 C--N 1.303 -1.438 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -176.48 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.3 mtt . . . . . 0 CA--C 1.498 -1.057 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -129.71 80.91 1.99 Allowed 'General case' 0 N--CA 1.434 -1.262 0 N-CA-C 105.202 -2.147 . . . . 0.0 105.202 173.501 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -123.55 -175.06 3.11 Favored 'General case' 0 C--N 1.296 -1.757 0 CA-C-N 114.48 -1.236 . . . . 0.0 112.661 -173.232 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . 0.416 ' CG ' ' HZ1' ' A' ' 6' ' ' LYS . 15.3 t70 -96.95 152.82 18.34 Favored 'General case' 0 C--N 1.287 -2.123 0 CA-C-N 113.508 -1.678 . . . . 0.0 109.982 -173.568 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 1.659 ' HE1' ' CE2' ' A' ' 5' ' ' PHE . 87.0 m-85 -134.65 122.76 22.71 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 109.138 -0.689 . . . . 0.0 109.138 -178.204 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.416 ' HZ1' ' CG ' ' A' ' 4' ' ' ASP . 63.0 mttp -134.07 155.77 79.79 Favored Pre-proline 0 C--N 1.301 -1.538 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.298 179.587 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_exo -45.43 125.52 7.53 Favored 'Trans proline' 0 C--N 1.359 1.086 0 C-N-CA 123.554 2.836 . . . . 0.0 113.05 177.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 115.33 -25.44 9.82 Favored Glycine 0 N--CA 1.428 -1.837 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.871 -179.352 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -74.66 151.57 39.27 Favored 'General case' 0 C--O 1.257 1.466 0 CA-C-O 121.501 0.667 . . . . 0.0 111.564 -177.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 79.3 mt -103.38 124.38 48.58 Favored 'General case' 0 N--CA 1.424 -1.731 0 CA-C-N 114.707 -1.133 . . . . 0.0 110.134 -175.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 8.1 pt -137.11 -173.89 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.896 0 CA-C-O 122.752 1.263 . . . . 0.0 112.2 -173.344 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.422 ' CD1' ' HB2' ' A' ' 64' ' ' ASN . 22.0 m-85 -125.49 131.26 52.87 Favored 'General case' 0 N--CA 1.399 -2.99 0 N-CA-C 105.277 -2.12 . . . . 0.0 105.277 170.879 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -107.47 128.39 54.45 Favored 'General case' 0 C--N 1.265 -3.081 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.011 -174.027 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.636 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -120.02 117.85 29.09 Favored 'General case' 0 N--CA 1.389 -3.524 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 -179.03 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.455 ' HB2' ' HB2' ' A' ' 18' ' ' TYR . 82.1 mtp -97.08 158.39 15.46 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.053 -177.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.6 tttp -67.23 115.8 7.3 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 176.38 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.56 -18.53 55.05 Favored Glycine 0 N--CA 1.446 -0.681 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.429 179.729 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 0.455 ' HB2' ' HB2' ' A' ' 15' ' ' MET . 88.1 m-85 -119.96 143.86 36.24 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 117.117 0.459 . . . . 0.0 111.173 -177.744 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -68.85 170.95 14.31 Favored 'Trans proline' 0 CA--C 1.539 0.73 0 C-N-CA 123.115 2.543 . . . . 0.0 112.853 179.445 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.534 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 77.3 m80 -60.86 122.16 14.17 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.97 179.64 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 15.1 t-105 -121.58 137.48 27.11 Favored Pre-proline 0 C--N 1.304 -1.401 0 N-CA-C 107.497 -1.298 . . . . 0.0 107.497 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -61.09 123.62 13.24 Favored 'Trans proline' 0 C--O 1.243 0.736 0 C-N-CA 122.426 2.084 . . . . 0.0 111.507 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.9 166.71 24.16 Favored 'General case' 0 N--CA 1.422 -1.864 0 CA-C-O 121.39 0.614 . . . . 0.0 111.806 -176.764 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 46.7 ttt85 -114.02 139.94 48.85 Favored 'General case' 0 C--N 1.296 -1.745 0 CA-C-N 115.307 -0.86 . . . . 0.0 109.762 178.76 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.5 t -85.98 115.53 27.45 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 104.678 -2.342 . . . . 0.0 104.678 169.801 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -99.71 -178.0 3.74 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 119.356 -0.937 . . . . 0.0 110.533 -173.592 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.491 ' CD ' ' HZ2' ' A' ' 91' ' ' LYS . 1.7 mp0 -92.16 126.38 37.22 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-O 121.593 0.711 . . . . 0.0 112.017 -174.102 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.0 p -100.57 117.06 63.53 Favored Pre-proline 0 N--CA 1.426 -1.644 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 174.201 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -84.7 151.58 11.5 Favored 'Trans proline' 0 C--O 1.252 1.217 0 C-N-CA 122.541 2.16 . . . . 0.0 113.467 -178.27 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -59.2 122.4 13.74 Favored 'General case' 0 C--N 1.314 -0.963 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 172.793 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.437 ' C ' ' H ' ' A' ' 33' ' ' VAL . . . 110.72 -8.88 30.03 Favored Glycine 0 N--CA 1.431 -1.677 0 C-N-CA 119.803 -1.189 . . . . 0.0 112.267 -179.021 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -75.0 41.39 0.16 Allowed 'General case' 0 N--CA 1.489 1.48 0 CA-C-N 117.377 0.589 . . . . 0.0 111.91 176.203 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.437 ' H ' ' C ' ' A' ' 31' ' ' GLY 0.344 30.1 m 44.19 -41.82 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 C-N-CA 131.042 3.737 . . . . 0.0 118.958 -177.752 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 18.6 ptmt -86.1 138.35 34.78 Favored Pre-proline 0 C--N 1.288 -2.067 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -176.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -81.71 171.48 13.2 Favored 'Trans proline' 0 C--O 1.26 1.587 0 C-N-CA 122.325 2.017 . . . . 0.0 108.359 168.702 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_endo -56.89 126.81 23.44 Favored 'Trans proline' 0 N--CA 1.451 -0.991 0 C-N-CA 121.366 1.377 . . . . 0.0 109.796 177.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.3 m -104.63 8.48 35.27 Favored 'General case' 0 C--N 1.293 -1.882 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.212 -172.008 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 82.88 8.03 0.74 Allowed 'General case' 0 N--CA 1.506 2.35 0 C-N-CA 126.654 1.981 . . . . 0.0 107.654 -170.326 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.453 ' HA ' ' HA2' ' A' ' 54' ' ' GLY . 56.5 mttm -124.32 160.72 27.42 Favored 'General case' 0 N--CA 1.412 -2.333 0 CA-C-N 113.255 -1.793 . . . . 0.0 111.274 178.23 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 71.0 mt -122.05 157.03 59.03 Favored Pre-proline 0 C--N 1.279 -2.467 0 CA-C-N 113.615 -1.629 . . . . 0.0 108.491 -176.646 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -75.4 122.59 7.11 Favored 'Trans proline' 0 N--CA 1.456 -0.682 0 C-N-CA 121.796 1.664 . . . . 0.0 109.978 174.369 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 41.2 mm -116.8 122.72 70.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -175.73 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 86.0 t80 -103.45 116.05 31.67 Favored 'General case' 0 C--N 1.282 -2.347 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 178.627 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 -76.71 129.66 36.65 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-O 121.047 0.451 . . . . 0.0 112.022 179.448 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 60.3 m-85 -78.96 151.33 31.7 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.258 177.581 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.511 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 77.28 -19.7 3.59 Favored Glycine 0 C--O 1.254 1.38 0 N-CA-C 114.534 0.573 . . . . 0.0 114.534 177.008 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 46.4 p -119.23 -23.04 6.89 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 117.43 0.615 . . . . 0.0 110.248 174.708 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.0 m-70 68.76 21.68 7.67 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.975 0.91 . . . . 0.0 112.546 179.176 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -80.28 164.89 22.85 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.838 178.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 2.2 m -130.29 140.16 50.68 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.241 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -141.24 -179.72 6.28 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 123.641 0.776 . . . . 0.0 109.843 -178.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 1.644 ' HD1' ' CD2' ' A' ' 52' ' ' PHE . 85.8 m-85 -133.19 112.32 11.62 Favored 'General case' 0 C--O 1.249 1.038 0 CA-C-O 121.605 0.717 . . . . 0.0 110.464 178.751 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.448 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 82.0 mt -135.84 147.4 48.24 Favored 'General case' 0 C--N 1.29 -1.993 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.453 ' HA2' ' HA ' ' A' ' 39' ' ' LYS . . . -94.77 177.23 35.54 Favored Glycine 0 CA--C 1.479 -2.169 0 C-N-CA 119.908 -1.139 . . . . 0.0 111.554 -177.196 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -62.25 -17.47 57.19 Favored 'Trans proline' 0 C--O 1.212 -0.821 0 C-N-CA 123.249 2.632 . . . . 0.0 112.096 -177.535 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.55 1.47 48.97 Favored 'General case' 0 N--CA 1.425 -1.708 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.964 178.111 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.448 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 71.9 m-20 -107.92 -16.25 14.35 Favored 'General case' 0 C--N 1.29 -2.021 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.209 176.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.451 HG12 ' O ' ' A' ' 54' ' ' GLY . 12.0 pt -117.55 157.28 18.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.057 -174.059 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 0.513 ' HB3' HD22 ' A' ' 64' ' ' ASN . 98.0 m-85 -137.92 143.31 39.35 Favored Pre-proline 0 C--N 1.297 -1.711 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -69.29 148.44 68.13 Favored 'Trans proline' 0 C--O 1.245 0.873 0 C-N-CA 122.975 2.45 . . . . 0.0 114.934 -172.516 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 1.634 ' HE1' ' CE2' ' A' ' 61' ' ' TYR . 54.4 t80 -55.82 -34.71 65.6 Favored 'General case' 0 C--O 1.221 -0.434 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.078 177.002 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.1 m -52.86 -44.24 66.67 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.169 -0.923 . . . . 0.0 112.224 -179.028 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -93.3 -26.55 17.26 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 121.644 0.735 . . . . 0.0 111.497 -177.089 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.513 HD22 ' HB3' ' A' ' 59' ' ' PHE . 40.8 m-80 -91.21 0.57 57.5 Favored 'General case' 0 C--O 1.203 -1.377 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -174.446 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.45 ' HB3' ' NZ ' ' A' ' 65' ' ' LYS . 4.5 ttpm? -65.95 -47.68 73.83 Favored 'General case' 0 C--N 1.29 -2.006 0 CA-C-O 121.446 0.641 . . . . 0.0 110.079 179.292 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.438 ' CD ' ' HZ2' ' A' ' 65' ' ' LYS . 12.1 mp0 -68.7 -36.34 78.35 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-O 122.331 1.062 . . . . 0.0 109.65 178.306 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 47.4 mtmt -79.16 -59.75 2.64 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 114.264 -1.335 . . . . 0.0 112.764 -174.34 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 1.643 ' HD2' ' CD1' ' A' ' 68' ' ' TYR . 47.8 m-85 -121.73 4.43 10.04 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 112.394 0.516 . . . . 0.0 112.394 -172.23 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -82.35 34.11 2.69 Favored Glycine 0 CA--C 1.524 0.649 0 C-N-CA 121.28 -0.486 . . . . 0.0 113.211 -177.454 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 2.6 mppt? -122.92 144.37 42.85 Favored Pre-proline 0 N--CA 1.439 -1.017 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.318 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.531 ' HB3' ' OD1' ' A' ' 78' ' ' ASN . 82.8 Cg_exo -46.19 128.67 12.18 Favored 'Trans proline' 0 C--O 1.263 1.772 0 C-N-CA 123.984 3.123 . . . . 0.0 115.142 -176.248 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . 0.505 ' HB2' ' CD1' ' A' ' 77' ' ' PHE . 1.7 t-20 -102.73 -166.96 1.33 Allowed 'General case' 0 C--N 1.269 -2.9 0 CA-C-N 114.516 -1.22 . . . . 0.0 109.356 -178.208 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . 0.459 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 1.9 mptp? -120.61 18.39 12.0 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 178.332 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 37.1 mmt180 -102.75 132.46 48.89 Favored 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 114.343 -1.298 . . . . 0.0 109.269 176.543 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.8 tmtm? -68.37 127.66 33.76 Favored 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 175.477 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.511 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 107.17 -25.67 21.29 Favored Glycine 0 N--CA 1.416 -2.637 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.29 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 1.655 ' HE1' ' CE2' ' A' ' 77' ' ' PHE . 16.0 t80 -76.56 -45.4 30.69 Favored 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 -178.088 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.531 ' OD1' ' HB3' ' A' ' 71' ' ' PRO . 53.6 m-80 -71.61 -41.8 68.46 Favored 'General case' 0 CA--C 1.498 -1.045 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.45 -178.459 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -67.76 -33.64 75.23 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.18 179.487 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.97 -34.71 65.05 Favored Glycine 0 N--CA 1.43 -1.741 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.984 178.342 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.547 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 95.3 mt -61.97 -35.23 77.85 Favored 'General case' 0 C--O 1.215 -0.727 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 174.483 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 71.3 t90 -71.37 -48.78 47.89 Favored 'General case' 0 N--CA 1.431 -1.397 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.326 176.598 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -58.87 -40.53 84.64 Favored 'General case' 0 C--O 1.2 -1.537 0 N-CA-C 112.944 0.72 . . . . 0.0 112.944 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 19.0 tt -71.27 -21.36 21.8 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 CA-C-O 121.128 0.489 . . . . 0.0 110.795 -175.506 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -92.1 -43.78 9.18 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.066 -177.359 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.565 ' N ' HD21 ' A' ' 86' ' ' ASN . 0.8 OUTLIER -92.52 -44.27 8.72 Favored 'General case' 0 N--CA 1.481 1.115 0 CA-C-O 121.327 0.584 . . . . 0.0 112.182 -173.528 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.489 ' OD1' ' HG3' ' A' ' 89' ' ' LYS . 61.5 t30 -133.36 67.91 76.68 Favored Pre-proline 0 C--N 1.299 -1.614 0 C-N-CA 119.809 -0.756 . . . . 0.0 110.786 -178.698 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -68.09 -6.75 17.96 Favored 'Trans proline' 0 C--N 1.369 1.637 0 C-N-CA 123.193 2.595 . . . . 0.0 111.65 -178.227 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . 0.489 ' HG3' ' OD1' ' A' ' 87' ' ' ASN . 5.5 ptmm? -102.53 20.75 16.49 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-N 113.941 -1.481 . . . . 0.0 110.825 179.812 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 7.9 p -79.24 153.25 4.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 176.166 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.491 ' HZ2' ' CD ' ' A' ' 27' ' ' GLU . 68.0 mttm -138.23 -168.12 2.31 Favored 'General case' 0 C--O 1.251 1.14 0 CA-C-O 122.012 0.91 . . . . 0.0 111.502 -178.194 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 3.6 p90 -75.04 -167.55 0.62 Allowed 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 126.125 1.77 . . . . 0.0 111.012 176.444 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 4.9 m . . . . . 0 CA--C 1.546 0.82 0 C-N-CA 124.09 0.956 . . . . 0.0 113.492 -175.574 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.522 ' SD ' ' HD1' ' A' ' 59' ' ' PHE . 1.5 mpt? . . . . . 0 N--CA 1.494 1.73 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -95.23 70.88 3.24 Favored 'General case' 0 N--CA 1.433 -1.316 0 CA-C-O 121.925 0.869 . . . . 0.0 109.917 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . 0.415 HH21 ' HB3' ' A' ' 60' ' ' PRO . 18.4 ptt85 -130.09 178.85 6.24 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 173.288 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -89.74 145.33 25.27 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 175.643 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 67.6 m-85 -115.67 122.12 44.6 Favored 'General case' 0 C--N 1.283 -2.296 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 -179.418 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.416 ' O ' ' HB2' ' A' ' 9' ' ' ASP . 48.4 mttm -96.35 144.3 27.61 Favored Pre-proline 0 C--N 1.294 -1.831 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.918 -170.364 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -58.0 116.02 2.94 Favored 'Trans proline' 0 N--CA 1.462 -0.369 0 C-N-CA 121.731 1.621 . . . . 0.0 110.002 175.133 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 109.52 -7.4 32.04 Favored Glycine 0 N--CA 1.433 -1.543 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.335 -176.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . 0.416 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 5.2 t70 -69.57 152.57 44.62 Favored 'General case' 0 C--O 1.251 1.175 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -177.86 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.4 mt -104.91 120.91 42.57 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 121.375 0.607 . . . . 0.0 109.85 -175.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.0 pt -140.45 -175.49 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.416 -2.165 0 CA-C-O 122.25 1.024 . . . . 0.0 112.024 -174.734 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -124.62 128.95 49.65 Favored 'General case' 0 N--CA 1.409 -2.497 0 N-CA-C 105.64 -1.985 . . . . 0.0 105.64 171.068 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.404 ' CB ' HG22 ' A' ' 42' ' ' ILE . . . -117.02 141.41 48.29 Favored 'General case' 0 C--N 1.278 -2.513 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.798 -176.62 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.688 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -123.24 124.46 43.07 Favored 'General case' 0 N--CA 1.405 -2.72 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.693 -177.437 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.438 ' HG2' HD22 ' A' ' 53' ' ' LEU . 44.6 mtm -115.87 158.2 23.32 Favored 'General case' 0 CA--C 1.499 -1.017 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 175.574 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.3 tttp -65.45 116.91 7.23 Favored 'General case' 0 C--N 1.311 -1.095 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 178.305 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.33 -12.38 58.49 Favored Glycine 0 C--O 1.247 0.93 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -178.058 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 1.664 ' HE2' ' CE1' ' A' ' 18' ' ' TYR . 7.8 m-85 -110.59 149.46 40.32 Favored Pre-proline 0 C--N 1.307 -1.279 0 C-N-CA 123.196 0.598 . . . . 0.0 109.872 178.528 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -81.41 171.45 13.61 Favored 'Trans proline' 0 N--CA 1.442 -1.512 0 C-N-CA 122.118 1.879 . . . . 0.0 108.173 171.323 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . 0.465 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 80.8 m80 -64.46 111.28 2.61 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 174.829 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 9.6 t-105 -110.85 141.03 23.29 Favored Pre-proline 0 C--N 1.292 -1.925 0 C-N-CA 123.585 0.754 . . . . 0.0 109.12 -170.001 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -64.49 118.2 5.19 Favored 'Trans proline' 0 C--O 1.245 0.845 0 C-N-CA 122.147 1.898 . . . . 0.0 110.359 177.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -139.92 166.51 24.44 Favored 'General case' 0 N--CA 1.408 -2.526 0 CA-C-O 121.118 0.485 . . . . 0.0 110.311 -175.537 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.472 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 10.7 ttp180 -115.3 145.35 42.56 Favored 'General case' 0 C--N 1.285 -2.237 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.135 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 52.4 t -74.63 119.91 23.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 104.728 -2.323 . . . . 0.0 104.728 170.099 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.465 ' CG ' ' HZ2' ' A' ' 91' ' ' LYS . 4.1 t70 -84.78 179.0 7.43 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -172.219 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -106.0 150.36 25.79 Favored 'General case' 0 N--CA 1.429 -1.507 0 C-N-CA 119.278 -0.969 . . . . 0.0 111.72 -175.276 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 47.8 t -69.36 119.38 70.14 Favored Pre-proline 0 CA--C 1.505 -0.775 0 CA-C-N 115.448 -0.796 . . . . 0.0 108.902 178.491 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -75.6 143.62 27.44 Favored 'Trans proline' 0 N--CA 1.423 -2.649 0 C-N-CA 121.805 1.67 . . . . 0.0 113.215 -177.756 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -61.84 136.38 57.96 Favored 'General case' 0 C--O 1.259 1.56 0 N-CA-C 107.065 -1.457 . . . . 0.0 107.065 171.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.21 -13.05 55.4 Favored Glycine 0 N--CA 1.43 -1.718 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -175.283 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -82.79 84.96 7.17 Favored 'General case' 0 C--O 1.207 -1.178 0 CA-C-O 121.809 0.814 . . . . 0.0 110.542 175.112 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.4 m -99.96 8.3 8.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 114.33 -1.304 . . . . 0.0 109.217 176.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 9.4 mptt -81.69 139.43 47.2 Favored Pre-proline 0 N--CA 1.426 -1.635 0 CA-C-N 114.191 -1.368 . . . . 0.0 108.542 -179.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -62.57 147.28 95.04 Favored 'Trans proline' 0 C--O 1.244 0.789 0 C-N-CA 122.246 1.964 . . . . 0.0 112.103 179.654 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -62.98 128.76 23.86 Favored 'Trans proline' 0 N--CA 1.451 -0.975 0 C-N-CA 122.405 2.07 . . . . 0.0 111.697 -178.523 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' THR . . . . . 0.513 ' O ' HG21 ' A' ' 37' ' ' THR . 4.2 m -78.66 9.51 4.04 Favored 'General case' 0 C--N 1.301 -1.515 0 C-N-CA 123.885 0.874 . . . . 0.0 112.241 -177.037 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 5.0 p30 80.91 9.94 1.02 Allowed 'General case' 0 N--CA 1.499 2.006 0 C-N-CA 125.784 1.633 . . . . 0.0 110.691 -178.401 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 62.1 mttp -125.3 164.9 19.36 Favored 'General case' 0 C--N 1.293 -1.866 0 CA-C-N 113.367 -1.742 . . . . 0.0 111.12 -179.331 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . 0.402 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 88.8 mt -116.99 147.17 39.57 Favored Pre-proline 0 C--N 1.287 -2.151 0 CA-C-N 114.33 -1.304 . . . . 0.0 109.246 -178.07 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . 0.405 ' HB2' ' HB3' ' A' ' 26' ' ' ASP . 68.9 Cg_endo -73.06 123.86 9.16 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 122.33 2.02 . . . . 0.0 110.523 177.565 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.404 HG22 ' CB ' ' A' ' 13' ' ' ALA . 43.4 mm -120.86 127.56 75.95 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 -176.753 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.653 ' HD2' ' CD1' ' A' ' 43' ' ' PHE . 87.7 t80 -107.14 120.69 42.8 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 178.846 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 -86.66 131.7 34.08 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-O 121.254 0.55 . . . . 0.0 112.247 179.028 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.472 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 67.6 m-85 -85.83 158.44 19.97 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.694 179.326 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.524 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 75.31 -20.32 2.1 Favored Glycine 0 C--O 1.248 1.015 0 C-N-CA 123.526 0.584 . . . . 0.0 114.538 179.139 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 18.3 p -119.38 -23.04 6.81 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 122.305 -0.527 . . . . 0.0 109.73 173.005 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.41 ' HA ' ' CZ ' ' A' ' 43' ' ' PHE . 11.5 m-70 67.67 26.18 7.98 Favored 'General case' 0 C--N 1.348 0.507 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.818 179.507 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -79.4 161.89 25.87 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.698 -0.852 . . . . 0.0 108.698 177.373 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 6.9 m -136.12 140.43 43.68 Favored 'General case' 0 C--N 1.284 -2.25 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 176.794 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -142.74 179.35 7.05 Favored 'General case' 0 C--N 1.287 -2.124 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.289 -175.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 1.635 ' HD1' ' CD2' ' A' ' 52' ' ' PHE . 84.8 m-85 -134.0 115.07 13.91 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.305 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.438 HD22 ' HG2' ' A' ' 15' ' ' MET . 87.4 mt -129.44 166.49 19.49 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 -177.67 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -93.03 167.7 29.49 Favored Glycine 0 N--CA 1.423 -2.18 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -67.03 -6.89 17.11 Favored 'Trans proline' 0 N--CA 1.481 0.747 0 C-N-CA 123.303 2.669 . . . . 0.0 112.828 -176.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 20.8 pttp -93.05 -18.17 22.97 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.366 178.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.2 m-20 -99.98 1.25 42.41 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.188 -175.226 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.3 pt -125.94 145.84 32.71 Favored 'Isoleucine or valine' 0 C--O 1.258 1.551 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.754 179.359 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 0.522 ' HD1' ' SD ' ' A' ' 1' ' ' MET . 83.0 m-85 -136.32 144.82 49.3 Favored Pre-proline 0 C--N 1.288 -2.087 0 CA-C-N 114.823 -1.081 . . . . 0.0 108.554 -177.131 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . 0.415 ' HB3' HH21 ' A' ' 3' ' ' ARG . 35.0 Cg_endo -68.34 127.82 16.37 Favored 'Trans proline' 0 N--CA 1.483 0.857 0 C-N-CA 122.746 2.298 . . . . 0.0 113.956 -179.121 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -51.97 -39.34 59.17 Favored 'General case' 0 C--O 1.217 -0.626 0 C-N-CA 123.87 0.868 . . . . 0.0 111.043 -179.536 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.5 m -57.28 -40.33 77.54 Favored 'General case' 0 C--N 1.307 -1.27 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.185 -178.072 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -95.75 -19.19 19.85 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.278 0.561 . . . . 0.0 112.21 -172.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.453 ' ND2' ' HB3' ' A' ' 59' ' ' PHE . 0.5 OUTLIER -124.19 26.88 7.29 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 114.703 1.371 . . . . 0.0 114.703 -178.214 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.482 ' HZ2' ' CD ' ' A' ' 66' ' ' GLU . 17.0 pttm -70.1 -30.91 68.24 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 174.698 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.482 ' CD ' ' HZ2' ' A' ' 65' ' ' LYS . 19.8 mp0 -65.25 -39.06 92.17 Favored 'General case' 0 C--O 1.251 1.151 0 CA-C-O 122.557 1.17 . . . . 0.0 108.617 175.091 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 35.8 mtpt -76.44 -59.96 2.55 Favored 'General case' 0 N--CA 1.427 -1.618 0 CA-C-N 113.918 -1.492 . . . . 0.0 112.029 -175.07 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . 1.66 ' HE1' ' CE2' ' A' ' 68' ' ' TYR . 21.0 m-85 -107.67 -9.75 15.78 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.482 -0.781 . . . . 0.0 112.428 -168.297 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -82.3 41.55 2.8 Favored Glycine 0 C--O 1.22 -0.726 0 C-N-CA 121.245 -0.503 . . . . 0.0 113.21 -176.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 38.4 mtmm -122.96 124.95 26.44 Favored Pre-proline 0 C--N 1.308 -1.202 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 177.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -56.96 127.17 24.72 Favored 'Trans proline' 0 C--O 1.251 1.167 0 C-N-CA 122.23 1.954 . . . . 0.0 114.686 -172.239 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -84.76 -170.46 3.13 Favored 'General case' 0 CA--C 1.484 -1.594 0 CA-C-N 113.875 -1.511 . . . . 0.0 108.304 176.608 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . 0.405 ' HA ' ' HD3' ' A' ' 73' ' ' LYS . 40.0 mmtm -111.46 22.0 15.57 Favored 'General case' 0 C--N 1.285 -2.201 0 CA-C-O 122.592 1.187 . . . . 0.0 107.821 173.88 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -87.06 127.89 35.11 Favored 'General case' 0 C--O 1.251 1.162 0 CA-C-N 113.548 -1.66 . . . . 0.0 107.547 173.279 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -65.29 134.79 54.38 Favored 'General case' 0 N--CA 1.439 -0.997 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 176.47 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.524 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 100.2 -25.73 27.18 Favored Glycine 0 N--CA 1.42 -2.374 0 C-N-CA 121.405 -0.426 . . . . 0.0 112.363 -178.242 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 1.665 ' HD1' ' CD2' ' A' ' 77' ' ' PHE . 23.2 t80 -73.36 -42.61 62.0 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 -177.709 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.473 ' N ' HD21 ' A' ' 78' ' ' ASN . 0.7 OUTLIER -72.87 -41.37 64.79 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 -177.323 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 16.3 mt-10 -65.06 -39.89 93.91 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 114.411 -1.268 . . . . 0.0 109.857 178.464 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -68.63 -32.29 74.47 Favored Glycine 0 CA--C 1.499 -0.936 0 CA-C-N 115.741 -0.663 . . . . 0.0 112.636 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 90.8 mt -62.9 -32.86 74.22 Favored 'General case' 0 C--O 1.214 -0.798 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 174.764 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 73.6 t90 -73.48 -48.27 34.72 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.382 176.541 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -58.3 -41.32 84.19 Favored 'General case' 0 C--O 1.203 -1.384 0 N-CA-C 112.87 0.693 . . . . 0.0 112.87 179.669 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.3 tt -71.29 -21.24 21.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-O 121.145 0.497 . . . . 0.0 110.619 -175.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -90.36 -42.42 10.95 Favored 'General case' 0 N--CA 1.437 -1.112 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.108 -177.196 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.558 ' N ' HD21 ' A' ' 86' ' ' ASN . 0.8 OUTLIER -92.22 -50.16 5.81 Favored 'General case' 0 CA--C 1.494 -1.188 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.136 -174.154 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 64.6 t30 -132.72 75.9 72.17 Favored Pre-proline 0 C--N 1.303 -1.442 0 C-N-CA 119.725 -0.79 . . . . 0.0 110.152 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.471 ' O ' ' HD3' ' A' ' 24' ' ' ARG . 42.5 Cg_endo -68.52 -6.51 17.86 Favored 'Trans proline' 0 N--CA 1.477 0.542 0 C-N-CA 122.795 2.33 . . . . 0.0 114.143 -174.211 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 61.5 pttt -102.96 15.94 28.02 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-O 120.85 0.357 . . . . 0.0 110.182 -179.053 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 9.8 p -82.92 148.63 5.02 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-O 121.473 0.654 . . . . 0.0 111.376 -176.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.615 ' HA ' ' CZ ' ' A' ' 43' ' ' PHE . 16.2 ptpt -151.0 -175.33 5.1 Favored 'General case' 0 N--CA 1.424 -1.74 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 173.522 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 79.2 t80 -75.91 -44.19 41.5 Favored 'General case' 0 C--N 1.321 -0.67 0 C-N-CA 119.513 -0.875 . . . . 0.0 111.221 -178.299 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' SER . . . . . 0.467 ' O ' ' HG3' ' A' ' 91' ' ' LYS . 33.2 p . . . . . 0 N--CA 1.422 -1.849 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 178.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 92.9 mtp . . . . . 0 CA--C 1.492 -1.283 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -129.85 82.04 2.05 Favored 'General case' 0 N--CA 1.421 -1.909 0 N-CA-C 103.901 -2.629 . . . . 0.0 103.901 172.302 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 11.6 ptp180 -105.7 162.55 13.43 Favored 'General case' 0 C--N 1.294 -1.81 0 CA-C-N 114.597 -1.183 . . . . 0.0 111.51 -174.046 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 9.6 p-10 -95.09 -174.0 3.11 Favored 'General case' 0 C--N 1.28 -2.415 0 C-N-CA 126.107 1.763 . . . . 0.0 108.86 175.241 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . 1.644 ' HD1' ' CD2' ' A' ' 5' ' ' PHE . 76.4 m-85 -118.94 112.99 20.31 Favored 'General case' 0 N--CA 1.427 -1.575 0 CA-C-O 120.958 0.408 . . . . 0.0 109.987 -177.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 29.6 mttp -110.27 153.53 43.31 Favored Pre-proline 0 C--N 1.307 -1.281 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 -177.405 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -62.15 115.4 2.82 Favored 'Trans proline' 0 N--CA 1.448 -1.193 0 N-CA-C 107.08 -1.931 . . . . 0.0 107.08 169.02 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 114.93 -19.05 15.94 Favored Glycine 0 N--CA 1.424 -2.152 0 C-N-CA 120.411 -0.899 . . . . 0.0 112.391 -174.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -78.45 152.19 32.26 Favored 'General case' 0 C--O 1.253 1.268 0 CA-C-N 117.397 0.599 . . . . 0.0 109.446 -177.065 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 82.5 mt -98.03 127.32 43.91 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 122.917 0.487 . . . . 0.0 111.211 -171.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -140.08 -178.78 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.046 0 CA-C-O 121.956 0.884 . . . . 0.0 112.555 -174.718 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 1.633 ' HE2' ' CE1' ' A' ' 12' ' ' PHE . 69.0 m-85 -120.98 125.4 47.26 Favored 'General case' 0 C--N 1.291 -1.971 0 N-CA-C 105.429 -2.063 . . . . 0.0 105.429 172.47 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.419 ' HB2' HD13 ' A' ' 53' ' ' LEU . . . -111.22 146.35 37.08 Favored 'General case' 0 C--N 1.277 -2.545 0 O-C-N 123.531 0.519 . . . . 0.0 111.035 -174.54 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.463 ' HD3' ' C ' ' A' ' 14' ' ' LYS . 7.5 tmtm? -117.9 117.66 29.87 Favored 'General case' 0 N--CA 1.419 -1.998 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.707 -177.746 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' MET . . . . . 0.416 ' HE1' ' CD1' ' A' ' 18' ' ' TYR . 70.1 mtm -112.28 159.38 18.69 Favored 'General case' 0 C--O 1.248 0.999 0 CA-C-O 120.962 0.41 . . . . 0.0 111.364 173.384 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 26.2 ttpp -67.71 116.82 8.83 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 176.025 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.52 -4.91 64.43 Favored Glycine 0 C--O 1.239 0.432 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -176.305 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . 1.644 ' HE2' ' CE1' ' A' ' 18' ' ' TYR . 35.3 m-85 -118.13 145.39 36.85 Favored Pre-proline 0 C--O 1.254 1.335 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 179.325 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -79.79 171.93 14.86 Favored 'Trans proline' 0 N--CA 1.445 -1.324 0 C-N-CA 123.16 2.573 . . . . 0.0 108.281 170.093 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 79.1 m80 -63.93 111.51 2.52 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 177.063 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 10.2 t-105 -110.18 140.51 22.47 Favored Pre-proline 0 C--N 1.295 -1.767 0 CA-C-N 114.866 -1.061 . . . . 0.0 109.369 -170.188 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -65.85 118.15 5.24 Favored 'Trans proline' 0 C--O 1.243 0.744 0 C-N-CA 122.008 1.805 . . . . 0.0 110.184 177.233 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -145.94 167.19 23.91 Favored 'General case' 0 N--CA 1.413 -2.307 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 -175.632 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.59 ' HD3' ' O ' ' A' ' 88' ' ' PRO . 10.0 ttp180 -122.29 149.06 44.25 Favored 'General case' 0 C--N 1.272 -2.782 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 51.5 t -72.34 121.07 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 104.647 -2.353 . . . . 0.0 104.647 169.135 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -84.0 172.44 12.03 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 -170.656 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -105.48 127.11 52.83 Favored 'General case' 0 N--CA 1.431 -1.386 0 CA-C-O 121.506 0.669 . . . . 0.0 111.772 -176.872 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 62.1 t -77.06 127.89 82.48 Favored Pre-proline 0 C--N 1.315 -0.904 0 CA-C-N 114.585 -1.189 . . . . 0.0 110.502 -176.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -72.8 151.77 51.79 Favored 'Trans proline' 0 N--CA 1.433 -2.037 0 C-N-CA 121.7 1.6 . . . . 0.0 112.767 178.201 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -71.03 151.49 44.53 Favored 'General case' 0 C--N 1.31 -1.116 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 172.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 88.04 -7.08 82.49 Favored Glycine 0 N--CA 1.425 -2.097 0 C-N-CA 120.533 -0.841 . . . . 0.0 111.083 -175.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.41 80.44 3.14 Favored 'General case' 0 C--O 1.207 -1.165 0 CA-C-O 122.037 0.922 . . . . 0.0 110.985 173.845 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.3 m -98.55 8.74 7.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 CA-C-N 114.246 -1.343 . . . . 0.0 109.504 176.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 9.6 mptt -79.26 140.36 56.69 Favored Pre-proline 0 C--N 1.3 -1.568 0 CA-C-N 114.1 -1.409 . . . . 0.0 107.723 179.621 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -63.53 133.49 40.09 Favored 'Trans proline' 0 CA--C 1.537 0.651 0 C-N-CA 121.775 1.65 . . . . 0.0 112.458 -177.628 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -90.77 171.64 3.33 Favored 'Trans proline' 0 N--CA 1.437 -1.799 0 C-N-CA 122.533 2.156 . . . . 0.0 111.836 179.086 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 5.5 m -77.1 7.39 5.06 Favored 'General case' 0 CA--C 1.561 1.384 0 C-N-CA 123.4 0.68 . . . . 0.0 110.568 178.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 41.8 m-80 69.72 19.61 7.18 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 124.804 1.241 . . . . 0.0 110.777 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.468 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 88.6 mttt -129.35 177.01 7.49 Favored 'General case' 0 N--CA 1.431 -1.407 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.179 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 66.6 mt -84.16 140.8 39.71 Favored Pre-proline 0 C--N 1.314 -0.97 0 O-C-N 123.609 0.568 . . . . 0.0 109.574 -177.488 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -72.74 123.93 9.36 Favored 'Trans proline' 0 C--O 1.222 -0.276 0 C-N-CA 122.395 2.064 . . . . 0.0 110.186 178.767 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 47.6 mm -120.85 123.43 70.2 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 0 O-C-N 121.924 -0.485 . . . . 0.0 110.401 -176.495 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.636 ' HD1' ' CD2' ' A' ' 43' ' ' PHE . 77.4 t80 -106.09 119.13 38.4 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 177.889 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 1.611 ' HD1' ' CD2' ' A' ' 44' ' ' PHE . 80.4 m-85 -83.39 131.91 35.02 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-O 121.314 0.578 . . . . 0.0 112.141 179.591 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 46.1 m-85 -85.01 154.5 22.07 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.406 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.544 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 73.44 -21.16 1.17 Allowed Glycine 0 C--N 1.308 -0.981 0 C-N-CA 124.184 0.897 . . . . 0.0 114.977 179.679 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.4 p -115.98 -22.92 8.78 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 117.942 0.871 . . . . 0.0 109.668 173.409 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.402 ' HE2' ' CD ' ' A' ' 83' ' ' GLU . 55.9 m170 69.73 23.17 5.83 Favored 'General case' 0 CA--C 1.518 -0.285 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.595 176.319 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -76.51 160.79 29.17 Favored 'General case' 0 N--CA 1.443 -0.785 0 CA-C-N 115.261 -0.881 . . . . 0.0 108.745 177.035 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.2 m -136.3 138.31 41.6 Favored 'General case' 0 C--N 1.279 -2.473 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.093 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -140.2 -179.62 6.09 Favored 'General case' 0 C--N 1.282 -2.343 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.0 -177.267 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -133.03 111.21 10.8 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 175.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.443 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 87.2 mt -129.25 150.9 50.43 Favored 'General case' 0 C--N 1.288 -2.094 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.293 -176.227 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . 0.468 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -85.17 172.84 47.87 Favored Glycine 0 N--CA 1.424 -2.156 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 -176.54 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -65.04 -16.65 56.35 Favored 'Trans proline' 0 C--O 1.208 -0.992 0 C-N-CA 122.266 1.977 . . . . 0.0 112.407 -177.478 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.75 -1.14 44.04 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-O 121.301 0.572 . . . . 0.0 112.197 177.205 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.443 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 69.4 m-20 -104.22 -4.83 22.54 Favored 'General case' 0 C--N 1.295 -1.791 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 179.513 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.7 pt -128.2 156.58 40.41 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.707 0 CA-C-N 114.898 -1.046 . . . . 0.0 109.1 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 0.413 ' HB3' ' ND2' ' A' ' 64' ' ' ASN . 88.6 m-85 -136.72 136.76 22.08 Favored Pre-proline 0 C--N 1.287 -2.115 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 -179.625 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . 0.466 ' HG2' ' HB2' ' A' ' 63' ' ' GLU . 20.5 Cg_endo -64.43 132.92 35.19 Favored 'Trans proline' 0 C--N 1.318 -1.079 0 C-N-CA 122.273 1.982 . . . . 0.0 112.416 -177.621 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.42 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 60.7 t80 -58.63 -39.76 81.41 Favored 'General case' 0 C--O 1.206 -1.214 0 C-N-CA 123.695 0.798 . . . . 0.0 110.839 -178.331 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 29.5 t -62.06 -36.09 80.58 Favored 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.484 -176.009 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . 0.466 ' HB2' ' HG2' ' A' ' 60' ' ' PRO . 1.3 mp0 -95.05 -18.0 21.39 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 113.172 0.805 . . . . 0.0 113.172 -175.2 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.413 ' ND2' ' HB3' ' A' ' 59' ' ' PHE . 37.3 m-80 -123.55 16.07 9.6 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 112.778 0.658 . . . . 0.0 112.778 -175.814 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.49 ' HG2' ' OE2' ' A' ' 66' ' ' GLU . 21.4 pttm -66.8 -32.19 73.3 Favored 'General case' 0 N--CA 1.484 1.268 0 CA-C-O 121.273 0.559 . . . . 0.0 110.703 -178.062 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.49 ' OE2' ' HG2' ' A' ' 65' ' ' LYS . 2.7 mp0 -70.36 -25.39 63.25 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 -179.537 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 43.6 mttp -91.05 -59.66 2.11 Favored 'General case' 0 N--CA 1.422 -1.826 0 CA-C-N 114.271 -1.331 . . . . 0.0 111.297 -171.01 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 56.1 m-85 -105.76 -0.62 25.24 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.806 -172.254 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.9 56.43 4.81 Favored Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.74 179.292 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -128.61 128.53 23.54 Favored Pre-proline 0 C--N 1.317 -0.845 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.806 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_exo -54.57 137.9 74.01 Favored 'Trans proline' 0 C--N 1.349 0.575 0 C-N-CA 122.969 2.446 . . . . 0.0 112.169 177.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 15.9 m-80 -116.04 -179.34 3.63 Favored 'General case' 0 CA--C 1.472 -2.049 0 N-CA-C 113.845 1.054 . . . . 0.0 113.845 -178.633 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . 0.462 ' HD3' ' N ' ' A' ' 73' ' ' LYS . 2.8 mppt? -93.27 1.9 56.83 Favored 'General case' 0 N--CA 1.429 -1.494 0 CA-C-N 112.921 -1.945 . . . . 0.0 108.247 -178.516 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 5.6 mmt180 -84.54 116.34 23.08 Favored 'General case' 0 N--CA 1.426 -1.645 0 CA-C-N 114.889 -1.051 . . . . 0.0 109.783 176.43 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.521 ' HZ2' ' CD ' ' A' ' 79' ' ' GLU . 8.7 tmtt? -56.5 125.92 24.22 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 175.632 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.544 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.03 -25.44 20.42 Favored Glycine 0 N--CA 1.434 -1.451 0 C-N-CA 121.222 -0.514 . . . . 0.0 112.081 -179.363 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 1.665 ' HE1' ' CE2' ' A' ' 77' ' ' PHE . 14.1 t80 -70.29 -40.28 74.39 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 122.068 0.937 . . . . 0.0 108.738 -176.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -68.47 -43.64 76.55 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 114.198 -1.364 . . . . 0.0 108.986 -176.808 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . 0.521 ' CD ' ' HZ2' ' A' ' 75' ' ' LYS . 23.5 mt-10 -68.49 -35.57 77.72 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 114.39 -1.277 . . . . 0.0 109.964 179.765 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -68.45 -33.66 77.65 Favored Glycine 0 N--CA 1.438 -1.186 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.24 177.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.409 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 95.4 mt -62.76 -33.83 75.98 Favored 'General case' 0 C--O 1.213 -0.818 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 174.596 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 72.8 t90 -71.92 -49.54 36.84 Favored 'General case' 0 N--CA 1.441 -0.901 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.778 176.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.402 ' CD ' ' HE2' ' A' ' 48' ' ' HIS . 46.7 mt-10 -58.25 -40.35 81.53 Favored 'General case' 0 C--O 1.204 -1.335 0 N-CA-C 112.895 0.702 . . . . 0.0 112.895 179.503 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.0 tt -71.18 -21.21 21.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.179 0.514 . . . . 0.0 110.583 -176.571 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -89.03 -42.9 11.48 Favored 'General case' 0 N--CA 1.439 -1.011 0 CA-C-N 115.47 -0.787 . . . . 0.0 110.019 -177.856 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.547 ' N ' HD21 ' A' ' 86' ' ' ASN . 0.8 OUTLIER -89.49 -48.66 7.17 Favored 'General case' 0 CA--C 1.493 -1.225 0 CA-C-N 115.92 -0.582 . . . . 0.0 112.077 -174.295 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -132.29 76.87 71.84 Favored Pre-proline 0 C--N 1.302 -1.481 0 C-N-CA 120.17 -0.612 . . . . 0.0 109.761 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . 0.59 ' O ' ' HD3' ' A' ' 24' ' ' ARG . 28.8 Cg_endo -62.97 -16.96 57.61 Favored 'Trans proline' 0 C--O 1.218 -0.515 0 C-N-CA 122.808 2.339 . . . . 0.0 115.719 -171.399 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 8.5 ptmm? -106.58 20.64 18.71 Favored 'General case' 0 C--O 1.259 1.573 0 C-N-CA 119.317 -0.953 . . . . 0.0 111.323 -179.213 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 9.0 p -70.06 146.4 12.33 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-O 122.168 0.985 . . . . 0.0 113.283 -174.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.479 ' HA ' ' CZ ' ' A' ' 43' ' ' PHE . 0.2 OUTLIER -145.39 146.23 31.47 Favored 'General case' 0 N--CA 1.417 -2.113 0 N-CA-C 104.422 -2.436 . . . . 0.0 104.422 169.661 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 54.2 t80 -75.78 106.07 7.15 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.817 -0.753 . . . . 0.0 110.107 -175.259 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 14.0 m . . . . . 0 C--N 1.29 -2.015 0 CA-C-N 114.404 -1.271 . . . . 0.0 109.975 -177.505 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.4 mmt . . . . . 0 CA--C 1.487 -1.442 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -120.92 77.99 1.35 Allowed 'General case' 0 N--CA 1.426 -1.633 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 176.677 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 31.4 ptt-85 -117.75 171.88 7.74 Favored 'General case' 0 C--N 1.296 -1.727 0 CA-C-N 114.583 -1.19 . . . . 0.0 109.004 179.296 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 12.0 p-10 -91.93 -179.4 5.29 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 177.075 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -111.13 101.34 9.87 Favored 'General case' 0 N--CA 1.427 -1.618 0 CA-C-O 121.452 0.644 . . . . 0.0 110.152 -176.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.532 ' HB2' ' HZ1' ' A' ' 6' ' ' LYS . 0.1 OUTLIER -94.36 145.98 30.7 Favored Pre-proline 0 C--N 1.304 -1.39 0 CA-C-N 114.913 -1.039 . . . . 0.0 109.326 -177.079 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -53.28 122.23 10.83 Favored 'Trans proline' 0 C--O 1.238 0.523 0 C-N-CA 122.336 2.024 . . . . 0.0 109.579 172.118 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 109.58 -9.91 32.72 Favored Glycine 0 N--CA 1.427 -1.904 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.051 -177.258 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -79.9 153.51 28.96 Favored 'General case' 0 C--O 1.251 1.166 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -179.297 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.0 mt -105.64 126.39 52.09 Favored 'General case' 0 C--N 1.291 -1.97 0 CA-C-O 121.251 0.548 . . . . 0.0 109.892 -175.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 9.3 pt -140.84 -172.66 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.832 0 CA-C-O 122.256 1.027 . . . . 0.0 111.813 -174.616 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.55 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 72.8 m-85 -126.15 134.44 51.3 Favored 'General case' 0 N--CA 1.411 -2.377 0 N-CA-C 105.894 -1.891 . . . . 0.0 105.894 172.342 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . 0.441 ' HB2' ' CD1' ' A' ' 53' ' ' LEU . . . -113.44 141.92 46.52 Favored 'General case' 0 C--N 1.273 -2.72 0 O-C-N 123.776 0.673 . . . . 0.0 110.235 -176.28 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' LYS . . . . . 0.472 ' HD3' ' C ' ' A' ' 14' ' ' LYS . 7.5 tmtm? -113.15 117.72 32.73 Favored 'General case' 0 N--CA 1.422 -1.837 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.834 -177.441 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 72.1 mtm -109.54 158.48 17.96 Favored 'General case' 0 C--O 1.254 1.331 0 CA-C-O 121.26 0.552 . . . . 0.0 111.056 173.241 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 61.4 tttm -68.46 117.26 9.99 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.682 178.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.3 -1.55 76.85 Favored Glycine 0 C--O 1.238 0.361 0 C-N-CA 121.0 -0.619 . . . . 0.0 111.768 -178.746 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -120.39 150.68 52.37 Favored Pre-proline 0 C--O 1.258 1.52 0 CA-C-N 115.636 -0.282 . . . . 0.0 111.061 -179.202 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -74.97 171.97 17.26 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 123.286 2.657 . . . . 0.0 109.691 172.513 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -67.3 110.97 3.75 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 176.788 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 3.9 t-105 -98.78 137.48 20.57 Favored Pre-proline 0 C--N 1.297 -1.681 0 CA-C-N 114.801 -1.091 . . . . 0.0 108.542 -171.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -64.49 118.13 5.13 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 121.763 1.642 . . . . 0.0 110.148 177.72 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -135.85 166.79 22.48 Favored 'General case' 0 N--CA 1.411 -2.398 0 CA-C-O 121.519 0.676 . . . . 0.0 110.975 -175.181 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.497 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 64.4 ttt-85 -115.66 141.76 47.65 Favored 'General case' 0 C--N 1.28 -2.423 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.455 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 48.1 t -77.65 119.92 27.26 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.249 0 N-CA-C 103.957 -2.608 . . . . 0.0 103.957 169.816 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -102.33 -179.58 4.03 Favored 'General case' 0 C--N 1.283 -2.294 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.858 -170.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLU . . . . . 0.405 ' CD ' HH12 ' A' ' 24' ' ' ARG . 30.5 mp0 -91.47 168.39 11.57 Favored 'General case' 0 N--CA 1.424 -1.731 0 CA-C-O 121.622 0.725 . . . . 0.0 110.504 -178.684 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 75.4 t -92.83 124.08 59.62 Favored Pre-proline 0 C--N 1.304 -1.402 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 175.361 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -71.0 149.26 58.65 Favored 'Trans proline' 0 N--CA 1.435 -1.953 0 C-N-CA 121.512 1.474 . . . . 0.0 112.085 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -68.13 141.51 56.04 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 177.172 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.62 -33.61 6.32 Favored Glycine 0 C--N 1.293 -1.843 0 N-CA-C 109.059 -1.616 . . . . 0.0 109.059 -175.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -80.87 85.97 6.1 Favored 'General case' 0 N--CA 1.433 -1.301 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 176.071 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.3 m -90.47 6.09 5.0 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 CA-C-N 114.95 -1.023 . . . . 0.0 112.105 -177.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 14.0 ptmm? -71.09 152.58 94.73 Favored Pre-proline 0 N--CA 1.424 -1.728 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.688 179.426 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -69.41 167.95 22.51 Favored 'Trans proline' 0 C--O 1.274 2.303 0 C-N-CA 121.855 1.703 . . . . 0.0 110.058 173.005 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -56.4 143.16 87.85 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 122.599 2.199 . . . . 0.0 111.374 177.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.0 m -85.17 8.42 18.32 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.748 -176.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 74.05 11.48 4.36 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 125.096 1.359 . . . . 0.0 108.354 -172.07 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . 0.532 ' HE3' ' HA ' ' A' ' 53' ' ' LEU . 22.5 mtpp -139.76 153.24 47.11 Favored 'General case' 0 N--CA 1.415 -2.209 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 179.801 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 80.7 mt -103.55 154.62 37.73 Favored Pre-proline 0 C--N 1.29 -2.002 0 O-C-N 124.023 0.827 . . . . 0.0 109.772 -175.605 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -71.15 122.32 8.62 Favored 'Trans proline' 0 N--CA 1.451 -0.991 0 C-N-CA 121.521 1.481 . . . . 0.0 109.734 174.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ILE . . . . . 0.406 HG13 ' HB2' ' A' ' 53' ' ' LEU . 44.9 mm -118.53 116.81 52.48 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.935 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -176.585 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 1.669 ' HE1' ' CE2' ' A' ' 43' ' ' PHE . 79.0 t80 -93.33 122.34 35.64 Favored 'General case' 0 C--N 1.268 -2.972 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 179.718 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . 1.651 ' HD1' ' CD2' ' A' ' 44' ' ' PHE . 71.7 m-85 -88.51 124.91 34.47 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.347 0.594 . . . . 0.0 112.542 178.434 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.497 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 78.2 m-85 -74.64 152.53 39.19 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.536 176.053 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.542 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 79.78 -19.97 5.79 Favored Glycine 0 C--N 1.308 -1.02 0 CA-C-N 116.289 -0.414 . . . . 0.0 113.701 178.786 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.0 p -116.62 -22.79 8.48 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 117.166 0.483 . . . . 0.0 110.149 175.48 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.55 ' O ' ' HA ' ' A' ' 92' ' ' PHE . 49.7 m170 70.22 14.23 7.63 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 124.321 1.048 . . . . 0.0 112.017 177.123 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 57.4 mm-40 -92.4 168.15 11.49 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.873 -179.113 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.0 m -129.48 142.15 50.85 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-O 121.2 0.524 . . . . 0.0 109.908 179.606 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -137.89 -178.9 5.46 Favored 'General case' 0 C--N 1.295 -1.791 0 C-N-CA 124.096 0.958 . . . . 0.0 110.023 -177.499 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -128.53 116.0 18.99 Favored 'General case' 0 CA--C 1.5 -0.975 0 CA-C-O 120.851 0.357 . . . . 0.0 110.637 179.141 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.532 ' HA ' ' HE3' ' A' ' 39' ' ' LYS . 89.0 mt -131.59 151.32 51.7 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.793 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -85.69 174.38 48.19 Favored Glycine 0 N--CA 1.433 -1.514 0 C-N-CA 120.564 -0.827 . . . . 0.0 111.192 -176.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 -6.87 19.67 Favored 'Trans proline' 0 C--O 1.212 -0.794 0 C-N-CA 122.591 2.194 . . . . 0.0 112.98 -176.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.528 ' NZ ' ' HB2' ' A' ' 56' ' ' LYS . 5.8 mtmp? -97.99 -15.59 20.02 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 177.317 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.434 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 9.7 m-20 -99.72 1.78 43.65 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 114.585 -1.189 . . . . 0.0 108.58 -168.121 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.2 pt -132.06 152.11 36.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 114.19 -1.368 . . . . 0.0 110.187 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' PHE . . . . . 1.644 ' HD1' ' CD2' ' A' ' 59' ' ' PHE . 85.5 m-85 -135.29 141.31 37.3 Favored Pre-proline 0 C--N 1.302 -1.457 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 179.543 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -66.11 132.23 29.28 Favored 'Trans proline' 0 C--N 1.33 -0.432 0 C-N-CA 122.801 2.334 . . . . 0.0 113.36 -177.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' TYR . . . . . 0.55 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 50.3 t80 -59.48 -41.1 89.02 Favored 'General case' 0 C--O 1.208 -1.116 0 C-N-CA 123.639 0.776 . . . . 0.0 110.209 -179.496 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.1 p -59.41 -42.67 92.36 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 115.171 -0.922 . . . . 0.0 112.99 -176.19 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -96.48 -2.88 44.38 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 112.886 0.698 . . . . 0.0 112.886 -179.094 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 36.8 m-80 -132.14 15.04 4.67 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 113.185 0.809 . . . . 0.0 113.185 -176.317 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.492 ' HG2' ' OE2' ' A' ' 66' ' ' GLU . 20.5 pttm -66.02 -29.16 69.47 Favored 'General case' 0 N--CA 1.487 1.415 0 CA-C-O 121.735 0.778 . . . . 0.0 110.831 -179.18 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . 0.492 ' OE2' ' HG2' ' A' ' 65' ' ' LYS . 2.9 mp0 -68.21 -36.78 80.07 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 179.476 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 40.9 mttp -84.19 -59.78 2.29 Favored 'General case' 0 N--CA 1.428 -1.542 0 CA-C-N 113.405 -1.725 . . . . 0.0 111.583 -170.42 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 36.2 m-85 -105.51 -4.91 20.71 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.386 -170.807 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -81.7 56.45 4.92 Favored Glycine 0 N--CA 1.444 -0.805 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 177.748 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.534 ' O ' ' HE1' ' A' ' 77' ' ' PHE . 0.0 OUTLIER -119.33 158.55 48.44 Favored Pre-proline 0 C--N 1.305 -1.352 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 -177.55 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -73.36 167.24 27.81 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 121.883 1.722 . . . . 0.0 111.926 175.14 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -152.65 -177.63 6.36 Favored 'General case' 0 C--N 1.308 -1.23 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.226 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 30.9 mmmt -97.08 -10.56 25.81 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 122.243 0.217 . . . . 0.0 110.795 178.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 27.4 mmt180 -67.17 124.38 22.93 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 177.456 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.61 137.22 40.62 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 176.345 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . 0.542 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 100.97 -26.14 25.77 Favored Glycine 0 N--CA 1.426 -2.013 0 N-CA-C 108.926 -1.67 . . . . 0.0 108.926 -174.53 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' PHE . . . . . 0.534 ' HE1' ' O ' ' A' ' 70' ' ' LYS . 20.6 t80 -77.04 -46.52 23.48 Favored 'General case' 0 N--CA 1.44 -0.939 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.473 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -60.37 -50.29 74.19 Favored 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 115.164 -0.925 . . . . 0.0 108.597 177.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 20.5 mp0 -61.09 -41.7 97.15 Favored 'General case' 0 N--CA 1.435 -1.207 0 CA-C-N 113.797 -1.547 . . . . 0.0 110.513 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.06 -34.55 64.76 Favored Glycine 0 CA--C 1.496 -1.11 0 CA-C-N 115.879 -0.601 . . . . 0.0 113.403 -178.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 32.3 tp -63.62 -30.62 71.71 Favored 'General case' 0 C--O 1.204 -1.325 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 176.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 79.1 t90 -77.04 -47.12 21.48 Favored 'General case' 0 N--CA 1.437 -1.109 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.031 175.237 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 39.0 mt-10 -58.93 -42.28 89.37 Favored 'General case' 0 C--O 1.196 -1.711 0 N-CA-C 113.202 0.816 . . . . 0.0 113.202 -178.723 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 21.1 tt -63.33 -33.18 59.63 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -175.631 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -81.61 -34.24 31.04 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.126 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.7 m-80 -100.52 -46.54 5.18 Favored 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 112.94 0.719 . . . . 0.0 112.94 -172.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 64.9 t30 -133.58 73.64 72.28 Favored Pre-proline 0 C--N 1.3 -1.565 0 CA-C-O 121.058 0.456 . . . . 0.0 110.686 -178.166 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -73.61 -5.61 17.37 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 122.978 2.452 . . . . 0.0 112.791 -176.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 61.5 pttt -100.3 12.84 36.19 Favored 'General case' 0 C--N 1.308 -1.2 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.874 -177.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 10.0 p -72.55 154.61 7.35 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.704 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -179.631 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.4 mptp? -126.99 -172.37 2.63 Favored 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 122.743 0.417 . . . . 0.0 111.655 -176.118 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.55 ' HA ' ' O ' ' A' ' 48' ' ' HIS . 63.9 t80 -45.86 158.49 0.09 Allowed 'General case' 0 CA--C 1.559 1.299 0 C-N-CA 126.802 2.041 . . . . 0.0 115.132 -174.324 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 16.4 m . . . . . 0 CA--C 1.559 1.322 0 C-N-CA 127.762 2.425 . . . . 0.0 115.585 -176.999 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 . . . . . 0 N--CA 1.416 -2.126 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 25.9 mttp -94.84 147.49 33.2 Favored Pre-proline 0 C--N 1.291 -1.964 0 CA-C-N 114.583 -1.19 . . . . 0.0 108.783 -173.184 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -63.19 115.64 3.1 Favored 'Trans proline' 0 N--CA 1.448 -1.157 0 N-CA-C 107.549 -1.751 . . . . 0.0 107.549 170.845 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 110.07 -8.47 31.3 Favored Glycine 0 N--CA 1.422 -2.253 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.214 -174.917 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -73.1 154.92 40.19 Favored 'General case' 0 C--O 1.253 1.28 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 -178.214 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 71.1 mt -102.12 122.56 44.37 Favored 'General case' 0 C--N 1.298 -1.665 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.553 -173.064 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -139.97 178.88 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 CA-C-O 122.458 1.123 . . . . 0.0 113.206 -175.154 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.497 ' HD2' ' ND2' ' A' ' 64' ' ' ASN . 47.5 m-85 -115.89 127.87 55.35 Favored 'General case' 0 C--N 1.278 -2.516 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 170.422 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.556 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -108.43 124.68 50.78 Favored 'General case' 0 C--N 1.273 -2.757 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.579 -175.313 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.599 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -105.93 123.39 47.89 Favored 'General case' 0 N--CA 1.404 -2.768 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.34 -177.759 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 68.4 mtm -120.63 158.17 27.97 Favored 'General case' 0 C--N 1.317 -0.847 0 C-N-CA 123.344 0.657 . . . . 0.0 109.231 176.584 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -67.53 117.07 8.99 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.08 -5.81 57.94 Favored Glycine 0 C--O 1.251 1.195 0 N-CA-C 111.518 -0.633 . . . . 0.0 111.518 178.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -124.04 147.25 53.65 Favored Pre-proline 0 N--CA 1.426 -1.666 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 -179.37 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -74.49 170.98 19.03 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 121.805 1.67 . . . . 0.0 109.273 174.249 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' HIS . . . . . 0.575 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 65.8 m80 -59.97 110.78 1.27 Allowed 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 175.715 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -102.22 137.95 19.59 Favored Pre-proline 0 C--N 1.308 -1.22 0 C-N-CA 124.017 0.927 . . . . 0.0 109.53 -170.786 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -64.38 118.16 5.15 Favored 'Trans proline' 0 C--O 1.242 0.694 0 C-N-CA 121.869 1.712 . . . . 0.0 110.636 178.643 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.98 166.12 26.22 Favored 'General case' 0 N--CA 1.415 -2.188 0 CA-C-O 121.181 0.515 . . . . 0.0 110.403 -176.27 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.443 ' HD3' ' O ' ' A' ' 88' ' ' PRO . 11.4 ttp180 -114.63 146.25 41.06 Favored 'General case' 0 C--N 1.282 -2.351 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.496 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.6 t -73.28 117.03 16.37 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 104.098 -2.556 . . . . 0.0 104.098 168.893 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -92.97 -178.0 4.67 Favored 'General case' 0 C--N 1.281 -2.405 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 -170.334 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 . . . . . 0 N--CA 1.429 -1.493 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 178.455 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.501 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 47.6 mmtt . . . . . 0 N--CA 1.409 -2.504 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.479 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 79.4 mt -113.25 153.28 45.54 Favored Pre-proline 0 C--N 1.263 -3.186 0 O-C-N 124.812 1.32 . . . . 0.0 108.696 -177.432 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -69.68 123.61 10.3 Favored 'Trans proline' 0 N--CA 1.457 -0.667 0 C-N-CA 121.658 1.572 . . . . 0.0 109.667 174.794 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.402 ' O ' ' HA ' ' A' ' 50' ' ' THR . 50.7 mm -120.58 122.44 68.04 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 CA-C-O 120.879 0.371 . . . . 0.0 110.454 -176.665 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.545 ' CE1' ' HA ' ' A' ' 48' ' ' HIS . 35.0 t80 -98.05 114.84 27.11 Favored 'General case' 0 C--N 1.285 -2.196 0 C-N-CA 123.441 0.697 . . . . 0.0 109.754 178.746 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 81.3 m-85 -79.79 129.93 34.9 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 177.85 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 73.1 m-85 -82.42 154.85 24.97 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.574 177.967 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.54 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 74.38 -20.65 1.6 Allowed Glycine 0 C--N 1.31 -0.883 0 CA-C-N 115.442 -0.799 . . . . 0.0 114.411 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 38.1 p -116.41 -22.64 8.68 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 117.911 0.856 . . . . 0.0 109.391 173.302 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' HIS . . . . . 0.545 ' HA ' ' CE1' ' A' ' 43' ' ' PHE . 12.5 m-70 68.12 22.61 8.26 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 114.959 -1.019 . . . . 0.0 112.98 177.825 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -79.34 172.3 13.99 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.975 178.729 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.402 ' HA ' ' O ' ' A' ' 42' ' ' ILE . 3.8 m -140.95 138.18 33.62 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 177.415 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -140.16 -179.0 5.72 Favored 'General case' 0 C--N 1.288 -2.107 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.383 -176.634 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.479 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 62.0 m-85 -129.59 109.94 11.42 Favored 'General case' 0 N--CA 1.445 -0.68 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 177.018 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.556 HD12 ' HB1' ' A' ' 13' ' ' ALA . 94.6 mt -129.08 153.57 47.51 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 -179.565 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.501 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -87.97 171.82 41.32 Favored Glycine 0 CA--C 1.49 -1.492 0 C-N-CA 120.307 -0.949 . . . . 0.0 112.191 -174.727 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -61.73 -19.0 63.63 Favored 'Trans proline' 0 C--O 1.239 0.532 0 C-N-CA 123.088 2.526 . . . . 0.0 111.982 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -91.86 -19.95 21.97 Favored 'General case' 0 N--CA 1.433 -1.29 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.903 179.473 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.409 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 24.7 m-20 -82.07 -20.86 37.36 Favored 'General case' 0 CA--C 1.493 -1.234 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.298 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.404 ' HA ' ' O ' ' A' ' 12' ' ' PHE . 15.5 pt -110.19 151.56 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.687 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.65 -176.359 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -135.73 137.66 26.18 Favored Pre-proline 0 C--O 1.185 -2.327 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -66.32 127.36 17.27 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 122.486 2.124 . . . . 0.0 113.938 -175.408 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 75.3 t80 -57.8 -32.48 67.6 Favored 'General case' 0 C--O 1.205 -1.279 0 CA-C-N 114.713 -1.13 . . . . 0.0 111.694 -175.101 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.59 -57.45 11.04 Favored 'General case' 0 C--N 1.293 -1.889 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -69.42 -34.53 74.6 Favored 'General case' 0 C--O 1.219 -0.518 0 CA-C-O 121.506 0.669 . . . . 0.0 111.555 -177.513 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.497 ' ND2' ' HD2' ' A' ' 12' ' ' PHE 0.309 1.0 OUTLIER -109.81 23.74 13.98 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 115.32 1.6 . . . . 0.0 115.32 -175.715 . . . . . . . . 4 4 . 1 . 001 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.429 ' HZ1' ' CG ' ' A' ' 85' ' ' ASP . 15.8 ttmm -63.27 -27.38 69.29 Favored 'General case' 0 N--CA 1.481 1.095 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.217 171.742 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.463 ' CD ' ' HG2' ' A' ' 67' ' ' LYS . 1.2 pp20? -77.41 -35.46 54.19 Favored 'General case' 0 N--CA 1.423 -1.796 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.215 176.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.463 ' HG2' ' CD ' ' A' ' 66' ' ' GLU . 0.1 OUTLIER -77.37 -59.74 2.66 Favored 'General case' 0 N--CA 1.439 -0.982 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.119 -174.381 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -105.82 -4.11 21.17 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.986 -169.603 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -79.7 59.86 4.41 Favored Glycine 0 N--CA 1.436 -1.347 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 176.682 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.403 ' HD3' ' HA ' ' A' ' 70' ' ' LYS . 38.7 mmtm -132.34 134.34 24.81 Favored Pre-proline 0 C--N 1.32 -0.679 0 C-N-CA 122.936 0.495 . . . . 0.0 111.259 -179.301 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.458 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 78.1 Cg_exo -48.31 131.3 22.45 Favored 'Trans proline' 0 C--O 1.273 2.248 0 C-N-CA 123.911 3.074 . . . . 0.0 113.75 178.945 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.552 ' HB2' ' CD1' ' A' ' 77' ' ' PHE . 1.2 t-20 -113.82 -178.21 3.32 Favored 'General case' 0 N--CA 1.406 -2.633 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.953 -174.146 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.614 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 7.3 mptt -110.81 10.65 22.52 Favored 'General case' 0 N--CA 1.425 -1.696 0 CA-C-O 122.485 1.136 . . . . 0.0 108.375 -178.252 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 31.2 mmt180 -96.45 129.52 43.79 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 114.204 -1.362 . . . . 0.0 108.567 173.81 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.424 ' HG3' ' OE2' ' A' ' 79' ' ' GLU . 61.9 tttp -69.7 144.35 52.85 Favored 'General case' 0 N--CA 1.446 -0.663 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 174.7 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.54 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 91.47 -25.91 13.83 Favored Glycine 0 C--O 1.208 -1.469 0 N-CA-C 111.761 -0.536 . . . . 0.0 111.761 -177.517 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.552 ' CD1' ' HB2' ' A' ' 72' ' ' ASN . 32.5 t80 -69.78 -53.63 17.42 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-O 121.85 0.834 . . . . 0.0 109.423 -178.653 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.458 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 87.5 m-20 -69.93 -32.84 71.33 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.905 -176.569 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' GLU . . . . . 0.424 ' OE2' ' HG3' ' A' ' 75' ' ' LYS . 28.1 mt-10 -72.09 -37.68 69.52 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 114.738 -1.119 . . . . 0.0 108.382 178.243 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.04 -31.63 66.58 Favored Glycine 0 N--CA 1.428 -1.86 0 CA-C-N 115.007 -0.997 . . . . 0.0 112.462 177.333 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 86.0 mt -55.95 -34.74 65.95 Favored 'General case' 0 N--CA 1.474 0.746 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 175.136 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.4 t90 -75.91 -50.71 14.23 Favored 'General case' 0 N--CA 1.426 -1.635 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.457 177.952 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -54.98 -48.37 73.35 Favored 'General case' 0 C--O 1.2 -1.537 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -178.327 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.2 tt -67.43 -25.5 33.53 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.172 0 N-CA-C 112.205 0.446 . . . . 0.0 112.205 -175.277 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.429 ' CG ' ' HZ1' ' A' ' 65' ' ' LYS . 6.7 t0 -94.39 -22.59 18.22 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.261 0.553 . . . . 0.0 110.488 -174.197 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -106.96 -57.49 2.06 Favored 'General case' 0 CA--C 1.505 -0.777 0 CA-C-O 121.291 0.567 . . . . 0.0 111.366 -179.285 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -127.6 76.02 77.27 Favored Pre-proline 0 C--N 1.313 -1.015 0 C-N-CA 119.849 -0.74 . . . . 0.0 110.413 -179.072 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.443 ' O ' ' HD3' ' A' ' 24' ' ' ARG . 48.6 Cg_endo -69.73 -6.54 18.83 Favored 'Trans proline' 0 N--CA 1.483 0.857 0 C-N-CA 122.722 2.282 . . . . 0.0 113.93 -175.393 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.2 pttm . . . . . 0 C--N 1.301 -1.536 0 CA-C-O 121.19 0.519 . . . . 0.0 109.699 -178.207 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 5' ' ' PHE . . . . . 0.557 ' CE2' HG13 ' A' ' 58' ' ' ILE . 56.4 m-85 . . . . . 0 N--CA 1.428 -1.554 0 N-CA-C 116.131 1.901 . . . . 0.0 116.131 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.36 149.15 54.32 Favored Pre-proline 0 N--CA 1.423 -1.808 0 CA-C-N 113.166 -1.834 . . . . 0.0 106.71 179.694 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -58.56 130.44 37.31 Favored 'Trans proline' 0 C--O 1.236 0.41 0 C-N-CA 122.008 1.805 . . . . 0.0 109.97 173.688 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 104.72 -16.58 47.34 Favored Glycine 0 N--CA 1.433 -1.528 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.988 -179.357 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -79.59 162.31 25.4 Favored 'General case' 0 C--O 1.25 1.099 0 CA-C-N 117.216 0.508 . . . . 0.0 110.156 -175.917 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.512 HD21 ' HB2' ' A' ' 88' ' ' PRO . 58.0 mt -100.34 122.66 43.48 Favored 'General case' 0 CA--C 1.496 -1.116 0 C-N-CA 122.81 0.444 . . . . 0.0 110.395 -172.676 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -138.37 179.86 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.308 0 CA-C-O 122.5 1.143 . . . . 0.0 113.696 -173.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.574 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 61.0 m-85 -113.76 130.06 56.5 Favored 'General case' 0 C--N 1.283 -2.321 0 CA-C-N 113.775 -1.557 . . . . 0.0 107.684 170.671 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.434 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -107.7 118.23 36.19 Favored 'General case' 0 N--CA 1.398 -3.042 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -176.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.603 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -105.28 122.72 46.53 Favored 'General case' 0 N--CA 1.399 -2.987 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.192 -176.887 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 70.1 mtm -118.33 158.17 25.72 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.237 177.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 59.3 tttm -65.8 116.58 7.13 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.551 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.15 -2.45 65.81 Favored Glycine 0 C--O 1.251 1.159 0 N-CA-C 111.632 -0.587 . . . . 0.0 111.632 179.335 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' TYR . . . . . 0.419 ' HA ' ' HD3' ' A' ' 19' ' ' PRO . 81.5 m-85 -120.9 150.94 54.09 Favored Pre-proline 0 N--CA 1.427 -1.61 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -178.801 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 18' ' ' TYR . 4.9 Cg_exo -77.61 171.09 18.08 Favored 'Trans proline' 0 N--CA 1.44 -1.622 0 C-N-CA 121.815 1.677 . . . . 0.0 109.312 174.654 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' HIS . . . . . 0.496 ' HB3' ' HB3' ' A' ' 12' ' ' PHE . 69.7 m80 -62.01 111.18 1.82 Allowed 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 175.421 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -100.67 137.53 19.88 Favored Pre-proline 0 C--N 1.301 -1.521 0 N-CA-C 109.209 -0.664 . . . . 0.0 109.209 -172.181 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -65.99 118.05 5.17 Favored 'Trans proline' 0 C--O 1.243 0.762 0 C-N-CA 121.561 1.507 . . . . 0.0 110.932 178.234 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.34 166.85 25.09 Favored 'General case' 0 N--CA 1.419 -1.985 0 CA-C-N 116.223 -0.444 . . . . 0.0 109.815 -176.785 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.425 ' HB2' ' CE2' ' A' ' 45' ' ' PHE . 14.2 ttp180 -116.58 147.89 41.43 Favored 'General case' 0 C--N 1.28 -2.415 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.342 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 40.6 t -74.14 123.83 30.29 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.199 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 171.865 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -87.91 169.76 11.73 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 -173.054 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.302 -1.461 0 CA-C-O 121.542 0.687 . . . . 0.0 111.511 -177.394 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.445 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 81.4 mttt . . . . . 0 N--CA 1.424 -1.747 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.442 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 86.8 mt -86.04 144.76 39.43 Favored Pre-proline 0 C--N 1.313 -0.979 0 O-C-N 123.681 0.613 . . . . 0.0 109.863 -176.573 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -73.37 123.97 9.09 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.046 1.831 . . . . 0.0 109.819 175.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 51.1 mm -118.42 125.9 74.68 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.879 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.412 -176.461 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -101.34 113.9 27.4 Favored 'General case' 0 C--N 1.291 -1.971 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 178.03 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -81.02 130.57 35.08 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-O 121.102 0.477 . . . . 0.0 111.861 178.517 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.429 ' CD2' ' HB ' ' A' ' 84' ' ' ILE . 74.1 m-85 -83.73 156.37 22.61 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 176.091 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.456 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 75.59 -20.15 2.31 Favored Glycine 0 C--N 1.314 -0.675 0 CA-C-N 115.922 -0.581 . . . . 0.0 113.957 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 24.7 p -119.08 -23.19 6.92 Favored 'General case' 0 C--N 1.308 -1.232 0 O-C-N 122.383 -0.48 . . . . 0.0 110.084 174.98 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 61.69 27.98 17.22 Favored 'General case' 0 C--N 1.354 0.788 0 CA-C-O 121.712 0.767 . . . . 0.0 111.536 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -85.35 159.9 19.91 Favored 'General case' 0 CA--C 1.491 -1.317 0 CA-C-N 114.043 -1.435 . . . . 0.0 108.783 176.051 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.5 m -130.05 136.72 49.69 Favored 'General case' 0 C--N 1.268 -2.946 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.126 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -140.08 -179.24 5.85 Favored 'General case' 0 C--N 1.284 -2.243 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.688 -176.15 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.442 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 79.6 m-85 -132.21 110.76 10.87 Favored 'General case' 0 CA--C 1.499 -1.011 0 C-N-CA 123.351 0.66 . . . . 0.0 109.464 177.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.434 HD12 ' HB1' ' A' ' 13' ' ' ALA . 95.9 mt -126.53 151.68 47.54 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.445 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -75.9 162.67 52.99 Favored Glycine 0 N--CA 1.416 -2.648 0 C-N-CA 119.968 -1.111 . . . . 0.0 110.677 -176.192 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.438 ' O ' ' HE2' ' A' ' 5' ' ' PHE . 17.9 Cg_endo -62.42 -19.99 69.08 Favored 'Trans proline' 0 C--O 1.191 -1.874 0 C-N-CA 122.237 1.958 . . . . 0.0 111.162 179.177 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.427 ' HE3' ' HA ' ' A' ' 56' ' ' LYS . 0.0 OUTLIER -99.48 -0.4 40.8 Favored 'General case' 0 C--N 1.286 -2.166 0 O-C-N 121.441 -0.787 . . . . 0.0 111.537 178.278 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -89.57 -20.95 23.15 Favored 'General case' 0 CA--C 1.488 -1.41 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 175.434 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.557 HG13 ' CE2' ' A' ' 5' ' ' PHE . 18.4 pt -110.59 157.24 11.41 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.75 0 CA-C-N 114.174 -1.375 . . . . 0.0 110.223 -175.872 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -139.36 147.31 52.23 Favored Pre-proline 0 C--N 1.303 -1.432 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 -177.317 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' PRO . . . . . 0.429 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 38.6 Cg_endo -64.89 129.68 23.94 Favored 'Trans proline' 0 C--O 1.243 0.728 0 C-N-CA 122.657 2.238 . . . . 0.0 113.081 -175.661 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.574 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 82.2 t80 -60.94 -37.12 81.22 Favored 'General case' 0 C--O 1.205 -1.264 0 CA-C-N 115.447 -0.797 . . . . 0.0 111.983 -177.077 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 22.6 t -63.63 -54.05 41.88 Favored 'General case' 0 C--N 1.307 -1.269 0 CA-C-O 120.946 0.403 . . . . 0.0 110.635 -175.332 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.429 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 4.2 mp0 -71.01 -25.84 62.86 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-O 121.376 0.608 . . . . 0.0 112.304 -178.073 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.464 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 28.0 m-80 -105.48 12.67 31.15 Favored 'General case' 0 C--N 1.293 -1.878 0 C-N-CA 120.536 -0.466 . . . . 0.0 111.917 -176.76 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.3 tttp -63.19 -37.87 88.94 Favored 'General case' 0 N--CA 1.479 1.001 0 CA-C-O 121.153 0.502 . . . . 0.0 110.92 -179.544 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 18.2 mm-40 -71.57 -24.01 61.84 Favored 'General case' 0 CA--C 1.488 -1.417 0 CA-C-O 121.831 0.824 . . . . 0.0 112.151 176.823 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.464 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 35.6 mtpt -85.79 -58.47 2.64 Favored 'General case' 0 C--N 1.266 -3.053 0 CA-C-N 114.135 -1.393 . . . . 0.0 111.426 -176.181 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 38.3 m-85 -125.17 0.75 7.84 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.995 -0.548 . . . . 0.0 112.006 -172.831 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -94.29 32.11 6.2 Favored Glycine 0 CA--C 1.496 -1.104 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.236 -175.261 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 50.0 mtmt -130.21 153.93 81.28 Favored Pre-proline 0 C--N 1.301 -1.515 0 C-N-CA 122.808 0.443 . . . . 0.0 110.138 178.787 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_exo -42.68 144.24 1.39 Allowed 'Trans proline' 0 C--N 1.363 1.298 0 C-N-CA 124.583 3.522 . . . . 0.0 117.328 -172.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 -137.13 -166.25 1.89 Allowed 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 105.073 -2.195 . . . . 0.0 105.073 173.894 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 3.5 mmmp? -116.55 2.26 13.02 Favored 'General case' 0 N--CA 1.416 -2.138 0 C-N-CA 119.019 -1.072 . . . . 0.0 113.28 174.863 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 14.2 mmt180 -61.39 128.92 38.68 Favored 'General case' 0 C--N 1.324 -0.539 0 O-C-N 124.167 0.917 . . . . 0.0 109.012 175.189 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.8 tmtm? -68.78 123.55 21.24 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.585 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.456 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 105.91 -25.05 25.14 Favored Glycine 0 N--CA 1.428 -1.884 0 N-CA-C 110.164 -1.175 . . . . 0.0 110.164 -177.893 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.6 t80 -76.6 -44.78 32.98 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -60.82 -50.04 75.06 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.61 178.337 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -68.16 -40.59 82.28 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.314 -178.426 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -72.24 -30.89 64.37 Favored Glycine 0 CA--C 1.489 -1.531 0 CA-C-N 115.646 -0.707 . . . . 0.0 112.955 -177.204 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 44.0 tp -62.39 -35.51 79.43 Favored 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.086 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.7 t90 -70.57 -48.61 54.47 Favored 'General case' 0 N--CA 1.425 -1.721 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.95 177.416 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -54.82 -51.35 66.1 Favored 'General case' 0 C--O 1.202 -1.447 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -179.382 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.429 ' HB ' ' CD2' ' A' ' 45' ' ' PHE . 17.6 tt -68.13 -24.01 29.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 112.223 0.453 . . . . 0.0 112.223 -175.329 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 6.3 t0 -94.61 -21.21 18.97 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-O 121.252 0.549 . . . . 0.0 110.458 -175.109 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -109.83 -56.78 2.27 Favored 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 121.268 0.556 . . . . 0.0 111.603 -178.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -125.17 71.66 63.84 Favored Pre-proline 0 C--N 1.316 -0.886 0 C-N-CA 120.169 -0.612 . . . . 0.0 110.126 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.512 ' HB2' HD21 ' A' ' 10' ' ' LEU . 60.1 Cg_endo -73.13 -6.12 18.37 Favored 'Trans proline' 0 N--CA 1.475 0.389 0 C-N-CA 122.527 2.151 . . . . 0.0 113.46 -174.643 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.3 pttm . . . . . 0 C--N 1.305 -1.333 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.019 -178.451 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 . . . . . 0 N--CA 1.413 -2.276 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -134.65 154.67 79.68 Favored Pre-proline 0 C--N 1.283 -2.324 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.402 -176.53 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -49.6 123.25 10.14 Favored 'Trans proline' 0 C--N 1.35 0.63 0 C-N-CA 123.365 2.71 . . . . 0.0 111.992 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 112.85 -17.49 22.68 Favored Glycine 0 N--CA 1.424 -2.165 0 CA-C-N 115.656 -0.702 . . . . 0.0 112.24 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -75.44 156.84 34.88 Favored 'General case' 0 C--O 1.249 1.041 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -177.129 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.1 mt -106.92 120.49 42.18 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 -174.525 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.438 HG22 ' HA ' ' A' ' 60' ' ' PRO . 2.9 pp -137.01 -179.63 3.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 CA-C-O 122.528 1.156 . . . . 0.0 113.42 -174.236 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.441 ' HB3' ' HB3' ' A' ' 20' ' ' HIS . 33.2 m-85 -113.57 130.52 56.35 Favored 'General case' 0 C--N 1.275 -2.665 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 170.401 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -107.24 116.39 31.85 Favored 'General case' 0 C--N 1.268 -2.952 0 CA-C-N 115.26 -0.882 . . . . 0.0 108.839 -174.895 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.58 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -112.87 120.89 43.02 Favored 'General case' 0 N--CA 1.394 -3.256 0 CA-C-N 114.572 -1.194 . . . . 0.0 108.856 -178.888 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 68.1 mtm -105.64 158.48 16.67 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 179.485 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -65.74 116.42 6.93 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -178.825 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.32 -2.63 63.31 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.726 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -125.13 148.27 59.88 Favored Pre-proline 0 N--CA 1.438 -1.04 0 CA-C-O 120.595 0.236 . . . . 0.0 110.593 -178.131 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -72.24 170.53 18.89 Favored 'Trans proline' 0 N--CA 1.455 -0.789 0 C-N-CA 122.444 2.096 . . . . 0.0 111.747 177.424 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' HIS . . . . . 0.441 ' HB3' ' HB3' ' A' ' 12' ' ' PHE . 90.7 m-70 -67.12 111.69 4.03 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 108.895 -0.779 . . . . 0.0 108.895 178.136 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 13.0 t-105 -109.63 136.03 20.32 Favored Pre-proline 0 C--N 1.314 -0.977 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 -176.743 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -62.08 120.34 7.88 Favored 'Trans proline' 0 C--O 1.244 0.799 0 C-N-CA 122.536 2.157 . . . . 0.0 112.45 -178.591 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -148.1 166.07 28.94 Favored 'General case' 0 N--CA 1.431 -1.38 0 CA-C-O 120.932 0.396 . . . . 0.0 110.806 -177.121 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.478 HH21 ' CG ' ' A' ' 26' ' ' ASP . 12.2 ttp180 -109.85 144.53 38.19 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 178.769 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 68.9 t -73.69 107.25 4.15 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.405 0 N-CA-C 102.709 -3.071 . . . . 0.0 102.709 166.489 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.478 ' CG ' HH21 ' A' ' 24' ' ' ARG . 0.4 OUTLIER -88.64 -178.22 5.75 Favored 'General case' 0 C--N 1.271 -2.808 0 C-N-CA 119.654 -0.818 . . . . 0.0 111.957 -168.241 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 . . . . . 0 C--N 1.285 -2.205 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.956 -173.253 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.449 ' HE2' ' N ' ' A' ' 54' ' ' GLY . 31.6 mtpt . . . . . 0 N--CA 1.425 -1.691 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 79.8 mt -85.74 144.2 39.32 Favored Pre-proline 0 C--N 1.302 -1.499 0 O-C-N 123.212 0.32 . . . . 0.0 110.175 -176.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -71.25 123.91 10.0 Favored 'Trans proline' 0 N--CA 1.457 -0.622 0 C-N-CA 122.046 1.83 . . . . 0.0 109.764 175.962 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.414 HG13 ' HB2' ' A' ' 53' ' ' LEU . 51.4 mm -120.49 122.7 68.77 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 O-C-N 122.165 -0.334 . . . . 0.0 110.265 -176.013 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 88.0 t80 -104.95 114.48 28.71 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 178.842 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -74.9 132.7 41.66 Favored 'General case' 0 C--N 1.319 -0.737 0 O-C-N 123.655 0.597 . . . . 0.0 111.335 179.513 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -90.19 158.1 17.39 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.269 177.586 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.563 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 75.84 -19.9 2.54 Favored Glycine 0 C--N 1.311 -0.852 0 CA-C-N 115.631 -0.713 . . . . 0.0 113.529 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 60.5 p -119.27 -22.68 7.02 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 122.419 -0.46 . . . . 0.0 109.941 175.439 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.1 m170 66.98 25.57 9.3 Favored 'General case' 0 C--N 1.352 0.697 0 C-N-CA 124.12 0.968 . . . . 0.0 111.752 179.434 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -84.42 178.04 7.9 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.329 178.239 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 8.9 m -144.01 147.42 33.85 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.433 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -147.23 -179.79 7.08 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 123.827 0.851 . . . . 0.0 109.776 -178.844 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -133.06 110.82 10.48 Favored 'General case' 0 C--O 1.252 1.235 0 CA-C-O 121.524 0.678 . . . . 0.0 109.353 177.755 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.579 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 96.2 mt -127.86 155.76 43.63 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.354 -176.863 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.449 ' N ' ' HE2' ' A' ' 39' ' ' LYS . . . -94.69 174.47 33.24 Favored Glycine 0 N--CA 1.425 -2.053 0 N-CA-C 110.152 -1.179 . . . . 0.0 110.152 -178.342 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -66.31 -11.04 29.73 Favored 'Trans proline' 0 C--O 1.208 -1.024 0 C-N-CA 122.797 2.332 . . . . 0.0 112.799 -177.218 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 20.7 pttp -97.62 -7.96 29.95 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 122.211 1.005 . . . . 0.0 110.245 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.579 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 65.5 m-20 -100.64 -10.24 21.12 Favored 'General case' 0 C--N 1.287 -2.152 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.577 -176.04 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 12.2 pt -125.23 154.97 33.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.42 -175.154 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -142.49 140.74 19.23 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 179.424 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' PRO . . . . . 0.438 ' HA ' HG22 ' A' ' 11' ' ' ILE . 33.8 Cg_endo -65.64 127.66 18.44 Favored 'Trans proline' 0 C--O 1.243 0.751 0 C-N-CA 122.774 2.316 . . . . 0.0 114.13 -173.73 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 65.2 t80 -62.48 -30.61 71.38 Favored 'General case' 0 CA--C 1.505 -0.774 0 C-N-CA 124.105 0.962 . . . . 0.0 109.437 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.8 m -55.02 -35.48 64.47 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-N 114.908 -1.042 . . . . 0.0 111.88 -179.534 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . 0.284 55.0 mt-10 -85.75 -54.11 4.72 Favored 'General case' 0 CA--C 1.483 -1.618 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 172.048 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.416 ' CG ' ' HE2' ' A' ' 67' ' ' LYS . 31.6 m-80 -67.96 9.87 0.26 Allowed 'General case' 0 CA--C 1.473 -1.991 0 C-N-CA 127.628 2.371 . . . . 0.0 113.867 -164.238 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 55.6 tttp -66.85 -33.8 76.4 Favored 'General case' 0 N--CA 1.394 -3.269 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 174.693 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.727 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -80.43 -33.41 36.94 Favored 'General case' 0 N--CA 1.429 -1.525 0 CA-C-N 115.016 -0.993 . . . . 0.0 113.573 172.86 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.727 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 24.5 mtmm -77.54 -59.47 2.77 Favored 'General case' 0 CA--C 1.503 -0.843 0 N-CA-C 113.169 0.803 . . . . 0.0 113.169 -178.951 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -120.22 6.77 10.72 Favored 'General case' 0 C--N 1.281 -2.391 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.957 -174.333 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.5 11.99 35.96 Favored Glycine 0 CA--C 1.524 0.636 0 CA-C-N 116.29 -0.413 . . . . 0.0 114.087 -177.809 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -97.93 127.11 38.13 Favored Pre-proline 0 N--CA 1.441 -0.902 0 CA-C-N 117.162 0.481 . . . . 0.0 110.083 178.729 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -65.15 128.39 20.44 Favored 'Trans proline' 0 N--CA 1.446 -1.319 0 C-N-CA 122.42 2.08 . . . . 0.0 114.862 -176.05 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -102.35 -157.32 0.6 Allowed 'General case' 0 C--N 1.292 -1.911 0 CA-C-N 113.705 -1.589 . . . . 0.0 108.814 177.839 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.419 ' HA ' ' HD3' ' A' ' 73' ' ' LYS . 43.2 mmtm -108.58 15.39 23.82 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 120.444 -0.503 . . . . 0.0 111.359 -179.43 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 39.5 mmt180 -80.02 121.44 25.5 Favored 'General case' 0 CA--C 1.513 -0.476 0 C-N-CA 117.95 -1.5 . . . . 0.0 108.9 171.904 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 11.0 tppt? -74.06 126.76 31.23 Favored 'General case' 0 N--CA 1.428 -1.551 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.563 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.32 -25.82 18.67 Favored Glycine 0 N--CA 1.424 -2.165 0 N-CA-C 109.114 -1.594 . . . . 0.0 109.114 -173.153 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 6.8 t80 -76.72 -46.97 23.37 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 179.586 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 11.2 m120 -56.51 -52.53 64.41 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-N 114.944 -1.025 . . . . 0.0 109.009 178.124 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 21.7 mp0 -61.37 -40.91 96.05 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 113.793 -1.549 . . . . 0.0 110.297 -178.704 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -67.19 -37.66 91.4 Favored Glycine 0 N--CA 1.437 -1.242 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.562 -179.558 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 90.7 mt -60.82 -34.67 74.89 Favored 'General case' 0 CA--C 1.509 -0.629 0 N-CA-C 110.224 -0.288 . . . . 0.0 110.224 176.369 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 84.9 t90 -71.7 -50.96 25.57 Favored 'General case' 0 N--CA 1.432 -1.33 0 O-C-N 123.589 0.555 . . . . 0.0 109.557 177.244 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -56.1 -50.78 70.09 Favored 'General case' 0 C--O 1.202 -1.409 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -178.528 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.3 tt -66.78 -25.87 35.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 112.486 0.55 . . . . 0.0 112.486 -174.743 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -93.29 -19.43 21.39 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-O 121.591 0.71 . . . . 0.0 110.621 -173.896 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.9 m-80 -114.04 -56.29 2.41 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.362 -177.035 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.521 ' OD1' ' HG2' ' A' ' 89' ' ' LYS . 65.3 t30 -128.42 75.51 79.18 Favored Pre-proline 0 C--N 1.311 -1.095 0 C-N-CA 119.831 -0.748 . . . . 0.0 111.22 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -69.73 -6.3 18.25 Favored 'Trans proline' 0 N--CA 1.481 0.736 0 C-N-CA 122.704 2.269 . . . . 0.0 113.481 -176.761 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' LYS . . . . . 0.521 ' HG2' ' OD1' ' A' ' 87' ' ' ASN . 9.5 ptpp? . . . . . 0 C--N 1.316 -0.889 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -176.776 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' PHE . . . . . 0.401 ' CE2' HG13 ' A' ' 58' ' ' ILE . 88.8 m-85 . . . . . 0 N--CA 1.439 -0.987 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 9.2 pttp -135.13 166.72 26.94 Favored Pre-proline 0 N--CA 1.43 -1.455 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 177.31 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -59.44 149.34 82.21 Favored 'Trans proline' 0 C--O 1.265 1.87 0 C-N-CA 122.052 1.834 . . . . 0.0 112.451 175.47 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 98.51 -14.24 62.2 Favored Glycine 0 N--CA 1.434 -1.439 0 CA-C-N 115.683 -0.689 . . . . 0.0 113.36 176.7 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -84.22 154.76 22.85 Favored 'General case' 0 C--O 1.242 0.695 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 -177.217 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.45 ' HB3' HD11 ' A' ' 84' ' ' ILE . 83.2 mt -99.54 128.68 45.66 Favored 'General case' 0 CA--C 1.498 -1.03 0 CA-C-N 114.888 -1.051 . . . . 0.0 109.163 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -141.62 -178.62 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-O 122.131 0.967 . . . . 0.0 112.418 -175.15 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 48.1 m-85 -112.84 129.77 56.33 Favored 'General case' 0 C--N 1.279 -2.464 0 N-CA-C 106.508 -1.664 . . . . 0.0 106.508 170.836 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.45 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -107.49 132.23 53.45 Favored 'General case' 0 C--N 1.275 -2.658 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -176.072 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.507 ' C ' ' HD3' ' A' ' 14' ' ' LYS . 7.3 tmtm? -113.79 117.26 30.98 Favored 'General case' 0 N--CA 1.41 -2.434 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.877 -177.103 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 54.9 mtm -114.41 158.69 21.19 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.724 173.691 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 39.5 ttpt -62.5 118.72 7.94 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 176.595 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.33 -12.86 68.64 Favored Glycine 0 C--O 1.243 0.716 0 C-N-CA 121.034 -0.603 . . . . 0.0 111.65 -178.881 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -106.62 151.31 40.39 Favored Pre-proline 0 C--O 1.256 1.446 0 C-N-CA 122.811 0.444 . . . . 0.0 111.137 -179.343 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -82.27 172.41 11.68 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 C-N-CA 123.435 2.757 . . . . 0.0 108.91 173.499 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -65.94 110.47 2.91 Favored 'General case' 0 C--N 1.31 -1.117 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 175.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -104.37 138.24 19.46 Favored Pre-proline 0 C--N 1.303 -1.439 0 CA-C-N 115.318 -0.856 . . . . 0.0 108.909 -171.76 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -68.01 117.59 5.02 Favored 'Trans proline' 0 N--CA 1.451 -1.003 0 C-N-CA 121.484 1.456 . . . . 0.0 109.867 177.042 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -145.28 167.05 23.78 Favored 'General case' 0 N--CA 1.415 -2.2 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 -176.145 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.564 ' HB3' ' CE2' ' A' ' 45' ' ' PHE . 8.1 ptt85 -123.53 155.89 36.7 Favored 'General case' 0 C--N 1.281 -2.375 0 C-N-CA 119.149 -1.02 . . . . 0.0 109.356 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.7 t -86.32 117.7 31.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 N-CA-C 106.002 -1.851 . . . . 0.0 106.002 174.187 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -91.73 176.08 6.66 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -175.272 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 11.8 mp0 . . . . . 0 N--CA 1.421 -1.912 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.949 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.618 ' HE3' ' HA ' ' A' ' 53' ' ' LEU . 22.0 mtpp . . . . . 0 N--CA 1.416 -2.139 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 73.3 mt -99.38 155.12 36.87 Favored Pre-proline 0 C--N 1.299 -1.601 0 C-N-CA 123.189 0.596 . . . . 0.0 109.65 -174.515 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -74.64 121.92 7.03 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 121.158 1.239 . . . . 0.0 109.399 174.804 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.51 HG13 ' HB2' ' A' ' 53' ' ' LEU . 49.8 mm -115.39 118.65 59.47 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 CA-C-O 120.898 0.38 . . . . 0.0 110.393 -176.407 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.498 ' CE1' ' HA ' ' A' ' 48' ' ' HIS . 58.3 t80 -97.74 116.27 29.63 Favored 'General case' 0 C--N 1.283 -2.303 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.342 179.147 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.421 ' CE2' ' HB2' ' A' ' 51' ' ' ALA . 73.3 m-85 -77.75 130.72 37.1 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-O 121.055 0.455 . . . . 0.0 111.669 177.775 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.564 ' CE2' ' HB3' ' A' ' 24' ' ' ARG . 59.6 m-85 -81.89 150.08 27.95 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.65 176.198 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.479 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 82.01 -20.59 7.94 Favored Glycine 0 C--N 1.313 -0.749 0 C-N-CA 123.875 0.75 . . . . 0.0 114.394 177.909 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 41.3 p -119.56 -22.49 6.93 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 117.521 0.661 . . . . 0.0 110.316 174.331 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' HIS . . . . . 0.498 ' HA ' ' CE1' ' A' ' 43' ' ' PHE . 11.5 m-70 69.03 19.42 8.11 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 123.655 0.782 . . . . 0.0 111.899 -178.308 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -77.29 177.15 8.15 Favored 'General case' 0 N--CA 1.446 -0.638 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.262 177.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.9 m -142.41 144.83 33.28 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 109.675 -0.491 . . . . 0.0 109.675 -179.031 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.421 ' HB2' ' CE2' ' A' ' 44' ' ' PHE . . . -137.98 171.76 13.93 Favored 'General case' 0 C--N 1.29 -1.984 0 CA-C-N 115.397 -0.819 . . . . 0.0 109.516 178.536 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -124.62 108.4 12.02 Favored 'General case' 0 CA--C 1.482 -1.659 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 174.759 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.618 ' HA ' ' HE3' ' A' ' 39' ' ' LYS . 94.5 mt -134.85 139.83 45.35 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 -178.892 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.496 ' HA2' ' HA ' ' A' ' 39' ' ' LYS . . . -87.78 177.95 46.8 Favored Glycine 0 N--CA 1.415 -2.717 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -175.245 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -67.21 -10.94 30.37 Favored 'Trans proline' 0 C--N 1.319 -0.977 0 C-N-CA 122.445 2.096 . . . . 0.0 112.589 -177.161 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 30.7 mmtm -100.07 -8.14 24.13 Favored 'General case' 0 C--N 1.305 -1.361 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 175.401 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.569 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 4.3 m-20 -98.15 -12.62 21.56 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-O 121.853 0.835 . . . . 0.0 108.771 -178.262 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.401 HG13 ' CE2' ' A' ' 5' ' ' PHE . 15.1 pt -112.63 157.71 13.27 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.231 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.941 -177.738 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 -130.93 144.87 55.3 Favored Pre-proline 0 C--N 1.298 -1.647 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 -177.267 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' PRO . . . . . 0.453 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 42.4 Cg_endo -66.04 127.93 18.64 Favored 'Trans proline' 0 CA--C 1.503 -1.034 0 C-N-CA 122.475 2.117 . . . . 0.0 112.949 -177.483 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 85.3 t80 -61.68 -36.91 82.23 Favored 'General case' 0 C--O 1.206 -1.224 0 CA-C-N 114.816 -1.084 . . . . 0.0 112.149 -176.411 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.418 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 14.0 m -65.85 -50.09 65.82 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-O 121.144 0.497 . . . . 0.0 110.92 -175.707 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.453 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 3.1 mp0 -79.21 -5.25 53.84 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.656 -0.702 . . . . 0.0 112.533 -177.055 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.443 ' OD1' ' HD2' ' A' ' 67' ' ' LYS . 33.3 m-80 -125.45 12.5 8.11 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 120.591 -0.444 . . . . 0.0 112.089 178.364 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 62.9 tttp -70.92 -32.22 69.08 Favored 'General case' 0 N--CA 1.479 1.02 0 CA-C-O 122.03 0.919 . . . . 0.0 110.25 -179.344 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.639 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -74.82 -30.37 61.36 Favored 'General case' 0 N--CA 1.404 -2.772 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.649 175.981 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.639 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 49.3 mttp -80.14 -56.73 4.02 Favored 'General case' 0 CA--C 1.505 -0.766 0 CA-C-N 115.626 -0.715 . . . . 0.0 112.584 -178.267 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 54.5 m-85 -114.24 7.19 16.46 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.471 0.653 . . . . 0.0 111.837 -172.878 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -91.46 51.98 3.05 Favored Glycine 0 C--N 1.294 -1.755 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.637 -176.232 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.64 141.94 41.98 Favored Pre-proline 0 C--N 1.293 -1.866 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 175.509 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -65.67 126.91 16.89 Favored 'Trans proline' 0 N--CA 1.445 -1.345 0 C-N-CA 121.297 1.331 . . . . 0.0 114.425 -173.311 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -83.91 -173.0 4.47 Favored 'General case' 0 CA--C 1.484 -1.589 0 CA-C-N 114.078 -1.419 . . . . 0.0 109.059 178.819 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.532 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 1.1 mptp? -107.4 20.75 18.49 Favored 'General case' 0 C--N 1.282 -2.355 0 CA-C-O 122.664 1.221 . . . . 0.0 108.003 172.899 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 13.7 mmt180 -87.12 121.09 29.1 Favored 'General case' 0 N--CA 1.436 -1.172 0 CA-C-N 113.504 -1.68 . . . . 0.0 107.174 173.539 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 28.2 tptp -60.76 124.13 19.52 Favored 'General case' 0 C--N 1.311 -1.087 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 177.307 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.479 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.21 -25.13 21.1 Favored Glycine 0 N--CA 1.437 -1.256 0 N-CA-C 111.452 -0.659 . . . . 0.0 111.452 -179.246 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 15.2 t80 -74.53 -36.02 63.14 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-O 121.337 0.589 . . . . 0.0 109.837 -176.687 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -74.77 -41.98 59.03 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -175.836 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -67.9 -34.69 77.13 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 114.336 -1.302 . . . . 0.0 109.452 178.586 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -66.64 -35.0 89.22 Favored Glycine 0 CA--C 1.493 -1.285 0 CA-C-N 115.659 -0.7 . . . . 0.0 112.167 178.227 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 87.8 mt -63.65 -35.28 80.01 Favored 'General case' 0 C--O 1.215 -0.723 0 CA-C-O 121.035 0.445 . . . . 0.0 109.845 175.101 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 86.2 t90 -67.43 -49.06 65.36 Favored 'General case' 0 N--CA 1.429 -1.507 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 177.171 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -58.25 -45.44 87.81 Favored 'General case' 0 C--O 1.208 -1.094 0 N-CA-C 113.221 0.822 . . . . 0.0 113.221 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.45 HD11 ' HB3' ' A' ' 10' ' ' LEU . 19.9 tt -73.18 -29.48 28.49 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -173.881 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -87.23 -18.47 30.22 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 31.8 m-80 -111.63 -54.4 2.61 Favored 'General case' 0 CA--C 1.503 -0.836 0 CA-C-O 121.273 0.559 . . . . 0.0 112.161 -176.344 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.5 t30 -128.56 72.47 80.73 Favored Pre-proline 0 C--N 1.306 -1.316 0 C-N-CA 119.765 -0.774 . . . . 0.0 110.724 -179.218 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -72.85 -5.82 17.89 Favored 'Trans proline' 0 N--CA 1.478 0.582 0 C-N-CA 122.597 2.198 . . . . 0.0 113.447 -175.807 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.2 pttm . . . . . 0 C--N 1.307 -1.256 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.908 -178.602 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 . . . . . 0 N--CA 1.433 -1.303 0 CA-C-O 121.327 0.584 . . . . 0.0 110.945 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 24.1 mtmm -119.55 155.97 53.84 Favored Pre-proline 0 C--N 1.291 -1.975 0 CA-C-N 114.703 -1.135 . . . . 0.0 108.013 -178.446 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -55.04 120.76 8.72 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 121.723 1.615 . . . . 0.0 109.497 174.063 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 115.94 -24.4 10.15 Favored Glycine 0 N--CA 1.432 -1.573 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.38 -175.472 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -62.03 123.69 18.79 Favored 'General case' 0 C--O 1.25 1.102 0 CA-C-N 117.494 0.647 . . . . 0.0 110.74 177.476 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.422 HD23 ' HG3' ' A' ' 24' ' ' ARG . 85.2 mt -79.93 124.26 28.51 Favored 'General case' 0 CA--C 1.483 -1.601 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 177.316 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 9.3 pt -141.07 -175.12 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.036 0 CA-C-O 122.592 1.187 . . . . 0.0 112.792 -172.839 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.523 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 60.8 m-85 -122.24 130.35 53.09 Favored 'General case' 0 N--CA 1.405 -2.686 0 CA-C-N 113.42 -1.718 . . . . 0.0 106.56 170.706 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.473 ' HB2' HG21 ' A' ' 42' ' ' ILE . . . -108.8 124.25 50.31 Favored 'General case' 0 C--N 1.275 -2.651 0 O-C-N 123.931 0.769 . . . . 0.0 109.494 -177.711 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.525 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.9 OUTLIER -108.46 126.69 53.18 Favored 'General case' 0 C--N 1.272 -2.781 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.228 -177.462 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 63.5 mtm -125.59 157.75 36.37 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.682 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 1.3 ttpm? -61.34 115.95 4.25 Favored 'General case' 0 C--O 1.247 0.971 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.903 179.134 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.63 -5.68 64.62 Favored Glycine 0 C--O 1.251 1.165 0 O-C-N 123.506 0.504 . . . . 0.0 112.094 178.241 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 88.8 m-85 -120.81 151.02 54.04 Favored Pre-proline 0 N--CA 1.426 -1.656 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -177.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.18 171.09 17.62 Favored 'Trans proline' 0 N--CA 1.443 -1.495 0 C-N-CA 121.676 1.584 . . . . 0.0 109.082 174.705 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' HIS . . . . . 0.477 ' HB3' ' HB3' ' A' ' 12' ' ' PHE . 86.3 m-70 -61.22 110.41 1.39 Allowed 'General case' 0 CA--C 1.549 0.941 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 175.947 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -99.34 138.39 20.51 Favored Pre-proline 0 C--N 1.31 -1.132 0 C-N-CA 123.377 0.671 . . . . 0.0 109.874 -171.071 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo -60.72 118.2 5.05 Favored 'Trans proline' 0 C--O 1.245 0.861 0 C-N-CA 121.746 1.631 . . . . 0.0 110.709 177.25 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.8 167.19 22.87 Favored 'General case' 0 N--CA 1.413 -2.309 0 CA-C-O 120.898 0.38 . . . . 0.0 110.309 -176.481 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.422 ' HG3' HD23 ' A' ' 10' ' ' LEU . 24.4 ttp-105 -125.81 147.04 49.54 Favored 'General case' 0 C--N 1.288 -2.083 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 175.346 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 48.1 t -72.78 119.04 18.85 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 N-CA-C 105.714 -1.958 . . . . 0.0 105.714 171.62 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -90.31 -177.5 5.12 Favored 'General case' 0 C--N 1.307 -1.247 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -175.754 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 . . . . . 0 C--N 1.282 -2.341 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -175.685 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 90.4 mttt . . . . . 0 N--CA 1.423 -1.81 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 87.9 mt -99.96 141.23 22.38 Favored Pre-proline 0 C--N 1.291 -1.946 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.268 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -71.72 123.4 9.37 Favored 'Trans proline' 0 N--CA 1.454 -0.824 0 C-N-CA 122.037 1.824 . . . . 0.0 109.852 176.607 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.473 HG21 ' HB2' ' A' ' 13' ' ' ALA . 42.4 mm -118.08 120.76 65.47 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 CA-C-N 116.196 -0.457 . . . . 0.0 109.837 -175.542 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 66.1 t80 -97.92 120.1 37.71 Favored 'General case' 0 C--N 1.281 -2.383 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -85.2 131.46 34.43 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.257 0.551 . . . . 0.0 111.972 178.28 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -84.96 155.04 21.79 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.712 176.394 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.571 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 79.22 -19.57 5.47 Favored Glycine 0 C--N 1.314 -0.669 0 C-N-CA 123.257 0.456 . . . . 0.0 113.418 179.11 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 16.3 p -118.61 -23.13 7.2 Favored 'General case' 0 C--N 1.307 -1.26 0 O-C-N 122.561 -0.376 . . . . 0.0 110.215 175.817 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.7 m170 67.46 19.19 10.06 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 123.509 0.724 . . . . 0.0 111.768 -179.237 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 19.2 mm-40 -87.65 168.27 13.16 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.205 179.59 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.7 m -134.55 142.5 46.99 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 121.067 0.46 . . . . 0.0 109.769 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -139.05 179.66 6.37 Favored 'General case' 0 C--N 1.293 -1.891 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.201 -178.441 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -134.13 117.39 16.52 Favored 'General case' 0 C--O 1.262 1.726 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.679 177.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 94.8 mt -129.5 174.56 9.53 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.17 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.37 164.94 21.34 Favored Glycine 0 N--CA 1.417 -2.597 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.16 -5.4 13.62 Favored 'Trans proline' 0 C--O 1.249 1.074 0 C-N-CA 123.752 2.968 . . . . 0.0 112.905 -178.179 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 23.0 pttm -97.57 -19.78 18.12 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.009 178.366 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -96.83 0.37 49.18 Favored 'General case' 0 CA--C 1.5 -0.943 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.598 -173.789 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.2 pt -123.43 144.78 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.995 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.725 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -130.55 147.13 64.74 Favored Pre-proline 0 C--N 1.289 -2.037 0 CA-C-N 114.631 -1.168 . . . . 0.0 108.006 -177.668 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -66.74 132.49 28.79 Favored 'Trans proline' 0 C--N 1.328 -0.548 0 C-N-CA 122.474 2.116 . . . . 0.0 112.558 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.523 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 53.4 t80 -64.0 -37.79 88.72 Favored 'General case' 0 C--O 1.201 -1.488 0 CA-C-N 114.939 -1.028 . . . . 0.0 112.25 -176.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -62.76 -54.35 40.49 Favored 'General case' 0 C--N 1.292 -1.92 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -176.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 3.6 mp0 -71.58 -26.23 62.52 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-O 121.71 0.766 . . . . 0.0 111.23 -178.266 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.466 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 29.9 m-80 -106.82 10.12 30.79 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -175.45 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -65.44 -31.27 72.26 Favored 'General case' 0 N--CA 1.483 1.195 0 CA-C-O 121.354 0.597 . . . . 0.0 111.898 -178.117 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.525 ' HA ' ' NZ ' ' A' ' 70' ' ' LYS . 55.5 mm-40 -75.97 -28.92 58.05 Favored 'General case' 0 C--N 1.285 -2.211 0 C-N-CA 119.391 -0.924 . . . . 0.0 111.842 178.277 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.466 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 33.2 mtpt -78.04 -59.26 2.85 Favored 'General case' 0 C--N 1.281 -2.407 0 CA-C-N 113.963 -1.471 . . . . 0.0 111.052 -176.769 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.449 ' CD2' ' HB3' ' A' ' 64' ' ' ASN . 19.9 m-85 -109.96 -9.47 14.76 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.384 -171.229 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -86.0 47.62 3.81 Favored Glycine 0 C--N 1.311 -0.857 0 N-CA-C 111.291 -0.724 . . . . 0.0 111.291 -178.716 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.525 ' NZ ' ' HA ' ' A' ' 66' ' ' GLU . 47.7 mmtm -127.91 147.77 64.43 Favored Pre-proline 0 C--N 1.307 -1.263 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.532 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.479 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 77.4 Cg_exo -48.01 128.94 17.4 Favored 'Trans proline' 0 C--N 1.363 1.318 0 C-N-CA 123.662 2.908 . . . . 0.0 114.782 -176.225 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.46 ' HB2' ' CD1' ' A' ' 77' ' ' PHE . 1.9 t-20 -112.22 -165.48 1.0 Allowed 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 114.747 -1.115 . . . . 0.0 109.559 -175.449 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 38.6 mmtm -121.53 12.68 10.82 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.686 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 24.2 mmt180 -93.9 128.39 40.17 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 114.874 -1.057 . . . . 0.0 109.712 174.582 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 28.1 tptp -68.89 122.5 18.75 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 177.18 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.571 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 107.14 -20.83 32.48 Favored Glycine 0 N--CA 1.438 -1.189 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 -179.254 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.46 ' CD1' ' HB2' ' A' ' 72' ' ' ASN . 35.6 t80 -75.2 -44.1 48.28 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-O 121.61 0.719 . . . . 0.0 109.701 -177.069 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.479 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 92.8 m-20 -76.38 -35.07 58.85 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 114.893 -1.048 . . . . 0.0 110.63 -174.112 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -70.12 -35.5 74.15 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.183 -1.044 . . . . 0.0 108.183 174.913 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -65.75 -35.63 91.22 Favored Glycine 0 N--CA 1.435 -1.413 0 CA-C-N 115.112 -0.949 . . . . 0.0 111.968 177.697 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.439 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 95.8 mt -56.16 -38.32 70.73 Favored 'General case' 0 C--O 1.219 -0.52 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 175.589 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 73.0 t90 -74.19 -49.08 25.07 Favored 'General case' 0 N--CA 1.426 -1.635 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.417 178.691 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -57.0 -46.82 82.02 Favored 'General case' 0 C--O 1.203 -1.343 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.251 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.8 tt -70.18 -24.57 26.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 120.628 -0.429 . . . . 0.0 112.033 -175.219 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -93.52 -19.69 20.98 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.058 0.456 . . . . 0.0 110.141 -175.053 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -111.56 -54.34 2.62 Favored 'General case' 0 N--CA 1.483 1.198 0 CA-C-O 121.351 0.596 . . . . 0.0 111.863 -179.286 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.1 t30 -126.24 71.98 71.12 Favored Pre-proline 0 C--N 1.312 -1.065 0 O-C-N 121.999 -0.438 . . . . 0.0 110.93 -177.715 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -73.2 -6.49 19.0 Favored 'Trans proline' 0 CA--C 1.53 0.309 0 C-N-CA 122.242 1.961 . . . . 0.0 113.232 -175.819 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.4 pttm . . . . . 0 C--N 1.313 -1.018 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.973 -176.306 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 . . . . . 0 N--CA 1.439 -0.998 0 CA-C-O 120.753 0.311 . . . . 0.0 110.438 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.527 ' O ' ' HB2' ' A' ' 9' ' ' ASP . 47.9 mmtm -111.51 155.62 42.64 Favored Pre-proline 0 C--N 1.304 -1.392 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 -178.59 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_exo -58.33 121.46 10.02 Favored 'Trans proline' 0 C--O 1.237 0.46 0 C-N-CA 121.78 1.653 . . . . 0.0 108.448 171.105 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . 0.582 ' HA2' ' NH1' ' A' ' 24' ' ' ARG . . . 108.72 -11.95 35.31 Favored Glycine 0 N--CA 1.425 -2.034 0 C-N-CA 120.55 -0.834 . . . . 0.0 112.449 -176.505 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.527 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 0.8 OUTLIER -64.39 133.51 52.73 Favored 'General case' 0 C--O 1.252 1.202 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -178.025 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 78.8 mt -89.27 119.97 30.22 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.419 ' HA ' ' HA ' ' A' ' 60' ' ' PRO . 7.5 pt -139.03 -173.54 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.841 0 CA-C-O 122.753 1.263 . . . . 0.0 112.956 -172.037 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.622 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 84.2 m-85 -127.48 125.41 40.42 Favored 'General case' 0 N--CA 1.403 -2.809 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 171.861 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.521 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -113.43 134.45 54.65 Favored 'General case' 0 C--N 1.266 -3.024 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.617 -176.573 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.638 ' HB2' ' CD2' ' A' ' 20' ' ' HIS . 0.0 OUTLIER -109.04 121.15 44.53 Favored 'General case' 0 N--CA 1.408 -2.532 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.396 -178.616 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 71.5 mtm -112.18 158.88 19.14 Favored 'General case' 0 C--N 1.315 -0.934 0 C-N-CA 123.587 0.755 . . . . 0.0 109.24 176.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 24.9 ttmm -66.18 117.41 8.45 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.106 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.38 -7.07 56.06 Favored Glycine 0 C--O 1.246 0.875 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -178.639 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 65.2 m-85 -123.21 148.15 54.01 Favored Pre-proline 0 N--CA 1.435 -1.222 0 C-N-CA 122.994 0.518 . . . . 0.0 110.684 179.206 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -79.34 171.6 15.81 Favored 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 122.116 1.877 . . . . 0.0 108.28 170.83 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' HIS . . . . . 0.638 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 78.9 m80 -58.16 111.19 1.11 Allowed 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 175.774 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' TRP . . . . . 0.42 ' O ' ' HA ' ' A' ' 12' ' ' PHE . 11.5 t-105 -111.74 141.69 25.2 Favored Pre-proline 0 C--N 1.302 -1.46 0 C-N-CA 123.561 0.744 . . . . 0.0 109.343 -170.526 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.424 ' HD3' ' CE2' ' A' ' 77' ' ' PHE . 26.3 Cg_exo -57.76 118.71 5.63 Favored 'Trans proline' 0 C--N 1.36 1.14 0 C-N-CA 122.274 1.983 . . . . 0.0 110.994 178.328 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -145.53 167.34 23.25 Favored 'General case' 0 N--CA 1.407 -2.584 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 -177.617 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.582 ' NH1' ' HA2' ' A' ' 8' ' ' GLY . 32.7 ttp85 -123.23 144.52 49.34 Favored 'General case' 0 C--N 1.276 -2.589 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 177.648 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 58.7 t -74.58 113.74 13.53 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.99 0 N-CA-C 104.793 -2.299 . . . . 0.0 104.793 170.749 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -86.88 -176.01 5.6 Favored 'General case' 0 C--N 1.29 -2.015 0 O-C-N 123.554 0.534 . . . . 0.0 111.084 -172.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 33.6 mm-40 . . . . . 0 C--N 1.3 -1.584 0 CA-C-O 121.622 0.725 . . . . 0.0 109.81 -173.209 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.423 ' HB3' ' O ' ' A' ' 53' ' ' LEU . 62.4 mttp . . . . . 0 N--CA 1.433 -1.322 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.435 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 95.8 mt -90.84 139.69 26.14 Favored Pre-proline 0 C--N 1.297 -1.709 0 O-C-N 123.894 0.746 . . . . 0.0 110.134 -177.632 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -71.38 123.22 9.35 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.262 1.974 . . . . 0.0 109.779 176.813 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.423 HG21 ' CB ' ' A' ' 13' ' ' ALA . 39.7 mm -122.17 121.59 64.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.932 -0.48 . . . . 0.0 109.993 -176.951 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -106.35 118.96 38.01 Favored 'General case' 0 C--N 1.29 -2.001 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 178.06 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 73.6 m-85 -82.32 136.07 35.08 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -179.408 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -85.58 148.85 25.73 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.9 178.334 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.458 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 78.94 -21.08 4.16 Favored Glycine 0 C--N 1.308 -1.019 0 C-N-CA 123.72 0.676 . . . . 0.0 114.168 176.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 30.7 p -119.74 -22.46 6.85 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 117.523 0.662 . . . . 0.0 110.674 174.802 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.4 m-70 67.01 21.9 10.15 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 123.649 0.779 . . . . 0.0 111.563 -178.793 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.8 mt-10 -72.42 163.61 27.71 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.064 175.821 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.7 m -136.87 140.05 42.1 Favored 'General case' 0 C--N 1.275 -2.645 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.346 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -141.05 176.07 9.11 Favored 'General case' 0 C--N 1.286 -2.18 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.273 -179.668 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.435 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 97.7 m-85 -133.98 111.07 10.11 Favored 'General case' 0 N--CA 1.431 -1.423 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 174.52 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.521 HD12 ' HB1' ' A' ' 13' ' ' ALA . 85.9 mt -125.69 170.42 11.55 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -177.527 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -95.08 167.17 26.35 Favored Glycine 0 N--CA 1.42 -2.398 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 178.166 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -66.38 -6.85 15.96 Favored 'Trans proline' 0 N--CA 1.484 0.923 0 C-N-CA 123.357 2.705 . . . . 0.0 112.743 -177.793 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.9 ptmm? -92.37 -19.88 21.64 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.725 178.738 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -102.45 5.05 39.38 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-O 121.281 0.562 . . . . 0.0 111.623 -174.864 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.9 pt -125.22 147.53 29.87 Favored 'Isoleucine or valine' 0 C--O 1.266 1.954 0 CA-C-N 114.653 -1.158 . . . . 0.0 110.372 178.791 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' PHE . . . . . 0.42 ' HB3' ' ND2' ' A' ' 64' ' ' ASN . 88.8 m-85 -136.37 133.11 19.17 Favored Pre-proline 0 C--N 1.289 -2.035 0 CA-C-N 114.686 -1.143 . . . . 0.0 108.355 -179.543 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' PRO . . . . . 0.419 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 22.5 Cg_endo -68.3 144.06 60.83 Favored 'Trans proline' 0 CA--C 1.499 -1.264 0 C-N-CA 122.971 2.447 . . . . 0.0 114.04 -177.397 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.622 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 83.9 t80 -58.88 -38.26 78.42 Favored 'General case' 0 C--O 1.203 -1.377 0 CA-C-N 114.305 -1.316 . . . . 0.0 110.579 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.48 -47.57 83.38 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 113.744 1.016 . . . . 0.0 113.744 -175.947 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -93.33 -8.27 42.46 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-O 121.357 0.599 . . . . 0.0 111.597 -177.395 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.445 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 24.0 m-80 -124.91 14.12 8.53 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -175.164 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -63.37 -37.78 88.61 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 10.4 mp0 -66.08 -34.68 78.62 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 122.796 1.284 . . . . 0.0 109.326 177.127 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.445 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 35.4 mtpt -75.48 -59.55 2.7 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-N 113.396 -1.729 . . . . 0.0 112.008 -174.555 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.43 ' CD2' ' HB3' ' A' ' 64' ' ' ASN . 18.5 m-85 -115.11 -15.4 11.7 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.982 -171.068 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.77 10.77 30.19 Favored Glycine 0 N--CA 1.472 1.042 0 CA-C-O 121.213 0.341 . . . . 0.0 113.207 -175.226 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 23.2 pttm -93.04 149.9 38.32 Favored Pre-proline 0 C--N 1.298 -1.671 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -66.91 128.19 18.33 Favored 'Trans proline' 0 N--CA 1.441 -1.56 0 C-N-CA 120.845 1.03 . . . . 0.0 112.287 178.069 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 41.4 m-80 -113.19 -173.41 2.25 Favored 'General case' 0 C--N 1.295 -1.795 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 47.4 mmtm -96.75 15.87 20.72 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-O 121.238 0.542 . . . . 0.0 112.269 -176.066 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -87.94 120.94 29.77 Favored 'General case' 0 C--N 1.309 -1.187 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 174.352 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.4 tppt? -74.71 130.43 39.49 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 177.111 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.458 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.24 -25.78 18.96 Favored Glycine 0 N--CA 1.435 -1.381 0 N-CA-C 108.819 -1.712 . . . . 0.0 108.819 -174.053 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.424 ' CE2' ' HD3' ' A' ' 22' ' ' PRO . 11.2 t80 -76.79 -44.71 31.71 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.749 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 10.0 m120 -60.25 -47.89 84.07 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 22.2 mp0 -63.5 -37.06 85.85 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 113.778 -1.555 . . . . 0.0 110.194 179.341 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -67.55 -34.56 84.5 Favored Glycine 0 N--CA 1.442 -0.924 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.309 177.437 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 95.5 mt -62.78 -33.95 76.24 Favored 'General case' 0 C--O 1.216 -0.694 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 175.39 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 69.8 t90 -71.62 -49.44 40.12 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.624 175.24 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -60.43 -34.69 74.34 Favored 'General case' 0 C--O 1.21 -0.98 0 N-CA-C 113.882 1.067 . . . . 0.0 113.882 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.6 tt -72.77 -21.41 19.59 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-O 121.214 0.531 . . . . 0.0 110.3 -176.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -89.92 -46.74 8.33 Favored 'General case' 0 N--CA 1.435 -1.211 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.719 -178.62 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -86.92 -35.88 18.67 Favored 'General case' 0 C--O 1.252 1.227 0 CA-C-O 121.63 0.728 . . . . 0.0 111.843 -173.766 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -134.08 63.6 62.6 Favored Pre-proline 0 C--N 1.298 -1.669 0 C-N-CA 118.892 -1.123 . . . . 0.0 112.873 -179.58 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -72.04 -5.74 17.71 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 122.791 2.327 . . . . 0.0 110.838 177.955 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' LYS . . . . . 0.418 ' HG2' ' H ' ' A' ' 89' ' ' LYS . 16.5 pttp . . . . . 0 C--N 1.302 -1.478 0 C-N-CA 125.378 1.471 . . . . 0.0 110.81 -176.807 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 . . . . . 0 N--CA 1.43 -1.452 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 27.5 mtmm -124.31 156.92 66.21 Favored Pre-proline 0 C--N 1.289 -2.059 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 -176.122 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo -51.87 117.62 3.72 Favored 'Trans proline' 0 N--CA 1.461 -0.39 0 C-N-CA 122.17 1.913 . . . . 0.0 110.416 173.683 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.45 -23.55 10.32 Favored Glycine 0 N--CA 1.427 -1.902 0 CA-C-O 119.452 -0.638 . . . . 0.0 112.694 -176.475 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -64.98 123.68 20.08 Favored 'General case' 0 C--O 1.25 1.11 0 CA-C-N 117.573 0.686 . . . . 0.0 110.115 177.213 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.8 mt -80.05 129.48 34.53 Favored 'General case' 0 CA--C 1.49 -1.363 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 176.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 8.1 pt -143.17 -172.7 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.421 -1.884 0 CA-C-O 122.479 1.133 . . . . 0.0 112.4 -173.08 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.451 ' HB3' ' HB3' ' A' ' 20' ' ' HIS . 31.9 m-85 -128.58 129.07 45.42 Favored 'General case' 0 N--CA 1.402 -2.873 0 CA-C-N 113.288 -1.778 . . . . 0.0 106.55 172.784 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.557 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -108.78 128.92 55.31 Favored 'General case' 0 C--N 1.271 -2.834 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.446 -174.346 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.606 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -106.39 124.12 49.11 Favored 'General case' 0 N--CA 1.403 -2.782 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.039 -178.697 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 69.1 mtm -121.42 158.38 28.46 Favored 'General case' 0 CA--C 1.508 -0.667 0 C-N-CA 123.219 0.608 . . . . 0.0 109.814 176.897 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -64.66 116.52 6.32 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 178.667 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.44 -2.43 65.14 Favored Glycine 0 C--O 1.246 0.868 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -121.93 146.35 45.95 Favored Pre-proline 0 N--CA 1.428 -1.567 0 C-N-CA 122.731 0.412 . . . . 0.0 110.388 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -75.82 171.29 18.45 Favored 'Trans proline' 0 N--CA 1.444 -1.428 0 C-N-CA 121.798 1.665 . . . . 0.0 108.467 172.439 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' HIS . . . . . 0.477 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 69.2 m80 -61.53 111.15 1.69 Allowed 'General case' 0 CA--C 1.548 0.883 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 175.854 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 7.8 t-105 -102.96 139.26 19.96 Favored Pre-proline 0 C--N 1.304 -1.405 0 C-N-CA 123.852 0.861 . . . . 0.0 109.31 -171.969 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_exo -59.08 118.66 5.59 Favored 'Trans proline' 0 C--N 1.354 0.84 0 C-N-CA 121.875 1.716 . . . . 0.0 110.869 177.868 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.81 167.05 23.0 Favored 'General case' 0 N--CA 1.414 -2.227 0 CA-C-O 121.227 0.537 . . . . 0.0 110.417 -177.456 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 36.6 ttt-85 -119.05 139.89 50.98 Favored 'General case' 0 C--N 1.285 -2.198 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 177.843 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 60.2 t -75.34 111.12 11.22 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.951 0 N-CA-C 103.817 -2.66 . . . . 0.0 103.817 168.058 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -89.37 -177.55 5.39 Favored 'General case' 0 C--N 1.289 -2.032 0 C-N-CA 119.535 -0.866 . . . . 0.0 111.451 -170.293 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 . . . . . 0 C--N 1.293 -1.876 0 CA-C-O 121.875 0.845 . . . . 0.0 113.201 -171.131 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.634 ' HE3' ' HA ' ' A' ' 53' ' ' LEU . 22.5 mtpp . . . . . 0 N--CA 1.418 -2.035 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 71.2 mt -98.44 153.9 37.8 Favored Pre-proline 0 C--N 1.288 -2.079 0 O-C-N 123.54 0.525 . . . . 0.0 110.356 -173.676 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -71.4 122.36 8.58 Favored 'Trans proline' 0 C--N 1.354 0.826 0 C-N-CA 121.788 1.659 . . . . 0.0 109.798 176.476 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.422 HG13 ' HB2' ' A' ' 53' ' ' LEU . 43.8 mm -117.84 119.9 62.99 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.943 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 -176.487 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 86.2 t80 -98.27 117.68 33.2 Favored 'General case' 0 C--N 1.28 -2.437 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 178.901 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -81.78 129.85 34.87 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 121.419 0.628 . . . . 0.0 112.672 178.647 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.405 ' HB3' ' HA2' ' A' ' 80' ' ' GLY . 72.1 m-85 -80.45 151.96 29.03 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.819 177.433 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.436 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 78.23 -20.68 3.86 Favored Glycine 0 C--N 1.315 -0.628 0 C-N-CA 123.562 0.601 . . . . 0.0 114.306 177.716 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 36.2 p -119.37 -22.59 6.99 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 117.533 0.666 . . . . 0.0 109.849 174.323 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.0 m-70 67.7 22.74 8.87 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.883 0.873 . . . . 0.0 112.308 179.011 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -78.41 169.3 18.48 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.335 177.596 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 6.3 m -139.36 137.82 36.08 Favored 'General case' 0 C--N 1.289 -2.059 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 177.04 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -138.58 -179.55 5.88 Favored 'General case' 0 C--N 1.28 -2.436 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.614 -176.754 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 87.3 m-85 -131.31 109.79 10.62 Favored 'General case' 0 CA--C 1.491 -1.318 0 C-N-CA 123.662 0.785 . . . . 0.0 109.294 177.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.634 ' HA ' ' HE3' ' A' ' 39' ' ' LYS . 96.2 mt -126.77 152.29 47.08 Favored 'General case' 0 C--N 1.295 -1.803 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.076 -178.689 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.422 ' O ' HG12 ' A' ' 58' ' ' ILE . . . -80.43 168.17 51.32 Favored Glycine 0 N--CA 1.429 -1.802 0 N-CA-C 110.564 -1.015 . . . . 0.0 110.564 -177.551 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -65.18 -18.42 61.19 Favored 'Trans proline' 0 C--O 1.209 -0.966 0 C-N-CA 122.337 2.025 . . . . 0.0 112.13 -178.479 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 10.8 mmtm -99.56 2.05 44.34 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 113.206 0.817 . . . . 0.0 113.206 173.703 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -94.04 -12.02 29.48 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 173.656 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.451 HG22 ' HA ' ' A' ' 13' ' ' ALA . 15.9 pt -125.77 151.58 32.01 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.705 0 CA-C-N 114.459 -1.246 . . . . 0.0 109.698 -176.801 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' PHE . . . . . 0.451 ' HB3' HD21 ' A' ' 64' ' ' ASN . 96.4 m-85 -138.23 147.48 55.96 Favored Pre-proline 0 C--N 1.296 -1.754 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 -179.192 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -63.38 140.99 79.51 Favored 'Trans proline' 0 C--O 1.241 0.632 0 C-N-CA 123.19 2.593 . . . . 0.0 114.817 -174.503 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 40.5 t80 -56.03 -33.31 64.81 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 114.32 -1.309 . . . . 0.0 111.841 177.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.8 m -60.05 -41.9 93.3 Favored 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.527 -177.618 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . 0.301 48.8 mt-10 -75.98 -51.59 12.05 Favored 'General case' 0 CA--C 1.488 -1.426 0 CA-C-O 123.319 1.533 . . . . 0.0 108.656 176.6 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.451 HD21 ' HB3' ' A' ' 59' ' ' PHE . 37.0 m-80 -80.66 2.75 24.54 Favored 'General case' 0 N--CA 1.415 -2.211 0 CA-C-N 112.801 -1.999 . . . . 0.0 113.847 -161.439 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -68.92 -37.4 78.89 Favored 'General case' 0 N--CA 1.433 -1.286 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 176.424 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 56.8 mm-40 -80.83 -37.4 30.11 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.104 -0.498 . . . . 0.0 112.159 175.343 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 39.7 mtpt -70.96 -57.37 4.63 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 124.701 1.251 . . . . 0.0 111.171 -173.964 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 61.8 m-85 -126.97 7.24 6.63 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.213 -174.797 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -91.98 41.24 2.83 Favored Glycine 0 CA--C 1.496 -1.096 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -178.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.405 ' O ' ' HE1' ' A' ' 77' ' ' PHE . 30.4 mmtp -128.77 151.02 76.52 Favored Pre-proline 0 C--N 1.299 -1.616 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 -177.595 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.472 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 52.6 Cg_exo -48.42 148.44 7.81 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 123.642 2.895 . . . . 0.0 114.816 -176.415 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -140.17 -175.73 4.35 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-N 115.087 -0.96 . . . . 0.0 109.933 -178.886 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.2 mmmm -95.53 -3.26 46.9 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-O 120.804 0.335 . . . . 0.0 110.474 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 18.0 mmt180 -80.25 121.02 25.11 Favored 'General case' 0 C--N 1.309 -1.164 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.064 176.317 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -73.63 135.39 43.8 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 174.641 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.436 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 103.76 -25.31 27.01 Favored Glycine 0 N--CA 1.436 -1.332 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 -177.123 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.405 ' HE1' ' O ' ' A' ' 70' ' ' LYS . 55.7 t80 -74.73 -44.93 47.4 Favored 'General case' 0 N--CA 1.437 -1.077 0 CA-C-N 114.722 -0.739 . . . . 0.0 109.08 -178.925 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.472 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 89.4 m-20 -76.82 -35.75 57.37 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.062 -176.2 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 8.2 mp0 -67.73 -36.55 80.78 Favored 'General case' 0 N--CA 1.433 -1.311 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 174.376 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.405 ' HA2' ' HB3' ' A' ' 45' ' ' PHE . . . -70.47 -34.38 68.08 Favored Glycine 0 CA--C 1.496 -1.155 0 CA-C-N 115.445 -0.798 . . . . 0.0 112.094 177.584 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 40.9 tp -60.62 -36.53 78.84 Favored 'General case' 0 N--CA 1.432 -1.331 0 C-N-CA 123.955 0.902 . . . . 0.0 108.947 175.849 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 76.1 t90 -72.14 -47.39 51.41 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.054 175.469 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -61.15 -36.87 80.95 Favored 'General case' 0 C--O 1.193 -1.915 0 N-CA-C 114.009 1.114 . . . . 0.0 114.009 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.4 tt -70.67 -26.51 28.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 119.282 -0.967 . . . . 0.0 111.772 -176.723 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -83.77 -37.06 23.1 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.176 178.238 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 30.8 m-80 -101.86 -31.35 10.76 Favored 'General case' 0 C--O 1.257 1.487 0 CA-C-O 122.063 0.935 . . . . 0.0 112.738 -173.123 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 57.3 t30 -129.06 60.2 49.18 Favored Pre-proline 0 C--N 1.29 -2.014 0 O-C-N 121.628 -0.67 . . . . 0.0 112.539 -177.743 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -77.77 -5.74 15.57 Favored 'Trans proline' 0 N--CA 1.486 1.076 0 C-N-CA 122.211 1.94 . . . . 0.0 110.747 178.244 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 23.1 pttm . . . . . 0 C--N 1.312 -1.023 0 CA-C-N 113.718 -1.583 . . . . 0.0 111.063 -174.606 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 . . . . . 0 N--CA 1.447 -0.617 0 CA-C-O 120.788 0.328 . . . . 0.0 111.645 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.489 ' HD2' ' N ' ' A' ' 6' ' ' LYS . 7.5 mptt -121.04 147.24 46.02 Favored Pre-proline 0 C--N 1.31 -1.119 0 N-CA-C 108.172 -1.048 . . . . 0.0 108.172 -178.842 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -56.98 121.13 9.53 Favored 'Trans proline' 0 N--CA 1.452 -0.967 0 C-N-CA 121.456 1.438 . . . . 0.0 109.32 172.884 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.66 -25.33 9.11 Favored Glycine 0 N--CA 1.42 -2.41 0 CA-C-O 118.671 -1.072 . . . . 0.0 114.142 -177.14 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.354 3.7 p30 -79.37 149.71 31.6 Favored 'General case' 0 C--O 1.243 0.748 0 CA-C-N 119.453 1.626 . . . . 0.0 113.557 -179.496 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.419 HD21 ' HB2' ' A' ' 88' ' ' PRO . 78.5 mt -86.74 128.54 35.02 Favored 'General case' 0 C--O 1.253 1.268 0 CA-C-N 114.605 -1.18 . . . . 0.0 110.851 -175.812 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -141.77 -177.2 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.466 0 CA-C-O 121.785 0.803 . . . . 0.0 112.255 -175.632 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.431 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 49.1 m-85 -113.65 128.25 56.36 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 107.211 -1.403 . . . . 0.0 107.211 172.531 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.444 ' HB2' HG21 ' A' ' 42' ' ' ILE . . . -108.3 120.31 42.0 Favored 'General case' 0 C--N 1.274 -2.69 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.684 -175.382 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.576 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 1.1 tmmt? -109.72 126.65 53.94 Favored 'General case' 0 C--N 1.27 -2.866 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.619 -177.638 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 69.6 mtm -120.48 158.55 27.01 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.489 179.264 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -68.77 117.02 9.94 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 179.497 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.27 -3.07 61.54 Favored Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -179.655 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -122.94 150.3 58.74 Favored Pre-proline 0 N--CA 1.435 -1.195 0 CA-C-O 120.744 0.307 . . . . 0.0 110.855 -179.118 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -74.91 170.74 19.74 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 122.134 1.889 . . . . 0.0 109.498 172.68 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' HIS . . . . . 0.445 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 76.3 m80 -66.77 111.55 3.77 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 177.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 10.6 t-105 -97.06 138.98 21.27 Favored Pre-proline 0 C--N 1.311 -1.093 0 C-N-CA 123.541 0.737 . . . . 0.0 109.689 -174.234 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.438 ' HB2' HG21 ' A' ' 84' ' ' ILE . 22.7 Cg_endo -69.05 117.76 5.25 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 121.254 1.303 . . . . 0.0 110.123 175.866 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.5 167.1 24.52 Favored 'General case' 0 N--CA 1.426 -1.625 0 CA-C-O 121.137 0.494 . . . . 0.0 110.528 -174.619 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.408 HH22 ' CD ' ' A' ' 27' ' ' GLU . 12.7 ttp180 -111.75 145.21 39.76 Favored 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 179.069 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.3 t -68.61 121.32 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.866 0 N-CA-C 104.821 -2.289 . . . . 0.0 104.821 169.898 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -91.24 175.66 6.86 Favored 'General case' 0 C--N 1.281 -2.395 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 -171.161 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.408 ' CD ' HH22 ' A' ' 24' ' ' ARG . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -1.695 0 CA-C-O 121.385 0.612 . . . . 0.0 110.229 179.453 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.412 ' HD3' ' HA ' ' A' ' 53' ' ' LEU . 71.6 mttt . . . . . 0 N--CA 1.415 -2.192 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 75.0 mt -100.19 150.42 36.88 Favored Pre-proline 0 C--N 1.291 -1.944 0 O-C-N 124.368 1.042 . . . . 0.0 109.257 -175.871 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -75.49 133.33 15.75 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 121.684 1.589 . . . . 0.0 109.427 174.868 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.444 HG21 ' HB2' ' A' ' 13' ' ' ALA . 51.3 mm -124.47 126.74 72.33 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -176.692 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 65.2 t80 -105.51 115.02 29.55 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 -179.434 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.416 ' HE2' ' HB2' ' A' ' 51' ' ' ALA . 95.1 m-85 -79.23 136.18 36.99 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.245 0.545 . . . . 0.0 111.613 179.524 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -87.54 157.08 19.25 Favored 'General case' 0 C--N 1.301 -1.515 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.559 177.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 76.11 -21.27 2.25 Favored Glycine 0 CA--C 1.502 -0.775 0 C-N-CA 124.669 1.128 . . . . 0.0 114.134 179.163 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.404 ' CG2' ' HA3' ' A' ' 76' ' ' GLY . 40.4 p -120.01 -23.24 6.42 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 117.294 0.547 . . . . 0.0 110.199 174.956 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 51.7 m170 67.78 23.3 8.58 Favored 'General case' 0 C--N 1.342 0.25 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.681 178.758 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -73.78 162.7 28.86 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 175.482 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.8 m -137.5 142.33 41.48 Favored 'General case' 0 C--N 1.281 -2.371 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.416 ' HB2' ' HE2' ' A' ' 44' ' ' PHE . . . -139.65 -179.68 6.06 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.169 -178.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 80.2 m-85 -131.69 109.27 10.06 Favored 'General case' 0 N--CA 1.439 -0.989 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 175.274 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.511 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 96.0 mt -127.51 152.94 46.95 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.652 -175.171 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.97 171.72 37.71 Favored Glycine 0 N--CA 1.424 -2.164 0 C-N-CA 119.564 -1.303 . . . . 0.0 111.589 -174.797 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -66.12 -5.65 12.82 Favored 'Trans proline' 0 C--O 1.251 1.131 0 C-N-CA 123.235 2.624 . . . . 0.0 112.172 179.639 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -98.72 -16.87 18.81 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 114.961 -1.018 . . . . 0.0 111.774 175.062 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.511 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 40.9 m-20 -94.12 -8.7 38.8 Favored 'General case' 0 C--N 1.31 -1.15 0 CA-C-O 121.188 0.518 . . . . 0.0 110.118 -177.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.424 ' HA ' ' O ' ' A' ' 12' ' ' PHE . 14.3 pt -119.59 149.63 22.18 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.607 -176.195 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 57.6 m-85 -132.56 148.54 70.02 Favored Pre-proline 0 C--O 1.192 -1.945 0 N-CA-C 107.428 -1.323 . . . . 0.0 107.428 -177.381 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' PRO . . . . . 0.449 ' O ' ' HB2' ' A' ' 64' ' ' ASN . 41.4 Cg_endo -66.2 132.32 29.38 Favored 'Trans proline' 0 C--N 1.322 -0.854 0 C-N-CA 121.94 1.76 . . . . 0.0 111.956 -179.236 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.431 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 66.5 t80 -69.38 -38.48 78.05 Favored 'General case' 0 C--O 1.204 -1.327 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -177.338 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 22.7 t -76.31 -33.63 59.03 Favored 'General case' 0 C--N 1.295 -1.8 0 C-N-CA 120.087 -0.645 . . . . 0.0 111.402 -172.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.507 ' C ' HD22 ' A' ' 64' ' ' ASN . 2.8 mp0 -95.69 -1.7 49.51 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.522 -177.778 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.507 HD22 ' C ' ' A' ' 63' ' ' GLU . 0.9 OUTLIER -131.17 15.34 5.12 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 178.232 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -69.75 -32.24 70.65 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.465 0.65 . . . . 0.0 110.1 -179.535 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.603 ' H ' ' CD ' ' A' ' 66' ' ' GLU . 1.5 mp0 -66.1 -31.61 72.58 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 178.103 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.482 ' HD3' ' CG ' ' A' ' 64' ' ' ASN . 37.7 mtpt -82.22 -60.25 2.28 Favored 'General case' 0 N--CA 1.428 -1.567 0 CA-C-N 114.303 -1.317 . . . . 0.0 111.501 -175.594 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -106.71 -1.15 23.01 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.434 -0.803 . . . . 0.0 113.057 -168.302 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.71 56.91 4.23 Favored Glycine 0 C--N 1.311 -0.827 0 C-N-CA 120.994 -0.622 . . . . 0.0 111.953 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 58.7 mttp -125.86 125.61 24.86 Favored Pre-proline 0 C--N 1.313 -1.021 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.27 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -53.15 128.8 30.51 Favored 'Trans proline' 0 C--O 1.263 1.763 0 C-N-CA 123.451 2.767 . . . . 0.0 114.414 -177.167 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -94.94 -172.43 2.7 Favored 'General case' 0 N--CA 1.407 -2.613 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.636 178.383 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.53 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 2.0 mptp? -106.98 -11.01 15.78 Favored 'General case' 0 N--CA 1.417 -2.118 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -178.506 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.94 118.13 9.3 Favored 'General case' 0 N--CA 1.41 -2.429 0 N-CA-C 106.272 -1.751 . . . . 0.0 106.272 169.71 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 9.3 tptp -69.9 140.25 53.09 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 107.888 -1.152 . . . . 0.0 107.888 179.013 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.404 ' HA3' ' CG2' ' A' ' 47' ' ' THR . . . 107.93 -24.04 24.25 Favored Glycine 0 N--CA 1.413 -2.889 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 -173.15 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -75.47 -38.79 59.39 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -68.64 -47.33 66.88 Favored 'General case' 0 CA--C 1.506 -0.739 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 -177.681 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 36.1 mp0 -61.66 -42.34 98.77 Favored 'General case' 0 N--CA 1.426 -1.661 0 CA-C-N 113.152 -1.84 . . . . 0.0 110.068 178.794 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.1 -37.0 72.6 Favored Glycine 0 CA--C 1.484 -1.846 0 CA-C-N 115.751 -0.659 . . . . 0.0 113.305 -179.243 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 38.3 tp -62.55 -31.1 71.84 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 176.782 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.0 t90 -74.76 -51.18 14.86 Favored 'General case' 0 N--CA 1.429 -1.501 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.248 175.006 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 -55.06 -45.84 75.34 Favored 'General case' 0 C--O 1.203 -1.346 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 -178.755 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.438 HG21 ' HB2' ' A' ' 22' ' ' PRO . 20.2 tt -68.73 -27.89 37.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -176.033 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -93.42 -16.96 24.03 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.252 0.549 . . . . 0.0 110.302 -173.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -109.91 -56.51 2.31 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-O 121.16 0.505 . . . . 0.0 111.527 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -128.27 75.19 79.2 Favored Pre-proline 0 C--N 1.313 -0.982 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.199 -177.65 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.419 ' HB2' HD21 ' A' ' 10' ' ' LEU . 56.4 Cg_endo -73.62 -5.26 16.79 Favored 'Trans proline' 0 C--N 1.332 -0.298 0 C-N-CA 122.699 2.266 . . . . 0.0 112.988 -177.701 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 26.1 pttm . . . . . 0 C--O 1.249 1.054 0 CA-C-O 121.38 0.609 . . . . 0.0 109.972 -176.393 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 5' ' ' PHE . . . . . 0.489 ' CE2' HG13 ' A' ' 58' ' ' ILE . 91.3 m-85 . . . . . 0 CA--C 1.498 -1.047 0 N-CA-C 117.575 2.435 . . . . 0.0 117.575 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.493 ' HG3' ' OD1' ' A' ' 9' ' ' ASP . 3.8 ptmm? -134.65 156.3 78.8 Favored Pre-proline 0 N--CA 1.413 -2.276 0 CA-C-N 112.076 -2.329 . . . . 0.0 107.684 177.086 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.88 141.1 95.77 Favored 'Trans proline' 0 C--O 1.253 1.234 0 C-N-CA 122.497 2.132 . . . . 0.0 112.455 178.244 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 104.81 -14.17 49.56 Favored Glycine 0 N--CA 1.44 -1.039 0 C-N-CA 121.231 -0.509 . . . . 0.0 113.033 178.18 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.493 ' OD1' ' HG3' ' A' ' 6' ' ' LYS . 1.4 m-20 -79.05 145.87 33.6 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-O 121.087 0.47 . . . . 0.0 111.412 -179.381 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 83.6 mt -95.3 127.43 41.34 Favored 'General case' 0 C--O 1.25 1.116 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.45 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.475 HG22 ' HA ' ' A' ' 60' ' ' PRO . 2.9 pp -139.54 -178.63 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.205 0 CA-C-O 122.489 1.138 . . . . 0.0 113.761 -173.053 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.498 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 86.3 m-85 -119.43 128.59 54.17 Favored 'General case' 0 N--CA 1.408 -2.564 0 N-CA-C 105.203 -2.147 . . . . 0.0 105.203 170.766 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.501 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -108.09 140.84 40.68 Favored 'General case' 0 C--N 1.279 -2.477 0 O-C-N 123.702 0.626 . . . . 0.0 110.045 -173.569 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.483 ' HD3' ' C ' ' A' ' 14' ' ' LYS . 7.6 tmtm? -114.96 115.66 27.24 Favored 'General case' 0 N--CA 1.414 -2.273 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.834 -176.742 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.408 ' HB2' ' HB2' ' A' ' 18' ' ' TYR . 69.8 mtm -108.12 158.93 16.99 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 172.846 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 24.4 tptm -62.59 130.04 43.3 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 177.509 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 83.02 -25.5 4.73 Favored Glycine 0 C--O 1.218 -0.888 0 O-C-N 123.539 0.524 . . . . 0.0 112.568 -177.835 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' TYR . . . . . 0.408 ' HB2' ' HB2' ' A' ' 15' ' ' MET . 53.5 m-85 -93.21 149.85 38.13 Favored Pre-proline 0 C--O 1.257 1.488 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -177.225 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -75.78 171.7 17.69 Favored 'Trans proline' 0 N--CA 1.449 -1.112 0 C-N-CA 123.395 2.73 . . . . 0.0 109.646 171.251 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' HIS . . . . . 0.453 ' HB3' ' HB3' ' A' ' 12' ' ' PHE . 79.8 m80 -69.9 111.53 5.68 Favored 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 178.461 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 8.5 t-105 -100.17 136.39 20.1 Favored Pre-proline 0 C--N 1.309 -1.175 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.961 -173.27 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_endo -65.88 117.79 4.94 Favored 'Trans proline' 0 CA--C 1.542 0.9 0 C-N-CA 121.789 1.66 . . . . 0.0 110.789 176.439 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.44 167.51 23.46 Favored 'General case' 0 N--CA 1.426 -1.645 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -174.577 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.503 ' HB3' ' CE2' ' A' ' 45' ' ' PHE . 9.2 ptt180 -111.25 160.57 16.86 Favored 'General case' 0 C--N 1.291 -1.965 0 C-N-CA 119.507 -0.877 . . . . 0.0 109.182 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 42.3 t -89.47 116.05 30.24 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.163 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 170.064 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.406 ' HB2' ' HB2' ' A' ' 41' ' ' PRO . 1.7 m-20 -87.84 173.53 8.89 Favored 'General case' 0 C--N 1.281 -2.407 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.976 -175.013 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.417 -2.1 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 175.613 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.513 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 34.3 mmtt . . . . . 0 N--CA 1.41 -2.469 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.431 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 74.6 mt -96.63 154.27 38.52 Favored Pre-proline 0 C--N 1.271 -2.814 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 -178.147 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.406 ' HB2' ' HB2' ' A' ' 26' ' ' ASP . 45.8 Cg_endo -74.96 126.48 10.02 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 C-N-CA 121.517 1.478 . . . . 0.0 109.276 173.634 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 50.6 mm -125.3 110.13 23.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-O 121.116 0.484 . . . . 0.0 111.407 -175.934 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 70.2 t80 -90.26 117.52 29.06 Favored 'General case' 0 C--N 1.279 -2.497 0 C-N-CA 124.46 1.104 . . . . 0.0 109.899 176.791 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -78.13 128.83 34.4 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.9 177.616 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.503 ' CE2' ' HB3' ' A' ' 24' ' ' ARG . 58.8 m-85 -78.14 152.04 32.99 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.254 177.657 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 80.96 -21.05 5.93 Favored Glycine 0 C--N 1.308 -1.027 0 C-N-CA 124.565 1.079 . . . . 0.0 114.592 177.45 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.457 ' CG2' ' HA3' ' A' ' 76' ' ' GLY . 32.6 p -119.88 -22.73 6.66 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 117.467 0.633 . . . . 0.0 110.349 174.682 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 68.11 23.17 8.09 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.854 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -75.12 169.64 17.63 Favored 'General case' 0 C--N 1.35 0.602 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 175.076 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.4 m -141.47 145.66 35.51 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 121.539 -0.726 . . . . 0.0 110.005 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -139.99 -179.9 6.22 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 123.835 0.854 . . . . 0.0 109.842 178.93 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.431 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 93.0 m-85 -133.23 109.67 9.58 Favored 'General case' 0 CA--C 1.491 -1.29 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 174.332 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.53 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 79.5 mt -134.13 144.6 48.64 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 -178.867 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.513 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -83.26 177.05 52.97 Favored Glycine 0 N--CA 1.417 -2.596 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 -174.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -66.23 -17.51 54.49 Favored 'Trans proline' 0 C--N 1.319 -0.985 0 C-N-CA 122.112 1.875 . . . . 0.0 112.481 -176.746 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 16.8 mmmt -98.86 -3.58 35.03 Favored 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 120.204 -0.598 . . . . 0.0 110.923 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.53 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 12.8 m-20 -96.55 -9.2 30.01 Favored 'General case' 0 N--CA 1.481 1.105 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.792 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.489 HG13 ' CE2' ' A' ' 5' ' ' PHE . 12.5 pt -115.63 152.43 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.231 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.428 -176.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -126.05 131.68 24.06 Favored Pre-proline 0 C--N 1.301 -1.542 0 CA-C-N 115.238 -0.892 . . . . 0.0 108.753 -177.612 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' PRO . . . . . 0.525 ' HG2' ' HB2' ' A' ' 63' ' ' GLU . 34.1 Cg_endo -67.6 131.51 24.67 Favored 'Trans proline' 0 C--N 1.322 -0.821 0 C-N-CA 122.708 2.272 . . . . 0.0 113.202 -175.521 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.498 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 43.3 t80 -52.37 -42.19 63.74 Favored 'General case' 0 C--O 1.205 -1.257 0 C-N-CA 123.992 0.917 . . . . 0.0 111.337 179.62 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.2 t -64.94 -37.0 86.19 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.476 -175.383 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.525 ' HB2' ' HG2' ' A' ' 60' ' ' PRO . 29.9 mt-10 -97.03 -7.08 33.78 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.992 0.425 . . . . 0.0 111.949 -175.703 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.479 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 27.2 m-80 -133.53 17.77 3.96 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 112.416 0.525 . . . . 0.0 112.416 -175.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.448 ' HG2' ' OE1' ' A' ' 66' ' ' GLU . 3.6 ptpp? -67.29 -36.13 80.91 Favored 'General case' 0 N--CA 1.498 1.968 0 C-N-CA 120.042 -0.663 . . . . 0.0 110.611 -176.149 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.448 ' OE1' ' HG2' ' A' ' 65' ' ' LYS . 28.8 mp0 -64.94 -35.45 81.21 Favored 'General case' 0 C--O 1.255 1.346 0 CA-C-O 123.241 1.496 . . . . 0.0 108.836 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.479 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 37.6 mtpt -76.38 -59.33 2.81 Favored 'General case' 0 C--N 1.294 -1.834 0 CA-C-N 112.931 -1.94 . . . . 0.0 111.912 -174.744 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.411 ' CD2' ' HB3' ' A' ' 64' ' ' ASN . 23.2 m-85 -112.1 -1.94 15.16 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 -169.084 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -83.85 45.69 3.52 Favored Glycine 0 C--N 1.309 -0.961 0 C-N-CA 120.654 -0.784 . . . . 0.0 113.373 -176.776 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 17.3 pttm -132.75 143.74 49.98 Favored Pre-proline 0 N--CA 1.43 -1.448 0 O-C-N 122.591 -0.358 . . . . 0.0 111.561 176.818 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_exo -49.42 158.13 1.83 Allowed 'Trans proline' 0 C--N 1.361 1.236 0 C-N-CA 124.577 3.518 . . . . 0.0 117.06 -173.053 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -131.48 -178.42 4.85 Favored 'General case' 0 N--CA 1.416 -2.164 0 CA-C-N 113.647 -1.615 . . . . 0.0 108.31 178.317 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -90.69 -18.51 24.94 Favored 'General case' 0 C--N 1.308 -1.199 0 O-C-N 123.693 0.621 . . . . 0.0 109.659 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.54 115.57 5.9 Favored 'General case' 0 N--CA 1.414 -2.229 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 175.496 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.447 ' HD3' ' H ' ' A' ' 76' ' ' GLY . 14.0 tppt? -64.73 133.42 52.05 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 175.638 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.457 ' HA3' ' CG2' ' A' ' 47' ' ' THR . . . 108.46 -24.75 21.62 Favored Glycine 0 N--CA 1.414 -2.788 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -174.095 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -75.6 -37.91 59.46 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -65.96 -49.55 67.48 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 -178.487 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 23.5 mp0 -64.58 -39.07 93.07 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 113.202 -1.817 . . . . 0.0 110.522 -179.687 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.64 -35.05 62.63 Favored Glycine 0 CA--C 1.48 -2.145 0 CA-C-N 116.063 -0.517 . . . . 0.0 113.011 -179.41 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 37.7 tp -62.51 -33.31 74.63 Favored 'General case' 0 N--CA 1.423 -1.802 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 176.029 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 70.5 t90 -74.34 -49.11 24.21 Favored 'General case' 0 N--CA 1.426 -1.626 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.602 175.854 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -55.04 -46.09 75.27 Favored 'General case' 0 C--O 1.188 -2.154 0 N-CA-C 112.644 0.609 . . . . 0.0 112.644 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 17.0 tt -68.56 -23.22 27.73 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-O 121.082 0.468 . . . . 0.0 111.629 -174.054 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -92.34 -41.93 10.09 Favored 'General case' 0 N--CA 1.423 -1.785 0 CA-C-O 121.585 0.707 . . . . 0.0 109.819 -175.443 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -97.73 -39.73 8.91 Favored 'General case' 0 N--CA 1.48 1.038 0 CA-C-O 121.713 0.768 . . . . 0.0 112.061 -173.838 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 65.2 t30 -134.99 63.33 57.24 Favored Pre-proline 0 C--N 1.296 -1.759 0 C-N-CA 119.797 -0.761 . . . . 0.0 111.673 -178.428 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -68.13 -6.57 17.58 Favored 'Trans proline' 0 C--N 1.371 1.711 0 C-N-CA 122.81 2.34 . . . . 0.0 111.742 -178.438 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 24.7 pttm . . . . . 0 C--N 1.311 -1.103 0 CA-C-N 114.555 -1.202 . . . . 0.0 109.828 -177.44 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 5' ' ' PHE . . . . . 0.494 ' C ' ' HD2' ' A' ' 6' ' ' LYS . 84.3 m-85 . . . . . 0 CA--C 1.496 -1.116 0 CA-C-O 120.959 0.409 . . . . 0.0 110.014 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.494 ' HD2' ' C ' ' A' ' 5' ' ' PHE . 13.4 mmmt -116.81 153.69 49.33 Favored Pre-proline 0 N--CA 1.433 -1.29 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 -178.251 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.6 Cg_exo -52.82 134.45 54.58 Favored 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 122.755 2.303 . . . . 0.0 112.369 177.602 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 107.58 -25.21 21.97 Favored Glycine 0 N--CA 1.432 -1.613 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.77 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -72.24 150.23 43.85 Favored 'General case' 0 C--O 1.252 1.216 0 CA-C-O 121.582 0.706 . . . . 0.0 112.224 -177.099 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 76.5 mt -100.04 127.96 46.19 Favored 'General case' 0 N--CA 1.423 -1.794 0 CA-C-N 114.352 -1.294 . . . . 0.0 109.754 -177.116 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 8.6 pt -140.12 -173.6 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 CA-C-O 122.348 1.071 . . . . 0.0 111.897 -174.446 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.414 ' HB3' ' HB3' ' A' ' 20' ' ' HIS . 66.5 m-85 -126.31 124.31 40.02 Favored 'General case' 0 N--CA 1.412 -2.363 0 N-CA-C 106.174 -1.787 . . . . 0.0 106.174 172.162 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.439 ' CB ' HG21 ' A' ' 42' ' ' ILE . . . -108.89 131.28 55.17 Favored 'General case' 0 C--N 1.28 -2.431 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.343 -174.572 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.625 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -113.54 122.18 46.46 Favored 'General case' 0 N--CA 1.401 -2.911 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.116 -177.76 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 70.2 mtm -110.43 158.03 18.93 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 175.736 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 60.2 tttm -67.29 116.62 8.26 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 110.145 -0.317 . . . . 0.0 110.145 -179.224 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.81 -2.75 62.26 Favored Glycine 0 C--O 1.248 0.975 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -121.86 151.79 58.32 Favored Pre-proline 0 N--CA 1.434 -1.268 0 C-N-CA 122.829 0.452 . . . . 0.0 109.905 -178.844 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -76.5 171.37 18.18 Favored 'Trans proline' 0 N--CA 1.448 -1.157 0 C-N-CA 122.296 1.997 . . . . 0.0 109.815 175.1 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' HIS . . . . . 0.536 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 76.2 m80 -66.76 110.94 3.46 Favored 'General case' 0 C--N 1.312 -1.061 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 176.269 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -99.88 138.15 20.29 Favored Pre-proline 0 C--N 1.296 -1.718 0 C-N-CA 123.942 0.897 . . . . 0.0 109.324 -171.316 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -63.59 118.28 5.22 Favored 'Trans proline' 0 C--O 1.244 0.808 0 C-N-CA 121.918 1.746 . . . . 0.0 110.043 177.219 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -141.82 167.54 21.91 Favored 'General case' 0 N--CA 1.415 -2.195 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.761 -175.195 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.409 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 56.1 ttt-85 -123.73 141.15 52.29 Favored 'General case' 0 C--N 1.289 -2.03 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 178.191 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 45.6 t -77.64 125.27 37.2 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 175.029 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -94.2 171.04 9.08 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 120.57 -0.452 . . . . 0.0 109.855 -175.741 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 . . . . . 0 C--N 1.305 -1.367 0 CA-C-O 121.915 0.864 . . . . 0.0 113.293 -178.116 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 62.6 mttp . . . . . 0 N--CA 1.424 -1.758 0 CA-C-O 120.826 0.346 . . . . 0.0 110.364 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 85.0 mt -112.55 147.29 36.77 Favored Pre-proline 0 C--N 1.286 -2.194 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.487 -176.727 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -73.73 122.58 7.89 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 121.749 1.632 . . . . 0.0 109.535 176.141 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.439 HG21 ' CB ' ' A' ' 13' ' ' ALA . 45.7 mm -118.22 111.01 32.32 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.251 -174.743 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.461 ' CZ ' ' HA ' ' A' ' 48' ' ' HIS . 91.1 t80 -91.24 118.73 30.72 Favored 'General case' 0 C--N 1.286 -2.153 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.288 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -83.03 133.23 35.1 Favored 'General case' 0 C--O 1.249 1.03 0 CA-C-O 121.107 0.479 . . . . 0.0 112.163 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.409 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 72.0 m-85 -81.43 152.34 27.45 Favored 'General case' 0 N--CA 1.433 -1.31 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.154 175.144 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.436 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 81.24 -19.47 8.2 Favored Glycine 0 C--N 1.309 -0.95 0 C-N-CA 123.366 0.507 . . . . 0.0 113.555 178.412 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.473 ' HB ' ' OE1' ' A' ' 49' ' ' GLU . 35.9 p -118.92 -22.78 7.17 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 122.267 -0.549 . . . . 0.0 110.578 176.426 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' HIS . . . . . 0.461 ' HA ' ' CZ ' ' A' ' 43' ' ' PHE . 13.3 m170 66.43 25.6 10.22 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 123.308 0.643 . . . . 0.0 110.879 -179.729 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.473 ' OE1' ' HB ' ' A' ' 47' ' ' THR . 45.9 mt-10 -97.45 175.47 6.22 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.454 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 10.0 m -143.76 143.85 31.56 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-O 121.172 0.511 . . . . 0.0 109.815 -179.241 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -131.37 178.26 6.85 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 114.814 -1.084 . . . . 0.0 109.675 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -133.38 109.82 9.6 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 176.598 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.416 HD12 ' HB1' ' A' ' 13' ' ' ALA . 88.9 mt -125.65 163.7 22.2 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 -177.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -85.22 162.8 37.05 Favored Glycine 0 N--CA 1.419 -2.454 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 178.856 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -63.88 -15.17 47.48 Favored 'Trans proline' 0 C--O 1.208 -0.989 0 C-N-CA 123.006 2.471 . . . . 0.0 112.257 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.08 4.96 51.1 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 115.648 -0.705 . . . . 0.0 112.75 178.002 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -113.67 1.77 15.02 Favored 'General case' 0 C--N 1.292 -1.911 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.143 177.155 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 17.6 pt -127.13 150.74 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.823 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' PHE . . . . . 0.531 ' HB3' ' ND2' ' A' ' 64' ' ' ASN . 93.3 m-85 -136.29 142.37 39.45 Favored Pre-proline 0 C--N 1.295 -1.794 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo -65.09 137.88 54.25 Favored 'Trans proline' 0 C--O 1.249 1.046 0 C-N-CA 122.835 2.357 . . . . 0.0 112.922 -177.748 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.404 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 25.4 t80 -56.38 -42.69 78.29 Favored 'General case' 0 C--O 1.208 -1.093 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.172 178.335 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.6 m -53.87 -43.43 69.59 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 115.677 -0.692 . . . . 0.0 112.509 -175.259 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -95.62 -17.23 21.51 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.259 0.552 . . . . 0.0 112.031 -176.688 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.531 ' ND2' ' HB3' ' A' ' 59' ' ' PHE . 28.0 m-80 -116.73 10.54 14.32 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -173.027 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.508 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 19.4 pttp -68.69 -35.44 77.2 Favored 'General case' 0 C--O 1.21 -0.994 0 CA-C-O 121.137 0.494 . . . . 0.0 111.032 -177.296 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.508 ' OE1' ' HG3' ' A' ' 65' ' ' LYS . 2.1 mm-40 -73.01 -22.48 60.66 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 122.177 0.989 . . . . 0.0 108.819 -178.923 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.445 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 41.5 mtpt -83.42 -59.61 2.4 Favored 'General case' 0 N--CA 1.436 -1.148 0 CA-C-N 114.561 -1.2 . . . . 0.0 110.609 -177.606 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.493 ' CD2' ' HB3' ' A' ' 64' ' ' ASN . 27.2 m-85 -105.72 -8.12 18.02 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 115.475 -0.784 . . . . 0.0 112.697 -169.35 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -79.25 52.12 4.01 Favored Glycine 0 C--O 1.219 -0.816 0 C-N-CA 121.583 -0.342 . . . . 0.0 112.781 -177.874 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.7 ptpp? -132.96 132.9 22.66 Favored Pre-proline 0 C--N 1.301 -1.536 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 176.535 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -65.49 128.89 21.17 Favored 'Trans proline' 0 N--CA 1.446 -1.316 0 C-N-CA 122.655 2.237 . . . . 0.0 115.531 -172.193 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.6 m-20 -93.92 -170.81 2.41 Favored 'General case' 0 CA--C 1.487 -1.474 0 N-CA-C 106.205 -1.776 . . . . 0.0 106.205 173.829 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.503 ' HA ' ' HD3' ' A' ' 73' ' ' LYS 0.273 70.9 mmtt -110.09 28.93 8.12 Favored 'General case' 0 C--N 1.291 -1.977 0 CA-C-O 122.593 1.187 . . . . 0.0 110.592 171.35 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 14.7 mmt180 -82.51 125.34 31.01 Favored 'General case' 0 C--O 1.25 1.099 0 N-CA-C 106.341 -1.725 . . . . 0.0 106.341 170.511 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.401 ' HG3' ' OE2' ' A' ' 79' ' ' GLU . 61.2 tttp -66.73 139.24 57.81 Favored 'General case' 0 C--N 1.318 -0.798 0 C-N-CA 119.83 -0.748 . . . . 0.0 109.882 176.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.436 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 95.87 -25.2 26.28 Favored Glycine 0 N--CA 1.428 -1.895 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -175.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.402 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 31.7 t80 -75.87 -47.06 26.98 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-O 121.196 0.522 . . . . 0.0 109.702 -178.062 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.546 HD22 ' N ' ' A' ' 78' ' ' ASN . 0.7 OUTLIER -67.4 -37.86 83.76 Favored 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.892 0.853 . . . . 0.0 109.142 -179.256 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 79' ' ' GLU . . . . . 0.401 ' OE2' ' HG3' ' A' ' 75' ' ' LYS . 26.1 mt-10 -72.44 -36.1 68.46 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 114.024 -1.444 . . . . 0.0 109.593 -179.158 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -69.66 -33.89 72.08 Favored Glycine 0 CA--C 1.494 -1.271 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.641 178.455 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.402 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 94.7 mt -60.51 -38.79 85.52 Favored 'General case' 0 C--O 1.21 -0.976 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 174.863 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 85.4 t90 -66.66 -46.07 76.89 Favored 'General case' 0 N--CA 1.429 -1.476 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.695 177.836 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -61.48 -43.46 98.82 Favored 'General case' 0 C--O 1.204 -1.339 0 N-CA-C 113.076 0.769 . . . . 0.0 113.076 179.564 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.1 tt -70.8 -33.45 52.52 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 120.379 -0.528 . . . . 0.0 112.056 -175.556 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -88.98 -5.85 57.66 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 112.758 0.651 . . . . 0.0 112.758 -178.697 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 31.9 m-80 -123.57 -51.12 1.84 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-O 121.388 0.613 . . . . 0.0 112.089 -179.137 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.7 t30 -126.45 67.56 65.59 Favored Pre-proline 0 C--N 1.305 -1.341 0 O-C-N 121.94 -0.475 . . . . 0.0 110.186 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -74.78 -5.95 17.51 Favored 'Trans proline' 0 N--CA 1.48 0.698 0 C-N-CA 122.314 2.009 . . . . 0.0 112.289 -175.934 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.7 pttp . . . . . 0 C--N 1.3 -1.573 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.083 -178.404 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 . . . . . 0 N--CA 1.422 -1.851 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.592 ' HG2' ' OD2' ' A' ' 9' ' ' ASP . 1.6 pttm -135.22 152.49 76.96 Favored Pre-proline 0 C--N 1.289 -2.039 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 -175.277 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo -49.09 121.7 7.25 Favored 'Trans proline' 0 C--N 1.352 0.723 0 C-N-CA 122.657 2.238 . . . . 0.0 111.138 176.493 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.38 -30.48 6.45 Favored Glycine 0 N--CA 1.423 -2.206 0 CA-C-O 118.991 -0.894 . . . . 0.0 113.637 -178.51 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.592 ' OD2' ' HG2' ' A' ' 6' ' ' LYS 0.335 2.9 p30 -78.71 147.93 33.27 Favored 'General case' 0 C--O 1.248 1.009 0 CA-C-N 118.859 1.329 . . . . 0.0 113.268 -179.161 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.425 HD22 HG13 ' A' ' 84' ' ' ILE . 82.3 mt -91.42 129.1 37.45 Favored 'General case' 0 CA--C 1.488 -1.44 0 CA-C-N 114.203 -1.362 . . . . 0.0 110.312 -175.783 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 12.1 pt -140.39 -173.03 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 CA-C-O 122.374 1.083 . . . . 0.0 111.993 -174.118 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 38.4 m-85 -120.71 132.33 55.01 Favored 'General case' 0 N--CA 1.414 -2.236 0 CA-C-N 113.979 -1.464 . . . . 0.0 107.077 171.344 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.502 ' HB2' HG21 ' A' ' 42' ' ' ILE . . . -108.92 124.02 50.0 Favored 'General case' 0 C--N 1.272 -2.788 0 O-C-N 123.947 0.779 . . . . 0.0 109.337 -178.811 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.634 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -109.33 120.27 42.0 Favored 'General case' 0 N--CA 1.398 -3.043 0 CA-C-N 116.184 -0.462 . . . . 0.0 109.916 -179.145 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 66.5 mtm -114.68 157.89 22.52 Favored 'General case' 0 C--N 1.314 -0.977 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 175.955 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 41.7 ttmt -66.31 117.63 8.85 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 116.712 -0.222 . . . . 0.0 110.429 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.92 -3.88 65.17 Favored Glycine 0 C--O 1.251 1.206 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.651 178.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 77.5 m-85 -120.9 151.44 54.85 Favored Pre-proline 0 N--CA 1.428 -1.573 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 -179.211 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -77.58 171.27 17.81 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 122.112 1.875 . . . . 0.0 109.611 175.562 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' HIS . . . . . 0.459 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 70.0 m80 -63.15 110.99 2.03 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 174.843 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 7.5 t-105 -99.4 137.68 20.37 Favored Pre-proline 0 C--N 1.303 -1.456 0 C-N-CA 123.331 0.653 . . . . 0.0 109.239 -172.535 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -63.97 117.83 4.81 Favored 'Trans proline' 0 C--O 1.245 0.863 0 C-N-CA 121.796 1.664 . . . . 0.0 110.089 176.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.21 167.83 21.21 Favored 'General case' 0 N--CA 1.413 -2.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.143 -175.109 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.415 HH22 ' CD ' ' A' ' 27' ' ' GLU . 10.6 ttp180 -124.7 148.06 48.23 Favored 'General case' 0 C--N 1.282 -2.33 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 176.571 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.7 t -72.41 118.69 17.84 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 N-CA-C 105.275 -2.12 . . . . 0.0 105.275 170.31 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -84.76 172.43 11.49 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -171.732 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.415 ' CD ' HH22 ' A' ' 24' ' ' ARG . 0.5 OUTLIER . . . . . 0 C--N 1.309 -1.158 0 CA-C-O 121.669 0.747 . . . . 0.0 112.533 -175.465 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 63.0 mttp . . . . . 0 N--CA 1.418 -2.051 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.429 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 92.8 mt -98.89 141.6 23.16 Favored Pre-proline 0 C--N 1.287 -2.148 0 O-C-N 123.977 0.798 . . . . 0.0 109.937 -176.537 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -70.65 123.27 9.65 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.053 1.836 . . . . 0.0 109.429 176.082 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.502 HG21 ' HB2' ' A' ' 13' ' ' ALA . 39.5 mm -116.35 117.05 54.21 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.123 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 -175.775 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 72.7 t80 -94.28 115.89 28.2 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -81.54 129.1 34.54 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 123.425 0.453 . . . . 0.0 111.387 177.821 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -80.07 150.64 30.24 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.694 176.249 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.513 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 80.78 -19.91 6.95 Favored Glycine 0 C--N 1.311 -0.827 0 CA-C-N 116.216 -0.447 . . . . 0.0 113.739 179.152 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.4 p -119.33 -23.74 6.61 Favored 'General case' 0 C--N 1.309 -1.16 0 O-C-N 122.074 -0.662 . . . . 0.0 110.556 174.974 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 68.02 13.66 9.17 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 123.987 0.915 . . . . 0.0 112.231 -178.973 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.7 mm-40 -76.52 164.11 26.27 Favored 'General case' 0 CA--C 1.493 -1.226 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.263 178.222 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.411 ' HA ' ' O ' ' A' ' 42' ' ' ILE . 4.2 m -133.2 136.85 45.9 Favored 'General case' 0 C--N 1.283 -2.298 0 CA-C-O 121.425 0.631 . . . . 0.0 109.773 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -128.53 178.02 6.6 Favored 'General case' 0 C--N 1.284 -2.256 0 CA-C-N 115.013 -0.994 . . . . 0.0 109.914 -179.302 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.429 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 95.9 m-85 -133.63 110.25 9.75 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 176.527 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 94.9 mt -124.71 160.53 28.36 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 -179.35 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -87.81 167.53 36.73 Favored Glycine 0 N--CA 1.42 -2.383 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 178.941 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.402 ' HA ' HD11 ' A' ' 58' ' ' ILE . 38.1 Cg_endo -66.65 -6.96 16.65 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 123.16 2.573 . . . . 0.0 112.334 -178.782 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 7.9 ptmm? -97.31 -4.32 38.89 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.415 178.411 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.2 m-20 -115.27 5.66 14.76 Favored 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.891 -176.587 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.402 HD11 ' HA ' ' A' ' 55' ' ' PRO . 14.3 pt -131.38 150.7 34.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.796 0 CA-C-N 114.737 -1.12 . . . . 0.0 108.981 179.885 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -141.66 147.19 44.65 Favored Pre-proline 0 C--N 1.295 -1.778 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 -179.371 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -62.06 133.24 43.06 Favored 'Trans proline' 0 CA--C 1.511 -0.667 0 C-N-CA 123.043 2.495 . . . . 0.0 113.256 -177.45 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -64.62 -36.97 85.98 Favored 'General case' 0 C--O 1.207 -1.177 0 CA-C-N 114.88 -1.055 . . . . 0.0 110.7 -177.214 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 10.6 m -63.95 -39.65 94.64 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.239 -178.22 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -89.05 -7.43 55.9 Favored 'General case' 0 C--O 1.218 -0.582 0 N-CA-C 111.879 0.326 . . . . 0.0 111.879 -177.534 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 39.0 m-80 -123.92 13.39 9.16 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -179.476 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.8 ttmm -67.05 -34.36 77.51 Favored 'General case' 0 N--CA 1.473 0.694 0 CA-C-O 121.667 0.746 . . . . 0.0 109.648 -179.669 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.573 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -79.16 -20.25 48.96 Favored 'General case' 0 N--CA 1.408 -2.55 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.347 178.072 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.573 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 8.2 mttm -87.92 -59.28 2.29 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.979 179.529 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 66.0 m-85 -112.53 1.32 15.81 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.3 -171.789 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.6 55.97 4.15 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 111.601 -0.599 . . . . 0.0 111.601 178.229 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 58.4 mttp -129.54 123.71 21.48 Favored Pre-proline 0 C--N 1.31 -1.131 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 -179.712 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -63.0 128.2 22.35 Favored 'Trans proline' 0 N--CA 1.444 -1.424 0 C-N-CA 121.839 1.693 . . . . 0.0 114.132 -175.931 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -93.24 -171.84 2.78 Favored 'General case' 0 CA--C 1.482 -1.667 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 176.44 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.465 ' HA ' ' HD3' ' A' ' 73' ' ' LYS 0.268 71.4 mmtt -109.42 27.56 9.42 Favored 'General case' 0 C--N 1.289 -2.045 0 CA-C-O 122.613 1.197 . . . . 0.0 110.361 171.041 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 13.8 mmt180 -80.14 127.64 32.56 Favored 'General case' 0 C--O 1.25 1.11 0 N-CA-C 105.168 -2.16 . . . . 0.0 105.168 169.421 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.412 ' HG2' ' HZ3' ' A' ' 75' ' ' LYS . 42.9 tttm -67.77 141.89 56.41 Favored 'General case' 0 C--N 1.32 -0.699 0 C-N-CA 119.228 -0.989 . . . . 0.0 108.721 179.456 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.513 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 94.17 -25.31 22.83 Favored Glycine 0 N--CA 1.426 -1.985 0 C-N-CA 120.881 -0.676 . . . . 0.0 111.846 -177.08 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.423 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 20.6 t80 -72.87 -44.73 60.98 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.336 0.588 . . . . 0.0 109.585 -177.613 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.569 HD22 ' N ' ' A' ' 78' ' ' ASN . 0.7 OUTLIER -70.34 -42.21 72.18 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 -178.949 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -65.99 -38.48 88.59 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-N 114.447 -1.251 . . . . 0.0 109.451 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -68.51 -34.84 80.07 Favored Glycine 0 N--CA 1.433 -1.505 0 CA-C-N 115.349 -0.842 . . . . 0.0 113.057 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.423 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 94.6 mt -60.61 -35.43 76.12 Favored 'General case' 0 C--O 1.216 -0.668 0 CA-C-O 121.309 0.576 . . . . 0.0 109.782 175.701 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 83.1 t90 -70.78 -48.97 51.46 Favored 'General case' 0 N--CA 1.433 -1.284 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.724 176.53 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -58.15 -45.33 87.61 Favored 'General case' 0 C--O 1.205 -1.289 0 N-CA-C 113.042 0.756 . . . . 0.0 113.042 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.425 HG13 HD22 ' A' ' 10' ' ' LEU . 20.7 tt -68.82 -31.23 49.86 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -174.021 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -90.58 -10.34 43.77 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -179.027 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 31.7 m-80 -117.78 -53.99 2.37 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-O 121.223 0.535 . . . . 0.0 112.215 -178.373 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -127.86 75.77 77.92 Favored Pre-proline 0 C--N 1.304 -1.396 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.189 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.81 -7.7 21.97 Favored 'Trans proline' 0 N--CA 1.488 1.188 0 C-N-CA 122.87 2.38 . . . . 0.0 112.688 -176.569 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.3 pttp . . . . . 0 C--N 1.302 -1.461 0 C-N-CA 123.982 0.913 . . . . 0.0 109.738 -178.344 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 5' ' ' PHE . . . . . 0.452 ' CE2' HG13 ' A' ' 58' ' ' ILE . 88.9 m-85 . . . . . 0 N--CA 1.432 -1.341 0 CA-C-O 121.758 0.79 . . . . 0.0 113.053 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.636 ' HG2' ' OD2' ' A' ' 9' ' ' ASP . 16.8 pttm -134.6 160.09 69.74 Favored Pre-proline 0 C--N 1.305 -1.35 0 CA-C-N 114.889 -1.05 . . . . 0.0 108.336 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -51.25 122.65 10.46 Favored 'Trans proline' 0 C--N 1.347 0.499 0 C-N-CA 122.496 2.131 . . . . 0.0 111.879 175.328 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.1 -22.59 11.25 Favored Glycine 0 N--CA 1.429 -1.77 0 CA-C-O 119.351 -0.694 . . . . 0.0 113.381 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.636 ' OD2' ' HG2' ' A' ' 6' ' ' LYS . 37.3 m-20 -66.0 128.95 38.09 Favored 'General case' 0 C--O 1.247 0.953 0 CA-C-N 117.659 0.729 . . . . 0.0 112.097 -179.456 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.4 HD21 ' HB2' ' A' ' 88' ' ' PRO . 77.2 mt -83.83 124.43 30.94 Favored 'General case' 0 CA--C 1.485 -1.545 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 176.036 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 10.3 pt -140.24 -174.3 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 CA-C-O 122.367 1.079 . . . . 0.0 112.261 -172.137 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.493 ' HB3' ' HB3' ' A' ' 20' ' ' HIS . 45.6 m-85 -119.77 126.96 52.32 Favored 'General case' 0 N--CA 1.404 -2.741 0 CA-C-N 113.181 -1.827 . . . . 0.0 106.973 170.529 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.434 ' CB ' HG21 ' A' ' 42' ' ' ILE . . . -108.98 121.76 45.81 Favored 'General case' 0 C--N 1.27 -2.869 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.312 -178.241 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.617 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -104.77 119.57 39.3 Favored 'General case' 0 N--CA 1.401 -2.887 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.939 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 72.4 mtm -104.07 159.01 16.03 Favored 'General case' 0 C--N 1.312 -1.058 0 C-N-CA 123.172 0.589 . . . . 0.0 110.215 179.406 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.4 tttp -65.37 116.22 6.45 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.553 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.13 -8.04 64.75 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.627 178.755 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 65.8 m-85 -128.72 147.85 66.09 Favored Pre-proline 0 N--CA 1.444 -0.744 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -178.647 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -68.7 170.89 14.26 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.845 2.363 . . . . 0.0 111.909 177.747 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' HIS . . . . . 0.561 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 74.6 m80 -60.83 111.64 1.73 Allowed 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.114 178.229 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 4.0 t-105 -101.85 136.89 19.44 Favored Pre-proline 0 C--N 1.313 -1.002 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -176.818 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -64.7 117.64 4.7 Favored 'Trans proline' 0 C--O 1.241 0.649 0 C-N-CA 121.779 1.653 . . . . 0.0 110.432 176.83 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -141.16 167.38 22.32 Favored 'General case' 0 N--CA 1.413 -2.282 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.69 -174.749 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 32.7 ttt180 -109.96 138.35 46.46 Favored 'General case' 0 C--N 1.291 -1.969 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 176.857 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 64.4 t -74.68 111.68 10.92 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.068 0 N-CA-C 103.501 -2.777 . . . . 0.0 103.501 166.908 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -86.26 -177.58 6.27 Favored 'General case' 0 C--N 1.282 -2.329 0 C-N-CA 119.543 -0.863 . . . . 0.0 112.105 -169.728 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 . . . . . 0 C--N 1.294 -1.838 0 CA-C-O 121.966 0.889 . . . . 0.0 112.861 -171.776 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 62.5 mttp . . . . . 0 N--CA 1.429 -1.497 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 96.5 mt -97.42 139.93 21.72 Favored Pre-proline 0 C--N 1.293 -1.876 0 O-C-N 123.995 0.809 . . . . 0.0 109.87 -179.333 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -70.29 123.45 9.94 Favored 'Trans proline' 0 N--CA 1.46 -0.475 0 C-N-CA 122.484 2.123 . . . . 0.0 110.247 177.512 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.434 HG21 ' CB ' ' A' ' 13' ' ' ALA . 42.4 mm -117.8 120.52 64.9 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.788 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 -177.072 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 93.0 t80 -105.22 117.68 34.63 Favored 'General case' 0 C--N 1.286 -2.194 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 178.733 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.432 ' HE2' ' HB2' ' A' ' 51' ' ' ALA . 89.6 m-85 -82.93 135.69 34.82 Favored 'General case' 0 C--N 1.308 -1.212 0 CA-C-O 121.435 0.636 . . . . 0.0 112.332 179.493 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -85.48 151.72 23.75 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.469 178.155 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.427 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 80.84 -20.91 5.96 Favored Glycine 0 C--N 1.309 -0.939 0 C-N-CA 124.553 1.073 . . . . 0.0 114.124 177.657 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.499 ' CG2' ' HA3' ' A' ' 76' ' ' GLY . 37.0 p -119.8 -23.14 6.55 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-N 117.279 0.539 . . . . 0.0 110.201 175.084 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 43.4 m170 67.96 22.37 8.6 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.282 -178.263 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -71.75 164.2 26.41 Favored 'General case' 0 C--N 1.346 0.418 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 176.254 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.4 m -138.37 140.92 39.62 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -179.806 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.432 ' HB2' ' HE2' ' A' ' 44' ' ' PHE . . . -141.41 177.68 7.95 Favored 'General case' 0 C--N 1.289 -2.034 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.183 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 95.7 m-85 -134.36 117.57 16.49 Favored 'General case' 0 N--CA 1.434 -1.238 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 176.755 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.413 HD12 ' HB1' ' A' ' 13' ' ' ALA . 90.7 mt -127.61 169.27 13.94 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.257 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.26 162.8 29.84 Favored Glycine 0 N--CA 1.413 -2.846 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -66.78 -5.98 14.52 Favored 'Trans proline' 0 N--CA 1.487 1.125 0 C-N-CA 123.88 3.053 . . . . 0.0 112.578 -179.476 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.3 ptmm? -97.89 -6.98 31.2 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 114.875 -1.057 . . . . 0.0 111.686 177.186 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -112.52 6.26 18.4 Favored 'General case' 0 C--N 1.294 -1.806 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.995 -175.432 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.452 HG13 ' CE2' ' A' ' 5' ' ' PHE . 14.2 pt -127.28 147.06 32.16 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 CA-C-N 114.853 -1.067 . . . . 0.0 110.396 179.39 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 -140.26 147.62 50.82 Favored Pre-proline 0 C--N 1.302 -1.474 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -177.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -62.09 132.34 38.73 Favored 'Trans proline' 0 N--CA 1.481 0.749 0 C-N-CA 123.315 2.677 . . . . 0.0 113.955 -176.617 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.443 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 77.8 t80 -61.03 -40.7 94.59 Favored 'General case' 0 C--O 1.207 -1.136 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.652 -178.406 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 m -60.45 -40.15 90.11 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.81 -175.583 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -95.25 -4.08 46.39 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 115.763 -0.653 . . . . 0.0 112.193 -174.971 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 29.6 m-80 -125.64 15.36 8.15 Favored 'General case' 0 N--CA 1.446 -0.645 0 CA-C-O 120.427 0.156 . . . . 0.0 111.404 178.589 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 57.2 tttp -69.58 -36.2 76.04 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 121.627 0.727 . . . . 0.0 109.545 -178.355 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.561 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -75.15 -22.42 58.13 Favored 'General case' 0 N--CA 1.416 -2.131 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.964 176.502 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.561 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 7.8 mtmm -84.84 -54.08 4.91 Favored 'General case' 0 N--CA 1.437 -1.09 0 CA-C-N 115.743 -0.662 . . . . 0.0 112.621 179.661 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -122.0 -4.21 9.07 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -173.116 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.69 52.21 4.38 Favored Glycine 0 N--CA 1.468 0.826 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.103 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.2 ptpt -133.01 156.27 80.24 Favored Pre-proline 0 C--N 1.306 -1.325 0 C-N-CA 123.456 0.703 . . . . 0.0 109.676 -177.464 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_exo -49.15 153.11 4.52 Favored 'Trans proline' 0 C--N 1.355 0.897 0 C-N-CA 123.781 2.987 . . . . 0.0 115.889 -177.784 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -136.53 -173.38 3.4 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 114.545 -1.207 . . . . 0.0 109.106 179.634 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 47.5 mmtm -100.8 -14.54 17.97 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 179.222 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 4.1 mmm180 -70.79 123.53 22.17 Favored 'General case' 0 N--CA 1.436 -1.147 0 CA-C-O 121.186 0.517 . . . . 0.0 110.697 175.031 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 16.6 tppt? -68.38 126.4 29.49 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 174.823 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.499 ' HA3' ' CG2' ' A' ' 47' ' ' THR . . . 108.56 -19.53 31.1 Favored Glycine 0 N--CA 1.416 -2.668 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -177.013 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.436 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 16.6 t80 -76.31 -45.49 32.14 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -179.584 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.7 m-80 -69.91 -39.94 75.89 Favored 'General case' 0 CA--C 1.5 -0.957 0 CA-C-O 121.942 0.877 . . . . 0.0 108.957 -179.624 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 30.4 mp0 -64.87 -36.22 83.66 Favored 'General case' 0 N--CA 1.425 -1.72 0 CA-C-N 114.06 -1.427 . . . . 0.0 109.468 177.317 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.35 -31.48 68.64 Favored Glycine 0 CA--C 1.49 -1.49 0 CA-C-N 115.385 -0.825 . . . . 0.0 112.431 178.756 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.436 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 96.0 mt -58.84 -39.98 82.89 Favored 'General case' 0 C--O 1.212 -0.913 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 174.481 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 83.1 t90 -67.97 -48.7 65.11 Favored 'General case' 0 N--CA 1.432 -1.365 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.283 177.874 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -59.31 -43.4 92.64 Favored 'General case' 0 C--O 1.207 -1.135 0 N-CA-C 113.5 0.926 . . . . 0.0 113.5 -179.258 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.1 tt -71.98 -28.44 30.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 C-N-CA 120.23 -0.588 . . . . 0.0 112.209 -174.354 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -86.86 -17.37 33.49 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 112.062 0.393 . . . . 0.0 112.062 179.457 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 32.1 m-80 -114.46 -51.19 2.77 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-O 121.366 0.603 . . . . 0.0 112.471 -175.996 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.8 t30 -127.93 68.16 75.0 Favored Pre-proline 0 C--N 1.305 -1.364 0 O-C-N 121.883 -0.511 . . . . 0.0 110.678 -178.369 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.4 ' HB2' HD21 ' A' ' 10' ' ' LEU . 61.6 Cg_endo -75.77 -5.83 16.86 Favored 'Trans proline' 0 C--N 1.348 0.508 0 C-N-CA 122.025 1.817 . . . . 0.0 112.208 -177.591 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 19.8 pttp . . . . . 0 C--N 1.299 -1.592 0 CA-C-N 114.737 -1.119 . . . . 0.0 110.429 -178.779 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 . . . . . 0 N--CA 1.42 -1.965 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.1 mttp -105.45 153.53 39.69 Favored Pre-proline 0 C--N 1.298 -1.656 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.638 -172.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -62.44 116.51 3.56 Favored 'Trans proline' 0 N--CA 1.457 -0.667 0 N-CA-C 107.921 -1.607 . . . . 0.0 107.921 170.397 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 108.62 -10.34 35.35 Favored Glycine 0 N--CA 1.426 -1.974 0 C-N-CA 120.833 -0.698 . . . . 0.0 112.172 -175.426 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -73.09 154.96 40.18 Favored 'General case' 0 C--O 1.253 1.245 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 -178.397 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.493 HD21 ' HB2' ' A' ' 88' ' ' PRO . 79.9 mt -105.36 123.67 48.26 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 -173.439 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.9 pp -140.28 177.56 4.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 CA-C-O 122.058 0.932 . . . . 0.0 112.934 -174.14 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.527 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 74.6 m-85 -110.31 129.54 55.72 Favored 'General case' 0 C--N 1.284 -2.263 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 170.662 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.404 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -108.0 118.49 36.88 Favored 'General case' 0 C--N 1.277 -2.569 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.136 -176.345 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.614 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -107.14 122.64 46.91 Favored 'General case' 0 N--CA 1.4 -2.957 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.384 -179.092 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.47 ' HG2' HD21 ' A' ' 53' ' ' LEU . 30.2 mtm -127.08 158.25 37.49 Favored 'General case' 0 CA--C 1.493 -1.22 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 176.905 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -64.17 117.23 6.84 Favored 'General case' 0 C--N 1.307 -1.255 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 178.44 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.05 -16.11 57.47 Favored Glycine 0 C--O 1.249 1.034 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 -178.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -105.47 151.04 39.65 Favored Pre-proline 0 N--CA 1.43 -1.466 0 C-N-CA 123.175 0.59 . . . . 0.0 109.623 178.811 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -83.12 171.69 11.3 Favored 'Trans proline' 0 N--CA 1.439 -1.685 0 C-N-CA 122.122 1.882 . . . . 0.0 107.416 169.933 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' HIS . . . . . 0.489 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 70.6 m80 -61.83 109.97 1.4 Allowed 'General case' 0 CA--C 1.542 0.648 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 174.023 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -105.15 136.79 19.14 Favored Pre-proline 0 C--N 1.305 -1.342 0 C-N-CA 123.131 0.572 . . . . 0.0 109.53 -170.517 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -65.02 117.84 4.9 Favored 'Trans proline' 0 N--CA 1.455 -0.754 0 C-N-CA 121.321 1.347 . . . . 0.0 110.433 177.497 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.92 166.61 24.15 Favored 'General case' 0 N--CA 1.413 -2.292 0 CA-C-O 121.279 0.561 . . . . 0.0 110.157 -175.694 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.473 ' HB2' ' CE2' ' A' ' 45' ' ' PHE . 31.7 ttp85 -116.68 145.83 43.17 Favored 'General case' 0 C--N 1.283 -2.303 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.554 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.6 t -76.49 123.88 33.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 105.302 -2.11 . . . . 0.0 105.302 171.667 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -90.93 -177.1 4.85 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -173.478 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.404 ' CD ' HH22 ' A' ' 24' ' ' ARG . 15.0 mp0 . . . . . 0 N--CA 1.423 -1.809 0 CA-C-O 121.87 0.843 . . . . 0.0 111.499 -176.867 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.557 ' HE2' ' N ' ' A' ' 54' ' ' GLY . 30.3 mtpt . . . . . 0 N--CA 1.429 -1.475 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.401 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 91.8 mt -88.16 147.05 39.54 Favored Pre-proline 0 C--N 1.304 -1.388 0 C-N-CA 122.721 0.408 . . . . 0.0 110.369 -176.033 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -71.54 123.87 9.84 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.438 2.092 . . . . 0.0 110.295 177.419 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 49.3 mm -119.02 125.17 74.27 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 O-C-N 122.064 -0.398 . . . . 0.0 110.613 -176.344 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -104.77 114.52 28.79 Favored 'General case' 0 C--N 1.288 -2.104 0 C-N-CA 123.431 0.692 . . . . 0.0 109.144 177.766 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.417 ' HE2' ' HB2' ' A' ' 51' ' ' ALA . 96.9 m-85 -77.97 137.27 38.22 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.014 0.435 . . . . 0.0 111.681 178.035 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.473 ' CE2' ' HB2' ' A' ' 24' ' ' ARG . 70.5 m-85 -89.16 156.44 18.79 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.492 177.168 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.442 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 74.02 -20.78 1.44 Allowed Glycine 0 N--CA 1.469 0.878 0 C-N-CA 124.578 1.085 . . . . 0.0 114.454 178.734 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.2 p -119.15 -22.67 7.08 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 173.584 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 11.2 m170 65.87 24.7 11.27 Favored 'General case' 0 C--N 1.348 0.519 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.107 179.06 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -73.34 167.39 21.33 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 115.388 -0.824 . . . . 0.0 108.904 176.794 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.6 m -137.82 140.81 40.71 Favored 'General case' 0 C--N 1.287 -2.122 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.847 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.417 ' HB2' ' HE2' ' A' ' 44' ' ' PHE . . . -145.37 -179.32 6.58 Favored 'General case' 0 C--N 1.293 -1.859 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.131 -178.202 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.401 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 83.4 m-85 -132.2 110.71 10.84 Favored 'General case' 0 C--O 1.246 0.886 0 CA-C-N 115.217 -0.902 . . . . 0.0 109.427 177.193 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.532 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 93.8 mt -129.48 154.64 46.8 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.656 -177.415 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.557 ' N ' ' HE2' ' A' ' 39' ' ' LYS . . . -95.87 176.34 33.32 Favored Glycine 0 N--CA 1.432 -1.585 0 C-N-CA 120.016 -1.088 . . . . 0.0 111.301 -174.831 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -66.22 -7.53 17.63 Favored 'Trans proline' 0 C--O 1.239 0.566 0 C-N-CA 122.966 2.444 . . . . 0.0 112.311 -178.541 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.7 mtpp -97.3 -15.16 20.9 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.238 177.054 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.532 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 40.9 m-20 -93.39 -14.38 26.89 Favored 'General case' 0 CA--C 1.49 -1.346 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.084 -178.488 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.446 ' HA ' ' O ' ' A' ' 12' ' ' PHE . 17.9 pt -119.12 148.58 21.96 Favored 'Isoleucine or valine' 0 C--O 1.268 2.04 0 CA-C-O 122.482 1.134 . . . . 0.0 112.849 -171.947 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 80.8 m-85 -136.08 133.25 19.56 Favored Pre-proline 0 C--N 1.292 -1.895 0 CA-C-N 113.885 -1.507 . . . . 0.0 106.951 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' PRO . . . . . 0.49 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 35.8 Cg_endo -64.12 127.91 20.45 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.881 2.388 . . . . 0.0 113.147 -177.2 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.527 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 72.0 t80 -58.86 -35.38 72.85 Favored 'General case' 0 C--O 1.197 -1.674 0 CA-C-N 114.062 -1.426 . . . . 0.0 112.915 -174.78 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.427 ' HB3' ' OE1' ' A' ' 63' ' ' GLU . 28.2 t -67.63 -52.19 41.15 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.191 0.52 . . . . 0.0 110.478 -177.808 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.49 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 2.6 mp0 -81.32 -5.67 58.07 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.128 -175.58 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.409 ' OD1' ' HE2' ' A' ' 67' ' ' LYS . 24.2 m-80 -126.59 15.12 7.61 Favored 'General case' 0 C--N 1.311 -1.079 0 C-N-CA 122.893 0.477 . . . . 0.0 111.557 -179.558 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -67.85 -35.89 79.36 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-O 121.722 0.772 . . . . 0.0 110.093 -179.488 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.606 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -72.01 -28.31 63.31 Favored 'General case' 0 N--CA 1.408 -2.566 0 CA-C-N 115.648 -0.705 . . . . 0.0 111.99 176.864 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.606 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 7.0 mtmm -80.2 -58.17 3.27 Favored 'General case' 0 N--CA 1.439 -0.979 0 CA-C-N 115.729 -0.668 . . . . 0.0 112.452 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 76.4 m-85 -113.67 -10.98 13.02 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -172.368 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.4 56.22 4.09 Favored Glycine 0 C--N 1.314 -0.648 0 C-N-CA 121.332 -0.461 . . . . 0.0 112.834 -177.556 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.419 ' O ' ' HE1' ' A' ' 77' ' ' PHE . 4.5 ptpp? -132.54 147.42 65.53 Favored Pre-proline 0 C--N 1.303 -1.416 0 CA-C-O 119.244 -0.408 . . . . 0.0 110.084 178.702 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.445 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 87.0 Cg_exo -50.2 156.92 3.36 Favored 'Trans proline' 0 C--N 1.355 0.914 0 C-N-CA 124.031 3.154 . . . . 0.0 114.803 -179.413 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -143.04 -173.34 3.88 Favored 'General case' 0 N--CA 1.433 -1.29 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.532 179.189 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.411 ' HD3' ' N ' ' A' ' 73' ' ' LYS . 0.1 OUTLIER -93.79 1.11 56.55 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.047 -179.809 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 30.9 mmt180 -82.79 120.6 25.83 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.687 176.72 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.441 ' HD3' ' N ' ' A' ' 76' ' ' GLY . 8.1 tmtt? -70.03 127.15 31.85 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 175.316 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.442 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 106.8 -25.41 22.7 Favored Glycine 0 CA--C 1.501 -0.817 0 N-CA-C 110.598 -1.001 . . . . 0.0 110.598 -178.821 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.419 ' HE1' ' O ' ' A' ' 70' ' ' LYS . 54.1 t80 -72.11 -42.06 66.51 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-O 121.74 0.781 . . . . 0.0 109.557 -177.432 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.445 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 87.2 m-20 -79.07 -33.81 44.24 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.668 -173.977 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -71.55 -33.37 69.06 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 175.111 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.34 -37.26 70.52 Favored Glycine 0 N--CA 1.432 -1.601 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.432 177.395 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 43.9 tp -59.74 -33.58 71.83 Favored 'General case' 0 N--CA 1.434 -1.249 0 C-N-CA 124.007 0.923 . . . . 0.0 108.855 175.03 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 82.0 t90 -72.46 -51.02 21.98 Favored 'General case' 0 N--CA 1.434 -1.236 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.022 175.668 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 35.6 mt-10 -53.8 -49.76 67.63 Favored 'General case' 0 C--O 1.206 -1.189 0 N-CA-C 112.797 0.666 . . . . 0.0 112.797 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 19.3 tt -67.94 -23.87 29.69 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 N-CA-C 112.573 0.583 . . . . 0.0 112.573 -173.782 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -94.31 -22.67 18.21 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 121.409 0.623 . . . . 0.0 110.686 -176.417 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 28.4 m-80 -105.97 -55.17 2.37 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-O 121.435 0.636 . . . . 0.0 111.785 -176.845 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 67.4 t30 -127.62 72.61 78.13 Favored Pre-proline 0 C--N 1.312 -1.032 0 C-N-CA 119.969 -0.693 . . . . 0.0 110.228 179.584 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.493 ' HB2' HD21 ' A' ' 10' ' ' LEU . 57.0 Cg_endo -74.81 -6.76 18.57 Favored 'Trans proline' 0 C--O 1.221 -0.326 0 C-N-CA 122.128 1.886 . . . . 0.0 112.815 -176.223 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.4 pttm . . . . . 0 C--N 1.303 -1.413 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.986 -178.085 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 . . . . . 0 N--CA 1.425 -1.717 0 N-CA-C 107.753 -1.202 . . . . 0.0 107.753 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.506 ' H ' ' HB2' ' A' ' 9' ' ' ASP . 32.3 mttp -104.76 158.36 32.18 Favored Pre-proline 0 C--N 1.298 -1.661 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -174.793 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.484 ' HB3' ' HA ' ' A' ' 27' ' ' GLU . 37.1 Cg_exo -63.46 117.02 3.99 Favored 'Trans proline' 0 N--CA 1.451 -0.986 0 N-CA-C 107.385 -1.813 . . . . 0.0 107.385 167.296 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 101.66 -1.42 52.72 Favored Glycine 0 N--CA 1.435 -1.421 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.458 -175.602 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.506 ' HB2' ' H ' ' A' ' 6' ' ' LYS . 4.9 t70 -78.11 154.94 30.82 Favored 'General case' 0 C--O 1.254 1.339 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 64.3 mt -102.54 124.83 48.82 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.44 -172.542 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.41 HD11 HD12 ' A' ' 42' ' ' ILE . 7.9 pt -141.39 -177.11 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.825 0 CA-C-O 122.295 1.045 . . . . 0.0 112.82 -174.911 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.509 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 76.4 m-85 -120.83 126.49 50.2 Favored 'General case' 0 N--CA 1.417 -2.099 0 C-N-CA 126.232 1.813 . . . . 0.0 106.241 170.771 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.479 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -108.96 128.85 55.3 Favored 'General case' 0 C--N 1.27 -2.859 0 O-C-N 123.625 0.578 . . . . 0.0 109.632 -178.022 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.622 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -114.36 122.13 45.74 Favored 'General case' 0 N--CA 1.407 -2.596 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.707 -179.593 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 63.4 mtm -116.31 158.83 22.8 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 177.218 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -63.94 117.13 6.56 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 174.454 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.54 -5.52 54.73 Favored Glycine 0 C--N 1.315 -0.622 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -176.858 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' TYR . . . . . 0.429 ' HA ' ' HD3' ' A' ' 19' ' ' PRO . 21.8 m-85 -126.51 136.57 28.85 Favored Pre-proline 0 N--CA 1.436 -1.164 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -179.782 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 18' ' ' TYR . 14.3 Cg_exo -70.21 171.12 15.54 Favored 'Trans proline' 0 N--CA 1.444 -1.399 0 C-N-CA 122.212 1.941 . . . . 0.0 108.628 169.427 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' HIS . . . . . 0.512 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 80.2 m80 -63.55 110.75 2.09 Favored 'General case' 0 C--N 1.312 -1.049 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.722 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 10.4 t-105 -107.88 136.65 19.7 Favored Pre-proline 0 C--N 1.306 -1.304 0 C-N-CA 123.316 0.646 . . . . 0.0 109.885 -171.91 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -62.97 118.14 5.04 Favored 'Trans proline' 0 C--O 1.244 0.782 0 C-N-CA 122.214 1.943 . . . . 0.0 111.137 178.812 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -139.7 166.2 25.24 Favored 'General case' 0 N--CA 1.409 -2.5 0 CA-C-O 121.525 0.679 . . . . 0.0 111.285 -176.145 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.526 HH21 ' CD ' ' A' ' 27' ' ' GLU . 17.2 ttt-85 -111.49 139.01 47.27 Favored 'General case' 0 C--N 1.285 -2.204 0 C-N-CA 124.179 0.992 . . . . 0.0 108.404 177.729 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 58.9 t -75.84 121.86 28.6 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 N-CA-C 104.986 -2.228 . . . . 0.0 104.986 170.656 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.401 ' HB3' ' HB2' ' A' ' 41' ' ' PRO . 3.9 t0 -84.02 172.61 11.86 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 -173.275 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.526 ' CD ' HH21 ' A' ' 24' ' ' ARG . 4.4 mp0 . . . . . 0 N--CA 1.411 -2.398 0 CA-C-O 122.256 1.026 . . . . 0.0 112.522 -177.555 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 86.5 mttt . . . . . 0 N--CA 1.414 -2.266 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 84.4 mt -106.81 146.29 32.79 Favored Pre-proline 0 C--N 1.282 -2.329 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 178.654 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.401 ' HB2' ' HB3' ' A' ' 26' ' ' ASP . 60.1 Cg_endo -73.62 128.95 13.1 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 121.888 1.725 . . . . 0.0 109.395 176.805 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.429 HG21 ' CB ' ' A' ' 13' ' ' ALA . 37.0 mm -118.41 125.73 74.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.987 -0.446 . . . . 0.0 110.799 -174.166 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -109.71 115.34 29.68 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 176.726 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -79.04 139.09 38.22 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-O 121.0 0.429 . . . . 0.0 111.794 179.003 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 -90.26 160.4 16.19 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.385 177.141 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.529 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 73.06 -21.53 1.01 Allowed Glycine 0 C--N 1.311 -0.828 0 C-N-CA 124.932 1.253 . . . . 0.0 114.315 179.228 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.435 HG23 ' HA3' ' A' ' 76' ' ' GLY . 37.1 p -119.98 -22.3 6.78 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 117.559 0.68 . . . . 0.0 109.685 173.037 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.1 m170 66.88 24.87 9.62 Favored 'General case' 0 C--N 1.35 0.629 0 CA-C-N 115.406 -0.815 . . . . 0.0 111.153 -179.517 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -71.94 167.17 20.65 Favored 'General case' 0 C--N 1.347 0.462 0 CA-C-N 115.179 -0.919 . . . . 0.0 108.728 175.764 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.9 m -137.45 145.95 43.74 Favored 'General case' 0 C--N 1.289 -2.034 0 O-C-N 121.576 -0.702 . . . . 0.0 109.581 -178.678 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -150.57 178.43 9.08 Favored 'General case' 0 C--N 1.308 -1.197 0 O-C-N 123.533 0.521 . . . . 0.0 111.404 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -134.26 114.74 13.35 Favored 'General case' 0 C--O 1.262 1.745 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.575 175.945 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.479 HD12 ' HB1' ' A' ' 13' ' ' ALA . 94.6 mt -130.99 158.75 39.45 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -179.159 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.0 172.55 36.92 Favored Glycine 0 N--CA 1.429 -1.796 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.414 ' HA ' HD11 ' A' ' 58' ' ' ILE . 36.4 Cg_endo -65.89 -6.84 15.14 Favored 'Trans proline' 0 C--O 1.21 -0.91 0 C-N-CA 123.046 2.497 . . . . 0.0 112.438 -178.926 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.2 ptmm? -97.52 -5.02 36.76 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 115.333 -0.849 . . . . 0.0 111.764 179.518 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -115.86 5.8 14.14 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -177.868 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.414 HD11 ' HA ' ' A' ' 55' ' ' PRO . 16.8 pt -126.53 150.63 32.37 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 CA-C-N 115.073 -0.967 . . . . 0.0 110.487 -178.639 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 -131.94 135.32 26.45 Favored Pre-proline 0 C--O 1.188 -2.167 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 177.912 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' PRO . . . . . 0.545 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 37.8 Cg_endo -66.82 131.01 24.53 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 C-N-CA 122.841 2.361 . . . . 0.0 114.007 -177.791 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.509 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 65.4 t80 -63.54 -33.79 76.36 Favored 'General case' 0 C--O 1.204 -1.328 0 CA-C-N 114.889 -1.05 . . . . 0.0 112.159 -174.331 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.15 -54.31 35.81 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -177.121 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.545 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 2.1 pm0 -89.68 1.32 56.2 Favored 'General case' 0 N--CA 1.433 -1.298 0 N-CA-C 114.276 1.213 . . . . 0.0 114.276 -178.905 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 26.8 m-80 -122.8 15.18 10.11 Favored 'General case' 0 C--N 1.314 -0.935 0 C-N-CA 123.327 0.651 . . . . 0.0 111.132 175.613 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.46 ' HZ1' ' CG ' ' A' ' 85' ' ' ASP . 16.5 ttmm -65.13 -33.32 75.75 Favored 'General case' 0 N--CA 1.476 0.855 0 CA-C-O 121.579 0.704 . . . . 0.0 110.189 179.473 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.599 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -80.25 -28.95 38.35 Favored 'General case' 0 N--CA 1.403 -2.819 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.098 177.33 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.599 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 8.3 mttm -76.71 -59.09 2.92 Favored 'General case' 0 CA--C 1.505 -0.778 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.253 -179.24 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -112.1 -4.28 14.49 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -173.443 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -75.64 51.76 2.68 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 121.715 -0.279 . . . . 0.0 113.11 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 4.3 ptpp? -132.44 135.71 26.75 Favored Pre-proline 0 C--N 1.311 -1.09 0 O-C-N 122.459 -0.436 . . . . 0.0 110.161 179.144 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -66.91 128.24 18.42 Favored 'Trans proline' 0 C--O 1.25 1.111 0 C-N-CA 122.787 2.325 . . . . 0.0 116.316 -171.178 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 4.8 m-20 -84.69 -168.93 2.39 Favored 'General case' 0 CA--C 1.483 -1.633 0 CA-C-N 113.784 -1.553 . . . . 0.0 108.165 175.311 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.438 ' HD3' ' HA ' ' A' ' 73' ' ' LYS . 39.4 mmtm -108.53 10.49 27.19 Favored 'General case' 0 C--N 1.287 -2.146 0 CA-C-O 121.842 0.829 . . . . 0.0 109.475 175.36 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ARG . . . . . 0.427 HH21 HG21 ' A' ' 47' ' ' THR . 4.5 mmm-85 -77.45 122.8 25.69 Favored 'General case' 0 N--CA 1.417 -2.099 0 CA-C-N 115.04 -0.982 . . . . 0.0 109.199 170.664 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 15.6 tppt? -65.17 129.54 40.1 Favored 'General case' 0 N--CA 1.429 -1.523 0 N-CA-C 107.551 -1.278 . . . . 0.0 107.551 173.58 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.529 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.21 -25.19 20.9 Favored Glycine 0 N--CA 1.415 -2.742 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -176.142 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -76.63 -41.13 47.03 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-O 121.356 0.598 . . . . 0.0 109.39 -178.817 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -71.31 -43.85 66.28 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 -176.289 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 25.2 mp0 -63.11 -41.77 99.42 Favored 'General case' 0 N--CA 1.428 -1.554 0 CA-C-N 113.577 -1.647 . . . . 0.0 109.634 177.712 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -65.38 -37.6 94.02 Favored Glycine 0 N--CA 1.44 -1.052 0 CA-C-N 115.449 -0.796 . . . . 0.0 112.804 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 87.9 mt -59.56 -35.12 73.62 Favored 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 176.094 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.3 t90 -74.29 -50.32 19.38 Favored 'General case' 0 N--CA 1.425 -1.712 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.295 177.501 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 26.8 mt-10 -53.74 -49.94 67.06 Favored 'General case' 0 C--O 1.188 -2.175 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -179.512 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.8 tt -67.99 -23.48 29.09 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 N-CA-C 112.256 0.465 . . . . 0.0 112.256 -173.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' ASP . . . . . 0.46 ' CG ' ' HZ1' ' A' ' 65' ' ' LYS . 15.2 t70 -94.21 -32.52 13.66 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-O 121.497 0.665 . . . . 0.0 110.05 -175.053 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -103.43 -44.89 5.02 Favored 'General case' 0 C--O 1.257 1.456 0 CA-C-O 121.911 0.862 . . . . 0.0 111.504 -176.679 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 60.7 t30 -131.76 61.32 57.65 Favored Pre-proline 0 C--N 1.296 -1.73 0 C-N-CA 119.983 -0.687 . . . . 0.0 112.329 -176.595 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -71.12 -7.68 21.91 Favored 'Trans proline' 0 C--N 1.372 1.789 0 C-N-CA 122.19 1.926 . . . . 0.0 110.465 179.078 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' LYS . . . . . 0.409 ' H ' ' HG2' ' A' ' 89' ' ' LYS . 22.7 pttm . . . . . 0 C--N 1.307 -1.249 0 CA-C-N 113.159 -1.837 . . . . 0.0 109.197 -175.49 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 . . . . . 0 N--CA 1.397 -3.124 0 CA-C-O 121.514 0.673 . . . . 0.0 109.399 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 25.9 mtmm -120.67 156.65 55.82 Favored Pre-proline 0 C--N 1.274 -2.677 0 CA-C-N 113.886 -1.506 . . . . 0.0 107.695 -172.287 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.444 ' HB3' ' HA ' ' A' ' 27' ' ' GLU . 52.5 Cg_exo -57.4 120.94 9.19 Favored 'Trans proline' 0 N--CA 1.461 -0.436 0 C-N-CA 121.825 1.683 . . . . 0.0 110.566 176.311 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.22 -24.28 10.03 Favored Glycine 0 N--CA 1.426 -2.029 0 CA-C-O 119.138 -0.812 . . . . 0.0 113.452 -178.426 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 32.8 m-20 -63.3 137.31 58.14 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 117.769 0.784 . . . . 0.0 111.725 -179.181 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 95.6 mt -90.18 126.58 35.86 Favored 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 176.64 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -142.08 -174.97 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-O 122.197 0.998 . . . . 0.0 112.899 -174.497 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -115.71 130.0 56.69 Favored 'General case' 0 C--N 1.28 -2.431 0 CA-C-N 114.083 -1.417 . . . . 0.0 107.416 170.335 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.621 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -107.43 114.36 28.31 Favored 'General case' 0 C--N 1.275 -2.654 0 CA-C-N 114.866 -1.061 . . . . 0.0 109.426 -173.372 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.616 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.9 OUTLIER -103.76 128.24 51.16 Favored 'General case' 0 C--N 1.264 -3.129 0 CA-C-N 114.343 -1.299 . . . . 0.0 109.54 -178.597 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.402 ' HB2' ' HB2' ' A' ' 18' ' ' TYR . 68.2 mtm -113.84 158.25 21.27 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.967 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -70.26 116.77 11.0 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 120.607 -0.437 . . . . 0.0 109.879 -178.626 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 93.99 0.11 66.36 Favored Glycine 0 N--CA 1.448 -0.518 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.97 178.92 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' TYR . . . . . 0.402 ' HB2' ' HB2' ' A' ' 15' ' ' MET . 99.5 m-85 -129.75 152.23 79.47 Favored Pre-proline 0 N--CA 1.439 -0.996 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 -177.825 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -68.97 170.33 15.87 Favored 'Trans proline' 0 N--CA 1.457 -0.652 0 C-N-CA 122.4 2.067 . . . . 0.0 112.197 177.811 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 57.5 m80 -71.5 114.26 9.4 Favored 'General case' 0 CA--C 1.552 1.02 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.605 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 11.1 t-105 -101.35 136.91 19.55 Favored Pre-proline 0 C--N 1.31 -1.127 0 C-N-CA 123.142 0.577 . . . . 0.0 109.468 -176.604 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -64.77 117.87 4.91 Favored 'Trans proline' 0 CA--C 1.542 0.911 0 C-N-CA 121.978 1.786 . . . . 0.0 110.741 177.624 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.55 167.12 24.5 Favored 'General case' 0 N--CA 1.426 -1.66 0 CA-C-O 121.242 0.544 . . . . 0.0 111.214 -174.512 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.411 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 41.9 ttt-85 -115.4 143.52 45.17 Favored 'General case' 0 C--N 1.291 -1.965 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 179.552 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 64.9 t -79.21 114.2 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 104.385 -2.45 . . . . 0.0 104.385 168.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -90.74 -179.55 5.55 Favored 'General case' 0 C--N 1.29 -1.985 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.878 -171.45 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.444 ' HA ' ' HB3' ' A' ' 7' ' ' PRO . 32.2 mp0 . . . . . 0 N--CA 1.439 -0.993 0 CA-C-O 121.948 0.88 . . . . 0.0 112.593 -175.9 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.435 ' HE2' ' N ' ' A' ' 54' ' ' GLY . 8.9 mmpt? . . . . . 0 N--CA 1.429 -1.518 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 87.8 mt -128.41 155.59 78.32 Favored Pre-proline 0 C--N 1.283 -2.298 0 C-N-CA 125.306 1.442 . . . . 0.0 107.253 178.763 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -71.22 122.8 9.05 Favored 'Trans proline' 0 CA--C 1.536 0.617 0 C-N-CA 121.697 1.598 . . . . 0.0 110.679 177.552 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.462 HG13 ' HB2' ' A' ' 53' ' ' LEU . 49.2 mm -122.51 124.68 71.3 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.083 0 CA-C-O 120.753 0.311 . . . . 0.0 110.355 -176.377 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 80.9 t80 -106.96 116.41 31.87 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 178.756 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -79.27 132.09 36.36 Favored 'General case' 0 C--O 1.244 0.805 0 CA-C-O 121.016 0.436 . . . . 0.0 110.923 179.746 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.411 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 66.9 m-85 -82.81 158.6 22.71 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.029 178.829 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.51 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 74.99 -20.11 1.97 Allowed Glycine 0 C--O 1.256 1.473 0 C-N-CA 124.513 1.054 . . . . 0.0 114.454 178.787 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.537 HG23 ' HA3' ' A' ' 76' ' ' GLY . 31.2 p -119.32 -23.88 6.57 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 122.237 -0.566 . . . . 0.0 109.957 175.273 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 44.8 m170 67.74 23.09 8.71 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.432 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -74.98 166.43 23.67 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 176.352 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.5 m -137.11 145.71 44.21 Favored 'General case' 0 C--N 1.286 -2.192 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 -179.758 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -146.76 179.52 7.51 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 123.136 0.575 . . . . 0.0 109.71 -179.526 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -131.75 109.29 10.05 Favored 'General case' 0 N--CA 1.432 -1.339 0 N-CA-C 109.003 -0.739 . . . . 0.0 109.003 176.488 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.621 HD12 ' HB1' ' A' ' 13' ' ' ALA . 88.7 mt -130.26 149.29 52.02 Favored 'General case' 0 C--N 1.287 -2.145 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 -178.826 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.435 ' N ' ' HE2' ' A' ' 39' ' ' LYS . . . -95.37 178.07 35.29 Favored Glycine 0 N--CA 1.417 -2.57 0 C-N-CA 119.707 -1.235 . . . . 0.0 112.104 -174.059 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.1 -9.3 16.6 Favored 'Trans proline' 0 N--CA 1.479 0.667 0 C-N-CA 123.224 2.616 . . . . 0.0 111.831 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 42.6 mtmt -98.29 -1.57 41.5 Favored 'General case' 0 N--CA 1.431 -1.385 0 CA-C-N 114.879 -1.055 . . . . 0.0 110.705 -179.653 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.54 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 36.8 m-20 -115.22 -9.65 12.22 Favored 'General case' 0 CA--C 1.5 -0.957 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.484 -179.436 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 9.5 pt -119.91 152.71 22.65 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.127 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.751 -173.562 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -138.99 147.59 54.42 Favored Pre-proline 0 C--N 1.297 -1.68 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -178.416 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' PRO . . . . . 0.533 ' HG2' ' OE2' ' A' ' 63' ' ' GLU . 11.7 Cg_endo -58.11 139.61 91.1 Favored 'Trans proline' 0 CA--C 1.516 -0.383 0 C-N-CA 122.758 2.305 . . . . 0.0 114.432 -175.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.403 ' O ' ' HB3' ' A' ' 65' ' ' LYS . 16.3 t80 -65.18 -35.84 82.33 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 115.214 -0.903 . . . . 0.0 111.451 177.151 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 10.5 m -48.91 -57.19 6.84 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 112.953 0.723 . . . . 0.0 112.953 -175.319 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.533 ' OE2' ' HG2' ' A' ' 60' ' ' PRO . 0.0 OUTLIER -95.79 -14.43 23.29 Favored 'General case' 0 N--CA 1.432 -1.352 0 N-CA-C 114.903 1.446 . . . . 0.0 114.903 178.867 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.454 ' HB2' ' O ' ' A' ' 60' ' ' PRO . 22.6 m-80 -88.85 -8.0 55.12 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 121.681 -0.637 . . . . 0.0 112.648 179.221 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.418 ' O ' ' HA3' ' A' ' 69' ' ' GLY . 11.6 ptmm? -60.52 -38.28 83.88 Favored 'General case' 0 C--O 1.201 -1.466 0 CA-C-O 121.182 0.515 . . . . 0.0 111.308 -176.89 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 55.9 mm-40 -82.3 -33.85 28.89 Favored 'General case' 0 CA--C 1.477 -1.832 0 C-N-CA 119.453 -0.899 . . . . 0.0 112.426 177.494 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 29.9 mtmm -67.52 -58.92 3.87 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 124.725 1.265 . . . . 0.0 111.526 -176.118 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 84.4 m-85 -111.66 -1.87 15.57 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-O 121.551 0.691 . . . . 0.0 111.447 -175.632 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' GLY . . . . . 0.418 ' HA3' ' O ' ' A' ' 65' ' ' LYS . . . -91.46 54.68 3.13 Favored Glycine 0 N--CA 1.429 -1.775 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 177.96 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.497 ' HA ' ' HE3' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -117.93 149.06 44.68 Favored Pre-proline 0 C--N 1.299 -1.623 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 177.709 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.501 ' HB3' ' OD1' ' A' ' 78' ' ' ASN . 70.2 Cg_exo -49.43 146.65 13.8 Favored 'Trans proline' 0 C--O 1.243 0.727 0 C-N-CA 123.338 2.692 . . . . 0.0 114.868 -176.828 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -131.0 -171.06 2.48 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.829 -178.617 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 45.9 mmtm -104.9 -11.05 16.91 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-O 121.235 0.541 . . . . 0.0 109.618 179.538 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 3.2 mmm180 -73.57 121.64 20.96 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.039 173.176 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.94 127.47 31.54 Favored 'General case' 0 N--CA 1.435 -1.189 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 174.226 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.537 ' HA3' HG23 ' A' ' 47' ' ' THR . . . 108.86 -21.12 28.15 Favored Glycine 0 N--CA 1.409 -3.132 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.854 -177.61 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.563 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 12.6 t80 -76.26 -43.2 42.91 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 -179.435 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.501 ' OD1' ' HB3' ' A' ' 71' ' ' PRO . 52.5 m-80 -70.66 -43.25 69.51 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.739 -178.808 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -68.36 -33.3 74.04 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 115.362 -0.836 . . . . 0.0 109.771 179.011 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -66.73 -34.94 88.91 Favored Glycine 0 CA--C 1.491 -1.423 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.797 178.64 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.563 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 98.2 mt -62.26 -41.57 98.56 Favored 'General case' 0 C--O 1.212 -0.915 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 174.922 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 85.7 t90 -65.5 -45.85 81.97 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.647 178.564 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 54.9 mt-10 -59.72 -47.46 85.56 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 112.837 0.68 . . . . 0.0 112.837 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.8 tt -74.85 -27.48 20.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 C-N-CA 120.248 -0.581 . . . . 0.0 111.959 -175.174 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -84.39 -10.89 57.17 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 122.647 0.379 . . . . 0.0 111.83 178.913 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 32.3 m-80 -125.32 -56.29 1.53 Allowed 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -175.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -123.62 79.69 55.29 Favored Pre-proline 0 C--N 1.315 -0.932 0 CA-C-O 121.17 0.51 . . . . 0.0 110.479 -177.23 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -68.62 -6.96 19.07 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 123.129 2.552 . . . . 0.0 115.01 -175.155 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 7.3 ptmm? . . . . . 0 C--O 1.263 1.77 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 177.279 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 . . . . . 0 N--CA 1.413 -2.303 0 CA-C-O 121.089 0.471 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.8 mppt? -101.01 151.42 37.62 Favored Pre-proline 0 C--N 1.303 -1.454 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 -174.117 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -59.13 121.85 10.6 Favored 'Trans proline' 0 C--O 1.235 0.328 0 C-N-CA 122.145 1.896 . . . . 0.0 110.278 174.613 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 111.43 -11.37 28.38 Favored Glycine 0 N--CA 1.43 -1.721 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.889 -177.963 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -79.13 162.41 25.83 Favored 'General case' 0 C--O 1.258 1.532 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 -177.873 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.425 HD21 ' HB2' ' A' ' 88' ' ' PRO . 99.0 mt -114.56 129.22 56.65 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 123.442 0.697 . . . . 0.0 109.127 -175.779 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.9 pp -142.75 -177.87 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 CA-C-O 121.856 0.836 . . . . 0.0 112.672 -172.566 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.487 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 66.0 m-85 -119.91 118.86 31.86 Favored 'General case' 0 C--N 1.289 -2.048 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 172.738 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.504 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -112.67 143.11 44.43 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.46 -173.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.617 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -119.74 123.53 43.97 Favored 'General case' 0 N--CA 1.4 -2.947 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.348 -178.206 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 71.2 mtm -113.77 158.53 20.84 Favored 'General case' 0 CA--C 1.5 -0.981 0 N-CA-C 108.52 -0.918 . . . . 0.0 108.52 175.315 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 29.1 tptp -69.61 124.07 22.99 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 120.41 -0.516 . . . . 0.0 109.828 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.97 -12.55 60.7 Favored Glycine 0 C--N 1.303 -1.303 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.086 -176.765 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 72.3 m-85 -117.99 148.87 44.37 Favored Pre-proline 0 N--CA 1.433 -1.315 0 C-N-CA 123.088 0.555 . . . . 0.0 110.501 179.602 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -79.52 171.84 15.27 Favored 'Trans proline' 0 N--CA 1.449 -1.104 0 C-N-CA 122.315 2.01 . . . . 0.0 108.483 170.896 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' HIS . . . . . 0.535 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 79.7 m80 -57.95 111.86 1.31 Allowed 'General case' 0 CA--C 1.537 0.472 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 175.21 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 10.2 t-105 -112.33 142.27 26.64 Favored Pre-proline 0 C--N 1.294 -1.807 0 C-N-CA 123.983 0.913 . . . . 0.0 108.872 -169.957 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -62.63 118.49 5.38 Favored 'Trans proline' 0 C--O 1.245 0.847 0 C-N-CA 122.326 2.018 . . . . 0.0 110.57 178.054 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.45 166.98 23.2 Favored 'General case' 0 N--CA 1.41 -2.46 0 CA-C-O 121.702 0.763 . . . . 0.0 111.481 -175.874 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.417 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 36.3 ttt85 -114.38 139.42 49.49 Favored 'General case' 0 C--N 1.276 -2.63 0 C-N-CA 124.255 1.022 . . . . 0.0 110.604 -177.358 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 50.3 t -82.19 110.15 17.06 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.991 0 N-CA-C 104.025 -2.583 . . . . 0.0 104.025 169.77 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -91.45 168.12 11.77 Favored 'General case' 0 C--N 1.274 -2.707 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.107 -169.387 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.305 -1.361 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 177.509 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 84.1 mttt . . . . . 0 N--CA 1.417 -2.102 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 72.8 mt -118.15 146.98 40.53 Favored Pre-proline 0 C--N 1.285 -2.2 0 O-C-N 124.364 1.04 . . . . 0.0 108.79 -178.89 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -72.95 123.3 8.8 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 C-N-CA 121.724 1.616 . . . . 0.0 109.524 175.382 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 48.7 mm -115.84 115.6 49.76 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.121 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.21 -175.809 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 74.3 t80 -95.63 115.95 28.16 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 178.58 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.425 ' HE1' ' HB3' ' A' ' 51' ' ' ALA . 74.2 m-85 -82.66 133.67 35.16 Favored 'General case' 0 C--N 1.293 -1.86 0 N-CA-C 112.686 0.625 . . . . 0.0 112.686 179.82 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.417 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 71.6 m-85 -84.21 151.0 25.1 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.641 179.523 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.538 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 78.14 -20.45 3.92 Favored Glycine 0 C--N 1.305 -1.188 0 C-N-CA 123.816 0.722 . . . . 0.0 114.109 178.835 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 32.0 p -119.07 -22.66 7.13 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 117.412 0.606 . . . . 0.0 109.939 175.085 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.8 m-70 66.43 22.49 10.71 Favored 'General case' 0 C--N 1.35 0.607 0 C-N-CA 123.667 0.787 . . . . 0.0 112.024 179.393 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -74.31 161.88 29.44 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 176.344 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.3 m -136.04 135.96 39.85 Favored 'General case' 0 C--N 1.278 -2.503 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 176.749 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ALA . . . . . 0.425 ' HB3' ' HE1' ' A' ' 44' ' ' PHE . . . -136.28 178.92 6.68 Favored 'General case' 0 C--N 1.277 -2.572 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.151 -177.046 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -133.49 109.65 9.42 Favored 'General case' 0 C--O 1.262 1.761 0 CA-C-N 115.326 -0.852 . . . . 0.0 108.713 175.066 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.504 HD12 ' HB1' ' A' ' 13' ' ' ALA . 64.8 mt -125.49 161.94 26.01 Favored 'General case' 0 C--N 1.29 -1.999 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 -178.612 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.53 169.58 35.95 Favored Glycine 0 N--CA 1.422 -2.25 0 C-N-CA 119.878 -1.153 . . . . 0.0 110.296 -179.451 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.85 -6.59 14.51 Favored 'Trans proline' 0 C--O 1.212 -0.818 0 C-N-CA 123.087 2.525 . . . . 0.0 112.223 -179.503 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 5.9 ptmm? -97.73 -2.06 42.07 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 115.358 -0.837 . . . . 0.0 111.768 178.985 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -116.13 6.37 13.96 Favored 'General case' 0 C--N 1.293 -1.875 0 CA-C-O 121.134 0.492 . . . . 0.0 112.158 -179.069 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 11.5 pt -130.55 152.42 37.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.599 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -139.28 147.47 53.1 Favored Pre-proline 0 C--N 1.303 -1.434 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -178.84 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -60.55 129.82 31.05 Favored 'Trans proline' 0 N--CA 1.481 0.786 0 C-N-CA 123.2 2.6 . . . . 0.0 112.919 -177.003 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.487 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 3.4 t80 -58.67 -34.28 71.06 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 113.819 1.044 . . . . 0.0 113.819 -177.526 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 30.4 t -60.62 -57.96 10.5 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 123.427 0.455 . . . . 0.0 111.226 -177.786 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 15.9 mp0 -75.72 -27.36 58.14 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-O 122.059 0.933 . . . . 0.0 110.988 -175.434 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 37.5 m-80 -95.54 5.09 52.42 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 113.484 0.92 . . . . 0.0 113.484 -176.023 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.444 ' HE2' ' CE1' ' A' ' 61' ' ' TYR . 17.6 ttmm -62.69 -39.09 92.9 Favored 'General case' 0 C--O 1.21 -1.024 0 CA-C-O 120.986 0.422 . . . . 0.0 111.295 177.55 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.465 ' HA ' ' HD3' ' A' ' 70' ' ' LYS . 38.8 mm-40 -80.91 -16.81 52.58 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-O 122.008 0.908 . . . . 0.0 112.205 177.901 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 19.3 mtpp -85.2 -56.7 3.41 Favored 'General case' 0 C--N 1.268 -2.941 0 CA-C-N 114.462 -1.244 . . . . 0.0 111.733 -178.575 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 35.1 m-85 -125.4 5.25 7.67 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.08 -174.023 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -99.98 25.41 28.38 Favored Glycine 0 C--N 1.304 -1.201 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 -178.416 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.465 ' HD3' ' HA ' ' A' ' 66' ' ' GLU . 27.7 mmmt -96.8 153.33 38.69 Favored Pre-proline 0 C--N 1.307 -1.281 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 -179.173 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -58.31 128.2 27.67 Favored 'Trans proline' 0 C--O 1.252 1.18 0 C-N-CA 121.981 1.787 . . . . 0.0 112.974 -179.517 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 16.2 m-80 -114.82 177.64 4.57 Favored 'General case' 0 CA--C 1.47 -2.113 0 CA-C-N 114.955 -1.02 . . . . 0.0 112.226 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.558 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 9.5 mptt -96.03 7.45 46.34 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 113.84 -1.527 . . . . 0.0 108.385 -178.37 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 11.1 mmt180 -88.27 122.79 32.2 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 175.177 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 10.2 tptp -77.04 144.38 38.65 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 177.278 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.538 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 95.13 -26.47 19.0 Favored Glycine 0 C--O 1.21 -1.367 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -173.873 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.466 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 27.0 t80 -76.61 -41.36 46.29 Favored 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 178.153 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 11.6 m120 -61.4 -49.22 77.77 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 177.886 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 6.1 mp0 -60.85 -40.73 94.0 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 113.711 -1.586 . . . . 0.0 110.352 179.309 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -67.54 -35.75 87.1 Favored Glycine 0 N--CA 1.44 -1.034 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.821 179.432 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.466 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 94.8 mt -61.92 -37.18 83.72 Favored 'General case' 0 C--O 1.218 -0.574 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 175.386 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 85.3 t90 -67.98 -48.34 66.06 Favored 'General case' 0 N--CA 1.427 -1.597 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.46 177.605 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -59.14 -46.7 87.67 Favored 'General case' 0 C--O 1.206 -1.196 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 179.719 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.402 HD11 ' HB3' ' A' ' 10' ' ' LEU . 19.0 tt -71.79 -27.83 28.95 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 C-N-CA 120.619 -0.432 . . . . 0.0 112.164 -174.842 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -89.57 -11.51 42.53 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 112.262 0.468 . . . . 0.0 112.262 -179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 32.4 m-80 -120.81 -57.55 1.88 Allowed 'General case' 0 N--CA 1.477 0.912 0 CA-C-O 121.16 0.505 . . . . 0.0 112.052 -176.813 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -128.59 73.64 80.63 Favored Pre-proline 0 C--N 1.308 -1.214 0 C-N-CA 120.418 -0.513 . . . . 0.0 110.305 -179.386 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.425 ' HB2' HD21 ' A' ' 10' ' ' LEU . 41.3 Cg_endo -70.13 -6.13 18.06 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 C-N-CA 123.178 2.585 . . . . 0.0 112.431 -176.97 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.9 pttp . . . . . 0 C--N 1.291 -1.969 0 CA-C-N 114.261 -1.336 . . . . 0.0 110.152 -179.651 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 . . . . . 0 N--CA 1.43 -1.469 0 N-CA-C 109.138 -0.689 . . . . 0.0 109.138 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -134.07 155.77 79.79 Favored Pre-proline 0 C--N 1.301 -1.538 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.298 179.587 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_exo -45.43 125.52 7.53 Favored 'Trans proline' 0 C--N 1.359 1.086 0 C-N-CA 123.554 2.836 . . . . 0.0 113.05 177.959 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 115.33 -25.44 9.82 Favored Glycine 0 N--CA 1.428 -1.837 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.871 -179.352 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -74.66 151.57 39.27 Favored 'General case' 0 C--O 1.257 1.466 0 CA-C-O 121.501 0.667 . . . . 0.0 111.564 -177.862 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.421 HD22 HG13 ' A' ' 84' ' ' ILE . 79.3 mt -103.38 124.38 48.58 Favored 'General case' 0 N--CA 1.424 -1.731 0 CA-C-N 114.707 -1.133 . . . . 0.0 110.134 -175.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 8.1 pt -137.11 -173.89 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.896 0 CA-C-O 122.752 1.263 . . . . 0.0 112.2 -173.344 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.448 ' CD1' ' HB2' ' A' ' 64' ' ' ASN . 22.0 m-85 -125.49 131.26 52.87 Favored 'General case' 0 N--CA 1.399 -2.99 0 N-CA-C 105.277 -2.12 . . . . 0.0 105.277 170.879 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.554 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -107.47 128.39 54.45 Favored 'General case' 0 C--N 1.265 -3.081 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.011 -174.027 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.593 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -120.02 117.85 29.09 Favored 'General case' 0 N--CA 1.389 -3.524 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 -179.03 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.477 ' HB2' ' HB2' ' A' ' 18' ' ' TYR . 82.1 mtp -97.08 158.39 15.46 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.053 -177.922 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.6 tttp -67.23 115.8 7.3 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 176.38 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.56 -18.53 55.05 Favored Glycine 0 N--CA 1.446 -0.681 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.429 179.729 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' TYR . . . . . 0.477 ' HB2' ' HB2' ' A' ' 15' ' ' MET . 88.1 m-85 -119.96 143.86 36.24 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 117.117 0.459 . . . . 0.0 111.173 -177.744 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -68.85 170.95 14.31 Favored 'Trans proline' 0 CA--C 1.539 0.73 0 C-N-CA 123.115 2.543 . . . . 0.0 112.853 179.445 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' HIS . . . . . 0.543 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 77.3 m80 -60.86 122.16 14.17 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.97 179.64 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 15.1 t-105 -121.58 137.48 27.11 Favored Pre-proline 0 C--N 1.304 -1.401 0 N-CA-C 107.497 -1.298 . . . . 0.0 107.497 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -61.09 123.62 13.24 Favored 'Trans proline' 0 C--O 1.243 0.736 0 C-N-CA 122.426 2.084 . . . . 0.0 111.507 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.9 166.71 24.16 Favored 'General case' 0 N--CA 1.422 -1.864 0 CA-C-O 121.39 0.614 . . . . 0.0 111.806 -176.764 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 46.7 ttt85 -114.02 139.94 48.85 Favored 'General case' 0 C--N 1.296 -1.745 0 CA-C-N 115.307 -0.86 . . . . 0.0 109.762 178.76 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.5 t -85.98 115.53 27.45 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 104.678 -2.342 . . . . 0.0 104.678 169.801 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.416 ' O ' ' HG2' ' A' ' 41' ' ' PRO . 3.6 t70 -99.71 -178.0 3.74 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 119.356 -0.937 . . . . 0.0 110.533 -173.592 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 . . . . . 0 N--CA 1.43 -1.441 0 CA-C-O 121.593 0.711 . . . . 0.0 112.017 -174.102 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.522 ' HA ' ' HA2' ' A' ' 54' ' ' GLY . 56.5 mttm . . . . . 0 N--CA 1.412 -2.333 0 CA-C-O 121.179 0.514 . . . . 0.0 111.274 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 71.0 mt -122.05 157.03 59.03 Favored Pre-proline 0 C--N 1.279 -2.467 0 CA-C-N 113.615 -1.629 . . . . 0.0 108.491 -176.646 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.416 ' HG2' ' O ' ' A' ' 26' ' ' ASP . 47.5 Cg_endo -75.4 122.59 7.11 Favored 'Trans proline' 0 N--CA 1.456 -0.682 0 C-N-CA 121.796 1.664 . . . . 0.0 109.978 174.369 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.432 HG13 ' HB2' ' A' ' 53' ' ' LEU . 41.2 mm -116.8 122.72 70.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -175.73 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 86.0 t80 -103.45 116.05 31.67 Favored 'General case' 0 C--N 1.282 -2.347 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 178.627 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 -76.71 129.66 36.65 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-O 121.047 0.451 . . . . 0.0 112.022 179.448 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.473 ' HB3' ' HA2' ' A' ' 80' ' ' GLY . 60.3 m-85 -78.96 151.33 31.7 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.258 177.581 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.523 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 77.28 -19.7 3.59 Favored Glycine 0 C--O 1.254 1.38 0 N-CA-C 114.534 0.573 . . . . 0.0 114.534 177.008 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 46.4 p -119.23 -23.04 6.89 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 117.43 0.615 . . . . 0.0 110.248 174.708 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.0 m-70 68.76 21.68 7.67 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.975 0.91 . . . . 0.0 112.546 179.176 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -80.28 164.89 22.85 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.838 178.812 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 2.2 m -130.29 140.16 50.68 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.241 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -141.24 -179.72 6.28 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 123.641 0.776 . . . . 0.0 109.843 -178.358 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -133.19 112.32 11.62 Favored 'General case' 0 C--O 1.249 1.038 0 CA-C-O 121.605 0.717 . . . . 0.0 110.464 178.751 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.554 HD12 ' HB1' ' A' ' 13' ' ' ALA . 82.0 mt -135.84 147.4 48.24 Favored 'General case' 0 C--N 1.29 -1.993 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.522 ' HA2' ' HA ' ' A' ' 39' ' ' LYS . . . -94.77 177.23 35.54 Favored Glycine 0 CA--C 1.479 -2.169 0 C-N-CA 119.908 -1.139 . . . . 0.0 111.554 -177.196 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -62.25 -17.47 57.19 Favored 'Trans proline' 0 C--O 1.212 -0.821 0 C-N-CA 123.249 2.632 . . . . 0.0 112.096 -177.535 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.55 1.47 48.97 Favored 'General case' 0 N--CA 1.425 -1.708 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.964 178.111 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.538 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 71.9 m-20 -107.92 -16.25 14.35 Favored 'General case' 0 C--N 1.29 -2.021 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.209 176.863 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.438 HG12 ' O ' ' A' ' 54' ' ' GLY . 12.0 pt -117.55 157.28 18.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.057 -174.059 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -137.92 143.31 39.35 Favored Pre-proline 0 C--N 1.297 -1.711 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -69.29 148.44 68.13 Favored 'Trans proline' 0 C--O 1.245 0.873 0 C-N-CA 122.975 2.45 . . . . 0.0 114.934 -172.516 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 54.4 t80 -55.82 -34.71 65.6 Favored 'General case' 0 C--O 1.221 -0.434 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.078 177.002 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.1 m -52.86 -44.24 66.67 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.169 -0.923 . . . . 0.0 112.224 -179.028 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -93.3 -26.55 17.26 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 121.644 0.735 . . . . 0.0 111.497 -177.089 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.448 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 16.8 m120 -91.21 0.57 57.5 Favored 'General case' 0 C--O 1.203 -1.377 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -174.446 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.555 ' HZ3' ' CD ' ' A' ' 66' ' ' GLU . 4.5 ttpm? -65.95 -47.68 73.83 Favored 'General case' 0 C--N 1.29 -2.006 0 CA-C-O 121.446 0.641 . . . . 0.0 110.079 179.292 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.555 ' CD ' ' HZ3' ' A' ' 65' ' ' LYS . 12.1 mp0 -68.7 -36.34 78.35 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-O 122.331 1.062 . . . . 0.0 109.65 178.306 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 47.4 mtmt -79.16 -59.75 2.64 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 114.264 -1.335 . . . . 0.0 112.764 -174.34 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' TYR . . . . . 0.405 ' HD2' HD21 ' A' ' 64' ' ' ASN . 47.8 m-85 -121.73 4.43 10.04 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 112.394 0.516 . . . . 0.0 112.394 -172.23 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -82.35 34.11 2.69 Favored Glycine 0 CA--C 1.524 0.649 0 C-N-CA 121.28 -0.486 . . . . 0.0 113.211 -177.454 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 2.6 mppt? -122.92 144.37 42.85 Favored Pre-proline 0 N--CA 1.439 -1.017 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.318 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' PRO . . . . . 0.48 ' HB3' ' OD1' ' A' ' 78' ' ' ASN . 82.8 Cg_exo -46.19 128.67 12.18 Favored 'Trans proline' 0 C--O 1.263 1.772 0 C-N-CA 123.984 3.123 . . . . 0.0 115.142 -176.248 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ASN . . . . . 0.52 ' HB2' ' CD1' ' A' ' 77' ' ' PHE . 1.7 t-20 -102.73 -166.96 1.33 Allowed 'General case' 0 C--N 1.269 -2.9 0 CA-C-N 114.516 -1.22 . . . . 0.0 109.356 -178.208 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.458 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 1.9 mptp? -120.61 18.39 12.0 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 178.332 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 37.1 mmt180 -102.75 132.46 48.89 Favored 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 114.343 -1.298 . . . . 0.0 109.269 176.543 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.8 tmtm? -68.37 127.66 33.76 Favored 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 175.477 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.523 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 107.17 -25.67 21.29 Favored Glycine 0 N--CA 1.416 -2.637 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.29 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.557 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 16.0 t80 -76.56 -45.4 30.69 Favored 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 -178.088 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.48 ' OD1' ' HB3' ' A' ' 71' ' ' PRO . 53.6 m-80 -71.61 -41.8 68.46 Favored 'General case' 0 CA--C 1.498 -1.045 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.45 -178.459 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -67.76 -33.64 75.23 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.18 179.487 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.473 ' HA2' ' HB3' ' A' ' 45' ' ' PHE . . . -70.97 -34.71 65.05 Favored Glycine 0 N--CA 1.43 -1.741 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.984 178.342 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.557 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 95.3 mt -61.97 -35.23 77.85 Favored 'General case' 0 C--O 1.215 -0.727 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 174.483 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 71.3 t90 -71.37 -48.78 47.89 Favored 'General case' 0 N--CA 1.431 -1.397 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.326 176.598 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -58.87 -40.53 84.64 Favored 'General case' 0 C--O 1.2 -1.537 0 N-CA-C 112.944 0.72 . . . . 0.0 112.944 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.421 HG13 HD22 ' A' ' 10' ' ' LEU . 19.0 tt -71.27 -21.36 21.8 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 CA-C-O 121.128 0.489 . . . . 0.0 110.795 -175.506 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -92.1 -43.78 9.18 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.066 -177.359 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -92.52 -44.27 8.72 Favored 'General case' 0 N--CA 1.481 1.115 0 CA-C-O 121.327 0.584 . . . . 0.0 112.182 -173.528 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.506 ' OD1' ' HG3' ' A' ' 89' ' ' LYS . 61.5 t30 -133.36 67.91 76.68 Favored Pre-proline 0 C--N 1.299 -1.614 0 C-N-CA 119.809 -0.756 . . . . 0.0 110.786 -178.698 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -68.09 -6.75 17.96 Favored 'Trans proline' 0 C--N 1.369 1.637 0 C-N-CA 123.193 2.595 . . . . 0.0 111.65 -178.227 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' LYS . . . . . 0.506 ' HG3' ' OD1' ' A' ' 87' ' ' ASN . 5.5 ptmm? . . . . . 0 C--N 1.297 -1.684 0 CA-C-N 113.941 -1.481 . . . . 0.0 110.825 179.812 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' PHE . . . . . 0.45 ' HB3' HG21 ' A' ' 25' ' ' VAL . 67.6 m-85 . . . . . 0 N--CA 1.423 -1.805 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.419 ' O ' ' HB2' ' A' ' 9' ' ' ASP . 48.4 mttm -96.35 144.3 27.61 Favored Pre-proline 0 C--N 1.294 -1.831 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.918 -170.364 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -58.0 116.02 2.94 Favored 'Trans proline' 0 N--CA 1.462 -0.369 0 C-N-CA 121.731 1.621 . . . . 0.0 110.002 175.133 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 109.52 -7.4 32.04 Favored Glycine 0 N--CA 1.433 -1.543 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.335 -176.817 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ASP . . . . . 0.419 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 5.2 t70 -69.57 152.57 44.62 Favored 'General case' 0 C--O 1.251 1.175 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -177.86 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.4 mt -104.91 120.91 42.57 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 121.375 0.607 . . . . 0.0 109.85 -175.955 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.0 pt -140.45 -175.49 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.416 -2.165 0 CA-C-O 122.25 1.024 . . . . 0.0 112.024 -174.734 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.485 ' HD2' ' ND2' ' A' ' 64' ' ' ASN . 56.1 m-85 -124.62 128.95 49.65 Favored 'General case' 0 N--CA 1.409 -2.497 0 N-CA-C 105.64 -1.985 . . . . 0.0 105.64 171.068 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.497 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -117.02 141.41 48.29 Favored 'General case' 0 C--N 1.278 -2.513 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.798 -176.62 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.626 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -123.24 124.46 43.07 Favored 'General case' 0 N--CA 1.405 -2.72 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.693 -177.437 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.496 ' HG2' HD21 ' A' ' 53' ' ' LEU . 44.6 mtm -115.87 158.2 23.32 Favored 'General case' 0 CA--C 1.499 -1.017 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 175.574 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.3 tttp -65.45 116.91 7.23 Favored 'General case' 0 C--N 1.311 -1.095 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 178.305 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.33 -12.38 58.49 Favored Glycine 0 C--O 1.247 0.93 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -178.058 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 7.8 m-85 -110.59 149.46 40.32 Favored Pre-proline 0 C--N 1.307 -1.279 0 C-N-CA 123.196 0.598 . . . . 0.0 109.872 178.528 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -81.41 171.45 13.61 Favored 'Trans proline' 0 N--CA 1.442 -1.512 0 C-N-CA 122.118 1.879 . . . . 0.0 108.173 171.323 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' HIS . . . . . 0.474 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 80.8 m80 -64.46 111.28 2.61 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 174.829 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 9.6 t-105 -110.85 141.03 23.29 Favored Pre-proline 0 C--N 1.292 -1.925 0 C-N-CA 123.585 0.754 . . . . 0.0 109.12 -170.001 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -64.49 118.2 5.19 Favored 'Trans proline' 0 C--O 1.245 0.845 0 C-N-CA 122.147 1.898 . . . . 0.0 110.359 177.68 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -139.92 166.51 24.44 Favored 'General case' 0 N--CA 1.408 -2.526 0 CA-C-O 121.118 0.485 . . . . 0.0 110.311 -175.537 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.494 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 10.7 ttp180 -115.3 145.35 42.56 Favored 'General case' 0 C--N 1.285 -2.237 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.135 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.45 HG21 ' HB3' ' A' ' 5' ' ' PHE . 52.4 t -74.63 119.91 23.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 104.728 -2.323 . . . . 0.0 104.728 170.099 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.442 ' HB3' ' HB2' ' A' ' 41' ' ' PRO . 4.1 t70 -84.78 179.0 7.43 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -172.219 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 . . . . . 0 N--CA 1.429 -1.507 0 C-N-CA 119.278 -0.969 . . . . 0.0 111.72 -175.276 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 62.1 mttp . . . . . 0 N--CA 1.428 -1.551 0 CA-C-O 121.055 0.455 . . . . 0.0 111.12 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 40' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 88.8 mt -116.99 147.17 39.57 Favored Pre-proline 0 C--N 1.287 -2.151 0 CA-C-N 114.33 -1.304 . . . . 0.0 109.246 -178.07 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' PRO . . . . . 0.442 ' HB2' ' HB3' ' A' ' 26' ' ' ASP . 68.9 Cg_endo -73.06 123.86 9.16 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 122.33 2.02 . . . . 0.0 110.523 177.565 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.412 HG21 ' CB ' ' A' ' 13' ' ' ALA . 43.4 mm -120.86 127.56 75.95 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 -176.753 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.441 ' CZ ' ' HA ' ' A' ' 48' ' ' HIS . 87.7 t80 -107.14 120.69 42.8 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 178.846 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 -86.66 131.7 34.08 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-O 121.254 0.55 . . . . 0.0 112.247 179.028 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.494 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 67.6 m-85 -85.83 158.44 19.97 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.694 179.326 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.533 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 75.31 -20.32 2.1 Favored Glycine 0 C--O 1.248 1.015 0 C-N-CA 123.526 0.584 . . . . 0.0 114.538 179.139 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 18.3 p -119.38 -23.04 6.81 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 122.305 -0.527 . . . . 0.0 109.73 173.005 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' HIS . . . . . 0.441 ' HA ' ' CZ ' ' A' ' 43' ' ' PHE . 11.5 m-70 67.67 26.18 7.98 Favored 'General case' 0 C--N 1.348 0.507 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.818 179.507 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -79.4 161.89 25.87 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.698 -0.852 . . . . 0.0 108.698 177.373 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 6.9 m -136.12 140.43 43.68 Favored 'General case' 0 C--N 1.284 -2.25 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 176.794 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -142.74 179.35 7.05 Favored 'General case' 0 C--N 1.287 -2.124 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.289 -175.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.409 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 84.8 m-85 -134.0 115.07 13.91 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.305 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.497 HD12 ' HB1' ' A' ' 13' ' ' ALA . 87.4 mt -129.44 166.49 19.49 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 -177.67 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -93.03 167.7 29.49 Favored Glycine 0 N--CA 1.423 -2.18 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -67.03 -6.89 17.11 Favored 'Trans proline' 0 N--CA 1.481 0.747 0 C-N-CA 123.303 2.669 . . . . 0.0 112.828 -176.983 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 20.8 pttp -93.05 -18.17 22.97 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.366 178.8 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.2 m-20 -99.98 1.25 42.41 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.188 -175.226 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.3 pt -125.94 145.84 32.71 Favored 'Isoleucine or valine' 0 C--O 1.258 1.551 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.754 179.359 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -136.32 144.82 49.3 Favored Pre-proline 0 C--N 1.288 -2.087 0 CA-C-N 114.823 -1.081 . . . . 0.0 108.554 -177.131 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -68.34 127.82 16.37 Favored 'Trans proline' 0 N--CA 1.483 0.857 0 C-N-CA 122.746 2.298 . . . . 0.0 113.956 -179.121 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -51.97 -39.34 59.17 Favored 'General case' 0 C--O 1.217 -0.626 0 C-N-CA 123.87 0.868 . . . . 0.0 111.043 -179.536 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.5 m -57.28 -40.33 77.54 Favored 'General case' 0 C--N 1.307 -1.27 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.185 -178.072 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -95.75 -19.19 19.85 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.278 0.561 . . . . 0.0 112.21 -172.792 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.485 ' ND2' ' HD2' ' A' ' 12' ' ' PHE . 0.7 OUTLIER -124.19 26.88 7.29 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 114.703 1.371 . . . . 0.0 114.703 -178.214 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.43 ' HZ3' ' CD ' ' A' ' 66' ' ' GLU . 17.0 pttm -70.1 -30.91 68.24 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 174.698 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.43 ' CD ' ' HZ3' ' A' ' 65' ' ' LYS . 19.8 mp0 -65.25 -39.06 92.17 Favored 'General case' 0 C--O 1.251 1.151 0 CA-C-O 122.557 1.17 . . . . 0.0 108.617 175.091 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.443 ' HB3' ' HE2' ' A' ' 67' ' ' LYS . 35.8 mtpt -76.44 -59.96 2.55 Favored 'General case' 0 N--CA 1.427 -1.618 0 CA-C-N 113.918 -1.492 . . . . 0.0 112.029 -175.07 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 21.0 m-85 -107.67 -9.75 15.78 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.482 -0.781 . . . . 0.0 112.428 -168.297 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -82.3 41.55 2.8 Favored Glycine 0 C--O 1.22 -0.726 0 C-N-CA 121.245 -0.503 . . . . 0.0 113.21 -176.826 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 38.4 mtmm -122.96 124.95 26.44 Favored Pre-proline 0 C--N 1.308 -1.202 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 177.773 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -56.96 127.17 24.72 Favored 'Trans proline' 0 C--O 1.251 1.167 0 C-N-CA 122.23 1.954 . . . . 0.0 114.686 -172.239 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 4.8 m-20 -84.76 -170.46 3.13 Favored 'General case' 0 CA--C 1.484 -1.594 0 CA-C-N 113.875 -1.511 . . . . 0.0 108.304 176.608 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 40.0 mmtm -111.46 22.0 15.57 Favored 'General case' 0 C--N 1.285 -2.201 0 CA-C-O 122.592 1.187 . . . . 0.0 107.821 173.88 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -87.06 127.89 35.11 Favored 'General case' 0 C--O 1.251 1.162 0 CA-C-N 113.548 -1.66 . . . . 0.0 107.547 173.279 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -65.29 134.79 54.38 Favored 'General case' 0 N--CA 1.439 -0.997 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 176.47 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.533 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 100.2 -25.73 27.18 Favored Glycine 0 N--CA 1.42 -2.374 0 C-N-CA 121.405 -0.426 . . . . 0.0 112.363 -178.242 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.405 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 23.2 t80 -73.36 -42.61 62.0 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 -177.709 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -72.87 -41.37 64.79 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 -177.323 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 16.3 mt-10 -65.06 -39.89 93.91 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 114.411 -1.268 . . . . 0.0 109.857 178.464 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -68.63 -32.29 74.47 Favored Glycine 0 CA--C 1.499 -0.936 0 CA-C-N 115.741 -0.663 . . . . 0.0 112.636 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.405 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 90.8 mt -62.9 -32.86 74.22 Favored 'General case' 0 C--O 1.214 -0.798 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 174.764 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 73.6 t90 -73.48 -48.27 34.72 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.382 176.541 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -58.3 -41.32 84.19 Favored 'General case' 0 C--O 1.203 -1.384 0 N-CA-C 112.87 0.693 . . . . 0.0 112.87 179.669 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.3 tt -71.29 -21.24 21.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-O 121.145 0.497 . . . . 0.0 110.619 -175.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -90.36 -42.42 10.95 Favored 'General case' 0 N--CA 1.437 -1.112 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.108 -177.196 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -92.22 -50.16 5.81 Favored 'General case' 0 CA--C 1.494 -1.188 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.136 -174.154 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 64.6 t30 -132.72 75.9 72.17 Favored Pre-proline 0 C--N 1.303 -1.442 0 C-N-CA 119.725 -0.79 . . . . 0.0 110.152 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.494 ' O ' ' HD3' ' A' ' 24' ' ' ARG . 42.5 Cg_endo -68.52 -6.51 17.86 Favored 'Trans proline' 0 N--CA 1.477 0.542 0 C-N-CA 122.795 2.33 . . . . 0.0 114.143 -174.211 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 61.5 pttt . . . . . 0 C--N 1.304 -1.393 0 CA-C-O 120.85 0.357 . . . . 0.0 110.182 -179.053 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 76.4 m-85 . . . . . 0 N--CA 1.427 -1.575 0 CA-C-O 120.958 0.408 . . . . 0.0 109.987 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.403 ' O ' ' HB ' ' A' ' 25' ' ' VAL . 29.6 mttp -110.27 153.53 43.31 Favored Pre-proline 0 C--N 1.307 -1.281 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 -177.405 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -62.15 115.4 2.82 Favored 'Trans proline' 0 N--CA 1.448 -1.193 0 N-CA-C 107.08 -1.931 . . . . 0.0 107.08 169.02 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 114.93 -19.05 15.94 Favored Glycine 0 N--CA 1.424 -2.152 0 C-N-CA 120.411 -0.899 . . . . 0.0 112.391 -174.835 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -78.45 152.19 32.26 Favored 'General case' 0 C--O 1.253 1.268 0 CA-C-N 117.397 0.599 . . . . 0.0 109.446 -177.065 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.403 HD22 HG13 ' A' ' 84' ' ' ILE . 82.5 mt -98.03 127.32 43.91 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 122.917 0.487 . . . . 0.0 111.211 -171.974 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.458 HG22 ' HA ' ' A' ' 60' ' ' PRO . 2.8 pp -140.08 -178.78 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.046 0 CA-C-O 121.956 0.884 . . . . 0.0 112.555 -174.718 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.43 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 69.0 m-85 -120.98 125.4 47.26 Favored 'General case' 0 C--N 1.291 -1.971 0 N-CA-C 105.429 -2.063 . . . . 0.0 105.429 172.47 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.487 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -111.22 146.35 37.08 Favored 'General case' 0 C--N 1.277 -2.545 0 O-C-N 123.531 0.519 . . . . 0.0 111.035 -174.54 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.481 ' HD3' ' C ' ' A' ' 14' ' ' LYS . 7.5 tmtm? -117.9 117.66 29.87 Favored 'General case' 0 N--CA 1.419 -1.998 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.707 -177.746 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.447 ' HB2' ' HB2' ' A' ' 18' ' ' TYR . 70.1 mtm -112.28 159.38 18.69 Favored 'General case' 0 C--O 1.248 0.999 0 CA-C-O 120.962 0.41 . . . . 0.0 111.364 173.384 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 26.2 ttpp -67.71 116.82 8.83 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 176.025 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.52 -4.91 64.43 Favored Glycine 0 C--O 1.239 0.432 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -176.305 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' TYR . . . . . 0.447 ' HB2' ' HB2' ' A' ' 15' ' ' MET . 35.3 m-85 -118.13 145.39 36.85 Favored Pre-proline 0 C--O 1.254 1.335 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 179.325 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -79.79 171.93 14.86 Favored 'Trans proline' 0 N--CA 1.445 -1.324 0 C-N-CA 123.16 2.573 . . . . 0.0 108.281 170.093 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -63.93 111.51 2.52 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 177.063 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 10.2 t-105 -110.18 140.51 22.47 Favored Pre-proline 0 C--N 1.295 -1.767 0 CA-C-N 114.866 -1.061 . . . . 0.0 109.369 -170.188 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -65.85 118.15 5.24 Favored 'Trans proline' 0 C--O 1.243 0.744 0 C-N-CA 122.008 1.805 . . . . 0.0 110.184 177.233 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -145.94 167.19 23.91 Favored 'General case' 0 N--CA 1.413 -2.307 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 -175.632 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.606 ' HD3' ' O ' ' A' ' 88' ' ' PRO . 10.0 ttp180 -122.29 149.06 44.25 Favored 'General case' 0 C--N 1.272 -2.782 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.403 ' HB ' ' O ' ' A' ' 6' ' ' LYS . 51.5 t -72.34 121.07 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 104.647 -2.353 . . . . 0.0 104.647 169.135 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -84.0 172.44 12.03 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 -170.656 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.431 -1.386 0 CA-C-O 121.506 0.669 . . . . 0.0 111.772 -176.872 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.462 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 88.6 mttt . . . . . 0 N--CA 1.431 -1.407 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 66.6 mt -84.16 140.8 39.71 Favored Pre-proline 0 C--N 1.314 -0.97 0 O-C-N 123.609 0.568 . . . . 0.0 109.574 -177.488 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -72.74 123.93 9.36 Favored 'Trans proline' 0 C--O 1.222 -0.276 0 C-N-CA 122.395 2.064 . . . . 0.0 110.186 178.767 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 47.6 mm -120.85 123.43 70.2 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 0 O-C-N 121.924 -0.485 . . . . 0.0 110.401 -176.495 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 77.4 t80 -106.09 119.13 38.4 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 177.889 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.415 ' CE2' ' HB3' ' A' ' 13' ' ' ALA . 80.4 m-85 -83.39 131.91 35.02 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-O 121.314 0.578 . . . . 0.0 112.141 179.591 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.433 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 46.1 m-85 -85.01 154.5 22.07 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.406 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.556 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 73.44 -21.16 1.17 Allowed Glycine 0 C--N 1.308 -0.981 0 C-N-CA 124.184 0.897 . . . . 0.0 114.977 179.679 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.4 p -115.98 -22.92 8.78 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 117.942 0.871 . . . . 0.0 109.668 173.409 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' HIS . . . . . 0.441 ' HE2' ' CD ' ' A' ' 83' ' ' GLU . 55.9 m170 69.73 23.17 5.83 Favored 'General case' 0 CA--C 1.518 -0.285 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.595 176.319 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -76.51 160.79 29.17 Favored 'General case' 0 N--CA 1.443 -0.785 0 CA-C-N 115.261 -0.881 . . . . 0.0 108.745 177.035 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.2 m -136.3 138.31 41.6 Favored 'General case' 0 C--N 1.279 -2.473 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.093 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -140.2 -179.62 6.09 Favored 'General case' 0 C--N 1.282 -2.343 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.0 -177.267 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -133.03 111.21 10.8 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 175.599 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.546 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 87.2 mt -129.25 150.9 50.43 Favored 'General case' 0 C--N 1.288 -2.094 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.293 -176.227 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.462 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -85.17 172.84 47.87 Favored Glycine 0 N--CA 1.424 -2.156 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 -176.54 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -65.04 -16.65 56.35 Favored 'Trans proline' 0 C--O 1.208 -0.992 0 C-N-CA 122.266 1.977 . . . . 0.0 112.407 -177.478 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.75 -1.14 44.04 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-O 121.301 0.572 . . . . 0.0 112.197 177.205 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.546 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 69.4 m-20 -104.22 -4.83 22.54 Favored 'General case' 0 C--N 1.295 -1.791 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 179.513 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.7 pt -128.2 156.58 40.41 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.707 0 CA-C-N 114.898 -1.046 . . . . 0.0 109.1 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' PHE . . . . . 0.425 ' HB3' ' ND2' ' A' ' 64' ' ' ASN . 88.6 m-85 -136.72 136.76 22.08 Favored Pre-proline 0 C--N 1.287 -2.115 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 -179.625 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' PRO . . . . . 0.485 ' HG2' ' HB2' ' A' ' 63' ' ' GLU . 20.5 Cg_endo -64.43 132.92 35.19 Favored 'Trans proline' 0 C--N 1.318 -1.079 0 C-N-CA 122.273 1.982 . . . . 0.0 112.416 -177.621 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.43 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 60.7 t80 -58.63 -39.76 81.41 Favored 'General case' 0 C--O 1.206 -1.214 0 C-N-CA 123.695 0.798 . . . . 0.0 110.839 -178.331 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 29.5 t -62.06 -36.09 80.58 Favored 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.484 -176.009 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' GLU . . . . . 0.485 ' HB2' ' HG2' ' A' ' 60' ' ' PRO . 1.3 mp0 -95.05 -18.0 21.39 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 113.172 0.805 . . . . 0.0 113.172 -175.2 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.425 ' ND2' ' HB3' ' A' ' 59' ' ' PHE . 37.3 m-80 -123.55 16.07 9.6 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 112.778 0.658 . . . . 0.0 112.778 -175.814 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.499 ' HG2' ' OE2' ' A' ' 66' ' ' GLU . 21.4 pttm -66.8 -32.19 73.3 Favored 'General case' 0 N--CA 1.484 1.268 0 CA-C-O 121.273 0.559 . . . . 0.0 110.703 -178.062 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.561 ' H ' ' CD ' ' A' ' 66' ' ' GLU . 2.7 mp0 -70.36 -25.39 63.25 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 -179.537 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 43.6 mttp -91.05 -59.66 2.11 Favored 'General case' 0 N--CA 1.422 -1.826 0 CA-C-N 114.271 -1.331 . . . . 0.0 111.297 -171.01 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 56.1 m-85 -105.76 -0.62 25.24 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.806 -172.254 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.9 56.43 4.81 Favored Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.74 179.292 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -128.61 128.53 23.54 Favored Pre-proline 0 C--N 1.317 -0.845 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.806 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_exo -54.57 137.9 74.01 Favored 'Trans proline' 0 C--N 1.349 0.575 0 C-N-CA 122.969 2.446 . . . . 0.0 112.169 177.928 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 15.9 m-80 -116.04 -179.34 3.63 Favored 'General case' 0 CA--C 1.472 -2.049 0 N-CA-C 113.845 1.054 . . . . 0.0 113.845 -178.633 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' LYS . . . . . 0.451 ' HD3' ' N ' ' A' ' 73' ' ' LYS . 2.8 mppt? -93.27 1.9 56.83 Favored 'General case' 0 N--CA 1.429 -1.494 0 CA-C-N 112.921 -1.945 . . . . 0.0 108.247 -178.516 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 5.6 mmt180 -84.54 116.34 23.08 Favored 'General case' 0 N--CA 1.426 -1.645 0 CA-C-N 114.889 -1.051 . . . . 0.0 109.783 176.43 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.433 ' HD3' ' N ' ' A' ' 76' ' ' GLY . 8.7 tmtt? -56.5 125.92 24.22 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 175.632 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.556 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.03 -25.44 20.42 Favored Glycine 0 N--CA 1.434 -1.451 0 C-N-CA 121.222 -0.514 . . . . 0.0 112.081 -179.363 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.421 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 14.1 t80 -70.29 -40.28 74.39 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 122.068 0.937 . . . . 0.0 108.738 -176.905 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -68.47 -43.64 76.55 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 114.198 -1.364 . . . . 0.0 108.986 -176.808 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -68.49 -35.57 77.72 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 114.39 -1.277 . . . . 0.0 109.964 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' GLY . . . . . 0.402 ' HA2' ' HB3' ' A' ' 45' ' ' PHE . . . -68.45 -33.66 77.65 Favored Glycine 0 N--CA 1.438 -1.186 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.24 177.8 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.421 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 95.4 mt -62.76 -33.83 75.98 Favored 'General case' 0 C--O 1.213 -0.818 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 174.596 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 72.8 t90 -71.92 -49.54 36.84 Favored 'General case' 0 N--CA 1.441 -0.901 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.778 176.336 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' GLU . . . . . 0.441 ' CD ' ' HE2' ' A' ' 48' ' ' HIS . 46.7 mt-10 -58.25 -40.35 81.53 Favored 'General case' 0 C--O 1.204 -1.335 0 N-CA-C 112.895 0.702 . . . . 0.0 112.895 179.503 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.403 HG13 HD22 ' A' ' 10' ' ' LEU . 18.0 tt -71.18 -21.21 21.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.179 0.514 . . . . 0.0 110.583 -176.571 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -89.03 -42.9 11.48 Favored 'General case' 0 N--CA 1.439 -1.011 0 CA-C-N 115.47 -0.787 . . . . 0.0 110.019 -177.856 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -89.49 -48.66 7.17 Favored 'General case' 0 CA--C 1.493 -1.225 0 CA-C-N 115.92 -0.582 . . . . 0.0 112.077 -174.295 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -132.29 76.87 71.84 Favored Pre-proline 0 C--N 1.302 -1.481 0 C-N-CA 120.17 -0.612 . . . . 0.0 109.761 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.606 ' O ' ' HD3' ' A' ' 24' ' ' ARG . 28.8 Cg_endo -62.97 -16.96 57.61 Favored 'Trans proline' 0 C--O 1.218 -0.515 0 C-N-CA 122.808 2.339 . . . . 0.0 115.719 -171.399 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' LYS . . . . . 0.42 ' HA ' ' HD3' ' A' ' 24' ' ' ARG . 8.5 ptmm? . . . . . 0 C--O 1.259 1.573 0 C-N-CA 119.317 -0.953 . . . . 0.0 111.323 -179.213 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 . . . . . 0 N--CA 1.427 -1.618 0 CA-C-O 121.452 0.644 . . . . 0.0 110.152 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.36 145.98 30.7 Favored Pre-proline 0 C--N 1.304 -1.39 0 CA-C-N 114.913 -1.039 . . . . 0.0 109.326 -177.079 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -53.28 122.23 10.83 Favored 'Trans proline' 0 C--O 1.238 0.523 0 C-N-CA 122.336 2.024 . . . . 0.0 109.579 172.118 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 109.58 -9.91 32.72 Favored Glycine 0 N--CA 1.427 -1.904 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.051 -177.258 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -79.9 153.51 28.96 Favored 'General case' 0 C--O 1.251 1.166 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -179.297 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.0 mt -105.64 126.39 52.09 Favored 'General case' 0 C--N 1.291 -1.97 0 CA-C-O 121.251 0.548 . . . . 0.0 109.892 -175.556 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.414 ' HA ' ' H ' ' A' ' 61' ' ' TYR . 9.3 pt -140.84 -172.66 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.832 0 CA-C-O 122.256 1.027 . . . . 0.0 111.813 -174.616 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.563 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 72.8 m-85 -126.15 134.44 51.3 Favored 'General case' 0 N--CA 1.411 -2.377 0 N-CA-C 105.894 -1.891 . . . . 0.0 105.894 172.342 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ALA . . . . . 0.581 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -113.44 141.92 46.52 Favored 'General case' 0 C--N 1.273 -2.72 0 O-C-N 123.776 0.673 . . . . 0.0 110.235 -176.28 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' LYS . . . . . 0.479 ' HD3' ' C ' ' A' ' 14' ' ' LYS . 7.5 tmtm? -113.15 117.72 32.73 Favored 'General case' 0 N--CA 1.422 -1.837 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.834 -177.441 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' MET . . . . . 0.422 ' HB2' ' HB2' ' A' ' 18' ' ' TYR . 72.1 mtm -109.54 158.48 17.96 Favored 'General case' 0 C--O 1.254 1.331 0 CA-C-O 121.26 0.552 . . . . 0.0 111.056 173.241 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 61.4 tttm -68.46 117.26 9.99 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.682 178.853 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.3 -1.55 76.85 Favored Glycine 0 C--O 1.238 0.361 0 C-N-CA 121.0 -0.619 . . . . 0.0 111.768 -178.746 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' TYR . . . . . 0.444 ' HA ' ' HD3' ' A' ' 19' ' ' PRO . 61.7 m-85 -120.39 150.68 52.37 Favored Pre-proline 0 C--O 1.258 1.52 0 CA-C-N 115.636 -0.282 . . . . 0.0 111.061 -179.202 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 18' ' ' TYR . 6.4 Cg_exo -74.97 171.97 17.26 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 123.286 2.657 . . . . 0.0 109.691 172.513 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 91.2 m-70 -67.3 110.97 3.75 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 176.788 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 3.9 t-105 -98.78 137.48 20.57 Favored Pre-proline 0 C--N 1.297 -1.681 0 CA-C-N 114.801 -1.091 . . . . 0.0 108.542 -171.905 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -64.49 118.13 5.13 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 121.763 1.642 . . . . 0.0 110.148 177.72 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -135.85 166.79 22.48 Favored 'General case' 0 N--CA 1.411 -2.398 0 CA-C-O 121.519 0.676 . . . . 0.0 110.975 -175.181 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.507 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 64.4 ttt-85 -115.66 141.76 47.65 Favored 'General case' 0 C--N 1.28 -2.423 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.455 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 48.1 t -77.65 119.92 27.26 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.249 0 N-CA-C 103.957 -2.608 . . . . 0.0 103.957 169.816 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -102.33 -179.58 4.03 Favored 'General case' 0 C--N 1.283 -2.294 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.858 -170.977 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLU . . . . . 0.409 ' CD ' HH12 ' A' ' 24' ' ' ARG . 30.5 mp0 . . . . . 0 N--CA 1.424 -1.731 0 CA-C-O 121.622 0.725 . . . . 0.0 110.504 -178.684 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' LYS . . . . . 0.617 ' HE3' ' HA ' ' A' ' 53' ' ' LEU . 22.5 mtpp . . . . . 0 N--CA 1.415 -2.209 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 80.7 mt -103.55 154.62 37.73 Favored Pre-proline 0 C--N 1.29 -2.002 0 O-C-N 124.023 0.827 . . . . 0.0 109.772 -175.605 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -71.15 122.32 8.62 Favored 'Trans proline' 0 N--CA 1.451 -0.991 0 C-N-CA 121.521 1.481 . . . . 0.0 109.734 174.875 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' ILE . . . . . 0.474 HG13 ' HB2' ' A' ' 53' ' ' LEU . 44.9 mm -118.53 116.81 52.48 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.935 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -176.585 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.408 ' CZ ' ' HA ' ' A' ' 48' ' ' HIS . 79.0 t80 -93.33 122.34 35.64 Favored 'General case' 0 C--N 1.268 -2.972 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 179.718 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -88.51 124.91 34.47 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.347 0.594 . . . . 0.0 112.542 178.434 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.507 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 78.2 m-85 -74.64 152.53 39.19 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.536 176.053 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' GLY . . . . . 0.55 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 79.78 -19.97 5.79 Favored Glycine 0 C--N 1.308 -1.02 0 CA-C-N 116.289 -0.414 . . . . 0.0 113.701 178.786 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.0 p -116.62 -22.79 8.48 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 117.166 0.483 . . . . 0.0 110.149 175.48 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' HIS . . . . . 0.408 ' HA ' ' CZ ' ' A' ' 43' ' ' PHE . 49.7 m170 70.22 14.23 7.63 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 124.321 1.048 . . . . 0.0 112.017 177.123 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 57.4 mm-40 -92.4 168.15 11.49 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.873 -179.113 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.0 m -129.48 142.15 50.85 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-O 121.2 0.524 . . . . 0.0 109.908 179.606 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -137.89 -178.9 5.46 Favored 'General case' 0 C--N 1.295 -1.791 0 C-N-CA 124.096 0.958 . . . . 0.0 110.023 -177.499 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -128.53 116.0 18.99 Favored 'General case' 0 CA--C 1.5 -0.975 0 CA-C-O 120.851 0.357 . . . . 0.0 110.637 179.141 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.617 ' HA ' ' HE3' ' A' ' 39' ' ' LYS . 89.0 mt -131.59 151.32 51.7 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.793 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' GLY . . . . . 0.418 ' HA2' ' HA ' ' A' ' 39' ' ' LYS . . . -85.69 174.38 48.19 Favored Glycine 0 N--CA 1.433 -1.514 0 C-N-CA 120.564 -0.827 . . . . 0.0 111.192 -176.911 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 -6.87 19.67 Favored 'Trans proline' 0 C--O 1.212 -0.794 0 C-N-CA 122.591 2.194 . . . . 0.0 112.98 -176.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.54 ' NZ ' ' HB2' ' A' ' 56' ' ' LYS . 5.8 mtmp? -97.99 -15.59 20.02 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 177.317 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.51 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 9.7 m-20 -99.72 1.78 43.65 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 114.585 -1.189 . . . . 0.0 108.58 -168.121 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.2 pt -132.06 152.11 36.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 114.19 -1.368 . . . . 0.0 110.187 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -135.29 141.31 37.3 Favored Pre-proline 0 C--N 1.302 -1.457 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 179.543 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -66.11 132.23 29.28 Favored 'Trans proline' 0 C--N 1.33 -0.432 0 C-N-CA 122.801 2.334 . . . . 0.0 113.36 -177.884 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' TYR . . . . . 0.563 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 50.3 t80 -59.48 -41.1 89.02 Favored 'General case' 0 C--O 1.208 -1.116 0 C-N-CA 123.639 0.776 . . . . 0.0 110.209 -179.496 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.1 p -59.41 -42.67 92.36 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 115.171 -0.922 . . . . 0.0 112.99 -176.19 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -96.48 -2.88 44.38 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 112.886 0.698 . . . . 0.0 112.886 -179.094 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.4 ' OD1' ' HD2' ' A' ' 67' ' ' LYS . 36.8 m-80 -132.14 15.04 4.67 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 113.185 0.809 . . . . 0.0 113.185 -176.317 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' LYS . . . . . 0.505 ' HG2' ' OE2' ' A' ' 66' ' ' GLU . 20.5 pttm -66.02 -29.16 69.47 Favored 'General case' 0 N--CA 1.487 1.415 0 CA-C-O 121.735 0.778 . . . . 0.0 110.831 -179.18 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' GLU . . . . . 0.573 ' H ' ' CD ' ' A' ' 66' ' ' GLU . 2.9 mp0 -68.21 -36.78 80.07 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 179.476 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.4 ' HD2' ' OD1' ' A' ' 64' ' ' ASN . 40.9 mttp -84.19 -59.78 2.29 Favored 'General case' 0 N--CA 1.428 -1.542 0 CA-C-N 113.405 -1.725 . . . . 0.0 111.583 -170.42 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 36.2 m-85 -105.51 -4.91 20.71 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.386 -170.807 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -81.7 56.45 4.92 Favored Glycine 0 N--CA 1.444 -0.805 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 177.748 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.529 ' O ' ' HE1' ' A' ' 77' ' ' PHE . 0.0 OUTLIER -119.33 158.55 48.44 Favored Pre-proline 0 C--N 1.305 -1.352 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 -177.55 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -73.36 167.24 27.81 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 121.883 1.722 . . . . 0.0 111.926 175.14 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -152.65 -177.63 6.36 Favored 'General case' 0 C--N 1.308 -1.23 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.226 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 30.9 mmmt -97.08 -10.56 25.81 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 122.243 0.217 . . . . 0.0 110.795 178.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 27.4 mmt180 -67.17 124.38 22.93 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 177.456 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.61 137.22 40.62 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 176.345 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' GLY . . . . . 0.55 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 100.97 -26.14 25.77 Favored Glycine 0 N--CA 1.426 -2.013 0 N-CA-C 108.926 -1.67 . . . . 0.0 108.926 -174.53 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' PHE . . . . . 0.529 ' HE1' ' O ' ' A' ' 70' ' ' LYS . 20.6 t80 -77.04 -46.52 23.48 Favored 'General case' 0 N--CA 1.44 -0.939 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.473 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -60.37 -50.29 74.19 Favored 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 115.164 -0.925 . . . . 0.0 108.597 177.96 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 20.5 mp0 -61.09 -41.7 97.15 Favored 'General case' 0 N--CA 1.435 -1.207 0 CA-C-N 113.797 -1.547 . . . . 0.0 110.513 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.06 -34.55 64.76 Favored Glycine 0 CA--C 1.496 -1.11 0 CA-C-N 115.879 -0.601 . . . . 0.0 113.403 -178.445 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 32.3 tp -63.62 -30.62 71.71 Favored 'General case' 0 C--O 1.204 -1.325 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 176.932 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 79.1 t90 -77.04 -47.12 21.48 Favored 'General case' 0 N--CA 1.437 -1.109 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.031 175.237 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 39.0 mt-10 -58.93 -42.28 89.37 Favored 'General case' 0 C--O 1.196 -1.711 0 N-CA-C 113.202 0.816 . . . . 0.0 113.202 -178.723 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 21.1 tt -63.33 -33.18 59.63 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -175.631 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -81.61 -34.24 31.04 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.126 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.7 m-80 -100.52 -46.54 5.18 Favored 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 112.94 0.719 . . . . 0.0 112.94 -172.848 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 64.9 t30 -133.58 73.64 72.28 Favored Pre-proline 0 C--N 1.3 -1.565 0 CA-C-O 121.058 0.456 . . . . 0.0 110.686 -178.166 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -73.61 -5.61 17.37 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 122.978 2.452 . . . . 0.0 112.791 -176.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 61.5 pttt . . . . . 0 C--N 1.308 -1.2 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.874 -177.982 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.0 mmt . . . . . 0 CA--C 1.497 -1.075 0 N-CA-C 110.203 -0.295 . . . . 0.0 110.203 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -121.61 75.37 1.18 Allowed 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 175.324 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.412 ' HG3' ' O ' ' A' ' 4' ' ' ASP . 8.0 ptt180 -147.22 -172.91 4.12 Favored 'General case' 0 C--N 1.297 -1.674 0 N-CA-C 106.286 -1.746 . . . . 0.0 106.286 176.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ASP . . . . . 0.412 ' O ' ' HG3' ' A' ' 3' ' ' ARG . 3.6 p-10 -89.55 155.37 19.32 Favored 'General case' 0 C--O 1.257 1.457 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 179.388 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -133.51 118.35 18.21 Favored 'General case' 0 N--CA 1.416 -2.126 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 25.9 mttp -94.84 147.49 33.2 Favored Pre-proline 0 C--N 1.291 -1.964 0 CA-C-N 114.583 -1.19 . . . . 0.0 108.783 -173.184 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -63.19 115.64 3.1 Favored 'Trans proline' 0 N--CA 1.448 -1.157 0 N-CA-C 107.549 -1.751 . . . . 0.0 107.549 170.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 110.07 -8.47 31.3 Favored Glycine 0 N--CA 1.422 -2.253 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.214 -174.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -73.1 154.92 40.19 Favored 'General case' 0 C--O 1.253 1.28 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 -178.214 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 71.1 mt -102.12 122.56 44.37 Favored 'General case' 0 C--N 1.298 -1.665 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.553 -173.064 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -139.97 178.88 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 CA-C-O 122.458 1.123 . . . . 0.0 113.206 -175.154 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.497 ' HD2' ' ND2' ' A' ' 64' ' ' ASN . 47.5 m-85 -115.89 127.87 55.35 Favored 'General case' 0 C--N 1.278 -2.516 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 170.422 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.556 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -108.43 124.68 50.78 Favored 'General case' 0 C--N 1.273 -2.757 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.579 -175.313 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.599 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -105.93 123.39 47.89 Favored 'General case' 0 N--CA 1.404 -2.768 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.34 -177.759 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 68.4 mtm -120.63 158.17 27.97 Favored 'General case' 0 C--N 1.317 -0.847 0 C-N-CA 123.344 0.657 . . . . 0.0 109.231 176.584 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -67.53 117.07 8.99 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.08 -5.81 57.94 Favored Glycine 0 C--O 1.251 1.195 0 N-CA-C 111.518 -0.633 . . . . 0.0 111.518 178.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -124.04 147.25 53.65 Favored Pre-proline 0 N--CA 1.426 -1.666 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 -179.37 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -74.49 170.98 19.03 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 121.805 1.67 . . . . 0.0 109.273 174.249 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' HIS . . . . . 0.575 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 65.8 m80 -59.97 110.78 1.27 Allowed 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 175.715 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -102.22 137.95 19.59 Favored Pre-proline 0 C--N 1.308 -1.22 0 C-N-CA 124.017 0.927 . . . . 0.0 109.53 -170.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -64.38 118.16 5.15 Favored 'Trans proline' 0 C--O 1.242 0.694 0 C-N-CA 121.869 1.712 . . . . 0.0 110.636 178.643 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.98 166.12 26.22 Favored 'General case' 0 N--CA 1.415 -2.188 0 CA-C-O 121.181 0.515 . . . . 0.0 110.403 -176.27 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.443 ' HD3' ' O ' ' A' ' 88' ' ' PRO . 11.4 ttp180 -114.63 146.25 41.06 Favored 'General case' 0 C--N 1.282 -2.351 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.496 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.6 t -73.28 117.03 16.37 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 104.098 -2.556 . . . . 0.0 104.098 168.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.44 ' CG ' ' HZ1' ' A' ' 91' ' ' LYS . 4.6 t70 -92.97 -178.0 4.67 Favored 'General case' 0 C--N 1.281 -2.405 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 -170.334 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -100.51 169.78 8.84 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 178.455 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 52.3 t -67.3 119.89 68.46 Favored Pre-proline 0 C--N 1.311 -1.081 0 C-N-CA 120.766 -0.374 . . . . 0.0 110.209 -177.155 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -74.65 152.02 42.11 Favored 'Trans proline' 0 N--CA 1.421 -2.744 0 C-N-CA 121.877 1.718 . . . . 0.0 112.468 -179.087 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -68.45 129.21 39.24 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-N 115.42 -0.809 . . . . 0.0 108.947 179.299 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.17 -18.57 45.38 Favored Glycine 0 N--CA 1.434 -1.454 0 CA-C-N 115.461 -0.791 . . . . 0.0 111.439 -178.452 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -79.05 94.42 5.31 Favored 'General case' 0 N--CA 1.441 -0.924 0 CA-C-O 121.406 0.622 . . . . 0.0 110.819 179.2 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.2 m -89.31 6.09 4.35 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.158 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.934 178.538 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.437 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 0.1 OUTLIER -82.43 128.23 67.85 Favored Pre-proline 0 N--CA 1.427 -1.597 0 CA-C-N 115.429 -0.805 . . . . 0.0 112.903 -179.207 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 34' ' ' LYS . 13.7 Cg_exo -70.99 170.27 18.44 Favored 'Trans proline' 0 C--O 1.265 1.833 0 C-N-CA 122.474 2.116 . . . . 0.0 110.431 175.007 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -52.24 127.89 25.38 Favored 'Trans proline' 0 C--N 1.359 1.112 0 C-N-CA 122.735 2.29 . . . . 0.0 110.787 177.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.2 m -105.94 9.0 32.79 Favored 'General case' 0 C--N 1.287 -2.121 0 CA-C-N 114.712 -1.131 . . . . 0.0 108.97 -173.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 46.9 m-80 78.92 8.53 1.95 Allowed 'General case' 0 N--CA 1.492 1.653 0 C-N-CA 125.969 1.708 . . . . 0.0 108.155 -170.478 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.501 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 47.6 mmtt -118.63 149.52 41.25 Favored 'General case' 0 N--CA 1.409 -2.504 0 CA-C-N 113.346 -1.752 . . . . 0.0 107.444 174.292 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.479 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 79.4 mt -113.25 153.28 45.54 Favored Pre-proline 0 C--N 1.263 -3.186 0 O-C-N 124.812 1.32 . . . . 0.0 108.696 -177.432 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -69.68 123.61 10.3 Favored 'Trans proline' 0 N--CA 1.457 -0.667 0 C-N-CA 121.658 1.572 . . . . 0.0 109.667 174.794 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.402 ' O ' ' HA ' ' A' ' 50' ' ' THR . 50.7 mm -120.58 122.44 68.04 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 CA-C-O 120.879 0.371 . . . . 0.0 110.454 -176.665 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.545 ' CE1' ' HA ' ' A' ' 48' ' ' HIS . 35.0 t80 -98.05 114.84 27.11 Favored 'General case' 0 C--N 1.285 -2.196 0 C-N-CA 123.441 0.697 . . . . 0.0 109.754 178.746 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 81.3 m-85 -79.79 129.93 34.9 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 177.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 73.1 m-85 -82.42 154.85 24.97 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.574 177.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.54 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 74.38 -20.65 1.6 Allowed Glycine 0 C--N 1.31 -0.883 0 CA-C-N 115.442 -0.799 . . . . 0.0 114.411 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 38.1 p -116.41 -22.64 8.68 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 117.911 0.856 . . . . 0.0 109.391 173.302 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' HIS . . . . . 0.545 ' HA ' ' CE1' ' A' ' 43' ' ' PHE . 12.5 m-70 68.12 22.61 8.26 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 114.959 -1.019 . . . . 0.0 112.98 177.825 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -79.34 172.3 13.99 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.975 178.729 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.402 ' HA ' ' O ' ' A' ' 42' ' ' ILE . 3.8 m -140.95 138.18 33.62 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 177.415 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -140.16 -179.0 5.72 Favored 'General case' 0 C--N 1.288 -2.107 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.383 -176.634 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.479 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 62.0 m-85 -129.59 109.94 11.42 Favored 'General case' 0 N--CA 1.445 -0.68 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 177.018 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.556 HD12 ' HB1' ' A' ' 13' ' ' ALA . 94.6 mt -129.08 153.57 47.51 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 -179.565 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.501 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -87.97 171.82 41.32 Favored Glycine 0 CA--C 1.49 -1.492 0 C-N-CA 120.307 -0.949 . . . . 0.0 112.191 -174.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -61.73 -19.0 63.63 Favored 'Trans proline' 0 C--O 1.239 0.532 0 C-N-CA 123.088 2.526 . . . . 0.0 111.982 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -91.86 -19.95 21.97 Favored 'General case' 0 N--CA 1.433 -1.29 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.903 179.473 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.409 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 24.7 m-20 -82.07 -20.86 37.36 Favored 'General case' 0 CA--C 1.493 -1.234 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.298 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.404 ' HA ' ' O ' ' A' ' 12' ' ' PHE . 15.5 pt -110.19 151.56 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.687 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.65 -176.359 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -135.73 137.66 26.18 Favored Pre-proline 0 C--O 1.185 -2.327 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -66.32 127.36 17.27 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 122.486 2.124 . . . . 0.0 113.938 -175.408 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 75.3 t80 -57.8 -32.48 67.6 Favored 'General case' 0 C--O 1.205 -1.279 0 CA-C-N 114.713 -1.13 . . . . 0.0 111.694 -175.101 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.59 -57.45 11.04 Favored 'General case' 0 C--N 1.293 -1.889 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -69.42 -34.53 74.6 Favored 'General case' 0 C--O 1.219 -0.518 0 CA-C-O 121.506 0.669 . . . . 0.0 111.555 -177.513 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.497 ' ND2' ' HD2' ' A' ' 12' ' ' PHE 0.309 1.0 OUTLIER -109.81 23.74 13.98 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 115.32 1.6 . . . . 0.0 115.32 -175.715 . . . . . . . . 4 4 . 1 . 001 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.429 ' HZ1' ' CG ' ' A' ' 85' ' ' ASP . 15.8 ttmm -63.27 -27.38 69.29 Favored 'General case' 0 N--CA 1.481 1.095 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.217 171.742 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.463 ' CD ' ' HG2' ' A' ' 67' ' ' LYS . 1.2 pp20? -77.41 -35.46 54.19 Favored 'General case' 0 N--CA 1.423 -1.796 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.215 176.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.463 ' HG2' ' CD ' ' A' ' 66' ' ' GLU . 0.1 OUTLIER -77.37 -59.74 2.66 Favored 'General case' 0 N--CA 1.439 -0.982 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.119 -174.381 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -105.82 -4.11 21.17 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.986 -169.603 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -79.7 59.86 4.41 Favored Glycine 0 N--CA 1.436 -1.347 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 176.682 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.403 ' HD3' ' HA ' ' A' ' 70' ' ' LYS . 38.7 mmtm -132.34 134.34 24.81 Favored Pre-proline 0 C--N 1.32 -0.679 0 C-N-CA 122.936 0.495 . . . . 0.0 111.259 -179.301 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.458 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 78.1 Cg_exo -48.31 131.3 22.45 Favored 'Trans proline' 0 C--O 1.273 2.248 0 C-N-CA 123.911 3.074 . . . . 0.0 113.75 178.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.552 ' HB2' ' CD1' ' A' ' 77' ' ' PHE . 1.2 t-20 -113.82 -178.21 3.32 Favored 'General case' 0 N--CA 1.406 -2.633 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.953 -174.146 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.614 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 7.3 mptt -110.81 10.65 22.52 Favored 'General case' 0 N--CA 1.425 -1.696 0 CA-C-O 122.485 1.136 . . . . 0.0 108.375 -178.252 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 31.2 mmt180 -96.45 129.52 43.79 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 114.204 -1.362 . . . . 0.0 108.567 173.81 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.424 ' HG3' ' OE2' ' A' ' 79' ' ' GLU . 61.9 tttp -69.7 144.35 52.85 Favored 'General case' 0 N--CA 1.446 -0.663 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 174.7 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.54 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 91.47 -25.91 13.83 Favored Glycine 0 C--O 1.208 -1.469 0 N-CA-C 111.761 -0.536 . . . . 0.0 111.761 -177.517 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.552 ' CD1' ' HB2' ' A' ' 72' ' ' ASN . 32.5 t80 -69.78 -53.63 17.42 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-O 121.85 0.834 . . . . 0.0 109.423 -178.653 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.458 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 87.5 m-20 -69.93 -32.84 71.33 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.905 -176.569 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLU . . . . . 0.424 ' OE2' ' HG3' ' A' ' 75' ' ' LYS . 28.1 mt-10 -72.09 -37.68 69.52 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 114.738 -1.119 . . . . 0.0 108.382 178.243 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.04 -31.63 66.58 Favored Glycine 0 N--CA 1.428 -1.86 0 CA-C-N 115.007 -0.997 . . . . 0.0 112.462 177.333 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 86.0 mt -55.95 -34.74 65.95 Favored 'General case' 0 N--CA 1.474 0.746 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 175.136 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.4 t90 -75.91 -50.71 14.23 Favored 'General case' 0 N--CA 1.426 -1.635 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.457 177.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -54.98 -48.37 73.35 Favored 'General case' 0 C--O 1.2 -1.537 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -178.327 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.2 tt -67.43 -25.5 33.53 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.172 0 N-CA-C 112.205 0.446 . . . . 0.0 112.205 -175.277 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.429 ' CG ' ' HZ1' ' A' ' 65' ' ' LYS . 6.7 t0 -94.39 -22.59 18.22 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.261 0.553 . . . . 0.0 110.488 -174.197 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -106.96 -57.49 2.06 Favored 'General case' 0 CA--C 1.505 -0.777 0 CA-C-O 121.291 0.567 . . . . 0.0 111.366 -179.285 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -127.6 76.02 77.27 Favored Pre-proline 0 C--N 1.313 -1.015 0 C-N-CA 119.849 -0.74 . . . . 0.0 110.413 -179.072 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.443 ' O ' ' HD3' ' A' ' 24' ' ' ARG . 48.6 Cg_endo -69.73 -6.54 18.83 Favored 'Trans proline' 0 N--CA 1.483 0.857 0 C-N-CA 122.722 2.282 . . . . 0.0 113.93 -175.393 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.2 pttm -103.22 20.3 17.96 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 121.19 0.519 . . . . 0.0 109.699 -178.207 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 14.7 p -78.6 119.19 27.21 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.006 0 CA-C-O 122.193 0.997 . . . . 0.0 113.173 -176.263 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.44 ' HZ1' ' CG ' ' A' ' 26' ' ' ASP . 18.2 ptpt -162.1 171.97 16.62 Favored 'General case' 0 N--CA 1.419 -2.002 0 CA-C-N 114.757 -1.11 . . . . 0.0 108.275 172.582 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -88.4 -174.61 4.68 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 123.553 0.533 . . . . 0.0 109.656 -179.106 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.9 p . . . . . 0 N--CA 1.434 -1.228 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 179.353 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.409 ' N ' ' HG2' ' A' ' 63' ' ' GLU . 98.0 mmm . . . . . 0 CA--C 1.49 -1.352 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -94.86 69.92 3.37 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 178.258 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 15.5 ptt180 -121.96 160.58 24.56 Favored 'General case' 0 C--N 1.286 -2.156 0 CA-C-N 113.61 -1.632 . . . . 0.0 109.729 -179.215 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -114.75 -170.12 1.68 Allowed 'General case' 0 C--O 1.261 1.673 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 174.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.557 ' CE2' HG13 ' A' ' 58' ' ' ILE . 56.4 m-85 -109.01 145.52 35.41 Favored 'General case' 0 C--N 1.288 -2.078 0 N-CA-C 116.131 1.901 . . . . 0.0 116.131 -165.496 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.36 149.15 54.32 Favored Pre-proline 0 N--CA 1.423 -1.808 0 CA-C-N 113.166 -1.834 . . . . 0.0 106.71 179.694 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -58.56 130.44 37.31 Favored 'Trans proline' 0 C--O 1.236 0.41 0 C-N-CA 122.008 1.805 . . . . 0.0 109.97 173.688 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 104.72 -16.58 47.34 Favored Glycine 0 N--CA 1.433 -1.528 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.988 -179.357 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -79.59 162.31 25.4 Favored 'General case' 0 C--O 1.25 1.099 0 CA-C-N 117.216 0.508 . . . . 0.0 110.156 -175.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.512 HD21 ' HB2' ' A' ' 88' ' ' PRO . 58.0 mt -100.34 122.66 43.48 Favored 'General case' 0 CA--C 1.496 -1.116 0 C-N-CA 122.81 0.444 . . . . 0.0 110.395 -172.676 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -138.37 179.86 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.308 0 CA-C-O 122.5 1.143 . . . . 0.0 113.696 -173.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.574 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 61.0 m-85 -113.76 130.06 56.5 Favored 'General case' 0 C--N 1.283 -2.321 0 CA-C-N 113.775 -1.557 . . . . 0.0 107.684 170.671 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.434 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -107.7 118.23 36.19 Favored 'General case' 0 N--CA 1.398 -3.042 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -176.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.603 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -105.28 122.72 46.53 Favored 'General case' 0 N--CA 1.399 -2.987 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.192 -176.887 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 70.1 mtm -118.33 158.17 25.72 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.237 177.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 59.3 tttm -65.8 116.58 7.13 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.551 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.15 -2.45 65.81 Favored Glycine 0 C--O 1.251 1.159 0 N-CA-C 111.632 -0.587 . . . . 0.0 111.632 179.335 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.419 ' HA ' ' HD3' ' A' ' 19' ' ' PRO . 81.5 m-85 -120.9 150.94 54.09 Favored Pre-proline 0 N--CA 1.427 -1.61 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -178.801 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 18' ' ' TYR . 4.9 Cg_exo -77.61 171.09 18.08 Favored 'Trans proline' 0 N--CA 1.44 -1.622 0 C-N-CA 121.815 1.677 . . . . 0.0 109.312 174.654 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' HIS . . . . . 0.496 ' HB3' ' HB3' ' A' ' 12' ' ' PHE . 69.7 m80 -62.01 111.18 1.82 Allowed 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 175.421 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -100.67 137.53 19.88 Favored Pre-proline 0 C--N 1.301 -1.521 0 N-CA-C 109.209 -0.664 . . . . 0.0 109.209 -172.181 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -65.99 118.05 5.17 Favored 'Trans proline' 0 C--O 1.243 0.762 0 C-N-CA 121.561 1.507 . . . . 0.0 110.932 178.234 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.34 166.85 25.09 Favored 'General case' 0 N--CA 1.419 -1.985 0 CA-C-N 116.223 -0.444 . . . . 0.0 109.815 -176.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.425 ' HB2' ' CE2' ' A' ' 45' ' ' PHE . 14.2 ttp180 -116.58 147.89 41.43 Favored 'General case' 0 C--N 1.28 -2.415 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.342 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 40.6 t -74.14 123.83 30.29 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.199 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 171.865 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -87.91 169.76 11.73 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 -173.054 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -113.44 132.21 55.73 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-O 121.542 0.687 . . . . 0.0 111.511 -177.394 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.4 p -87.13 124.8 67.94 Favored Pre-proline 0 N--CA 1.432 -1.335 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.313 -179.247 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -76.48 158.49 36.36 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.453 2.102 . . . . 0.0 112.474 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 20.1 t0 -70.82 149.13 47.14 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 174.62 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.97 -23.49 35.44 Favored Glycine 0 C--N 1.29 -1.995 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 -174.143 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -93.84 38.94 1.07 Allowed 'General case' 0 C--O 1.201 -1.449 0 CA-C-O 121.819 0.819 . . . . 0.0 109.753 176.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.5 m -73.72 8.47 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 113.422 -1.717 . . . . 0.0 113.756 -175.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 3.5 mppt? -72.93 142.86 83.49 Favored Pre-proline 0 C--N 1.3 -1.576 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 176.254 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.424 ' HA ' ' HD3' ' A' ' 36' ' ' PRO . 17.8 Cg_endo -59.4 133.86 54.92 Favored 'Trans proline' 0 CA--C 1.537 0.66 0 C-N-CA 122.039 1.826 . . . . 0.0 113.111 -176.811 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 35' ' ' PRO . 89.4 Cg_endo -87.1 172.43 6.23 Favored 'Trans proline' 0 N--CA 1.439 -1.702 0 C-N-CA 122.984 2.456 . . . . 0.0 111.85 179.332 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.405 ' O ' ' HB3' ' A' ' 38' ' ' ASN . 4.8 m -60.2 8.79 0.02 OUTLIER 'General case' 0 CA--C 1.58 2.099 0 C-N-CA 126.548 1.939 . . . . 0.0 113.735 179.448 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.405 ' HB3' ' O ' ' A' ' 37' ' ' THR . 0.5 OUTLIER 74.66 9.79 4.14 Favored 'General case' 0 N--CA 1.481 1.105 0 CA-C-O 123.479 1.609 . . . . 0.0 110.05 -177.215 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.445 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 81.4 mttt -127.74 169.99 13.23 Favored 'General case' 0 N--CA 1.424 -1.747 0 CA-C-N 114.244 -1.343 . . . . 0.0 110.134 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.442 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 86.8 mt -86.04 144.76 39.43 Favored Pre-proline 0 C--N 1.313 -0.979 0 O-C-N 123.681 0.613 . . . . 0.0 109.863 -176.573 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -73.37 123.97 9.09 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.046 1.831 . . . . 0.0 109.819 175.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 51.1 mm -118.42 125.9 74.68 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.879 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.412 -176.461 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -101.34 113.9 27.4 Favored 'General case' 0 C--N 1.291 -1.971 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 178.03 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -81.02 130.57 35.08 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-O 121.102 0.477 . . . . 0.0 111.861 178.517 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.429 ' CD2' ' HB ' ' A' ' 84' ' ' ILE . 74.1 m-85 -83.73 156.37 22.61 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 176.091 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.456 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 75.59 -20.15 2.31 Favored Glycine 0 C--N 1.314 -0.675 0 CA-C-N 115.922 -0.581 . . . . 0.0 113.957 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 24.7 p -119.08 -23.19 6.92 Favored 'General case' 0 C--N 1.308 -1.232 0 O-C-N 122.383 -0.48 . . . . 0.0 110.084 174.98 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 61.69 27.98 17.22 Favored 'General case' 0 C--N 1.354 0.788 0 CA-C-O 121.712 0.767 . . . . 0.0 111.536 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -85.35 159.9 19.91 Favored 'General case' 0 CA--C 1.491 -1.317 0 CA-C-N 114.043 -1.435 . . . . 0.0 108.783 176.051 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.5 m -130.05 136.72 49.69 Favored 'General case' 0 C--N 1.268 -2.946 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.126 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -140.08 -179.24 5.85 Favored 'General case' 0 C--N 1.284 -2.243 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.688 -176.15 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.442 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 79.6 m-85 -132.21 110.76 10.87 Favored 'General case' 0 CA--C 1.499 -1.011 0 C-N-CA 123.351 0.66 . . . . 0.0 109.464 177.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.434 HD12 ' HB1' ' A' ' 13' ' ' ALA . 95.9 mt -126.53 151.68 47.54 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.445 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -75.9 162.67 52.99 Favored Glycine 0 N--CA 1.416 -2.648 0 C-N-CA 119.968 -1.111 . . . . 0.0 110.677 -176.192 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.438 ' O ' ' HE2' ' A' ' 5' ' ' PHE . 17.9 Cg_endo -62.42 -19.99 69.08 Favored 'Trans proline' 0 C--O 1.191 -1.874 0 C-N-CA 122.237 1.958 . . . . 0.0 111.162 179.177 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.427 ' HA ' ' HE3' ' A' ' 56' ' ' LYS . 0.0 OUTLIER -99.48 -0.4 40.8 Favored 'General case' 0 C--N 1.286 -2.166 0 O-C-N 121.441 -0.787 . . . . 0.0 111.537 178.278 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -89.57 -20.95 23.15 Favored 'General case' 0 CA--C 1.488 -1.41 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 175.434 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.557 HG13 ' CE2' ' A' ' 5' ' ' PHE . 18.4 pt -110.59 157.24 11.41 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.75 0 CA-C-N 114.174 -1.375 . . . . 0.0 110.223 -175.872 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -139.36 147.31 52.23 Favored Pre-proline 0 C--N 1.303 -1.432 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 -177.317 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.429 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 38.6 Cg_endo -64.89 129.68 23.94 Favored 'Trans proline' 0 C--O 1.243 0.728 0 C-N-CA 122.657 2.238 . . . . 0.0 113.081 -175.661 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.574 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 82.2 t80 -60.94 -37.12 81.22 Favored 'General case' 0 C--O 1.205 -1.264 0 CA-C-N 115.447 -0.797 . . . . 0.0 111.983 -177.077 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 22.6 t -63.63 -54.05 41.88 Favored 'General case' 0 C--N 1.307 -1.269 0 CA-C-O 120.946 0.403 . . . . 0.0 110.635 -175.332 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.429 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 4.2 mp0 -71.01 -25.84 62.86 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-O 121.376 0.608 . . . . 0.0 112.304 -178.073 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.464 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 28.0 m-80 -105.48 12.67 31.15 Favored 'General case' 0 C--N 1.293 -1.878 0 C-N-CA 120.536 -0.466 . . . . 0.0 111.917 -176.76 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.3 tttp -63.19 -37.87 88.94 Favored 'General case' 0 N--CA 1.479 1.001 0 CA-C-O 121.153 0.502 . . . . 0.0 110.92 -179.544 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 18.2 mm-40 -71.57 -24.01 61.84 Favored 'General case' 0 CA--C 1.488 -1.417 0 CA-C-O 121.831 0.824 . . . . 0.0 112.151 176.823 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.464 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 35.6 mtpt -85.79 -58.47 2.64 Favored 'General case' 0 C--N 1.266 -3.053 0 CA-C-N 114.135 -1.393 . . . . 0.0 111.426 -176.181 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 38.3 m-85 -125.17 0.75 7.84 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.995 -0.548 . . . . 0.0 112.006 -172.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -94.29 32.11 6.2 Favored Glycine 0 CA--C 1.496 -1.104 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.236 -175.261 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 50.0 mtmt -130.21 153.93 81.28 Favored Pre-proline 0 C--N 1.301 -1.515 0 C-N-CA 122.808 0.443 . . . . 0.0 110.138 178.787 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_exo -42.68 144.24 1.39 Allowed 'Trans proline' 0 C--N 1.363 1.298 0 C-N-CA 124.583 3.522 . . . . 0.0 117.328 -172.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 -137.13 -166.25 1.89 Allowed 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 105.073 -2.195 . . . . 0.0 105.073 173.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 3.5 mmmp? -116.55 2.26 13.02 Favored 'General case' 0 N--CA 1.416 -2.138 0 C-N-CA 119.019 -1.072 . . . . 0.0 113.28 174.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 14.2 mmt180 -61.39 128.92 38.68 Favored 'General case' 0 C--N 1.324 -0.539 0 O-C-N 124.167 0.917 . . . . 0.0 109.012 175.189 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.8 tmtm? -68.78 123.55 21.24 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.585 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.456 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 105.91 -25.05 25.14 Favored Glycine 0 N--CA 1.428 -1.884 0 N-CA-C 110.164 -1.175 . . . . 0.0 110.164 -177.893 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.6 t80 -76.6 -44.78 32.98 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -60.82 -50.04 75.06 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.61 178.337 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -68.16 -40.59 82.28 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.314 -178.426 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -72.24 -30.89 64.37 Favored Glycine 0 CA--C 1.489 -1.531 0 CA-C-N 115.646 -0.707 . . . . 0.0 112.955 -177.204 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 44.0 tp -62.39 -35.51 79.43 Favored 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.086 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.7 t90 -70.57 -48.61 54.47 Favored 'General case' 0 N--CA 1.425 -1.721 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.95 177.416 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -54.82 -51.35 66.1 Favored 'General case' 0 C--O 1.202 -1.447 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -179.382 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.429 ' HB ' ' CD2' ' A' ' 45' ' ' PHE . 17.6 tt -68.13 -24.01 29.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 112.223 0.453 . . . . 0.0 112.223 -175.329 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 6.3 t0 -94.61 -21.21 18.97 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-O 121.252 0.549 . . . . 0.0 110.458 -175.109 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -109.83 -56.78 2.27 Favored 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 121.268 0.556 . . . . 0.0 111.603 -178.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -125.17 71.66 63.84 Favored Pre-proline 0 C--N 1.316 -0.886 0 C-N-CA 120.169 -0.612 . . . . 0.0 110.126 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.512 ' HB2' HD21 ' A' ' 10' ' ' LEU . 60.1 Cg_endo -73.13 -6.12 18.37 Favored 'Trans proline' 0 N--CA 1.475 0.389 0 C-N-CA 122.527 2.151 . . . . 0.0 113.46 -174.643 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.3 pttm -95.1 13.81 24.03 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.019 -178.451 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 9.8 p -86.3 141.79 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.328 0 CA-C-O 121.052 0.453 . . . . 0.0 110.639 -179.582 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 30.5 mtpp -128.25 -70.13 0.7 Allowed 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 175.436 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -97.92 115.63 28.5 Favored 'General case' 0 C--N 1.29 -2.003 0 CA-C-N 114.83 -1.077 . . . . 0.0 111.272 -178.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 25.7 p . . . . . 0 C--N 1.277 -2.585 0 N-CA-C 105.087 -2.19 . . . . 0.0 105.087 173.761 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.423 ' HB2' ' HG3' ' A' ' 3' ' ' ARG . 64.5 mtt . . . . . 0 N--CA 1.477 0.903 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -100.01 -5.49 28.04 Favored 'General case' 0 C--O 1.207 -1.16 0 CA-C-O 121.226 0.536 . . . . 0.0 110.613 176.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.423 ' HG3' ' HB2' ' A' ' 1' ' ' MET . 0.1 OUTLIER -83.87 -20.23 33.45 Favored 'General case' 0 N--CA 1.479 1.014 0 CA-C-O 122.892 1.33 . . . . 0.0 109.722 178.833 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -108.61 132.36 53.96 Favored 'General case' 0 C--N 1.258 -3.411 0 CA-C-N 112.252 -2.249 . . . . 0.0 109.783 178.676 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -110.2 124.95 52.52 Favored 'General case' 0 N--CA 1.413 -2.276 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.401 -174.405 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -134.65 154.67 79.68 Favored Pre-proline 0 C--N 1.283 -2.324 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.402 -176.53 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -49.6 123.25 10.14 Favored 'Trans proline' 0 C--N 1.35 0.63 0 C-N-CA 123.365 2.71 . . . . 0.0 111.992 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 112.85 -17.49 22.68 Favored Glycine 0 N--CA 1.424 -2.165 0 CA-C-N 115.656 -0.702 . . . . 0.0 112.24 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -75.44 156.84 34.88 Favored 'General case' 0 C--O 1.249 1.041 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -177.129 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.1 mt -106.92 120.49 42.18 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 -174.525 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.438 HG22 ' HA ' ' A' ' 60' ' ' PRO . 2.9 pp -137.01 -179.63 3.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 CA-C-O 122.528 1.156 . . . . 0.0 113.42 -174.236 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.441 ' HB3' ' HB3' ' A' ' 20' ' ' HIS . 33.2 m-85 -113.57 130.52 56.35 Favored 'General case' 0 C--N 1.275 -2.665 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 170.401 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -107.24 116.39 31.85 Favored 'General case' 0 C--N 1.268 -2.952 0 CA-C-N 115.26 -0.882 . . . . 0.0 108.839 -174.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.58 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -112.87 120.89 43.02 Favored 'General case' 0 N--CA 1.394 -3.256 0 CA-C-N 114.572 -1.194 . . . . 0.0 108.856 -178.888 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 68.1 mtm -105.64 158.48 16.67 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 179.485 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -65.74 116.42 6.93 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -178.825 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.32 -2.63 63.31 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.726 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -125.13 148.27 59.88 Favored Pre-proline 0 N--CA 1.438 -1.04 0 CA-C-O 120.595 0.236 . . . . 0.0 110.593 -178.131 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -72.24 170.53 18.89 Favored 'Trans proline' 0 N--CA 1.455 -0.789 0 C-N-CA 122.444 2.096 . . . . 0.0 111.747 177.424 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' HIS . . . . . 0.441 ' HB3' ' HB3' ' A' ' 12' ' ' PHE . 90.7 m-70 -67.12 111.69 4.03 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 108.895 -0.779 . . . . 0.0 108.895 178.136 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 13.0 t-105 -109.63 136.03 20.32 Favored Pre-proline 0 C--N 1.314 -0.977 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 -176.743 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -62.08 120.34 7.88 Favored 'Trans proline' 0 C--O 1.244 0.799 0 C-N-CA 122.536 2.157 . . . . 0.0 112.45 -178.591 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -148.1 166.07 28.94 Favored 'General case' 0 N--CA 1.431 -1.38 0 CA-C-O 120.932 0.396 . . . . 0.0 110.806 -177.121 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.478 HH21 ' CG ' ' A' ' 26' ' ' ASP . 12.2 ttp180 -109.85 144.53 38.19 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 178.769 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 68.9 t -73.69 107.25 4.15 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.405 0 N-CA-C 102.709 -3.071 . . . . 0.0 102.709 166.489 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.478 ' CG ' HH21 ' A' ' 24' ' ' ARG . 0.4 OUTLIER -88.64 -178.22 5.75 Favored 'General case' 0 C--N 1.271 -2.808 0 C-N-CA 119.654 -0.818 . . . . 0.0 111.957 -168.241 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 -103.69 152.06 22.26 Favored 'General case' 0 C--N 1.285 -2.205 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.956 -173.253 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 39.9 t -90.48 121.56 68.26 Favored Pre-proline 0 C--N 1.312 -1.049 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 179.604 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -78.81 144.05 19.0 Favored 'Trans proline' 0 N--CA 1.438 -1.755 0 C-N-CA 121.771 1.648 . . . . 0.0 113.598 -178.041 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -54.17 130.47 38.49 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.079 173.053 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 110.36 -27.09 11.98 Favored Glycine 0 C--N 1.295 -1.722 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 -177.399 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -78.69 80.81 5.04 Favored 'General case' 0 N--CA 1.439 -0.976 0 CA-C-O 121.988 0.899 . . . . 0.0 109.917 175.904 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.2 m -95.86 4.04 9.19 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 CA-C-N 114.406 -1.27 . . . . 0.0 110.532 179.315 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 31.0 mmtp -84.26 129.43 58.15 Favored Pre-proline 0 C--N 1.299 -1.62 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 178.05 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -64.09 134.95 45.03 Favored 'Trans proline' 0 N--CA 1.455 -0.753 0 C-N-CA 122.029 1.819 . . . . 0.0 112.543 -178.086 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.4 ' C ' ' H ' ' A' ' 38' ' ' ASN . 69.7 Cg_endo -78.41 172.05 15.91 Favored 'Trans proline' 0 N--CA 1.443 -1.481 0 C-N-CA 122.695 2.263 . . . . 0.0 111.888 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.6 m -70.31 8.14 0.86 Allowed 'General case' 0 CA--C 1.565 1.551 0 C-N-CA 125.178 1.391 . . . . 0.0 111.552 -179.172 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.4 ' H ' ' C ' ' A' ' 36' ' ' PRO . 47.9 m-80 75.8 14.11 2.74 Favored 'General case' 0 N--CA 1.481 1.119 0 C-N-CA 125.333 1.453 . . . . 0.0 110.527 -177.494 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.449 ' HE2' ' N ' ' A' ' 54' ' ' GLY . 31.6 mtpt -113.09 166.74 11.14 Favored 'General case' 0 N--CA 1.425 -1.691 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 177.754 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 79.8 mt -85.74 144.2 39.32 Favored Pre-proline 0 C--N 1.302 -1.499 0 O-C-N 123.212 0.32 . . . . 0.0 110.175 -176.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -71.25 123.91 10.0 Favored 'Trans proline' 0 N--CA 1.457 -0.622 0 C-N-CA 122.046 1.83 . . . . 0.0 109.764 175.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.414 HG13 ' HB2' ' A' ' 53' ' ' LEU . 51.4 mm -120.49 122.7 68.77 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 O-C-N 122.165 -0.334 . . . . 0.0 110.265 -176.013 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 88.0 t80 -104.95 114.48 28.71 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 178.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -74.9 132.7 41.66 Favored 'General case' 0 C--N 1.319 -0.737 0 O-C-N 123.655 0.597 . . . . 0.0 111.335 179.513 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -90.19 158.1 17.39 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.269 177.586 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.563 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 75.84 -19.9 2.54 Favored Glycine 0 C--N 1.311 -0.852 0 CA-C-N 115.631 -0.713 . . . . 0.0 113.529 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 60.5 p -119.27 -22.68 7.02 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 122.419 -0.46 . . . . 0.0 109.941 175.439 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.1 m170 66.98 25.57 9.3 Favored 'General case' 0 C--N 1.352 0.697 0 C-N-CA 124.12 0.968 . . . . 0.0 111.752 179.434 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -84.42 178.04 7.9 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.329 178.239 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 8.9 m -144.01 147.42 33.85 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.433 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -147.23 -179.79 7.08 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 123.827 0.851 . . . . 0.0 109.776 -178.844 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -133.06 110.82 10.48 Favored 'General case' 0 C--O 1.252 1.235 0 CA-C-O 121.524 0.678 . . . . 0.0 109.353 177.755 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.579 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 96.2 mt -127.86 155.76 43.63 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.354 -176.863 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.449 ' N ' ' HE2' ' A' ' 39' ' ' LYS . . . -94.69 174.47 33.24 Favored Glycine 0 N--CA 1.425 -2.053 0 N-CA-C 110.152 -1.179 . . . . 0.0 110.152 -178.342 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -66.31 -11.04 29.73 Favored 'Trans proline' 0 C--O 1.208 -1.024 0 C-N-CA 122.797 2.332 . . . . 0.0 112.799 -177.218 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 20.7 pttp -97.62 -7.96 29.95 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 122.211 1.005 . . . . 0.0 110.245 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.579 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 65.5 m-20 -100.64 -10.24 21.12 Favored 'General case' 0 C--N 1.287 -2.152 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.577 -176.04 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 12.2 pt -125.23 154.97 33.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.42 -175.154 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -142.49 140.74 19.23 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 179.424 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.438 ' HA ' HG22 ' A' ' 11' ' ' ILE . 33.8 Cg_endo -65.64 127.66 18.44 Favored 'Trans proline' 0 C--O 1.243 0.751 0 C-N-CA 122.774 2.316 . . . . 0.0 114.13 -173.73 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 65.2 t80 -62.48 -30.61 71.38 Favored 'General case' 0 CA--C 1.505 -0.774 0 C-N-CA 124.105 0.962 . . . . 0.0 109.437 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.8 m -55.02 -35.48 64.47 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-N 114.908 -1.042 . . . . 0.0 111.88 -179.534 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . 0.284 55.0 mt-10 -85.75 -54.11 4.72 Favored 'General case' 0 CA--C 1.483 -1.618 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 172.048 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.416 ' CG ' ' HE2' ' A' ' 67' ' ' LYS . 31.6 m-80 -67.96 9.87 0.26 Allowed 'General case' 0 CA--C 1.473 -1.991 0 C-N-CA 127.628 2.371 . . . . 0.0 113.867 -164.238 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 55.6 tttp -66.85 -33.8 76.4 Favored 'General case' 0 N--CA 1.394 -3.269 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 174.693 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.727 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -80.43 -33.41 36.94 Favored 'General case' 0 N--CA 1.429 -1.525 0 CA-C-N 115.016 -0.993 . . . . 0.0 113.573 172.86 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.727 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 24.5 mtmm -77.54 -59.47 2.77 Favored 'General case' 0 CA--C 1.503 -0.843 0 N-CA-C 113.169 0.803 . . . . 0.0 113.169 -178.951 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -120.22 6.77 10.72 Favored 'General case' 0 C--N 1.281 -2.391 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.957 -174.333 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.5 11.99 35.96 Favored Glycine 0 CA--C 1.524 0.636 0 CA-C-N 116.29 -0.413 . . . . 0.0 114.087 -177.809 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -97.93 127.11 38.13 Favored Pre-proline 0 N--CA 1.441 -0.902 0 CA-C-N 117.162 0.481 . . . . 0.0 110.083 178.729 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -65.15 128.39 20.44 Favored 'Trans proline' 0 N--CA 1.446 -1.319 0 C-N-CA 122.42 2.08 . . . . 0.0 114.862 -176.05 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -102.35 -157.32 0.6 Allowed 'General case' 0 C--N 1.292 -1.911 0 CA-C-N 113.705 -1.589 . . . . 0.0 108.814 177.839 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.419 ' HA ' ' HD3' ' A' ' 73' ' ' LYS . 43.2 mmtm -108.58 15.39 23.82 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 120.444 -0.503 . . . . 0.0 111.359 -179.43 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 39.5 mmt180 -80.02 121.44 25.5 Favored 'General case' 0 CA--C 1.513 -0.476 0 C-N-CA 117.95 -1.5 . . . . 0.0 108.9 171.904 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 11.0 tppt? -74.06 126.76 31.23 Favored 'General case' 0 N--CA 1.428 -1.551 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.563 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.32 -25.82 18.67 Favored Glycine 0 N--CA 1.424 -2.165 0 N-CA-C 109.114 -1.594 . . . . 0.0 109.114 -173.153 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 6.8 t80 -76.72 -46.97 23.37 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 179.586 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 11.2 m120 -56.51 -52.53 64.41 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-N 114.944 -1.025 . . . . 0.0 109.009 178.124 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 21.7 mp0 -61.37 -40.91 96.05 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 113.793 -1.549 . . . . 0.0 110.297 -178.704 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -67.19 -37.66 91.4 Favored Glycine 0 N--CA 1.437 -1.242 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.562 -179.558 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 90.7 mt -60.82 -34.67 74.89 Favored 'General case' 0 CA--C 1.509 -0.629 0 N-CA-C 110.224 -0.288 . . . . 0.0 110.224 176.369 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 84.9 t90 -71.7 -50.96 25.57 Favored 'General case' 0 N--CA 1.432 -1.33 0 O-C-N 123.589 0.555 . . . . 0.0 109.557 177.244 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -56.1 -50.78 70.09 Favored 'General case' 0 C--O 1.202 -1.409 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -178.528 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.3 tt -66.78 -25.87 35.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 112.486 0.55 . . . . 0.0 112.486 -174.743 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -93.29 -19.43 21.39 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-O 121.591 0.71 . . . . 0.0 110.621 -173.896 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.9 m-80 -114.04 -56.29 2.41 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.362 -177.035 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.521 ' OD1' ' HG2' ' A' ' 89' ' ' LYS . 65.3 t30 -128.42 75.51 79.18 Favored Pre-proline 0 C--N 1.311 -1.095 0 C-N-CA 119.831 -0.748 . . . . 0.0 111.22 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -69.73 -6.3 18.25 Favored 'Trans proline' 0 N--CA 1.481 0.736 0 C-N-CA 122.704 2.269 . . . . 0.0 113.481 -176.761 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' LYS . . . . . 0.521 ' HG2' ' OD1' ' A' ' 87' ' ' ASN . 9.5 ptpp? -97.55 6.26 48.36 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -176.776 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 10.2 p -68.35 148.08 11.99 Favored 'Isoleucine or valine' 0 C--O 1.246 0.909 0 CA-C-O 121.732 0.777 . . . . 0.0 111.818 -175.84 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 39.1 mmtm -144.66 -49.78 0.27 Allowed 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 177.328 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 62.9 t80 -134.88 168.65 18.68 Favored 'General case' 0 C--N 1.286 -2.165 0 N-CA-C 104.757 -2.312 . . . . 0.0 104.757 176.072 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 25.0 m . . . . . 0 C--N 1.324 -0.543 0 O-C-N 124.318 1.011 . . . . 0.0 111.569 -177.934 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.8 mtt . . . . . 0 CA--C 1.5 -0.957 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -127.83 79.78 1.92 Allowed 'General case' 0 N--CA 1.436 -1.163 0 N-CA-C 106.857 -1.535 . . . . 0.0 106.857 175.258 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 11.5 ptm180 -137.69 176.31 8.82 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-N 114.442 -1.254 . . . . 0.0 110.321 -177.282 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -115.08 -176.58 2.94 Favored 'General case' 0 C--O 1.252 1.199 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 174.18 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.401 ' CE2' HG13 ' A' ' 58' ' ' ILE . 88.8 m-85 -114.27 150.41 34.45 Favored 'General case' 0 C--N 1.29 -1.998 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 -169.516 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 9.2 pttp -135.13 166.72 26.94 Favored Pre-proline 0 N--CA 1.43 -1.455 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 177.31 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -59.44 149.34 82.21 Favored 'Trans proline' 0 C--O 1.265 1.87 0 C-N-CA 122.052 1.834 . . . . 0.0 112.451 175.47 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 98.51 -14.24 62.2 Favored Glycine 0 N--CA 1.434 -1.439 0 CA-C-N 115.683 -0.689 . . . . 0.0 113.36 176.7 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -84.22 154.76 22.85 Favored 'General case' 0 C--O 1.242 0.695 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 -177.217 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.45 ' HB3' HD11 ' A' ' 84' ' ' ILE . 83.2 mt -99.54 128.68 45.66 Favored 'General case' 0 CA--C 1.498 -1.03 0 CA-C-N 114.888 -1.051 . . . . 0.0 109.163 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -141.62 -178.62 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-O 122.131 0.967 . . . . 0.0 112.418 -175.15 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 48.1 m-85 -112.84 129.77 56.33 Favored 'General case' 0 C--N 1.279 -2.464 0 N-CA-C 106.508 -1.664 . . . . 0.0 106.508 170.836 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.45 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -107.49 132.23 53.45 Favored 'General case' 0 C--N 1.275 -2.658 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -176.072 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.507 ' C ' ' HD3' ' A' ' 14' ' ' LYS . 7.3 tmtm? -113.79 117.26 30.98 Favored 'General case' 0 N--CA 1.41 -2.434 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.877 -177.103 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 54.9 mtm -114.41 158.69 21.19 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.724 173.691 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 39.5 ttpt -62.5 118.72 7.94 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 176.595 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.33 -12.86 68.64 Favored Glycine 0 C--O 1.243 0.716 0 C-N-CA 121.034 -0.603 . . . . 0.0 111.65 -178.881 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -106.62 151.31 40.39 Favored Pre-proline 0 C--O 1.256 1.446 0 C-N-CA 122.811 0.444 . . . . 0.0 111.137 -179.343 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -82.27 172.41 11.68 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 C-N-CA 123.435 2.757 . . . . 0.0 108.91 173.499 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -65.94 110.47 2.91 Favored 'General case' 0 C--N 1.31 -1.117 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 175.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -104.37 138.24 19.46 Favored Pre-proline 0 C--N 1.303 -1.439 0 CA-C-N 115.318 -0.856 . . . . 0.0 108.909 -171.76 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -68.01 117.59 5.02 Favored 'Trans proline' 0 N--CA 1.451 -1.003 0 C-N-CA 121.484 1.456 . . . . 0.0 109.867 177.042 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -145.28 167.05 23.78 Favored 'General case' 0 N--CA 1.415 -2.2 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 -176.145 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.564 ' HB3' ' CE2' ' A' ' 45' ' ' PHE . 8.1 ptt85 -123.53 155.89 36.7 Favored 'General case' 0 C--N 1.281 -2.375 0 C-N-CA 119.149 -1.02 . . . . 0.0 109.356 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.7 t -86.32 117.7 31.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 N-CA-C 106.002 -1.851 . . . . 0.0 106.002 174.187 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -91.73 176.08 6.66 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -175.272 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 11.8 mp0 -92.7 162.5 14.12 Favored 'General case' 0 N--CA 1.421 -1.912 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 45.3 t -77.52 123.47 86.74 Favored Pre-proline 0 C--N 1.304 -1.385 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 175.765 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -76.57 148.15 29.09 Favored 'Trans proline' 0 N--CA 1.431 -2.162 0 C-N-CA 121.481 1.454 . . . . 0.0 112.611 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -60.1 134.22 56.84 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 175.376 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 110.06 -31.76 7.22 Favored Glycine 0 C--N 1.278 -2.648 0 N-CA-C 109.456 -1.457 . . . . 0.0 109.456 -175.863 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -83.01 82.72 8.12 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-O 121.926 0.87 . . . . 0.0 109.551 176.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.6 m -90.24 6.83 4.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 CA-C-N 114.475 -1.239 . . . . 0.0 110.858 179.475 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 30.8 mmtp -86.53 130.32 49.66 Favored Pre-proline 0 C--N 1.296 -1.75 0 CA-C-N 114.943 -1.026 . . . . 0.0 108.831 179.02 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -64.43 150.18 88.71 Favored 'Trans proline' 0 C--O 1.243 0.736 0 C-N-CA 122.213 1.942 . . . . 0.0 112.105 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -62.6 144.48 94.37 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 122.468 2.112 . . . . 0.0 112.407 -179.289 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.8 m -71.45 8.74 0.97 Allowed 'General case' 0 CA--C 1.566 1.575 0 C-N-CA 125.69 1.596 . . . . 0.0 112.284 -178.237 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 85.85 7.69 0.35 Allowed 'General case' 0 N--CA 1.501 2.117 0 C-N-CA 127.551 2.341 . . . . 0.0 108.849 -173.092 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.618 ' HE3' ' HA ' ' A' ' 53' ' ' LEU . 22.0 mtpp -122.13 155.82 34.93 Favored 'General case' 0 N--CA 1.416 -2.139 0 CA-C-N 113.657 -1.611 . . . . 0.0 107.321 176.27 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 73.3 mt -99.38 155.12 36.87 Favored Pre-proline 0 C--N 1.299 -1.601 0 C-N-CA 123.189 0.596 . . . . 0.0 109.65 -174.515 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -74.64 121.92 7.03 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 121.158 1.239 . . . . 0.0 109.399 174.804 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.51 HG13 ' HB2' ' A' ' 53' ' ' LEU . 49.8 mm -115.39 118.65 59.47 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 CA-C-O 120.898 0.38 . . . . 0.0 110.393 -176.407 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.498 ' CE1' ' HA ' ' A' ' 48' ' ' HIS . 58.3 t80 -97.74 116.27 29.63 Favored 'General case' 0 C--N 1.283 -2.303 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.342 179.147 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.421 ' CE2' ' HB2' ' A' ' 51' ' ' ALA . 73.3 m-85 -77.75 130.72 37.1 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-O 121.055 0.455 . . . . 0.0 111.669 177.775 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.564 ' CE2' ' HB3' ' A' ' 24' ' ' ARG . 59.6 m-85 -81.89 150.08 27.95 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.65 176.198 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.479 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 82.01 -20.59 7.94 Favored Glycine 0 C--N 1.313 -0.749 0 C-N-CA 123.875 0.75 . . . . 0.0 114.394 177.909 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 41.3 p -119.56 -22.49 6.93 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 117.521 0.661 . . . . 0.0 110.316 174.331 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' HIS . . . . . 0.498 ' HA ' ' CE1' ' A' ' 43' ' ' PHE . 11.5 m-70 69.03 19.42 8.11 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 123.655 0.782 . . . . 0.0 111.899 -178.308 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -77.29 177.15 8.15 Favored 'General case' 0 N--CA 1.446 -0.638 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.262 177.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.9 m -142.41 144.83 33.28 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 109.675 -0.491 . . . . 0.0 109.675 -179.031 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.421 ' HB2' ' CE2' ' A' ' 44' ' ' PHE . . . -137.98 171.76 13.93 Favored 'General case' 0 C--N 1.29 -1.984 0 CA-C-N 115.397 -0.819 . . . . 0.0 109.516 178.536 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -124.62 108.4 12.02 Favored 'General case' 0 CA--C 1.482 -1.659 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 174.759 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.618 ' HA ' ' HE3' ' A' ' 39' ' ' LYS . 94.5 mt -134.85 139.83 45.35 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 -178.892 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.496 ' HA2' ' HA ' ' A' ' 39' ' ' LYS . . . -87.78 177.95 46.8 Favored Glycine 0 N--CA 1.415 -2.717 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -175.245 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -67.21 -10.94 30.37 Favored 'Trans proline' 0 C--N 1.319 -0.977 0 C-N-CA 122.445 2.096 . . . . 0.0 112.589 -177.161 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 30.7 mmtm -100.07 -8.14 24.13 Favored 'General case' 0 C--N 1.305 -1.361 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 175.401 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.569 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 4.3 m-20 -98.15 -12.62 21.56 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-O 121.853 0.835 . . . . 0.0 108.771 -178.262 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.401 HG13 ' CE2' ' A' ' 5' ' ' PHE . 15.1 pt -112.63 157.71 13.27 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.231 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.941 -177.738 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 -130.93 144.87 55.3 Favored Pre-proline 0 C--N 1.298 -1.647 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 -177.267 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.453 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 42.4 Cg_endo -66.04 127.93 18.64 Favored 'Trans proline' 0 CA--C 1.503 -1.034 0 C-N-CA 122.475 2.117 . . . . 0.0 112.949 -177.483 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 85.3 t80 -61.68 -36.91 82.23 Favored 'General case' 0 C--O 1.206 -1.224 0 CA-C-N 114.816 -1.084 . . . . 0.0 112.149 -176.411 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.418 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 14.0 m -65.85 -50.09 65.82 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-O 121.144 0.497 . . . . 0.0 110.92 -175.707 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.453 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 3.1 mp0 -79.21 -5.25 53.84 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.656 -0.702 . . . . 0.0 112.533 -177.055 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.443 ' OD1' ' HD2' ' A' ' 67' ' ' LYS . 33.3 m-80 -125.45 12.5 8.11 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 120.591 -0.444 . . . . 0.0 112.089 178.364 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 62.9 tttp -70.92 -32.22 69.08 Favored 'General case' 0 N--CA 1.479 1.02 0 CA-C-O 122.03 0.919 . . . . 0.0 110.25 -179.344 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.639 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -74.82 -30.37 61.36 Favored 'General case' 0 N--CA 1.404 -2.772 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.649 175.981 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.639 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 49.3 mttp -80.14 -56.73 4.02 Favored 'General case' 0 CA--C 1.505 -0.766 0 CA-C-N 115.626 -0.715 . . . . 0.0 112.584 -178.267 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 54.5 m-85 -114.24 7.19 16.46 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.471 0.653 . . . . 0.0 111.837 -172.878 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -91.46 51.98 3.05 Favored Glycine 0 C--N 1.294 -1.755 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.637 -176.232 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.64 141.94 41.98 Favored Pre-proline 0 C--N 1.293 -1.866 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 175.509 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -65.67 126.91 16.89 Favored 'Trans proline' 0 N--CA 1.445 -1.345 0 C-N-CA 121.297 1.331 . . . . 0.0 114.425 -173.311 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -83.91 -173.0 4.47 Favored 'General case' 0 CA--C 1.484 -1.589 0 CA-C-N 114.078 -1.419 . . . . 0.0 109.059 178.819 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.532 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 1.1 mptp? -107.4 20.75 18.49 Favored 'General case' 0 C--N 1.282 -2.355 0 CA-C-O 122.664 1.221 . . . . 0.0 108.003 172.899 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 13.7 mmt180 -87.12 121.09 29.1 Favored 'General case' 0 N--CA 1.436 -1.172 0 CA-C-N 113.504 -1.68 . . . . 0.0 107.174 173.539 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 28.2 tptp -60.76 124.13 19.52 Favored 'General case' 0 C--N 1.311 -1.087 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 177.307 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.479 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.21 -25.13 21.1 Favored Glycine 0 N--CA 1.437 -1.256 0 N-CA-C 111.452 -0.659 . . . . 0.0 111.452 -179.246 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 15.2 t80 -74.53 -36.02 63.14 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-O 121.337 0.589 . . . . 0.0 109.837 -176.687 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 2.2 m-20 -74.77 -41.98 59.03 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -175.836 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -67.9 -34.69 77.13 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 114.336 -1.302 . . . . 0.0 109.452 178.586 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -66.64 -35.0 89.22 Favored Glycine 0 CA--C 1.493 -1.285 0 CA-C-N 115.659 -0.7 . . . . 0.0 112.167 178.227 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 87.8 mt -63.65 -35.28 80.01 Favored 'General case' 0 C--O 1.215 -0.723 0 CA-C-O 121.035 0.445 . . . . 0.0 109.845 175.101 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 86.2 t90 -67.43 -49.06 65.36 Favored 'General case' 0 N--CA 1.429 -1.507 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 177.171 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -58.25 -45.44 87.81 Favored 'General case' 0 C--O 1.208 -1.094 0 N-CA-C 113.221 0.822 . . . . 0.0 113.221 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.45 HD11 ' HB3' ' A' ' 10' ' ' LEU . 19.9 tt -73.18 -29.48 28.49 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -173.881 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -87.23 -18.47 30.22 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 31.8 m-80 -111.63 -54.4 2.61 Favored 'General case' 0 CA--C 1.503 -0.836 0 CA-C-O 121.273 0.559 . . . . 0.0 112.161 -176.344 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.403 ' ND2' ' HB ' ' A' ' 90' ' ' VAL . 66.5 t30 -128.56 72.47 80.73 Favored Pre-proline 0 C--N 1.306 -1.316 0 C-N-CA 119.765 -0.774 . . . . 0.0 110.724 -179.218 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -72.85 -5.82 17.89 Favored 'Trans proline' 0 N--CA 1.478 0.582 0 C-N-CA 122.597 2.198 . . . . 0.0 113.447 -175.807 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.2 pttm -95.87 12.65 29.47 Favored 'General case' 0 C--N 1.307 -1.256 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.908 -178.602 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.403 ' HB ' ' ND2' ' A' ' 87' ' ' ASN . 9.4 p -87.55 152.32 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.26 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 178.385 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.4 ' HB3' ' HE2' ' A' ' 91' ' ' LYS . 16.9 ptpt -141.13 -165.26 1.92 Allowed 'General case' 0 N--CA 1.433 -1.311 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 177.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 13.3 m-85 -34.99 -71.4 0.07 Allowed 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 126.602 1.961 . . . . 0.0 112.174 -175.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 50.1 m . . . . . 0 C--N 1.299 -1.618 0 N-CA-C 106.556 -1.646 . . . . 0.0 106.556 179.27 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.503 -0.833 0 N-CA-C 103.999 -2.593 . . . . 0.0 103.999 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.58 -30.62 71.71 Favored 'General case' 0 C--N 1.307 -1.259 0 O-C-N 123.694 0.621 . . . . 0.0 110.477 176.479 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 10.1 ptp180 -102.53 165.81 10.88 Favored 'General case' 0 C--O 1.266 1.97 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 176.435 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 9.6 p-10 -90.05 173.77 8.01 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 106.976 -1.491 . . . . 0.0 106.976 175.068 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -133.86 119.93 19.78 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 120.22 -0.592 . . . . 0.0 110.945 -175.721 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 24.1 mtmm -119.55 155.97 53.84 Favored Pre-proline 0 C--N 1.291 -1.975 0 CA-C-N 114.703 -1.135 . . . . 0.0 108.013 -178.446 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -55.04 120.76 8.72 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 121.723 1.615 . . . . 0.0 109.497 174.063 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 115.94 -24.4 10.15 Favored Glycine 0 N--CA 1.432 -1.573 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.38 -175.472 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -62.03 123.69 18.79 Favored 'General case' 0 C--O 1.25 1.102 0 CA-C-N 117.494 0.647 . . . . 0.0 110.74 177.476 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.422 HD23 ' HG3' ' A' ' 24' ' ' ARG . 85.2 mt -79.93 124.26 28.51 Favored 'General case' 0 CA--C 1.483 -1.601 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 177.316 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 9.3 pt -141.07 -175.12 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.036 0 CA-C-O 122.592 1.187 . . . . 0.0 112.792 -172.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.523 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 60.8 m-85 -122.24 130.35 53.09 Favored 'General case' 0 N--CA 1.405 -2.686 0 CA-C-N 113.42 -1.718 . . . . 0.0 106.56 170.706 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.473 ' HB2' HG21 ' A' ' 42' ' ' ILE . . . -108.8 124.25 50.31 Favored 'General case' 0 C--N 1.275 -2.651 0 O-C-N 123.931 0.769 . . . . 0.0 109.494 -177.711 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.525 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.9 OUTLIER -108.46 126.69 53.18 Favored 'General case' 0 C--N 1.272 -2.781 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.228 -177.462 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 63.5 mtm -125.59 157.75 36.37 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.682 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 1.3 ttpm? -61.34 115.95 4.25 Favored 'General case' 0 C--O 1.247 0.971 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.903 179.134 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.63 -5.68 64.62 Favored Glycine 0 C--O 1.251 1.165 0 O-C-N 123.506 0.504 . . . . 0.0 112.094 178.241 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 88.8 m-85 -120.81 151.02 54.04 Favored Pre-proline 0 N--CA 1.426 -1.656 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -177.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.18 171.09 17.62 Favored 'Trans proline' 0 N--CA 1.443 -1.495 0 C-N-CA 121.676 1.584 . . . . 0.0 109.082 174.705 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' HIS . . . . . 0.477 ' HB3' ' HB3' ' A' ' 12' ' ' PHE . 86.3 m-70 -61.22 110.41 1.39 Allowed 'General case' 0 CA--C 1.549 0.941 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 175.947 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -99.34 138.39 20.51 Favored Pre-proline 0 C--N 1.31 -1.132 0 C-N-CA 123.377 0.671 . . . . 0.0 109.874 -171.071 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo -60.72 118.2 5.05 Favored 'Trans proline' 0 C--O 1.245 0.861 0 C-N-CA 121.746 1.631 . . . . 0.0 110.709 177.25 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.8 167.19 22.87 Favored 'General case' 0 N--CA 1.413 -2.309 0 CA-C-O 120.898 0.38 . . . . 0.0 110.309 -176.481 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.422 ' HG3' HD23 ' A' ' 10' ' ' LEU . 24.4 ttp-105 -125.81 147.04 49.54 Favored 'General case' 0 C--N 1.288 -2.083 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 175.346 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 48.1 t -72.78 119.04 18.85 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 N-CA-C 105.714 -1.958 . . . . 0.0 105.714 171.62 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -90.31 -177.5 5.12 Favored 'General case' 0 C--N 1.307 -1.247 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -175.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -101.26 168.68 9.4 Favored 'General case' 0 C--N 1.282 -2.341 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -175.685 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 48.4 t -83.43 124.07 76.11 Favored Pre-proline 0 C--N 1.309 -1.178 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 177.294 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -72.18 138.0 29.77 Favored 'Trans proline' 0 N--CA 1.43 -2.229 0 C-N-CA 121.429 1.42 . . . . 0.0 112.615 -179.476 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -71.0 148.99 47.09 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 174.306 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.03 -16.43 61.35 Favored Glycine 0 N--CA 1.429 -1.788 0 C-N-CA 120.726 -0.749 . . . . 0.0 111.299 -176.132 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.82 92.92 1.63 Allowed 'General case' 0 N--CA 1.442 -0.848 0 CA-C-O 121.451 0.644 . . . . 0.0 110.554 177.183 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.9 m -78.2 -8.13 11.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.373 178.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 25.6 mmmt -108.05 119.89 48.58 Favored Pre-proline 0 N--CA 1.416 -2.157 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 174.707 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_exo -70.58 155.13 63.85 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 121.978 1.785 . . . . 0.0 110.639 177.146 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -71.62 168.59 23.24 Favored 'Trans proline' 0 N--CA 1.449 -1.14 0 C-N-CA 121.907 1.738 . . . . 0.0 112.545 -179.17 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.531 ' O ' ' HB3' ' A' ' 38' ' ' ASN . 4.7 m -64.62 10.23 0.07 Allowed 'General case' 0 CA--C 1.571 1.777 0 C-N-CA 126.603 1.961 . . . . 0.0 113.465 -178.469 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.531 ' HB3' ' O ' ' A' ' 37' ' ' THR . 0.7 OUTLIER 81.32 10.96 0.83 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-O 124.172 1.939 . . . . 0.0 108.701 -172.139 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -95.79 166.6 11.73 Favored 'General case' 0 N--CA 1.423 -1.81 0 CA-C-N 112.825 -1.989 . . . . 0.0 108.712 175.066 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 87.9 mt -99.96 141.23 22.38 Favored Pre-proline 0 C--N 1.291 -1.946 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.268 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -71.72 123.4 9.37 Favored 'Trans proline' 0 N--CA 1.454 -0.824 0 C-N-CA 122.037 1.824 . . . . 0.0 109.852 176.607 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.473 HG21 ' HB2' ' A' ' 13' ' ' ALA . 42.4 mm -118.08 120.76 65.47 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 CA-C-N 116.196 -0.457 . . . . 0.0 109.837 -175.542 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 66.1 t80 -97.92 120.1 37.71 Favored 'General case' 0 C--N 1.281 -2.383 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -85.2 131.46 34.43 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.257 0.551 . . . . 0.0 111.972 178.28 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -84.96 155.04 21.79 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.712 176.394 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.571 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 79.22 -19.57 5.47 Favored Glycine 0 C--N 1.314 -0.669 0 C-N-CA 123.257 0.456 . . . . 0.0 113.418 179.11 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 16.3 p -118.61 -23.13 7.2 Favored 'General case' 0 C--N 1.307 -1.26 0 O-C-N 122.561 -0.376 . . . . 0.0 110.215 175.817 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.7 m170 67.46 19.19 10.06 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 123.509 0.724 . . . . 0.0 111.768 -179.237 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 19.2 mm-40 -87.65 168.27 13.16 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.205 179.59 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.7 m -134.55 142.5 46.99 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 121.067 0.46 . . . . 0.0 109.769 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -139.05 179.66 6.37 Favored 'General case' 0 C--N 1.293 -1.891 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.201 -178.441 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -134.13 117.39 16.52 Favored 'General case' 0 C--O 1.262 1.726 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.679 177.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 94.8 mt -129.5 174.56 9.53 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.17 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.37 164.94 21.34 Favored Glycine 0 N--CA 1.417 -2.597 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.16 -5.4 13.62 Favored 'Trans proline' 0 C--O 1.249 1.074 0 C-N-CA 123.752 2.968 . . . . 0.0 112.905 -178.179 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 23.0 pttm -97.57 -19.78 18.12 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.009 178.366 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -96.83 0.37 49.18 Favored 'General case' 0 CA--C 1.5 -0.943 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.598 -173.789 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.2 pt -123.43 144.78 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.995 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.725 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -130.55 147.13 64.74 Favored Pre-proline 0 C--N 1.289 -2.037 0 CA-C-N 114.631 -1.168 . . . . 0.0 108.006 -177.668 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -66.74 132.49 28.79 Favored 'Trans proline' 0 C--N 1.328 -0.548 0 C-N-CA 122.474 2.116 . . . . 0.0 112.558 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.523 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 53.4 t80 -64.0 -37.79 88.72 Favored 'General case' 0 C--O 1.201 -1.488 0 CA-C-N 114.939 -1.028 . . . . 0.0 112.25 -176.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -62.76 -54.35 40.49 Favored 'General case' 0 C--N 1.292 -1.92 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -176.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 3.6 mp0 -71.58 -26.23 62.52 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-O 121.71 0.766 . . . . 0.0 111.23 -178.266 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.466 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 29.9 m-80 -106.82 10.12 30.79 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -175.45 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -65.44 -31.27 72.26 Favored 'General case' 0 N--CA 1.483 1.195 0 CA-C-O 121.354 0.597 . . . . 0.0 111.898 -178.117 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.525 ' HA ' ' NZ ' ' A' ' 70' ' ' LYS . 55.5 mm-40 -75.97 -28.92 58.05 Favored 'General case' 0 C--N 1.285 -2.211 0 C-N-CA 119.391 -0.924 . . . . 0.0 111.842 178.277 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.466 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 33.2 mtpt -78.04 -59.26 2.85 Favored 'General case' 0 C--N 1.281 -2.407 0 CA-C-N 113.963 -1.471 . . . . 0.0 111.052 -176.769 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.449 ' CD2' ' HB3' ' A' ' 64' ' ' ASN . 19.9 m-85 -109.96 -9.47 14.76 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.384 -171.229 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -86.0 47.62 3.81 Favored Glycine 0 C--N 1.311 -0.857 0 N-CA-C 111.291 -0.724 . . . . 0.0 111.291 -178.716 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.525 ' NZ ' ' HA ' ' A' ' 66' ' ' GLU . 47.7 mmtm -127.91 147.77 64.43 Favored Pre-proline 0 C--N 1.307 -1.263 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.532 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.479 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 77.4 Cg_exo -48.01 128.94 17.4 Favored 'Trans proline' 0 C--N 1.363 1.318 0 C-N-CA 123.662 2.908 . . . . 0.0 114.782 -176.225 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.46 ' HB2' ' CD1' ' A' ' 77' ' ' PHE . 1.9 t-20 -112.22 -165.48 1.0 Allowed 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 114.747 -1.115 . . . . 0.0 109.559 -175.449 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 38.6 mmtm -121.53 12.68 10.82 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.686 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 24.2 mmt180 -93.9 128.39 40.17 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 114.874 -1.057 . . . . 0.0 109.712 174.582 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 28.1 tptp -68.89 122.5 18.75 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 177.18 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.571 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 107.14 -20.83 32.48 Favored Glycine 0 N--CA 1.438 -1.189 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 -179.254 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.46 ' CD1' ' HB2' ' A' ' 72' ' ' ASN . 35.6 t80 -75.2 -44.1 48.28 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-O 121.61 0.719 . . . . 0.0 109.701 -177.069 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.479 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 92.8 m-20 -76.38 -35.07 58.85 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 114.893 -1.048 . . . . 0.0 110.63 -174.112 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -70.12 -35.5 74.15 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.183 -1.044 . . . . 0.0 108.183 174.913 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -65.75 -35.63 91.22 Favored Glycine 0 N--CA 1.435 -1.413 0 CA-C-N 115.112 -0.949 . . . . 0.0 111.968 177.697 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.439 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 95.8 mt -56.16 -38.32 70.73 Favored 'General case' 0 C--O 1.219 -0.52 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 175.589 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 73.0 t90 -74.19 -49.08 25.07 Favored 'General case' 0 N--CA 1.426 -1.635 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.417 178.691 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -57.0 -46.82 82.02 Favored 'General case' 0 C--O 1.203 -1.343 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.251 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.8 tt -70.18 -24.57 26.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 120.628 -0.429 . . . . 0.0 112.033 -175.219 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -93.52 -19.69 20.98 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.058 0.456 . . . . 0.0 110.141 -175.053 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -111.56 -54.34 2.62 Favored 'General case' 0 N--CA 1.483 1.198 0 CA-C-O 121.351 0.596 . . . . 0.0 111.863 -179.286 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.1 t30 -126.24 71.98 71.12 Favored Pre-proline 0 C--N 1.312 -1.065 0 O-C-N 121.999 -0.438 . . . . 0.0 110.93 -177.715 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -73.2 -6.49 19.0 Favored 'Trans proline' 0 CA--C 1.53 0.309 0 C-N-CA 122.242 1.961 . . . . 0.0 113.232 -175.819 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.4 pttm -95.91 12.55 29.87 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.973 -176.306 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 8.4 p -72.78 158.73 6.04 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.303 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 178.199 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 65.8 mmtt -119.36 171.52 8.27 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 112.618 0.599 . . . . 0.0 112.618 -175.716 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 7.4 p90 -66.41 128.42 36.09 Favored 'General case' 0 N--CA 1.441 -0.89 0 CA-C-N 114.239 -1.346 . . . . 0.0 111.08 177.883 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 22.6 p . . . . . 0 N--CA 1.432 -1.352 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.734 -175.175 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.477 0.884 0 N-CA-C 105.462 -2.051 . . . . 0.0 105.462 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -79.21 -25.55 42.69 Favored 'General case' 0 C--N 1.313 -0.992 0 O-C-N 123.585 0.553 . . . . 0.0 110.266 177.515 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 47.2 ptt85 -93.75 170.16 9.78 Favored 'General case' 0 C--O 1.253 1.26 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 177.426 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -91.02 179.44 5.74 Favored 'General case' 0 N--CA 1.433 -1.317 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.464 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -130.26 143.05 50.54 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-O 120.753 0.311 . . . . 0.0 110.438 -173.248 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.527 ' O ' ' HB2' ' A' ' 9' ' ' ASP . 47.9 mmtm -111.51 155.62 42.64 Favored Pre-proline 0 C--N 1.304 -1.392 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 -178.59 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_exo -58.33 121.46 10.02 Favored 'Trans proline' 0 C--O 1.237 0.46 0 C-N-CA 121.78 1.653 . . . . 0.0 108.448 171.105 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . 0.582 ' HA2' ' NH1' ' A' ' 24' ' ' ARG . . . 108.72 -11.95 35.31 Favored Glycine 0 N--CA 1.425 -2.034 0 C-N-CA 120.55 -0.834 . . . . 0.0 112.449 -176.505 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.527 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 0.8 OUTLIER -64.39 133.51 52.73 Favored 'General case' 0 C--O 1.252 1.202 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -178.025 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 78.8 mt -89.27 119.97 30.22 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.419 ' HA ' ' HA ' ' A' ' 60' ' ' PRO . 7.5 pt -139.03 -173.54 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.841 0 CA-C-O 122.753 1.263 . . . . 0.0 112.956 -172.037 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.622 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 84.2 m-85 -127.48 125.41 40.42 Favored 'General case' 0 N--CA 1.403 -2.809 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 171.861 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.521 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -113.43 134.45 54.65 Favored 'General case' 0 C--N 1.266 -3.024 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.617 -176.573 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.638 ' HB2' ' CD2' ' A' ' 20' ' ' HIS . 0.0 OUTLIER -109.04 121.15 44.53 Favored 'General case' 0 N--CA 1.408 -2.532 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.396 -178.616 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 71.5 mtm -112.18 158.88 19.14 Favored 'General case' 0 C--N 1.315 -0.934 0 C-N-CA 123.587 0.755 . . . . 0.0 109.24 176.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 24.9 ttmm -66.18 117.41 8.45 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.106 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.38 -7.07 56.06 Favored Glycine 0 C--O 1.246 0.875 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -178.639 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 65.2 m-85 -123.21 148.15 54.01 Favored Pre-proline 0 N--CA 1.435 -1.222 0 C-N-CA 122.994 0.518 . . . . 0.0 110.684 179.206 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -79.34 171.6 15.81 Favored 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 122.116 1.877 . . . . 0.0 108.28 170.83 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' HIS . . . . . 0.638 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 78.9 m80 -58.16 111.19 1.11 Allowed 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 175.774 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' TRP . . . . . 0.42 ' O ' ' HA ' ' A' ' 12' ' ' PHE . 11.5 t-105 -111.74 141.69 25.2 Favored Pre-proline 0 C--N 1.302 -1.46 0 C-N-CA 123.561 0.744 . . . . 0.0 109.343 -170.526 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.424 ' HD3' ' CE2' ' A' ' 77' ' ' PHE . 26.3 Cg_exo -57.76 118.71 5.63 Favored 'Trans proline' 0 C--N 1.36 1.14 0 C-N-CA 122.274 1.983 . . . . 0.0 110.994 178.328 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -145.53 167.34 23.25 Favored 'General case' 0 N--CA 1.407 -2.584 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 -177.617 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.582 ' NH1' ' HA2' ' A' ' 8' ' ' GLY . 32.7 ttp85 -123.23 144.52 49.34 Favored 'General case' 0 C--N 1.276 -2.589 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 177.648 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 58.7 t -74.58 113.74 13.53 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.99 0 N-CA-C 104.793 -2.299 . . . . 0.0 104.793 170.749 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.58 ' OD1' ' HA ' ' A' ' 91' ' ' LYS . 1.1 t70 -86.88 -176.01 5.6 Favored 'General case' 0 C--N 1.29 -2.015 0 O-C-N 123.554 0.534 . . . . 0.0 111.084 -172.0 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 33.6 mm-40 -91.56 164.28 13.83 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 121.622 0.725 . . . . 0.0 109.81 -173.209 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.7 t -93.8 120.9 65.52 Favored Pre-proline 0 C--N 1.301 -1.522 0 N-CA-C 107.197 -1.408 . . . . 0.0 107.197 172.261 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -71.99 142.88 39.49 Favored 'Trans proline' 0 N--CA 1.431 -2.155 0 C-N-CA 121.57 1.513 . . . . 0.0 113.365 -178.019 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 18.1 t0 -71.11 152.84 43.05 Favored 'General case' 0 C--O 1.251 1.161 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 170.585 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 85.48 0.39 88.19 Favored Glycine 0 N--CA 1.421 -2.31 0 C-N-CA 120.087 -1.054 . . . . 0.0 110.882 -174.363 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.29 76.36 1.84 Allowed 'General case' 0 C--O 1.208 -1.106 0 CA-C-O 122.163 0.982 . . . . 0.0 110.98 173.013 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 26.8 m -96.31 6.39 8.08 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 CA-C-N 114.154 -1.384 . . . . 0.0 109.767 177.413 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.609 ' H ' ' HD2' ' A' ' 34' ' ' LYS . 0.0 OUTLIER -107.79 141.39 22.98 Favored Pre-proline 0 N--CA 1.409 -2.499 0 N-CA-C 106.584 -1.635 . . . . 0.0 106.584 178.524 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.422 ' HA ' ' HD3' ' A' ' 36' ' ' PRO . 20.8 Cg_endo -62.19 134.13 47.37 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 121.969 1.779 . . . . 0.0 112.58 -178.096 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 35' ' ' PRO . 3.3 Cg_exo -76.64 171.76 17.44 Favored 'Trans proline' 0 N--CA 1.447 -1.208 0 C-N-CA 122.438 2.092 . . . . 0.0 111.49 176.897 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 5.9 m -71.26 6.96 1.45 Allowed 'General case' 0 C--O 1.265 1.882 0 C-N-CA 124.413 1.085 . . . . 0.0 111.92 -178.776 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.1 m-80 63.74 28.07 14.81 Favored 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 124.359 1.064 . . . . 0.0 109.65 -179.415 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.423 ' HB3' ' O ' ' A' ' 53' ' ' LEU . 62.4 mttp -139.91 -179.55 6.01 Favored 'General case' 0 N--CA 1.433 -1.322 0 CA-C-N 114.748 -1.115 . . . . 0.0 109.237 -178.422 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.435 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 95.8 mt -90.84 139.69 26.14 Favored Pre-proline 0 C--N 1.297 -1.709 0 O-C-N 123.894 0.746 . . . . 0.0 110.134 -177.632 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -71.38 123.22 9.35 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.262 1.974 . . . . 0.0 109.779 176.813 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.423 HG21 ' CB ' ' A' ' 13' ' ' ALA . 39.7 mm -122.17 121.59 64.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.932 -0.48 . . . . 0.0 109.993 -176.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -106.35 118.96 38.01 Favored 'General case' 0 C--N 1.29 -2.001 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 178.06 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 73.6 m-85 -82.32 136.07 35.08 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -179.408 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -85.58 148.85 25.73 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.9 178.334 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.458 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 78.94 -21.08 4.16 Favored Glycine 0 C--N 1.308 -1.019 0 C-N-CA 123.72 0.676 . . . . 0.0 114.168 176.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 30.7 p -119.74 -22.46 6.85 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 117.523 0.662 . . . . 0.0 110.674 174.802 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.4 m-70 67.01 21.9 10.15 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 123.649 0.779 . . . . 0.0 111.563 -178.793 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.8 mt-10 -72.42 163.61 27.71 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.064 175.821 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.7 m -136.87 140.05 42.1 Favored 'General case' 0 C--N 1.275 -2.645 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.346 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -141.05 176.07 9.11 Favored 'General case' 0 C--N 1.286 -2.18 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.273 -179.668 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.435 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 97.7 m-85 -133.98 111.07 10.11 Favored 'General case' 0 N--CA 1.431 -1.423 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 174.52 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.521 HD12 ' HB1' ' A' ' 13' ' ' ALA . 85.9 mt -125.69 170.42 11.55 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -177.527 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -95.08 167.17 26.35 Favored Glycine 0 N--CA 1.42 -2.398 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 178.166 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -66.38 -6.85 15.96 Favored 'Trans proline' 0 N--CA 1.484 0.923 0 C-N-CA 123.357 2.705 . . . . 0.0 112.743 -177.793 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.9 ptmm? -92.37 -19.88 21.64 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.725 178.738 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -102.45 5.05 39.38 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-O 121.281 0.562 . . . . 0.0 111.623 -174.864 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.9 pt -125.22 147.53 29.87 Favored 'Isoleucine or valine' 0 C--O 1.266 1.954 0 CA-C-N 114.653 -1.158 . . . . 0.0 110.372 178.791 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.42 ' HB3' ' ND2' ' A' ' 64' ' ' ASN . 88.8 m-85 -136.37 133.11 19.17 Favored Pre-proline 0 C--N 1.289 -2.035 0 CA-C-N 114.686 -1.143 . . . . 0.0 108.355 -179.543 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.419 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 22.5 Cg_endo -68.3 144.06 60.83 Favored 'Trans proline' 0 CA--C 1.499 -1.264 0 C-N-CA 122.971 2.447 . . . . 0.0 114.04 -177.397 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.622 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 83.9 t80 -58.88 -38.26 78.42 Favored 'General case' 0 C--O 1.203 -1.377 0 CA-C-N 114.305 -1.316 . . . . 0.0 110.579 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.48 -47.57 83.38 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 113.744 1.016 . . . . 0.0 113.744 -175.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -93.33 -8.27 42.46 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-O 121.357 0.599 . . . . 0.0 111.597 -177.395 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.445 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 24.0 m-80 -124.91 14.12 8.53 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -175.164 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -63.37 -37.78 88.61 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 10.4 mp0 -66.08 -34.68 78.62 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 122.796 1.284 . . . . 0.0 109.326 177.127 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.445 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 35.4 mtpt -75.48 -59.55 2.7 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-N 113.396 -1.729 . . . . 0.0 112.008 -174.555 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.43 ' CD2' ' HB3' ' A' ' 64' ' ' ASN . 18.5 m-85 -115.11 -15.4 11.7 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.982 -171.068 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.77 10.77 30.19 Favored Glycine 0 N--CA 1.472 1.042 0 CA-C-O 121.213 0.341 . . . . 0.0 113.207 -175.226 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 23.2 pttm -93.04 149.9 38.32 Favored Pre-proline 0 C--N 1.298 -1.671 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -66.91 128.19 18.33 Favored 'Trans proline' 0 N--CA 1.441 -1.56 0 C-N-CA 120.845 1.03 . . . . 0.0 112.287 178.069 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 41.4 m-80 -113.19 -173.41 2.25 Favored 'General case' 0 C--N 1.295 -1.795 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 47.4 mmtm -96.75 15.87 20.72 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-O 121.238 0.542 . . . . 0.0 112.269 -176.066 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -87.94 120.94 29.77 Favored 'General case' 0 C--N 1.309 -1.187 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 174.352 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.4 tppt? -74.71 130.43 39.49 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 177.111 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.458 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.24 -25.78 18.96 Favored Glycine 0 N--CA 1.435 -1.381 0 N-CA-C 108.819 -1.712 . . . . 0.0 108.819 -174.053 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.424 ' CE2' ' HD3' ' A' ' 22' ' ' PRO . 11.2 t80 -76.79 -44.71 31.71 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.749 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 10.0 m120 -60.25 -47.89 84.07 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 22.2 mp0 -63.5 -37.06 85.85 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 113.778 -1.555 . . . . 0.0 110.194 179.341 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -67.55 -34.56 84.5 Favored Glycine 0 N--CA 1.442 -0.924 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.309 177.437 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 95.5 mt -62.78 -33.95 76.24 Favored 'General case' 0 C--O 1.216 -0.694 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 175.39 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 69.8 t90 -71.62 -49.44 40.12 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.624 175.24 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -60.43 -34.69 74.34 Favored 'General case' 0 C--O 1.21 -0.98 0 N-CA-C 113.882 1.067 . . . . 0.0 113.882 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.6 tt -72.77 -21.41 19.59 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-O 121.214 0.531 . . . . 0.0 110.3 -176.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -89.92 -46.74 8.33 Favored 'General case' 0 N--CA 1.435 -1.211 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.719 -178.62 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -86.92 -35.88 18.67 Favored 'General case' 0 C--O 1.252 1.227 0 CA-C-O 121.63 0.728 . . . . 0.0 111.843 -173.766 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -134.08 63.6 62.6 Favored Pre-proline 0 C--N 1.298 -1.669 0 C-N-CA 118.892 -1.123 . . . . 0.0 112.873 -179.58 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -72.04 -5.74 17.71 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 122.791 2.327 . . . . 0.0 110.838 177.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' LYS . . . . . 0.418 ' HG2' ' H ' ' A' ' 89' ' ' LYS . 16.5 pttp -99.09 17.08 20.69 Favored 'General case' 0 C--N 1.302 -1.478 0 C-N-CA 125.378 1.471 . . . . 0.0 110.81 -176.807 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 9.6 p -81.2 166.02 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.849 0 N-CA-C 107.969 -1.122 . . . . 0.0 107.969 175.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.58 ' HA ' ' OD1' ' A' ' 26' ' ' ASP . 2.4 mtmp? -147.55 -176.07 5.1 Favored 'General case' 0 C--O 1.252 1.225 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -178.335 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -43.34 -53.86 5.02 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 124.972 1.42 . . . . 0.0 108.682 175.53 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 4.1 p . . . . . 0 N--CA 1.4 -2.957 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 173.074 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.3 mtt . . . . . 0 C--O 1.194 -1.823 0 N-CA-C 106.956 -1.498 . . . . 0.0 106.956 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -79.22 -30.2 43.16 Favored 'General case' 0 C--O 1.251 1.161 0 CA-C-N 118.639 0.654 . . . . 0.0 111.356 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.537 ' HG3' ' N ' ' A' ' 4' ' ' ASP . 23.3 ptt180 -89.02 -49.61 6.67 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.594 -177.625 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ASP . . . . . 0.537 ' N ' ' HG3' ' A' ' 3' ' ' ARG . 5.8 p-10 -117.58 147.15 43.1 Favored 'General case' 0 C--N 1.274 -2.681 0 CA-C-N 114.273 -1.33 . . . . 0.0 109.462 -174.201 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -137.02 121.45 18.23 Favored 'General case' 0 C--N 1.298 -1.638 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 27.5 mtmm -124.31 156.92 66.21 Favored Pre-proline 0 C--N 1.289 -2.059 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 -176.122 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo -51.87 117.62 3.72 Favored 'Trans proline' 0 N--CA 1.461 -0.39 0 C-N-CA 122.17 1.913 . . . . 0.0 110.416 173.683 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.45 -23.55 10.32 Favored Glycine 0 N--CA 1.427 -1.902 0 CA-C-O 119.452 -0.638 . . . . 0.0 112.694 -176.475 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -64.98 123.68 20.08 Favored 'General case' 0 C--O 1.25 1.11 0 CA-C-N 117.573 0.686 . . . . 0.0 110.115 177.213 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.8 mt -80.05 129.48 34.53 Favored 'General case' 0 CA--C 1.49 -1.363 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 176.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 8.1 pt -143.17 -172.7 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.421 -1.884 0 CA-C-O 122.479 1.133 . . . . 0.0 112.4 -173.08 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.451 ' HB3' ' HB3' ' A' ' 20' ' ' HIS . 31.9 m-85 -128.58 129.07 45.42 Favored 'General case' 0 N--CA 1.402 -2.873 0 CA-C-N 113.288 -1.778 . . . . 0.0 106.55 172.784 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.557 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -108.78 128.92 55.31 Favored 'General case' 0 C--N 1.271 -2.834 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.446 -174.346 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.606 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -106.39 124.12 49.11 Favored 'General case' 0 N--CA 1.403 -2.782 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.039 -178.697 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 69.1 mtm -121.42 158.38 28.46 Favored 'General case' 0 CA--C 1.508 -0.667 0 C-N-CA 123.219 0.608 . . . . 0.0 109.814 176.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -64.66 116.52 6.32 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 178.667 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.44 -2.43 65.14 Favored Glycine 0 C--O 1.246 0.868 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -121.93 146.35 45.95 Favored Pre-proline 0 N--CA 1.428 -1.567 0 C-N-CA 122.731 0.412 . . . . 0.0 110.388 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -75.82 171.29 18.45 Favored 'Trans proline' 0 N--CA 1.444 -1.428 0 C-N-CA 121.798 1.665 . . . . 0.0 108.467 172.439 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' HIS . . . . . 0.477 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 69.2 m80 -61.53 111.15 1.69 Allowed 'General case' 0 CA--C 1.548 0.883 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 175.854 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 7.8 t-105 -102.96 139.26 19.96 Favored Pre-proline 0 C--N 1.304 -1.405 0 C-N-CA 123.852 0.861 . . . . 0.0 109.31 -171.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_exo -59.08 118.66 5.59 Favored 'Trans proline' 0 C--N 1.354 0.84 0 C-N-CA 121.875 1.716 . . . . 0.0 110.869 177.868 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.81 167.05 23.0 Favored 'General case' 0 N--CA 1.414 -2.227 0 CA-C-O 121.227 0.537 . . . . 0.0 110.417 -177.456 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 36.6 ttt-85 -119.05 139.89 50.98 Favored 'General case' 0 C--N 1.285 -2.198 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 177.843 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 60.2 t -75.34 111.12 11.22 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.951 0 N-CA-C 103.817 -2.66 . . . . 0.0 103.817 168.058 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -89.37 -177.55 5.39 Favored 'General case' 0 C--N 1.289 -2.032 0 C-N-CA 119.535 -0.866 . . . . 0.0 111.451 -170.293 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -104.99 141.94 35.67 Favored 'General case' 0 C--N 1.293 -1.876 0 CA-C-O 121.875 0.845 . . . . 0.0 113.201 -171.131 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.1 t -88.86 128.56 51.75 Favored Pre-proline 0 C--N 1.312 -1.056 0 CA-C-N 114.59 -1.186 . . . . 0.0 109.828 -176.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -71.93 149.08 52.74 Favored 'Trans proline' 0 N--CA 1.434 -1.983 0 C-N-CA 121.623 1.549 . . . . 0.0 112.477 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -68.08 146.78 53.15 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 174.734 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.43 -27.5 20.05 Favored Glycine 0 C--N 1.292 -1.865 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 -174.666 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -79.18 78.47 5.64 Favored 'General case' 0 N--CA 1.434 -1.233 0 CA-C-O 122.1 0.952 . . . . 0.0 110.004 175.849 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.0 m -94.19 6.92 6.61 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 114.383 -1.281 . . . . 0.0 111.035 -179.798 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 31.3 mmtp -81.56 126.89 74.91 Favored Pre-proline 0 C--N 1.297 -1.705 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.048 179.297 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_endo -65.54 135.21 41.36 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 122.053 1.835 . . . . 0.0 112.263 -179.543 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -80.07 171.47 15.17 Favored 'Trans proline' 0 N--CA 1.443 -1.485 0 C-N-CA 122.445 2.096 . . . . 0.0 112.512 -179.07 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.3 m -72.86 8.94 1.29 Allowed 'General case' 0 CA--C 1.563 1.449 0 C-N-CA 125.576 1.55 . . . . 0.0 111.44 -179.024 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 49.0 m-80 78.42 13.41 1.48 Allowed 'General case' 0 N--CA 1.485 1.301 0 C-N-CA 125.209 1.404 . . . . 0.0 109.758 -174.789 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.634 ' HE3' ' HA ' ' A' ' 53' ' ' LEU . 22.5 mtpp -111.46 152.14 27.77 Favored 'General case' 0 N--CA 1.418 -2.035 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 175.275 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 71.2 mt -98.44 153.9 37.8 Favored Pre-proline 0 C--N 1.288 -2.079 0 O-C-N 123.54 0.525 . . . . 0.0 110.356 -173.676 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -71.4 122.36 8.58 Favored 'Trans proline' 0 C--N 1.354 0.826 0 C-N-CA 121.788 1.659 . . . . 0.0 109.798 176.476 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.422 HG13 ' HB2' ' A' ' 53' ' ' LEU . 43.8 mm -117.84 119.9 62.99 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.943 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 -176.487 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 86.2 t80 -98.27 117.68 33.2 Favored 'General case' 0 C--N 1.28 -2.437 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 178.901 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -81.78 129.85 34.87 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 121.419 0.628 . . . . 0.0 112.672 178.647 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.405 ' HB3' ' HA2' ' A' ' 80' ' ' GLY . 72.1 m-85 -80.45 151.96 29.03 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.819 177.433 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.436 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 78.23 -20.68 3.86 Favored Glycine 0 C--N 1.315 -0.628 0 C-N-CA 123.562 0.601 . . . . 0.0 114.306 177.716 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 36.2 p -119.37 -22.59 6.99 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 117.533 0.666 . . . . 0.0 109.849 174.323 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.0 m-70 67.7 22.74 8.87 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.883 0.873 . . . . 0.0 112.308 179.011 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -78.41 169.3 18.48 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.335 177.596 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 6.3 m -139.36 137.82 36.08 Favored 'General case' 0 C--N 1.289 -2.059 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 177.04 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -138.58 -179.55 5.88 Favored 'General case' 0 C--N 1.28 -2.436 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.614 -176.754 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 87.3 m-85 -131.31 109.79 10.62 Favored 'General case' 0 CA--C 1.491 -1.318 0 C-N-CA 123.662 0.785 . . . . 0.0 109.294 177.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.634 ' HA ' ' HE3' ' A' ' 39' ' ' LYS . 96.2 mt -126.77 152.29 47.08 Favored 'General case' 0 C--N 1.295 -1.803 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.076 -178.689 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.422 ' O ' HG12 ' A' ' 58' ' ' ILE . . . -80.43 168.17 51.32 Favored Glycine 0 N--CA 1.429 -1.802 0 N-CA-C 110.564 -1.015 . . . . 0.0 110.564 -177.551 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -65.18 -18.42 61.19 Favored 'Trans proline' 0 C--O 1.209 -0.966 0 C-N-CA 122.337 2.025 . . . . 0.0 112.13 -178.479 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 10.8 mmtm -99.56 2.05 44.34 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 113.206 0.817 . . . . 0.0 113.206 173.703 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -94.04 -12.02 29.48 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 173.656 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.451 HG22 ' HA ' ' A' ' 13' ' ' ALA . 15.9 pt -125.77 151.58 32.01 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.705 0 CA-C-N 114.459 -1.246 . . . . 0.0 109.698 -176.801 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.451 ' HB3' HD21 ' A' ' 64' ' ' ASN . 96.4 m-85 -138.23 147.48 55.96 Favored Pre-proline 0 C--N 1.296 -1.754 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 -179.192 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -63.38 140.99 79.51 Favored 'Trans proline' 0 C--O 1.241 0.632 0 C-N-CA 123.19 2.593 . . . . 0.0 114.817 -174.503 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 40.5 t80 -56.03 -33.31 64.81 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 114.32 -1.309 . . . . 0.0 111.841 177.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.8 m -60.05 -41.9 93.3 Favored 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.527 -177.618 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . 0.301 48.8 mt-10 -75.98 -51.59 12.05 Favored 'General case' 0 CA--C 1.488 -1.426 0 CA-C-O 123.319 1.533 . . . . 0.0 108.656 176.6 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.451 HD21 ' HB3' ' A' ' 59' ' ' PHE . 37.0 m-80 -80.66 2.75 24.54 Favored 'General case' 0 N--CA 1.415 -2.211 0 CA-C-N 112.801 -1.999 . . . . 0.0 113.847 -161.439 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -68.92 -37.4 78.89 Favored 'General case' 0 N--CA 1.433 -1.286 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 176.424 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 56.8 mm-40 -80.83 -37.4 30.11 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.104 -0.498 . . . . 0.0 112.159 175.343 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 39.7 mtpt -70.96 -57.37 4.63 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 124.701 1.251 . . . . 0.0 111.171 -173.964 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 61.8 m-85 -126.97 7.24 6.63 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.213 -174.797 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -91.98 41.24 2.83 Favored Glycine 0 CA--C 1.496 -1.096 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -178.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.405 ' O ' ' HE1' ' A' ' 77' ' ' PHE . 30.4 mmtp -128.77 151.02 76.52 Favored Pre-proline 0 C--N 1.299 -1.616 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 -177.595 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.472 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 52.6 Cg_exo -48.42 148.44 7.81 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 123.642 2.895 . . . . 0.0 114.816 -176.415 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -140.17 -175.73 4.35 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-N 115.087 -0.96 . . . . 0.0 109.933 -178.886 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.2 mmmm -95.53 -3.26 46.9 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-O 120.804 0.335 . . . . 0.0 110.474 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 18.0 mmt180 -80.25 121.02 25.11 Favored 'General case' 0 C--N 1.309 -1.164 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.064 176.317 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -73.63 135.39 43.8 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 174.641 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.436 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 103.76 -25.31 27.01 Favored Glycine 0 N--CA 1.436 -1.332 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 -177.123 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.405 ' HE1' ' O ' ' A' ' 70' ' ' LYS . 55.7 t80 -74.73 -44.93 47.4 Favored 'General case' 0 N--CA 1.437 -1.077 0 CA-C-N 114.722 -0.739 . . . . 0.0 109.08 -178.925 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.472 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 89.4 m-20 -76.82 -35.75 57.37 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.062 -176.2 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 8.2 mp0 -67.73 -36.55 80.78 Favored 'General case' 0 N--CA 1.433 -1.311 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 174.376 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.405 ' HA2' ' HB3' ' A' ' 45' ' ' PHE . . . -70.47 -34.38 68.08 Favored Glycine 0 CA--C 1.496 -1.155 0 CA-C-N 115.445 -0.798 . . . . 0.0 112.094 177.584 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 40.9 tp -60.62 -36.53 78.84 Favored 'General case' 0 N--CA 1.432 -1.331 0 C-N-CA 123.955 0.902 . . . . 0.0 108.947 175.849 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 76.1 t90 -72.14 -47.39 51.41 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.054 175.469 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -61.15 -36.87 80.95 Favored 'General case' 0 C--O 1.193 -1.915 0 N-CA-C 114.009 1.114 . . . . 0.0 114.009 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.4 tt -70.67 -26.51 28.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 119.282 -0.967 . . . . 0.0 111.772 -176.723 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -83.77 -37.06 23.1 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.176 178.238 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 30.8 m-80 -101.86 -31.35 10.76 Favored 'General case' 0 C--O 1.257 1.487 0 CA-C-O 122.063 0.935 . . . . 0.0 112.738 -173.123 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 57.3 t30 -129.06 60.2 49.18 Favored Pre-proline 0 C--N 1.29 -2.014 0 O-C-N 121.628 -0.67 . . . . 0.0 112.539 -177.743 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -77.77 -5.74 15.57 Favored 'Trans proline' 0 N--CA 1.486 1.076 0 C-N-CA 122.211 1.94 . . . . 0.0 110.747 178.244 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 23.1 pttm -93.09 4.31 54.22 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 113.718 -1.583 . . . . 0.0 111.063 -174.606 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 9.9 p -73.49 162.63 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.008 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 179.61 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.6 mptp? -127.99 179.64 5.47 Favored 'General case' 0 C--O 1.262 1.731 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 176.782 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 41.4 p90 -49.93 133.22 22.59 Favored 'General case' 0 C--O 1.241 0.617 0 O-C-N 124.142 0.901 . . . . 0.0 109.097 170.416 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 41.5 m . . . . . 0 C--N 1.304 -1.382 0 N-CA-C 115.039 1.496 . . . . 0.0 115.039 -170.657 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 18.5 mmt . . . . . 0 CA--C 1.484 -1.588 0 CA-C-O 118.646 -0.692 . . . . 0.0 109.354 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -53.12 -40.59 64.31 Favored 'General case' 0 C--O 1.213 -0.868 0 O-C-N 124.603 1.19 . . . . 0.0 111.305 178.404 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.421 ' NE ' ' HB3' ' A' ' 60' ' ' PRO . 4.8 ptp180 -98.73 158.93 15.3 Favored 'General case' 0 C--O 1.262 1.713 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 175.805 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ASP . . . . . 0.436 ' OD2' ' HE3' ' A' ' 6' ' ' LYS . 13.7 p-10 -93.21 157.51 16.23 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 105.487 -2.042 . . . . 0.0 105.487 170.06 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -117.97 139.31 51.35 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.645 -170.007 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.489 ' HD2' ' N ' ' A' ' 6' ' ' LYS . 7.5 mptt -121.04 147.24 46.02 Favored Pre-proline 0 C--N 1.31 -1.119 0 N-CA-C 108.172 -1.048 . . . . 0.0 108.172 -178.842 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -56.98 121.13 9.53 Favored 'Trans proline' 0 N--CA 1.452 -0.967 0 C-N-CA 121.456 1.438 . . . . 0.0 109.32 172.884 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.66 -25.33 9.11 Favored Glycine 0 N--CA 1.42 -2.41 0 CA-C-O 118.671 -1.072 . . . . 0.0 114.142 -177.14 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.354 3.7 p30 -79.37 149.71 31.6 Favored 'General case' 0 C--O 1.243 0.748 0 CA-C-N 119.453 1.626 . . . . 0.0 113.557 -179.496 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.419 HD21 ' HB2' ' A' ' 88' ' ' PRO . 78.5 mt -86.74 128.54 35.02 Favored 'General case' 0 C--O 1.253 1.268 0 CA-C-N 114.605 -1.18 . . . . 0.0 110.851 -175.812 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -141.77 -177.2 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.466 0 CA-C-O 121.785 0.803 . . . . 0.0 112.255 -175.632 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.431 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 49.1 m-85 -113.65 128.25 56.36 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 107.211 -1.403 . . . . 0.0 107.211 172.531 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.444 ' HB2' HG21 ' A' ' 42' ' ' ILE . . . -108.3 120.31 42.0 Favored 'General case' 0 C--N 1.274 -2.69 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.684 -175.382 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.576 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 1.1 tmmt? -109.72 126.65 53.94 Favored 'General case' 0 C--N 1.27 -2.866 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.619 -177.638 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 69.6 mtm -120.48 158.55 27.01 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.489 179.264 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -68.77 117.02 9.94 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 179.497 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.27 -3.07 61.54 Favored Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -179.655 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -122.94 150.3 58.74 Favored Pre-proline 0 N--CA 1.435 -1.195 0 CA-C-O 120.744 0.307 . . . . 0.0 110.855 -179.118 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -74.91 170.74 19.74 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 122.134 1.889 . . . . 0.0 109.498 172.68 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' HIS . . . . . 0.445 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 76.3 m80 -66.77 111.55 3.77 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 177.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 10.6 t-105 -97.06 138.98 21.27 Favored Pre-proline 0 C--N 1.311 -1.093 0 C-N-CA 123.541 0.737 . . . . 0.0 109.689 -174.234 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.438 ' HB2' HG21 ' A' ' 84' ' ' ILE . 22.7 Cg_endo -69.05 117.76 5.25 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 121.254 1.303 . . . . 0.0 110.123 175.866 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.5 167.1 24.52 Favored 'General case' 0 N--CA 1.426 -1.625 0 CA-C-O 121.137 0.494 . . . . 0.0 110.528 -174.619 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.427 ' NH2' ' HG2' ' A' ' 91' ' ' LYS . 12.7 ttp180 -111.75 145.21 39.76 Favored 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 179.069 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.3 t -68.61 121.32 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.866 0 N-CA-C 104.821 -2.289 . . . . 0.0 104.821 169.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.532 ' CG ' ' HZ2' ' A' ' 91' ' ' LYS . 15.4 t70 -91.24 175.66 6.86 Favored 'General case' 0 C--N 1.281 -2.395 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 -171.161 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.408 ' CD ' HH22 ' A' ' 24' ' ' ARG . 0.3 OUTLIER -118.22 123.83 46.41 Favored 'General case' 0 N--CA 1.425 -1.695 0 CA-C-O 121.385 0.612 . . . . 0.0 110.229 179.453 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.1 p -83.02 124.62 76.42 Favored Pre-proline 0 N--CA 1.433 -1.282 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.089 -178.744 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -80.89 165.05 19.99 Favored 'Trans proline' 0 C--O 1.247 0.928 0 C-N-CA 122.482 2.121 . . . . 0.0 112.276 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 9.6 p-10 -79.05 154.31 29.53 Favored 'General case' 0 N--CA 1.426 -1.671 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 173.078 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 92.23 -19.89 46.91 Favored Glycine 0 C--N 1.296 -1.64 0 C-N-CA 119.764 -1.208 . . . . 0.0 110.951 -177.031 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.58 130.63 47.78 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 174.756 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 26.8 m -71.14 -10.62 14.18 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 N-CA-C 113.915 1.08 . . . . 0.0 113.915 -175.687 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.467 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 0.1 OUTLIER -108.15 122.73 39.72 Favored Pre-proline 0 N--CA 1.412 -2.326 0 C-N-CA 119.86 -0.736 . . . . 0.0 112.905 179.82 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.467 ' HD3' ' HA ' ' A' ' 34' ' ' LYS . 9.8 Cg_exo -72.81 172.12 15.96 Favored 'Trans proline' 0 C--O 1.264 1.803 0 C-N-CA 122.587 2.192 . . . . 0.0 110.587 174.718 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_endo -50.5 128.04 22.29 Favored 'Trans proline' 0 C--N 1.363 1.311 0 C-N-CA 122.858 2.372 . . . . 0.0 110.431 176.232 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.6 m -102.03 8.49 40.91 Favored 'General case' 0 C--N 1.286 -2.158 0 CA-C-N 115.027 -0.988 . . . . 0.0 110.005 -172.279 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 44.7 m-80 75.52 9.98 3.55 Favored 'General case' 0 N--CA 1.493 1.697 0 C-N-CA 124.843 1.257 . . . . 0.0 109.29 -173.821 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.412 ' HD3' ' HA ' ' A' ' 53' ' ' LEU . 71.6 mttt -132.28 162.0 32.09 Favored 'General case' 0 N--CA 1.415 -2.192 0 CA-C-N 113.88 -1.509 . . . . 0.0 108.609 177.605 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 75.0 mt -100.19 150.42 36.88 Favored Pre-proline 0 C--N 1.291 -1.944 0 O-C-N 124.368 1.042 . . . . 0.0 109.257 -175.871 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -75.49 133.33 15.75 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 121.684 1.589 . . . . 0.0 109.427 174.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.444 HG21 ' HB2' ' A' ' 13' ' ' ALA . 51.3 mm -124.47 126.74 72.33 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -176.692 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 65.2 t80 -105.51 115.02 29.55 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 -179.434 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.416 ' HE2' ' HB2' ' A' ' 51' ' ' ALA . 95.1 m-85 -79.23 136.18 36.99 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.245 0.545 . . . . 0.0 111.613 179.524 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -87.54 157.08 19.25 Favored 'General case' 0 C--N 1.301 -1.515 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.559 177.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 76.11 -21.27 2.25 Favored Glycine 0 CA--C 1.502 -0.775 0 C-N-CA 124.669 1.128 . . . . 0.0 114.134 179.163 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.404 ' CG2' ' HA3' ' A' ' 76' ' ' GLY . 40.4 p -120.01 -23.24 6.42 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 117.294 0.547 . . . . 0.0 110.199 174.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 51.7 m170 67.78 23.3 8.58 Favored 'General case' 0 C--N 1.342 0.25 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.681 178.758 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -73.78 162.7 28.86 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 175.482 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.8 m -137.5 142.33 41.48 Favored 'General case' 0 C--N 1.281 -2.371 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.416 ' HB2' ' HE2' ' A' ' 44' ' ' PHE . . . -139.65 -179.68 6.06 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.169 -178.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 80.2 m-85 -131.69 109.27 10.06 Favored 'General case' 0 N--CA 1.439 -0.989 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 175.274 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.511 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 96.0 mt -127.51 152.94 46.95 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.652 -175.171 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.97 171.72 37.71 Favored Glycine 0 N--CA 1.424 -2.164 0 C-N-CA 119.564 -1.303 . . . . 0.0 111.589 -174.797 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -66.12 -5.65 12.82 Favored 'Trans proline' 0 C--O 1.251 1.131 0 C-N-CA 123.235 2.624 . . . . 0.0 112.172 179.639 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -98.72 -16.87 18.81 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 114.961 -1.018 . . . . 0.0 111.774 175.062 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.511 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 40.9 m-20 -94.12 -8.7 38.8 Favored 'General case' 0 C--N 1.31 -1.15 0 CA-C-O 121.188 0.518 . . . . 0.0 110.118 -177.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.424 ' HA ' ' O ' ' A' ' 12' ' ' PHE . 14.3 pt -119.59 149.63 22.18 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.607 -176.195 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 57.6 m-85 -132.56 148.54 70.02 Favored Pre-proline 0 C--O 1.192 -1.945 0 N-CA-C 107.428 -1.323 . . . . 0.0 107.428 -177.381 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.449 ' O ' ' HB2' ' A' ' 64' ' ' ASN . 41.4 Cg_endo -66.2 132.32 29.38 Favored 'Trans proline' 0 C--N 1.322 -0.854 0 C-N-CA 121.94 1.76 . . . . 0.0 111.956 -179.236 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.431 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 66.5 t80 -69.38 -38.48 78.05 Favored 'General case' 0 C--O 1.204 -1.327 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -177.338 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 22.7 t -76.31 -33.63 59.03 Favored 'General case' 0 C--N 1.295 -1.8 0 C-N-CA 120.087 -0.645 . . . . 0.0 111.402 -172.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.507 ' C ' HD22 ' A' ' 64' ' ' ASN . 2.8 mp0 -95.69 -1.7 49.51 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.522 -177.778 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.507 HD22 ' C ' ' A' ' 63' ' ' GLU . 0.9 OUTLIER -131.17 15.34 5.12 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 178.232 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -69.75 -32.24 70.65 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.465 0.65 . . . . 0.0 110.1 -179.535 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.603 ' H ' ' CD ' ' A' ' 66' ' ' GLU . 1.5 mp0 -66.1 -31.61 72.58 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 178.103 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.482 ' HD3' ' CG ' ' A' ' 64' ' ' ASN . 37.7 mtpt -82.22 -60.25 2.28 Favored 'General case' 0 N--CA 1.428 -1.567 0 CA-C-N 114.303 -1.317 . . . . 0.0 111.501 -175.594 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -106.71 -1.15 23.01 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.434 -0.803 . . . . 0.0 113.057 -168.302 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.71 56.91 4.23 Favored Glycine 0 C--N 1.311 -0.827 0 C-N-CA 120.994 -0.622 . . . . 0.0 111.953 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 58.7 mttp -125.86 125.61 24.86 Favored Pre-proline 0 C--N 1.313 -1.021 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.27 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -53.15 128.8 30.51 Favored 'Trans proline' 0 C--O 1.263 1.763 0 C-N-CA 123.451 2.767 . . . . 0.0 114.414 -177.167 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -94.94 -172.43 2.7 Favored 'General case' 0 N--CA 1.407 -2.613 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.636 178.383 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.53 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 2.0 mptp? -106.98 -11.01 15.78 Favored 'General case' 0 N--CA 1.417 -2.118 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -178.506 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.94 118.13 9.3 Favored 'General case' 0 N--CA 1.41 -2.429 0 N-CA-C 106.272 -1.751 . . . . 0.0 106.272 169.71 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 9.3 tptp -69.9 140.25 53.09 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 107.888 -1.152 . . . . 0.0 107.888 179.013 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.404 ' HA3' ' CG2' ' A' ' 47' ' ' THR . . . 107.93 -24.04 24.25 Favored Glycine 0 N--CA 1.413 -2.889 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 -173.15 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -75.47 -38.79 59.39 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -68.64 -47.33 66.88 Favored 'General case' 0 CA--C 1.506 -0.739 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 -177.681 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 36.1 mp0 -61.66 -42.34 98.77 Favored 'General case' 0 N--CA 1.426 -1.661 0 CA-C-N 113.152 -1.84 . . . . 0.0 110.068 178.794 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.1 -37.0 72.6 Favored Glycine 0 CA--C 1.484 -1.846 0 CA-C-N 115.751 -0.659 . . . . 0.0 113.305 -179.243 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 38.3 tp -62.55 -31.1 71.84 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 176.782 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.0 t90 -74.76 -51.18 14.86 Favored 'General case' 0 N--CA 1.429 -1.501 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.248 175.006 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 -55.06 -45.84 75.34 Favored 'General case' 0 C--O 1.203 -1.346 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 -178.755 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.438 HG21 ' HB2' ' A' ' 22' ' ' PRO . 20.2 tt -68.73 -27.89 37.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -176.033 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -93.42 -16.96 24.03 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.252 0.549 . . . . 0.0 110.302 -173.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -109.91 -56.51 2.31 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-O 121.16 0.505 . . . . 0.0 111.527 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.501 HD22 ' HB ' ' A' ' 90' ' ' VAL . 6.8 t30 -128.27 75.19 79.2 Favored Pre-proline 0 C--N 1.313 -0.982 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.199 -177.65 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.419 ' HB2' HD21 ' A' ' 10' ' ' LEU . 56.4 Cg_endo -73.62 -5.26 16.79 Favored 'Trans proline' 0 C--N 1.332 -0.298 0 C-N-CA 122.699 2.266 . . . . 0.0 112.988 -177.701 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 26.1 pttm -87.46 8.73 23.46 Favored 'General case' 0 C--O 1.249 1.054 0 CA-C-O 121.38 0.609 . . . . 0.0 109.972 -176.393 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.501 ' HB ' HD22 ' A' ' 87' ' ' ASN 0.252 11.2 p -75.54 105.89 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.509 0 CA-C-O 122.475 1.131 . . . . 0.0 112.237 179.741 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.532 ' HZ2' ' CG ' ' A' ' 26' ' ' ASP . 20.2 tptm 173.13 -53.73 0.01 OUTLIER 'General case' 0 N--CA 1.431 -1.412 0 CA-C-N 112.437 -2.165 . . . . 0.0 107.326 -177.309 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 85.8 t80 -120.18 -63.23 1.39 Allowed 'General case' 0 C--N 1.299 -1.611 0 CA-C-N 114.53 -1.214 . . . . 0.0 109.719 -178.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.7 m . . . . . 0 C--N 1.316 -0.858 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.788 -179.813 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.0 mpp? . . . . . 0 CA--C 1.499 -1.002 0 CA-C-O 120.651 0.263 . . . . 0.0 111.03 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -99.81 70.25 1.62 Allowed 'General case' 0 N--CA 1.435 -1.182 0 N-CA-C 107.71 -1.218 . . . . 0.0 107.71 178.191 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 2.2 ptp180 -91.79 -176.05 4.34 Favored 'General case' 0 C--N 1.29 -2.021 0 CA-C-N 113.983 -1.462 . . . . 0.0 111.233 -178.304 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -143.42 -173.03 3.83 Favored 'General case' 0 N--CA 1.428 -1.553 0 N-CA-C 105.366 -2.087 . . . . 0.0 105.366 174.115 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.489 ' CE2' HG13 ' A' ' 58' ' ' ILE . 91.3 m-85 -125.37 149.1 48.44 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 117.575 2.435 . . . . 0.0 117.575 -170.771 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.493 ' HG3' ' OD1' ' A' ' 9' ' ' ASP . 3.8 ptmm? -134.65 156.3 78.8 Favored Pre-proline 0 N--CA 1.413 -2.276 0 CA-C-N 112.076 -2.329 . . . . 0.0 107.684 177.086 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.88 141.1 95.77 Favored 'Trans proline' 0 C--O 1.253 1.234 0 C-N-CA 122.497 2.132 . . . . 0.0 112.455 178.244 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 104.81 -14.17 49.56 Favored Glycine 0 N--CA 1.44 -1.039 0 C-N-CA 121.231 -0.509 . . . . 0.0 113.033 178.18 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.493 ' OD1' ' HG3' ' A' ' 6' ' ' LYS . 1.4 m-20 -79.05 145.87 33.6 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-O 121.087 0.47 . . . . 0.0 111.412 -179.381 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 83.6 mt -95.3 127.43 41.34 Favored 'General case' 0 C--O 1.25 1.116 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.45 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.475 HG22 ' HA ' ' A' ' 60' ' ' PRO . 2.9 pp -139.54 -178.63 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.205 0 CA-C-O 122.489 1.138 . . . . 0.0 113.761 -173.053 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.498 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 86.3 m-85 -119.43 128.59 54.17 Favored 'General case' 0 N--CA 1.408 -2.564 0 N-CA-C 105.203 -2.147 . . . . 0.0 105.203 170.766 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.501 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -108.09 140.84 40.68 Favored 'General case' 0 C--N 1.279 -2.477 0 O-C-N 123.702 0.626 . . . . 0.0 110.045 -173.569 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.483 ' HD3' ' C ' ' A' ' 14' ' ' LYS . 7.6 tmtm? -114.96 115.66 27.24 Favored 'General case' 0 N--CA 1.414 -2.273 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.834 -176.742 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.408 ' HB2' ' HB2' ' A' ' 18' ' ' TYR . 69.8 mtm -108.12 158.93 16.99 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 172.846 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 24.4 tptm -62.59 130.04 43.3 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 177.509 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 83.02 -25.5 4.73 Favored Glycine 0 C--O 1.218 -0.888 0 O-C-N 123.539 0.524 . . . . 0.0 112.568 -177.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.408 ' HB2' ' HB2' ' A' ' 15' ' ' MET . 53.5 m-85 -93.21 149.85 38.13 Favored Pre-proline 0 C--O 1.257 1.488 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -177.225 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -75.78 171.7 17.69 Favored 'Trans proline' 0 N--CA 1.449 -1.112 0 C-N-CA 123.395 2.73 . . . . 0.0 109.646 171.251 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' HIS . . . . . 0.453 ' HB3' ' HB3' ' A' ' 12' ' ' PHE . 79.8 m80 -69.9 111.53 5.68 Favored 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 178.461 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 8.5 t-105 -100.17 136.39 20.1 Favored Pre-proline 0 C--N 1.309 -1.175 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.961 -173.27 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_endo -65.88 117.79 4.94 Favored 'Trans proline' 0 CA--C 1.542 0.9 0 C-N-CA 121.789 1.66 . . . . 0.0 110.789 176.439 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.44 167.51 23.46 Favored 'General case' 0 N--CA 1.426 -1.645 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -174.577 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.503 ' HB3' ' CE2' ' A' ' 45' ' ' PHE . 9.2 ptt180 -111.25 160.57 16.86 Favored 'General case' 0 C--N 1.291 -1.965 0 C-N-CA 119.507 -0.877 . . . . 0.0 109.182 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 42.3 t -89.47 116.05 30.24 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.163 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 170.064 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.406 ' HB2' ' HB2' ' A' ' 41' ' ' PRO . 1.7 m-20 -87.84 173.53 8.89 Favored 'General case' 0 C--N 1.281 -2.407 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.976 -175.013 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.02 166.22 11.11 Favored 'General case' 0 N--CA 1.417 -2.1 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 175.613 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.2 p -98.56 115.47 65.76 Favored Pre-proline 0 C--N 1.294 -1.833 0 C-N-CA 120.05 -0.66 . . . . 0.0 110.931 -177.523 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_endo -88.59 164.3 6.45 Favored 'Trans proline' 0 N--CA 1.448 -1.156 0 C-N-CA 123.058 2.505 . . . . 0.0 113.108 -178.187 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -73.15 142.01 47.45 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 106.416 -1.698 . . . . 0.0 106.416 172.236 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.92 -17.88 51.33 Favored Glycine 0 C--N 1.291 -1.917 0 C-N-CA 119.797 -1.192 . . . . 0.0 111.078 -177.792 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -65.51 103.64 0.87 Allowed 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 173.88 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 31.9 m -69.74 -19.91 23.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 N-CA-C 114.082 1.141 . . . . 0.0 114.082 -174.692 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.562 ' HD3' ' O ' ' A' ' 34' ' ' LYS . 0.0 OUTLIER -108.25 129.49 24.0 Favored Pre-proline 0 N--CA 1.41 -2.437 0 C-N-CA 119.736 -0.786 . . . . 0.0 111.515 -179.458 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -68.9 171.49 13.42 Favored 'Trans proline' 0 C--O 1.265 1.831 0 C-N-CA 123.401 2.734 . . . . 0.0 113.701 -176.628 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -55.83 133.28 57.08 Favored 'Trans proline' 0 C--N 1.364 1.374 0 C-N-CA 123.127 2.552 . . . . 0.0 110.757 174.546 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.7 m -110.02 8.95 24.27 Favored 'General case' 0 C--N 1.291 -1.961 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.186 -174.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 45.2 m-80 78.98 8.6 1.91 Allowed 'General case' 0 N--CA 1.496 1.87 0 C-N-CA 126.027 1.731 . . . . 0.0 108.747 -172.057 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.513 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 34.3 mmtt -113.1 153.39 28.29 Favored 'General case' 0 N--CA 1.41 -2.469 0 CA-C-N 113.278 -1.783 . . . . 0.0 107.075 174.238 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.431 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 74.6 mt -96.63 154.27 38.52 Favored Pre-proline 0 C--N 1.271 -2.814 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 -178.147 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.406 ' HB2' ' HB2' ' A' ' 26' ' ' ASP . 45.8 Cg_endo -74.96 126.48 10.02 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 C-N-CA 121.517 1.478 . . . . 0.0 109.276 173.634 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 50.6 mm -125.3 110.13 23.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-O 121.116 0.484 . . . . 0.0 111.407 -175.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 70.2 t80 -90.26 117.52 29.06 Favored 'General case' 0 C--N 1.279 -2.497 0 C-N-CA 124.46 1.104 . . . . 0.0 109.899 176.791 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -78.13 128.83 34.4 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.9 177.616 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.503 ' CE2' ' HB3' ' A' ' 24' ' ' ARG . 58.8 m-85 -78.14 152.04 32.99 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.254 177.657 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 80.96 -21.05 5.93 Favored Glycine 0 C--N 1.308 -1.027 0 C-N-CA 124.565 1.079 . . . . 0.0 114.592 177.45 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.457 ' CG2' ' HA3' ' A' ' 76' ' ' GLY . 32.6 p -119.88 -22.73 6.66 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 117.467 0.633 . . . . 0.0 110.349 174.682 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 68.11 23.17 8.09 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.854 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -75.12 169.64 17.63 Favored 'General case' 0 C--N 1.35 0.602 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 175.076 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.4 m -141.47 145.66 35.51 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 121.539 -0.726 . . . . 0.0 110.005 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -139.99 -179.9 6.22 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 123.835 0.854 . . . . 0.0 109.842 178.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.431 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 93.0 m-85 -133.23 109.67 9.58 Favored 'General case' 0 CA--C 1.491 -1.29 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 174.332 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.53 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 79.5 mt -134.13 144.6 48.64 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 -178.867 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.513 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -83.26 177.05 52.97 Favored Glycine 0 N--CA 1.417 -2.596 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 -174.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -66.23 -17.51 54.49 Favored 'Trans proline' 0 C--N 1.319 -0.985 0 C-N-CA 122.112 1.875 . . . . 0.0 112.481 -176.746 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 16.8 mmmt -98.86 -3.58 35.03 Favored 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 120.204 -0.598 . . . . 0.0 110.923 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.53 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 12.8 m-20 -96.55 -9.2 30.01 Favored 'General case' 0 N--CA 1.481 1.105 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.792 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.489 HG13 ' CE2' ' A' ' 5' ' ' PHE . 12.5 pt -115.63 152.43 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.231 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.428 -176.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -126.05 131.68 24.06 Favored Pre-proline 0 C--N 1.301 -1.542 0 CA-C-N 115.238 -0.892 . . . . 0.0 108.753 -177.612 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.525 ' HG2' ' HB2' ' A' ' 63' ' ' GLU . 34.1 Cg_endo -67.6 131.51 24.67 Favored 'Trans proline' 0 C--N 1.322 -0.821 0 C-N-CA 122.708 2.272 . . . . 0.0 113.202 -175.521 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.498 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 43.3 t80 -52.37 -42.19 63.74 Favored 'General case' 0 C--O 1.205 -1.257 0 C-N-CA 123.992 0.917 . . . . 0.0 111.337 179.62 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.2 t -64.94 -37.0 86.19 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.476 -175.383 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.525 ' HB2' ' HG2' ' A' ' 60' ' ' PRO . 29.9 mt-10 -97.03 -7.08 33.78 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.992 0.425 . . . . 0.0 111.949 -175.703 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.479 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 27.2 m-80 -133.53 17.77 3.96 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 112.416 0.525 . . . . 0.0 112.416 -175.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.448 ' HG2' ' OE1' ' A' ' 66' ' ' GLU . 3.6 ptpp? -67.29 -36.13 80.91 Favored 'General case' 0 N--CA 1.498 1.968 0 C-N-CA 120.042 -0.663 . . . . 0.0 110.611 -176.149 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.448 ' OE1' ' HG2' ' A' ' 65' ' ' LYS . 28.8 mp0 -64.94 -35.45 81.21 Favored 'General case' 0 C--O 1.255 1.346 0 CA-C-O 123.241 1.496 . . . . 0.0 108.836 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.479 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 37.6 mtpt -76.38 -59.33 2.81 Favored 'General case' 0 C--N 1.294 -1.834 0 CA-C-N 112.931 -1.94 . . . . 0.0 111.912 -174.744 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.411 ' CD2' ' HB3' ' A' ' 64' ' ' ASN . 23.2 m-85 -112.1 -1.94 15.16 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 -169.084 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -83.85 45.69 3.52 Favored Glycine 0 C--N 1.309 -0.961 0 C-N-CA 120.654 -0.784 . . . . 0.0 113.373 -176.776 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 17.3 pttm -132.75 143.74 49.98 Favored Pre-proline 0 N--CA 1.43 -1.448 0 O-C-N 122.591 -0.358 . . . . 0.0 111.561 176.818 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_exo -49.42 158.13 1.83 Allowed 'Trans proline' 0 C--N 1.361 1.236 0 C-N-CA 124.577 3.518 . . . . 0.0 117.06 -173.053 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -131.48 -178.42 4.85 Favored 'General case' 0 N--CA 1.416 -2.164 0 CA-C-N 113.647 -1.615 . . . . 0.0 108.31 178.317 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -90.69 -18.51 24.94 Favored 'General case' 0 C--N 1.308 -1.199 0 O-C-N 123.693 0.621 . . . . 0.0 109.659 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.54 115.57 5.9 Favored 'General case' 0 N--CA 1.414 -2.229 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 175.496 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.447 ' HD3' ' H ' ' A' ' 76' ' ' GLY . 14.0 tppt? -64.73 133.42 52.05 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 175.638 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.457 ' HA3' ' CG2' ' A' ' 47' ' ' THR . . . 108.46 -24.75 21.62 Favored Glycine 0 N--CA 1.414 -2.788 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -174.095 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -75.6 -37.91 59.46 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -65.96 -49.55 67.48 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 -178.487 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 23.5 mp0 -64.58 -39.07 93.07 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 113.202 -1.817 . . . . 0.0 110.522 -179.687 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.64 -35.05 62.63 Favored Glycine 0 CA--C 1.48 -2.145 0 CA-C-N 116.063 -0.517 . . . . 0.0 113.011 -179.41 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 37.7 tp -62.51 -33.31 74.63 Favored 'General case' 0 N--CA 1.423 -1.802 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 176.029 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 70.5 t90 -74.34 -49.11 24.21 Favored 'General case' 0 N--CA 1.426 -1.626 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.602 175.854 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -55.04 -46.09 75.27 Favored 'General case' 0 C--O 1.188 -2.154 0 N-CA-C 112.644 0.609 . . . . 0.0 112.644 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 17.0 tt -68.56 -23.22 27.73 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-O 121.082 0.468 . . . . 0.0 111.629 -174.054 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -92.34 -41.93 10.09 Favored 'General case' 0 N--CA 1.423 -1.785 0 CA-C-O 121.585 0.707 . . . . 0.0 109.819 -175.443 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -97.73 -39.73 8.91 Favored 'General case' 0 N--CA 1.48 1.038 0 CA-C-O 121.713 0.768 . . . . 0.0 112.061 -173.838 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 65.2 t30 -134.99 63.33 57.24 Favored Pre-proline 0 C--N 1.296 -1.759 0 C-N-CA 119.797 -0.761 . . . . 0.0 111.673 -178.428 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -68.13 -6.57 17.58 Favored 'Trans proline' 0 C--N 1.371 1.711 0 C-N-CA 122.81 2.34 . . . . 0.0 111.742 -178.438 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 24.7 pttm -102.12 19.94 17.61 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 114.555 -1.202 . . . . 0.0 109.828 -177.44 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 14.6 p -71.7 141.33 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 CA-C-O 121.447 0.641 . . . . 0.0 110.242 179.301 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.664 ' HE2' ' O ' ' A' ' 93' ' ' SER . 19.6 ptmt -74.4 146.56 42.85 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.584 -178.881 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -46.6 -64.98 0.63 Allowed 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 125.425 1.49 . . . . 0.0 111.652 -178.656 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' SER . . . . . 0.664 ' O ' ' HE2' ' A' ' 91' ' ' LYS . 46.6 t . . . . . 0 C--N 1.292 -1.931 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 178.255 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.9 mtt . . . . . 0 CA--C 1.503 -0.85 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -97.32 72.33 2.4 Favored 'General case' 0 N--CA 1.44 -0.974 0 N-CA-C 105.846 -1.909 . . . . 0.0 105.846 175.377 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -117.55 175.86 5.44 Favored 'General case' 0 C--N 1.286 -2.156 0 CA-C-N 113.412 -1.722 . . . . 0.0 111.697 -174.161 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -127.33 162.42 26.31 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 105.8 -1.926 . . . . 0.0 105.8 176.067 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.494 ' C ' ' HD2' ' A' ' 6' ' ' LYS . 84.3 m-85 -105.37 121.24 43.5 Favored 'General case' 0 C--N 1.293 -1.857 0 CA-C-O 120.959 0.409 . . . . 0.0 110.014 -172.466 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.494 ' HD2' ' C ' ' A' ' 5' ' ' PHE . 13.4 mmmt -116.81 153.69 49.33 Favored Pre-proline 0 N--CA 1.433 -1.29 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 -178.251 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.6 Cg_exo -52.82 134.45 54.58 Favored 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 122.755 2.303 . . . . 0.0 112.369 177.602 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 107.58 -25.21 21.97 Favored Glycine 0 N--CA 1.432 -1.613 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.77 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -72.24 150.23 43.85 Favored 'General case' 0 C--O 1.252 1.216 0 CA-C-O 121.582 0.706 . . . . 0.0 112.224 -177.099 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 76.5 mt -100.04 127.96 46.19 Favored 'General case' 0 N--CA 1.423 -1.794 0 CA-C-N 114.352 -1.294 . . . . 0.0 109.754 -177.116 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 8.6 pt -140.12 -173.6 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 CA-C-O 122.348 1.071 . . . . 0.0 111.897 -174.446 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.414 ' HB3' ' HB3' ' A' ' 20' ' ' HIS . 66.5 m-85 -126.31 124.31 40.02 Favored 'General case' 0 N--CA 1.412 -2.363 0 N-CA-C 106.174 -1.787 . . . . 0.0 106.174 172.162 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.439 ' CB ' HG21 ' A' ' 42' ' ' ILE . . . -108.89 131.28 55.17 Favored 'General case' 0 C--N 1.28 -2.431 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.343 -174.572 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.625 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -113.54 122.18 46.46 Favored 'General case' 0 N--CA 1.401 -2.911 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.116 -177.76 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 70.2 mtm -110.43 158.03 18.93 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 175.736 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 60.2 tttm -67.29 116.62 8.26 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 110.145 -0.317 . . . . 0.0 110.145 -179.224 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.81 -2.75 62.26 Favored Glycine 0 C--O 1.248 0.975 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -121.86 151.79 58.32 Favored Pre-proline 0 N--CA 1.434 -1.268 0 C-N-CA 122.829 0.452 . . . . 0.0 109.905 -178.844 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -76.5 171.37 18.18 Favored 'Trans proline' 0 N--CA 1.448 -1.157 0 C-N-CA 122.296 1.997 . . . . 0.0 109.815 175.1 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' HIS . . . . . 0.536 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 76.2 m80 -66.76 110.94 3.46 Favored 'General case' 0 C--N 1.312 -1.061 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 176.269 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -99.88 138.15 20.29 Favored Pre-proline 0 C--N 1.296 -1.718 0 C-N-CA 123.942 0.897 . . . . 0.0 109.324 -171.316 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -63.59 118.28 5.22 Favored 'Trans proline' 0 C--O 1.244 0.808 0 C-N-CA 121.918 1.746 . . . . 0.0 110.043 177.219 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -141.82 167.54 21.91 Favored 'General case' 0 N--CA 1.415 -2.195 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.761 -175.195 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.409 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 56.1 ttt-85 -123.73 141.15 52.29 Favored 'General case' 0 C--N 1.289 -2.03 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 178.191 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 45.6 t -77.64 125.27 37.2 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 175.029 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.458 ' OD1' ' HE3' ' A' ' 91' ' ' LYS . 5.4 t70 -94.2 171.04 9.08 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 120.57 -0.452 . . . . 0.0 109.855 -175.741 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -100.88 124.43 46.56 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-O 121.915 0.864 . . . . 0.0 113.293 -178.116 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.2 p -81.51 133.51 52.85 Favored Pre-proline 0 N--CA 1.437 -1.122 0 CA-C-N 114.357 -1.292 . . . . 0.0 108.297 177.254 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -70.67 141.09 40.7 Favored 'Trans proline' 0 N--CA 1.456 -0.7 0 C-N-CA 122.051 1.834 . . . . 0.0 112.763 -179.306 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -74.25 149.31 40.83 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 172.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 89.11 -3.83 84.48 Favored Glycine 0 C--N 1.291 -1.93 0 C-N-CA 120.508 -0.854 . . . . 0.0 111.725 -175.701 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -57.34 116.64 3.43 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-O 121.117 0.484 . . . . 0.0 110.381 175.36 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.6 m -63.62 -21.35 28.35 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 CA-C-N 115.558 -0.746 . . . . 0.0 112.754 -178.86 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 44.7 mmtm -107.94 118.87 51.79 Favored Pre-proline 0 N--CA 1.424 -1.739 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 171.757 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.94 166.79 28.79 Favored 'Trans proline' 0 C--O 1.246 0.879 0 C-N-CA 122.446 2.097 . . . . 0.0 111.33 178.416 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -54.52 129.52 35.25 Favored 'Trans proline' 0 C--N 1.358 1.062 0 C-N-CA 122.679 2.253 . . . . 0.0 111.953 179.335 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.413 HG22 ' O ' ' A' ' 37' ' ' THR . 4.9 m -73.64 9.48 1.41 Allowed 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 125.661 1.584 . . . . 0.0 112.722 -174.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 5.1 p30 87.44 9.16 0.17 Allowed 'General case' 0 N--CA 1.502 2.169 0 C-N-CA 126.853 2.061 . . . . 0.0 109.752 -173.554 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 62.6 mttp -126.18 162.23 25.87 Favored 'General case' 0 C--N 1.294 -1.845 0 CA-C-N 113.283 -1.78 . . . . 0.0 110.364 178.16 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 85.0 mt -112.55 147.29 36.77 Favored Pre-proline 0 C--N 1.286 -2.194 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.487 -176.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -73.73 122.58 7.89 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 121.749 1.632 . . . . 0.0 109.535 176.141 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.439 HG21 ' CB ' ' A' ' 13' ' ' ALA . 45.7 mm -118.22 111.01 32.32 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.251 -174.743 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.461 ' CZ ' ' HA ' ' A' ' 48' ' ' HIS . 91.1 t80 -91.24 118.73 30.72 Favored 'General case' 0 C--N 1.286 -2.153 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.288 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -83.03 133.23 35.1 Favored 'General case' 0 C--O 1.249 1.03 0 CA-C-O 121.107 0.479 . . . . 0.0 112.163 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.409 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 72.0 m-85 -81.43 152.34 27.45 Favored 'General case' 0 N--CA 1.433 -1.31 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.154 175.144 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.436 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 81.24 -19.47 8.2 Favored Glycine 0 C--N 1.309 -0.95 0 C-N-CA 123.366 0.507 . . . . 0.0 113.555 178.412 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.473 ' HB ' ' OE1' ' A' ' 49' ' ' GLU . 35.9 p -118.92 -22.78 7.17 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 122.267 -0.549 . . . . 0.0 110.578 176.426 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' HIS . . . . . 0.461 ' HA ' ' CZ ' ' A' ' 43' ' ' PHE . 13.3 m170 66.43 25.6 10.22 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 123.308 0.643 . . . . 0.0 110.879 -179.729 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.473 ' OE1' ' HB ' ' A' ' 47' ' ' THR . 45.9 mt-10 -97.45 175.47 6.22 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.454 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 10.0 m -143.76 143.85 31.56 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-O 121.172 0.511 . . . . 0.0 109.815 -179.241 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -131.37 178.26 6.85 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 114.814 -1.084 . . . . 0.0 109.675 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -133.38 109.82 9.6 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 176.598 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.416 HD12 ' HB1' ' A' ' 13' ' ' ALA . 88.9 mt -125.65 163.7 22.2 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 -177.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -85.22 162.8 37.05 Favored Glycine 0 N--CA 1.419 -2.454 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 178.856 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -63.88 -15.17 47.48 Favored 'Trans proline' 0 C--O 1.208 -0.989 0 C-N-CA 123.006 2.471 . . . . 0.0 112.257 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.08 4.96 51.1 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 115.648 -0.705 . . . . 0.0 112.75 178.002 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -113.67 1.77 15.02 Favored 'General case' 0 C--N 1.292 -1.911 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.143 177.155 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 17.6 pt -127.13 150.74 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.823 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.531 ' HB3' ' ND2' ' A' ' 64' ' ' ASN . 93.3 m-85 -136.29 142.37 39.45 Favored Pre-proline 0 C--N 1.295 -1.794 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo -65.09 137.88 54.25 Favored 'Trans proline' 0 C--O 1.249 1.046 0 C-N-CA 122.835 2.357 . . . . 0.0 112.922 -177.748 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.404 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 25.4 t80 -56.38 -42.69 78.29 Favored 'General case' 0 C--O 1.208 -1.093 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.172 178.335 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.6 m -53.87 -43.43 69.59 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 115.677 -0.692 . . . . 0.0 112.509 -175.259 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -95.62 -17.23 21.51 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.259 0.552 . . . . 0.0 112.031 -176.688 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.531 ' ND2' ' HB3' ' A' ' 59' ' ' PHE . 28.0 m-80 -116.73 10.54 14.32 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -173.027 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.508 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 19.4 pttp -68.69 -35.44 77.2 Favored 'General case' 0 C--O 1.21 -0.994 0 CA-C-O 121.137 0.494 . . . . 0.0 111.032 -177.296 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.508 ' OE1' ' HG3' ' A' ' 65' ' ' LYS . 2.1 mm-40 -73.01 -22.48 60.66 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 122.177 0.989 . . . . 0.0 108.819 -178.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.445 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 41.5 mtpt -83.42 -59.61 2.4 Favored 'General case' 0 N--CA 1.436 -1.148 0 CA-C-N 114.561 -1.2 . . . . 0.0 110.609 -177.606 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.493 ' CD2' ' HB3' ' A' ' 64' ' ' ASN . 27.2 m-85 -105.72 -8.12 18.02 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 115.475 -0.784 . . . . 0.0 112.697 -169.35 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -79.25 52.12 4.01 Favored Glycine 0 C--O 1.219 -0.816 0 C-N-CA 121.583 -0.342 . . . . 0.0 112.781 -177.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.7 ptpp? -132.96 132.9 22.66 Favored Pre-proline 0 C--N 1.301 -1.536 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 176.535 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -65.49 128.89 21.17 Favored 'Trans proline' 0 N--CA 1.446 -1.316 0 C-N-CA 122.655 2.237 . . . . 0.0 115.531 -172.193 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.6 m-20 -93.92 -170.81 2.41 Favored 'General case' 0 CA--C 1.487 -1.474 0 N-CA-C 106.205 -1.776 . . . . 0.0 106.205 173.829 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.503 ' HD3' ' HA ' ' A' ' 73' ' ' LYS 0.273 70.9 mmtt -110.09 28.93 8.12 Favored 'General case' 0 C--N 1.291 -1.977 0 CA-C-O 122.593 1.187 . . . . 0.0 110.592 171.35 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 14.7 mmt180 -82.51 125.34 31.01 Favored 'General case' 0 C--O 1.25 1.099 0 N-CA-C 106.341 -1.725 . . . . 0.0 106.341 170.511 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.401 ' HG3' ' OE2' ' A' ' 79' ' ' GLU . 61.2 tttp -66.73 139.24 57.81 Favored 'General case' 0 C--N 1.318 -0.798 0 C-N-CA 119.83 -0.748 . . . . 0.0 109.882 176.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.436 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 95.87 -25.2 26.28 Favored Glycine 0 N--CA 1.428 -1.895 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -175.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.402 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 31.7 t80 -75.87 -47.06 26.98 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-O 121.196 0.522 . . . . 0.0 109.702 -178.062 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.546 ' N ' HD22 ' A' ' 78' ' ' ASN . 0.7 OUTLIER -67.4 -37.86 83.76 Favored 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.892 0.853 . . . . 0.0 109.142 -179.256 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLU . . . . . 0.401 ' OE2' ' HG3' ' A' ' 75' ' ' LYS . 26.1 mt-10 -72.44 -36.1 68.46 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 114.024 -1.444 . . . . 0.0 109.593 -179.158 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -69.66 -33.89 72.08 Favored Glycine 0 CA--C 1.494 -1.271 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.641 178.455 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.402 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 94.7 mt -60.51 -38.79 85.52 Favored 'General case' 0 C--O 1.21 -0.976 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 174.863 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 85.4 t90 -66.66 -46.07 76.89 Favored 'General case' 0 N--CA 1.429 -1.476 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.695 177.836 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -61.48 -43.46 98.82 Favored 'General case' 0 C--O 1.204 -1.339 0 N-CA-C 113.076 0.769 . . . . 0.0 113.076 179.564 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.1 tt -70.8 -33.45 52.52 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 120.379 -0.528 . . . . 0.0 112.056 -175.556 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -88.98 -5.85 57.66 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 112.758 0.651 . . . . 0.0 112.758 -178.697 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 31.9 m-80 -123.57 -51.12 1.84 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-O 121.388 0.613 . . . . 0.0 112.089 -179.137 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.408 ' ND2' ' HB ' ' A' ' 90' ' ' VAL . 66.7 t30 -126.45 67.56 65.59 Favored Pre-proline 0 C--N 1.305 -1.341 0 O-C-N 121.94 -0.475 . . . . 0.0 110.186 -179.422 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -74.78 -5.95 17.51 Favored 'Trans proline' 0 N--CA 1.48 0.698 0 C-N-CA 122.314 2.009 . . . . 0.0 112.289 -175.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.7 pttp -93.86 15.19 17.25 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.083 -178.404 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.408 ' HB ' ' ND2' ' A' ' 87' ' ' ASN . 10.0 p -89.9 147.7 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.583 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 176.172 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.458 ' HE3' ' OD1' ' A' ' 26' ' ' ASP . 18.2 ptmt -144.67 -163.17 1.64 Allowed 'General case' 0 C--N 1.309 -1.181 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 177.142 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -29.56 104.03 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 C-N-CA 125.352 1.461 . . . . 0.0 113.737 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 22.8 t . . . . . 0 N--CA 1.425 -1.696 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 178.535 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.7 mtt . . . . . 0 CA--C 1.501 -0.908 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -130.5 82.76 2.08 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 104.098 -2.556 . . . . 0.0 104.098 172.788 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 14.2 ptm180 -122.09 -152.14 0.5 Allowed 'General case' 0 C--N 1.293 -1.862 0 CA-C-N 114.252 -1.34 . . . . 0.0 112.251 -171.789 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -82.02 156.32 24.69 Favored 'General case' 0 N--CA 1.435 -1.202 0 C-N-CA 124.509 1.124 . . . . 0.0 109.948 -179.104 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 -134.79 131.75 37.87 Favored 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 178.692 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.592 ' HG2' ' OD2' ' A' ' 9' ' ' ASP . 1.6 pttm -135.22 152.49 76.96 Favored Pre-proline 0 C--N 1.289 -2.039 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 -175.277 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo -49.09 121.7 7.25 Favored 'Trans proline' 0 C--N 1.352 0.723 0 C-N-CA 122.657 2.238 . . . . 0.0 111.138 176.493 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.38 -30.48 6.45 Favored Glycine 0 N--CA 1.423 -2.206 0 CA-C-O 118.991 -0.894 . . . . 0.0 113.637 -178.51 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.592 ' OD2' ' HG2' ' A' ' 6' ' ' LYS 0.335 2.9 p30 -78.71 147.93 33.27 Favored 'General case' 0 C--O 1.248 1.009 0 CA-C-N 118.859 1.329 . . . . 0.0 113.268 -179.161 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.425 HD22 HG13 ' A' ' 84' ' ' ILE . 82.3 mt -91.42 129.1 37.45 Favored 'General case' 0 CA--C 1.488 -1.44 0 CA-C-N 114.203 -1.362 . . . . 0.0 110.312 -175.783 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 12.1 pt -140.39 -173.03 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 CA-C-O 122.374 1.083 . . . . 0.0 111.993 -174.118 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 38.4 m-85 -120.71 132.33 55.01 Favored 'General case' 0 N--CA 1.414 -2.236 0 CA-C-N 113.979 -1.464 . . . . 0.0 107.077 171.344 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.502 ' HB2' HG21 ' A' ' 42' ' ' ILE . . . -108.92 124.02 50.0 Favored 'General case' 0 C--N 1.272 -2.788 0 O-C-N 123.947 0.779 . . . . 0.0 109.337 -178.811 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.634 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -109.33 120.27 42.0 Favored 'General case' 0 N--CA 1.398 -3.043 0 CA-C-N 116.184 -0.462 . . . . 0.0 109.916 -179.145 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 66.5 mtm -114.68 157.89 22.52 Favored 'General case' 0 C--N 1.314 -0.977 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 175.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 41.7 ttmt -66.31 117.63 8.85 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 116.712 -0.222 . . . . 0.0 110.429 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.92 -3.88 65.17 Favored Glycine 0 C--O 1.251 1.206 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.651 178.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 77.5 m-85 -120.9 151.44 54.85 Favored Pre-proline 0 N--CA 1.428 -1.573 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 -179.211 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -77.58 171.27 17.81 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 122.112 1.875 . . . . 0.0 109.611 175.562 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' HIS . . . . . 0.459 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 70.0 m80 -63.15 110.99 2.03 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 174.843 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 7.5 t-105 -99.4 137.68 20.37 Favored Pre-proline 0 C--N 1.303 -1.456 0 C-N-CA 123.331 0.653 . . . . 0.0 109.239 -172.535 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -63.97 117.83 4.81 Favored 'Trans proline' 0 C--O 1.245 0.863 0 C-N-CA 121.796 1.664 . . . . 0.0 110.089 176.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.21 167.83 21.21 Favored 'General case' 0 N--CA 1.413 -2.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.143 -175.109 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.415 HH22 ' CD ' ' A' ' 27' ' ' GLU . 10.6 ttp180 -124.7 148.06 48.23 Favored 'General case' 0 C--N 1.282 -2.33 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 176.571 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.7 t -72.41 118.69 17.84 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 N-CA-C 105.275 -2.12 . . . . 0.0 105.275 170.31 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -84.76 172.43 11.49 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -171.732 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.415 ' CD ' HH22 ' A' ' 24' ' ' ARG . 0.5 OUTLIER -108.76 135.74 49.48 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-O 121.669 0.747 . . . . 0.0 112.533 -175.465 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 45.6 t -86.44 124.9 69.11 Favored Pre-proline 0 C--N 1.31 -1.143 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 178.639 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -72.72 140.9 33.11 Favored 'Trans proline' 0 N--CA 1.43 -2.264 0 C-N-CA 121.356 1.371 . . . . 0.0 112.566 -179.564 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -69.6 147.88 50.12 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 174.66 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.38 -16.08 61.46 Favored Glycine 0 C--N 1.296 -1.677 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.692 -176.119 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -67.25 118.71 11.01 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-O 121.308 0.575 . . . . 0.0 110.593 177.379 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.7 m -79.38 -0.01 3.46 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 115.703 -0.681 . . . . 0.0 112.273 -179.497 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 69.7 mmtt -103.17 118.35 58.15 Favored Pre-proline 0 N--CA 1.428 -1.556 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 175.312 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -82.63 166.43 15.48 Favored 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 122.454 2.103 . . . . 0.0 111.505 178.745 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 14.2 Cg_endo -59.63 144.07 99.51 Favored 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 122.204 1.936 . . . . 0.0 111.942 178.326 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.42 ' O ' HG22 ' A' ' 37' ' ' THR . 5.6 m -73.54 9.08 1.5 Allowed 'General case' 0 C--N 1.309 -1.173 0 C-N-CA 125.185 1.394 . . . . 0.0 112.644 -175.882 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 4.6 p30 87.11 9.43 0.18 Allowed 'General case' 0 N--CA 1.503 2.189 0 C-N-CA 126.829 2.051 . . . . 0.0 109.314 -173.489 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -131.47 170.06 15.21 Favored 'General case' 0 N--CA 1.418 -2.051 0 CA-C-N 112.74 -2.027 . . . . 0.0 109.192 178.591 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.429 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 92.8 mt -98.89 141.6 23.16 Favored Pre-proline 0 C--N 1.287 -2.148 0 O-C-N 123.977 0.798 . . . . 0.0 109.937 -176.537 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -70.65 123.27 9.65 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.053 1.836 . . . . 0.0 109.429 176.082 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.502 HG21 ' HB2' ' A' ' 13' ' ' ALA . 39.5 mm -116.35 117.05 54.21 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.123 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 -175.775 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 72.7 t80 -94.28 115.89 28.2 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -81.54 129.1 34.54 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 123.425 0.453 . . . . 0.0 111.387 177.821 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -80.07 150.64 30.24 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.694 176.249 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.513 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 80.78 -19.91 6.95 Favored Glycine 0 C--N 1.311 -0.827 0 CA-C-N 116.216 -0.447 . . . . 0.0 113.739 179.152 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.4 p -119.33 -23.74 6.61 Favored 'General case' 0 C--N 1.309 -1.16 0 O-C-N 122.074 -0.662 . . . . 0.0 110.556 174.974 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 68.02 13.66 9.17 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 123.987 0.915 . . . . 0.0 112.231 -178.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.7 mm-40 -76.52 164.11 26.27 Favored 'General case' 0 CA--C 1.493 -1.226 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.263 178.222 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.411 ' HA ' ' O ' ' A' ' 42' ' ' ILE . 4.2 m -133.2 136.85 45.9 Favored 'General case' 0 C--N 1.283 -2.298 0 CA-C-O 121.425 0.631 . . . . 0.0 109.773 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -128.53 178.02 6.6 Favored 'General case' 0 C--N 1.284 -2.256 0 CA-C-N 115.013 -0.994 . . . . 0.0 109.914 -179.302 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.429 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 95.9 m-85 -133.63 110.25 9.75 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 176.527 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 94.9 mt -124.71 160.53 28.36 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 -179.35 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -87.81 167.53 36.73 Favored Glycine 0 N--CA 1.42 -2.383 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 178.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.402 ' HA ' HD11 ' A' ' 58' ' ' ILE . 38.1 Cg_endo -66.65 -6.96 16.65 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 123.16 2.573 . . . . 0.0 112.334 -178.782 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 7.9 ptmm? -97.31 -4.32 38.89 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.415 178.411 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.2 m-20 -115.27 5.66 14.76 Favored 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.891 -176.587 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.402 HD11 ' HA ' ' A' ' 55' ' ' PRO . 14.3 pt -131.38 150.7 34.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.796 0 CA-C-N 114.737 -1.12 . . . . 0.0 108.981 179.885 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -141.66 147.19 44.65 Favored Pre-proline 0 C--N 1.295 -1.778 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 -179.371 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -62.06 133.24 43.06 Favored 'Trans proline' 0 CA--C 1.511 -0.667 0 C-N-CA 123.043 2.495 . . . . 0.0 113.256 -177.45 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -64.62 -36.97 85.98 Favored 'General case' 0 C--O 1.207 -1.177 0 CA-C-N 114.88 -1.055 . . . . 0.0 110.7 -177.214 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 10.6 m -63.95 -39.65 94.64 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.239 -178.22 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -89.05 -7.43 55.9 Favored 'General case' 0 C--O 1.218 -0.582 0 N-CA-C 111.879 0.326 . . . . 0.0 111.879 -177.534 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 39.0 m-80 -123.92 13.39 9.16 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -179.476 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.8 ttmm -67.05 -34.36 77.51 Favored 'General case' 0 N--CA 1.473 0.694 0 CA-C-O 121.667 0.746 . . . . 0.0 109.648 -179.669 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.573 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -79.16 -20.25 48.96 Favored 'General case' 0 N--CA 1.408 -2.55 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.347 178.072 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.573 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 8.2 mttm -87.92 -59.28 2.29 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.979 179.529 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 66.0 m-85 -112.53 1.32 15.81 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.3 -171.789 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.6 55.97 4.15 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 111.601 -0.599 . . . . 0.0 111.601 178.229 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 58.4 mttp -129.54 123.71 21.48 Favored Pre-proline 0 C--N 1.31 -1.131 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 -179.712 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -63.0 128.2 22.35 Favored 'Trans proline' 0 N--CA 1.444 -1.424 0 C-N-CA 121.839 1.693 . . . . 0.0 114.132 -175.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -93.24 -171.84 2.78 Favored 'General case' 0 CA--C 1.482 -1.667 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 176.44 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.465 ' HA ' ' HD3' ' A' ' 73' ' ' LYS 0.268 71.4 mmtt -109.42 27.56 9.42 Favored 'General case' 0 C--N 1.289 -2.045 0 CA-C-O 122.613 1.197 . . . . 0.0 110.361 171.041 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 13.8 mmt180 -80.14 127.64 32.56 Favored 'General case' 0 C--O 1.25 1.11 0 N-CA-C 105.168 -2.16 . . . . 0.0 105.168 169.421 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.412 ' HG2' ' HZ3' ' A' ' 75' ' ' LYS . 42.9 tttm -67.77 141.89 56.41 Favored 'General case' 0 C--N 1.32 -0.699 0 C-N-CA 119.228 -0.989 . . . . 0.0 108.721 179.456 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.513 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 94.17 -25.31 22.83 Favored Glycine 0 N--CA 1.426 -1.985 0 C-N-CA 120.881 -0.676 . . . . 0.0 111.846 -177.08 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.423 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 20.6 t80 -72.87 -44.73 60.98 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.336 0.588 . . . . 0.0 109.585 -177.613 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.569 HD22 ' N ' ' A' ' 78' ' ' ASN . 0.7 OUTLIER -70.34 -42.21 72.18 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 -178.949 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -65.99 -38.48 88.59 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-N 114.447 -1.251 . . . . 0.0 109.451 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -68.51 -34.84 80.07 Favored Glycine 0 N--CA 1.433 -1.505 0 CA-C-N 115.349 -0.842 . . . . 0.0 113.057 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.423 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 94.6 mt -60.61 -35.43 76.12 Favored 'General case' 0 C--O 1.216 -0.668 0 CA-C-O 121.309 0.576 . . . . 0.0 109.782 175.701 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 83.1 t90 -70.78 -48.97 51.46 Favored 'General case' 0 N--CA 1.433 -1.284 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.724 176.53 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -58.15 -45.33 87.61 Favored 'General case' 0 C--O 1.205 -1.289 0 N-CA-C 113.042 0.756 . . . . 0.0 113.042 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.425 HG13 HD22 ' A' ' 10' ' ' LEU . 20.7 tt -68.82 -31.23 49.86 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -174.021 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -90.58 -10.34 43.77 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -179.027 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 31.7 m-80 -117.78 -53.99 2.37 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-O 121.223 0.535 . . . . 0.0 112.215 -178.373 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -127.86 75.77 77.92 Favored Pre-proline 0 C--N 1.304 -1.396 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.189 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.81 -7.7 21.97 Favored 'Trans proline' 0 N--CA 1.488 1.188 0 C-N-CA 122.87 2.38 . . . . 0.0 112.688 -176.569 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.3 pttp -105.36 21.08 17.78 Favored 'General case' 0 C--N 1.302 -1.461 0 C-N-CA 123.982 0.913 . . . . 0.0 109.738 -178.344 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 11.5 p -66.61 78.42 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.558 1.275 0 N-CA-C 115.64 1.719 . . . . 0.0 115.64 -175.792 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.426 ' HA ' ' HE2' ' A' ' 91' ' ' LYS . 9.1 mmpt? -75.34 -46.64 31.97 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 103.413 -2.81 . . . . 0.0 103.413 166.303 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -132.35 149.49 52.34 Favored 'General case' 0 N--CA 1.423 -1.781 0 N-CA-C 104.23 -2.507 . . . . 0.0 104.23 173.187 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 8.1 t . . . . . 0 C--N 1.294 -1.81 0 C-N-CA 119.229 -0.988 . . . . 0.0 109.423 -177.492 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.608 ' HB3' ' O ' ' A' ' 3' ' ' ARG . 10.2 tpt . . . . . 0 C--O 1.214 -0.797 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ALA . . . . . 0.461 ' H ' ' HG3' ' A' ' 1' ' ' MET . . . -66.79 -13.19 61.2 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-O 121.979 0.895 . . . . 0.0 110.301 174.309 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.608 ' O ' ' HB3' ' A' ' 1' ' ' MET . 6.0 ptp180 -135.48 158.28 44.77 Favored 'General case' 0 N--CA 1.426 -1.658 0 N-CA-C 101.41 -3.552 . . . . 0.0 101.41 173.114 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . 0.326 0.2 OUTLIER -120.56 175.8 5.81 Favored 'General case' 0 C--N 1.286 -2.166 0 C-N-CA 115.105 -2.638 . . . . 0.0 114.329 179.59 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.452 ' CE2' HG13 ' A' ' 58' ' ' ILE . 88.9 m-85 -106.37 152.5 23.5 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 124.045 0.841 . . . . 0.0 113.053 -167.331 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.636 ' HG2' ' OD2' ' A' ' 9' ' ' ASP . 16.8 pttm -134.6 160.09 69.74 Favored Pre-proline 0 C--N 1.305 -1.35 0 CA-C-N 114.889 -1.05 . . . . 0.0 108.336 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -51.25 122.65 10.46 Favored 'Trans proline' 0 C--N 1.347 0.499 0 C-N-CA 122.496 2.131 . . . . 0.0 111.879 175.328 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.1 -22.59 11.25 Favored Glycine 0 N--CA 1.429 -1.77 0 CA-C-O 119.351 -0.694 . . . . 0.0 113.381 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.636 ' OD2' ' HG2' ' A' ' 6' ' ' LYS . 37.3 m-20 -66.0 128.95 38.09 Favored 'General case' 0 C--O 1.247 0.953 0 CA-C-N 117.659 0.729 . . . . 0.0 112.097 -179.456 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.4 HD21 ' HB2' ' A' ' 88' ' ' PRO . 77.2 mt -83.83 124.43 30.94 Favored 'General case' 0 CA--C 1.485 -1.545 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 176.036 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 10.3 pt -140.24 -174.3 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 CA-C-O 122.367 1.079 . . . . 0.0 112.261 -172.137 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.493 ' HB3' ' HB3' ' A' ' 20' ' ' HIS . 45.6 m-85 -119.77 126.96 52.32 Favored 'General case' 0 N--CA 1.404 -2.741 0 CA-C-N 113.181 -1.827 . . . . 0.0 106.973 170.529 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.434 ' CB ' HG21 ' A' ' 42' ' ' ILE . . . -108.98 121.76 45.81 Favored 'General case' 0 C--N 1.27 -2.869 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.312 -178.241 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.617 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -104.77 119.57 39.3 Favored 'General case' 0 N--CA 1.401 -2.887 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.939 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 72.4 mtm -104.07 159.01 16.03 Favored 'General case' 0 C--N 1.312 -1.058 0 C-N-CA 123.172 0.589 . . . . 0.0 110.215 179.406 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.4 tttp -65.37 116.22 6.45 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.553 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.13 -8.04 64.75 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.627 178.755 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 65.8 m-85 -128.72 147.85 66.09 Favored Pre-proline 0 N--CA 1.444 -0.744 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -178.647 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -68.7 170.89 14.26 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.845 2.363 . . . . 0.0 111.909 177.747 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' HIS . . . . . 0.561 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 74.6 m80 -60.83 111.64 1.73 Allowed 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.114 178.229 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 4.0 t-105 -101.85 136.89 19.44 Favored Pre-proline 0 C--N 1.313 -1.002 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -176.818 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -64.7 117.64 4.7 Favored 'Trans proline' 0 C--O 1.241 0.649 0 C-N-CA 121.779 1.653 . . . . 0.0 110.432 176.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -141.16 167.38 22.32 Favored 'General case' 0 N--CA 1.413 -2.282 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.69 -174.749 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 32.7 ttt180 -109.96 138.35 46.46 Favored 'General case' 0 C--N 1.291 -1.969 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 176.857 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 64.4 t -74.68 111.68 10.92 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.068 0 N-CA-C 103.501 -2.777 . . . . 0.0 103.501 166.908 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -86.26 -177.58 6.27 Favored 'General case' 0 C--N 1.282 -2.329 0 C-N-CA 119.543 -0.863 . . . . 0.0 112.105 -169.728 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -104.24 143.56 32.78 Favored 'General case' 0 C--N 1.294 -1.838 0 CA-C-O 121.966 0.889 . . . . 0.0 112.861 -171.776 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.3 t -105.09 126.92 29.77 Favored Pre-proline 0 C--N 1.31 -1.136 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 178.728 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -71.04 137.84 32.56 Favored 'Trans proline' 0 N--CA 1.433 -2.087 0 C-N-CA 121.319 1.346 . . . . 0.0 112.605 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -71.65 149.69 45.31 Favored 'General case' 0 C--N 1.31 -1.13 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 173.756 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 92.43 -10.89 73.35 Favored Glycine 0 C--N 1.294 -1.759 0 C-N-CA 120.553 -0.832 . . . . 0.0 111.793 -176.097 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -65.71 101.68 0.66 Allowed 'General case' 0 C--O 1.219 -0.537 0 CA-C-O 121.439 0.638 . . . . 0.0 110.929 176.485 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 26.0 m -85.11 7.95 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.79 0.805 . . . . 0.0 111.804 179.741 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 26.7 mmmt -97.59 128.93 32.86 Favored Pre-proline 0 C--N 1.291 -1.969 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 176.852 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -64.18 141.98 78.24 Favored 'Trans proline' 0 CA--C 1.534 0.499 0 C-N-CA 122.012 1.808 . . . . 0.0 112.039 179.666 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -75.55 171.25 18.58 Favored 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 122.369 2.046 . . . . 0.0 112.238 -179.339 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.2 m -73.03 7.46 2.07 Favored 'General case' 0 C--O 1.262 1.745 0 C-N-CA 124.548 1.139 . . . . 0.0 111.562 -178.753 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 39.8 m-80 65.53 25.16 11.79 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 124.499 1.12 . . . . 0.0 108.98 -177.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 62.5 mttp -142.99 179.72 6.87 Favored 'General case' 0 N--CA 1.429 -1.497 0 CA-C-N 114.255 -1.339 . . . . 0.0 108.644 -178.173 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 96.5 mt -97.42 139.93 21.72 Favored Pre-proline 0 C--N 1.293 -1.876 0 O-C-N 123.995 0.809 . . . . 0.0 109.87 -179.333 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -70.29 123.45 9.94 Favored 'Trans proline' 0 N--CA 1.46 -0.475 0 C-N-CA 122.484 2.123 . . . . 0.0 110.247 177.512 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.434 HG21 ' CB ' ' A' ' 13' ' ' ALA . 42.4 mm -117.8 120.52 64.9 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.788 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 -177.072 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 93.0 t80 -105.22 117.68 34.63 Favored 'General case' 0 C--N 1.286 -2.194 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 178.733 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.432 ' HE2' ' HB2' ' A' ' 51' ' ' ALA . 89.6 m-85 -82.93 135.69 34.82 Favored 'General case' 0 C--N 1.308 -1.212 0 CA-C-O 121.435 0.636 . . . . 0.0 112.332 179.493 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -85.48 151.72 23.75 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.469 178.155 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.427 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 80.84 -20.91 5.96 Favored Glycine 0 C--N 1.309 -0.939 0 C-N-CA 124.553 1.073 . . . . 0.0 114.124 177.657 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.499 ' CG2' ' HA3' ' A' ' 76' ' ' GLY . 37.0 p -119.8 -23.14 6.55 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-N 117.279 0.539 . . . . 0.0 110.201 175.084 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 43.4 m170 67.96 22.37 8.6 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.282 -178.263 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -71.75 164.2 26.41 Favored 'General case' 0 C--N 1.346 0.418 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 176.254 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.4 m -138.37 140.92 39.62 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -179.806 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.432 ' HB2' ' HE2' ' A' ' 44' ' ' PHE . . . -141.41 177.68 7.95 Favored 'General case' 0 C--N 1.289 -2.034 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.183 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 95.7 m-85 -134.36 117.57 16.49 Favored 'General case' 0 N--CA 1.434 -1.238 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 176.755 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.413 HD12 ' HB1' ' A' ' 13' ' ' ALA . 90.7 mt -127.61 169.27 13.94 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.257 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.26 162.8 29.84 Favored Glycine 0 N--CA 1.413 -2.846 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -66.78 -5.98 14.52 Favored 'Trans proline' 0 N--CA 1.487 1.125 0 C-N-CA 123.88 3.053 . . . . 0.0 112.578 -179.476 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.3 ptmm? -97.89 -6.98 31.2 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 114.875 -1.057 . . . . 0.0 111.686 177.186 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -112.52 6.26 18.4 Favored 'General case' 0 C--N 1.294 -1.806 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.995 -175.432 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.452 HG13 ' CE2' ' A' ' 5' ' ' PHE . 14.2 pt -127.28 147.06 32.16 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 CA-C-N 114.853 -1.067 . . . . 0.0 110.396 179.39 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 -140.26 147.62 50.82 Favored Pre-proline 0 C--N 1.302 -1.474 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -177.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -62.09 132.34 38.73 Favored 'Trans proline' 0 N--CA 1.481 0.749 0 C-N-CA 123.315 2.677 . . . . 0.0 113.955 -176.617 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.443 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 77.8 t80 -61.03 -40.7 94.59 Favored 'General case' 0 C--O 1.207 -1.136 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.652 -178.406 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 m -60.45 -40.15 90.11 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.81 -175.583 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -95.25 -4.08 46.39 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 115.763 -0.653 . . . . 0.0 112.193 -174.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 29.6 m-80 -125.64 15.36 8.15 Favored 'General case' 0 N--CA 1.446 -0.645 0 CA-C-O 120.427 0.156 . . . . 0.0 111.404 178.589 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 57.2 tttp -69.58 -36.2 76.04 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 121.627 0.727 . . . . 0.0 109.545 -178.355 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.561 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -75.15 -22.42 58.13 Favored 'General case' 0 N--CA 1.416 -2.131 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.964 176.502 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.561 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 7.8 mtmm -84.84 -54.08 4.91 Favored 'General case' 0 N--CA 1.437 -1.09 0 CA-C-N 115.743 -0.662 . . . . 0.0 112.621 179.661 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -122.0 -4.21 9.07 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -173.116 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.69 52.21 4.38 Favored Glycine 0 N--CA 1.468 0.826 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.103 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.2 ptpt -133.01 156.27 80.24 Favored Pre-proline 0 C--N 1.306 -1.325 0 C-N-CA 123.456 0.703 . . . . 0.0 109.676 -177.464 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_exo -49.15 153.11 4.52 Favored 'Trans proline' 0 C--N 1.355 0.897 0 C-N-CA 123.781 2.987 . . . . 0.0 115.889 -177.784 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -136.53 -173.38 3.4 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 114.545 -1.207 . . . . 0.0 109.106 179.634 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 47.5 mmtm -100.8 -14.54 17.97 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 179.222 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 4.1 mmm180 -70.79 123.53 22.17 Favored 'General case' 0 N--CA 1.436 -1.147 0 CA-C-O 121.186 0.517 . . . . 0.0 110.697 175.031 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 16.6 tppt? -68.38 126.4 29.49 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 174.823 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.499 ' HA3' ' CG2' ' A' ' 47' ' ' THR . . . 108.56 -19.53 31.1 Favored Glycine 0 N--CA 1.416 -2.668 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -177.013 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.436 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 16.6 t80 -76.31 -45.49 32.14 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -179.584 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.7 m-80 -69.91 -39.94 75.89 Favored 'General case' 0 CA--C 1.5 -0.957 0 CA-C-O 121.942 0.877 . . . . 0.0 108.957 -179.624 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 30.4 mp0 -64.87 -36.22 83.66 Favored 'General case' 0 N--CA 1.425 -1.72 0 CA-C-N 114.06 -1.427 . . . . 0.0 109.468 177.317 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.35 -31.48 68.64 Favored Glycine 0 CA--C 1.49 -1.49 0 CA-C-N 115.385 -0.825 . . . . 0.0 112.431 178.756 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.436 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 96.0 mt -58.84 -39.98 82.89 Favored 'General case' 0 C--O 1.212 -0.913 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 174.481 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 83.1 t90 -67.97 -48.7 65.11 Favored 'General case' 0 N--CA 1.432 -1.365 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.283 177.874 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -59.31 -43.4 92.64 Favored 'General case' 0 C--O 1.207 -1.135 0 N-CA-C 113.5 0.926 . . . . 0.0 113.5 -179.258 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.1 tt -71.98 -28.44 30.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 C-N-CA 120.23 -0.588 . . . . 0.0 112.209 -174.354 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -86.86 -17.37 33.49 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 112.062 0.393 . . . . 0.0 112.062 179.457 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 32.1 m-80 -114.46 -51.19 2.77 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-O 121.366 0.603 . . . . 0.0 112.471 -175.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.475 ' ND2' ' HB ' ' A' ' 90' ' ' VAL . 66.8 t30 -127.93 68.16 75.0 Favored Pre-proline 0 C--N 1.305 -1.364 0 O-C-N 121.883 -0.511 . . . . 0.0 110.678 -178.369 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.4 ' HB2' HD21 ' A' ' 10' ' ' LEU . 61.6 Cg_endo -75.77 -5.83 16.86 Favored 'Trans proline' 0 C--N 1.348 0.508 0 C-N-CA 122.025 1.817 . . . . 0.0 112.208 -177.591 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 19.8 pttp -93.4 14.67 17.82 Favored 'General case' 0 C--N 1.299 -1.592 0 CA-C-N 114.737 -1.119 . . . . 0.0 110.429 -178.779 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.475 ' HB ' ' ND2' ' A' ' 87' ' ' ASN . 13.4 p -80.8 83.48 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.117 0 CA-C-O 122.581 1.181 . . . . 0.0 111.896 178.869 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -109.28 21.53 16.99 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-O 122.475 1.131 . . . . 0.0 111.465 -178.419 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 -93.45 -0.13 56.55 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 114.617 -1.174 . . . . 0.0 109.028 179.005 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 14.3 m . . . . . 0 N--CA 1.444 -0.751 0 C-N-CA 124.948 1.299 . . . . 0.0 111.522 -177.176 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.7 mmm . . . . . 0 C--O 1.21 -1.017 0 CA-C-O 119.44 -0.314 . . . . 0.0 110.28 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -81.23 -7.17 59.52 Favored 'General case' 0 C--O 1.218 -0.595 0 O-C-N 124.203 0.939 . . . . 0.0 113.404 -176.387 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 47.7 ptt85 -95.77 177.29 5.83 Favored 'General case' 0 CA--C 1.511 -0.542 0 C-N-CA 118.954 -1.098 . . . . 0.0 109.587 177.826 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -84.45 165.75 17.87 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -177.847 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -131.35 125.73 33.45 Favored 'General case' 0 N--CA 1.42 -1.965 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.1 mttp -105.45 153.53 39.69 Favored Pre-proline 0 C--N 1.298 -1.656 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.638 -172.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -62.44 116.51 3.56 Favored 'Trans proline' 0 N--CA 1.457 -0.667 0 N-CA-C 107.921 -1.607 . . . . 0.0 107.921 170.397 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 108.62 -10.34 35.35 Favored Glycine 0 N--CA 1.426 -1.974 0 C-N-CA 120.833 -0.698 . . . . 0.0 112.172 -175.426 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -73.09 154.96 40.18 Favored 'General case' 0 C--O 1.253 1.245 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 -178.397 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.493 HD21 ' HB2' ' A' ' 88' ' ' PRO . 79.9 mt -105.36 123.67 48.26 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 -173.439 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.9 pp -140.28 177.56 4.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 CA-C-O 122.058 0.932 . . . . 0.0 112.934 -174.14 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.527 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 74.6 m-85 -110.31 129.54 55.72 Favored 'General case' 0 C--N 1.284 -2.263 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 170.662 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.404 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -108.0 118.49 36.88 Favored 'General case' 0 C--N 1.277 -2.569 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.136 -176.345 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.614 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -107.14 122.64 46.91 Favored 'General case' 0 N--CA 1.4 -2.957 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.384 -179.092 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.47 ' HG2' HD21 ' A' ' 53' ' ' LEU . 30.2 mtm -127.08 158.25 37.49 Favored 'General case' 0 CA--C 1.493 -1.22 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 176.905 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -64.17 117.23 6.84 Favored 'General case' 0 C--N 1.307 -1.255 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 178.44 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.05 -16.11 57.47 Favored Glycine 0 C--O 1.249 1.034 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 -178.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -105.47 151.04 39.65 Favored Pre-proline 0 N--CA 1.43 -1.466 0 C-N-CA 123.175 0.59 . . . . 0.0 109.623 178.811 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -83.12 171.69 11.3 Favored 'Trans proline' 0 N--CA 1.439 -1.685 0 C-N-CA 122.122 1.882 . . . . 0.0 107.416 169.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' HIS . . . . . 0.489 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 70.6 m80 -61.83 109.97 1.4 Allowed 'General case' 0 CA--C 1.542 0.648 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 174.023 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -105.15 136.79 19.14 Favored Pre-proline 0 C--N 1.305 -1.342 0 C-N-CA 123.131 0.572 . . . . 0.0 109.53 -170.517 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -65.02 117.84 4.9 Favored 'Trans proline' 0 N--CA 1.455 -0.754 0 C-N-CA 121.321 1.347 . . . . 0.0 110.433 177.497 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.92 166.61 24.15 Favored 'General case' 0 N--CA 1.413 -2.292 0 CA-C-O 121.279 0.561 . . . . 0.0 110.157 -175.694 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.473 ' HB2' ' CE2' ' A' ' 45' ' ' PHE . 31.7 ttp85 -116.68 145.83 43.17 Favored 'General case' 0 C--N 1.283 -2.303 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.554 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.6 t -76.49 123.88 33.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 105.302 -2.11 . . . . 0.0 105.302 171.667 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -90.93 -177.1 4.85 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -173.478 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.404 ' CD ' HH22 ' A' ' 24' ' ' ARG . 15.0 mp0 -91.09 156.68 17.72 Favored 'General case' 0 N--CA 1.423 -1.809 0 CA-C-O 121.87 0.843 . . . . 0.0 111.499 -176.867 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 61.5 t -112.26 126.74 27.89 Favored Pre-proline 0 C--N 1.313 -1.012 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 175.751 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_endo -73.0 136.34 24.71 Favored 'Trans proline' 0 N--CA 1.431 -2.201 0 C-N-CA 121.131 1.221 . . . . 0.0 112.182 178.293 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -74.83 150.24 39.33 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 174.178 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 88.15 -4.71 85.41 Favored Glycine 0 N--CA 1.428 -1.869 0 C-N-CA 120.452 -0.88 . . . . 0.0 111.909 -175.871 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -67.36 94.66 0.4 Allowed 'General case' 0 N--CA 1.448 -0.528 0 CA-C-O 121.409 0.624 . . . . 0.0 111.074 176.511 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 31.3 m -83.82 1.87 3.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.691 178.554 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 31.1 mmtp -86.41 124.83 69.28 Favored Pre-proline 0 C--N 1.304 -1.408 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 177.086 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -65.07 134.5 39.89 Favored 'Trans proline' 0 N--CA 1.453 -0.88 0 C-N-CA 121.862 1.708 . . . . 0.0 111.976 -179.091 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -82.43 171.17 12.58 Favored 'Trans proline' 0 N--CA 1.441 -1.573 0 C-N-CA 122.176 1.917 . . . . 0.0 111.638 -179.702 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.4 m -78.12 7.23 6.51 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 123.316 0.646 . . . . 0.0 110.511 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 41.8 m-80 70.69 18.06 6.42 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 124.819 1.248 . . . . 0.0 110.213 -177.877 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.557 ' HE2' ' N ' ' A' ' 54' ' ' GLY . 30.3 mtpt -122.87 166.67 14.64 Favored 'General case' 0 N--CA 1.429 -1.475 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 -179.746 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.401 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 91.8 mt -88.16 147.05 39.54 Favored Pre-proline 0 C--N 1.304 -1.388 0 C-N-CA 122.721 0.408 . . . . 0.0 110.369 -176.033 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -71.54 123.87 9.84 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.438 2.092 . . . . 0.0 110.295 177.419 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 49.3 mm -119.02 125.17 74.27 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 O-C-N 122.064 -0.398 . . . . 0.0 110.613 -176.344 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -104.77 114.52 28.79 Favored 'General case' 0 C--N 1.288 -2.104 0 C-N-CA 123.431 0.692 . . . . 0.0 109.144 177.766 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.417 ' HE2' ' HB2' ' A' ' 51' ' ' ALA . 96.9 m-85 -77.97 137.27 38.22 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.014 0.435 . . . . 0.0 111.681 178.035 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.473 ' CE2' ' HB2' ' A' ' 24' ' ' ARG . 70.5 m-85 -89.16 156.44 18.79 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.492 177.168 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.442 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 74.02 -20.78 1.44 Allowed Glycine 0 N--CA 1.469 0.878 0 C-N-CA 124.578 1.085 . . . . 0.0 114.454 178.734 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.2 p -119.15 -22.67 7.08 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 173.584 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 11.2 m170 65.87 24.7 11.27 Favored 'General case' 0 C--N 1.348 0.519 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.107 179.06 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -73.34 167.39 21.33 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 115.388 -0.824 . . . . 0.0 108.904 176.794 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.6 m -137.82 140.81 40.71 Favored 'General case' 0 C--N 1.287 -2.122 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.847 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.417 ' HB2' ' HE2' ' A' ' 44' ' ' PHE . . . -145.37 -179.32 6.58 Favored 'General case' 0 C--N 1.293 -1.859 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.131 -178.202 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.401 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 83.4 m-85 -132.2 110.71 10.84 Favored 'General case' 0 C--O 1.246 0.886 0 CA-C-N 115.217 -0.902 . . . . 0.0 109.427 177.193 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.532 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 93.8 mt -129.48 154.64 46.8 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.656 -177.415 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.557 ' N ' ' HE2' ' A' ' 39' ' ' LYS . . . -95.87 176.34 33.32 Favored Glycine 0 N--CA 1.432 -1.585 0 C-N-CA 120.016 -1.088 . . . . 0.0 111.301 -174.831 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -66.22 -7.53 17.63 Favored 'Trans proline' 0 C--O 1.239 0.566 0 C-N-CA 122.966 2.444 . . . . 0.0 112.311 -178.541 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.7 mtpp -97.3 -15.16 20.9 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.238 177.054 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.532 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 40.9 m-20 -93.39 -14.38 26.89 Favored 'General case' 0 CA--C 1.49 -1.346 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.084 -178.488 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.446 ' HA ' ' O ' ' A' ' 12' ' ' PHE . 17.9 pt -119.12 148.58 21.96 Favored 'Isoleucine or valine' 0 C--O 1.268 2.04 0 CA-C-O 122.482 1.134 . . . . 0.0 112.849 -171.947 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 80.8 m-85 -136.08 133.25 19.56 Favored Pre-proline 0 C--N 1.292 -1.895 0 CA-C-N 113.885 -1.507 . . . . 0.0 106.951 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.49 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 35.8 Cg_endo -64.12 127.91 20.45 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.881 2.388 . . . . 0.0 113.147 -177.2 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.527 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 72.0 t80 -58.86 -35.38 72.85 Favored 'General case' 0 C--O 1.197 -1.674 0 CA-C-N 114.062 -1.426 . . . . 0.0 112.915 -174.78 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.427 ' HB3' ' OE1' ' A' ' 63' ' ' GLU . 28.2 t -67.63 -52.19 41.15 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.191 0.52 . . . . 0.0 110.478 -177.808 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.49 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 2.6 mp0 -81.32 -5.67 58.07 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.128 -175.58 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.409 ' OD1' ' HE2' ' A' ' 67' ' ' LYS . 24.2 m-80 -126.59 15.12 7.61 Favored 'General case' 0 C--N 1.311 -1.079 0 C-N-CA 122.893 0.477 . . . . 0.0 111.557 -179.558 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -67.85 -35.89 79.36 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-O 121.722 0.772 . . . . 0.0 110.093 -179.488 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.606 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -72.01 -28.31 63.31 Favored 'General case' 0 N--CA 1.408 -2.566 0 CA-C-N 115.648 -0.705 . . . . 0.0 111.99 176.864 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.606 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 7.0 mtmm -80.2 -58.17 3.27 Favored 'General case' 0 N--CA 1.439 -0.979 0 CA-C-N 115.729 -0.668 . . . . 0.0 112.452 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 76.4 m-85 -113.67 -10.98 13.02 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -172.368 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.4 56.22 4.09 Favored Glycine 0 C--N 1.314 -0.648 0 C-N-CA 121.332 -0.461 . . . . 0.0 112.834 -177.556 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.419 ' O ' ' HE1' ' A' ' 77' ' ' PHE . 4.5 ptpp? -132.54 147.42 65.53 Favored Pre-proline 0 C--N 1.303 -1.416 0 CA-C-O 119.244 -0.408 . . . . 0.0 110.084 178.702 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.445 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 87.0 Cg_exo -50.2 156.92 3.36 Favored 'Trans proline' 0 C--N 1.355 0.914 0 C-N-CA 124.031 3.154 . . . . 0.0 114.803 -179.413 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -143.04 -173.34 3.88 Favored 'General case' 0 N--CA 1.433 -1.29 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.532 179.189 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.411 ' HD3' ' N ' ' A' ' 73' ' ' LYS . 0.1 OUTLIER -93.79 1.11 56.55 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.047 -179.809 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 30.9 mmt180 -82.79 120.6 25.83 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.687 176.72 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.441 ' HD3' ' N ' ' A' ' 76' ' ' GLY . 8.1 tmtt? -70.03 127.15 31.85 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 175.316 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.442 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 106.8 -25.41 22.7 Favored Glycine 0 CA--C 1.501 -0.817 0 N-CA-C 110.598 -1.001 . . . . 0.0 110.598 -178.821 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.419 ' HE1' ' O ' ' A' ' 70' ' ' LYS . 54.1 t80 -72.11 -42.06 66.51 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-O 121.74 0.781 . . . . 0.0 109.557 -177.432 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.445 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 87.2 m-20 -79.07 -33.81 44.24 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.668 -173.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -71.55 -33.37 69.06 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 175.111 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.34 -37.26 70.52 Favored Glycine 0 N--CA 1.432 -1.601 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.432 177.395 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 43.9 tp -59.74 -33.58 71.83 Favored 'General case' 0 N--CA 1.434 -1.249 0 C-N-CA 124.007 0.923 . . . . 0.0 108.855 175.03 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 82.0 t90 -72.46 -51.02 21.98 Favored 'General case' 0 N--CA 1.434 -1.236 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.022 175.668 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 35.6 mt-10 -53.8 -49.76 67.63 Favored 'General case' 0 C--O 1.206 -1.189 0 N-CA-C 112.797 0.666 . . . . 0.0 112.797 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 19.3 tt -67.94 -23.87 29.69 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 N-CA-C 112.573 0.583 . . . . 0.0 112.573 -173.782 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -94.31 -22.67 18.21 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 121.409 0.623 . . . . 0.0 110.686 -176.417 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 28.4 m-80 -105.97 -55.17 2.37 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-O 121.435 0.636 . . . . 0.0 111.785 -176.845 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 67.4 t30 -127.62 72.61 78.13 Favored Pre-proline 0 C--N 1.312 -1.032 0 C-N-CA 119.969 -0.693 . . . . 0.0 110.228 179.584 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.493 ' HB2' HD21 ' A' ' 10' ' ' LEU . 57.0 Cg_endo -74.81 -6.76 18.57 Favored 'Trans proline' 0 C--O 1.221 -0.326 0 C-N-CA 122.128 1.886 . . . . 0.0 112.815 -176.223 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.4 pttm -97.6 17.75 17.06 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.986 -178.085 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 14.9 p -75.52 113.68 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.996 0 CA-C-O 122.575 1.179 . . . . 0.0 112.947 -178.296 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -113.5 143.89 43.77 Favored 'General case' 0 N--CA 1.423 -1.817 0 N-CA-C 105.082 -2.192 . . . . 0.0 105.082 174.019 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 24.5 p90 -114.76 161.48 18.12 Favored 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.007 -177.689 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 20.4 m . . . . . 0 N--CA 1.471 0.625 0 C-N-CA 125.767 1.627 . . . . 0.0 110.902 -179.612 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.3 mtt . . . . . 0 CA--C 1.506 -0.746 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -68.31 -15.66 63.65 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 112.767 0.655 . . . . 0.0 112.767 -179.08 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.554 ' HG3' ' OD1' ' A' ' 4' ' ' ASP . 8.2 ptm180 -95.86 -39.67 9.7 Favored 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 113.037 0.754 . . . . 0.0 113.037 -179.344 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ASP . . . . . 0.554 ' OD1' ' HG3' ' A' ' 3' ' ' ARG . 4.9 p-10 -152.69 162.4 41.3 Favored 'General case' 0 C--N 1.275 -2.673 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.383 -177.46 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -125.76 120.37 30.43 Favored 'General case' 0 N--CA 1.425 -1.717 0 N-CA-C 107.753 -1.202 . . . . 0.0 107.753 178.23 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.506 ' H ' ' HB2' ' A' ' 9' ' ' ASP . 32.3 mttp -104.76 158.36 32.18 Favored Pre-proline 0 C--N 1.298 -1.661 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -174.793 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.484 ' HB3' ' HA ' ' A' ' 27' ' ' GLU . 37.1 Cg_exo -63.46 117.02 3.99 Favored 'Trans proline' 0 N--CA 1.451 -0.986 0 N-CA-C 107.385 -1.813 . . . . 0.0 107.385 167.296 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 101.66 -1.42 52.72 Favored Glycine 0 N--CA 1.435 -1.421 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.458 -175.602 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.506 ' HB2' ' H ' ' A' ' 6' ' ' LYS . 4.9 t70 -78.11 154.94 30.82 Favored 'General case' 0 C--O 1.254 1.339 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 64.3 mt -102.54 124.83 48.82 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.44 -172.542 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.41 HD11 HD12 ' A' ' 42' ' ' ILE . 7.9 pt -141.39 -177.11 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.825 0 CA-C-O 122.295 1.045 . . . . 0.0 112.82 -174.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.509 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 76.4 m-85 -120.83 126.49 50.2 Favored 'General case' 0 N--CA 1.417 -2.099 0 C-N-CA 126.232 1.813 . . . . 0.0 106.241 170.771 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.479 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -108.96 128.85 55.3 Favored 'General case' 0 C--N 1.27 -2.859 0 O-C-N 123.625 0.578 . . . . 0.0 109.632 -178.022 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.622 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -114.36 122.13 45.74 Favored 'General case' 0 N--CA 1.407 -2.596 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.707 -179.593 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 63.4 mtm -116.31 158.83 22.8 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 177.218 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -63.94 117.13 6.56 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 174.454 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.54 -5.52 54.73 Favored Glycine 0 C--N 1.315 -0.622 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -176.858 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.429 ' HA ' ' HD3' ' A' ' 19' ' ' PRO . 21.8 m-85 -126.51 136.57 28.85 Favored Pre-proline 0 N--CA 1.436 -1.164 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -179.782 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 18' ' ' TYR . 14.3 Cg_exo -70.21 171.12 15.54 Favored 'Trans proline' 0 N--CA 1.444 -1.399 0 C-N-CA 122.212 1.941 . . . . 0.0 108.628 169.427 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' HIS . . . . . 0.512 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 80.2 m80 -63.55 110.75 2.09 Favored 'General case' 0 C--N 1.312 -1.049 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.722 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 10.4 t-105 -107.88 136.65 19.7 Favored Pre-proline 0 C--N 1.306 -1.304 0 C-N-CA 123.316 0.646 . . . . 0.0 109.885 -171.91 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -62.97 118.14 5.04 Favored 'Trans proline' 0 C--O 1.244 0.782 0 C-N-CA 122.214 1.943 . . . . 0.0 111.137 178.812 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -139.7 166.2 25.24 Favored 'General case' 0 N--CA 1.409 -2.5 0 CA-C-O 121.525 0.679 . . . . 0.0 111.285 -176.145 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.526 HH21 ' CD ' ' A' ' 27' ' ' GLU . 17.2 ttt-85 -111.49 139.01 47.27 Favored 'General case' 0 C--N 1.285 -2.204 0 C-N-CA 124.179 0.992 . . . . 0.0 108.404 177.729 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 58.9 t -75.84 121.86 28.6 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 N-CA-C 104.986 -2.228 . . . . 0.0 104.986 170.656 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.401 ' HB3' ' HB2' ' A' ' 41' ' ' PRO . 3.9 t0 -84.02 172.61 11.86 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 -173.275 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.526 ' CD ' HH21 ' A' ' 24' ' ' ARG . 4.4 mp0 -92.62 123.23 35.76 Favored 'General case' 0 N--CA 1.411 -2.398 0 CA-C-O 122.256 1.026 . . . . 0.0 112.522 -177.555 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.7 p -106.1 126.67 30.01 Favored Pre-proline 0 N--CA 1.425 -1.71 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 174.105 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_endo -73.67 136.11 22.85 Favored 'Trans proline' 0 N--CA 1.445 -1.35 0 C-N-CA 121.481 1.454 . . . . 0.0 111.718 178.478 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -77.83 147.82 35.0 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 174.369 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 83.49 5.5 88.45 Favored Glycine 0 N--CA 1.427 -1.924 0 C-N-CA 120.557 -0.83 . . . . 0.0 111.678 -175.32 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -60.67 138.32 58.09 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-O 121.117 0.484 . . . . 0.0 110.59 176.263 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.7 m -62.91 -22.09 29.6 Favored 'Isoleucine or valine' 0 C--O 1.243 0.725 0 CA-C-N 115.476 -0.784 . . . . 0.0 111.986 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 23.5 mmmt -108.48 118.06 52.99 Favored Pre-proline 0 N--CA 1.416 -2.167 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 172.142 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -78.58 155.98 28.04 Favored 'Trans proline' 0 N--CA 1.453 -0.887 0 C-N-CA 121.785 1.657 . . . . 0.0 111.957 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -64.82 136.9 51.17 Favored 'Trans proline' 0 N--CA 1.451 -1.022 0 C-N-CA 122.18 1.92 . . . . 0.0 111.857 179.239 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.0 m -72.34 9.05 1.11 Allowed 'General case' 0 CA--C 1.567 1.6 0 C-N-CA 125.399 1.479 . . . . 0.0 112.392 -177.4 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER 84.27 8.12 0.53 Allowed 'General case' 0 N--CA 1.503 2.211 0 C-N-CA 126.986 2.114 . . . . 0.0 108.221 -171.814 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 86.5 mttt -109.08 162.24 14.43 Favored 'General case' 0 N--CA 1.414 -2.266 0 CA-C-N 113.036 -1.893 . . . . 0.0 109.637 176.268 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 84.4 mt -106.81 146.29 32.79 Favored Pre-proline 0 C--N 1.282 -2.329 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 178.654 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.401 ' HB2' ' HB3' ' A' ' 26' ' ' ASP . 60.1 Cg_endo -73.62 128.95 13.1 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 121.888 1.725 . . . . 0.0 109.395 176.805 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.429 HG21 ' CB ' ' A' ' 13' ' ' ALA . 37.0 mm -118.41 125.73 74.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.987 -0.446 . . . . 0.0 110.799 -174.166 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -109.71 115.34 29.68 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 176.726 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -79.04 139.09 38.22 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-O 121.0 0.429 . . . . 0.0 111.794 179.003 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 -90.26 160.4 16.19 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.385 177.141 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.529 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 73.06 -21.53 1.01 Allowed Glycine 0 C--N 1.311 -0.828 0 C-N-CA 124.932 1.253 . . . . 0.0 114.315 179.228 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.435 HG23 ' HA3' ' A' ' 76' ' ' GLY . 37.1 p -119.98 -22.3 6.78 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 117.559 0.68 . . . . 0.0 109.685 173.037 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.1 m170 66.88 24.87 9.62 Favored 'General case' 0 C--N 1.35 0.629 0 CA-C-N 115.406 -0.815 . . . . 0.0 111.153 -179.517 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -71.94 167.17 20.65 Favored 'General case' 0 C--N 1.347 0.462 0 CA-C-N 115.179 -0.919 . . . . 0.0 108.728 175.764 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.9 m -137.45 145.95 43.74 Favored 'General case' 0 C--N 1.289 -2.034 0 O-C-N 121.576 -0.702 . . . . 0.0 109.581 -178.678 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -150.57 178.43 9.08 Favored 'General case' 0 C--N 1.308 -1.197 0 O-C-N 123.533 0.521 . . . . 0.0 111.404 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -134.26 114.74 13.35 Favored 'General case' 0 C--O 1.262 1.745 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.575 175.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.479 HD12 ' HB1' ' A' ' 13' ' ' ALA . 94.6 mt -130.99 158.75 39.45 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -179.159 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.0 172.55 36.92 Favored Glycine 0 N--CA 1.429 -1.796 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.414 ' HA ' HD11 ' A' ' 58' ' ' ILE . 36.4 Cg_endo -65.89 -6.84 15.14 Favored 'Trans proline' 0 C--O 1.21 -0.91 0 C-N-CA 123.046 2.497 . . . . 0.0 112.438 -178.926 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.2 ptmm? -97.52 -5.02 36.76 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 115.333 -0.849 . . . . 0.0 111.764 179.518 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -115.86 5.8 14.14 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -177.868 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.414 HD11 ' HA ' ' A' ' 55' ' ' PRO . 16.8 pt -126.53 150.63 32.37 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 CA-C-N 115.073 -0.967 . . . . 0.0 110.487 -178.639 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 -131.94 135.32 26.45 Favored Pre-proline 0 C--O 1.188 -2.167 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 177.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.545 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 37.8 Cg_endo -66.82 131.01 24.53 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 C-N-CA 122.841 2.361 . . . . 0.0 114.007 -177.791 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.509 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 65.4 t80 -63.54 -33.79 76.36 Favored 'General case' 0 C--O 1.204 -1.328 0 CA-C-N 114.889 -1.05 . . . . 0.0 112.159 -174.331 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.15 -54.31 35.81 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -177.121 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.545 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 2.1 pm0 -89.68 1.32 56.2 Favored 'General case' 0 N--CA 1.433 -1.298 0 N-CA-C 114.276 1.213 . . . . 0.0 114.276 -178.905 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 26.8 m-80 -122.8 15.18 10.11 Favored 'General case' 0 C--N 1.314 -0.935 0 C-N-CA 123.327 0.651 . . . . 0.0 111.132 175.613 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.46 ' HZ1' ' CG ' ' A' ' 85' ' ' ASP . 16.5 ttmm -65.13 -33.32 75.75 Favored 'General case' 0 N--CA 1.476 0.855 0 CA-C-O 121.579 0.704 . . . . 0.0 110.189 179.473 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.599 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -80.25 -28.95 38.35 Favored 'General case' 0 N--CA 1.403 -2.819 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.098 177.33 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.599 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 8.3 mttm -76.71 -59.09 2.92 Favored 'General case' 0 CA--C 1.505 -0.778 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.253 -179.24 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -112.1 -4.28 14.49 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -173.443 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -75.64 51.76 2.68 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 121.715 -0.279 . . . . 0.0 113.11 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 4.3 ptpp? -132.44 135.71 26.75 Favored Pre-proline 0 C--N 1.311 -1.09 0 O-C-N 122.459 -0.436 . . . . 0.0 110.161 179.144 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -66.91 128.24 18.42 Favored 'Trans proline' 0 C--O 1.25 1.111 0 C-N-CA 122.787 2.325 . . . . 0.0 116.316 -171.178 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 4.8 m-20 -84.69 -168.93 2.39 Favored 'General case' 0 CA--C 1.483 -1.633 0 CA-C-N 113.784 -1.553 . . . . 0.0 108.165 175.311 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.438 ' HD3' ' HA ' ' A' ' 73' ' ' LYS . 39.4 mmtm -108.53 10.49 27.19 Favored 'General case' 0 C--N 1.287 -2.146 0 CA-C-O 121.842 0.829 . . . . 0.0 109.475 175.36 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ARG . . . . . 0.427 HH21 HG21 ' A' ' 47' ' ' THR . 4.5 mmm-85 -77.45 122.8 25.69 Favored 'General case' 0 N--CA 1.417 -2.099 0 CA-C-N 115.04 -0.982 . . . . 0.0 109.199 170.664 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 15.6 tppt? -65.17 129.54 40.1 Favored 'General case' 0 N--CA 1.429 -1.523 0 N-CA-C 107.551 -1.278 . . . . 0.0 107.551 173.58 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.529 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.21 -25.19 20.9 Favored Glycine 0 N--CA 1.415 -2.742 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -176.142 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -76.63 -41.13 47.03 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-O 121.356 0.598 . . . . 0.0 109.39 -178.817 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 2.5 m-20 -71.31 -43.85 66.28 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 -176.289 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 25.2 mp0 -63.11 -41.77 99.42 Favored 'General case' 0 N--CA 1.428 -1.554 0 CA-C-N 113.577 -1.647 . . . . 0.0 109.634 177.712 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -65.38 -37.6 94.02 Favored Glycine 0 N--CA 1.44 -1.052 0 CA-C-N 115.449 -0.796 . . . . 0.0 112.804 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 87.9 mt -59.56 -35.12 73.62 Favored 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 176.094 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.3 t90 -74.29 -50.32 19.38 Favored 'General case' 0 N--CA 1.425 -1.712 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.295 177.501 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 26.8 mt-10 -53.74 -49.94 67.06 Favored 'General case' 0 C--O 1.188 -2.175 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -179.512 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.8 tt -67.99 -23.48 29.09 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 N-CA-C 112.256 0.465 . . . . 0.0 112.256 -173.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' ASP . . . . . 0.46 ' CG ' ' HZ1' ' A' ' 65' ' ' LYS . 15.2 t70 -94.21 -32.52 13.66 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-O 121.497 0.665 . . . . 0.0 110.05 -175.053 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -103.43 -44.89 5.02 Favored 'General case' 0 C--O 1.257 1.456 0 CA-C-O 121.911 0.862 . . . . 0.0 111.504 -176.679 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 60.7 t30 -131.76 61.32 57.65 Favored Pre-proline 0 C--N 1.296 -1.73 0 C-N-CA 119.983 -0.687 . . . . 0.0 112.329 -176.595 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -71.12 -7.68 21.91 Favored 'Trans proline' 0 C--N 1.372 1.789 0 C-N-CA 122.19 1.926 . . . . 0.0 110.465 179.078 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' LYS . . . . . 0.409 ' H ' ' HG2' ' A' ' 89' ' ' LYS . 22.7 pttm -102.88 20.52 17.27 Favored 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 113.159 -1.837 . . . . 0.0 109.197 -175.49 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 7.4 p -53.56 108.17 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.847 0 CA-C-O 122.15 0.976 . . . . 0.0 112.452 -179.107 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.9 mmmp? 74.65 -66.87 0.28 Allowed 'General case' 0 CA--C 1.492 -1.282 0 CA-C-N 114.218 -1.356 . . . . 0.0 114.418 -179.089 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 46.2 t80 61.68 177.65 0.12 Allowed 'General case' 0 C--O 1.265 1.869 0 O-C-N 124.382 1.051 . . . . 0.0 110.02 -174.664 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 23.0 m . . . . . 0 C--N 1.309 -1.156 0 N-CA-C 112.241 0.46 . . . . 0.0 112.241 -177.865 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.0 mmt . . . . . 0 CA--C 1.495 -1.158 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -84.32 55.39 3.34 Favored 'General case' 0 C--O 1.248 1.012 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 173.2 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 14.0 ptp180 168.71 -164.92 0.01 OUTLIER 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 130.398 3.479 . . . . 0.0 104.451 -178.566 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . 0.291 3.6 p30 58.55 105.04 0.02 OUTLIER 'General case' 0 CA--C 1.495 -1.136 0 C-N-CA 125.061 1.344 . . . . 0.0 112.786 -178.46 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -113.45 123.46 50.1 Favored 'General case' 0 N--CA 1.397 -3.124 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.399 -172.113 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 25.9 mtmm -120.67 156.65 55.82 Favored Pre-proline 0 C--N 1.274 -2.677 0 CA-C-N 113.886 -1.506 . . . . 0.0 107.695 -172.287 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.444 ' HB3' ' HA ' ' A' ' 27' ' ' GLU . 52.5 Cg_exo -57.4 120.94 9.19 Favored 'Trans proline' 0 N--CA 1.461 -0.436 0 C-N-CA 121.825 1.683 . . . . 0.0 110.566 176.311 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.22 -24.28 10.03 Favored Glycine 0 N--CA 1.426 -2.029 0 CA-C-O 119.138 -0.812 . . . . 0.0 113.452 -178.426 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 32.8 m-20 -63.3 137.31 58.14 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 117.769 0.784 . . . . 0.0 111.725 -179.181 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 95.6 mt -90.18 126.58 35.86 Favored 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 176.64 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -142.08 -174.97 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-O 122.197 0.998 . . . . 0.0 112.899 -174.497 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -115.71 130.0 56.69 Favored 'General case' 0 C--N 1.28 -2.431 0 CA-C-N 114.083 -1.417 . . . . 0.0 107.416 170.335 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.621 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -107.43 114.36 28.31 Favored 'General case' 0 C--N 1.275 -2.654 0 CA-C-N 114.866 -1.061 . . . . 0.0 109.426 -173.372 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.616 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.9 OUTLIER -103.76 128.24 51.16 Favored 'General case' 0 C--N 1.264 -3.129 0 CA-C-N 114.343 -1.299 . . . . 0.0 109.54 -178.597 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.402 ' HB2' ' HB2' ' A' ' 18' ' ' TYR . 68.2 mtm -113.84 158.25 21.27 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -70.26 116.77 11.0 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 120.607 -0.437 . . . . 0.0 109.879 -178.626 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 93.99 0.11 66.36 Favored Glycine 0 N--CA 1.448 -0.518 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.97 178.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.402 ' HB2' ' HB2' ' A' ' 15' ' ' MET . 99.5 m-85 -129.75 152.23 79.47 Favored Pre-proline 0 N--CA 1.439 -0.996 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 -177.825 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -68.97 170.33 15.87 Favored 'Trans proline' 0 N--CA 1.457 -0.652 0 C-N-CA 122.4 2.067 . . . . 0.0 112.197 177.811 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 57.5 m80 -71.5 114.26 9.4 Favored 'General case' 0 CA--C 1.552 1.02 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.605 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 11.1 t-105 -101.35 136.91 19.55 Favored Pre-proline 0 C--N 1.31 -1.127 0 C-N-CA 123.142 0.577 . . . . 0.0 109.468 -176.604 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -64.77 117.87 4.91 Favored 'Trans proline' 0 CA--C 1.542 0.911 0 C-N-CA 121.978 1.786 . . . . 0.0 110.741 177.624 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.55 167.12 24.5 Favored 'General case' 0 N--CA 1.426 -1.66 0 CA-C-O 121.242 0.544 . . . . 0.0 111.214 -174.512 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.411 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 41.9 ttt-85 -115.4 143.52 45.17 Favored 'General case' 0 C--N 1.291 -1.965 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 179.552 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 64.9 t -79.21 114.2 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 104.385 -2.45 . . . . 0.0 104.385 168.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.439 ' CG ' ' HZ2' ' A' ' 91' ' ' LYS . 4.3 t70 -90.74 -179.55 5.55 Favored 'General case' 0 C--N 1.29 -1.985 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.878 -171.45 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.444 ' HA ' ' HB3' ' A' ' 7' ' ' PRO . 32.2 mp0 -92.61 151.23 20.24 Favored 'General case' 0 N--CA 1.439 -0.993 0 CA-C-O 121.948 0.88 . . . . 0.0 112.593 -175.9 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 8.1 p -113.74 130.74 23.52 Favored Pre-proline 0 N--CA 1.43 -1.454 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 176.209 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -66.2 139.12 54.07 Favored 'Trans proline' 0 C--O 1.248 0.996 0 C-N-CA 122.41 2.073 . . . . 0.0 114.108 -177.167 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -59.17 129.87 44.19 Favored 'General case' 0 CA--C 1.505 -0.762 0 CA-C-N 115.3 -0.864 . . . . 0.0 108.86 174.2 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 110.4 -17.33 28.75 Favored Glycine 0 C--N 1.297 -1.612 0 C-N-CA 120.364 -0.922 . . . . 0.0 111.181 -178.235 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -66.3 108.54 2.36 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-O 121.087 0.47 . . . . 0.0 109.766 175.011 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.9 m -79.01 6.42 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 115.51 -0.768 . . . . 0.0 113.005 -178.323 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 31.5 mmtp -83.59 118.32 71.15 Favored Pre-proline 0 C--N 1.301 -1.507 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.203 178.51 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -80.58 163.71 21.35 Favored 'Trans proline' 0 C--O 1.249 1.065 0 C-N-CA 122.186 1.924 . . . . 0.0 111.146 177.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -59.88 127.56 23.82 Favored 'Trans proline' 0 N--CA 1.452 -0.96 0 C-N-CA 121.825 1.683 . . . . 0.0 111.193 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.494 ' O ' ' HB2' ' A' ' 38' ' ' ASN . 3.2 m -95.53 8.94 41.86 Favored 'General case' 0 C--N 1.293 -1.857 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.424 -175.12 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ASN . . . . . 0.494 ' HB2' ' O ' ' A' ' 37' ' ' THR . 25.4 m-80 86.33 8.98 0.26 Allowed 'General case' 0 N--CA 1.493 1.725 0 C-N-CA 125.57 1.548 . . . . 0.0 109.065 -169.54 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.435 ' HE2' ' N ' ' A' ' 54' ' ' GLY . 8.9 mmpt? -124.12 155.94 37.54 Favored 'General case' 0 N--CA 1.429 -1.518 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 175.962 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 87.8 mt -128.41 155.59 78.32 Favored Pre-proline 0 C--N 1.283 -2.298 0 C-N-CA 125.306 1.442 . . . . 0.0 107.253 178.763 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -71.22 122.8 9.05 Favored 'Trans proline' 0 CA--C 1.536 0.617 0 C-N-CA 121.697 1.598 . . . . 0.0 110.679 177.552 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.462 HG13 ' HB2' ' A' ' 53' ' ' LEU . 49.2 mm -122.51 124.68 71.3 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.083 0 CA-C-O 120.753 0.311 . . . . 0.0 110.355 -176.377 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 80.9 t80 -106.96 116.41 31.87 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 178.756 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -79.27 132.09 36.36 Favored 'General case' 0 C--O 1.244 0.805 0 CA-C-O 121.016 0.436 . . . . 0.0 110.923 179.746 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.411 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 66.9 m-85 -82.81 158.6 22.71 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.029 178.829 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.51 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 74.99 -20.11 1.97 Allowed Glycine 0 C--O 1.256 1.473 0 C-N-CA 124.513 1.054 . . . . 0.0 114.454 178.787 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.537 HG23 ' HA3' ' A' ' 76' ' ' GLY . 31.2 p -119.32 -23.88 6.57 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 122.237 -0.566 . . . . 0.0 109.957 175.273 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 44.8 m170 67.74 23.09 8.71 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.432 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -74.98 166.43 23.67 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 176.352 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.5 m -137.11 145.71 44.21 Favored 'General case' 0 C--N 1.286 -2.192 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 -179.758 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -146.76 179.52 7.51 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 123.136 0.575 . . . . 0.0 109.71 -179.526 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -131.75 109.29 10.05 Favored 'General case' 0 N--CA 1.432 -1.339 0 N-CA-C 109.003 -0.739 . . . . 0.0 109.003 176.488 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.621 HD12 ' HB1' ' A' ' 13' ' ' ALA . 88.7 mt -130.26 149.29 52.02 Favored 'General case' 0 C--N 1.287 -2.145 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 -178.826 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.483 ' HA3' ' O ' ' A' ' 38' ' ' ASN . . . -95.37 178.07 35.29 Favored Glycine 0 N--CA 1.417 -2.57 0 C-N-CA 119.707 -1.235 . . . . 0.0 112.104 -174.059 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.1 -9.3 16.6 Favored 'Trans proline' 0 N--CA 1.479 0.667 0 C-N-CA 123.224 2.616 . . . . 0.0 111.831 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 42.6 mtmt -98.29 -1.57 41.5 Favored 'General case' 0 N--CA 1.431 -1.385 0 CA-C-N 114.879 -1.055 . . . . 0.0 110.705 -179.653 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.54 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 36.8 m-20 -115.22 -9.65 12.22 Favored 'General case' 0 CA--C 1.5 -0.957 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.484 -179.436 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 9.5 pt -119.91 152.71 22.65 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.127 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.751 -173.562 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -138.99 147.59 54.42 Favored Pre-proline 0 C--N 1.297 -1.68 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -178.416 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.533 ' HG2' ' OE2' ' A' ' 63' ' ' GLU . 11.7 Cg_endo -58.11 139.61 91.1 Favored 'Trans proline' 0 CA--C 1.516 -0.383 0 C-N-CA 122.758 2.305 . . . . 0.0 114.432 -175.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.403 ' O ' ' HB3' ' A' ' 65' ' ' LYS . 16.3 t80 -65.18 -35.84 82.33 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 115.214 -0.903 . . . . 0.0 111.451 177.151 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 10.5 m -48.91 -57.19 6.84 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 112.953 0.723 . . . . 0.0 112.953 -175.319 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.533 ' OE2' ' HG2' ' A' ' 60' ' ' PRO . 0.0 OUTLIER -95.79 -14.43 23.29 Favored 'General case' 0 N--CA 1.432 -1.352 0 N-CA-C 114.903 1.446 . . . . 0.0 114.903 178.867 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.454 ' HB2' ' O ' ' A' ' 60' ' ' PRO . 22.6 m-80 -88.85 -8.0 55.12 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 121.681 -0.637 . . . . 0.0 112.648 179.221 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.418 ' O ' ' HA3' ' A' ' 69' ' ' GLY . 11.6 ptmm? -60.52 -38.28 83.88 Favored 'General case' 0 C--O 1.201 -1.466 0 CA-C-O 121.182 0.515 . . . . 0.0 111.308 -176.89 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 55.9 mm-40 -82.3 -33.85 28.89 Favored 'General case' 0 CA--C 1.477 -1.832 0 C-N-CA 119.453 -0.899 . . . . 0.0 112.426 177.494 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 29.9 mtmm -67.52 -58.92 3.87 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 124.725 1.265 . . . . 0.0 111.526 -176.118 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 84.4 m-85 -111.66 -1.87 15.57 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-O 121.551 0.691 . . . . 0.0 111.447 -175.632 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' GLY . . . . . 0.418 ' HA3' ' O ' ' A' ' 65' ' ' LYS . . . -91.46 54.68 3.13 Favored Glycine 0 N--CA 1.429 -1.775 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 177.96 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.497 ' HA ' ' HE3' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -117.93 149.06 44.68 Favored Pre-proline 0 C--N 1.299 -1.623 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 177.709 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.501 ' HB3' ' OD1' ' A' ' 78' ' ' ASN . 70.2 Cg_exo -49.43 146.65 13.8 Favored 'Trans proline' 0 C--O 1.243 0.727 0 C-N-CA 123.338 2.692 . . . . 0.0 114.868 -176.828 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -131.0 -171.06 2.48 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.829 -178.617 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 45.9 mmtm -104.9 -11.05 16.91 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-O 121.235 0.541 . . . . 0.0 109.618 179.538 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 3.2 mmm180 -73.57 121.64 20.96 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.039 173.176 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.94 127.47 31.54 Favored 'General case' 0 N--CA 1.435 -1.189 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 174.226 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.537 ' HA3' HG23 ' A' ' 47' ' ' THR . . . 108.86 -21.12 28.15 Favored Glycine 0 N--CA 1.409 -3.132 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.854 -177.61 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.563 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 12.6 t80 -76.26 -43.2 42.91 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 -179.435 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.501 ' OD1' ' HB3' ' A' ' 71' ' ' PRO . 52.5 m-80 -70.66 -43.25 69.51 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.739 -178.808 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -68.36 -33.3 74.04 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 115.362 -0.836 . . . . 0.0 109.771 179.011 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -66.73 -34.94 88.91 Favored Glycine 0 CA--C 1.491 -1.423 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.797 178.64 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.563 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 98.2 mt -62.26 -41.57 98.56 Favored 'General case' 0 C--O 1.212 -0.915 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 174.922 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 85.7 t90 -65.5 -45.85 81.97 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.647 178.564 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 54.9 mt-10 -59.72 -47.46 85.56 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 112.837 0.68 . . . . 0.0 112.837 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.8 tt -74.85 -27.48 20.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 C-N-CA 120.248 -0.581 . . . . 0.0 111.959 -175.174 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -84.39 -10.89 57.17 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 122.647 0.379 . . . . 0.0 111.83 178.913 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 32.3 m-80 -125.32 -56.29 1.53 Allowed 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -175.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -123.62 79.69 55.29 Favored Pre-proline 0 C--N 1.315 -0.932 0 CA-C-O 121.17 0.51 . . . . 0.0 110.479 -177.23 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -68.62 -6.96 19.07 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 123.129 2.552 . . . . 0.0 115.01 -175.155 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 7.3 ptmm? -103.69 18.67 21.41 Favored 'General case' 0 C--O 1.263 1.77 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 177.279 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 7.3 p -72.87 121.89 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.866 0 CA-C-O 122.726 1.251 . . . . 0.0 112.244 -177.343 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.439 ' HZ2' ' CG ' ' A' ' 26' ' ' ASP . 60.8 pttt -173.36 172.25 3.8 Favored 'General case' 0 N--CA 1.405 -2.717 0 N-CA-C 103.511 -2.774 . . . . 0.0 103.511 174.862 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -44.91 -51.3 9.84 Favored 'General case' 0 C--N 1.312 -1.057 0 O-C-N 124.803 1.315 . . . . 0.0 112.779 -174.326 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 17.1 m . . . . . 0 N--CA 1.478 0.974 0 C-N-CA 124.651 1.181 . . . . 0.0 110.539 179.41 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.8 mtt . . . . . 0 CA--C 1.507 -0.711 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.91 -36.68 84.07 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 107.816 -1.179 . . . . 0.0 107.816 172.06 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 19.1 ptt180 -92.09 -175.31 4.04 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 105.634 -1.988 . . . . 0.0 105.634 172.015 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . 0.431 2.6 p30 58.73 -105.35 0.25 Allowed 'General case' 0 N--CA 1.412 -2.328 0 N-CA-C 114.377 1.251 . . . . 0.0 114.377 174.733 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -109.38 119.34 39.17 Favored 'General case' 1 C--N 1.209 -5.524 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.628 -178.987 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.8 mppt? -101.01 151.42 37.62 Favored Pre-proline 0 C--N 1.303 -1.454 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 -174.117 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -59.13 121.85 10.6 Favored 'Trans proline' 0 C--O 1.235 0.328 0 C-N-CA 122.145 1.896 . . . . 0.0 110.278 174.613 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 111.43 -11.37 28.38 Favored Glycine 0 N--CA 1.43 -1.721 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.889 -177.963 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -79.13 162.41 25.83 Favored 'General case' 0 C--O 1.258 1.532 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 -177.873 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.425 HD21 ' HB2' ' A' ' 88' ' ' PRO . 99.0 mt -114.56 129.22 56.65 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 123.442 0.697 . . . . 0.0 109.127 -175.779 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.9 pp -142.75 -177.87 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 CA-C-O 121.856 0.836 . . . . 0.0 112.672 -172.566 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.487 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 66.0 m-85 -119.91 118.86 31.86 Favored 'General case' 0 C--N 1.289 -2.048 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 172.738 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.504 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -112.67 143.11 44.43 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.46 -173.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.617 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -119.74 123.53 43.97 Favored 'General case' 0 N--CA 1.4 -2.947 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.348 -178.206 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 71.2 mtm -113.77 158.53 20.84 Favored 'General case' 0 CA--C 1.5 -0.981 0 N-CA-C 108.52 -0.918 . . . . 0.0 108.52 175.315 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 29.1 tptp -69.61 124.07 22.99 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 120.41 -0.516 . . . . 0.0 109.828 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.97 -12.55 60.7 Favored Glycine 0 C--N 1.303 -1.303 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.086 -176.765 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 72.3 m-85 -117.99 148.87 44.37 Favored Pre-proline 0 N--CA 1.433 -1.315 0 C-N-CA 123.088 0.555 . . . . 0.0 110.501 179.602 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -79.52 171.84 15.27 Favored 'Trans proline' 0 N--CA 1.449 -1.104 0 C-N-CA 122.315 2.01 . . . . 0.0 108.483 170.896 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' HIS . . . . . 0.535 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 79.7 m80 -57.95 111.86 1.31 Allowed 'General case' 0 CA--C 1.537 0.472 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 175.21 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 10.2 t-105 -112.33 142.27 26.64 Favored Pre-proline 0 C--N 1.294 -1.807 0 C-N-CA 123.983 0.913 . . . . 0.0 108.872 -169.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -62.63 118.49 5.38 Favored 'Trans proline' 0 C--O 1.245 0.847 0 C-N-CA 122.326 2.018 . . . . 0.0 110.57 178.054 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.45 166.98 23.2 Favored 'General case' 0 N--CA 1.41 -2.46 0 CA-C-O 121.702 0.763 . . . . 0.0 111.481 -175.874 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.417 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 36.3 ttt85 -114.38 139.42 49.49 Favored 'General case' 0 C--N 1.276 -2.63 0 C-N-CA 124.255 1.022 . . . . 0.0 110.604 -177.358 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 50.3 t -82.19 110.15 17.06 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.991 0 N-CA-C 104.025 -2.583 . . . . 0.0 104.025 169.77 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -91.45 168.12 11.77 Favored 'General case' 0 C--N 1.274 -2.707 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.107 -169.387 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -102.16 138.17 39.46 Favored 'General case' 0 C--N 1.305 -1.361 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 177.509 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 47.4 t -71.03 125.07 91.97 Favored Pre-proline 0 C--N 1.316 -0.868 0 CA-C-N 115.526 -0.761 . . . . 0.0 111.002 -175.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -83.19 161.54 15.38 Favored 'Trans proline' 0 N--CA 1.431 -2.17 0 C-N-CA 122.023 1.815 . . . . 0.0 111.8 177.27 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -69.54 145.85 52.29 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 175.402 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.92 -34.15 5.93 Favored Glycine 0 C--N 1.291 -1.946 0 N-CA-C 108.57 -1.812 . . . . 0.0 108.57 -174.704 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -95.22 43.82 1.09 Allowed 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 177.901 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.7 m -64.8 15.68 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.218 0 C-N-CA 127.475 2.31 . . . . 0.0 115.617 -172.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.401 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 0.1 OUTLIER -64.1 135.45 96.32 Favored Pre-proline 0 C--N 1.292 -1.927 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 178.258 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 34' ' ' LYS . 14.8 Cg_exo -67.24 164.56 29.91 Favored 'Trans proline' 0 C--O 1.262 1.708 0 C-N-CA 122.235 1.956 . . . . 0.0 111.822 179.792 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_endo -55.48 128.22 29.51 Favored 'Trans proline' 0 C--N 1.36 1.149 0 C-N-CA 122.678 2.252 . . . . 0.0 111.391 -179.552 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 7.5 m -101.45 8.8 41.94 Favored 'General case' 0 C--N 1.291 -1.944 0 CA-C-N 114.927 -1.033 . . . . 0.0 109.605 -175.134 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 73.59 8.97 5.01 Favored 'General case' 0 N--CA 1.482 1.156 0 CA-C-O 123.726 1.727 . . . . 0.0 109.202 -173.841 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 84.1 mttt -124.37 163.04 22.57 Favored 'General case' 0 N--CA 1.417 -2.102 0 CA-C-N 113.296 -1.775 . . . . 0.0 108.832 177.349 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 72.8 mt -118.15 146.98 40.53 Favored Pre-proline 0 C--N 1.285 -2.2 0 O-C-N 124.364 1.04 . . . . 0.0 108.79 -178.89 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -72.95 123.3 8.8 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 C-N-CA 121.724 1.616 . . . . 0.0 109.524 175.382 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 48.7 mm -115.84 115.6 49.76 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.121 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.21 -175.809 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 74.3 t80 -95.63 115.95 28.16 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 178.58 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.425 ' HE1' ' HB3' ' A' ' 51' ' ' ALA . 74.2 m-85 -82.66 133.67 35.16 Favored 'General case' 0 C--N 1.293 -1.86 0 N-CA-C 112.686 0.625 . . . . 0.0 112.686 179.82 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.417 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 71.6 m-85 -84.21 151.0 25.1 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.641 179.523 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.538 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 78.14 -20.45 3.92 Favored Glycine 0 C--N 1.305 -1.188 0 C-N-CA 123.816 0.722 . . . . 0.0 114.109 178.835 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 32.0 p -119.07 -22.66 7.13 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 117.412 0.606 . . . . 0.0 109.939 175.085 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.8 m-70 66.43 22.49 10.71 Favored 'General case' 0 C--N 1.35 0.607 0 C-N-CA 123.667 0.787 . . . . 0.0 112.024 179.393 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -74.31 161.88 29.44 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 176.344 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.3 m -136.04 135.96 39.85 Favored 'General case' 0 C--N 1.278 -2.503 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 176.749 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ALA . . . . . 0.425 ' HB3' ' HE1' ' A' ' 44' ' ' PHE . . . -136.28 178.92 6.68 Favored 'General case' 0 C--N 1.277 -2.572 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.151 -177.046 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -133.49 109.65 9.42 Favored 'General case' 0 C--O 1.262 1.761 0 CA-C-N 115.326 -0.852 . . . . 0.0 108.713 175.066 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.504 HD12 ' HB1' ' A' ' 13' ' ' ALA . 64.8 mt -125.49 161.94 26.01 Favored 'General case' 0 C--N 1.29 -1.999 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 -178.612 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.53 169.58 35.95 Favored Glycine 0 N--CA 1.422 -2.25 0 C-N-CA 119.878 -1.153 . . . . 0.0 110.296 -179.451 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.85 -6.59 14.51 Favored 'Trans proline' 0 C--O 1.212 -0.818 0 C-N-CA 123.087 2.525 . . . . 0.0 112.223 -179.503 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 5.9 ptmm? -97.73 -2.06 42.07 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 115.358 -0.837 . . . . 0.0 111.768 178.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -116.13 6.37 13.96 Favored 'General case' 0 C--N 1.293 -1.875 0 CA-C-O 121.134 0.492 . . . . 0.0 112.158 -179.069 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 11.5 pt -130.55 152.42 37.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.599 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -139.28 147.47 53.1 Favored Pre-proline 0 C--N 1.303 -1.434 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -178.84 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -60.55 129.82 31.05 Favored 'Trans proline' 0 N--CA 1.481 0.786 0 C-N-CA 123.2 2.6 . . . . 0.0 112.919 -177.003 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.487 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 3.4 t80 -58.67 -34.28 71.06 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 113.819 1.044 . . . . 0.0 113.819 -177.526 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 30.4 t -60.62 -57.96 10.5 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 123.427 0.455 . . . . 0.0 111.226 -177.786 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 15.9 mp0 -75.72 -27.36 58.14 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-O 122.059 0.933 . . . . 0.0 110.988 -175.434 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 37.5 m-80 -95.54 5.09 52.42 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 113.484 0.92 . . . . 0.0 113.484 -176.023 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.444 ' HE2' ' CE1' ' A' ' 61' ' ' TYR . 17.6 ttmm -62.69 -39.09 92.9 Favored 'General case' 0 C--O 1.21 -1.024 0 CA-C-O 120.986 0.422 . . . . 0.0 111.295 177.55 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.465 ' HA ' ' HD3' ' A' ' 70' ' ' LYS . 38.8 mm-40 -80.91 -16.81 52.58 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-O 122.008 0.908 . . . . 0.0 112.205 177.901 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 19.3 mtpp -85.2 -56.7 3.41 Favored 'General case' 0 C--N 1.268 -2.941 0 CA-C-N 114.462 -1.244 . . . . 0.0 111.733 -178.575 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 35.1 m-85 -125.4 5.25 7.67 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.08 -174.023 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -99.98 25.41 28.38 Favored Glycine 0 C--N 1.304 -1.201 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 -178.416 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.465 ' HD3' ' HA ' ' A' ' 66' ' ' GLU . 27.7 mmmt -96.8 153.33 38.69 Favored Pre-proline 0 C--N 1.307 -1.281 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 -179.173 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -58.31 128.2 27.67 Favored 'Trans proline' 0 C--O 1.252 1.18 0 C-N-CA 121.981 1.787 . . . . 0.0 112.974 -179.517 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 16.2 m-80 -114.82 177.64 4.57 Favored 'General case' 0 CA--C 1.47 -2.113 0 CA-C-N 114.955 -1.02 . . . . 0.0 112.226 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.558 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 9.5 mptt -96.03 7.45 46.34 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 113.84 -1.527 . . . . 0.0 108.385 -178.37 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 11.1 mmt180 -88.27 122.79 32.2 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 175.177 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 10.2 tptp -77.04 144.38 38.65 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 177.278 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.538 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 95.13 -26.47 19.0 Favored Glycine 0 C--O 1.21 -1.367 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -173.873 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.466 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 27.0 t80 -76.61 -41.36 46.29 Favored 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 178.153 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 11.6 m120 -61.4 -49.22 77.77 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 177.886 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 6.1 mp0 -60.85 -40.73 94.0 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 113.711 -1.586 . . . . 0.0 110.352 179.309 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -67.54 -35.75 87.1 Favored Glycine 0 N--CA 1.44 -1.034 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.821 179.432 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.466 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 94.8 mt -61.92 -37.18 83.72 Favored 'General case' 0 C--O 1.218 -0.574 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 175.386 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 85.3 t90 -67.98 -48.34 66.06 Favored 'General case' 0 N--CA 1.427 -1.597 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.46 177.605 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -59.14 -46.7 87.67 Favored 'General case' 0 C--O 1.206 -1.196 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 179.719 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.402 HD11 ' HB3' ' A' ' 10' ' ' LEU . 19.0 tt -71.79 -27.83 28.95 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 C-N-CA 120.619 -0.432 . . . . 0.0 112.164 -174.842 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -89.57 -11.51 42.53 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 112.262 0.468 . . . . 0.0 112.262 -179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 32.4 m-80 -120.81 -57.55 1.88 Allowed 'General case' 0 N--CA 1.477 0.912 0 CA-C-O 121.16 0.505 . . . . 0.0 112.052 -176.813 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -128.59 73.64 80.63 Favored Pre-proline 0 C--N 1.308 -1.214 0 C-N-CA 120.418 -0.513 . . . . 0.0 110.305 -179.386 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.425 ' HB2' HD21 ' A' ' 10' ' ' LEU . 41.3 Cg_endo -70.13 -6.13 18.06 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 C-N-CA 123.178 2.585 . . . . 0.0 112.431 -176.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.9 pttp -106.52 21.69 17.04 Favored 'General case' 0 C--N 1.291 -1.969 0 CA-C-N 114.261 -1.336 . . . . 0.0 110.152 -179.651 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 8.4 p -61.51 81.32 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.55 0.952 0 CA-C-O 123.753 1.739 . . . . 0.0 113.802 -178.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 59.9 mtpt -155.87 -38.75 0.08 Allowed 'General case' 0 C--N 1.281 -2.398 0 N-CA-C 102.541 -3.133 . . . . 0.0 102.541 179.044 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -78.16 141.77 38.46 Favored 'General case' 0 N--CA 1.428 -1.549 0 CA-C-N 112.714 -2.039 . . . . 0.0 106.363 168.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 14.6 m . . . . . 0 C--N 1.303 -1.438 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -176.48 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.3 mtt . . . . . 0 CA--C 1.498 -1.057 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -129.71 80.91 1.99 Allowed 'General case' 0 N--CA 1.434 -1.262 0 N-CA-C 105.202 -2.147 . . . . 0.0 105.202 173.501 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -123.55 -175.06 3.11 Favored 'General case' 0 C--N 1.296 -1.757 0 CA-C-N 114.48 -1.236 . . . . 0.0 112.661 -173.232 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ASP . . . . . 0.417 ' OD1' ' HG3' ' A' ' 6' ' ' LYS . 15.3 t70 -96.95 152.82 18.34 Favored 'General case' 0 C--N 1.287 -2.123 0 CA-C-N 113.508 -1.678 . . . . 0.0 109.982 -173.568 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -134.65 122.76 22.71 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 109.138 -0.689 . . . . 0.0 109.138 -178.204 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.417 ' HG3' ' OD1' ' A' ' 4' ' ' ASP . 63.0 mttp -134.07 155.77 79.79 Favored Pre-proline 0 C--N 1.301 -1.538 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.298 179.587 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_exo -45.43 125.52 7.53 Favored 'Trans proline' 0 C--N 1.359 1.086 0 C-N-CA 123.554 2.836 . . . . 0.0 113.05 177.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 115.33 -25.44 9.82 Favored Glycine 0 N--CA 1.428 -1.837 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.871 -179.352 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -74.66 151.57 39.27 Favored 'General case' 0 C--O 1.257 1.466 0 CA-C-O 121.501 0.667 . . . . 0.0 111.564 -177.862 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.421 HD22 HG13 ' A' ' 84' ' ' ILE . 79.3 mt -103.38 124.38 48.58 Favored 'General case' 0 N--CA 1.424 -1.731 0 CA-C-N 114.707 -1.133 . . . . 0.0 110.134 -175.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 8.1 pt -137.11 -173.89 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.896 0 CA-C-O 122.752 1.263 . . . . 0.0 112.2 -173.344 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.448 ' CD1' ' HB2' ' A' ' 64' ' ' ASN . 22.0 m-85 -125.49 131.26 52.87 Favored 'General case' 0 N--CA 1.399 -2.99 0 N-CA-C 105.277 -2.12 . . . . 0.0 105.277 170.879 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.554 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -107.47 128.39 54.45 Favored 'General case' 0 C--N 1.265 -3.081 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.011 -174.027 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.593 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -120.02 117.85 29.09 Favored 'General case' 0 N--CA 1.389 -3.524 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 -179.03 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.477 ' HB2' ' HB2' ' A' ' 18' ' ' TYR . 82.1 mtp -97.08 158.39 15.46 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.053 -177.922 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.6 tttp -67.23 115.8 7.3 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 176.38 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.56 -18.53 55.05 Favored Glycine 0 N--CA 1.446 -0.681 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.429 179.729 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.477 ' HB2' ' HB2' ' A' ' 15' ' ' MET . 88.1 m-85 -119.96 143.86 36.24 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 117.117 0.459 . . . . 0.0 111.173 -177.744 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -68.85 170.95 14.31 Favored 'Trans proline' 0 CA--C 1.539 0.73 0 C-N-CA 123.115 2.543 . . . . 0.0 112.853 179.445 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' HIS . . . . . 0.543 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 77.3 m80 -60.86 122.16 14.17 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.97 179.64 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 15.1 t-105 -121.58 137.48 27.11 Favored Pre-proline 0 C--N 1.304 -1.401 0 N-CA-C 107.497 -1.298 . . . . 0.0 107.497 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -61.09 123.62 13.24 Favored 'Trans proline' 0 C--O 1.243 0.736 0 C-N-CA 122.426 2.084 . . . . 0.0 111.507 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.9 166.71 24.16 Favored 'General case' 0 N--CA 1.422 -1.864 0 CA-C-O 121.39 0.614 . . . . 0.0 111.806 -176.764 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 46.7 ttt85 -114.02 139.94 48.85 Favored 'General case' 0 C--N 1.296 -1.745 0 CA-C-N 115.307 -0.86 . . . . 0.0 109.762 178.76 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.5 t -85.98 115.53 27.45 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 104.678 -2.342 . . . . 0.0 104.678 169.801 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.416 ' O ' ' HG2' ' A' ' 41' ' ' PRO . 3.6 t70 -99.71 -178.0 3.74 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 119.356 -0.937 . . . . 0.0 110.533 -173.592 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.424 ' CD ' ' HZ1' ' A' ' 91' ' ' LYS . 1.7 mp0 -92.16 126.38 37.22 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-O 121.593 0.711 . . . . 0.0 112.017 -174.102 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.0 p -100.57 117.06 63.53 Favored Pre-proline 0 N--CA 1.426 -1.644 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 174.201 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -84.7 151.58 11.5 Favored 'Trans proline' 0 C--O 1.252 1.217 0 C-N-CA 122.541 2.16 . . . . 0.0 113.467 -178.27 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -59.2 122.4 13.74 Favored 'General case' 0 C--N 1.314 -0.963 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 172.793 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.446 ' C ' ' H ' ' A' ' 33' ' ' VAL . . . 110.72 -8.88 30.03 Favored Glycine 0 N--CA 1.431 -1.677 0 C-N-CA 119.803 -1.189 . . . . 0.0 112.267 -179.021 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -75.0 41.39 0.16 Allowed 'General case' 0 N--CA 1.489 1.48 0 CA-C-N 117.377 0.589 . . . . 0.0 111.91 176.203 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.446 ' H ' ' C ' ' A' ' 31' ' ' GLY 0.344 30.1 m 44.19 -41.82 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 C-N-CA 131.042 3.737 . . . . 0.0 118.958 -177.752 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 18.6 ptmt -86.1 138.35 34.78 Favored Pre-proline 0 C--N 1.288 -2.067 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -176.833 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -81.71 171.48 13.2 Favored 'Trans proline' 0 C--O 1.26 1.587 0 C-N-CA 122.325 2.017 . . . . 0.0 108.359 168.702 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_endo -56.89 126.81 23.44 Favored 'Trans proline' 0 N--CA 1.451 -0.991 0 C-N-CA 121.366 1.377 . . . . 0.0 109.796 177.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.3 m -104.63 8.48 35.27 Favored 'General case' 0 C--N 1.293 -1.882 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.212 -172.008 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 82.88 8.03 0.74 Allowed 'General case' 0 N--CA 1.506 2.35 0 C-N-CA 126.654 1.981 . . . . 0.0 107.654 -170.326 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.522 ' HA ' ' HA2' ' A' ' 54' ' ' GLY . 56.5 mttm -124.32 160.72 27.42 Favored 'General case' 0 N--CA 1.412 -2.333 0 CA-C-N 113.255 -1.793 . . . . 0.0 111.274 178.23 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 71.0 mt -122.05 157.03 59.03 Favored Pre-proline 0 C--N 1.279 -2.467 0 CA-C-N 113.615 -1.629 . . . . 0.0 108.491 -176.646 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.416 ' HG2' ' O ' ' A' ' 26' ' ' ASP . 47.5 Cg_endo -75.4 122.59 7.11 Favored 'Trans proline' 0 N--CA 1.456 -0.682 0 C-N-CA 121.796 1.664 . . . . 0.0 109.978 174.369 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.432 HG13 ' HB2' ' A' ' 53' ' ' LEU . 41.2 mm -116.8 122.72 70.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -175.73 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 86.0 t80 -103.45 116.05 31.67 Favored 'General case' 0 C--N 1.282 -2.347 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 178.627 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 -76.71 129.66 36.65 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-O 121.047 0.451 . . . . 0.0 112.022 179.448 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.473 ' HB3' ' HA2' ' A' ' 80' ' ' GLY . 60.3 m-85 -78.96 151.33 31.7 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.258 177.581 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.523 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 77.28 -19.7 3.59 Favored Glycine 0 C--O 1.254 1.38 0 N-CA-C 114.534 0.573 . . . . 0.0 114.534 177.008 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 46.4 p -119.23 -23.04 6.89 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 117.43 0.615 . . . . 0.0 110.248 174.708 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.0 m-70 68.76 21.68 7.67 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.975 0.91 . . . . 0.0 112.546 179.176 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -80.28 164.89 22.85 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.838 178.812 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 2.2 m -130.29 140.16 50.68 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.241 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -141.24 -179.72 6.28 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 123.641 0.776 . . . . 0.0 109.843 -178.358 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -133.19 112.32 11.62 Favored 'General case' 0 C--O 1.249 1.038 0 CA-C-O 121.605 0.717 . . . . 0.0 110.464 178.751 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.554 HD12 ' HB1' ' A' ' 13' ' ' ALA . 82.0 mt -135.84 147.4 48.24 Favored 'General case' 0 C--N 1.29 -1.993 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.522 ' HA2' ' HA ' ' A' ' 39' ' ' LYS . . . -94.77 177.23 35.54 Favored Glycine 0 CA--C 1.479 -2.169 0 C-N-CA 119.908 -1.139 . . . . 0.0 111.554 -177.196 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -62.25 -17.47 57.19 Favored 'Trans proline' 0 C--O 1.212 -0.821 0 C-N-CA 123.249 2.632 . . . . 0.0 112.096 -177.535 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.55 1.47 48.97 Favored 'General case' 0 N--CA 1.425 -1.708 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.964 178.111 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.538 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 71.9 m-20 -107.92 -16.25 14.35 Favored 'General case' 0 C--N 1.29 -2.021 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.209 176.863 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.438 HG12 ' O ' ' A' ' 54' ' ' GLY . 12.0 pt -117.55 157.28 18.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.057 -174.059 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -137.92 143.31 39.35 Favored Pre-proline 0 C--N 1.297 -1.711 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -69.29 148.44 68.13 Favored 'Trans proline' 0 C--O 1.245 0.873 0 C-N-CA 122.975 2.45 . . . . 0.0 114.934 -172.516 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 54.4 t80 -55.82 -34.71 65.6 Favored 'General case' 0 C--O 1.221 -0.434 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.078 177.002 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.1 m -52.86 -44.24 66.67 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.169 -0.923 . . . . 0.0 112.224 -179.028 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -93.3 -26.55 17.26 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 121.644 0.735 . . . . 0.0 111.497 -177.089 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.448 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 16.8 m120 -91.21 0.57 57.5 Favored 'General case' 0 C--O 1.203 -1.377 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -174.446 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.555 ' HZ3' ' CD ' ' A' ' 66' ' ' GLU . 4.5 ttpm? -65.95 -47.68 73.83 Favored 'General case' 0 C--N 1.29 -2.006 0 CA-C-O 121.446 0.641 . . . . 0.0 110.079 179.292 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.555 ' CD ' ' HZ3' ' A' ' 65' ' ' LYS . 12.1 mp0 -68.7 -36.34 78.35 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-O 122.331 1.062 . . . . 0.0 109.65 178.306 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 47.4 mtmt -79.16 -59.75 2.64 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 114.264 -1.335 . . . . 0.0 112.764 -174.34 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' TYR . . . . . 0.405 ' HD2' HD21 ' A' ' 64' ' ' ASN . 47.8 m-85 -121.73 4.43 10.04 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 112.394 0.516 . . . . 0.0 112.394 -172.23 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -82.35 34.11 2.69 Favored Glycine 0 CA--C 1.524 0.649 0 C-N-CA 121.28 -0.486 . . . . 0.0 113.211 -177.454 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 2.6 mppt? -122.92 144.37 42.85 Favored Pre-proline 0 N--CA 1.439 -1.017 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.318 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.48 ' HB3' ' OD1' ' A' ' 78' ' ' ASN . 82.8 Cg_exo -46.19 128.67 12.18 Favored 'Trans proline' 0 C--O 1.263 1.772 0 C-N-CA 123.984 3.123 . . . . 0.0 115.142 -176.248 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ASN . . . . . 0.52 ' HB2' ' CD1' ' A' ' 77' ' ' PHE . 1.7 t-20 -102.73 -166.96 1.33 Allowed 'General case' 0 C--N 1.269 -2.9 0 CA-C-N 114.516 -1.22 . . . . 0.0 109.356 -178.208 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.458 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 1.9 mptp? -120.61 18.39 12.0 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 178.332 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 37.1 mmt180 -102.75 132.46 48.89 Favored 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 114.343 -1.298 . . . . 0.0 109.269 176.543 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.8 tmtm? -68.37 127.66 33.76 Favored 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 175.477 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.523 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 107.17 -25.67 21.29 Favored Glycine 0 N--CA 1.416 -2.637 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.29 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.557 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 16.0 t80 -76.56 -45.4 30.69 Favored 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 -178.088 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.48 ' OD1' ' HB3' ' A' ' 71' ' ' PRO . 53.6 m-80 -71.61 -41.8 68.46 Favored 'General case' 0 CA--C 1.498 -1.045 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.45 -178.459 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -67.76 -33.64 75.23 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.18 179.487 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.473 ' HA2' ' HB3' ' A' ' 45' ' ' PHE . . . -70.97 -34.71 65.05 Favored Glycine 0 N--CA 1.43 -1.741 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.984 178.342 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.557 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 95.3 mt -61.97 -35.23 77.85 Favored 'General case' 0 C--O 1.215 -0.727 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 174.483 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 71.3 t90 -71.37 -48.78 47.89 Favored 'General case' 0 N--CA 1.431 -1.397 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.326 176.598 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -58.87 -40.53 84.64 Favored 'General case' 0 C--O 1.2 -1.537 0 N-CA-C 112.944 0.72 . . . . 0.0 112.944 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.421 HG13 HD22 ' A' ' 10' ' ' LEU . 19.0 tt -71.27 -21.36 21.8 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 CA-C-O 121.128 0.489 . . . . 0.0 110.795 -175.506 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -92.1 -43.78 9.18 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.066 -177.359 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -92.52 -44.27 8.72 Favored 'General case' 0 N--CA 1.481 1.115 0 CA-C-O 121.327 0.584 . . . . 0.0 112.182 -173.528 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.506 ' OD1' ' HG3' ' A' ' 89' ' ' LYS . 61.5 t30 -133.36 67.91 76.68 Favored Pre-proline 0 C--N 1.299 -1.614 0 C-N-CA 119.809 -0.756 . . . . 0.0 110.786 -178.698 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -68.09 -6.75 17.96 Favored 'Trans proline' 0 C--N 1.369 1.637 0 C-N-CA 123.193 2.595 . . . . 0.0 111.65 -178.227 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' LYS . . . . . 0.506 ' HG3' ' OD1' ' A' ' 87' ' ' ASN . 5.5 ptmm? -102.53 20.75 16.49 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-N 113.941 -1.481 . . . . 0.0 110.825 179.812 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 7.9 p -79.24 153.25 4.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 176.166 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.424 ' HZ1' ' CD ' ' A' ' 27' ' ' GLU . 68.0 mttm -138.23 -168.12 2.31 Favored 'General case' 0 C--O 1.251 1.14 0 CA-C-O 122.012 0.91 . . . . 0.0 111.502 -178.194 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 3.6 p90 -75.04 -167.55 0.62 Allowed 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 126.125 1.77 . . . . 0.0 111.012 176.444 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 4.9 m . . . . . 0 CA--C 1.546 0.82 0 C-N-CA 124.09 0.956 . . . . 0.0 113.492 -175.574 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.518 ' SD ' ' HD1' ' A' ' 59' ' ' PHE . 1.5 mpt? . . . . . 0 N--CA 1.494 1.73 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -95.23 70.88 3.24 Favored 'General case' 0 N--CA 1.433 -1.316 0 CA-C-O 121.925 0.869 . . . . 0.0 109.917 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ARG . . . . . 0.478 HH21 ' HB3' ' A' ' 60' ' ' PRO . 18.4 ptt85 -130.09 178.85 6.24 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 173.288 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -89.74 145.33 25.27 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 175.643 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' PHE . . . . . 0.45 ' HB3' HG21 ' A' ' 25' ' ' VAL . 67.6 m-85 -115.67 122.12 44.6 Favored 'General case' 0 C--N 1.283 -2.296 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 -179.418 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.419 ' O ' ' HB2' ' A' ' 9' ' ' ASP . 48.4 mttm -96.35 144.3 27.61 Favored Pre-proline 0 C--N 1.294 -1.831 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.918 -170.364 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -58.0 116.02 2.94 Favored 'Trans proline' 0 N--CA 1.462 -0.369 0 C-N-CA 121.731 1.621 . . . . 0.0 110.002 175.133 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 109.52 -7.4 32.04 Favored Glycine 0 N--CA 1.433 -1.543 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.335 -176.817 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASP . . . . . 0.419 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 5.2 t70 -69.57 152.57 44.62 Favored 'General case' 0 C--O 1.251 1.175 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -177.86 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.4 mt -104.91 120.91 42.57 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 121.375 0.607 . . . . 0.0 109.85 -175.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.0 pt -140.45 -175.49 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.416 -2.165 0 CA-C-O 122.25 1.024 . . . . 0.0 112.024 -174.734 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.485 ' HD2' ' ND2' ' A' ' 64' ' ' ASN . 56.1 m-85 -124.62 128.95 49.65 Favored 'General case' 0 N--CA 1.409 -2.497 0 N-CA-C 105.64 -1.985 . . . . 0.0 105.64 171.068 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.497 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -117.02 141.41 48.29 Favored 'General case' 0 C--N 1.278 -2.513 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.798 -176.62 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.626 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -123.24 124.46 43.07 Favored 'General case' 0 N--CA 1.405 -2.72 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.693 -177.437 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.496 ' HG2' HD21 ' A' ' 53' ' ' LEU . 44.6 mtm -115.87 158.2 23.32 Favored 'General case' 0 CA--C 1.499 -1.017 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 175.574 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.3 tttp -65.45 116.91 7.23 Favored 'General case' 0 C--N 1.311 -1.095 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 178.305 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.33 -12.38 58.49 Favored Glycine 0 C--O 1.247 0.93 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -178.058 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 7.8 m-85 -110.59 149.46 40.32 Favored Pre-proline 0 C--N 1.307 -1.279 0 C-N-CA 123.196 0.598 . . . . 0.0 109.872 178.528 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -81.41 171.45 13.61 Favored 'Trans proline' 0 N--CA 1.442 -1.512 0 C-N-CA 122.118 1.879 . . . . 0.0 108.173 171.323 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' HIS . . . . . 0.474 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 80.8 m80 -64.46 111.28 2.61 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 174.829 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 9.6 t-105 -110.85 141.03 23.29 Favored Pre-proline 0 C--N 1.292 -1.925 0 C-N-CA 123.585 0.754 . . . . 0.0 109.12 -170.001 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -64.49 118.2 5.19 Favored 'Trans proline' 0 C--O 1.245 0.845 0 C-N-CA 122.147 1.898 . . . . 0.0 110.359 177.68 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -139.92 166.51 24.44 Favored 'General case' 0 N--CA 1.408 -2.526 0 CA-C-O 121.118 0.485 . . . . 0.0 110.311 -175.537 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.494 ' HD3' ' O ' ' A' ' 88' ' ' PRO . 10.7 ttp180 -115.3 145.35 42.56 Favored 'General case' 0 C--N 1.285 -2.237 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.135 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.45 HG21 ' HB3' ' A' ' 5' ' ' PHE . 52.4 t -74.63 119.91 23.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 104.728 -2.323 . . . . 0.0 104.728 170.099 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.442 ' HB3' ' HB2' ' A' ' 41' ' ' PRO . 4.1 t70 -84.78 179.0 7.43 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -172.219 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -106.0 150.36 25.79 Favored 'General case' 0 N--CA 1.429 -1.507 0 C-N-CA 119.278 -0.969 . . . . 0.0 111.72 -175.276 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 47.8 t -69.36 119.38 70.14 Favored Pre-proline 0 CA--C 1.505 -0.775 0 CA-C-N 115.448 -0.796 . . . . 0.0 108.902 178.491 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -75.6 143.62 27.44 Favored 'Trans proline' 0 N--CA 1.423 -2.649 0 C-N-CA 121.805 1.67 . . . . 0.0 113.215 -177.756 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -61.84 136.38 57.96 Favored 'General case' 0 C--O 1.259 1.56 0 N-CA-C 107.065 -1.457 . . . . 0.0 107.065 171.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.21 -13.05 55.4 Favored Glycine 0 N--CA 1.43 -1.718 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -175.283 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -82.79 84.96 7.17 Favored 'General case' 0 C--O 1.207 -1.178 0 CA-C-O 121.809 0.814 . . . . 0.0 110.542 175.112 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.4 m -99.96 8.3 8.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 114.33 -1.304 . . . . 0.0 109.217 176.526 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 9.4 mptt -81.69 139.43 47.2 Favored Pre-proline 0 N--CA 1.426 -1.635 0 CA-C-N 114.191 -1.368 . . . . 0.0 108.542 -179.572 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -62.57 147.28 95.04 Favored 'Trans proline' 0 C--O 1.244 0.789 0 C-N-CA 122.246 1.964 . . . . 0.0 112.103 179.654 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -62.98 128.76 23.86 Favored 'Trans proline' 0 N--CA 1.451 -0.975 0 C-N-CA 122.405 2.07 . . . . 0.0 111.697 -178.523 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' THR . . . . . 0.437 HG22 ' O ' ' A' ' 37' ' ' THR . 4.2 m -78.66 9.51 4.04 Favored 'General case' 0 C--N 1.301 -1.515 0 C-N-CA 123.885 0.874 . . . . 0.0 112.241 -177.037 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 5.0 p30 80.91 9.94 1.02 Allowed 'General case' 0 N--CA 1.499 2.006 0 C-N-CA 125.784 1.633 . . . . 0.0 110.691 -178.401 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 62.1 mttp -125.3 164.9 19.36 Favored 'General case' 0 C--N 1.293 -1.866 0 CA-C-N 113.367 -1.742 . . . . 0.0 111.12 -179.331 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 88.8 mt -116.99 147.17 39.57 Favored Pre-proline 0 C--N 1.287 -2.151 0 CA-C-N 114.33 -1.304 . . . . 0.0 109.246 -178.07 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' PRO . . . . . 0.442 ' HB2' ' HB3' ' A' ' 26' ' ' ASP . 68.9 Cg_endo -73.06 123.86 9.16 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 122.33 2.02 . . . . 0.0 110.523 177.565 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.412 HG21 ' CB ' ' A' ' 13' ' ' ALA . 43.4 mm -120.86 127.56 75.95 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 -176.753 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.655 ' CZ ' ' HA ' ' A' ' 91' ' ' LYS . 87.7 t80 -107.14 120.69 42.8 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 178.846 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 -86.66 131.7 34.08 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-O 121.254 0.55 . . . . 0.0 112.247 179.028 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.494 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 67.6 m-85 -85.83 158.44 19.97 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.694 179.326 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.533 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 75.31 -20.32 2.1 Favored Glycine 0 C--O 1.248 1.015 0 C-N-CA 123.526 0.584 . . . . 0.0 114.538 179.139 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 18.3 p -119.38 -23.04 6.81 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 122.305 -0.527 . . . . 0.0 109.73 173.005 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' HIS . . . . . 0.441 ' HA ' ' CZ ' ' A' ' 43' ' ' PHE . 11.5 m-70 67.67 26.18 7.98 Favored 'General case' 0 C--N 1.348 0.507 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.818 179.507 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -79.4 161.89 25.87 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.698 -0.852 . . . . 0.0 108.698 177.373 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 6.9 m -136.12 140.43 43.68 Favored 'General case' 0 C--N 1.284 -2.25 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 176.794 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -142.74 179.35 7.05 Favored 'General case' 0 C--N 1.287 -2.124 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.289 -175.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.409 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 84.8 m-85 -134.0 115.07 13.91 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.305 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.497 HD12 ' HB1' ' A' ' 13' ' ' ALA . 87.4 mt -129.44 166.49 19.49 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 -177.67 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -93.03 167.7 29.49 Favored Glycine 0 N--CA 1.423 -2.18 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -67.03 -6.89 17.11 Favored 'Trans proline' 0 N--CA 1.481 0.747 0 C-N-CA 123.303 2.669 . . . . 0.0 112.828 -176.983 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 20.8 pttp -93.05 -18.17 22.97 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.366 178.8 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.2 m-20 -99.98 1.25 42.41 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.188 -175.226 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.3 pt -125.94 145.84 32.71 Favored 'Isoleucine or valine' 0 C--O 1.258 1.551 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.754 179.359 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.518 ' HD1' ' SD ' ' A' ' 1' ' ' MET . 83.0 m-85 -136.32 144.82 49.3 Favored Pre-proline 0 C--N 1.288 -2.087 0 CA-C-N 114.823 -1.081 . . . . 0.0 108.554 -177.131 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.478 ' HB3' HH21 ' A' ' 3' ' ' ARG . 35.0 Cg_endo -68.34 127.82 16.37 Favored 'Trans proline' 0 N--CA 1.483 0.857 0 C-N-CA 122.746 2.298 . . . . 0.0 113.956 -179.121 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -51.97 -39.34 59.17 Favored 'General case' 0 C--O 1.217 -0.626 0 C-N-CA 123.87 0.868 . . . . 0.0 111.043 -179.536 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.5 m -57.28 -40.33 77.54 Favored 'General case' 0 C--N 1.307 -1.27 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.185 -178.072 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -95.75 -19.19 19.85 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.278 0.561 . . . . 0.0 112.21 -172.792 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.485 ' ND2' ' HD2' ' A' ' 12' ' ' PHE . 0.7 OUTLIER -124.19 26.88 7.29 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 114.703 1.371 . . . . 0.0 114.703 -178.214 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.43 ' HZ3' ' CD ' ' A' ' 66' ' ' GLU . 17.0 pttm -70.1 -30.91 68.24 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 174.698 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.43 ' CD ' ' HZ3' ' A' ' 65' ' ' LYS . 19.8 mp0 -65.25 -39.06 92.17 Favored 'General case' 0 C--O 1.251 1.151 0 CA-C-O 122.557 1.17 . . . . 0.0 108.617 175.091 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.443 ' HB3' ' HE2' ' A' ' 67' ' ' LYS . 35.8 mtpt -76.44 -59.96 2.55 Favored 'General case' 0 N--CA 1.427 -1.618 0 CA-C-N 113.918 -1.492 . . . . 0.0 112.029 -175.07 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 21.0 m-85 -107.67 -9.75 15.78 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.482 -0.781 . . . . 0.0 112.428 -168.297 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -82.3 41.55 2.8 Favored Glycine 0 C--O 1.22 -0.726 0 C-N-CA 121.245 -0.503 . . . . 0.0 113.21 -176.826 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 38.4 mtmm -122.96 124.95 26.44 Favored Pre-proline 0 C--N 1.308 -1.202 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 177.773 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -56.96 127.17 24.72 Favored 'Trans proline' 0 C--O 1.251 1.167 0 C-N-CA 122.23 1.954 . . . . 0.0 114.686 -172.239 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 4.8 m-20 -84.76 -170.46 3.13 Favored 'General case' 0 CA--C 1.484 -1.594 0 CA-C-N 113.875 -1.511 . . . . 0.0 108.304 176.608 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 40.0 mmtm -111.46 22.0 15.57 Favored 'General case' 0 C--N 1.285 -2.201 0 CA-C-O 122.592 1.187 . . . . 0.0 107.821 173.88 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -87.06 127.89 35.11 Favored 'General case' 0 C--O 1.251 1.162 0 CA-C-N 113.548 -1.66 . . . . 0.0 107.547 173.279 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -65.29 134.79 54.38 Favored 'General case' 0 N--CA 1.439 -0.997 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 176.47 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.533 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 100.2 -25.73 27.18 Favored Glycine 0 N--CA 1.42 -2.374 0 C-N-CA 121.405 -0.426 . . . . 0.0 112.363 -178.242 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.405 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 23.2 t80 -73.36 -42.61 62.0 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 -177.709 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -72.87 -41.37 64.79 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 -177.323 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 16.3 mt-10 -65.06 -39.89 93.91 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 114.411 -1.268 . . . . 0.0 109.857 178.464 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -68.63 -32.29 74.47 Favored Glycine 0 CA--C 1.499 -0.936 0 CA-C-N 115.741 -0.663 . . . . 0.0 112.636 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.405 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 90.8 mt -62.9 -32.86 74.22 Favored 'General case' 0 C--O 1.214 -0.798 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 174.764 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 73.6 t90 -73.48 -48.27 34.72 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.382 176.541 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -58.3 -41.32 84.19 Favored 'General case' 0 C--O 1.203 -1.384 0 N-CA-C 112.87 0.693 . . . . 0.0 112.87 179.669 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.3 tt -71.29 -21.24 21.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-O 121.145 0.497 . . . . 0.0 110.619 -175.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -90.36 -42.42 10.95 Favored 'General case' 0 N--CA 1.437 -1.112 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.108 -177.196 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.7 m-20 -92.22 -50.16 5.81 Favored 'General case' 0 CA--C 1.494 -1.188 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.136 -174.154 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 64.6 t30 -132.72 75.9 72.17 Favored Pre-proline 0 C--N 1.303 -1.442 0 C-N-CA 119.725 -0.79 . . . . 0.0 110.152 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.494 ' O ' ' HD3' ' A' ' 24' ' ' ARG . 42.5 Cg_endo -68.52 -6.51 17.86 Favored 'Trans proline' 0 N--CA 1.477 0.542 0 C-N-CA 122.795 2.33 . . . . 0.0 114.143 -174.211 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 61.5 pttt -102.96 15.94 28.02 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-O 120.85 0.357 . . . . 0.0 110.182 -179.053 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 9.8 p -82.92 148.63 5.02 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-O 121.473 0.654 . . . . 0.0 111.376 -176.879 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.655 ' HA ' ' CZ ' ' A' ' 43' ' ' PHE . 16.2 ptpt -151.0 -175.33 5.1 Favored 'General case' 0 N--CA 1.424 -1.74 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 173.522 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 79.2 t80 -75.91 -44.19 41.5 Favored 'General case' 0 C--N 1.321 -0.67 0 C-N-CA 119.513 -0.875 . . . . 0.0 111.221 -178.299 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' SER . . . . . 0.479 ' O ' ' HG3' ' A' ' 91' ' ' LYS . 33.2 p . . . . . 0 N--CA 1.422 -1.849 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 178.897 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 92.9 mtp . . . . . 0 CA--C 1.492 -1.283 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -129.85 82.04 2.05 Favored 'General case' 0 N--CA 1.421 -1.909 0 N-CA-C 103.901 -2.629 . . . . 0.0 103.901 172.302 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 11.6 ptp180 -105.7 162.55 13.43 Favored 'General case' 0 C--N 1.294 -1.81 0 CA-C-N 114.597 -1.183 . . . . 0.0 111.51 -174.046 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 9.6 p-10 -95.09 -174.0 3.11 Favored 'General case' 0 C--N 1.28 -2.415 0 C-N-CA 126.107 1.763 . . . . 0.0 108.86 175.241 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 76.4 m-85 -118.94 112.99 20.31 Favored 'General case' 0 N--CA 1.427 -1.575 0 CA-C-O 120.958 0.408 . . . . 0.0 109.987 -177.915 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.403 ' O ' ' HB ' ' A' ' 25' ' ' VAL . 29.6 mttp -110.27 153.53 43.31 Favored Pre-proline 0 C--N 1.307 -1.281 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 -177.405 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -62.15 115.4 2.82 Favored 'Trans proline' 0 N--CA 1.448 -1.193 0 N-CA-C 107.08 -1.931 . . . . 0.0 107.08 169.02 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 114.93 -19.05 15.94 Favored Glycine 0 N--CA 1.424 -2.152 0 C-N-CA 120.411 -0.899 . . . . 0.0 112.391 -174.835 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -78.45 152.19 32.26 Favored 'General case' 0 C--O 1.253 1.268 0 CA-C-N 117.397 0.599 . . . . 0.0 109.446 -177.065 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.403 HD22 HG13 ' A' ' 84' ' ' ILE . 82.5 mt -98.03 127.32 43.91 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 122.917 0.487 . . . . 0.0 111.211 -171.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.458 HG22 ' HA ' ' A' ' 60' ' ' PRO . 2.8 pp -140.08 -178.78 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.046 0 CA-C-O 121.956 0.884 . . . . 0.0 112.555 -174.718 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.43 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 69.0 m-85 -120.98 125.4 47.26 Favored 'General case' 0 C--N 1.291 -1.971 0 N-CA-C 105.429 -2.063 . . . . 0.0 105.429 172.47 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.487 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -111.22 146.35 37.08 Favored 'General case' 0 C--N 1.277 -2.545 0 O-C-N 123.531 0.519 . . . . 0.0 111.035 -174.54 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.481 ' HD3' ' C ' ' A' ' 14' ' ' LYS . 7.5 tmtm? -117.9 117.66 29.87 Favored 'General case' 0 N--CA 1.419 -1.998 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.707 -177.746 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.447 ' HB2' ' HB2' ' A' ' 18' ' ' TYR . 70.1 mtm -112.28 159.38 18.69 Favored 'General case' 0 C--O 1.248 0.999 0 CA-C-O 120.962 0.41 . . . . 0.0 111.364 173.384 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 26.2 ttpp -67.71 116.82 8.83 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 176.025 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.52 -4.91 64.43 Favored Glycine 0 C--O 1.239 0.432 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -176.305 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.447 ' HB2' ' HB2' ' A' ' 15' ' ' MET . 35.3 m-85 -118.13 145.39 36.85 Favored Pre-proline 0 C--O 1.254 1.335 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 179.325 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -79.79 171.93 14.86 Favored 'Trans proline' 0 N--CA 1.445 -1.324 0 C-N-CA 123.16 2.573 . . . . 0.0 108.281 170.093 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 93.2 m-70 -63.93 111.51 2.52 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 177.063 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 10.2 t-105 -110.18 140.51 22.47 Favored Pre-proline 0 C--N 1.295 -1.767 0 CA-C-N 114.866 -1.061 . . . . 0.0 109.369 -170.188 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -65.85 118.15 5.24 Favored 'Trans proline' 0 C--O 1.243 0.744 0 C-N-CA 122.008 1.805 . . . . 0.0 110.184 177.233 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -145.94 167.19 23.91 Favored 'General case' 0 N--CA 1.413 -2.307 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 -175.632 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.606 ' HD3' ' O ' ' A' ' 88' ' ' PRO . 10.0 ttp180 -122.29 149.06 44.25 Favored 'General case' 0 C--N 1.272 -2.782 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.403 ' HB ' ' O ' ' A' ' 6' ' ' LYS . 51.5 t -72.34 121.07 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 104.647 -2.353 . . . . 0.0 104.647 169.135 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -84.0 172.44 12.03 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 -170.656 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -105.48 127.11 52.83 Favored 'General case' 0 N--CA 1.431 -1.386 0 CA-C-O 121.506 0.669 . . . . 0.0 111.772 -176.872 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 62.1 t -77.06 127.89 82.48 Favored Pre-proline 0 C--N 1.315 -0.904 0 CA-C-N 114.585 -1.189 . . . . 0.0 110.502 -176.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -72.8 151.77 51.79 Favored 'Trans proline' 0 N--CA 1.433 -2.037 0 C-N-CA 121.7 1.6 . . . . 0.0 112.767 178.201 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -71.03 151.49 44.53 Favored 'General case' 0 C--N 1.31 -1.116 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 172.869 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 88.04 -7.08 82.49 Favored Glycine 0 N--CA 1.425 -2.097 0 C-N-CA 120.533 -0.841 . . . . 0.0 111.083 -175.932 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.41 80.44 3.14 Favored 'General case' 0 C--O 1.207 -1.165 0 CA-C-O 122.037 0.922 . . . . 0.0 110.985 173.845 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.3 m -98.55 8.74 7.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 CA-C-N 114.246 -1.343 . . . . 0.0 109.504 176.854 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 9.6 mptt -79.26 140.36 56.69 Favored Pre-proline 0 C--N 1.3 -1.568 0 CA-C-N 114.1 -1.409 . . . . 0.0 107.723 179.621 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.443 ' HA ' ' HD3' ' A' ' 36' ' ' PRO . 29.4 Cg_endo -63.53 133.49 40.09 Favored 'Trans proline' 0 CA--C 1.537 0.651 0 C-N-CA 121.775 1.65 . . . . 0.0 112.458 -177.628 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 35' ' ' PRO . 86.4 Cg_endo -90.77 171.64 3.33 Favored 'Trans proline' 0 N--CA 1.437 -1.799 0 C-N-CA 122.533 2.156 . . . . 0.0 111.836 179.086 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 5.5 m -77.1 7.39 5.06 Favored 'General case' 0 CA--C 1.561 1.384 0 C-N-CA 123.4 0.68 . . . . 0.0 110.568 178.841 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 41.8 m-80 69.72 19.61 7.18 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 124.804 1.241 . . . . 0.0 110.777 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.462 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 88.6 mttt -129.35 177.01 7.49 Favored 'General case' 0 N--CA 1.431 -1.407 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.179 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 66.6 mt -84.16 140.8 39.71 Favored Pre-proline 0 C--N 1.314 -0.97 0 O-C-N 123.609 0.568 . . . . 0.0 109.574 -177.488 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -72.74 123.93 9.36 Favored 'Trans proline' 0 C--O 1.222 -0.276 0 C-N-CA 122.395 2.064 . . . . 0.0 110.186 178.767 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 47.6 mm -120.85 123.43 70.2 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 0 O-C-N 121.924 -0.485 . . . . 0.0 110.401 -176.495 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.477 ' CZ ' ' HA ' ' A' ' 91' ' ' LYS . 77.4 t80 -106.09 119.13 38.4 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 177.889 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.415 ' CE2' ' HB3' ' A' ' 13' ' ' ALA . 80.4 m-85 -83.39 131.91 35.02 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-O 121.314 0.578 . . . . 0.0 112.141 179.591 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.433 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 46.1 m-85 -85.01 154.5 22.07 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.406 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.556 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 73.44 -21.16 1.17 Allowed Glycine 0 C--N 1.308 -0.981 0 C-N-CA 124.184 0.897 . . . . 0.0 114.977 179.679 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.4 p -115.98 -22.92 8.78 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 117.942 0.871 . . . . 0.0 109.668 173.409 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' HIS . . . . . 0.441 ' HE2' ' CD ' ' A' ' 83' ' ' GLU . 55.9 m170 69.73 23.17 5.83 Favored 'General case' 0 CA--C 1.518 -0.285 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.595 176.319 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -76.51 160.79 29.17 Favored 'General case' 0 N--CA 1.443 -0.785 0 CA-C-N 115.261 -0.881 . . . . 0.0 108.745 177.035 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.2 m -136.3 138.31 41.6 Favored 'General case' 0 C--N 1.279 -2.473 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.093 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -140.2 -179.62 6.09 Favored 'General case' 0 C--N 1.282 -2.343 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.0 -177.267 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -133.03 111.21 10.8 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 175.599 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.546 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 87.2 mt -129.25 150.9 50.43 Favored 'General case' 0 C--N 1.288 -2.094 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.293 -176.227 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.462 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -85.17 172.84 47.87 Favored Glycine 0 N--CA 1.424 -2.156 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 -176.54 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -65.04 -16.65 56.35 Favored 'Trans proline' 0 C--O 1.208 -0.992 0 C-N-CA 122.266 1.977 . . . . 0.0 112.407 -177.478 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.75 -1.14 44.04 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-O 121.301 0.572 . . . . 0.0 112.197 177.205 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.546 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 69.4 m-20 -104.22 -4.83 22.54 Favored 'General case' 0 C--N 1.295 -1.791 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 179.513 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.7 pt -128.2 156.58 40.41 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.707 0 CA-C-N 114.898 -1.046 . . . . 0.0 109.1 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' PHE . . . . . 0.425 ' HB3' ' ND2' ' A' ' 64' ' ' ASN . 88.6 m-85 -136.72 136.76 22.08 Favored Pre-proline 0 C--N 1.287 -2.115 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 -179.625 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' PRO . . . . . 0.485 ' HG2' ' HB2' ' A' ' 63' ' ' GLU . 20.5 Cg_endo -64.43 132.92 35.19 Favored 'Trans proline' 0 C--N 1.318 -1.079 0 C-N-CA 122.273 1.982 . . . . 0.0 112.416 -177.621 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.43 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 60.7 t80 -58.63 -39.76 81.41 Favored 'General case' 0 C--O 1.206 -1.214 0 C-N-CA 123.695 0.798 . . . . 0.0 110.839 -178.331 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 29.5 t -62.06 -36.09 80.58 Favored 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.484 -176.009 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.485 ' HB2' ' HG2' ' A' ' 60' ' ' PRO . 1.3 mp0 -95.05 -18.0 21.39 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 113.172 0.805 . . . . 0.0 113.172 -175.2 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.425 ' ND2' ' HB3' ' A' ' 59' ' ' PHE . 37.3 m-80 -123.55 16.07 9.6 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 112.778 0.658 . . . . 0.0 112.778 -175.814 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.499 ' HG2' ' OE2' ' A' ' 66' ' ' GLU . 21.4 pttm -66.8 -32.19 73.3 Favored 'General case' 0 N--CA 1.484 1.268 0 CA-C-O 121.273 0.559 . . . . 0.0 110.703 -178.062 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.561 ' H ' ' CD ' ' A' ' 66' ' ' GLU . 2.7 mp0 -70.36 -25.39 63.25 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 -179.537 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 43.6 mttp -91.05 -59.66 2.11 Favored 'General case' 0 N--CA 1.422 -1.826 0 CA-C-N 114.271 -1.331 . . . . 0.0 111.297 -171.01 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 56.1 m-85 -105.76 -0.62 25.24 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.806 -172.254 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.9 56.43 4.81 Favored Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.74 179.292 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -128.61 128.53 23.54 Favored Pre-proline 0 C--N 1.317 -0.845 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.806 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_exo -54.57 137.9 74.01 Favored 'Trans proline' 0 C--N 1.349 0.575 0 C-N-CA 122.969 2.446 . . . . 0.0 112.169 177.928 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 15.9 m-80 -116.04 -179.34 3.63 Favored 'General case' 0 CA--C 1.472 -2.049 0 N-CA-C 113.845 1.054 . . . . 0.0 113.845 -178.633 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' LYS . . . . . 0.451 ' HD3' ' N ' ' A' ' 73' ' ' LYS . 2.8 mppt? -93.27 1.9 56.83 Favored 'General case' 0 N--CA 1.429 -1.494 0 CA-C-N 112.921 -1.945 . . . . 0.0 108.247 -178.516 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 5.6 mmt180 -84.54 116.34 23.08 Favored 'General case' 0 N--CA 1.426 -1.645 0 CA-C-N 114.889 -1.051 . . . . 0.0 109.783 176.43 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.433 ' HD3' ' N ' ' A' ' 76' ' ' GLY . 8.7 tmtt? -56.5 125.92 24.22 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 175.632 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.556 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.03 -25.44 20.42 Favored Glycine 0 N--CA 1.434 -1.451 0 C-N-CA 121.222 -0.514 . . . . 0.0 112.081 -179.363 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.421 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 14.1 t80 -70.29 -40.28 74.39 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 122.068 0.937 . . . . 0.0 108.738 -176.905 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -68.47 -43.64 76.55 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 114.198 -1.364 . . . . 0.0 108.986 -176.808 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -68.49 -35.57 77.72 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 114.39 -1.277 . . . . 0.0 109.964 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' GLY . . . . . 0.402 ' HA2' ' HB3' ' A' ' 45' ' ' PHE . . . -68.45 -33.66 77.65 Favored Glycine 0 N--CA 1.438 -1.186 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.24 177.8 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.421 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 95.4 mt -62.76 -33.83 75.98 Favored 'General case' 0 C--O 1.213 -0.818 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 174.596 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 72.8 t90 -71.92 -49.54 36.84 Favored 'General case' 0 N--CA 1.441 -0.901 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.778 176.336 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.441 ' CD ' ' HE2' ' A' ' 48' ' ' HIS . 46.7 mt-10 -58.25 -40.35 81.53 Favored 'General case' 0 C--O 1.204 -1.335 0 N-CA-C 112.895 0.702 . . . . 0.0 112.895 179.503 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.403 HG13 HD22 ' A' ' 10' ' ' LEU . 18.0 tt -71.18 -21.21 21.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.179 0.514 . . . . 0.0 110.583 -176.571 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -89.03 -42.9 11.48 Favored 'General case' 0 N--CA 1.439 -1.011 0 CA-C-N 115.47 -0.787 . . . . 0.0 110.019 -177.856 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -89.49 -48.66 7.17 Favored 'General case' 0 CA--C 1.493 -1.225 0 CA-C-N 115.92 -0.582 . . . . 0.0 112.077 -174.295 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -132.29 76.87 71.84 Favored Pre-proline 0 C--N 1.302 -1.481 0 C-N-CA 120.17 -0.612 . . . . 0.0 109.761 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.606 ' O ' ' HD3' ' A' ' 24' ' ' ARG . 28.8 Cg_endo -62.97 -16.96 57.61 Favored 'Trans proline' 0 C--O 1.218 -0.515 0 C-N-CA 122.808 2.339 . . . . 0.0 115.719 -171.399 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' LYS . . . . . 0.42 ' HA ' ' HD3' ' A' ' 24' ' ' ARG . 8.5 ptmm? -106.58 20.64 18.71 Favored 'General case' 0 C--O 1.259 1.573 0 C-N-CA 119.317 -0.953 . . . . 0.0 111.323 -179.213 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 9.0 p -70.06 146.4 12.33 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-O 122.168 0.985 . . . . 0.0 113.283 -174.917 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.477 ' HA ' ' CZ ' ' A' ' 43' ' ' PHE . 0.2 OUTLIER -145.39 146.23 31.47 Favored 'General case' 0 N--CA 1.417 -2.113 0 N-CA-C 104.422 -2.436 . . . . 0.0 104.422 169.661 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 54.2 t80 -75.78 106.07 7.15 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.817 -0.753 . . . . 0.0 110.107 -175.259 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 14.0 m . . . . . 0 C--N 1.29 -2.015 0 CA-C-N 114.404 -1.271 . . . . 0.0 109.975 -177.505 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.4 mmt . . . . . 0 CA--C 1.487 -1.442 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -120.92 77.99 1.35 Allowed 'General case' 0 N--CA 1.426 -1.633 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 176.677 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 31.4 ptt-85 -117.75 171.88 7.74 Favored 'General case' 0 C--N 1.296 -1.727 0 CA-C-N 114.583 -1.19 . . . . 0.0 109.004 179.296 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ASP . . . . . 0.406 ' OD1' ' HD2' ' A' ' 6' ' ' LYS . 12.0 p-10 -91.93 -179.4 5.29 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 177.075 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -111.13 101.34 9.87 Favored 'General case' 0 N--CA 1.427 -1.618 0 CA-C-O 121.452 0.644 . . . . 0.0 110.152 -176.825 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.406 ' HD2' ' OD1' ' A' ' 4' ' ' ASP . 0.1 OUTLIER -94.36 145.98 30.7 Favored Pre-proline 0 C--N 1.304 -1.39 0 CA-C-N 114.913 -1.039 . . . . 0.0 109.326 -177.079 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -53.28 122.23 10.83 Favored 'Trans proline' 0 C--O 1.238 0.523 0 C-N-CA 122.336 2.024 . . . . 0.0 109.579 172.118 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 109.58 -9.91 32.72 Favored Glycine 0 N--CA 1.427 -1.904 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.051 -177.258 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -79.9 153.51 28.96 Favored 'General case' 0 C--O 1.251 1.166 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -179.297 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.0 mt -105.64 126.39 52.09 Favored 'General case' 0 C--N 1.291 -1.97 0 CA-C-O 121.251 0.548 . . . . 0.0 109.892 -175.556 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.414 ' HA ' ' H ' ' A' ' 61' ' ' TYR . 9.3 pt -140.84 -172.66 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.832 0 CA-C-O 122.256 1.027 . . . . 0.0 111.813 -174.616 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.563 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 72.8 m-85 -126.15 134.44 51.3 Favored 'General case' 0 N--CA 1.411 -2.377 0 N-CA-C 105.894 -1.891 . . . . 0.0 105.894 172.342 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.581 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -113.44 141.92 46.52 Favored 'General case' 0 C--N 1.273 -2.72 0 O-C-N 123.776 0.673 . . . . 0.0 110.235 -176.28 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' LYS . . . . . 0.479 ' HD3' ' C ' ' A' ' 14' ' ' LYS . 7.5 tmtm? -113.15 117.72 32.73 Favored 'General case' 0 N--CA 1.422 -1.837 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.834 -177.441 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' MET . . . . . 0.422 ' HB2' ' HB2' ' A' ' 18' ' ' TYR . 72.1 mtm -109.54 158.48 17.96 Favored 'General case' 0 C--O 1.254 1.331 0 CA-C-O 121.26 0.552 . . . . 0.0 111.056 173.241 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 61.4 tttm -68.46 117.26 9.99 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.682 178.853 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.3 -1.55 76.85 Favored Glycine 0 C--O 1.238 0.361 0 C-N-CA 121.0 -0.619 . . . . 0.0 111.768 -178.746 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' TYR . . . . . 0.444 ' HA ' ' HD3' ' A' ' 19' ' ' PRO . 61.7 m-85 -120.39 150.68 52.37 Favored Pre-proline 0 C--O 1.258 1.52 0 CA-C-N 115.636 -0.282 . . . . 0.0 111.061 -179.202 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 18' ' ' TYR . 6.4 Cg_exo -74.97 171.97 17.26 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 123.286 2.657 . . . . 0.0 109.691 172.513 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 91.2 m-70 -67.3 110.97 3.75 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 176.788 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 3.9 t-105 -98.78 137.48 20.57 Favored Pre-proline 0 C--N 1.297 -1.681 0 CA-C-N 114.801 -1.091 . . . . 0.0 108.542 -171.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -64.49 118.13 5.13 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 121.763 1.642 . . . . 0.0 110.148 177.72 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -135.85 166.79 22.48 Favored 'General case' 0 N--CA 1.411 -2.398 0 CA-C-O 121.519 0.676 . . . . 0.0 110.975 -175.181 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.507 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 64.4 ttt-85 -115.66 141.76 47.65 Favored 'General case' 0 C--N 1.28 -2.423 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.455 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 48.1 t -77.65 119.92 27.26 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.249 0 N-CA-C 103.957 -2.608 . . . . 0.0 103.957 169.816 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -102.33 -179.58 4.03 Favored 'General case' 0 C--N 1.283 -2.294 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.858 -170.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLU . . . . . 0.409 ' CD ' HH12 ' A' ' 24' ' ' ARG . 30.5 mp0 -91.47 168.39 11.57 Favored 'General case' 0 N--CA 1.424 -1.731 0 CA-C-O 121.622 0.725 . . . . 0.0 110.504 -178.684 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 75.4 t -92.83 124.08 59.62 Favored Pre-proline 0 C--N 1.304 -1.402 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 175.361 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -71.0 149.26 58.65 Favored 'Trans proline' 0 N--CA 1.435 -1.953 0 C-N-CA 121.512 1.474 . . . . 0.0 112.085 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -68.13 141.51 56.04 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 177.172 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.62 -33.61 6.32 Favored Glycine 0 C--N 1.293 -1.843 0 N-CA-C 109.059 -1.616 . . . . 0.0 109.059 -175.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -80.87 85.97 6.1 Favored 'General case' 0 N--CA 1.433 -1.301 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 176.071 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.3 m -90.47 6.09 5.0 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 CA-C-N 114.95 -1.023 . . . . 0.0 112.105 -177.689 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 14.0 ptmm? -71.09 152.58 94.73 Favored Pre-proline 0 N--CA 1.424 -1.728 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.688 179.426 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -69.41 167.95 22.51 Favored 'Trans proline' 0 C--O 1.274 2.303 0 C-N-CA 121.855 1.703 . . . . 0.0 110.058 173.005 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -56.4 143.16 87.85 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 122.599 2.199 . . . . 0.0 111.374 177.763 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.0 m -85.17 8.42 18.32 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.748 -176.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 74.05 11.48 4.36 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 125.096 1.359 . . . . 0.0 108.354 -172.07 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' LYS . . . . . 0.617 ' HE3' ' HA ' ' A' ' 53' ' ' LEU . 22.5 mtpp -139.76 153.24 47.11 Favored 'General case' 0 N--CA 1.415 -2.209 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 179.801 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 80.7 mt -103.55 154.62 37.73 Favored Pre-proline 0 C--N 1.29 -2.002 0 O-C-N 124.023 0.827 . . . . 0.0 109.772 -175.605 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -71.15 122.32 8.62 Favored 'Trans proline' 0 N--CA 1.451 -0.991 0 C-N-CA 121.521 1.481 . . . . 0.0 109.734 174.875 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ILE . . . . . 0.474 HG13 ' HB2' ' A' ' 53' ' ' LEU . 44.9 mm -118.53 116.81 52.48 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.935 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -176.585 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.408 ' CZ ' ' HA ' ' A' ' 48' ' ' HIS . 79.0 t80 -93.33 122.34 35.64 Favored 'General case' 0 C--N 1.268 -2.972 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 179.718 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -88.51 124.91 34.47 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.347 0.594 . . . . 0.0 112.542 178.434 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.507 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 78.2 m-85 -74.64 152.53 39.19 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.536 176.053 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.55 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 79.78 -19.97 5.79 Favored Glycine 0 C--N 1.308 -1.02 0 CA-C-N 116.289 -0.414 . . . . 0.0 113.701 178.786 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.0 p -116.62 -22.79 8.48 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 117.166 0.483 . . . . 0.0 110.149 175.48 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' HIS . . . . . 0.575 ' O ' ' HA ' ' A' ' 92' ' ' PHE . 49.7 m170 70.22 14.23 7.63 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 124.321 1.048 . . . . 0.0 112.017 177.123 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 57.4 mm-40 -92.4 168.15 11.49 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.873 -179.113 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.0 m -129.48 142.15 50.85 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-O 121.2 0.524 . . . . 0.0 109.908 179.606 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -137.89 -178.9 5.46 Favored 'General case' 0 C--N 1.295 -1.791 0 C-N-CA 124.096 0.958 . . . . 0.0 110.023 -177.499 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -128.53 116.0 18.99 Favored 'General case' 0 CA--C 1.5 -0.975 0 CA-C-O 120.851 0.357 . . . . 0.0 110.637 179.141 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.617 ' HA ' ' HE3' ' A' ' 39' ' ' LYS . 89.0 mt -131.59 151.32 51.7 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.793 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLY . . . . . 0.418 ' HA2' ' HA ' ' A' ' 39' ' ' LYS . . . -85.69 174.38 48.19 Favored Glycine 0 N--CA 1.433 -1.514 0 C-N-CA 120.564 -0.827 . . . . 0.0 111.192 -176.911 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 -6.87 19.67 Favored 'Trans proline' 0 C--O 1.212 -0.794 0 C-N-CA 122.591 2.194 . . . . 0.0 112.98 -176.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.54 ' NZ ' ' HB2' ' A' ' 56' ' ' LYS . 5.8 mtmp? -97.99 -15.59 20.02 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 177.317 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.51 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 9.7 m-20 -99.72 1.78 43.65 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 114.585 -1.189 . . . . 0.0 108.58 -168.121 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.2 pt -132.06 152.11 36.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 114.19 -1.368 . . . . 0.0 110.187 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -135.29 141.31 37.3 Favored Pre-proline 0 C--N 1.302 -1.457 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 179.543 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -66.11 132.23 29.28 Favored 'Trans proline' 0 C--N 1.33 -0.432 0 C-N-CA 122.801 2.334 . . . . 0.0 113.36 -177.884 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' TYR . . . . . 0.563 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 50.3 t80 -59.48 -41.1 89.02 Favored 'General case' 0 C--O 1.208 -1.116 0 C-N-CA 123.639 0.776 . . . . 0.0 110.209 -179.496 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.1 p -59.41 -42.67 92.36 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 115.171 -0.922 . . . . 0.0 112.99 -176.19 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -96.48 -2.88 44.38 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 112.886 0.698 . . . . 0.0 112.886 -179.094 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.4 ' OD1' ' HD2' ' A' ' 67' ' ' LYS . 36.8 m-80 -132.14 15.04 4.67 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 113.185 0.809 . . . . 0.0 113.185 -176.317 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.505 ' HG2' ' OE2' ' A' ' 66' ' ' GLU . 20.5 pttm -66.02 -29.16 69.47 Favored 'General case' 0 N--CA 1.487 1.415 0 CA-C-O 121.735 0.778 . . . . 0.0 110.831 -179.18 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' GLU . . . . . 0.573 ' H ' ' CD ' ' A' ' 66' ' ' GLU . 2.9 mp0 -68.21 -36.78 80.07 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 179.476 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.4 ' HD2' ' OD1' ' A' ' 64' ' ' ASN . 40.9 mttp -84.19 -59.78 2.29 Favored 'General case' 0 N--CA 1.428 -1.542 0 CA-C-N 113.405 -1.725 . . . . 0.0 111.583 -170.42 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 36.2 m-85 -105.51 -4.91 20.71 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.386 -170.807 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -81.7 56.45 4.92 Favored Glycine 0 N--CA 1.444 -0.805 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 177.748 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.529 ' O ' ' HE1' ' A' ' 77' ' ' PHE . 0.0 OUTLIER -119.33 158.55 48.44 Favored Pre-proline 0 C--N 1.305 -1.352 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 -177.55 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -73.36 167.24 27.81 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 121.883 1.722 . . . . 0.0 111.926 175.14 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -152.65 -177.63 6.36 Favored 'General case' 0 C--N 1.308 -1.23 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.226 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 30.9 mmmt -97.08 -10.56 25.81 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 122.243 0.217 . . . . 0.0 110.795 178.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 27.4 mmt180 -67.17 124.38 22.93 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 177.456 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.61 137.22 40.62 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 176.345 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' GLY . . . . . 0.55 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 100.97 -26.14 25.77 Favored Glycine 0 N--CA 1.426 -2.013 0 N-CA-C 108.926 -1.67 . . . . 0.0 108.926 -174.53 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' PHE . . . . . 0.529 ' HE1' ' O ' ' A' ' 70' ' ' LYS . 20.6 t80 -77.04 -46.52 23.48 Favored 'General case' 0 N--CA 1.44 -0.939 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.473 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -60.37 -50.29 74.19 Favored 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 115.164 -0.925 . . . . 0.0 108.597 177.96 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 20.5 mp0 -61.09 -41.7 97.15 Favored 'General case' 0 N--CA 1.435 -1.207 0 CA-C-N 113.797 -1.547 . . . . 0.0 110.513 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.06 -34.55 64.76 Favored Glycine 0 CA--C 1.496 -1.11 0 CA-C-N 115.879 -0.601 . . . . 0.0 113.403 -178.445 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 32.3 tp -63.62 -30.62 71.71 Favored 'General case' 0 C--O 1.204 -1.325 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 176.932 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 79.1 t90 -77.04 -47.12 21.48 Favored 'General case' 0 N--CA 1.437 -1.109 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.031 175.237 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 39.0 mt-10 -58.93 -42.28 89.37 Favored 'General case' 0 C--O 1.196 -1.711 0 N-CA-C 113.202 0.816 . . . . 0.0 113.202 -178.723 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 21.1 tt -63.33 -33.18 59.63 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -175.631 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -81.61 -34.24 31.04 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.126 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.7 m-80 -100.52 -46.54 5.18 Favored 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 112.94 0.719 . . . . 0.0 112.94 -172.848 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 64.9 t30 -133.58 73.64 72.28 Favored Pre-proline 0 C--N 1.3 -1.565 0 CA-C-O 121.058 0.456 . . . . 0.0 110.686 -178.166 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -73.61 -5.61 17.37 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 122.978 2.452 . . . . 0.0 112.791 -176.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 61.5 pttt -100.3 12.84 36.19 Favored 'General case' 0 C--N 1.308 -1.2 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.874 -177.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 10.0 p -72.55 154.61 7.35 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.704 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -179.631 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.4 mptp? -126.99 -172.37 2.63 Favored 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 122.743 0.417 . . . . 0.0 111.655 -176.118 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.575 ' HA ' ' O ' ' A' ' 48' ' ' HIS . 63.9 t80 -45.86 158.49 0.09 Allowed 'General case' 0 CA--C 1.559 1.299 0 C-N-CA 126.802 2.041 . . . . 0.0 115.132 -174.324 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 16.4 m . . . . . 0 CA--C 1.559 1.322 0 C-N-CA 127.762 2.425 . . . . 0.0 115.585 -176.999 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 . . . . . 0 N--CA 1.416 -2.126 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 25.9 mttp -94.84 147.49 33.2 Favored Pre-proline 0 C--N 1.291 -1.964 0 CA-C-N 114.583 -1.19 . . . . 0.0 108.783 -173.184 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -63.19 115.64 3.1 Favored 'Trans proline' 0 N--CA 1.448 -1.157 0 N-CA-C 107.549 -1.751 . . . . 0.0 107.549 170.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 110.07 -8.47 31.3 Favored Glycine 0 N--CA 1.422 -2.253 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.214 -174.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -73.1 154.92 40.19 Favored 'General case' 0 C--O 1.253 1.28 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 -178.214 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 71.1 mt -102.12 122.56 44.37 Favored 'General case' 0 C--N 1.298 -1.665 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.553 -173.064 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -139.97 178.88 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 CA-C-O 122.458 1.123 . . . . 0.0 113.206 -175.154 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.475 ' HB3' ' HB3' ' A' ' 20' ' ' HIS . 47.5 m-85 -115.89 127.87 55.35 Favored 'General case' 0 C--N 1.278 -2.516 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 170.422 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.556 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -108.43 124.68 50.78 Favored 'General case' 0 C--N 1.273 -2.757 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.579 -175.313 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.599 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -105.93 123.39 47.89 Favored 'General case' 0 N--CA 1.404 -2.768 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.34 -177.759 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 68.4 mtm -120.63 158.17 27.97 Favored 'General case' 0 C--N 1.317 -0.847 0 C-N-CA 123.344 0.657 . . . . 0.0 109.231 176.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -67.53 117.07 8.99 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.08 -5.81 57.94 Favored Glycine 0 C--O 1.251 1.195 0 N-CA-C 111.518 -0.633 . . . . 0.0 111.518 178.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -124.04 147.25 53.65 Favored Pre-proline 0 N--CA 1.426 -1.666 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 -179.37 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -74.49 170.98 19.03 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 121.805 1.67 . . . . 0.0 109.273 174.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' HIS . . . . . 0.575 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 65.8 m80 -59.97 110.78 1.27 Allowed 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 175.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -102.22 137.95 19.59 Favored Pre-proline 0 C--N 1.308 -1.22 0 C-N-CA 124.017 0.927 . . . . 0.0 109.53 -170.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -64.38 118.16 5.15 Favored 'Trans proline' 0 C--O 1.242 0.694 0 C-N-CA 121.869 1.712 . . . . 0.0 110.636 178.643 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.98 166.12 26.22 Favored 'General case' 0 N--CA 1.415 -2.188 0 CA-C-O 121.181 0.515 . . . . 0.0 110.403 -176.27 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.443 ' HD3' ' O ' ' A' ' 88' ' ' PRO . 11.4 ttp180 -114.63 146.25 41.06 Favored 'General case' 0 C--N 1.282 -2.351 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.496 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.6 t -73.28 117.03 16.37 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 104.098 -2.556 . . . . 0.0 104.098 168.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -92.97 -178.0 4.67 Favored 'General case' 0 C--N 1.281 -2.405 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 -170.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 . . . . . 0 N--CA 1.429 -1.493 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 178.455 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.501 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 47.6 mmtt . . . . . 0 N--CA 1.409 -2.504 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.479 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 79.4 mt -113.25 153.28 45.54 Favored Pre-proline 0 C--N 1.263 -3.186 0 O-C-N 124.812 1.32 . . . . 0.0 108.696 -177.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -69.68 123.61 10.3 Favored 'Trans proline' 0 N--CA 1.457 -0.667 0 C-N-CA 121.658 1.572 . . . . 0.0 109.667 174.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.402 ' O ' ' HA ' ' A' ' 50' ' ' THR . 50.7 mm -120.58 122.44 68.04 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 CA-C-O 120.879 0.371 . . . . 0.0 110.454 -176.665 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.545 ' CE1' ' HA ' ' A' ' 48' ' ' HIS . 35.0 t80 -98.05 114.84 27.11 Favored 'General case' 0 C--N 1.285 -2.196 0 C-N-CA 123.441 0.697 . . . . 0.0 109.754 178.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 81.3 m-85 -79.79 129.93 34.9 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 177.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 73.1 m-85 -82.42 154.85 24.97 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.574 177.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.54 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 74.38 -20.65 1.6 Allowed Glycine 0 C--N 1.31 -0.883 0 CA-C-N 115.442 -0.799 . . . . 0.0 114.411 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 38.1 p -116.41 -22.64 8.68 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 117.911 0.856 . . . . 0.0 109.391 173.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . 0.545 ' HA ' ' CE1' ' A' ' 43' ' ' PHE . 12.5 m-70 68.12 22.61 8.26 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 114.959 -1.019 . . . . 0.0 112.98 177.825 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -79.34 172.3 13.99 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.975 178.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.402 ' HA ' ' O ' ' A' ' 42' ' ' ILE . 3.8 m -140.95 138.18 33.62 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 177.415 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -140.16 -179.0 5.72 Favored 'General case' 0 C--N 1.288 -2.107 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.383 -176.634 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.479 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 62.0 m-85 -129.59 109.94 11.42 Favored 'General case' 0 N--CA 1.445 -0.68 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 177.018 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.556 HD12 ' HB1' ' A' ' 13' ' ' ALA . 94.6 mt -129.08 153.57 47.51 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 -179.565 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.501 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -87.97 171.82 41.32 Favored Glycine 0 CA--C 1.49 -1.492 0 C-N-CA 120.307 -0.949 . . . . 0.0 112.191 -174.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -61.73 -19.0 63.63 Favored 'Trans proline' 0 C--O 1.239 0.532 0 C-N-CA 123.088 2.526 . . . . 0.0 111.982 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -91.86 -19.95 21.97 Favored 'General case' 0 N--CA 1.433 -1.29 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.903 179.473 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.409 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 24.7 m-20 -82.07 -20.86 37.36 Favored 'General case' 0 CA--C 1.493 -1.234 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.298 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.404 ' HA ' ' O ' ' A' ' 12' ' ' PHE . 15.5 pt -110.19 151.56 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.687 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.65 -176.359 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -135.73 137.66 26.18 Favored Pre-proline 0 C--O 1.185 -2.327 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -66.32 127.36 17.27 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 122.486 2.124 . . . . 0.0 113.938 -175.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 75.3 t80 -57.8 -32.48 67.6 Favored 'General case' 0 C--O 1.205 -1.279 0 CA-C-N 114.713 -1.13 . . . . 0.0 111.694 -175.101 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.59 -57.45 11.04 Favored 'General case' 0 C--N 1.293 -1.889 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -69.42 -34.53 74.6 Favored 'General case' 0 C--O 1.219 -0.518 0 CA-C-O 121.506 0.669 . . . . 0.0 111.555 -177.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . 0.309 0.8 OUTLIER -109.81 23.74 13.98 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 115.32 1.6 . . . . 0.0 115.32 -175.715 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.429 ' HZ1' ' CG ' ' A' ' 85' ' ' ASP . 15.8 ttmm -63.27 -27.38 69.29 Favored 'General case' 0 N--CA 1.481 1.095 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.217 171.742 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.463 ' CD ' ' HG2' ' A' ' 67' ' ' LYS . 1.2 pp20? -77.41 -35.46 54.19 Favored 'General case' 0 N--CA 1.423 -1.796 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.215 176.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.463 ' HG2' ' CD ' ' A' ' 66' ' ' GLU . 0.1 OUTLIER -77.37 -59.74 2.66 Favored 'General case' 0 N--CA 1.439 -0.982 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.119 -174.381 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -105.82 -4.11 21.17 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.986 -169.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -79.7 59.86 4.41 Favored Glycine 0 N--CA 1.436 -1.347 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 176.682 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.403 ' HD3' ' HA ' ' A' ' 70' ' ' LYS . 38.7 mmtm -132.34 134.34 24.81 Favored Pre-proline 0 C--N 1.32 -0.679 0 C-N-CA 122.936 0.495 . . . . 0.0 111.259 -179.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.458 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 78.1 Cg_exo -48.31 131.3 22.45 Favored 'Trans proline' 0 C--O 1.273 2.248 0 C-N-CA 123.911 3.074 . . . . 0.0 113.75 178.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.552 ' HB2' ' CD1' ' A' ' 77' ' ' PHE . 1.2 t-20 -113.82 -178.21 3.32 Favored 'General case' 0 N--CA 1.406 -2.633 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.953 -174.146 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.614 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 7.3 mptt -110.81 10.65 22.52 Favored 'General case' 0 N--CA 1.425 -1.696 0 CA-C-O 122.485 1.136 . . . . 0.0 108.375 -178.252 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 31.2 mmt180 -96.45 129.52 43.79 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 114.204 -1.362 . . . . 0.0 108.567 173.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.424 ' HG3' ' OE2' ' A' ' 79' ' ' GLU . 61.9 tttp -69.7 144.35 52.85 Favored 'General case' 0 N--CA 1.446 -0.663 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 174.7 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.54 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 91.47 -25.91 13.83 Favored Glycine 0 C--O 1.208 -1.469 0 N-CA-C 111.761 -0.536 . . . . 0.0 111.761 -177.517 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.552 ' CD1' ' HB2' ' A' ' 72' ' ' ASN . 32.5 t80 -69.78 -53.63 17.42 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-O 121.85 0.834 . . . . 0.0 109.423 -178.653 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.458 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 87.5 m-20 -69.93 -32.84 71.33 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.905 -176.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . 0.424 ' OE2' ' HG3' ' A' ' 75' ' ' LYS . 28.1 mt-10 -72.09 -37.68 69.52 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 114.738 -1.119 . . . . 0.0 108.382 178.243 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.04 -31.63 66.58 Favored Glycine 0 N--CA 1.428 -1.86 0 CA-C-N 115.007 -0.997 . . . . 0.0 112.462 177.333 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 86.0 mt -55.95 -34.74 65.95 Favored 'General case' 0 N--CA 1.474 0.746 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 175.136 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.4 t90 -75.91 -50.71 14.23 Favored 'General case' 0 N--CA 1.426 -1.635 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.457 177.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -54.98 -48.37 73.35 Favored 'General case' 0 C--O 1.2 -1.537 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -178.327 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.2 tt -67.43 -25.5 33.53 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.172 0 N-CA-C 112.205 0.446 . . . . 0.0 112.205 -175.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.429 ' CG ' ' HZ1' ' A' ' 65' ' ' LYS . 6.7 t0 -94.39 -22.59 18.22 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.261 0.553 . . . . 0.0 110.488 -174.197 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.466 HD22 ' N ' ' A' ' 86' ' ' ASN . 0.8 OUTLIER -106.96 -57.49 2.06 Favored 'General case' 0 CA--C 1.505 -0.777 0 CA-C-O 121.291 0.567 . . . . 0.0 111.366 -179.285 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -127.6 76.02 77.27 Favored Pre-proline 0 C--N 1.313 -1.015 0 C-N-CA 119.849 -0.74 . . . . 0.0 110.413 -179.072 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.443 ' O ' ' HD3' ' A' ' 24' ' ' ARG . 48.6 Cg_endo -69.73 -6.54 18.83 Favored 'Trans proline' 0 N--CA 1.483 0.857 0 C-N-CA 122.722 2.282 . . . . 0.0 113.93 -175.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.2 pttm . . . . . 0 C--N 1.301 -1.536 0 CA-C-O 121.19 0.519 . . . . 0.0 109.699 -178.207 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . 0.557 ' CE2' HG13 ' A' ' 58' ' ' ILE . 56.4 m-85 . . . . . 0 N--CA 1.428 -1.554 0 N-CA-C 116.131 1.901 . . . . 0.0 116.131 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.36 149.15 54.32 Favored Pre-proline 0 N--CA 1.423 -1.808 0 CA-C-N 113.166 -1.834 . . . . 0.0 106.71 179.694 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -58.56 130.44 37.31 Favored 'Trans proline' 0 C--O 1.236 0.41 0 C-N-CA 122.008 1.805 . . . . 0.0 109.97 173.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 104.72 -16.58 47.34 Favored Glycine 0 N--CA 1.433 -1.528 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.988 -179.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -79.59 162.31 25.4 Favored 'General case' 0 C--O 1.25 1.099 0 CA-C-N 117.216 0.508 . . . . 0.0 110.156 -175.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.512 HD21 ' HB2' ' A' ' 88' ' ' PRO . 58.0 mt -100.34 122.66 43.48 Favored 'General case' 0 CA--C 1.496 -1.116 0 C-N-CA 122.81 0.444 . . . . 0.0 110.395 -172.676 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -138.37 179.86 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.308 0 CA-C-O 122.5 1.143 . . . . 0.0 113.696 -173.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.574 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 61.0 m-85 -113.76 130.06 56.5 Favored 'General case' 0 C--N 1.283 -2.321 0 CA-C-N 113.775 -1.557 . . . . 0.0 107.684 170.671 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.434 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -107.7 118.23 36.19 Favored 'General case' 0 N--CA 1.398 -3.042 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -176.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.603 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -105.28 122.72 46.53 Favored 'General case' 0 N--CA 1.399 -2.987 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.192 -176.887 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 70.1 mtm -118.33 158.17 25.72 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.237 177.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 59.3 tttm -65.8 116.58 7.13 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.551 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.15 -2.45 65.81 Favored Glycine 0 C--O 1.251 1.159 0 N-CA-C 111.632 -0.587 . . . . 0.0 111.632 179.335 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . 0.419 ' HA ' ' HD3' ' A' ' 19' ' ' PRO . 81.5 m-85 -120.9 150.94 54.09 Favored Pre-proline 0 N--CA 1.427 -1.61 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -178.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 18' ' ' TYR . 4.9 Cg_exo -77.61 171.09 18.08 Favored 'Trans proline' 0 N--CA 1.44 -1.622 0 C-N-CA 121.815 1.677 . . . . 0.0 109.312 174.654 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' HIS . . . . . 0.496 ' HB3' ' HB3' ' A' ' 12' ' ' PHE . 69.7 m80 -62.01 111.18 1.82 Allowed 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 175.421 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -100.67 137.53 19.88 Favored Pre-proline 0 C--N 1.301 -1.521 0 N-CA-C 109.209 -0.664 . . . . 0.0 109.209 -172.181 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -65.99 118.05 5.17 Favored 'Trans proline' 0 C--O 1.243 0.762 0 C-N-CA 121.561 1.507 . . . . 0.0 110.932 178.234 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.34 166.85 25.09 Favored 'General case' 0 N--CA 1.419 -1.985 0 CA-C-N 116.223 -0.444 . . . . 0.0 109.815 -176.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.425 ' HB2' ' CE2' ' A' ' 45' ' ' PHE . 14.2 ttp180 -116.58 147.89 41.43 Favored 'General case' 0 C--N 1.28 -2.415 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.342 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 40.6 t -74.14 123.83 30.29 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.199 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 171.865 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -87.91 169.76 11.73 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 -173.054 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.302 -1.461 0 CA-C-O 121.542 0.687 . . . . 0.0 111.511 -177.394 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.445 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 81.4 mttt . . . . . 0 N--CA 1.424 -1.747 0 N-CA-C 110.134 -0.321 . . . . 0.0 110.134 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.442 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 86.8 mt -86.04 144.76 39.43 Favored Pre-proline 0 C--N 1.313 -0.979 0 O-C-N 123.681 0.613 . . . . 0.0 109.863 -176.573 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -73.37 123.97 9.09 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.046 1.831 . . . . 0.0 109.819 175.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 51.1 mm -118.42 125.9 74.68 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.879 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.412 -176.461 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -101.34 113.9 27.4 Favored 'General case' 0 C--N 1.291 -1.971 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 178.03 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -81.02 130.57 35.08 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-O 121.102 0.477 . . . . 0.0 111.861 178.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.429 ' CD2' ' HB ' ' A' ' 84' ' ' ILE . 74.1 m-85 -83.73 156.37 22.61 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 176.091 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.456 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 75.59 -20.15 2.31 Favored Glycine 0 C--N 1.314 -0.675 0 CA-C-N 115.922 -0.581 . . . . 0.0 113.957 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 24.7 p -119.08 -23.19 6.92 Favored 'General case' 0 C--N 1.308 -1.232 0 O-C-N 122.383 -0.48 . . . . 0.0 110.084 174.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 61.69 27.98 17.22 Favored 'General case' 0 C--N 1.354 0.788 0 CA-C-O 121.712 0.767 . . . . 0.0 111.536 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -85.35 159.9 19.91 Favored 'General case' 0 CA--C 1.491 -1.317 0 CA-C-N 114.043 -1.435 . . . . 0.0 108.783 176.051 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.5 m -130.05 136.72 49.69 Favored 'General case' 0 C--N 1.268 -2.946 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.126 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -140.08 -179.24 5.85 Favored 'General case' 0 C--N 1.284 -2.243 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.688 -176.15 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.442 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 79.6 m-85 -132.21 110.76 10.87 Favored 'General case' 0 CA--C 1.499 -1.011 0 C-N-CA 123.351 0.66 . . . . 0.0 109.464 177.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.434 HD12 ' HB1' ' A' ' 13' ' ' ALA . 95.9 mt -126.53 151.68 47.54 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.445 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -75.9 162.67 52.99 Favored Glycine 0 N--CA 1.416 -2.648 0 C-N-CA 119.968 -1.111 . . . . 0.0 110.677 -176.192 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.438 ' O ' ' HE2' ' A' ' 5' ' ' PHE . 17.9 Cg_endo -62.42 -19.99 69.08 Favored 'Trans proline' 0 C--O 1.191 -1.874 0 C-N-CA 122.237 1.958 . . . . 0.0 111.162 179.177 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.427 ' HE3' ' HA ' ' A' ' 56' ' ' LYS . 0.0 OUTLIER -99.48 -0.4 40.8 Favored 'General case' 0 C--N 1.286 -2.166 0 O-C-N 121.441 -0.787 . . . . 0.0 111.537 178.278 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -89.57 -20.95 23.15 Favored 'General case' 0 CA--C 1.488 -1.41 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 175.434 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.557 HG13 ' CE2' ' A' ' 5' ' ' PHE . 18.4 pt -110.59 157.24 11.41 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.75 0 CA-C-N 114.174 -1.375 . . . . 0.0 110.223 -175.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -139.36 147.31 52.23 Favored Pre-proline 0 C--N 1.303 -1.432 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 -177.317 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . 0.429 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 38.6 Cg_endo -64.89 129.68 23.94 Favored 'Trans proline' 0 C--O 1.243 0.728 0 C-N-CA 122.657 2.238 . . . . 0.0 113.081 -175.661 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.574 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 82.2 t80 -60.94 -37.12 81.22 Favored 'General case' 0 C--O 1.205 -1.264 0 CA-C-N 115.447 -0.797 . . . . 0.0 111.983 -177.077 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 22.6 t -63.63 -54.05 41.88 Favored 'General case' 0 C--N 1.307 -1.269 0 CA-C-O 120.946 0.403 . . . . 0.0 110.635 -175.332 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.429 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 4.2 mp0 -71.01 -25.84 62.86 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-O 121.376 0.608 . . . . 0.0 112.304 -178.073 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.464 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 28.0 m-80 -105.48 12.67 31.15 Favored 'General case' 0 C--N 1.293 -1.878 0 C-N-CA 120.536 -0.466 . . . . 0.0 111.917 -176.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.3 tttp -63.19 -37.87 88.94 Favored 'General case' 0 N--CA 1.479 1.001 0 CA-C-O 121.153 0.502 . . . . 0.0 110.92 -179.544 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 18.2 mm-40 -71.57 -24.01 61.84 Favored 'General case' 0 CA--C 1.488 -1.417 0 CA-C-O 121.831 0.824 . . . . 0.0 112.151 176.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.464 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 35.6 mtpt -85.79 -58.47 2.64 Favored 'General case' 0 C--N 1.266 -3.053 0 CA-C-N 114.135 -1.393 . . . . 0.0 111.426 -176.181 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 38.3 m-85 -125.17 0.75 7.84 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.995 -0.548 . . . . 0.0 112.006 -172.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -94.29 32.11 6.2 Favored Glycine 0 CA--C 1.496 -1.104 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.236 -175.261 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 50.0 mtmt -130.21 153.93 81.28 Favored Pre-proline 0 C--N 1.301 -1.515 0 C-N-CA 122.808 0.443 . . . . 0.0 110.138 178.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_exo -42.68 144.24 1.39 Allowed 'Trans proline' 0 C--N 1.363 1.298 0 C-N-CA 124.583 3.522 . . . . 0.0 117.328 -172.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 -137.13 -166.25 1.89 Allowed 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 105.073 -2.195 . . . . 0.0 105.073 173.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 3.5 mmmp? -116.55 2.26 13.02 Favored 'General case' 0 N--CA 1.416 -2.138 0 C-N-CA 119.019 -1.072 . . . . 0.0 113.28 174.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 14.2 mmt180 -61.39 128.92 38.68 Favored 'General case' 0 C--N 1.324 -0.539 0 O-C-N 124.167 0.917 . . . . 0.0 109.012 175.189 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.8 tmtm? -68.78 123.55 21.24 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.585 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.456 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 105.91 -25.05 25.14 Favored Glycine 0 N--CA 1.428 -1.884 0 N-CA-C 110.164 -1.175 . . . . 0.0 110.164 -177.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.6 t80 -76.6 -44.78 32.98 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -60.82 -50.04 75.06 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.61 178.337 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -68.16 -40.59 82.28 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.314 -178.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -72.24 -30.89 64.37 Favored Glycine 0 CA--C 1.489 -1.531 0 CA-C-N 115.646 -0.707 . . . . 0.0 112.955 -177.204 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 44.0 tp -62.39 -35.51 79.43 Favored 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.086 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.7 t90 -70.57 -48.61 54.47 Favored 'General case' 0 N--CA 1.425 -1.721 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.95 177.416 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -54.82 -51.35 66.1 Favored 'General case' 0 C--O 1.202 -1.447 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -179.382 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.429 ' HB ' ' CD2' ' A' ' 45' ' ' PHE . 17.6 tt -68.13 -24.01 29.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 112.223 0.453 . . . . 0.0 112.223 -175.329 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 6.3 t0 -94.61 -21.21 18.97 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-O 121.252 0.549 . . . . 0.0 110.458 -175.109 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.461 HD22 ' N ' ' A' ' 86' ' ' ASN . 0.8 OUTLIER -109.83 -56.78 2.27 Favored 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 121.268 0.556 . . . . 0.0 111.603 -178.95 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -125.17 71.66 63.84 Favored Pre-proline 0 C--N 1.316 -0.886 0 C-N-CA 120.169 -0.612 . . . . 0.0 110.126 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.512 ' HB2' HD21 ' A' ' 10' ' ' LEU . 60.1 Cg_endo -73.13 -6.12 18.37 Favored 'Trans proline' 0 N--CA 1.475 0.389 0 C-N-CA 122.527 2.151 . . . . 0.0 113.46 -174.643 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.3 pttm . . . . . 0 C--N 1.305 -1.333 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.019 -178.451 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 . . . . . 0 N--CA 1.413 -2.276 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -134.65 154.67 79.68 Favored Pre-proline 0 C--N 1.283 -2.324 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.402 -176.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -49.6 123.25 10.14 Favored 'Trans proline' 0 C--N 1.35 0.63 0 C-N-CA 123.365 2.71 . . . . 0.0 111.992 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 112.85 -17.49 22.68 Favored Glycine 0 N--CA 1.424 -2.165 0 CA-C-N 115.656 -0.702 . . . . 0.0 112.24 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -75.44 156.84 34.88 Favored 'General case' 0 C--O 1.249 1.041 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -177.129 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.1 mt -106.92 120.49 42.18 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 -174.525 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.438 HG22 ' HA ' ' A' ' 60' ' ' PRO . 2.9 pp -137.01 -179.63 3.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 CA-C-O 122.528 1.156 . . . . 0.0 113.42 -174.236 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.441 ' HB3' ' HB3' ' A' ' 20' ' ' HIS . 33.2 m-85 -113.57 130.52 56.35 Favored 'General case' 0 C--N 1.275 -2.665 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 170.401 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -107.24 116.39 31.85 Favored 'General case' 0 C--N 1.268 -2.952 0 CA-C-N 115.26 -0.882 . . . . 0.0 108.839 -174.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.58 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -112.87 120.89 43.02 Favored 'General case' 0 N--CA 1.394 -3.256 0 CA-C-N 114.572 -1.194 . . . . 0.0 108.856 -178.888 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 68.1 mtm -105.64 158.48 16.67 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 179.485 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -65.74 116.42 6.93 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -178.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.32 -2.63 63.31 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.726 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -125.13 148.27 59.88 Favored Pre-proline 0 N--CA 1.438 -1.04 0 CA-C-O 120.595 0.236 . . . . 0.0 110.593 -178.131 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -72.24 170.53 18.89 Favored 'Trans proline' 0 N--CA 1.455 -0.789 0 C-N-CA 122.444 2.096 . . . . 0.0 111.747 177.424 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' HIS . . . . . 0.464 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 79.4 m80 -67.12 111.69 4.03 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 108.895 -0.779 . . . . 0.0 108.895 178.136 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 13.0 t-105 -109.63 136.03 20.32 Favored Pre-proline 0 C--N 1.314 -0.977 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 -176.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -62.08 120.34 7.88 Favored 'Trans proline' 0 C--O 1.244 0.799 0 C-N-CA 122.536 2.157 . . . . 0.0 112.45 -178.591 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -148.1 166.07 28.94 Favored 'General case' 0 N--CA 1.431 -1.38 0 CA-C-O 120.932 0.396 . . . . 0.0 110.806 -177.121 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.478 HH21 ' CG ' ' A' ' 26' ' ' ASP . 12.2 ttp180 -109.85 144.53 38.19 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 178.769 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 68.9 t -73.69 107.25 4.15 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.405 0 N-CA-C 102.709 -3.071 . . . . 0.0 102.709 166.489 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.478 ' CG ' HH21 ' A' ' 24' ' ' ARG . 0.4 OUTLIER -88.64 -178.22 5.75 Favored 'General case' 0 C--N 1.271 -2.808 0 C-N-CA 119.654 -0.818 . . . . 0.0 111.957 -168.241 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 . . . . . 0 C--N 1.285 -2.205 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.956 -173.253 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.449 ' HE2' ' N ' ' A' ' 54' ' ' GLY . 31.6 mtpt . . . . . 0 N--CA 1.425 -1.691 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 79.8 mt -85.74 144.2 39.32 Favored Pre-proline 0 C--N 1.302 -1.499 0 O-C-N 123.212 0.32 . . . . 0.0 110.175 -176.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -71.25 123.91 10.0 Favored 'Trans proline' 0 N--CA 1.457 -0.622 0 C-N-CA 122.046 1.83 . . . . 0.0 109.764 175.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.414 HG13 ' HB2' ' A' ' 53' ' ' LEU . 51.4 mm -120.49 122.7 68.77 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 O-C-N 122.165 -0.334 . . . . 0.0 110.265 -176.013 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 88.0 t80 -104.95 114.48 28.71 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 178.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -74.9 132.7 41.66 Favored 'General case' 0 C--N 1.319 -0.737 0 O-C-N 123.655 0.597 . . . . 0.0 111.335 179.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -90.19 158.1 17.39 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.269 177.586 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.563 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 75.84 -19.9 2.54 Favored Glycine 0 C--N 1.311 -0.852 0 CA-C-N 115.631 -0.713 . . . . 0.0 113.529 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 60.5 p -119.27 -22.68 7.02 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 122.419 -0.46 . . . . 0.0 109.941 175.439 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.1 m170 66.98 25.57 9.3 Favored 'General case' 0 C--N 1.352 0.697 0 C-N-CA 124.12 0.968 . . . . 0.0 111.752 179.434 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -84.42 178.04 7.9 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.329 178.239 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 8.9 m -144.01 147.42 33.85 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -147.23 -179.79 7.08 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 123.827 0.851 . . . . 0.0 109.776 -178.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -133.06 110.82 10.48 Favored 'General case' 0 C--O 1.252 1.235 0 CA-C-O 121.524 0.678 . . . . 0.0 109.353 177.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.579 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 96.2 mt -127.86 155.76 43.63 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.354 -176.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.449 ' N ' ' HE2' ' A' ' 39' ' ' LYS . . . -94.69 174.47 33.24 Favored Glycine 0 N--CA 1.425 -2.053 0 N-CA-C 110.152 -1.179 . . . . 0.0 110.152 -178.342 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -66.31 -11.04 29.73 Favored 'Trans proline' 0 C--O 1.208 -1.024 0 C-N-CA 122.797 2.332 . . . . 0.0 112.799 -177.218 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 20.7 pttp -97.62 -7.96 29.95 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 122.211 1.005 . . . . 0.0 110.245 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.579 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 65.5 m-20 -100.64 -10.24 21.12 Favored 'General case' 0 C--N 1.287 -2.152 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.577 -176.04 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 12.2 pt -125.23 154.97 33.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.42 -175.154 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -142.49 140.74 19.23 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 179.424 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . 0.438 ' HA ' HG22 ' A' ' 11' ' ' ILE . 33.8 Cg_endo -65.64 127.66 18.44 Favored 'Trans proline' 0 C--O 1.243 0.751 0 C-N-CA 122.774 2.316 . . . . 0.0 114.13 -173.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 65.2 t80 -62.48 -30.61 71.38 Favored 'General case' 0 CA--C 1.505 -0.774 0 C-N-CA 124.105 0.962 . . . . 0.0 109.437 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.8 m -55.02 -35.48 64.47 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-N 114.908 -1.042 . . . . 0.0 111.88 -179.534 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . 0.284 55.0 mt-10 -85.75 -54.11 4.72 Favored 'General case' 0 CA--C 1.483 -1.618 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 172.048 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.416 ' CG ' ' HE2' ' A' ' 67' ' ' LYS . 31.6 m-80 -67.96 9.87 0.26 Allowed 'General case' 0 CA--C 1.473 -1.991 0 C-N-CA 127.628 2.371 . . . . 0.0 113.867 -164.238 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 55.6 tttp -66.85 -33.8 76.4 Favored 'General case' 0 N--CA 1.394 -3.269 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 174.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.727 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -80.43 -33.41 36.94 Favored 'General case' 0 N--CA 1.429 -1.525 0 CA-C-N 115.016 -0.993 . . . . 0.0 113.573 172.86 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.727 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 24.5 mtmm -77.54 -59.47 2.77 Favored 'General case' 0 CA--C 1.503 -0.843 0 N-CA-C 113.169 0.803 . . . . 0.0 113.169 -178.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -120.22 6.77 10.72 Favored 'General case' 0 C--N 1.281 -2.391 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.957 -174.333 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.5 11.99 35.96 Favored Glycine 0 CA--C 1.524 0.636 0 CA-C-N 116.29 -0.413 . . . . 0.0 114.087 -177.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -97.93 127.11 38.13 Favored Pre-proline 0 N--CA 1.441 -0.902 0 CA-C-N 117.162 0.481 . . . . 0.0 110.083 178.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -65.15 128.39 20.44 Favored 'Trans proline' 0 N--CA 1.446 -1.319 0 C-N-CA 122.42 2.08 . . . . 0.0 114.862 -176.05 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -102.35 -157.32 0.6 Allowed 'General case' 0 C--N 1.292 -1.911 0 CA-C-N 113.705 -1.589 . . . . 0.0 108.814 177.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.419 ' HA ' ' HD3' ' A' ' 73' ' ' LYS . 43.2 mmtm -108.58 15.39 23.82 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 120.444 -0.503 . . . . 0.0 111.359 -179.43 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 39.5 mmt180 -80.02 121.44 25.5 Favored 'General case' 0 CA--C 1.513 -0.476 0 C-N-CA 117.95 -1.5 . . . . 0.0 108.9 171.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 11.0 tppt? -74.06 126.76 31.23 Favored 'General case' 0 N--CA 1.428 -1.551 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.563 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.32 -25.82 18.67 Favored Glycine 0 N--CA 1.424 -2.165 0 N-CA-C 109.114 -1.594 . . . . 0.0 109.114 -173.153 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 6.8 t80 -76.72 -46.97 23.37 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 179.586 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 11.2 m120 -56.51 -52.53 64.41 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-N 114.944 -1.025 . . . . 0.0 109.009 178.124 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 21.7 mp0 -61.37 -40.91 96.05 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 113.793 -1.549 . . . . 0.0 110.297 -178.704 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -67.19 -37.66 91.4 Favored Glycine 0 N--CA 1.437 -1.242 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.562 -179.558 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 90.7 mt -60.82 -34.67 74.89 Favored 'General case' 0 CA--C 1.509 -0.629 0 N-CA-C 110.224 -0.288 . . . . 0.0 110.224 176.369 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 84.9 t90 -71.7 -50.96 25.57 Favored 'General case' 0 N--CA 1.432 -1.33 0 O-C-N 123.589 0.555 . . . . 0.0 109.557 177.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -56.1 -50.78 70.09 Favored 'General case' 0 C--O 1.202 -1.409 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -178.528 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.3 tt -66.78 -25.87 35.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 112.486 0.55 . . . . 0.0 112.486 -174.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -93.29 -19.43 21.39 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-O 121.591 0.71 . . . . 0.0 110.621 -173.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.9 m-80 -114.04 -56.29 2.41 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.362 -177.035 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.521 ' OD1' ' HG2' ' A' ' 89' ' ' LYS . 65.3 t30 -128.42 75.51 79.18 Favored Pre-proline 0 C--N 1.311 -1.095 0 C-N-CA 119.831 -0.748 . . . . 0.0 111.22 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -69.73 -6.3 18.25 Favored 'Trans proline' 0 N--CA 1.481 0.736 0 C-N-CA 122.704 2.269 . . . . 0.0 113.481 -176.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . 0.521 ' HG2' ' OD1' ' A' ' 87' ' ' ASN . 9.5 ptpp? . . . . . 0 C--N 1.316 -0.889 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -176.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . 0.401 ' CE2' HG13 ' A' ' 58' ' ' ILE . 88.8 m-85 . . . . . 0 N--CA 1.439 -0.987 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 9.2 pttp -135.13 166.72 26.94 Favored Pre-proline 0 N--CA 1.43 -1.455 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 177.31 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -59.44 149.34 82.21 Favored 'Trans proline' 0 C--O 1.265 1.87 0 C-N-CA 122.052 1.834 . . . . 0.0 112.451 175.47 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 98.51 -14.24 62.2 Favored Glycine 0 N--CA 1.434 -1.439 0 CA-C-N 115.683 -0.689 . . . . 0.0 113.36 176.7 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -84.22 154.76 22.85 Favored 'General case' 0 C--O 1.242 0.695 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 -177.217 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.45 ' HB3' HD11 ' A' ' 84' ' ' ILE . 83.2 mt -99.54 128.68 45.66 Favored 'General case' 0 CA--C 1.498 -1.03 0 CA-C-N 114.888 -1.051 . . . . 0.0 109.163 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -141.62 -178.62 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-O 122.131 0.967 . . . . 0.0 112.418 -175.15 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 48.1 m-85 -112.84 129.77 56.33 Favored 'General case' 0 C--N 1.279 -2.464 0 N-CA-C 106.508 -1.664 . . . . 0.0 106.508 170.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.45 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -107.49 132.23 53.45 Favored 'General case' 0 C--N 1.275 -2.658 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -176.072 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.507 ' C ' ' HD3' ' A' ' 14' ' ' LYS . 7.3 tmtm? -113.79 117.26 30.98 Favored 'General case' 0 N--CA 1.41 -2.434 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.877 -177.103 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 54.9 mtm -114.41 158.69 21.19 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.724 173.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 39.5 ttpt -62.5 118.72 7.94 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 176.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.33 -12.86 68.64 Favored Glycine 0 C--O 1.243 0.716 0 C-N-CA 121.034 -0.603 . . . . 0.0 111.65 -178.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -106.62 151.31 40.39 Favored Pre-proline 0 C--O 1.256 1.446 0 C-N-CA 122.811 0.444 . . . . 0.0 111.137 -179.343 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -82.27 172.41 11.68 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 C-N-CA 123.435 2.757 . . . . 0.0 108.91 173.499 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -65.94 110.47 2.91 Favored 'General case' 0 C--N 1.31 -1.117 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 175.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -104.37 138.24 19.46 Favored Pre-proline 0 C--N 1.303 -1.439 0 CA-C-N 115.318 -0.856 . . . . 0.0 108.909 -171.76 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -68.01 117.59 5.02 Favored 'Trans proline' 0 N--CA 1.451 -1.003 0 C-N-CA 121.484 1.456 . . . . 0.0 109.867 177.042 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -145.28 167.05 23.78 Favored 'General case' 0 N--CA 1.415 -2.2 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 -176.145 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.564 ' HB3' ' CE2' ' A' ' 45' ' ' PHE . 8.1 ptt85 -123.53 155.89 36.7 Favored 'General case' 0 C--N 1.281 -2.375 0 C-N-CA 119.149 -1.02 . . . . 0.0 109.356 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.7 t -86.32 117.7 31.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 N-CA-C 106.002 -1.851 . . . . 0.0 106.002 174.187 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -91.73 176.08 6.66 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -175.272 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 11.8 mp0 . . . . . 0 N--CA 1.421 -1.912 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.949 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.618 ' HE3' ' HA ' ' A' ' 53' ' ' LEU . 22.0 mtpp . . . . . 0 N--CA 1.416 -2.139 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 73.3 mt -99.38 155.12 36.87 Favored Pre-proline 0 C--N 1.299 -1.601 0 C-N-CA 123.189 0.596 . . . . 0.0 109.65 -174.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -74.64 121.92 7.03 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 121.158 1.239 . . . . 0.0 109.399 174.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.51 HG13 ' HB2' ' A' ' 53' ' ' LEU . 49.8 mm -115.39 118.65 59.47 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 CA-C-O 120.898 0.38 . . . . 0.0 110.393 -176.407 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.498 ' CE1' ' HA ' ' A' ' 48' ' ' HIS . 58.3 t80 -97.74 116.27 29.63 Favored 'General case' 0 C--N 1.283 -2.303 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.342 179.147 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.421 ' CE2' ' HB2' ' A' ' 51' ' ' ALA . 73.3 m-85 -77.75 130.72 37.1 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-O 121.055 0.455 . . . . 0.0 111.669 177.775 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.564 ' CE2' ' HB3' ' A' ' 24' ' ' ARG . 59.6 m-85 -81.89 150.08 27.95 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.65 176.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.479 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 82.01 -20.59 7.94 Favored Glycine 0 C--N 1.313 -0.749 0 C-N-CA 123.875 0.75 . . . . 0.0 114.394 177.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 41.3 p -119.56 -22.49 6.93 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 117.521 0.661 . . . . 0.0 110.316 174.331 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . 0.498 ' HA ' ' CE1' ' A' ' 43' ' ' PHE . 11.5 m-70 69.03 19.42 8.11 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 123.655 0.782 . . . . 0.0 111.899 -178.308 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -77.29 177.15 8.15 Favored 'General case' 0 N--CA 1.446 -0.638 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.262 177.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.9 m -142.41 144.83 33.28 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 109.675 -0.491 . . . . 0.0 109.675 -179.031 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.421 ' HB2' ' CE2' ' A' ' 44' ' ' PHE . . . -137.98 171.76 13.93 Favored 'General case' 0 C--N 1.29 -1.984 0 CA-C-N 115.397 -0.819 . . . . 0.0 109.516 178.536 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -124.62 108.4 12.02 Favored 'General case' 0 CA--C 1.482 -1.659 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 174.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.618 ' HA ' ' HE3' ' A' ' 39' ' ' LYS . 94.5 mt -134.85 139.83 45.35 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 -178.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.496 ' HA2' ' HA ' ' A' ' 39' ' ' LYS . . . -87.78 177.95 46.8 Favored Glycine 0 N--CA 1.415 -2.717 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -175.245 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -67.21 -10.94 30.37 Favored 'Trans proline' 0 C--N 1.319 -0.977 0 C-N-CA 122.445 2.096 . . . . 0.0 112.589 -177.161 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 30.7 mmtm -100.07 -8.14 24.13 Favored 'General case' 0 C--N 1.305 -1.361 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 175.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.569 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 4.3 m-20 -98.15 -12.62 21.56 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-O 121.853 0.835 . . . . 0.0 108.771 -178.262 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.401 HG13 ' CE2' ' A' ' 5' ' ' PHE . 15.1 pt -112.63 157.71 13.27 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.231 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.941 -177.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 -130.93 144.87 55.3 Favored Pre-proline 0 C--N 1.298 -1.647 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 -177.267 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . 0.453 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 42.4 Cg_endo -66.04 127.93 18.64 Favored 'Trans proline' 0 CA--C 1.503 -1.034 0 C-N-CA 122.475 2.117 . . . . 0.0 112.949 -177.483 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 85.3 t80 -61.68 -36.91 82.23 Favored 'General case' 0 C--O 1.206 -1.224 0 CA-C-N 114.816 -1.084 . . . . 0.0 112.149 -176.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.418 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 14.0 m -65.85 -50.09 65.82 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-O 121.144 0.497 . . . . 0.0 110.92 -175.707 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.453 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 3.1 mp0 -79.21 -5.25 53.84 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.656 -0.702 . . . . 0.0 112.533 -177.055 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.443 ' OD1' ' HD2' ' A' ' 67' ' ' LYS . 33.3 m-80 -125.45 12.5 8.11 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 120.591 -0.444 . . . . 0.0 112.089 178.364 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 62.9 tttp -70.92 -32.22 69.08 Favored 'General case' 0 N--CA 1.479 1.02 0 CA-C-O 122.03 0.919 . . . . 0.0 110.25 -179.344 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.639 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -74.82 -30.37 61.36 Favored 'General case' 0 N--CA 1.404 -2.772 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.649 175.981 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.639 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 49.3 mttp -80.14 -56.73 4.02 Favored 'General case' 0 CA--C 1.505 -0.766 0 CA-C-N 115.626 -0.715 . . . . 0.0 112.584 -178.267 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 54.5 m-85 -114.24 7.19 16.46 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.471 0.653 . . . . 0.0 111.837 -172.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -91.46 51.98 3.05 Favored Glycine 0 C--N 1.294 -1.755 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.637 -176.232 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.64 141.94 41.98 Favored Pre-proline 0 C--N 1.293 -1.866 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 175.509 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -65.67 126.91 16.89 Favored 'Trans proline' 0 N--CA 1.445 -1.345 0 C-N-CA 121.297 1.331 . . . . 0.0 114.425 -173.311 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -83.91 -173.0 4.47 Favored 'General case' 0 CA--C 1.484 -1.589 0 CA-C-N 114.078 -1.419 . . . . 0.0 109.059 178.819 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.532 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 1.1 mptp? -107.4 20.75 18.49 Favored 'General case' 0 C--N 1.282 -2.355 0 CA-C-O 122.664 1.221 . . . . 0.0 108.003 172.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 13.7 mmt180 -87.12 121.09 29.1 Favored 'General case' 0 N--CA 1.436 -1.172 0 CA-C-N 113.504 -1.68 . . . . 0.0 107.174 173.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 28.2 tptp -60.76 124.13 19.52 Favored 'General case' 0 C--N 1.311 -1.087 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 177.307 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.479 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.21 -25.13 21.1 Favored Glycine 0 N--CA 1.437 -1.256 0 N-CA-C 111.452 -0.659 . . . . 0.0 111.452 -179.246 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 15.2 t80 -74.53 -36.02 63.14 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-O 121.337 0.589 . . . . 0.0 109.837 -176.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.51 HD22 ' N ' ' A' ' 78' ' ' ASN . 0.7 OUTLIER -74.77 -41.98 59.03 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -175.836 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -67.9 -34.69 77.13 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 114.336 -1.302 . . . . 0.0 109.452 178.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -66.64 -35.0 89.22 Favored Glycine 0 CA--C 1.493 -1.285 0 CA-C-N 115.659 -0.7 . . . . 0.0 112.167 178.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 87.8 mt -63.65 -35.28 80.01 Favored 'General case' 0 C--O 1.215 -0.723 0 CA-C-O 121.035 0.445 . . . . 0.0 109.845 175.101 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 86.2 t90 -67.43 -49.06 65.36 Favored 'General case' 0 N--CA 1.429 -1.507 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 177.171 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -58.25 -45.44 87.81 Favored 'General case' 0 C--O 1.208 -1.094 0 N-CA-C 113.221 0.822 . . . . 0.0 113.221 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.45 HD11 ' HB3' ' A' ' 10' ' ' LEU . 19.9 tt -73.18 -29.48 28.49 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -173.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -87.23 -18.47 30.22 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 31.8 m-80 -111.63 -54.4 2.61 Favored 'General case' 0 CA--C 1.503 -0.836 0 CA-C-O 121.273 0.559 . . . . 0.0 112.161 -176.344 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.5 t30 -128.56 72.47 80.73 Favored Pre-proline 0 C--N 1.306 -1.316 0 C-N-CA 119.765 -0.774 . . . . 0.0 110.724 -179.218 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -72.85 -5.82 17.89 Favored 'Trans proline' 0 N--CA 1.478 0.582 0 C-N-CA 122.597 2.198 . . . . 0.0 113.447 -175.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.2 pttm . . . . . 0 C--N 1.307 -1.256 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.908 -178.602 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 . . . . . 0 N--CA 1.433 -1.303 0 CA-C-O 121.327 0.584 . . . . 0.0 110.945 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 24.1 mtmm -119.55 155.97 53.84 Favored Pre-proline 0 C--N 1.291 -1.975 0 CA-C-N 114.703 -1.135 . . . . 0.0 108.013 -178.446 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -55.04 120.76 8.72 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 121.723 1.615 . . . . 0.0 109.497 174.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 115.94 -24.4 10.15 Favored Glycine 0 N--CA 1.432 -1.573 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.38 -175.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -62.03 123.69 18.79 Favored 'General case' 0 C--O 1.25 1.102 0 CA-C-N 117.494 0.647 . . . . 0.0 110.74 177.476 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.422 HD23 ' HG3' ' A' ' 24' ' ' ARG . 85.2 mt -79.93 124.26 28.51 Favored 'General case' 0 CA--C 1.483 -1.601 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 177.316 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 9.3 pt -141.07 -175.12 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.036 0 CA-C-O 122.592 1.187 . . . . 0.0 112.792 -172.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.523 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 60.8 m-85 -122.24 130.35 53.09 Favored 'General case' 0 N--CA 1.405 -2.686 0 CA-C-N 113.42 -1.718 . . . . 0.0 106.56 170.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.473 ' HB2' HG21 ' A' ' 42' ' ' ILE . . . -108.8 124.25 50.31 Favored 'General case' 0 C--N 1.275 -2.651 0 O-C-N 123.931 0.769 . . . . 0.0 109.494 -177.711 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.525 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.9 OUTLIER -108.46 126.69 53.18 Favored 'General case' 0 C--N 1.272 -2.781 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.228 -177.462 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 63.5 mtm -125.59 157.75 36.37 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.682 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 1.3 ttpm? -61.34 115.95 4.25 Favored 'General case' 0 C--O 1.247 0.971 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.903 179.134 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.63 -5.68 64.62 Favored Glycine 0 C--O 1.251 1.165 0 O-C-N 123.506 0.504 . . . . 0.0 112.094 178.241 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 88.8 m-85 -120.81 151.02 54.04 Favored Pre-proline 0 N--CA 1.426 -1.656 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -177.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.18 171.09 17.62 Favored 'Trans proline' 0 N--CA 1.443 -1.495 0 C-N-CA 121.676 1.584 . . . . 0.0 109.082 174.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' HIS . . . . . 0.478 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 80.2 m80 -61.22 110.41 1.39 Allowed 'General case' 0 CA--C 1.549 0.941 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 175.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -99.34 138.39 20.51 Favored Pre-proline 0 C--N 1.31 -1.132 0 C-N-CA 123.377 0.671 . . . . 0.0 109.874 -171.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo -60.72 118.2 5.05 Favored 'Trans proline' 0 C--O 1.245 0.861 0 C-N-CA 121.746 1.631 . . . . 0.0 110.709 177.25 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.8 167.19 22.87 Favored 'General case' 0 N--CA 1.413 -2.309 0 CA-C-O 120.898 0.38 . . . . 0.0 110.309 -176.481 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.422 ' HG3' HD23 ' A' ' 10' ' ' LEU . 24.4 ttp-105 -125.81 147.04 49.54 Favored 'General case' 0 C--N 1.288 -2.083 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 175.346 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 48.1 t -72.78 119.04 18.85 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 N-CA-C 105.714 -1.958 . . . . 0.0 105.714 171.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -90.31 -177.5 5.12 Favored 'General case' 0 C--N 1.307 -1.247 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -175.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 . . . . . 0 C--N 1.282 -2.341 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -175.685 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 90.4 mttt . . . . . 0 N--CA 1.423 -1.81 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 87.9 mt -99.96 141.23 22.38 Favored Pre-proline 0 C--N 1.291 -1.946 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.268 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -71.72 123.4 9.37 Favored 'Trans proline' 0 N--CA 1.454 -0.824 0 C-N-CA 122.037 1.824 . . . . 0.0 109.852 176.607 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.473 HG21 ' HB2' ' A' ' 13' ' ' ALA . 42.4 mm -118.08 120.76 65.47 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 CA-C-N 116.196 -0.457 . . . . 0.0 109.837 -175.542 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 66.1 t80 -97.92 120.1 37.71 Favored 'General case' 0 C--N 1.281 -2.383 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -85.2 131.46 34.43 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.257 0.551 . . . . 0.0 111.972 178.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -84.96 155.04 21.79 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.712 176.394 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.571 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 79.22 -19.57 5.47 Favored Glycine 0 C--N 1.314 -0.669 0 C-N-CA 123.257 0.456 . . . . 0.0 113.418 179.11 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 16.3 p -118.61 -23.13 7.2 Favored 'General case' 0 C--N 1.307 -1.26 0 O-C-N 122.561 -0.376 . . . . 0.0 110.215 175.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.7 m170 67.46 19.19 10.06 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 123.509 0.724 . . . . 0.0 111.768 -179.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 19.2 mm-40 -87.65 168.27 13.16 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.205 179.59 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.7 m -134.55 142.5 46.99 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 121.067 0.46 . . . . 0.0 109.769 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -139.05 179.66 6.37 Favored 'General case' 0 C--N 1.293 -1.891 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.201 -178.441 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -134.13 117.39 16.52 Favored 'General case' 0 C--O 1.262 1.726 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.679 177.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 94.8 mt -129.5 174.56 9.53 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.17 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.37 164.94 21.34 Favored Glycine 0 N--CA 1.417 -2.597 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.16 -5.4 13.62 Favored 'Trans proline' 0 C--O 1.249 1.074 0 C-N-CA 123.752 2.968 . . . . 0.0 112.905 -178.179 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 23.0 pttm -97.57 -19.78 18.12 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.009 178.366 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -96.83 0.37 49.18 Favored 'General case' 0 CA--C 1.5 -0.943 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.598 -173.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.2 pt -123.43 144.78 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.995 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.725 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -130.55 147.13 64.74 Favored Pre-proline 0 C--N 1.289 -2.037 0 CA-C-N 114.631 -1.168 . . . . 0.0 108.006 -177.668 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -66.74 132.49 28.79 Favored 'Trans proline' 0 C--N 1.328 -0.548 0 C-N-CA 122.474 2.116 . . . . 0.0 112.558 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.523 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 53.4 t80 -64.0 -37.79 88.72 Favored 'General case' 0 C--O 1.201 -1.488 0 CA-C-N 114.939 -1.028 . . . . 0.0 112.25 -176.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -62.76 -54.35 40.49 Favored 'General case' 0 C--N 1.292 -1.92 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -176.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 3.6 mp0 -71.58 -26.23 62.52 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-O 121.71 0.766 . . . . 0.0 111.23 -178.266 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.466 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 29.9 m-80 -106.82 10.12 30.79 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -175.45 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -65.44 -31.27 72.26 Favored 'General case' 0 N--CA 1.483 1.195 0 CA-C-O 121.354 0.597 . . . . 0.0 111.898 -178.117 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.525 ' HA ' ' NZ ' ' A' ' 70' ' ' LYS . 55.5 mm-40 -75.97 -28.92 58.05 Favored 'General case' 0 C--N 1.285 -2.211 0 C-N-CA 119.391 -0.924 . . . . 0.0 111.842 178.277 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.466 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 33.2 mtpt -78.04 -59.26 2.85 Favored 'General case' 0 C--N 1.281 -2.407 0 CA-C-N 113.963 -1.471 . . . . 0.0 111.052 -176.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.449 ' CD2' ' HB3' ' A' ' 64' ' ' ASN . 19.9 m-85 -109.96 -9.47 14.76 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.384 -171.229 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -86.0 47.62 3.81 Favored Glycine 0 C--N 1.311 -0.857 0 N-CA-C 111.291 -0.724 . . . . 0.0 111.291 -178.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.525 ' NZ ' ' HA ' ' A' ' 66' ' ' GLU . 47.7 mmtm -127.91 147.77 64.43 Favored Pre-proline 0 C--N 1.307 -1.263 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.532 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.479 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 77.4 Cg_exo -48.01 128.94 17.4 Favored 'Trans proline' 0 C--N 1.363 1.318 0 C-N-CA 123.662 2.908 . . . . 0.0 114.782 -176.225 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.46 ' HB2' ' CD1' ' A' ' 77' ' ' PHE . 1.9 t-20 -112.22 -165.48 1.0 Allowed 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 114.747 -1.115 . . . . 0.0 109.559 -175.449 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 38.6 mmtm -121.53 12.68 10.82 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.686 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 24.2 mmt180 -93.9 128.39 40.17 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 114.874 -1.057 . . . . 0.0 109.712 174.582 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 28.1 tptp -68.89 122.5 18.75 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 177.18 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.571 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 107.14 -20.83 32.48 Favored Glycine 0 N--CA 1.438 -1.189 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 -179.254 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.46 ' CD1' ' HB2' ' A' ' 72' ' ' ASN . 35.6 t80 -75.2 -44.1 48.28 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-O 121.61 0.719 . . . . 0.0 109.701 -177.069 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.479 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 92.8 m-20 -76.38 -35.07 58.85 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 114.893 -1.048 . . . . 0.0 110.63 -174.112 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -70.12 -35.5 74.15 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.183 -1.044 . . . . 0.0 108.183 174.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -65.75 -35.63 91.22 Favored Glycine 0 N--CA 1.435 -1.413 0 CA-C-N 115.112 -0.949 . . . . 0.0 111.968 177.697 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.439 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 95.8 mt -56.16 -38.32 70.73 Favored 'General case' 0 C--O 1.219 -0.52 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 175.589 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 73.0 t90 -74.19 -49.08 25.07 Favored 'General case' 0 N--CA 1.426 -1.635 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.417 178.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -57.0 -46.82 82.02 Favored 'General case' 0 C--O 1.203 -1.343 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.8 tt -70.18 -24.57 26.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 120.628 -0.429 . . . . 0.0 112.033 -175.219 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -93.52 -19.69 20.98 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.058 0.456 . . . . 0.0 110.141 -175.053 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.462 HD22 ' N ' ' A' ' 86' ' ' ASN . 0.8 OUTLIER -111.56 -54.34 2.62 Favored 'General case' 0 N--CA 1.483 1.198 0 CA-C-O 121.351 0.596 . . . . 0.0 111.863 -179.286 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.1 t30 -126.24 71.98 71.12 Favored Pre-proline 0 C--N 1.312 -1.065 0 O-C-N 121.999 -0.438 . . . . 0.0 110.93 -177.715 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -73.2 -6.49 19.0 Favored 'Trans proline' 0 CA--C 1.53 0.309 0 C-N-CA 122.242 1.961 . . . . 0.0 113.232 -175.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.4 pttm . . . . . 0 C--N 1.313 -1.018 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.973 -176.306 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 . . . . . 0 N--CA 1.439 -0.998 0 CA-C-O 120.753 0.311 . . . . 0.0 110.438 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.527 ' O ' ' HB2' ' A' ' 9' ' ' ASP . 47.9 mmtm -111.51 155.62 42.64 Favored Pre-proline 0 C--N 1.304 -1.392 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 -178.59 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_exo -58.33 121.46 10.02 Favored 'Trans proline' 0 C--O 1.237 0.46 0 C-N-CA 121.78 1.653 . . . . 0.0 108.448 171.105 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . 0.582 ' HA2' ' NH1' ' A' ' 24' ' ' ARG . . . 108.72 -11.95 35.31 Favored Glycine 0 N--CA 1.425 -2.034 0 C-N-CA 120.55 -0.834 . . . . 0.0 112.449 -176.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.527 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 0.8 OUTLIER -64.39 133.51 52.73 Favored 'General case' 0 C--O 1.252 1.202 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -178.025 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 78.8 mt -89.27 119.97 30.22 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.419 ' HA ' ' HA ' ' A' ' 60' ' ' PRO . 7.5 pt -139.03 -173.54 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.841 0 CA-C-O 122.753 1.263 . . . . 0.0 112.956 -172.037 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.622 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 84.2 m-85 -127.48 125.41 40.42 Favored 'General case' 0 N--CA 1.403 -2.809 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 171.861 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.521 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -113.43 134.45 54.65 Favored 'General case' 0 C--N 1.266 -3.024 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.617 -176.573 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.638 ' HB2' ' CD2' ' A' ' 20' ' ' HIS . 0.0 OUTLIER -109.04 121.15 44.53 Favored 'General case' 0 N--CA 1.408 -2.532 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.396 -178.616 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 71.5 mtm -112.18 158.88 19.14 Favored 'General case' 0 C--N 1.315 -0.934 0 C-N-CA 123.587 0.755 . . . . 0.0 109.24 176.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 24.9 ttmm -66.18 117.41 8.45 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.106 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.38 -7.07 56.06 Favored Glycine 0 C--O 1.246 0.875 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -178.639 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 65.2 m-85 -123.21 148.15 54.01 Favored Pre-proline 0 N--CA 1.435 -1.222 0 C-N-CA 122.994 0.518 . . . . 0.0 110.684 179.206 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -79.34 171.6 15.81 Favored 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 122.116 1.877 . . . . 0.0 108.28 170.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' HIS . . . . . 0.638 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 78.9 m80 -58.16 111.19 1.11 Allowed 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 175.774 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . 0.42 ' O ' ' HA ' ' A' ' 12' ' ' PHE . 11.5 t-105 -111.74 141.69 25.2 Favored Pre-proline 0 C--N 1.302 -1.46 0 C-N-CA 123.561 0.744 . . . . 0.0 109.343 -170.526 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.424 ' HD3' ' CE2' ' A' ' 77' ' ' PHE . 26.3 Cg_exo -57.76 118.71 5.63 Favored 'Trans proline' 0 C--N 1.36 1.14 0 C-N-CA 122.274 1.983 . . . . 0.0 110.994 178.328 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -145.53 167.34 23.25 Favored 'General case' 0 N--CA 1.407 -2.584 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 -177.617 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.582 ' NH1' ' HA2' ' A' ' 8' ' ' GLY . 32.7 ttp85 -123.23 144.52 49.34 Favored 'General case' 0 C--N 1.276 -2.589 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 177.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 58.7 t -74.58 113.74 13.53 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.99 0 N-CA-C 104.793 -2.299 . . . . 0.0 104.793 170.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -86.88 -176.01 5.6 Favored 'General case' 0 C--N 1.29 -2.015 0 O-C-N 123.554 0.534 . . . . 0.0 111.084 -172.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 33.6 mm-40 . . . . . 0 C--N 1.3 -1.584 0 CA-C-O 121.622 0.725 . . . . 0.0 109.81 -173.209 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.423 ' HB3' ' O ' ' A' ' 53' ' ' LEU . 62.4 mttp . . . . . 0 N--CA 1.433 -1.322 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.435 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 95.8 mt -90.84 139.69 26.14 Favored Pre-proline 0 C--N 1.297 -1.709 0 O-C-N 123.894 0.746 . . . . 0.0 110.134 -177.632 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -71.38 123.22 9.35 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.262 1.974 . . . . 0.0 109.779 176.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.423 HG21 ' CB ' ' A' ' 13' ' ' ALA . 39.7 mm -122.17 121.59 64.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.932 -0.48 . . . . 0.0 109.993 -176.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -106.35 118.96 38.01 Favored 'General case' 0 C--N 1.29 -2.001 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 178.06 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 73.6 m-85 -82.32 136.07 35.08 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -179.408 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -85.58 148.85 25.73 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.9 178.334 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.458 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 78.94 -21.08 4.16 Favored Glycine 0 C--N 1.308 -1.019 0 C-N-CA 123.72 0.676 . . . . 0.0 114.168 176.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 30.7 p -119.74 -22.46 6.85 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 117.523 0.662 . . . . 0.0 110.674 174.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.4 m-70 67.01 21.9 10.15 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 123.649 0.779 . . . . 0.0 111.563 -178.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.8 mt-10 -72.42 163.61 27.71 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.064 175.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.7 m -136.87 140.05 42.1 Favored 'General case' 0 C--N 1.275 -2.645 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.346 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -141.05 176.07 9.11 Favored 'General case' 0 C--N 1.286 -2.18 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.273 -179.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.435 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 97.7 m-85 -133.98 111.07 10.11 Favored 'General case' 0 N--CA 1.431 -1.423 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 174.52 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.521 HD12 ' HB1' ' A' ' 13' ' ' ALA . 85.9 mt -125.69 170.42 11.55 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -177.527 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -95.08 167.17 26.35 Favored Glycine 0 N--CA 1.42 -2.398 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 178.166 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -66.38 -6.85 15.96 Favored 'Trans proline' 0 N--CA 1.484 0.923 0 C-N-CA 123.357 2.705 . . . . 0.0 112.743 -177.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.9 ptmm? -92.37 -19.88 21.64 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.725 178.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -102.45 5.05 39.38 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-O 121.281 0.562 . . . . 0.0 111.623 -174.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.9 pt -125.22 147.53 29.87 Favored 'Isoleucine or valine' 0 C--O 1.266 1.954 0 CA-C-N 114.653 -1.158 . . . . 0.0 110.372 178.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.42 ' HB3' ' ND2' ' A' ' 64' ' ' ASN . 88.8 m-85 -136.37 133.11 19.17 Favored Pre-proline 0 C--N 1.289 -2.035 0 CA-C-N 114.686 -1.143 . . . . 0.0 108.355 -179.543 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . 0.419 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 22.5 Cg_endo -68.3 144.06 60.83 Favored 'Trans proline' 0 CA--C 1.499 -1.264 0 C-N-CA 122.971 2.447 . . . . 0.0 114.04 -177.397 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.622 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 83.9 t80 -58.88 -38.26 78.42 Favored 'General case' 0 C--O 1.203 -1.377 0 CA-C-N 114.305 -1.316 . . . . 0.0 110.579 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.48 -47.57 83.38 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 113.744 1.016 . . . . 0.0 113.744 -175.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -93.33 -8.27 42.46 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-O 121.357 0.599 . . . . 0.0 111.597 -177.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.445 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 24.0 m-80 -124.91 14.12 8.53 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -175.164 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -63.37 -37.78 88.61 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 10.4 mp0 -66.08 -34.68 78.62 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 122.796 1.284 . . . . 0.0 109.326 177.127 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.445 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 35.4 mtpt -75.48 -59.55 2.7 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-N 113.396 -1.729 . . . . 0.0 112.008 -174.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.43 ' CD2' ' HB3' ' A' ' 64' ' ' ASN . 18.5 m-85 -115.11 -15.4 11.7 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.982 -171.068 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.77 10.77 30.19 Favored Glycine 0 N--CA 1.472 1.042 0 CA-C-O 121.213 0.341 . . . . 0.0 113.207 -175.226 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 23.2 pttm -93.04 149.9 38.32 Favored Pre-proline 0 C--N 1.298 -1.671 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -66.91 128.19 18.33 Favored 'Trans proline' 0 N--CA 1.441 -1.56 0 C-N-CA 120.845 1.03 . . . . 0.0 112.287 178.069 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 41.4 m-80 -113.19 -173.41 2.25 Favored 'General case' 0 C--N 1.295 -1.795 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 47.4 mmtm -96.75 15.87 20.72 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-O 121.238 0.542 . . . . 0.0 112.269 -176.066 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -87.94 120.94 29.77 Favored 'General case' 0 C--N 1.309 -1.187 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 174.352 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.4 tppt? -74.71 130.43 39.49 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 177.111 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.458 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.24 -25.78 18.96 Favored Glycine 0 N--CA 1.435 -1.381 0 N-CA-C 108.819 -1.712 . . . . 0.0 108.819 -174.053 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.424 ' CE2' ' HD3' ' A' ' 22' ' ' PRO . 11.2 t80 -76.79 -44.71 31.71 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.749 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 10.0 m120 -60.25 -47.89 84.07 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 22.2 mp0 -63.5 -37.06 85.85 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 113.778 -1.555 . . . . 0.0 110.194 179.341 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -67.55 -34.56 84.5 Favored Glycine 0 N--CA 1.442 -0.924 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.309 177.437 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 95.5 mt -62.78 -33.95 76.24 Favored 'General case' 0 C--O 1.216 -0.694 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 175.39 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 69.8 t90 -71.62 -49.44 40.12 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.624 175.24 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -60.43 -34.69 74.34 Favored 'General case' 0 C--O 1.21 -0.98 0 N-CA-C 113.882 1.067 . . . . 0.0 113.882 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.6 tt -72.77 -21.41 19.59 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-O 121.214 0.531 . . . . 0.0 110.3 -176.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -89.92 -46.74 8.33 Favored 'General case' 0 N--CA 1.435 -1.211 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.719 -178.62 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.585 HD22 ' N ' ' A' ' 86' ' ' ASN . 0.8 OUTLIER -86.92 -35.88 18.67 Favored 'General case' 0 C--O 1.252 1.227 0 CA-C-O 121.63 0.728 . . . . 0.0 111.843 -173.766 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -134.08 63.6 62.6 Favored Pre-proline 0 C--N 1.298 -1.669 0 C-N-CA 118.892 -1.123 . . . . 0.0 112.873 -179.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -72.04 -5.74 17.71 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 122.791 2.327 . . . . 0.0 110.838 177.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . 0.418 ' HG2' ' H ' ' A' ' 89' ' ' LYS . 16.5 pttp . . . . . 0 C--N 1.302 -1.478 0 C-N-CA 125.378 1.471 . . . . 0.0 110.81 -176.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 . . . . . 0 N--CA 1.43 -1.452 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 27.5 mtmm -124.31 156.92 66.21 Favored Pre-proline 0 C--N 1.289 -2.059 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 -176.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo -51.87 117.62 3.72 Favored 'Trans proline' 0 N--CA 1.461 -0.39 0 C-N-CA 122.17 1.913 . . . . 0.0 110.416 173.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.45 -23.55 10.32 Favored Glycine 0 N--CA 1.427 -1.902 0 CA-C-O 119.452 -0.638 . . . . 0.0 112.694 -176.475 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -64.98 123.68 20.08 Favored 'General case' 0 C--O 1.25 1.11 0 CA-C-N 117.573 0.686 . . . . 0.0 110.115 177.213 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.8 mt -80.05 129.48 34.53 Favored 'General case' 0 CA--C 1.49 -1.363 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 176.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 8.1 pt -143.17 -172.7 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.421 -1.884 0 CA-C-O 122.479 1.133 . . . . 0.0 112.4 -173.08 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.451 ' HB3' ' HB3' ' A' ' 20' ' ' HIS . 31.9 m-85 -128.58 129.07 45.42 Favored 'General case' 0 N--CA 1.402 -2.873 0 CA-C-N 113.288 -1.778 . . . . 0.0 106.55 172.784 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.557 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -108.78 128.92 55.31 Favored 'General case' 0 C--N 1.271 -2.834 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.446 -174.346 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.606 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -106.39 124.12 49.11 Favored 'General case' 0 N--CA 1.403 -2.782 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.039 -178.697 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 69.1 mtm -121.42 158.38 28.46 Favored 'General case' 0 CA--C 1.508 -0.667 0 C-N-CA 123.219 0.608 . . . . 0.0 109.814 176.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -64.66 116.52 6.32 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 178.667 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.44 -2.43 65.14 Favored Glycine 0 C--O 1.246 0.868 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -121.93 146.35 45.95 Favored Pre-proline 0 N--CA 1.428 -1.567 0 C-N-CA 122.731 0.412 . . . . 0.0 110.388 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -75.82 171.29 18.45 Favored 'Trans proline' 0 N--CA 1.444 -1.428 0 C-N-CA 121.798 1.665 . . . . 0.0 108.467 172.439 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' HIS . . . . . 0.477 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 69.2 m80 -61.53 111.15 1.69 Allowed 'General case' 0 CA--C 1.548 0.883 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 175.854 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 7.8 t-105 -102.96 139.26 19.96 Favored Pre-proline 0 C--N 1.304 -1.405 0 C-N-CA 123.852 0.861 . . . . 0.0 109.31 -171.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_exo -59.08 118.66 5.59 Favored 'Trans proline' 0 C--N 1.354 0.84 0 C-N-CA 121.875 1.716 . . . . 0.0 110.869 177.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.81 167.05 23.0 Favored 'General case' 0 N--CA 1.414 -2.227 0 CA-C-O 121.227 0.537 . . . . 0.0 110.417 -177.456 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 36.6 ttt-85 -119.05 139.89 50.98 Favored 'General case' 0 C--N 1.285 -2.198 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 177.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 60.2 t -75.34 111.12 11.22 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.951 0 N-CA-C 103.817 -2.66 . . . . 0.0 103.817 168.058 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -89.37 -177.55 5.39 Favored 'General case' 0 C--N 1.289 -2.032 0 C-N-CA 119.535 -0.866 . . . . 0.0 111.451 -170.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 . . . . . 0 C--N 1.293 -1.876 0 CA-C-O 121.875 0.845 . . . . 0.0 113.201 -171.131 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.634 ' HE3' ' HA ' ' A' ' 53' ' ' LEU . 22.5 mtpp . . . . . 0 N--CA 1.418 -2.035 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 71.2 mt -98.44 153.9 37.8 Favored Pre-proline 0 C--N 1.288 -2.079 0 O-C-N 123.54 0.525 . . . . 0.0 110.356 -173.676 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -71.4 122.36 8.58 Favored 'Trans proline' 0 C--N 1.354 0.826 0 C-N-CA 121.788 1.659 . . . . 0.0 109.798 176.476 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.422 HG13 ' HB2' ' A' ' 53' ' ' LEU . 43.8 mm -117.84 119.9 62.99 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.943 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 -176.487 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 86.2 t80 -98.27 117.68 33.2 Favored 'General case' 0 C--N 1.28 -2.437 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 178.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -81.78 129.85 34.87 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 121.419 0.628 . . . . 0.0 112.672 178.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.405 ' HB3' ' HA2' ' A' ' 80' ' ' GLY . 72.1 m-85 -80.45 151.96 29.03 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.819 177.433 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.436 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 78.23 -20.68 3.86 Favored Glycine 0 C--N 1.315 -0.628 0 C-N-CA 123.562 0.601 . . . . 0.0 114.306 177.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 36.2 p -119.37 -22.59 6.99 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 117.533 0.666 . . . . 0.0 109.849 174.323 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.0 m-70 67.7 22.74 8.87 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.883 0.873 . . . . 0.0 112.308 179.011 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -78.41 169.3 18.48 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.335 177.596 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 6.3 m -139.36 137.82 36.08 Favored 'General case' 0 C--N 1.289 -2.059 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 177.04 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -138.58 -179.55 5.88 Favored 'General case' 0 C--N 1.28 -2.436 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.614 -176.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 87.3 m-85 -131.31 109.79 10.62 Favored 'General case' 0 CA--C 1.491 -1.318 0 C-N-CA 123.662 0.785 . . . . 0.0 109.294 177.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.634 ' HA ' ' HE3' ' A' ' 39' ' ' LYS . 96.2 mt -126.77 152.29 47.08 Favored 'General case' 0 C--N 1.295 -1.803 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.076 -178.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.422 ' O ' HG12 ' A' ' 58' ' ' ILE . . . -80.43 168.17 51.32 Favored Glycine 0 N--CA 1.429 -1.802 0 N-CA-C 110.564 -1.015 . . . . 0.0 110.564 -177.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -65.18 -18.42 61.19 Favored 'Trans proline' 0 C--O 1.209 -0.966 0 C-N-CA 122.337 2.025 . . . . 0.0 112.13 -178.479 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 10.8 mmtm -99.56 2.05 44.34 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 113.206 0.817 . . . . 0.0 113.206 173.703 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -94.04 -12.02 29.48 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 173.656 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.451 HG22 ' HA ' ' A' ' 13' ' ' ALA . 15.9 pt -125.77 151.58 32.01 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.705 0 CA-C-N 114.459 -1.246 . . . . 0.0 109.698 -176.801 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.451 ' HB3' HD21 ' A' ' 64' ' ' ASN . 96.4 m-85 -138.23 147.48 55.96 Favored Pre-proline 0 C--N 1.296 -1.754 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 -179.192 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -63.38 140.99 79.51 Favored 'Trans proline' 0 C--O 1.241 0.632 0 C-N-CA 123.19 2.593 . . . . 0.0 114.817 -174.503 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 40.5 t80 -56.03 -33.31 64.81 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 114.32 -1.309 . . . . 0.0 111.841 177.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.8 m -60.05 -41.9 93.3 Favored 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.527 -177.618 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . 0.301 48.8 mt-10 -75.98 -51.59 12.05 Favored 'General case' 0 CA--C 1.488 -1.426 0 CA-C-O 123.319 1.533 . . . . 0.0 108.656 176.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.451 HD21 ' HB3' ' A' ' 59' ' ' PHE . 37.0 m-80 -80.66 2.75 24.54 Favored 'General case' 0 N--CA 1.415 -2.211 0 CA-C-N 112.801 -1.999 . . . . 0.0 113.847 -161.439 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -68.92 -37.4 78.89 Favored 'General case' 0 N--CA 1.433 -1.286 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 176.424 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 56.8 mm-40 -80.83 -37.4 30.11 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.104 -0.498 . . . . 0.0 112.159 175.343 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 39.7 mtpt -70.96 -57.37 4.63 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 124.701 1.251 . . . . 0.0 111.171 -173.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 61.8 m-85 -126.97 7.24 6.63 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.213 -174.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -91.98 41.24 2.83 Favored Glycine 0 CA--C 1.496 -1.096 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -178.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.405 ' O ' ' HE1' ' A' ' 77' ' ' PHE . 30.4 mmtp -128.77 151.02 76.52 Favored Pre-proline 0 C--N 1.299 -1.616 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 -177.595 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.472 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 52.6 Cg_exo -48.42 148.44 7.81 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 123.642 2.895 . . . . 0.0 114.816 -176.415 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -140.17 -175.73 4.35 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-N 115.087 -0.96 . . . . 0.0 109.933 -178.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.2 mmmm -95.53 -3.26 46.9 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-O 120.804 0.335 . . . . 0.0 110.474 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 18.0 mmt180 -80.25 121.02 25.11 Favored 'General case' 0 C--N 1.309 -1.164 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.064 176.317 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -73.63 135.39 43.8 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 174.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.436 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 103.76 -25.31 27.01 Favored Glycine 0 N--CA 1.436 -1.332 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 -177.123 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.405 ' HE1' ' O ' ' A' ' 70' ' ' LYS . 55.7 t80 -74.73 -44.93 47.4 Favored 'General case' 0 N--CA 1.437 -1.077 0 CA-C-N 114.722 -0.739 . . . . 0.0 109.08 -178.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.472 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 89.4 m-20 -76.82 -35.75 57.37 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.062 -176.2 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 8.2 mp0 -67.73 -36.55 80.78 Favored 'General case' 0 N--CA 1.433 -1.311 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 174.376 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.405 ' HA2' ' HB3' ' A' ' 45' ' ' PHE . . . -70.47 -34.38 68.08 Favored Glycine 0 CA--C 1.496 -1.155 0 CA-C-N 115.445 -0.798 . . . . 0.0 112.094 177.584 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 40.9 tp -60.62 -36.53 78.84 Favored 'General case' 0 N--CA 1.432 -1.331 0 C-N-CA 123.955 0.902 . . . . 0.0 108.947 175.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 76.1 t90 -72.14 -47.39 51.41 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.054 175.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -61.15 -36.87 80.95 Favored 'General case' 0 C--O 1.193 -1.915 0 N-CA-C 114.009 1.114 . . . . 0.0 114.009 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.4 tt -70.67 -26.51 28.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 119.282 -0.967 . . . . 0.0 111.772 -176.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -83.77 -37.06 23.1 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.176 178.238 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 30.8 m-80 -101.86 -31.35 10.76 Favored 'General case' 0 C--O 1.257 1.487 0 CA-C-O 122.063 0.935 . . . . 0.0 112.738 -173.123 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 57.3 t30 -129.06 60.2 49.18 Favored Pre-proline 0 C--N 1.29 -2.014 0 O-C-N 121.628 -0.67 . . . . 0.0 112.539 -177.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -77.77 -5.74 15.57 Favored 'Trans proline' 0 N--CA 1.486 1.076 0 C-N-CA 122.211 1.94 . . . . 0.0 110.747 178.244 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 23.1 pttm . . . . . 0 C--N 1.312 -1.023 0 CA-C-N 113.718 -1.583 . . . . 0.0 111.063 -174.606 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 . . . . . 0 N--CA 1.447 -0.617 0 CA-C-O 120.788 0.328 . . . . 0.0 111.645 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.489 ' HD2' ' N ' ' A' ' 6' ' ' LYS . 7.5 mptt -121.04 147.24 46.02 Favored Pre-proline 0 C--N 1.31 -1.119 0 N-CA-C 108.172 -1.048 . . . . 0.0 108.172 -178.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -56.98 121.13 9.53 Favored 'Trans proline' 0 N--CA 1.452 -0.967 0 C-N-CA 121.456 1.438 . . . . 0.0 109.32 172.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.66 -25.33 9.11 Favored Glycine 0 N--CA 1.42 -2.41 0 CA-C-O 118.671 -1.072 . . . . 0.0 114.142 -177.14 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.354 3.7 p30 -79.37 149.71 31.6 Favored 'General case' 0 C--O 1.243 0.748 0 CA-C-N 119.453 1.626 . . . . 0.0 113.557 -179.496 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.419 HD21 ' HB2' ' A' ' 88' ' ' PRO . 78.5 mt -86.74 128.54 35.02 Favored 'General case' 0 C--O 1.253 1.268 0 CA-C-N 114.605 -1.18 . . . . 0.0 110.851 -175.812 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -141.77 -177.2 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.466 0 CA-C-O 121.785 0.803 . . . . 0.0 112.255 -175.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.431 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 49.1 m-85 -113.65 128.25 56.36 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 107.211 -1.403 . . . . 0.0 107.211 172.531 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.444 ' HB2' HG21 ' A' ' 42' ' ' ILE . . . -108.3 120.31 42.0 Favored 'General case' 0 C--N 1.274 -2.69 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.684 -175.382 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.576 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 1.1 tmmt? -109.72 126.65 53.94 Favored 'General case' 0 C--N 1.27 -2.866 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.619 -177.638 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 69.6 mtm -120.48 158.55 27.01 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.489 179.264 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -68.77 117.02 9.94 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 179.497 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.27 -3.07 61.54 Favored Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -179.655 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -122.94 150.3 58.74 Favored Pre-proline 0 N--CA 1.435 -1.195 0 CA-C-O 120.744 0.307 . . . . 0.0 110.855 -179.118 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -74.91 170.74 19.74 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 122.134 1.889 . . . . 0.0 109.498 172.68 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' HIS . . . . . 0.445 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 76.3 m80 -66.77 111.55 3.77 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 177.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 10.6 t-105 -97.06 138.98 21.27 Favored Pre-proline 0 C--N 1.311 -1.093 0 C-N-CA 123.541 0.737 . . . . 0.0 109.689 -174.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.438 ' HB2' HG21 ' A' ' 84' ' ' ILE . 22.7 Cg_endo -69.05 117.76 5.25 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 121.254 1.303 . . . . 0.0 110.123 175.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.5 167.1 24.52 Favored 'General case' 0 N--CA 1.426 -1.625 0 CA-C-O 121.137 0.494 . . . . 0.0 110.528 -174.619 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.408 HH22 ' CD ' ' A' ' 27' ' ' GLU . 12.7 ttp180 -111.75 145.21 39.76 Favored 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 179.069 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.3 t -68.61 121.32 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.866 0 N-CA-C 104.821 -2.289 . . . . 0.0 104.821 169.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -91.24 175.66 6.86 Favored 'General case' 0 C--N 1.281 -2.395 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 -171.161 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.408 ' CD ' HH22 ' A' ' 24' ' ' ARG . 0.3 OUTLIER . . . . . 0 N--CA 1.425 -1.695 0 CA-C-O 121.385 0.612 . . . . 0.0 110.229 179.453 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.412 ' HD3' ' HA ' ' A' ' 53' ' ' LEU . 71.6 mttt . . . . . 0 N--CA 1.415 -2.192 0 N-CA-C 108.609 -0.886 . . . . 0.0 108.609 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 75.0 mt -100.19 150.42 36.88 Favored Pre-proline 0 C--N 1.291 -1.944 0 O-C-N 124.368 1.042 . . . . 0.0 109.257 -175.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -75.49 133.33 15.75 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 121.684 1.589 . . . . 0.0 109.427 174.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.444 HG21 ' HB2' ' A' ' 13' ' ' ALA . 51.3 mm -124.47 126.74 72.33 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -176.692 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 65.2 t80 -105.51 115.02 29.55 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 -179.434 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.416 ' HE2' ' HB2' ' A' ' 51' ' ' ALA . 95.1 m-85 -79.23 136.18 36.99 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.245 0.545 . . . . 0.0 111.613 179.524 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -87.54 157.08 19.25 Favored 'General case' 0 C--N 1.301 -1.515 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.559 177.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 76.11 -21.27 2.25 Favored Glycine 0 CA--C 1.502 -0.775 0 C-N-CA 124.669 1.128 . . . . 0.0 114.134 179.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.404 ' CG2' ' HA3' ' A' ' 76' ' ' GLY . 40.4 p -120.01 -23.24 6.42 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 117.294 0.547 . . . . 0.0 110.199 174.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 51.7 m170 67.78 23.3 8.58 Favored 'General case' 0 C--N 1.342 0.25 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.681 178.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -73.78 162.7 28.86 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 175.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.8 m -137.5 142.33 41.48 Favored 'General case' 0 C--N 1.281 -2.371 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.416 ' HB2' ' HE2' ' A' ' 44' ' ' PHE . . . -139.65 -179.68 6.06 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.169 -178.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 80.2 m-85 -131.69 109.27 10.06 Favored 'General case' 0 N--CA 1.439 -0.989 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 175.274 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.511 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 96.0 mt -127.51 152.94 46.95 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.652 -175.171 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.97 171.72 37.71 Favored Glycine 0 N--CA 1.424 -2.164 0 C-N-CA 119.564 -1.303 . . . . 0.0 111.589 -174.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -66.12 -5.65 12.82 Favored 'Trans proline' 0 C--O 1.251 1.131 0 C-N-CA 123.235 2.624 . . . . 0.0 112.172 179.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -98.72 -16.87 18.81 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 114.961 -1.018 . . . . 0.0 111.774 175.062 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.511 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 40.9 m-20 -94.12 -8.7 38.8 Favored 'General case' 0 C--N 1.31 -1.15 0 CA-C-O 121.188 0.518 . . . . 0.0 110.118 -177.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.424 ' HA ' ' O ' ' A' ' 12' ' ' PHE . 14.3 pt -119.59 149.63 22.18 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.607 -176.195 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 57.6 m-85 -132.56 148.54 70.02 Favored Pre-proline 0 C--O 1.192 -1.945 0 N-CA-C 107.428 -1.323 . . . . 0.0 107.428 -177.381 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . 0.449 ' O ' ' HB2' ' A' ' 64' ' ' ASN . 41.4 Cg_endo -66.2 132.32 29.38 Favored 'Trans proline' 0 C--N 1.322 -0.854 0 C-N-CA 121.94 1.76 . . . . 0.0 111.956 -179.236 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.431 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 66.5 t80 -69.38 -38.48 78.05 Favored 'General case' 0 C--O 1.204 -1.327 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -177.338 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 22.7 t -76.31 -33.63 59.03 Favored 'General case' 0 C--N 1.295 -1.8 0 C-N-CA 120.087 -0.645 . . . . 0.0 111.402 -172.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.507 ' C ' HD22 ' A' ' 64' ' ' ASN . 2.8 mp0 -95.69 -1.7 49.51 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.522 -177.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.507 HD22 ' C ' ' A' ' 63' ' ' GLU . 0.9 OUTLIER -131.17 15.34 5.12 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 178.232 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -69.75 -32.24 70.65 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.465 0.65 . . . . 0.0 110.1 -179.535 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.603 ' H ' ' CD ' ' A' ' 66' ' ' GLU . 1.5 mp0 -66.1 -31.61 72.58 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 178.103 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.482 ' HD3' ' CG ' ' A' ' 64' ' ' ASN . 37.7 mtpt -82.22 -60.25 2.28 Favored 'General case' 0 N--CA 1.428 -1.567 0 CA-C-N 114.303 -1.317 . . . . 0.0 111.501 -175.594 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -106.71 -1.15 23.01 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.434 -0.803 . . . . 0.0 113.057 -168.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.71 56.91 4.23 Favored Glycine 0 C--N 1.311 -0.827 0 C-N-CA 120.994 -0.622 . . . . 0.0 111.953 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 58.7 mttp -125.86 125.61 24.86 Favored Pre-proline 0 C--N 1.313 -1.021 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.27 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -53.15 128.8 30.51 Favored 'Trans proline' 0 C--O 1.263 1.763 0 C-N-CA 123.451 2.767 . . . . 0.0 114.414 -177.167 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -94.94 -172.43 2.7 Favored 'General case' 0 N--CA 1.407 -2.613 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.636 178.383 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.53 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 2.0 mptp? -106.98 -11.01 15.78 Favored 'General case' 0 N--CA 1.417 -2.118 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -178.506 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.94 118.13 9.3 Favored 'General case' 0 N--CA 1.41 -2.429 0 N-CA-C 106.272 -1.751 . . . . 0.0 106.272 169.71 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 9.3 tptp -69.9 140.25 53.09 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 107.888 -1.152 . . . . 0.0 107.888 179.013 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.404 ' HA3' ' CG2' ' A' ' 47' ' ' THR . . . 107.93 -24.04 24.25 Favored Glycine 0 N--CA 1.413 -2.889 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 -173.15 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -75.47 -38.79 59.39 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -68.64 -47.33 66.88 Favored 'General case' 0 CA--C 1.506 -0.739 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 -177.681 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 36.1 mp0 -61.66 -42.34 98.77 Favored 'General case' 0 N--CA 1.426 -1.661 0 CA-C-N 113.152 -1.84 . . . . 0.0 110.068 178.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.1 -37.0 72.6 Favored Glycine 0 CA--C 1.484 -1.846 0 CA-C-N 115.751 -0.659 . . . . 0.0 113.305 -179.243 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 38.3 tp -62.55 -31.1 71.84 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 176.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.0 t90 -74.76 -51.18 14.86 Favored 'General case' 0 N--CA 1.429 -1.501 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.248 175.006 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 -55.06 -45.84 75.34 Favored 'General case' 0 C--O 1.203 -1.346 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 -178.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.438 HG21 ' HB2' ' A' ' 22' ' ' PRO . 20.2 tt -68.73 -27.89 37.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -176.033 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -93.42 -16.96 24.03 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.252 0.549 . . . . 0.0 110.302 -173.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.435 HD22 ' N ' ' A' ' 86' ' ' ASN . 0.9 OUTLIER -109.91 -56.51 2.31 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-O 121.16 0.505 . . . . 0.0 111.527 179.605 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -128.27 75.19 79.2 Favored Pre-proline 0 C--N 1.313 -0.982 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.199 -177.65 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.419 ' HB2' HD21 ' A' ' 10' ' ' LEU . 56.4 Cg_endo -73.62 -5.26 16.79 Favored 'Trans proline' 0 C--N 1.332 -0.298 0 C-N-CA 122.699 2.266 . . . . 0.0 112.988 -177.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 26.1 pttm . . . . . 0 C--O 1.249 1.054 0 CA-C-O 121.38 0.609 . . . . 0.0 109.972 -176.393 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . 0.489 ' CE2' HG13 ' A' ' 58' ' ' ILE . 91.3 m-85 . . . . . 0 CA--C 1.498 -1.047 0 N-CA-C 117.575 2.435 . . . . 0.0 117.575 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.493 ' HG3' ' OD1' ' A' ' 9' ' ' ASP . 3.8 ptmm? -134.65 156.3 78.8 Favored Pre-proline 0 N--CA 1.413 -2.276 0 CA-C-N 112.076 -2.329 . . . . 0.0 107.684 177.086 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.88 141.1 95.77 Favored 'Trans proline' 0 C--O 1.253 1.234 0 C-N-CA 122.497 2.132 . . . . 0.0 112.455 178.244 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 104.81 -14.17 49.56 Favored Glycine 0 N--CA 1.44 -1.039 0 C-N-CA 121.231 -0.509 . . . . 0.0 113.033 178.18 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.493 ' OD1' ' HG3' ' A' ' 6' ' ' LYS . 1.4 m-20 -79.05 145.87 33.6 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-O 121.087 0.47 . . . . 0.0 111.412 -179.381 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 83.6 mt -95.3 127.43 41.34 Favored 'General case' 0 C--O 1.25 1.116 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.45 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.475 HG22 ' HA ' ' A' ' 60' ' ' PRO . 2.9 pp -139.54 -178.63 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.205 0 CA-C-O 122.489 1.138 . . . . 0.0 113.761 -173.053 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.498 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 86.3 m-85 -119.43 128.59 54.17 Favored 'General case' 0 N--CA 1.408 -2.564 0 N-CA-C 105.203 -2.147 . . . . 0.0 105.203 170.766 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.501 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -108.09 140.84 40.68 Favored 'General case' 0 C--N 1.279 -2.477 0 O-C-N 123.702 0.626 . . . . 0.0 110.045 -173.569 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.483 ' HD3' ' C ' ' A' ' 14' ' ' LYS . 7.6 tmtm? -114.96 115.66 27.24 Favored 'General case' 0 N--CA 1.414 -2.273 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.834 -176.742 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.408 ' HB2' ' HB2' ' A' ' 18' ' ' TYR . 69.8 mtm -108.12 158.93 16.99 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 172.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 24.4 tptm -62.59 130.04 43.3 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 177.509 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 83.02 -25.5 4.73 Favored Glycine 0 C--O 1.218 -0.888 0 O-C-N 123.539 0.524 . . . . 0.0 112.568 -177.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . 0.408 ' HB2' ' HB2' ' A' ' 15' ' ' MET . 53.5 m-85 -93.21 149.85 38.13 Favored Pre-proline 0 C--O 1.257 1.488 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -177.225 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -75.78 171.7 17.69 Favored 'Trans proline' 0 N--CA 1.449 -1.112 0 C-N-CA 123.395 2.73 . . . . 0.0 109.646 171.251 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' HIS . . . . . 0.453 ' HB3' ' HB3' ' A' ' 12' ' ' PHE . 79.8 m80 -69.9 111.53 5.68 Favored 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 178.461 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 8.5 t-105 -100.17 136.39 20.1 Favored Pre-proline 0 C--N 1.309 -1.175 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.961 -173.27 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_endo -65.88 117.79 4.94 Favored 'Trans proline' 0 CA--C 1.542 0.9 0 C-N-CA 121.789 1.66 . . . . 0.0 110.789 176.439 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.44 167.51 23.46 Favored 'General case' 0 N--CA 1.426 -1.645 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -174.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.503 ' HB3' ' CE2' ' A' ' 45' ' ' PHE . 9.2 ptt180 -111.25 160.57 16.86 Favored 'General case' 0 C--N 1.291 -1.965 0 C-N-CA 119.507 -0.877 . . . . 0.0 109.182 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 42.3 t -89.47 116.05 30.24 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.163 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 170.064 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.406 ' HB2' ' HB2' ' A' ' 41' ' ' PRO . 1.7 m-20 -87.84 173.53 8.89 Favored 'General case' 0 C--N 1.281 -2.407 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.976 -175.013 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.417 -2.1 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 175.613 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.513 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 34.3 mmtt . . . . . 0 N--CA 1.41 -2.469 0 N-CA-C 107.075 -1.454 . . . . 0.0 107.075 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.431 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 74.6 mt -96.63 154.27 38.52 Favored Pre-proline 0 C--N 1.271 -2.814 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 -178.147 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.406 ' HB2' ' HB2' ' A' ' 26' ' ' ASP . 45.8 Cg_endo -74.96 126.48 10.02 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 C-N-CA 121.517 1.478 . . . . 0.0 109.276 173.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 50.6 mm -125.3 110.13 23.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-O 121.116 0.484 . . . . 0.0 111.407 -175.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 70.2 t80 -90.26 117.52 29.06 Favored 'General case' 0 C--N 1.279 -2.497 0 C-N-CA 124.46 1.104 . . . . 0.0 109.899 176.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -78.13 128.83 34.4 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.9 177.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.503 ' CE2' ' HB3' ' A' ' 24' ' ' ARG . 58.8 m-85 -78.14 152.04 32.99 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.254 177.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 80.96 -21.05 5.93 Favored Glycine 0 C--N 1.308 -1.027 0 C-N-CA 124.565 1.079 . . . . 0.0 114.592 177.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.457 ' CG2' ' HA3' ' A' ' 76' ' ' GLY . 32.6 p -119.88 -22.73 6.66 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 117.467 0.633 . . . . 0.0 110.349 174.682 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 68.11 23.17 8.09 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.854 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -75.12 169.64 17.63 Favored 'General case' 0 C--N 1.35 0.602 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 175.076 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.4 m -141.47 145.66 35.51 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 121.539 -0.726 . . . . 0.0 110.005 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -139.99 -179.9 6.22 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 123.835 0.854 . . . . 0.0 109.842 178.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.431 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 93.0 m-85 -133.23 109.67 9.58 Favored 'General case' 0 CA--C 1.491 -1.29 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 174.332 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.53 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 79.5 mt -134.13 144.6 48.64 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 -178.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.513 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -83.26 177.05 52.97 Favored Glycine 0 N--CA 1.417 -2.596 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 -174.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -66.23 -17.51 54.49 Favored 'Trans proline' 0 C--N 1.319 -0.985 0 C-N-CA 122.112 1.875 . . . . 0.0 112.481 -176.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 16.8 mmmt -98.86 -3.58 35.03 Favored 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 120.204 -0.598 . . . . 0.0 110.923 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.53 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 12.8 m-20 -96.55 -9.2 30.01 Favored 'General case' 0 N--CA 1.481 1.105 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.792 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.489 HG13 ' CE2' ' A' ' 5' ' ' PHE . 12.5 pt -115.63 152.43 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.231 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.428 -176.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -126.05 131.68 24.06 Favored Pre-proline 0 C--N 1.301 -1.542 0 CA-C-N 115.238 -0.892 . . . . 0.0 108.753 -177.612 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . 0.525 ' HG2' ' HB2' ' A' ' 63' ' ' GLU . 34.1 Cg_endo -67.6 131.51 24.67 Favored 'Trans proline' 0 C--N 1.322 -0.821 0 C-N-CA 122.708 2.272 . . . . 0.0 113.202 -175.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.498 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 43.3 t80 -52.37 -42.19 63.74 Favored 'General case' 0 C--O 1.205 -1.257 0 C-N-CA 123.992 0.917 . . . . 0.0 111.337 179.62 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.2 t -64.94 -37.0 86.19 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.476 -175.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.525 ' HB2' ' HG2' ' A' ' 60' ' ' PRO . 29.9 mt-10 -97.03 -7.08 33.78 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.992 0.425 . . . . 0.0 111.949 -175.703 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.479 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 27.2 m-80 -133.53 17.77 3.96 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 112.416 0.525 . . . . 0.0 112.416 -175.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.448 ' HG2' ' OE1' ' A' ' 66' ' ' GLU . 3.6 ptpp? -67.29 -36.13 80.91 Favored 'General case' 0 N--CA 1.498 1.968 0 C-N-CA 120.042 -0.663 . . . . 0.0 110.611 -176.149 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.448 ' OE1' ' HG2' ' A' ' 65' ' ' LYS . 28.8 mp0 -64.94 -35.45 81.21 Favored 'General case' 0 C--O 1.255 1.346 0 CA-C-O 123.241 1.496 . . . . 0.0 108.836 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.479 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 37.6 mtpt -76.38 -59.33 2.81 Favored 'General case' 0 C--N 1.294 -1.834 0 CA-C-N 112.931 -1.94 . . . . 0.0 111.912 -174.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.411 ' CD2' ' HB3' ' A' ' 64' ' ' ASN . 23.2 m-85 -112.1 -1.94 15.16 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 -169.084 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -83.85 45.69 3.52 Favored Glycine 0 C--N 1.309 -0.961 0 C-N-CA 120.654 -0.784 . . . . 0.0 113.373 -176.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 17.3 pttm -132.75 143.74 49.98 Favored Pre-proline 0 N--CA 1.43 -1.448 0 O-C-N 122.591 -0.358 . . . . 0.0 111.561 176.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_exo -49.42 158.13 1.83 Allowed 'Trans proline' 0 C--N 1.361 1.236 0 C-N-CA 124.577 3.518 . . . . 0.0 117.06 -173.053 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -131.48 -178.42 4.85 Favored 'General case' 0 N--CA 1.416 -2.164 0 CA-C-N 113.647 -1.615 . . . . 0.0 108.31 178.317 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -90.69 -18.51 24.94 Favored 'General case' 0 C--N 1.308 -1.199 0 O-C-N 123.693 0.621 . . . . 0.0 109.659 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.54 115.57 5.9 Favored 'General case' 0 N--CA 1.414 -2.229 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 175.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.447 ' HD3' ' H ' ' A' ' 76' ' ' GLY . 14.0 tppt? -64.73 133.42 52.05 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 175.638 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.457 ' HA3' ' CG2' ' A' ' 47' ' ' THR . . . 108.46 -24.75 21.62 Favored Glycine 0 N--CA 1.414 -2.788 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -174.095 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -75.6 -37.91 59.46 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -65.96 -49.55 67.48 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 -178.487 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 23.5 mp0 -64.58 -39.07 93.07 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 113.202 -1.817 . . . . 0.0 110.522 -179.687 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.64 -35.05 62.63 Favored Glycine 0 CA--C 1.48 -2.145 0 CA-C-N 116.063 -0.517 . . . . 0.0 113.011 -179.41 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 37.7 tp -62.51 -33.31 74.63 Favored 'General case' 0 N--CA 1.423 -1.802 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 176.029 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 70.5 t90 -74.34 -49.11 24.21 Favored 'General case' 0 N--CA 1.426 -1.626 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.602 175.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -55.04 -46.09 75.27 Favored 'General case' 0 C--O 1.188 -2.154 0 N-CA-C 112.644 0.609 . . . . 0.0 112.644 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 17.0 tt -68.56 -23.22 27.73 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-O 121.082 0.468 . . . . 0.0 111.629 -174.054 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -92.34 -41.93 10.09 Favored 'General case' 0 N--CA 1.423 -1.785 0 CA-C-O 121.585 0.707 . . . . 0.0 109.819 -175.443 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.584 HD22 ' N ' ' A' ' 86' ' ' ASN . 0.7 OUTLIER -97.73 -39.73 8.91 Favored 'General case' 0 N--CA 1.48 1.038 0 CA-C-O 121.713 0.768 . . . . 0.0 112.061 -173.838 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 65.2 t30 -134.99 63.33 57.24 Favored Pre-proline 0 C--N 1.296 -1.759 0 C-N-CA 119.797 -0.761 . . . . 0.0 111.673 -178.428 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -68.13 -6.57 17.58 Favored 'Trans proline' 0 C--N 1.371 1.711 0 C-N-CA 122.81 2.34 . . . . 0.0 111.742 -178.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 24.7 pttm . . . . . 0 C--N 1.311 -1.103 0 CA-C-N 114.555 -1.202 . . . . 0.0 109.828 -177.44 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . 0.494 ' C ' ' HD2' ' A' ' 6' ' ' LYS . 84.3 m-85 . . . . . 0 CA--C 1.496 -1.116 0 CA-C-O 120.959 0.409 . . . . 0.0 110.014 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.494 ' HD2' ' C ' ' A' ' 5' ' ' PHE . 13.4 mmmt -116.81 153.69 49.33 Favored Pre-proline 0 N--CA 1.433 -1.29 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 -178.251 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.6 Cg_exo -52.82 134.45 54.58 Favored 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 122.755 2.303 . . . . 0.0 112.369 177.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 107.58 -25.21 21.97 Favored Glycine 0 N--CA 1.432 -1.613 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.77 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -72.24 150.23 43.85 Favored 'General case' 0 C--O 1.252 1.216 0 CA-C-O 121.582 0.706 . . . . 0.0 112.224 -177.099 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 76.5 mt -100.04 127.96 46.19 Favored 'General case' 0 N--CA 1.423 -1.794 0 CA-C-N 114.352 -1.294 . . . . 0.0 109.754 -177.116 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 8.6 pt -140.12 -173.6 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 CA-C-O 122.348 1.071 . . . . 0.0 111.897 -174.446 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.414 ' HB3' ' HB3' ' A' ' 20' ' ' HIS . 66.5 m-85 -126.31 124.31 40.02 Favored 'General case' 0 N--CA 1.412 -2.363 0 N-CA-C 106.174 -1.787 . . . . 0.0 106.174 172.162 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.439 ' CB ' HG21 ' A' ' 42' ' ' ILE . . . -108.89 131.28 55.17 Favored 'General case' 0 C--N 1.28 -2.431 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.343 -174.572 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.625 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -113.54 122.18 46.46 Favored 'General case' 0 N--CA 1.401 -2.911 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.116 -177.76 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 70.2 mtm -110.43 158.03 18.93 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 175.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 60.2 tttm -67.29 116.62 8.26 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 110.145 -0.317 . . . . 0.0 110.145 -179.224 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.81 -2.75 62.26 Favored Glycine 0 C--O 1.248 0.975 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -121.86 151.79 58.32 Favored Pre-proline 0 N--CA 1.434 -1.268 0 C-N-CA 122.829 0.452 . . . . 0.0 109.905 -178.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -76.5 171.37 18.18 Favored 'Trans proline' 0 N--CA 1.448 -1.157 0 C-N-CA 122.296 1.997 . . . . 0.0 109.815 175.1 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' HIS . . . . . 0.536 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 76.2 m80 -66.76 110.94 3.46 Favored 'General case' 0 C--N 1.312 -1.061 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 176.269 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -99.88 138.15 20.29 Favored Pre-proline 0 C--N 1.296 -1.718 0 C-N-CA 123.942 0.897 . . . . 0.0 109.324 -171.316 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -63.59 118.28 5.22 Favored 'Trans proline' 0 C--O 1.244 0.808 0 C-N-CA 121.918 1.746 . . . . 0.0 110.043 177.219 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -141.82 167.54 21.91 Favored 'General case' 0 N--CA 1.415 -2.195 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.761 -175.195 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.409 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 56.1 ttt-85 -123.73 141.15 52.29 Favored 'General case' 0 C--N 1.289 -2.03 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 178.191 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 45.6 t -77.64 125.27 37.2 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 175.029 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 5.4 t70 -94.2 171.04 9.08 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 120.57 -0.452 . . . . 0.0 109.855 -175.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 . . . . . 0 C--N 1.305 -1.367 0 CA-C-O 121.915 0.864 . . . . 0.0 113.293 -178.116 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 62.6 mttp . . . . . 0 N--CA 1.424 -1.758 0 CA-C-O 120.826 0.346 . . . . 0.0 110.364 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 85.0 mt -112.55 147.29 36.77 Favored Pre-proline 0 C--N 1.286 -2.194 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.487 -176.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -73.73 122.58 7.89 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 121.749 1.632 . . . . 0.0 109.535 176.141 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.439 HG21 ' CB ' ' A' ' 13' ' ' ALA . 45.7 mm -118.22 111.01 32.32 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.251 -174.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.461 ' CZ ' ' HA ' ' A' ' 48' ' ' HIS . 91.1 t80 -91.24 118.73 30.72 Favored 'General case' 0 C--N 1.286 -2.153 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.288 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -83.03 133.23 35.1 Favored 'General case' 0 C--O 1.249 1.03 0 CA-C-O 121.107 0.479 . . . . 0.0 112.163 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.409 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 72.0 m-85 -81.43 152.34 27.45 Favored 'General case' 0 N--CA 1.433 -1.31 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.154 175.144 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.436 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 81.24 -19.47 8.2 Favored Glycine 0 C--N 1.309 -0.95 0 C-N-CA 123.366 0.507 . . . . 0.0 113.555 178.412 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.473 ' HB ' ' OE1' ' A' ' 49' ' ' GLU . 35.9 p -118.92 -22.78 7.17 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 122.267 -0.549 . . . . 0.0 110.578 176.426 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . 0.461 ' HA ' ' CZ ' ' A' ' 43' ' ' PHE . 13.3 m170 66.43 25.6 10.22 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 123.308 0.643 . . . . 0.0 110.879 -179.729 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.473 ' OE1' ' HB ' ' A' ' 47' ' ' THR . 45.9 mt-10 -97.45 175.47 6.22 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.454 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 10.0 m -143.76 143.85 31.56 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-O 121.172 0.511 . . . . 0.0 109.815 -179.241 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -131.37 178.26 6.85 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 114.814 -1.084 . . . . 0.0 109.675 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -133.38 109.82 9.6 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 176.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.416 HD12 ' HB1' ' A' ' 13' ' ' ALA . 88.9 mt -125.65 163.7 22.2 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 -177.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -85.22 162.8 37.05 Favored Glycine 0 N--CA 1.419 -2.454 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 178.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -63.88 -15.17 47.48 Favored 'Trans proline' 0 C--O 1.208 -0.989 0 C-N-CA 123.006 2.471 . . . . 0.0 112.257 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.08 4.96 51.1 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 115.648 -0.705 . . . . 0.0 112.75 178.002 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -113.67 1.77 15.02 Favored 'General case' 0 C--N 1.292 -1.911 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.143 177.155 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 17.6 pt -127.13 150.74 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.823 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.531 ' HB3' ' ND2' ' A' ' 64' ' ' ASN . 93.3 m-85 -136.29 142.37 39.45 Favored Pre-proline 0 C--N 1.295 -1.794 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo -65.09 137.88 54.25 Favored 'Trans proline' 0 C--O 1.249 1.046 0 C-N-CA 122.835 2.357 . . . . 0.0 112.922 -177.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.404 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 25.4 t80 -56.38 -42.69 78.29 Favored 'General case' 0 C--O 1.208 -1.093 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.172 178.335 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.6 m -53.87 -43.43 69.59 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 115.677 -0.692 . . . . 0.0 112.509 -175.259 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -95.62 -17.23 21.51 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.259 0.552 . . . . 0.0 112.031 -176.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.531 ' ND2' ' HB3' ' A' ' 59' ' ' PHE . 28.0 m-80 -116.73 10.54 14.32 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -173.027 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.508 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 19.4 pttp -68.69 -35.44 77.2 Favored 'General case' 0 C--O 1.21 -0.994 0 CA-C-O 121.137 0.494 . . . . 0.0 111.032 -177.296 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.508 ' OE1' ' HG3' ' A' ' 65' ' ' LYS . 2.1 mm-40 -73.01 -22.48 60.66 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 122.177 0.989 . . . . 0.0 108.819 -178.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.445 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 41.5 mtpt -83.42 -59.61 2.4 Favored 'General case' 0 N--CA 1.436 -1.148 0 CA-C-N 114.561 -1.2 . . . . 0.0 110.609 -177.606 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . 0.493 ' CD2' ' HB3' ' A' ' 64' ' ' ASN . 27.2 m-85 -105.72 -8.12 18.02 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 115.475 -0.784 . . . . 0.0 112.697 -169.35 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -79.25 52.12 4.01 Favored Glycine 0 C--O 1.219 -0.816 0 C-N-CA 121.583 -0.342 . . . . 0.0 112.781 -177.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.7 ptpp? -132.96 132.9 22.66 Favored Pre-proline 0 C--N 1.301 -1.536 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 176.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -65.49 128.89 21.17 Favored 'Trans proline' 0 N--CA 1.446 -1.316 0 C-N-CA 122.655 2.237 . . . . 0.0 115.531 -172.193 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.424 HD22 ' N ' ' A' ' 72' ' ' ASN . 0.8 OUTLIER -93.92 -170.81 2.41 Favored 'General case' 0 CA--C 1.487 -1.474 0 N-CA-C 106.205 -1.776 . . . . 0.0 106.205 173.829 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.503 ' HD3' ' HA ' ' A' ' 73' ' ' LYS 0.273 70.9 mmtt -110.09 28.93 8.12 Favored 'General case' 0 C--N 1.291 -1.977 0 CA-C-O 122.593 1.187 . . . . 0.0 110.592 171.35 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 14.7 mmt180 -82.51 125.34 31.01 Favored 'General case' 0 C--O 1.25 1.099 0 N-CA-C 106.341 -1.725 . . . . 0.0 106.341 170.511 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.401 ' HG3' ' OE2' ' A' ' 79' ' ' GLU . 61.2 tttp -66.73 139.24 57.81 Favored 'General case' 0 C--N 1.318 -0.798 0 C-N-CA 119.83 -0.748 . . . . 0.0 109.882 176.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.436 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 95.87 -25.2 26.28 Favored Glycine 0 N--CA 1.428 -1.895 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -175.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.402 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 31.7 t80 -75.87 -47.06 26.98 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-O 121.196 0.522 . . . . 0.0 109.702 -178.062 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.546 ' N ' HD22 ' A' ' 78' ' ' ASN . 0.7 OUTLIER -67.4 -37.86 83.76 Favored 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.892 0.853 . . . . 0.0 109.142 -179.256 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . 0.401 ' OE2' ' HG3' ' A' ' 75' ' ' LYS . 26.1 mt-10 -72.44 -36.1 68.46 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 114.024 -1.444 . . . . 0.0 109.593 -179.158 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -69.66 -33.89 72.08 Favored Glycine 0 CA--C 1.494 -1.271 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.641 178.455 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.402 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 94.7 mt -60.51 -38.79 85.52 Favored 'General case' 0 C--O 1.21 -0.976 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 174.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 85.4 t90 -66.66 -46.07 76.89 Favored 'General case' 0 N--CA 1.429 -1.476 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.695 177.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -61.48 -43.46 98.82 Favored 'General case' 0 C--O 1.204 -1.339 0 N-CA-C 113.076 0.769 . . . . 0.0 113.076 179.564 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.1 tt -70.8 -33.45 52.52 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 120.379 -0.528 . . . . 0.0 112.056 -175.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -88.98 -5.85 57.66 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 112.758 0.651 . . . . 0.0 112.758 -178.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 31.9 m-80 -123.57 -51.12 1.84 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-O 121.388 0.613 . . . . 0.0 112.089 -179.137 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.7 t30 -126.45 67.56 65.59 Favored Pre-proline 0 C--N 1.305 -1.341 0 O-C-N 121.94 -0.475 . . . . 0.0 110.186 -179.422 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -74.78 -5.95 17.51 Favored 'Trans proline' 0 N--CA 1.48 0.698 0 C-N-CA 122.314 2.009 . . . . 0.0 112.289 -175.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.7 pttp . . . . . 0 C--N 1.3 -1.573 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.083 -178.404 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 . . . . . 0 N--CA 1.422 -1.851 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.592 ' HG2' ' OD2' ' A' ' 9' ' ' ASP . 1.6 pttm -135.22 152.49 76.96 Favored Pre-proline 0 C--N 1.289 -2.039 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 -175.277 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo -49.09 121.7 7.25 Favored 'Trans proline' 0 C--N 1.352 0.723 0 C-N-CA 122.657 2.238 . . . . 0.0 111.138 176.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.38 -30.48 6.45 Favored Glycine 0 N--CA 1.423 -2.206 0 CA-C-O 118.991 -0.894 . . . . 0.0 113.637 -178.51 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.592 ' OD2' ' HG2' ' A' ' 6' ' ' LYS 0.335 2.9 p30 -78.71 147.93 33.27 Favored 'General case' 0 C--O 1.248 1.009 0 CA-C-N 118.859 1.329 . . . . 0.0 113.268 -179.161 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.425 HD22 HG13 ' A' ' 84' ' ' ILE . 82.3 mt -91.42 129.1 37.45 Favored 'General case' 0 CA--C 1.488 -1.44 0 CA-C-N 114.203 -1.362 . . . . 0.0 110.312 -175.783 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 12.1 pt -140.39 -173.03 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 CA-C-O 122.374 1.083 . . . . 0.0 111.993 -174.118 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 38.4 m-85 -120.71 132.33 55.01 Favored 'General case' 0 N--CA 1.414 -2.236 0 CA-C-N 113.979 -1.464 . . . . 0.0 107.077 171.344 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.502 ' HB2' HG21 ' A' ' 42' ' ' ILE . . . -108.92 124.02 50.0 Favored 'General case' 0 C--N 1.272 -2.788 0 O-C-N 123.947 0.779 . . . . 0.0 109.337 -178.811 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.634 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -109.33 120.27 42.0 Favored 'General case' 0 N--CA 1.398 -3.043 0 CA-C-N 116.184 -0.462 . . . . 0.0 109.916 -179.145 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 66.5 mtm -114.68 157.89 22.52 Favored 'General case' 0 C--N 1.314 -0.977 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 175.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 41.7 ttmt -66.31 117.63 8.85 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 116.712 -0.222 . . . . 0.0 110.429 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.92 -3.88 65.17 Favored Glycine 0 C--O 1.251 1.206 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.651 178.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 77.5 m-85 -120.9 151.44 54.85 Favored Pre-proline 0 N--CA 1.428 -1.573 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 -179.211 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -77.58 171.27 17.81 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 122.112 1.875 . . . . 0.0 109.611 175.562 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' HIS . . . . . 0.459 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 70.0 m80 -63.15 110.99 2.03 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 174.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 7.5 t-105 -99.4 137.68 20.37 Favored Pre-proline 0 C--N 1.303 -1.456 0 C-N-CA 123.331 0.653 . . . . 0.0 109.239 -172.535 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -63.97 117.83 4.81 Favored 'Trans proline' 0 C--O 1.245 0.863 0 C-N-CA 121.796 1.664 . . . . 0.0 110.089 176.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.21 167.83 21.21 Favored 'General case' 0 N--CA 1.413 -2.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.143 -175.109 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.415 HH22 ' CD ' ' A' ' 27' ' ' GLU . 10.6 ttp180 -124.7 148.06 48.23 Favored 'General case' 0 C--N 1.282 -2.33 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 176.571 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.7 t -72.41 118.69 17.84 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 N-CA-C 105.275 -2.12 . . . . 0.0 105.275 170.31 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -84.76 172.43 11.49 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -171.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.415 ' CD ' HH22 ' A' ' 24' ' ' ARG . 0.5 OUTLIER . . . . . 0 C--N 1.309 -1.158 0 CA-C-O 121.669 0.747 . . . . 0.0 112.533 -175.465 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 63.0 mttp . . . . . 0 N--CA 1.418 -2.051 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.429 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 92.8 mt -98.89 141.6 23.16 Favored Pre-proline 0 C--N 1.287 -2.148 0 O-C-N 123.977 0.798 . . . . 0.0 109.937 -176.537 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -70.65 123.27 9.65 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.053 1.836 . . . . 0.0 109.429 176.082 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.502 HG21 ' HB2' ' A' ' 13' ' ' ALA . 39.5 mm -116.35 117.05 54.21 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.123 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 -175.775 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 72.7 t80 -94.28 115.89 28.2 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -81.54 129.1 34.54 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 123.425 0.453 . . . . 0.0 111.387 177.821 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -80.07 150.64 30.24 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.694 176.249 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.513 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 80.78 -19.91 6.95 Favored Glycine 0 C--N 1.311 -0.827 0 CA-C-N 116.216 -0.447 . . . . 0.0 113.739 179.152 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.4 p -119.33 -23.74 6.61 Favored 'General case' 0 C--N 1.309 -1.16 0 O-C-N 122.074 -0.662 . . . . 0.0 110.556 174.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 68.02 13.66 9.17 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 123.987 0.915 . . . . 0.0 112.231 -178.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.7 mm-40 -76.52 164.11 26.27 Favored 'General case' 0 CA--C 1.493 -1.226 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.263 178.222 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.411 ' HA ' ' O ' ' A' ' 42' ' ' ILE . 4.2 m -133.2 136.85 45.9 Favored 'General case' 0 C--N 1.283 -2.298 0 CA-C-O 121.425 0.631 . . . . 0.0 109.773 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -128.53 178.02 6.6 Favored 'General case' 0 C--N 1.284 -2.256 0 CA-C-N 115.013 -0.994 . . . . 0.0 109.914 -179.302 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.429 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 95.9 m-85 -133.63 110.25 9.75 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 176.527 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 94.9 mt -124.71 160.53 28.36 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 -179.35 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -87.81 167.53 36.73 Favored Glycine 0 N--CA 1.42 -2.383 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 178.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.402 ' HA ' HD11 ' A' ' 58' ' ' ILE . 38.1 Cg_endo -66.65 -6.96 16.65 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 123.16 2.573 . . . . 0.0 112.334 -178.782 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 7.9 ptmm? -97.31 -4.32 38.89 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.415 178.411 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.2 m-20 -115.27 5.66 14.76 Favored 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.891 -176.587 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.402 HD11 ' HA ' ' A' ' 55' ' ' PRO . 14.3 pt -131.38 150.7 34.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.796 0 CA-C-N 114.737 -1.12 . . . . 0.0 108.981 179.885 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -141.66 147.19 44.65 Favored Pre-proline 0 C--N 1.295 -1.778 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 -179.371 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -62.06 133.24 43.06 Favored 'Trans proline' 0 CA--C 1.511 -0.667 0 C-N-CA 123.043 2.495 . . . . 0.0 113.256 -177.45 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -64.62 -36.97 85.98 Favored 'General case' 0 C--O 1.207 -1.177 0 CA-C-N 114.88 -1.055 . . . . 0.0 110.7 -177.214 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 10.6 m -63.95 -39.65 94.64 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.239 -178.22 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -89.05 -7.43 55.9 Favored 'General case' 0 C--O 1.218 -0.582 0 N-CA-C 111.879 0.326 . . . . 0.0 111.879 -177.534 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 39.0 m-80 -123.92 13.39 9.16 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -179.476 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.8 ttmm -67.05 -34.36 77.51 Favored 'General case' 0 N--CA 1.473 0.694 0 CA-C-O 121.667 0.746 . . . . 0.0 109.648 -179.669 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.573 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -79.16 -20.25 48.96 Favored 'General case' 0 N--CA 1.408 -2.55 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.347 178.072 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.573 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 8.2 mttm -87.92 -59.28 2.29 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.979 179.529 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 66.0 m-85 -112.53 1.32 15.81 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.3 -171.789 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.6 55.97 4.15 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 111.601 -0.599 . . . . 0.0 111.601 178.229 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 58.4 mttp -129.54 123.71 21.48 Favored Pre-proline 0 C--N 1.31 -1.131 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 -179.712 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -63.0 128.2 22.35 Favored 'Trans proline' 0 N--CA 1.444 -1.424 0 C-N-CA 121.839 1.693 . . . . 0.0 114.132 -175.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -93.24 -171.84 2.78 Favored 'General case' 0 CA--C 1.482 -1.667 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 176.44 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.465 ' HA ' ' HD3' ' A' ' 73' ' ' LYS 0.268 71.4 mmtt -109.42 27.56 9.42 Favored 'General case' 0 C--N 1.289 -2.045 0 CA-C-O 122.613 1.197 . . . . 0.0 110.361 171.041 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 13.8 mmt180 -80.14 127.64 32.56 Favored 'General case' 0 C--O 1.25 1.11 0 N-CA-C 105.168 -2.16 . . . . 0.0 105.168 169.421 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.412 ' HG2' ' HZ3' ' A' ' 75' ' ' LYS . 42.9 tttm -67.77 141.89 56.41 Favored 'General case' 0 C--N 1.32 -0.699 0 C-N-CA 119.228 -0.989 . . . . 0.0 108.721 179.456 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.513 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 94.17 -25.31 22.83 Favored Glycine 0 N--CA 1.426 -1.985 0 C-N-CA 120.881 -0.676 . . . . 0.0 111.846 -177.08 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.423 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 20.6 t80 -72.87 -44.73 60.98 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.336 0.588 . . . . 0.0 109.585 -177.613 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.569 HD22 ' N ' ' A' ' 78' ' ' ASN . 0.7 OUTLIER -70.34 -42.21 72.18 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 -178.949 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -65.99 -38.48 88.59 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-N 114.447 -1.251 . . . . 0.0 109.451 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -68.51 -34.84 80.07 Favored Glycine 0 N--CA 1.433 -1.505 0 CA-C-N 115.349 -0.842 . . . . 0.0 113.057 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.423 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 94.6 mt -60.61 -35.43 76.12 Favored 'General case' 0 C--O 1.216 -0.668 0 CA-C-O 121.309 0.576 . . . . 0.0 109.782 175.701 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 83.1 t90 -70.78 -48.97 51.46 Favored 'General case' 0 N--CA 1.433 -1.284 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.724 176.53 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -58.15 -45.33 87.61 Favored 'General case' 0 C--O 1.205 -1.289 0 N-CA-C 113.042 0.756 . . . . 0.0 113.042 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.425 HG13 HD22 ' A' ' 10' ' ' LEU . 20.7 tt -68.82 -31.23 49.86 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -174.021 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -90.58 -10.34 43.77 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -179.027 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 31.7 m-80 -117.78 -53.99 2.37 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-O 121.223 0.535 . . . . 0.0 112.215 -178.373 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -127.86 75.77 77.92 Favored Pre-proline 0 C--N 1.304 -1.396 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.189 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.81 -7.7 21.97 Favored 'Trans proline' 0 N--CA 1.488 1.188 0 C-N-CA 122.87 2.38 . . . . 0.0 112.688 -176.569 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.3 pttp . . . . . 0 C--N 1.302 -1.461 0 C-N-CA 123.982 0.913 . . . . 0.0 109.738 -178.344 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . 0.452 ' CE2' HG13 ' A' ' 58' ' ' ILE . 88.9 m-85 . . . . . 0 N--CA 1.432 -1.341 0 CA-C-O 121.758 0.79 . . . . 0.0 113.053 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.636 ' HG2' ' OD2' ' A' ' 9' ' ' ASP . 16.8 pttm -134.6 160.09 69.74 Favored Pre-proline 0 C--N 1.305 -1.35 0 CA-C-N 114.889 -1.05 . . . . 0.0 108.336 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -51.25 122.65 10.46 Favored 'Trans proline' 0 C--N 1.347 0.499 0 C-N-CA 122.496 2.131 . . . . 0.0 111.879 175.328 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.1 -22.59 11.25 Favored Glycine 0 N--CA 1.429 -1.77 0 CA-C-O 119.351 -0.694 . . . . 0.0 113.381 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.636 ' OD2' ' HG2' ' A' ' 6' ' ' LYS . 37.3 m-20 -66.0 128.95 38.09 Favored 'General case' 0 C--O 1.247 0.953 0 CA-C-N 117.659 0.729 . . . . 0.0 112.097 -179.456 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.4 HD21 ' HB2' ' A' ' 88' ' ' PRO . 77.2 mt -83.83 124.43 30.94 Favored 'General case' 0 CA--C 1.485 -1.545 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 176.036 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 10.3 pt -140.24 -174.3 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 CA-C-O 122.367 1.079 . . . . 0.0 112.261 -172.137 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.493 ' HB3' ' HB3' ' A' ' 20' ' ' HIS . 45.6 m-85 -119.77 126.96 52.32 Favored 'General case' 0 N--CA 1.404 -2.741 0 CA-C-N 113.181 -1.827 . . . . 0.0 106.973 170.529 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.434 ' CB ' HG21 ' A' ' 42' ' ' ILE . . . -108.98 121.76 45.81 Favored 'General case' 0 C--N 1.27 -2.869 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.312 -178.241 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.617 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -104.77 119.57 39.3 Favored 'General case' 0 N--CA 1.401 -2.887 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.939 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 72.4 mtm -104.07 159.01 16.03 Favored 'General case' 0 C--N 1.312 -1.058 0 C-N-CA 123.172 0.589 . . . . 0.0 110.215 179.406 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.4 tttp -65.37 116.22 6.45 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.553 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.13 -8.04 64.75 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.627 178.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 65.8 m-85 -128.72 147.85 66.09 Favored Pre-proline 0 N--CA 1.444 -0.744 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -178.647 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -68.7 170.89 14.26 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.845 2.363 . . . . 0.0 111.909 177.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' HIS . . . . . 0.561 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 74.6 m80 -60.83 111.64 1.73 Allowed 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.114 178.229 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 4.0 t-105 -101.85 136.89 19.44 Favored Pre-proline 0 C--N 1.313 -1.002 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -176.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -64.7 117.64 4.7 Favored 'Trans proline' 0 C--O 1.241 0.649 0 C-N-CA 121.779 1.653 . . . . 0.0 110.432 176.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -141.16 167.38 22.32 Favored 'General case' 0 N--CA 1.413 -2.282 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.69 -174.749 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 32.7 ttt180 -109.96 138.35 46.46 Favored 'General case' 0 C--N 1.291 -1.969 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 176.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 64.4 t -74.68 111.68 10.92 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.068 0 N-CA-C 103.501 -2.777 . . . . 0.0 103.501 166.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -86.26 -177.58 6.27 Favored 'General case' 0 C--N 1.282 -2.329 0 C-N-CA 119.543 -0.863 . . . . 0.0 112.105 -169.728 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 . . . . . 0 C--N 1.294 -1.838 0 CA-C-O 121.966 0.889 . . . . 0.0 112.861 -171.776 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 62.5 mttp . . . . . 0 N--CA 1.429 -1.497 0 N-CA-C 108.644 -0.873 . . . . 0.0 108.644 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 96.5 mt -97.42 139.93 21.72 Favored Pre-proline 0 C--N 1.293 -1.876 0 O-C-N 123.995 0.809 . . . . 0.0 109.87 -179.333 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -70.29 123.45 9.94 Favored 'Trans proline' 0 N--CA 1.46 -0.475 0 C-N-CA 122.484 2.123 . . . . 0.0 110.247 177.512 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.434 HG21 ' CB ' ' A' ' 13' ' ' ALA . 42.4 mm -117.8 120.52 64.9 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.788 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 -177.072 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 93.0 t80 -105.22 117.68 34.63 Favored 'General case' 0 C--N 1.286 -2.194 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 178.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.432 ' HE2' ' HB2' ' A' ' 51' ' ' ALA . 89.6 m-85 -82.93 135.69 34.82 Favored 'General case' 0 C--N 1.308 -1.212 0 CA-C-O 121.435 0.636 . . . . 0.0 112.332 179.493 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -85.48 151.72 23.75 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.469 178.155 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.427 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 80.84 -20.91 5.96 Favored Glycine 0 C--N 1.309 -0.939 0 C-N-CA 124.553 1.073 . . . . 0.0 114.124 177.657 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.499 ' CG2' ' HA3' ' A' ' 76' ' ' GLY . 37.0 p -119.8 -23.14 6.55 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-N 117.279 0.539 . . . . 0.0 110.201 175.084 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 43.4 m170 67.96 22.37 8.6 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.282 -178.263 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -71.75 164.2 26.41 Favored 'General case' 0 C--N 1.346 0.418 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 176.254 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.4 m -138.37 140.92 39.62 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -179.806 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.432 ' HB2' ' HE2' ' A' ' 44' ' ' PHE . . . -141.41 177.68 7.95 Favored 'General case' 0 C--N 1.289 -2.034 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.183 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 95.7 m-85 -134.36 117.57 16.49 Favored 'General case' 0 N--CA 1.434 -1.238 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 176.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.413 HD12 ' HB1' ' A' ' 13' ' ' ALA . 90.7 mt -127.61 169.27 13.94 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.257 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.26 162.8 29.84 Favored Glycine 0 N--CA 1.413 -2.846 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -66.78 -5.98 14.52 Favored 'Trans proline' 0 N--CA 1.487 1.125 0 C-N-CA 123.88 3.053 . . . . 0.0 112.578 -179.476 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.3 ptmm? -97.89 -6.98 31.2 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 114.875 -1.057 . . . . 0.0 111.686 177.186 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -112.52 6.26 18.4 Favored 'General case' 0 C--N 1.294 -1.806 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.995 -175.432 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.452 HG13 ' CE2' ' A' ' 5' ' ' PHE . 14.2 pt -127.28 147.06 32.16 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 CA-C-N 114.853 -1.067 . . . . 0.0 110.396 179.39 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 -140.26 147.62 50.82 Favored Pre-proline 0 C--N 1.302 -1.474 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -177.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -62.09 132.34 38.73 Favored 'Trans proline' 0 N--CA 1.481 0.749 0 C-N-CA 123.315 2.677 . . . . 0.0 113.955 -176.617 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.443 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 77.8 t80 -61.03 -40.7 94.59 Favored 'General case' 0 C--O 1.207 -1.136 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.652 -178.406 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 m -60.45 -40.15 90.11 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.81 -175.583 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -95.25 -4.08 46.39 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 115.763 -0.653 . . . . 0.0 112.193 -174.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 29.6 m-80 -125.64 15.36 8.15 Favored 'General case' 0 N--CA 1.446 -0.645 0 CA-C-O 120.427 0.156 . . . . 0.0 111.404 178.589 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 57.2 tttp -69.58 -36.2 76.04 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 121.627 0.727 . . . . 0.0 109.545 -178.355 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.561 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -75.15 -22.42 58.13 Favored 'General case' 0 N--CA 1.416 -2.131 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.964 176.502 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.561 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 7.8 mtmm -84.84 -54.08 4.91 Favored 'General case' 0 N--CA 1.437 -1.09 0 CA-C-N 115.743 -0.662 . . . . 0.0 112.621 179.661 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -122.0 -4.21 9.07 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -173.116 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.69 52.21 4.38 Favored Glycine 0 N--CA 1.468 0.826 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.103 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.2 ptpt -133.01 156.27 80.24 Favored Pre-proline 0 C--N 1.306 -1.325 0 C-N-CA 123.456 0.703 . . . . 0.0 109.676 -177.464 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_exo -49.15 153.11 4.52 Favored 'Trans proline' 0 C--N 1.355 0.897 0 C-N-CA 123.781 2.987 . . . . 0.0 115.889 -177.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -136.53 -173.38 3.4 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 114.545 -1.207 . . . . 0.0 109.106 179.634 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 47.5 mmtm -100.8 -14.54 17.97 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 179.222 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 4.1 mmm180 -70.79 123.53 22.17 Favored 'General case' 0 N--CA 1.436 -1.147 0 CA-C-O 121.186 0.517 . . . . 0.0 110.697 175.031 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 16.6 tppt? -68.38 126.4 29.49 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 174.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.499 ' HA3' ' CG2' ' A' ' 47' ' ' THR . . . 108.56 -19.53 31.1 Favored Glycine 0 N--CA 1.416 -2.668 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -177.013 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.436 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 16.6 t80 -76.31 -45.49 32.14 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -179.584 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.7 m-80 -69.91 -39.94 75.89 Favored 'General case' 0 CA--C 1.5 -0.957 0 CA-C-O 121.942 0.877 . . . . 0.0 108.957 -179.624 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 30.4 mp0 -64.87 -36.22 83.66 Favored 'General case' 0 N--CA 1.425 -1.72 0 CA-C-N 114.06 -1.427 . . . . 0.0 109.468 177.317 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.35 -31.48 68.64 Favored Glycine 0 CA--C 1.49 -1.49 0 CA-C-N 115.385 -0.825 . . . . 0.0 112.431 178.756 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.436 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 96.0 mt -58.84 -39.98 82.89 Favored 'General case' 0 C--O 1.212 -0.913 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 174.481 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 83.1 t90 -67.97 -48.7 65.11 Favored 'General case' 0 N--CA 1.432 -1.365 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.283 177.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -59.31 -43.4 92.64 Favored 'General case' 0 C--O 1.207 -1.135 0 N-CA-C 113.5 0.926 . . . . 0.0 113.5 -179.258 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.1 tt -71.98 -28.44 30.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 C-N-CA 120.23 -0.588 . . . . 0.0 112.209 -174.354 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -86.86 -17.37 33.49 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 112.062 0.393 . . . . 0.0 112.062 179.457 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 32.1 m-80 -114.46 -51.19 2.77 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-O 121.366 0.603 . . . . 0.0 112.471 -175.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.8 t30 -127.93 68.16 75.0 Favored Pre-proline 0 C--N 1.305 -1.364 0 O-C-N 121.883 -0.511 . . . . 0.0 110.678 -178.369 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.4 ' HB2' HD21 ' A' ' 10' ' ' LEU . 61.6 Cg_endo -75.77 -5.83 16.86 Favored 'Trans proline' 0 C--N 1.348 0.508 0 C-N-CA 122.025 1.817 . . . . 0.0 112.208 -177.591 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 19.8 pttp . . . . . 0 C--N 1.299 -1.592 0 CA-C-N 114.737 -1.119 . . . . 0.0 110.429 -178.779 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 . . . . . 0 N--CA 1.42 -1.965 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.1 mttp -105.45 153.53 39.69 Favored Pre-proline 0 C--N 1.298 -1.656 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.638 -172.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -62.44 116.51 3.56 Favored 'Trans proline' 0 N--CA 1.457 -0.667 0 N-CA-C 107.921 -1.607 . . . . 0.0 107.921 170.397 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 108.62 -10.34 35.35 Favored Glycine 0 N--CA 1.426 -1.974 0 C-N-CA 120.833 -0.698 . . . . 0.0 112.172 -175.426 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -73.09 154.96 40.18 Favored 'General case' 0 C--O 1.253 1.245 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 -178.397 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.493 HD21 ' HB2' ' A' ' 88' ' ' PRO . 79.9 mt -105.36 123.67 48.26 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 -173.439 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.9 pp -140.28 177.56 4.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 CA-C-O 122.058 0.932 . . . . 0.0 112.934 -174.14 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.527 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 74.6 m-85 -110.31 129.54 55.72 Favored 'General case' 0 C--N 1.284 -2.263 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 170.662 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.404 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -108.0 118.49 36.88 Favored 'General case' 0 C--N 1.277 -2.569 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.136 -176.345 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.614 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -107.14 122.64 46.91 Favored 'General case' 0 N--CA 1.4 -2.957 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.384 -179.092 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.47 ' HG2' HD21 ' A' ' 53' ' ' LEU . 30.2 mtm -127.08 158.25 37.49 Favored 'General case' 0 CA--C 1.493 -1.22 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 176.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -64.17 117.23 6.84 Favored 'General case' 0 C--N 1.307 -1.255 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 178.44 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.05 -16.11 57.47 Favored Glycine 0 C--O 1.249 1.034 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 -178.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -105.47 151.04 39.65 Favored Pre-proline 0 N--CA 1.43 -1.466 0 C-N-CA 123.175 0.59 . . . . 0.0 109.623 178.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -83.12 171.69 11.3 Favored 'Trans proline' 0 N--CA 1.439 -1.685 0 C-N-CA 122.122 1.882 . . . . 0.0 107.416 169.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' HIS . . . . . 0.489 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 70.6 m80 -61.83 109.97 1.4 Allowed 'General case' 0 CA--C 1.542 0.648 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 174.023 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -105.15 136.79 19.14 Favored Pre-proline 0 C--N 1.305 -1.342 0 C-N-CA 123.131 0.572 . . . . 0.0 109.53 -170.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -65.02 117.84 4.9 Favored 'Trans proline' 0 N--CA 1.455 -0.754 0 C-N-CA 121.321 1.347 . . . . 0.0 110.433 177.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.92 166.61 24.15 Favored 'General case' 0 N--CA 1.413 -2.292 0 CA-C-O 121.279 0.561 . . . . 0.0 110.157 -175.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.473 ' HB2' ' CE2' ' A' ' 45' ' ' PHE . 31.7 ttp85 -116.68 145.83 43.17 Favored 'General case' 0 C--N 1.283 -2.303 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.554 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.6 t -76.49 123.88 33.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 105.302 -2.11 . . . . 0.0 105.302 171.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -90.93 -177.1 4.85 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -173.478 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.404 ' CD ' HH22 ' A' ' 24' ' ' ARG . 15.0 mp0 . . . . . 0 N--CA 1.423 -1.809 0 CA-C-O 121.87 0.843 . . . . 0.0 111.499 -176.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.557 ' HE2' ' N ' ' A' ' 54' ' ' GLY . 30.3 mtpt . . . . . 0 N--CA 1.429 -1.475 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.401 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 91.8 mt -88.16 147.05 39.54 Favored Pre-proline 0 C--N 1.304 -1.388 0 C-N-CA 122.721 0.408 . . . . 0.0 110.369 -176.033 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -71.54 123.87 9.84 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.438 2.092 . . . . 0.0 110.295 177.419 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 49.3 mm -119.02 125.17 74.27 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 O-C-N 122.064 -0.398 . . . . 0.0 110.613 -176.344 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -104.77 114.52 28.79 Favored 'General case' 0 C--N 1.288 -2.104 0 C-N-CA 123.431 0.692 . . . . 0.0 109.144 177.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.417 ' HE2' ' HB2' ' A' ' 51' ' ' ALA . 96.9 m-85 -77.97 137.27 38.22 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.014 0.435 . . . . 0.0 111.681 178.035 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.473 ' CE2' ' HB2' ' A' ' 24' ' ' ARG . 70.5 m-85 -89.16 156.44 18.79 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.492 177.168 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.442 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 74.02 -20.78 1.44 Allowed Glycine 0 N--CA 1.469 0.878 0 C-N-CA 124.578 1.085 . . . . 0.0 114.454 178.734 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.2 p -119.15 -22.67 7.08 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 173.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 11.2 m170 65.87 24.7 11.27 Favored 'General case' 0 C--N 1.348 0.519 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.107 179.06 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -73.34 167.39 21.33 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 115.388 -0.824 . . . . 0.0 108.904 176.794 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.6 m -137.82 140.81 40.71 Favored 'General case' 0 C--N 1.287 -2.122 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.417 ' HB2' ' HE2' ' A' ' 44' ' ' PHE . . . -145.37 -179.32 6.58 Favored 'General case' 0 C--N 1.293 -1.859 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.131 -178.202 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.401 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 83.4 m-85 -132.2 110.71 10.84 Favored 'General case' 0 C--O 1.246 0.886 0 CA-C-N 115.217 -0.902 . . . . 0.0 109.427 177.193 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.532 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 93.8 mt -129.48 154.64 46.8 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.656 -177.415 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.557 ' N ' ' HE2' ' A' ' 39' ' ' LYS . . . -95.87 176.34 33.32 Favored Glycine 0 N--CA 1.432 -1.585 0 C-N-CA 120.016 -1.088 . . . . 0.0 111.301 -174.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -66.22 -7.53 17.63 Favored 'Trans proline' 0 C--O 1.239 0.566 0 C-N-CA 122.966 2.444 . . . . 0.0 112.311 -178.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.7 mtpp -97.3 -15.16 20.9 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.238 177.054 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.532 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 40.9 m-20 -93.39 -14.38 26.89 Favored 'General case' 0 CA--C 1.49 -1.346 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.084 -178.488 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.446 ' HA ' ' O ' ' A' ' 12' ' ' PHE . 17.9 pt -119.12 148.58 21.96 Favored 'Isoleucine or valine' 0 C--O 1.268 2.04 0 CA-C-O 122.482 1.134 . . . . 0.0 112.849 -171.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 80.8 m-85 -136.08 133.25 19.56 Favored Pre-proline 0 C--N 1.292 -1.895 0 CA-C-N 113.885 -1.507 . . . . 0.0 106.951 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . 0.49 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 35.8 Cg_endo -64.12 127.91 20.45 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.881 2.388 . . . . 0.0 113.147 -177.2 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.527 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 72.0 t80 -58.86 -35.38 72.85 Favored 'General case' 0 C--O 1.197 -1.674 0 CA-C-N 114.062 -1.426 . . . . 0.0 112.915 -174.78 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.427 ' HB3' ' OE1' ' A' ' 63' ' ' GLU . 28.2 t -67.63 -52.19 41.15 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.191 0.52 . . . . 0.0 110.478 -177.808 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.49 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 2.6 mp0 -81.32 -5.67 58.07 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.128 -175.58 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.409 ' OD1' ' HE2' ' A' ' 67' ' ' LYS . 24.2 m-80 -126.59 15.12 7.61 Favored 'General case' 0 C--N 1.311 -1.079 0 C-N-CA 122.893 0.477 . . . . 0.0 111.557 -179.558 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -67.85 -35.89 79.36 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-O 121.722 0.772 . . . . 0.0 110.093 -179.488 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.606 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -72.01 -28.31 63.31 Favored 'General case' 0 N--CA 1.408 -2.566 0 CA-C-N 115.648 -0.705 . . . . 0.0 111.99 176.864 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.606 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 7.0 mtmm -80.2 -58.17 3.27 Favored 'General case' 0 N--CA 1.439 -0.979 0 CA-C-N 115.729 -0.668 . . . . 0.0 112.452 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 76.4 m-85 -113.67 -10.98 13.02 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -172.368 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.4 56.22 4.09 Favored Glycine 0 C--N 1.314 -0.648 0 C-N-CA 121.332 -0.461 . . . . 0.0 112.834 -177.556 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.419 ' O ' ' HE1' ' A' ' 77' ' ' PHE . 4.5 ptpp? -132.54 147.42 65.53 Favored Pre-proline 0 C--N 1.303 -1.416 0 CA-C-O 119.244 -0.408 . . . . 0.0 110.084 178.702 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.445 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 87.0 Cg_exo -50.2 156.92 3.36 Favored 'Trans proline' 0 C--N 1.355 0.914 0 C-N-CA 124.031 3.154 . . . . 0.0 114.803 -179.413 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -143.04 -173.34 3.88 Favored 'General case' 0 N--CA 1.433 -1.29 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.532 179.189 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.411 ' HD3' ' N ' ' A' ' 73' ' ' LYS . 0.1 OUTLIER -93.79 1.11 56.55 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.047 -179.809 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 30.9 mmt180 -82.79 120.6 25.83 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.687 176.72 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.441 ' HD3' ' N ' ' A' ' 76' ' ' GLY . 8.1 tmtt? -70.03 127.15 31.85 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 175.316 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.442 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 106.8 -25.41 22.7 Favored Glycine 0 CA--C 1.501 -0.817 0 N-CA-C 110.598 -1.001 . . . . 0.0 110.598 -178.821 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.419 ' HE1' ' O ' ' A' ' 70' ' ' LYS . 54.1 t80 -72.11 -42.06 66.51 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-O 121.74 0.781 . . . . 0.0 109.557 -177.432 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.445 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 87.2 m-20 -79.07 -33.81 44.24 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.668 -173.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -71.55 -33.37 69.06 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 175.111 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.34 -37.26 70.52 Favored Glycine 0 N--CA 1.432 -1.601 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.432 177.395 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 43.9 tp -59.74 -33.58 71.83 Favored 'General case' 0 N--CA 1.434 -1.249 0 C-N-CA 124.007 0.923 . . . . 0.0 108.855 175.03 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 82.0 t90 -72.46 -51.02 21.98 Favored 'General case' 0 N--CA 1.434 -1.236 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.022 175.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 35.6 mt-10 -53.8 -49.76 67.63 Favored 'General case' 0 C--O 1.206 -1.189 0 N-CA-C 112.797 0.666 . . . . 0.0 112.797 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 19.3 tt -67.94 -23.87 29.69 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 N-CA-C 112.573 0.583 . . . . 0.0 112.573 -173.782 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -94.31 -22.67 18.21 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 121.409 0.623 . . . . 0.0 110.686 -176.417 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 28.4 m-80 -105.97 -55.17 2.37 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-O 121.435 0.636 . . . . 0.0 111.785 -176.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 67.4 t30 -127.62 72.61 78.13 Favored Pre-proline 0 C--N 1.312 -1.032 0 C-N-CA 119.969 -0.693 . . . . 0.0 110.228 179.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.493 ' HB2' HD21 ' A' ' 10' ' ' LEU . 57.0 Cg_endo -74.81 -6.76 18.57 Favored 'Trans proline' 0 C--O 1.221 -0.326 0 C-N-CA 122.128 1.886 . . . . 0.0 112.815 -176.223 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.4 pttm . . . . . 0 C--N 1.303 -1.413 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.986 -178.085 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 . . . . . 0 N--CA 1.425 -1.717 0 N-CA-C 107.753 -1.202 . . . . 0.0 107.753 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.506 ' H ' ' HB2' ' A' ' 9' ' ' ASP . 32.3 mttp -104.76 158.36 32.18 Favored Pre-proline 0 C--N 1.298 -1.661 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -174.793 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.484 ' HB3' ' HA ' ' A' ' 27' ' ' GLU . 37.1 Cg_exo -63.46 117.02 3.99 Favored 'Trans proline' 0 N--CA 1.451 -0.986 0 N-CA-C 107.385 -1.813 . . . . 0.0 107.385 167.296 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 101.66 -1.42 52.72 Favored Glycine 0 N--CA 1.435 -1.421 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.458 -175.602 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.506 ' HB2' ' H ' ' A' ' 6' ' ' LYS . 4.9 t70 -78.11 154.94 30.82 Favored 'General case' 0 C--O 1.254 1.339 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 64.3 mt -102.54 124.83 48.82 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.44 -172.542 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.41 HD11 HD12 ' A' ' 42' ' ' ILE . 7.9 pt -141.39 -177.11 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.825 0 CA-C-O 122.295 1.045 . . . . 0.0 112.82 -174.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.509 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 76.4 m-85 -120.83 126.49 50.2 Favored 'General case' 0 N--CA 1.417 -2.099 0 C-N-CA 126.232 1.813 . . . . 0.0 106.241 170.771 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.479 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -108.96 128.85 55.3 Favored 'General case' 0 C--N 1.27 -2.859 0 O-C-N 123.625 0.578 . . . . 0.0 109.632 -178.022 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.622 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -114.36 122.13 45.74 Favored 'General case' 0 N--CA 1.407 -2.596 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.707 -179.593 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 63.4 mtm -116.31 158.83 22.8 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 177.218 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -63.94 117.13 6.56 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 174.454 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.54 -5.52 54.73 Favored Glycine 0 C--N 1.315 -0.622 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -176.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . 0.429 ' HA ' ' HD3' ' A' ' 19' ' ' PRO . 21.8 m-85 -126.51 136.57 28.85 Favored Pre-proline 0 N--CA 1.436 -1.164 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -179.782 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 18' ' ' TYR . 14.3 Cg_exo -70.21 171.12 15.54 Favored 'Trans proline' 0 N--CA 1.444 -1.399 0 C-N-CA 122.212 1.941 . . . . 0.0 108.628 169.427 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' HIS . . . . . 0.512 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 80.2 m80 -63.55 110.75 2.09 Favored 'General case' 0 C--N 1.312 -1.049 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.722 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 10.4 t-105 -107.88 136.65 19.7 Favored Pre-proline 0 C--N 1.306 -1.304 0 C-N-CA 123.316 0.646 . . . . 0.0 109.885 -171.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -62.97 118.14 5.04 Favored 'Trans proline' 0 C--O 1.244 0.782 0 C-N-CA 122.214 1.943 . . . . 0.0 111.137 178.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -139.7 166.2 25.24 Favored 'General case' 0 N--CA 1.409 -2.5 0 CA-C-O 121.525 0.679 . . . . 0.0 111.285 -176.145 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.526 HH21 ' CD ' ' A' ' 27' ' ' GLU . 17.2 ttt-85 -111.49 139.01 47.27 Favored 'General case' 0 C--N 1.285 -2.204 0 C-N-CA 124.179 0.992 . . . . 0.0 108.404 177.729 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 58.9 t -75.84 121.86 28.6 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 N-CA-C 104.986 -2.228 . . . . 0.0 104.986 170.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.401 ' HB3' ' HB2' ' A' ' 41' ' ' PRO . 3.9 t0 -84.02 172.61 11.86 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 -173.275 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.526 ' CD ' HH21 ' A' ' 24' ' ' ARG . 4.4 mp0 . . . . . 0 N--CA 1.411 -2.398 0 CA-C-O 122.256 1.026 . . . . 0.0 112.522 -177.555 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 86.5 mttt . . . . . 0 N--CA 1.414 -2.266 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 84.4 mt -106.81 146.29 32.79 Favored Pre-proline 0 C--N 1.282 -2.329 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 178.654 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.401 ' HB2' ' HB3' ' A' ' 26' ' ' ASP . 60.1 Cg_endo -73.62 128.95 13.1 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 121.888 1.725 . . . . 0.0 109.395 176.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.429 HG21 ' CB ' ' A' ' 13' ' ' ALA . 37.0 mm -118.41 125.73 74.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.987 -0.446 . . . . 0.0 110.799 -174.166 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -109.71 115.34 29.68 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 176.726 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -79.04 139.09 38.22 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-O 121.0 0.429 . . . . 0.0 111.794 179.003 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 -90.26 160.4 16.19 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.385 177.141 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.529 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 73.06 -21.53 1.01 Allowed Glycine 0 C--N 1.311 -0.828 0 C-N-CA 124.932 1.253 . . . . 0.0 114.315 179.228 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.435 HG23 ' HA3' ' A' ' 76' ' ' GLY . 37.1 p -119.98 -22.3 6.78 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 117.559 0.68 . . . . 0.0 109.685 173.037 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.1 m170 66.88 24.87 9.62 Favored 'General case' 0 C--N 1.35 0.629 0 CA-C-N 115.406 -0.815 . . . . 0.0 111.153 -179.517 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -71.94 167.17 20.65 Favored 'General case' 0 C--N 1.347 0.462 0 CA-C-N 115.179 -0.919 . . . . 0.0 108.728 175.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.9 m -137.45 145.95 43.74 Favored 'General case' 0 C--N 1.289 -2.034 0 O-C-N 121.576 -0.702 . . . . 0.0 109.581 -178.678 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -150.57 178.43 9.08 Favored 'General case' 0 C--N 1.308 -1.197 0 O-C-N 123.533 0.521 . . . . 0.0 111.404 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -134.26 114.74 13.35 Favored 'General case' 0 C--O 1.262 1.745 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.575 175.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.479 HD12 ' HB1' ' A' ' 13' ' ' ALA . 94.6 mt -130.99 158.75 39.45 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -179.159 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.0 172.55 36.92 Favored Glycine 0 N--CA 1.429 -1.796 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.414 ' HA ' HD11 ' A' ' 58' ' ' ILE . 36.4 Cg_endo -65.89 -6.84 15.14 Favored 'Trans proline' 0 C--O 1.21 -0.91 0 C-N-CA 123.046 2.497 . . . . 0.0 112.438 -178.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.2 ptmm? -97.52 -5.02 36.76 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 115.333 -0.849 . . . . 0.0 111.764 179.518 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -115.86 5.8 14.14 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -177.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.414 HD11 ' HA ' ' A' ' 55' ' ' PRO . 16.8 pt -126.53 150.63 32.37 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 CA-C-N 115.073 -0.967 . . . . 0.0 110.487 -178.639 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 -131.94 135.32 26.45 Favored Pre-proline 0 C--O 1.188 -2.167 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 177.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . 0.545 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 37.8 Cg_endo -66.82 131.01 24.53 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 C-N-CA 122.841 2.361 . . . . 0.0 114.007 -177.791 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.509 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 65.4 t80 -63.54 -33.79 76.36 Favored 'General case' 0 C--O 1.204 -1.328 0 CA-C-N 114.889 -1.05 . . . . 0.0 112.159 -174.331 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.15 -54.31 35.81 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -177.121 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.545 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 2.1 pm0 -89.68 1.32 56.2 Favored 'General case' 0 N--CA 1.433 -1.298 0 N-CA-C 114.276 1.213 . . . . 0.0 114.276 -178.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 26.8 m-80 -122.8 15.18 10.11 Favored 'General case' 0 C--N 1.314 -0.935 0 C-N-CA 123.327 0.651 . . . . 0.0 111.132 175.613 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.46 ' HZ1' ' CG ' ' A' ' 85' ' ' ASP . 16.5 ttmm -65.13 -33.32 75.75 Favored 'General case' 0 N--CA 1.476 0.855 0 CA-C-O 121.579 0.704 . . . . 0.0 110.189 179.473 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.599 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -80.25 -28.95 38.35 Favored 'General case' 0 N--CA 1.403 -2.819 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.098 177.33 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.599 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 8.3 mttm -76.71 -59.09 2.92 Favored 'General case' 0 CA--C 1.505 -0.778 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.253 -179.24 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -112.1 -4.28 14.49 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -173.443 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -75.64 51.76 2.68 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 121.715 -0.279 . . . . 0.0 113.11 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 4.3 ptpp? -132.44 135.71 26.75 Favored Pre-proline 0 C--N 1.311 -1.09 0 O-C-N 122.459 -0.436 . . . . 0.0 110.161 179.144 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -66.91 128.24 18.42 Favored 'Trans proline' 0 C--O 1.25 1.111 0 C-N-CA 122.787 2.325 . . . . 0.0 116.316 -171.178 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -84.69 -168.93 2.39 Favored 'General case' 0 CA--C 1.483 -1.633 0 CA-C-N 113.784 -1.553 . . . . 0.0 108.165 175.311 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.438 ' HD3' ' HA ' ' A' ' 73' ' ' LYS . 39.4 mmtm -108.53 10.49 27.19 Favored 'General case' 0 C--N 1.287 -2.146 0 CA-C-O 121.842 0.829 . . . . 0.0 109.475 175.36 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . 0.427 HH21 HG21 ' A' ' 47' ' ' THR . 4.5 mmm-85 -77.45 122.8 25.69 Favored 'General case' 0 N--CA 1.417 -2.099 0 CA-C-N 115.04 -0.982 . . . . 0.0 109.199 170.664 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 15.6 tppt? -65.17 129.54 40.1 Favored 'General case' 0 N--CA 1.429 -1.523 0 N-CA-C 107.551 -1.278 . . . . 0.0 107.551 173.58 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.529 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.21 -25.19 20.9 Favored Glycine 0 N--CA 1.415 -2.742 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -176.142 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -76.63 -41.13 47.03 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-O 121.356 0.598 . . . . 0.0 109.39 -178.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.484 ' N ' HD22 ' A' ' 78' ' ' ASN . 0.7 OUTLIER -71.31 -43.85 66.28 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 -176.289 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 25.2 mp0 -63.11 -41.77 99.42 Favored 'General case' 0 N--CA 1.428 -1.554 0 CA-C-N 113.577 -1.647 . . . . 0.0 109.634 177.712 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -65.38 -37.6 94.02 Favored Glycine 0 N--CA 1.44 -1.052 0 CA-C-N 115.449 -0.796 . . . . 0.0 112.804 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 87.9 mt -59.56 -35.12 73.62 Favored 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 176.094 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.3 t90 -74.29 -50.32 19.38 Favored 'General case' 0 N--CA 1.425 -1.712 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.295 177.501 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 26.8 mt-10 -53.74 -49.94 67.06 Favored 'General case' 0 C--O 1.188 -2.175 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -179.512 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.8 tt -67.99 -23.48 29.09 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 N-CA-C 112.256 0.465 . . . . 0.0 112.256 -173.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . 0.46 ' CG ' ' HZ1' ' A' ' 65' ' ' LYS . 15.2 t70 -94.21 -32.52 13.66 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-O 121.497 0.665 . . . . 0.0 110.05 -175.053 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.516 HD22 ' N ' ' A' ' 86' ' ' ASN . 0.8 OUTLIER -103.43 -44.89 5.02 Favored 'General case' 0 C--O 1.257 1.456 0 CA-C-O 121.911 0.862 . . . . 0.0 111.504 -176.679 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 60.7 t30 -131.76 61.32 57.65 Favored Pre-proline 0 C--N 1.296 -1.73 0 C-N-CA 119.983 -0.687 . . . . 0.0 112.329 -176.595 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -71.12 -7.68 21.91 Favored 'Trans proline' 0 C--N 1.372 1.789 0 C-N-CA 122.19 1.926 . . . . 0.0 110.465 179.078 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . 0.409 ' H ' ' HG2' ' A' ' 89' ' ' LYS . 22.7 pttm . . . . . 0 C--N 1.307 -1.249 0 CA-C-N 113.159 -1.837 . . . . 0.0 109.197 -175.49 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 . . . . . 0 N--CA 1.397 -3.124 0 CA-C-O 121.514 0.673 . . . . 0.0 109.399 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 25.9 mtmm -120.67 156.65 55.82 Favored Pre-proline 0 C--N 1.274 -2.677 0 CA-C-N 113.886 -1.506 . . . . 0.0 107.695 -172.287 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.444 ' HB3' ' HA ' ' A' ' 27' ' ' GLU . 52.5 Cg_exo -57.4 120.94 9.19 Favored 'Trans proline' 0 N--CA 1.461 -0.436 0 C-N-CA 121.825 1.683 . . . . 0.0 110.566 176.311 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.22 -24.28 10.03 Favored Glycine 0 N--CA 1.426 -2.029 0 CA-C-O 119.138 -0.812 . . . . 0.0 113.452 -178.426 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 32.8 m-20 -63.3 137.31 58.14 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 117.769 0.784 . . . . 0.0 111.725 -179.181 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 95.6 mt -90.18 126.58 35.86 Favored 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 176.64 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -142.08 -174.97 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-O 122.197 0.998 . . . . 0.0 112.899 -174.497 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -115.71 130.0 56.69 Favored 'General case' 0 C--N 1.28 -2.431 0 CA-C-N 114.083 -1.417 . . . . 0.0 107.416 170.335 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.621 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -107.43 114.36 28.31 Favored 'General case' 0 C--N 1.275 -2.654 0 CA-C-N 114.866 -1.061 . . . . 0.0 109.426 -173.372 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.616 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.9 OUTLIER -103.76 128.24 51.16 Favored 'General case' 0 C--N 1.264 -3.129 0 CA-C-N 114.343 -1.299 . . . . 0.0 109.54 -178.597 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.402 ' HB2' ' HB2' ' A' ' 18' ' ' TYR . 68.2 mtm -113.84 158.25 21.27 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -70.26 116.77 11.0 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 120.607 -0.437 . . . . 0.0 109.879 -178.626 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 93.99 0.11 66.36 Favored Glycine 0 N--CA 1.448 -0.518 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.97 178.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . 0.402 ' HB2' ' HB2' ' A' ' 15' ' ' MET . 99.5 m-85 -129.75 152.23 79.47 Favored Pre-proline 0 N--CA 1.439 -0.996 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 -177.825 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -68.97 170.33 15.87 Favored 'Trans proline' 0 N--CA 1.457 -0.652 0 C-N-CA 122.4 2.067 . . . . 0.0 112.197 177.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 57.5 m80 -71.5 114.26 9.4 Favored 'General case' 0 CA--C 1.552 1.02 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.605 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 11.1 t-105 -101.35 136.91 19.55 Favored Pre-proline 0 C--N 1.31 -1.127 0 C-N-CA 123.142 0.577 . . . . 0.0 109.468 -176.604 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -64.77 117.87 4.91 Favored 'Trans proline' 0 CA--C 1.542 0.911 0 C-N-CA 121.978 1.786 . . . . 0.0 110.741 177.624 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.55 167.12 24.5 Favored 'General case' 0 N--CA 1.426 -1.66 0 CA-C-O 121.242 0.544 . . . . 0.0 111.214 -174.512 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.411 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 41.9 ttt-85 -115.4 143.52 45.17 Favored 'General case' 0 C--N 1.291 -1.965 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 179.552 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 64.9 t -79.21 114.2 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 104.385 -2.45 . . . . 0.0 104.385 168.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -90.74 -179.55 5.55 Favored 'General case' 0 C--N 1.29 -1.985 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.878 -171.45 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.444 ' HA ' ' HB3' ' A' ' 7' ' ' PRO . 32.2 mp0 . . . . . 0 N--CA 1.439 -0.993 0 CA-C-O 121.948 0.88 . . . . 0.0 112.593 -175.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.435 ' HE2' ' N ' ' A' ' 54' ' ' GLY . 8.9 mmpt? . . . . . 0 N--CA 1.429 -1.518 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 87.8 mt -128.41 155.59 78.32 Favored Pre-proline 0 C--N 1.283 -2.298 0 C-N-CA 125.306 1.442 . . . . 0.0 107.253 178.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -71.22 122.8 9.05 Favored 'Trans proline' 0 CA--C 1.536 0.617 0 C-N-CA 121.697 1.598 . . . . 0.0 110.679 177.552 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.462 HG13 ' HB2' ' A' ' 53' ' ' LEU . 49.2 mm -122.51 124.68 71.3 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.083 0 CA-C-O 120.753 0.311 . . . . 0.0 110.355 -176.377 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 80.9 t80 -106.96 116.41 31.87 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 178.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -79.27 132.09 36.36 Favored 'General case' 0 C--O 1.244 0.805 0 CA-C-O 121.016 0.436 . . . . 0.0 110.923 179.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.411 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 66.9 m-85 -82.81 158.6 22.71 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.029 178.829 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.51 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 74.99 -20.11 1.97 Allowed Glycine 0 C--O 1.256 1.473 0 C-N-CA 124.513 1.054 . . . . 0.0 114.454 178.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.537 HG23 ' HA3' ' A' ' 76' ' ' GLY . 31.2 p -119.32 -23.88 6.57 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 122.237 -0.566 . . . . 0.0 109.957 175.273 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 44.8 m170 67.74 23.09 8.71 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.432 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -74.98 166.43 23.67 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 176.352 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.5 m -137.11 145.71 44.21 Favored 'General case' 0 C--N 1.286 -2.192 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 -179.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -146.76 179.52 7.51 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 123.136 0.575 . . . . 0.0 109.71 -179.526 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -131.75 109.29 10.05 Favored 'General case' 0 N--CA 1.432 -1.339 0 N-CA-C 109.003 -0.739 . . . . 0.0 109.003 176.488 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.621 HD12 ' HB1' ' A' ' 13' ' ' ALA . 88.7 mt -130.26 149.29 52.02 Favored 'General case' 0 C--N 1.287 -2.145 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 -178.826 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.435 ' N ' ' HE2' ' A' ' 39' ' ' LYS . . . -95.37 178.07 35.29 Favored Glycine 0 N--CA 1.417 -2.57 0 C-N-CA 119.707 -1.235 . . . . 0.0 112.104 -174.059 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.1 -9.3 16.6 Favored 'Trans proline' 0 N--CA 1.479 0.667 0 C-N-CA 123.224 2.616 . . . . 0.0 111.831 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 42.6 mtmt -98.29 -1.57 41.5 Favored 'General case' 0 N--CA 1.431 -1.385 0 CA-C-N 114.879 -1.055 . . . . 0.0 110.705 -179.653 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.54 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 36.8 m-20 -115.22 -9.65 12.22 Favored 'General case' 0 CA--C 1.5 -0.957 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.484 -179.436 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 9.5 pt -119.91 152.71 22.65 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.127 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.751 -173.562 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -138.99 147.59 54.42 Favored Pre-proline 0 C--N 1.297 -1.68 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -178.416 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . 0.533 ' HG2' ' OE2' ' A' ' 63' ' ' GLU . 11.7 Cg_endo -58.11 139.61 91.1 Favored 'Trans proline' 0 CA--C 1.516 -0.383 0 C-N-CA 122.758 2.305 . . . . 0.0 114.432 -175.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.403 ' O ' ' HB3' ' A' ' 65' ' ' LYS . 16.3 t80 -65.18 -35.84 82.33 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 115.214 -0.903 . . . . 0.0 111.451 177.151 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 10.5 m -48.91 -57.19 6.84 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 112.953 0.723 . . . . 0.0 112.953 -175.319 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.533 ' OE2' ' HG2' ' A' ' 60' ' ' PRO . 0.0 OUTLIER -95.79 -14.43 23.29 Favored 'General case' 0 N--CA 1.432 -1.352 0 N-CA-C 114.903 1.446 . . . . 0.0 114.903 178.867 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.454 ' HB2' ' O ' ' A' ' 60' ' ' PRO . 22.6 m-80 -88.85 -8.0 55.12 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 121.681 -0.637 . . . . 0.0 112.648 179.221 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.418 ' O ' ' HA3' ' A' ' 69' ' ' GLY . 11.6 ptmm? -60.52 -38.28 83.88 Favored 'General case' 0 C--O 1.201 -1.466 0 CA-C-O 121.182 0.515 . . . . 0.0 111.308 -176.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 55.9 mm-40 -82.3 -33.85 28.89 Favored 'General case' 0 CA--C 1.477 -1.832 0 C-N-CA 119.453 -0.899 . . . . 0.0 112.426 177.494 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 29.9 mtmm -67.52 -58.92 3.87 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 124.725 1.265 . . . . 0.0 111.526 -176.118 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 84.4 m-85 -111.66 -1.87 15.57 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-O 121.551 0.691 . . . . 0.0 111.447 -175.632 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . 0.418 ' HA3' ' O ' ' A' ' 65' ' ' LYS . . . -91.46 54.68 3.13 Favored Glycine 0 N--CA 1.429 -1.775 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 177.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.497 ' HA ' ' HE3' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -117.93 149.06 44.68 Favored Pre-proline 0 C--N 1.299 -1.623 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 177.709 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.501 ' HB3' ' OD1' ' A' ' 78' ' ' ASN . 70.2 Cg_exo -49.43 146.65 13.8 Favored 'Trans proline' 0 C--O 1.243 0.727 0 C-N-CA 123.338 2.692 . . . . 0.0 114.868 -176.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -131.0 -171.06 2.48 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.829 -178.617 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 45.9 mmtm -104.9 -11.05 16.91 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-O 121.235 0.541 . . . . 0.0 109.618 179.538 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 3.2 mmm180 -73.57 121.64 20.96 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.039 173.176 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.94 127.47 31.54 Favored 'General case' 0 N--CA 1.435 -1.189 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 174.226 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.537 ' HA3' HG23 ' A' ' 47' ' ' THR . . . 108.86 -21.12 28.15 Favored Glycine 0 N--CA 1.409 -3.132 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.854 -177.61 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.563 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 12.6 t80 -76.26 -43.2 42.91 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 -179.435 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.501 ' OD1' ' HB3' ' A' ' 71' ' ' PRO . 52.5 m-80 -70.66 -43.25 69.51 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.739 -178.808 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -68.36 -33.3 74.04 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 115.362 -0.836 . . . . 0.0 109.771 179.011 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -66.73 -34.94 88.91 Favored Glycine 0 CA--C 1.491 -1.423 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.797 178.64 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.563 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 98.2 mt -62.26 -41.57 98.56 Favored 'General case' 0 C--O 1.212 -0.915 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 174.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 85.7 t90 -65.5 -45.85 81.97 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.647 178.564 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 54.9 mt-10 -59.72 -47.46 85.56 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 112.837 0.68 . . . . 0.0 112.837 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.8 tt -74.85 -27.48 20.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 C-N-CA 120.248 -0.581 . . . . 0.0 111.959 -175.174 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -84.39 -10.89 57.17 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 122.647 0.379 . . . . 0.0 111.83 178.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 32.3 m-80 -125.32 -56.29 1.53 Allowed 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -175.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -123.62 79.69 55.29 Favored Pre-proline 0 C--N 1.315 -0.932 0 CA-C-O 121.17 0.51 . . . . 0.0 110.479 -177.23 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -68.62 -6.96 19.07 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 123.129 2.552 . . . . 0.0 115.01 -175.155 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 7.3 ptmm? . . . . . 0 C--O 1.263 1.77 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 177.279 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 . . . . . 0 N--CA 1.413 -2.303 0 CA-C-O 121.089 0.471 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.8 mppt? -101.01 151.42 37.62 Favored Pre-proline 0 C--N 1.303 -1.454 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 -174.117 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -59.13 121.85 10.6 Favored 'Trans proline' 0 C--O 1.235 0.328 0 C-N-CA 122.145 1.896 . . . . 0.0 110.278 174.613 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 111.43 -11.37 28.38 Favored Glycine 0 N--CA 1.43 -1.721 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.889 -177.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -79.13 162.41 25.83 Favored 'General case' 0 C--O 1.258 1.532 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 -177.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.425 HD21 ' HB2' ' A' ' 88' ' ' PRO . 99.0 mt -114.56 129.22 56.65 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 123.442 0.697 . . . . 0.0 109.127 -175.779 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.9 pp -142.75 -177.87 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 CA-C-O 121.856 0.836 . . . . 0.0 112.672 -172.566 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.487 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 66.0 m-85 -119.91 118.86 31.86 Favored 'General case' 0 C--N 1.289 -2.048 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 172.738 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.504 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -112.67 143.11 44.43 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.46 -173.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.617 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -119.74 123.53 43.97 Favored 'General case' 0 N--CA 1.4 -2.947 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.348 -178.206 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 71.2 mtm -113.77 158.53 20.84 Favored 'General case' 0 CA--C 1.5 -0.981 0 N-CA-C 108.52 -0.918 . . . . 0.0 108.52 175.315 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 29.1 tptp -69.61 124.07 22.99 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 120.41 -0.516 . . . . 0.0 109.828 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.97 -12.55 60.7 Favored Glycine 0 C--N 1.303 -1.303 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.086 -176.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 72.3 m-85 -117.99 148.87 44.37 Favored Pre-proline 0 N--CA 1.433 -1.315 0 C-N-CA 123.088 0.555 . . . . 0.0 110.501 179.602 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -79.52 171.84 15.27 Favored 'Trans proline' 0 N--CA 1.449 -1.104 0 C-N-CA 122.315 2.01 . . . . 0.0 108.483 170.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' HIS . . . . . 0.535 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 79.7 m80 -57.95 111.86 1.31 Allowed 'General case' 0 CA--C 1.537 0.472 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 175.21 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 10.2 t-105 -112.33 142.27 26.64 Favored Pre-proline 0 C--N 1.294 -1.807 0 C-N-CA 123.983 0.913 . . . . 0.0 108.872 -169.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -62.63 118.49 5.38 Favored 'Trans proline' 0 C--O 1.245 0.847 0 C-N-CA 122.326 2.018 . . . . 0.0 110.57 178.054 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.45 166.98 23.2 Favored 'General case' 0 N--CA 1.41 -2.46 0 CA-C-O 121.702 0.763 . . . . 0.0 111.481 -175.874 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.417 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 36.3 ttt85 -114.38 139.42 49.49 Favored 'General case' 0 C--N 1.276 -2.63 0 C-N-CA 124.255 1.022 . . . . 0.0 110.604 -177.358 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 50.3 t -82.19 110.15 17.06 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.991 0 N-CA-C 104.025 -2.583 . . . . 0.0 104.025 169.77 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -91.45 168.12 11.77 Favored 'General case' 0 C--N 1.274 -2.707 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.107 -169.387 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.305 -1.361 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 177.509 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 84.1 mttt . . . . . 0 N--CA 1.417 -2.102 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 72.8 mt -118.15 146.98 40.53 Favored Pre-proline 0 C--N 1.285 -2.2 0 O-C-N 124.364 1.04 . . . . 0.0 108.79 -178.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -72.95 123.3 8.8 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 C-N-CA 121.724 1.616 . . . . 0.0 109.524 175.382 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 48.7 mm -115.84 115.6 49.76 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.121 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.21 -175.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 74.3 t80 -95.63 115.95 28.16 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 178.58 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.425 ' HE1' ' HB3' ' A' ' 51' ' ' ALA . 74.2 m-85 -82.66 133.67 35.16 Favored 'General case' 0 C--N 1.293 -1.86 0 N-CA-C 112.686 0.625 . . . . 0.0 112.686 179.82 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.417 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 71.6 m-85 -84.21 151.0 25.1 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.641 179.523 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.538 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 78.14 -20.45 3.92 Favored Glycine 0 C--N 1.305 -1.188 0 C-N-CA 123.816 0.722 . . . . 0.0 114.109 178.835 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 32.0 p -119.07 -22.66 7.13 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 117.412 0.606 . . . . 0.0 109.939 175.085 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.8 m-70 66.43 22.49 10.71 Favored 'General case' 0 C--N 1.35 0.607 0 C-N-CA 123.667 0.787 . . . . 0.0 112.024 179.393 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -74.31 161.88 29.44 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 176.344 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.3 m -136.04 135.96 39.85 Favored 'General case' 0 C--N 1.278 -2.503 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 176.749 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . 0.425 ' HB3' ' HE1' ' A' ' 44' ' ' PHE . . . -136.28 178.92 6.68 Favored 'General case' 0 C--N 1.277 -2.572 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.151 -177.046 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -133.49 109.65 9.42 Favored 'General case' 0 C--O 1.262 1.761 0 CA-C-N 115.326 -0.852 . . . . 0.0 108.713 175.066 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.504 HD12 ' HB1' ' A' ' 13' ' ' ALA . 64.8 mt -125.49 161.94 26.01 Favored 'General case' 0 C--N 1.29 -1.999 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 -178.612 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.53 169.58 35.95 Favored Glycine 0 N--CA 1.422 -2.25 0 C-N-CA 119.878 -1.153 . . . . 0.0 110.296 -179.451 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.85 -6.59 14.51 Favored 'Trans proline' 0 C--O 1.212 -0.818 0 C-N-CA 123.087 2.525 . . . . 0.0 112.223 -179.503 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 5.9 ptmm? -97.73 -2.06 42.07 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 115.358 -0.837 . . . . 0.0 111.768 178.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -116.13 6.37 13.96 Favored 'General case' 0 C--N 1.293 -1.875 0 CA-C-O 121.134 0.492 . . . . 0.0 112.158 -179.069 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 11.5 pt -130.55 152.42 37.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.599 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -139.28 147.47 53.1 Favored Pre-proline 0 C--N 1.303 -1.434 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -178.84 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -60.55 129.82 31.05 Favored 'Trans proline' 0 N--CA 1.481 0.786 0 C-N-CA 123.2 2.6 . . . . 0.0 112.919 -177.003 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.487 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 3.4 t80 -58.67 -34.28 71.06 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 113.819 1.044 . . . . 0.0 113.819 -177.526 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 30.4 t -60.62 -57.96 10.5 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 123.427 0.455 . . . . 0.0 111.226 -177.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 15.9 mp0 -75.72 -27.36 58.14 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-O 122.059 0.933 . . . . 0.0 110.988 -175.434 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 37.5 m-80 -95.54 5.09 52.42 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 113.484 0.92 . . . . 0.0 113.484 -176.023 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.444 ' HE2' ' CE1' ' A' ' 61' ' ' TYR . 17.6 ttmm -62.69 -39.09 92.9 Favored 'General case' 0 C--O 1.21 -1.024 0 CA-C-O 120.986 0.422 . . . . 0.0 111.295 177.55 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.465 ' HA ' ' HD3' ' A' ' 70' ' ' LYS . 38.8 mm-40 -80.91 -16.81 52.58 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-O 122.008 0.908 . . . . 0.0 112.205 177.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 19.3 mtpp -85.2 -56.7 3.41 Favored 'General case' 0 C--N 1.268 -2.941 0 CA-C-N 114.462 -1.244 . . . . 0.0 111.733 -178.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 35.1 m-85 -125.4 5.25 7.67 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.08 -174.023 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -99.98 25.41 28.38 Favored Glycine 0 C--N 1.304 -1.201 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 -178.416 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.465 ' HD3' ' HA ' ' A' ' 66' ' ' GLU . 27.7 mmmt -96.8 153.33 38.69 Favored Pre-proline 0 C--N 1.307 -1.281 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 -179.173 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -58.31 128.2 27.67 Favored 'Trans proline' 0 C--O 1.252 1.18 0 C-N-CA 121.981 1.787 . . . . 0.0 112.974 -179.517 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 16.2 m-80 -114.82 177.64 4.57 Favored 'General case' 0 CA--C 1.47 -2.113 0 CA-C-N 114.955 -1.02 . . . . 0.0 112.226 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.558 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 9.5 mptt -96.03 7.45 46.34 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 113.84 -1.527 . . . . 0.0 108.385 -178.37 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 11.1 mmt180 -88.27 122.79 32.2 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 175.177 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 10.2 tptp -77.04 144.38 38.65 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 177.278 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.538 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 95.13 -26.47 19.0 Favored Glycine 0 C--O 1.21 -1.367 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -173.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.466 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 27.0 t80 -76.61 -41.36 46.29 Favored 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 178.153 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 11.6 m120 -61.4 -49.22 77.77 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 177.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 6.1 mp0 -60.85 -40.73 94.0 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 113.711 -1.586 . . . . 0.0 110.352 179.309 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -67.54 -35.75 87.1 Favored Glycine 0 N--CA 1.44 -1.034 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.821 179.432 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.466 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 94.8 mt -61.92 -37.18 83.72 Favored 'General case' 0 C--O 1.218 -0.574 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 175.386 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 85.3 t90 -67.98 -48.34 66.06 Favored 'General case' 0 N--CA 1.427 -1.597 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.46 177.605 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -59.14 -46.7 87.67 Favored 'General case' 0 C--O 1.206 -1.196 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 179.719 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.402 HD11 ' HB3' ' A' ' 10' ' ' LEU . 19.0 tt -71.79 -27.83 28.95 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 C-N-CA 120.619 -0.432 . . . . 0.0 112.164 -174.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -89.57 -11.51 42.53 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 112.262 0.468 . . . . 0.0 112.262 -179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 32.4 m-80 -120.81 -57.55 1.88 Allowed 'General case' 0 N--CA 1.477 0.912 0 CA-C-O 121.16 0.505 . . . . 0.0 112.052 -176.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -128.59 73.64 80.63 Favored Pre-proline 0 C--N 1.308 -1.214 0 C-N-CA 120.418 -0.513 . . . . 0.0 110.305 -179.386 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.425 ' HB2' HD21 ' A' ' 10' ' ' LEU . 41.3 Cg_endo -70.13 -6.13 18.06 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 C-N-CA 123.178 2.585 . . . . 0.0 112.431 -176.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.9 pttp . . . . . 0 C--N 1.291 -1.969 0 CA-C-N 114.261 -1.336 . . . . 0.0 110.152 -179.651 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 . . . . . 0 N--CA 1.43 -1.469 0 N-CA-C 109.138 -0.689 . . . . 0.0 109.138 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -134.07 155.77 79.79 Favored Pre-proline 0 C--N 1.301 -1.538 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.298 179.587 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_exo -45.43 125.52 7.53 Favored 'Trans proline' 0 C--N 1.359 1.086 0 C-N-CA 123.554 2.836 . . . . 0.0 113.05 177.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 115.33 -25.44 9.82 Favored Glycine 0 N--CA 1.428 -1.837 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.871 -179.352 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -74.66 151.57 39.27 Favored 'General case' 0 C--O 1.257 1.466 0 CA-C-O 121.501 0.667 . . . . 0.0 111.564 -177.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.421 HD22 HG13 ' A' ' 84' ' ' ILE . 79.3 mt -103.38 124.38 48.58 Favored 'General case' 0 N--CA 1.424 -1.731 0 CA-C-N 114.707 -1.133 . . . . 0.0 110.134 -175.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 8.1 pt -137.11 -173.89 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.896 0 CA-C-O 122.752 1.263 . . . . 0.0 112.2 -173.344 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.448 ' CD1' ' HB2' ' A' ' 64' ' ' ASN . 22.0 m-85 -125.49 131.26 52.87 Favored 'General case' 0 N--CA 1.399 -2.99 0 N-CA-C 105.277 -2.12 . . . . 0.0 105.277 170.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.554 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -107.47 128.39 54.45 Favored 'General case' 0 C--N 1.265 -3.081 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.011 -174.027 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.593 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -120.02 117.85 29.09 Favored 'General case' 0 N--CA 1.389 -3.524 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 -179.03 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.477 ' HB2' ' HB2' ' A' ' 18' ' ' TYR . 82.1 mtp -97.08 158.39 15.46 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.053 -177.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.6 tttp -67.23 115.8 7.3 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 176.38 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.56 -18.53 55.05 Favored Glycine 0 N--CA 1.446 -0.681 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.429 179.729 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . 0.477 ' HB2' ' HB2' ' A' ' 15' ' ' MET . 88.1 m-85 -119.96 143.86 36.24 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 117.117 0.459 . . . . 0.0 111.173 -177.744 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -68.85 170.95 14.31 Favored 'Trans proline' 0 CA--C 1.539 0.73 0 C-N-CA 123.115 2.543 . . . . 0.0 112.853 179.445 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' HIS . . . . . 0.543 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 77.3 m80 -60.86 122.16 14.17 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.97 179.64 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 15.1 t-105 -121.58 137.48 27.11 Favored Pre-proline 0 C--N 1.304 -1.401 0 N-CA-C 107.497 -1.298 . . . . 0.0 107.497 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -61.09 123.62 13.24 Favored 'Trans proline' 0 C--O 1.243 0.736 0 C-N-CA 122.426 2.084 . . . . 0.0 111.507 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.9 166.71 24.16 Favored 'General case' 0 N--CA 1.422 -1.864 0 CA-C-O 121.39 0.614 . . . . 0.0 111.806 -176.764 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 46.7 ttt85 -114.02 139.94 48.85 Favored 'General case' 0 C--N 1.296 -1.745 0 CA-C-N 115.307 -0.86 . . . . 0.0 109.762 178.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.5 t -85.98 115.53 27.45 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 104.678 -2.342 . . . . 0.0 104.678 169.801 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.416 ' O ' ' HG2' ' A' ' 41' ' ' PRO . 3.6 t70 -99.71 -178.0 3.74 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 119.356 -0.937 . . . . 0.0 110.533 -173.592 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 . . . . . 0 N--CA 1.43 -1.441 0 CA-C-O 121.593 0.711 . . . . 0.0 112.017 -174.102 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.522 ' HA ' ' HA2' ' A' ' 54' ' ' GLY . 56.5 mttm . . . . . 0 N--CA 1.412 -2.333 0 CA-C-O 121.179 0.514 . . . . 0.0 111.274 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 71.0 mt -122.05 157.03 59.03 Favored Pre-proline 0 C--N 1.279 -2.467 0 CA-C-N 113.615 -1.629 . . . . 0.0 108.491 -176.646 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.416 ' HG2' ' O ' ' A' ' 26' ' ' ASP . 47.5 Cg_endo -75.4 122.59 7.11 Favored 'Trans proline' 0 N--CA 1.456 -0.682 0 C-N-CA 121.796 1.664 . . . . 0.0 109.978 174.369 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.432 HG13 ' HB2' ' A' ' 53' ' ' LEU . 41.2 mm -116.8 122.72 70.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -175.73 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 86.0 t80 -103.45 116.05 31.67 Favored 'General case' 0 C--N 1.282 -2.347 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 178.627 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 -76.71 129.66 36.65 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-O 121.047 0.451 . . . . 0.0 112.022 179.448 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.473 ' HB3' ' HA2' ' A' ' 80' ' ' GLY . 60.3 m-85 -78.96 151.33 31.7 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.258 177.581 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.523 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 77.28 -19.7 3.59 Favored Glycine 0 C--O 1.254 1.38 0 N-CA-C 114.534 0.573 . . . . 0.0 114.534 177.008 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 46.4 p -119.23 -23.04 6.89 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 117.43 0.615 . . . . 0.0 110.248 174.708 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.0 m-70 68.76 21.68 7.67 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.975 0.91 . . . . 0.0 112.546 179.176 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -80.28 164.89 22.85 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.838 178.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 2.2 m -130.29 140.16 50.68 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.241 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -141.24 -179.72 6.28 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 123.641 0.776 . . . . 0.0 109.843 -178.358 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -133.19 112.32 11.62 Favored 'General case' 0 C--O 1.249 1.038 0 CA-C-O 121.605 0.717 . . . . 0.0 110.464 178.751 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.554 HD12 ' HB1' ' A' ' 13' ' ' ALA . 82.0 mt -135.84 147.4 48.24 Favored 'General case' 0 C--N 1.29 -1.993 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.522 ' HA2' ' HA ' ' A' ' 39' ' ' LYS . . . -94.77 177.23 35.54 Favored Glycine 0 CA--C 1.479 -2.169 0 C-N-CA 119.908 -1.139 . . . . 0.0 111.554 -177.196 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -62.25 -17.47 57.19 Favored 'Trans proline' 0 C--O 1.212 -0.821 0 C-N-CA 123.249 2.632 . . . . 0.0 112.096 -177.535 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.55 1.47 48.97 Favored 'General case' 0 N--CA 1.425 -1.708 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.964 178.111 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.538 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 71.9 m-20 -107.92 -16.25 14.35 Favored 'General case' 0 C--N 1.29 -2.021 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.209 176.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.438 HG12 ' O ' ' A' ' 54' ' ' GLY . 12.0 pt -117.55 157.28 18.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.057 -174.059 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.568 ' HB3' HD21 ' A' ' 64' ' ' ASN . 98.0 m-85 -137.92 143.31 39.35 Favored Pre-proline 0 C--N 1.297 -1.711 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -69.29 148.44 68.13 Favored 'Trans proline' 0 C--O 1.245 0.873 0 C-N-CA 122.975 2.45 . . . . 0.0 114.934 -172.516 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 54.4 t80 -55.82 -34.71 65.6 Favored 'General case' 0 C--O 1.221 -0.434 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.078 177.002 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.1 m -52.86 -44.24 66.67 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.169 -0.923 . . . . 0.0 112.224 -179.028 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -93.3 -26.55 17.26 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 121.644 0.735 . . . . 0.0 111.497 -177.089 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.568 HD21 ' HB3' ' A' ' 59' ' ' PHE . 40.8 m-80 -91.21 0.57 57.5 Favored 'General case' 0 C--O 1.203 -1.377 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -174.446 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.555 ' HZ3' ' CD ' ' A' ' 66' ' ' GLU . 4.5 ttpm? -65.95 -47.68 73.83 Favored 'General case' 0 C--N 1.29 -2.006 0 CA-C-O 121.446 0.641 . . . . 0.0 110.079 179.292 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.555 ' CD ' ' HZ3' ' A' ' 65' ' ' LYS . 12.1 mp0 -68.7 -36.34 78.35 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-O 122.331 1.062 . . . . 0.0 109.65 178.306 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 47.4 mtmt -79.16 -59.75 2.64 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 114.264 -1.335 . . . . 0.0 112.764 -174.34 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -121.73 4.43 10.04 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 112.394 0.516 . . . . 0.0 112.394 -172.23 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -82.35 34.11 2.69 Favored Glycine 0 CA--C 1.524 0.649 0 C-N-CA 121.28 -0.486 . . . . 0.0 113.211 -177.454 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 2.6 mppt? -122.92 144.37 42.85 Favored Pre-proline 0 N--CA 1.439 -1.017 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.318 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . 0.48 ' HB3' ' OD1' ' A' ' 78' ' ' ASN . 82.8 Cg_exo -46.19 128.67 12.18 Favored 'Trans proline' 0 C--O 1.263 1.772 0 C-N-CA 123.984 3.123 . . . . 0.0 115.142 -176.248 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . 0.52 ' HB2' ' CD1' ' A' ' 77' ' ' PHE . 1.7 t-20 -102.73 -166.96 1.33 Allowed 'General case' 0 C--N 1.269 -2.9 0 CA-C-N 114.516 -1.22 . . . . 0.0 109.356 -178.208 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.458 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 1.9 mptp? -120.61 18.39 12.0 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 178.332 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 37.1 mmt180 -102.75 132.46 48.89 Favored 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 114.343 -1.298 . . . . 0.0 109.269 176.543 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.8 tmtm? -68.37 127.66 33.76 Favored 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 175.477 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.523 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 107.17 -25.67 21.29 Favored Glycine 0 N--CA 1.416 -2.637 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.29 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.557 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 16.0 t80 -76.56 -45.4 30.69 Favored 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 -178.088 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.48 ' OD1' ' HB3' ' A' ' 71' ' ' PRO . 53.6 m-80 -71.61 -41.8 68.46 Favored 'General case' 0 CA--C 1.498 -1.045 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.45 -178.459 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -67.76 -33.64 75.23 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.18 179.487 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.473 ' HA2' ' HB3' ' A' ' 45' ' ' PHE . . . -70.97 -34.71 65.05 Favored Glycine 0 N--CA 1.43 -1.741 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.984 178.342 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.557 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 95.3 mt -61.97 -35.23 77.85 Favored 'General case' 0 C--O 1.215 -0.727 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 174.483 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 71.3 t90 -71.37 -48.78 47.89 Favored 'General case' 0 N--CA 1.431 -1.397 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.326 176.598 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -58.87 -40.53 84.64 Favored 'General case' 0 C--O 1.2 -1.537 0 N-CA-C 112.944 0.72 . . . . 0.0 112.944 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.421 HG13 HD22 ' A' ' 10' ' ' LEU . 19.0 tt -71.27 -21.36 21.8 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 CA-C-O 121.128 0.489 . . . . 0.0 110.795 -175.506 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -92.1 -43.78 9.18 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.066 -177.359 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.568 HD22 ' N ' ' A' ' 86' ' ' ASN . 0.8 OUTLIER -92.52 -44.27 8.72 Favored 'General case' 0 N--CA 1.481 1.115 0 CA-C-O 121.327 0.584 . . . . 0.0 112.182 -173.528 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.506 ' OD1' ' HG3' ' A' ' 89' ' ' LYS . 61.5 t30 -133.36 67.91 76.68 Favored Pre-proline 0 C--N 1.299 -1.614 0 C-N-CA 119.809 -0.756 . . . . 0.0 110.786 -178.698 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -68.09 -6.75 17.96 Favored 'Trans proline' 0 C--N 1.369 1.637 0 C-N-CA 123.193 2.595 . . . . 0.0 111.65 -178.227 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . 0.506 ' HG3' ' OD1' ' A' ' 87' ' ' ASN . 5.5 ptmm? . . . . . 0 C--N 1.297 -1.684 0 CA-C-N 113.941 -1.481 . . . . 0.0 110.825 179.812 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . 0.45 ' HB3' HG21 ' A' ' 25' ' ' VAL . 67.6 m-85 . . . . . 0 N--CA 1.423 -1.805 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.419 ' O ' ' HB2' ' A' ' 9' ' ' ASP . 48.4 mttm -96.35 144.3 27.61 Favored Pre-proline 0 C--N 1.294 -1.831 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.918 -170.364 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -58.0 116.02 2.94 Favored 'Trans proline' 0 N--CA 1.462 -0.369 0 C-N-CA 121.731 1.621 . . . . 0.0 110.002 175.133 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 109.52 -7.4 32.04 Favored Glycine 0 N--CA 1.433 -1.543 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.335 -176.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . 0.419 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 5.2 t70 -69.57 152.57 44.62 Favored 'General case' 0 C--O 1.251 1.175 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -177.86 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.4 mt -104.91 120.91 42.57 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 121.375 0.607 . . . . 0.0 109.85 -175.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.0 pt -140.45 -175.49 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.416 -2.165 0 CA-C-O 122.25 1.024 . . . . 0.0 112.024 -174.734 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -124.62 128.95 49.65 Favored 'General case' 0 N--CA 1.409 -2.497 0 N-CA-C 105.64 -1.985 . . . . 0.0 105.64 171.068 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.497 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -117.02 141.41 48.29 Favored 'General case' 0 C--N 1.278 -2.513 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.798 -176.62 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.626 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -123.24 124.46 43.07 Favored 'General case' 0 N--CA 1.405 -2.72 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.693 -177.437 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.496 ' HG2' HD21 ' A' ' 53' ' ' LEU . 44.6 mtm -115.87 158.2 23.32 Favored 'General case' 0 CA--C 1.499 -1.017 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 175.574 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.3 tttp -65.45 116.91 7.23 Favored 'General case' 0 C--N 1.311 -1.095 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 178.305 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.33 -12.38 58.49 Favored Glycine 0 C--O 1.247 0.93 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -178.058 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 7.8 m-85 -110.59 149.46 40.32 Favored Pre-proline 0 C--N 1.307 -1.279 0 C-N-CA 123.196 0.598 . . . . 0.0 109.872 178.528 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -81.41 171.45 13.61 Favored 'Trans proline' 0 N--CA 1.442 -1.512 0 C-N-CA 122.118 1.879 . . . . 0.0 108.173 171.323 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' HIS . . . . . 0.474 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 80.8 m80 -64.46 111.28 2.61 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 174.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 9.6 t-105 -110.85 141.03 23.29 Favored Pre-proline 0 C--N 1.292 -1.925 0 C-N-CA 123.585 0.754 . . . . 0.0 109.12 -170.001 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -64.49 118.2 5.19 Favored 'Trans proline' 0 C--O 1.245 0.845 0 C-N-CA 122.147 1.898 . . . . 0.0 110.359 177.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -139.92 166.51 24.44 Favored 'General case' 0 N--CA 1.408 -2.526 0 CA-C-O 121.118 0.485 . . . . 0.0 110.311 -175.537 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.494 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 10.7 ttp180 -115.3 145.35 42.56 Favored 'General case' 0 C--N 1.285 -2.237 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.135 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.45 HG21 ' HB3' ' A' ' 5' ' ' PHE . 52.4 t -74.63 119.91 23.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 104.728 -2.323 . . . . 0.0 104.728 170.099 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.442 ' HB3' ' HB2' ' A' ' 41' ' ' PRO . 4.1 t70 -84.78 179.0 7.43 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -172.219 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 . . . . . 0 N--CA 1.429 -1.507 0 C-N-CA 119.278 -0.969 . . . . 0.0 111.72 -175.276 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 62.1 mttp . . . . . 0 N--CA 1.428 -1.551 0 CA-C-O 121.055 0.455 . . . . 0.0 111.12 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 88.8 mt -116.99 147.17 39.57 Favored Pre-proline 0 C--N 1.287 -2.151 0 CA-C-N 114.33 -1.304 . . . . 0.0 109.246 -178.07 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . 0.442 ' HB2' ' HB3' ' A' ' 26' ' ' ASP . 68.9 Cg_endo -73.06 123.86 9.16 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 122.33 2.02 . . . . 0.0 110.523 177.565 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.412 HG21 ' CB ' ' A' ' 13' ' ' ALA . 43.4 mm -120.86 127.56 75.95 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 -176.753 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.441 ' CZ ' ' HA ' ' A' ' 48' ' ' HIS . 87.7 t80 -107.14 120.69 42.8 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 178.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 -86.66 131.7 34.08 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-O 121.254 0.55 . . . . 0.0 112.247 179.028 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.494 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 67.6 m-85 -85.83 158.44 19.97 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.694 179.326 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.533 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 75.31 -20.32 2.1 Favored Glycine 0 C--O 1.248 1.015 0 C-N-CA 123.526 0.584 . . . . 0.0 114.538 179.139 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 18.3 p -119.38 -23.04 6.81 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 122.305 -0.527 . . . . 0.0 109.73 173.005 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . 0.441 ' HA ' ' CZ ' ' A' ' 43' ' ' PHE . 11.5 m-70 67.67 26.18 7.98 Favored 'General case' 0 C--N 1.348 0.507 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.818 179.507 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -79.4 161.89 25.87 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.698 -0.852 . . . . 0.0 108.698 177.373 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 6.9 m -136.12 140.43 43.68 Favored 'General case' 0 C--N 1.284 -2.25 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 176.794 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -142.74 179.35 7.05 Favored 'General case' 0 C--N 1.287 -2.124 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.289 -175.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.409 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 84.8 m-85 -134.0 115.07 13.91 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.305 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.497 HD12 ' HB1' ' A' ' 13' ' ' ALA . 87.4 mt -129.44 166.49 19.49 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 -177.67 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -93.03 167.7 29.49 Favored Glycine 0 N--CA 1.423 -2.18 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -67.03 -6.89 17.11 Favored 'Trans proline' 0 N--CA 1.481 0.747 0 C-N-CA 123.303 2.669 . . . . 0.0 112.828 -176.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 20.8 pttp -93.05 -18.17 22.97 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.366 178.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.2 m-20 -99.98 1.25 42.41 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.188 -175.226 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.3 pt -125.94 145.84 32.71 Favored 'Isoleucine or valine' 0 C--O 1.258 1.551 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.754 179.359 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.469 ' HB3' ' ND2' ' A' ' 64' ' ' ASN . 83.0 m-85 -136.32 144.82 49.3 Favored Pre-proline 0 C--N 1.288 -2.087 0 CA-C-N 114.823 -1.081 . . . . 0.0 108.554 -177.131 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -68.34 127.82 16.37 Favored 'Trans proline' 0 N--CA 1.483 0.857 0 C-N-CA 122.746 2.298 . . . . 0.0 113.956 -179.121 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -51.97 -39.34 59.17 Favored 'General case' 0 C--O 1.217 -0.626 0 C-N-CA 123.87 0.868 . . . . 0.0 111.043 -179.536 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.5 m -57.28 -40.33 77.54 Favored 'General case' 0 C--N 1.307 -1.27 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.185 -178.072 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -95.75 -19.19 19.85 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.278 0.561 . . . . 0.0 112.21 -172.792 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.469 ' ND2' ' HB3' ' A' ' 59' ' ' PHE . 0.5 OUTLIER -124.19 26.88 7.29 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 114.703 1.371 . . . . 0.0 114.703 -178.214 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.43 ' HZ3' ' CD ' ' A' ' 66' ' ' GLU . 17.0 pttm -70.1 -30.91 68.24 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 174.698 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.43 ' CD ' ' HZ3' ' A' ' 65' ' ' LYS . 19.8 mp0 -65.25 -39.06 92.17 Favored 'General case' 0 C--O 1.251 1.151 0 CA-C-O 122.557 1.17 . . . . 0.0 108.617 175.091 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.443 ' HB3' ' HE2' ' A' ' 67' ' ' LYS . 35.8 mtpt -76.44 -59.96 2.55 Favored 'General case' 0 N--CA 1.427 -1.618 0 CA-C-N 113.918 -1.492 . . . . 0.0 112.029 -175.07 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 21.0 m-85 -107.67 -9.75 15.78 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.482 -0.781 . . . . 0.0 112.428 -168.297 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -82.3 41.55 2.8 Favored Glycine 0 C--O 1.22 -0.726 0 C-N-CA 121.245 -0.503 . . . . 0.0 113.21 -176.826 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 38.4 mtmm -122.96 124.95 26.44 Favored Pre-proline 0 C--N 1.308 -1.202 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 177.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -56.96 127.17 24.72 Favored 'Trans proline' 0 C--O 1.251 1.167 0 C-N-CA 122.23 1.954 . . . . 0.0 114.686 -172.239 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -84.76 -170.46 3.13 Favored 'General case' 0 CA--C 1.484 -1.594 0 CA-C-N 113.875 -1.511 . . . . 0.0 108.304 176.608 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 40.0 mmtm -111.46 22.0 15.57 Favored 'General case' 0 C--N 1.285 -2.201 0 CA-C-O 122.592 1.187 . . . . 0.0 107.821 173.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -87.06 127.89 35.11 Favored 'General case' 0 C--O 1.251 1.162 0 CA-C-N 113.548 -1.66 . . . . 0.0 107.547 173.279 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -65.29 134.79 54.38 Favored 'General case' 0 N--CA 1.439 -0.997 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 176.47 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.533 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 100.2 -25.73 27.18 Favored Glycine 0 N--CA 1.42 -2.374 0 C-N-CA 121.405 -0.426 . . . . 0.0 112.363 -178.242 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.405 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 23.2 t80 -73.36 -42.61 62.0 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 -177.709 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.491 HD22 ' N ' ' A' ' 78' ' ' ASN . 0.7 OUTLIER -72.87 -41.37 64.79 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 -177.323 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 16.3 mt-10 -65.06 -39.89 93.91 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 114.411 -1.268 . . . . 0.0 109.857 178.464 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -68.63 -32.29 74.47 Favored Glycine 0 CA--C 1.499 -0.936 0 CA-C-N 115.741 -0.663 . . . . 0.0 112.636 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.405 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 90.8 mt -62.9 -32.86 74.22 Favored 'General case' 0 C--O 1.214 -0.798 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 174.764 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 73.6 t90 -73.48 -48.27 34.72 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.382 176.541 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -58.3 -41.32 84.19 Favored 'General case' 0 C--O 1.203 -1.384 0 N-CA-C 112.87 0.693 . . . . 0.0 112.87 179.669 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.3 tt -71.29 -21.24 21.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-O 121.145 0.497 . . . . 0.0 110.619 -175.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -90.36 -42.42 10.95 Favored 'General case' 0 N--CA 1.437 -1.112 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.108 -177.196 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.567 HD22 ' N ' ' A' ' 86' ' ' ASN . 0.8 OUTLIER -92.22 -50.16 5.81 Favored 'General case' 0 CA--C 1.494 -1.188 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.136 -174.154 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 64.6 t30 -132.72 75.9 72.17 Favored Pre-proline 0 C--N 1.303 -1.442 0 C-N-CA 119.725 -0.79 . . . . 0.0 110.152 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.494 ' O ' ' HD3' ' A' ' 24' ' ' ARG . 42.5 Cg_endo -68.52 -6.51 17.86 Favored 'Trans proline' 0 N--CA 1.477 0.542 0 C-N-CA 122.795 2.33 . . . . 0.0 114.143 -174.211 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 61.5 pttt . . . . . 0 C--N 1.304 -1.393 0 CA-C-O 120.85 0.357 . . . . 0.0 110.182 -179.053 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 76.4 m-85 . . . . . 0 N--CA 1.427 -1.575 0 CA-C-O 120.958 0.408 . . . . 0.0 109.987 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.403 ' O ' ' HB ' ' A' ' 25' ' ' VAL . 29.6 mttp -110.27 153.53 43.31 Favored Pre-proline 0 C--N 1.307 -1.281 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 -177.405 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -62.15 115.4 2.82 Favored 'Trans proline' 0 N--CA 1.448 -1.193 0 N-CA-C 107.08 -1.931 . . . . 0.0 107.08 169.02 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 114.93 -19.05 15.94 Favored Glycine 0 N--CA 1.424 -2.152 0 C-N-CA 120.411 -0.899 . . . . 0.0 112.391 -174.835 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -78.45 152.19 32.26 Favored 'General case' 0 C--O 1.253 1.268 0 CA-C-N 117.397 0.599 . . . . 0.0 109.446 -177.065 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.403 HD22 HG13 ' A' ' 84' ' ' ILE . 82.5 mt -98.03 127.32 43.91 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 122.917 0.487 . . . . 0.0 111.211 -171.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.458 HG22 ' HA ' ' A' ' 60' ' ' PRO . 2.8 pp -140.08 -178.78 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.046 0 CA-C-O 121.956 0.884 . . . . 0.0 112.555 -174.718 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.43 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 69.0 m-85 -120.98 125.4 47.26 Favored 'General case' 0 C--N 1.291 -1.971 0 N-CA-C 105.429 -2.063 . . . . 0.0 105.429 172.47 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.487 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -111.22 146.35 37.08 Favored 'General case' 0 C--N 1.277 -2.545 0 O-C-N 123.531 0.519 . . . . 0.0 111.035 -174.54 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.481 ' HD3' ' C ' ' A' ' 14' ' ' LYS . 7.5 tmtm? -117.9 117.66 29.87 Favored 'General case' 0 N--CA 1.419 -1.998 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.707 -177.746 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.447 ' HB2' ' HB2' ' A' ' 18' ' ' TYR . 70.1 mtm -112.28 159.38 18.69 Favored 'General case' 0 C--O 1.248 0.999 0 CA-C-O 120.962 0.41 . . . . 0.0 111.364 173.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 26.2 ttpp -67.71 116.82 8.83 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 176.025 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.52 -4.91 64.43 Favored Glycine 0 C--O 1.239 0.432 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -176.305 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . 0.447 ' HB2' ' HB2' ' A' ' 15' ' ' MET . 35.3 m-85 -118.13 145.39 36.85 Favored Pre-proline 0 C--O 1.254 1.335 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 179.325 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -79.79 171.93 14.86 Favored 'Trans proline' 0 N--CA 1.445 -1.324 0 C-N-CA 123.16 2.573 . . . . 0.0 108.281 170.093 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 79.1 m80 -63.93 111.51 2.52 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 177.063 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 10.2 t-105 -110.18 140.51 22.47 Favored Pre-proline 0 C--N 1.295 -1.767 0 CA-C-N 114.866 -1.061 . . . . 0.0 109.369 -170.188 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -65.85 118.15 5.24 Favored 'Trans proline' 0 C--O 1.243 0.744 0 C-N-CA 122.008 1.805 . . . . 0.0 110.184 177.233 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -145.94 167.19 23.91 Favored 'General case' 0 N--CA 1.413 -2.307 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 -175.632 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.606 ' HD3' ' O ' ' A' ' 88' ' ' PRO . 10.0 ttp180 -122.29 149.06 44.25 Favored 'General case' 0 C--N 1.272 -2.782 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.403 ' HB ' ' O ' ' A' ' 6' ' ' LYS . 51.5 t -72.34 121.07 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 104.647 -2.353 . . . . 0.0 104.647 169.135 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -84.0 172.44 12.03 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 -170.656 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.431 -1.386 0 CA-C-O 121.506 0.669 . . . . 0.0 111.772 -176.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.462 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 88.6 mttt . . . . . 0 N--CA 1.431 -1.407 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 66.6 mt -84.16 140.8 39.71 Favored Pre-proline 0 C--N 1.314 -0.97 0 O-C-N 123.609 0.568 . . . . 0.0 109.574 -177.488 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -72.74 123.93 9.36 Favored 'Trans proline' 0 C--O 1.222 -0.276 0 C-N-CA 122.395 2.064 . . . . 0.0 110.186 178.767 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 47.6 mm -120.85 123.43 70.2 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 0 O-C-N 121.924 -0.485 . . . . 0.0 110.401 -176.495 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 77.4 t80 -106.09 119.13 38.4 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 177.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.415 ' CE2' ' HB3' ' A' ' 13' ' ' ALA . 80.4 m-85 -83.39 131.91 35.02 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-O 121.314 0.578 . . . . 0.0 112.141 179.591 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.433 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 46.1 m-85 -85.01 154.5 22.07 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.406 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.556 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 73.44 -21.16 1.17 Allowed Glycine 0 C--N 1.308 -0.981 0 C-N-CA 124.184 0.897 . . . . 0.0 114.977 179.679 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.4 p -115.98 -22.92 8.78 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 117.942 0.871 . . . . 0.0 109.668 173.409 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . 0.441 ' HE2' ' CD ' ' A' ' 83' ' ' GLU . 55.9 m170 69.73 23.17 5.83 Favored 'General case' 0 CA--C 1.518 -0.285 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.595 176.319 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -76.51 160.79 29.17 Favored 'General case' 0 N--CA 1.443 -0.785 0 CA-C-N 115.261 -0.881 . . . . 0.0 108.745 177.035 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.2 m -136.3 138.31 41.6 Favored 'General case' 0 C--N 1.279 -2.473 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.093 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -140.2 -179.62 6.09 Favored 'General case' 0 C--N 1.282 -2.343 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.0 -177.267 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -133.03 111.21 10.8 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 175.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.546 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 87.2 mt -129.25 150.9 50.43 Favored 'General case' 0 C--N 1.288 -2.094 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.293 -176.227 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.462 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -85.17 172.84 47.87 Favored Glycine 0 N--CA 1.424 -2.156 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 -176.54 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -65.04 -16.65 56.35 Favored 'Trans proline' 0 C--O 1.208 -0.992 0 C-N-CA 122.266 1.977 . . . . 0.0 112.407 -177.478 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.75 -1.14 44.04 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-O 121.301 0.572 . . . . 0.0 112.197 177.205 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.546 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 69.4 m-20 -104.22 -4.83 22.54 Favored 'General case' 0 C--N 1.295 -1.791 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 179.513 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.7 pt -128.2 156.58 40.41 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.707 0 CA-C-N 114.898 -1.046 . . . . 0.0 109.1 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . 0.425 ' HB3' ' ND2' ' A' ' 64' ' ' ASN . 88.6 m-85 -136.72 136.76 22.08 Favored Pre-proline 0 C--N 1.287 -2.115 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 -179.625 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . 0.485 ' HG2' ' HB2' ' A' ' 63' ' ' GLU . 20.5 Cg_endo -64.43 132.92 35.19 Favored 'Trans proline' 0 C--N 1.318 -1.079 0 C-N-CA 122.273 1.982 . . . . 0.0 112.416 -177.621 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.43 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 60.7 t80 -58.63 -39.76 81.41 Favored 'General case' 0 C--O 1.206 -1.214 0 C-N-CA 123.695 0.798 . . . . 0.0 110.839 -178.331 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 29.5 t -62.06 -36.09 80.58 Favored 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.484 -176.009 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . 0.485 ' HB2' ' HG2' ' A' ' 60' ' ' PRO . 1.3 mp0 -95.05 -18.0 21.39 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 113.172 0.805 . . . . 0.0 113.172 -175.2 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.425 ' ND2' ' HB3' ' A' ' 59' ' ' PHE . 37.3 m-80 -123.55 16.07 9.6 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 112.778 0.658 . . . . 0.0 112.778 -175.814 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.499 ' HG2' ' OE2' ' A' ' 66' ' ' GLU . 21.4 pttm -66.8 -32.19 73.3 Favored 'General case' 0 N--CA 1.484 1.268 0 CA-C-O 121.273 0.559 . . . . 0.0 110.703 -178.062 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.561 ' H ' ' CD ' ' A' ' 66' ' ' GLU . 2.7 mp0 -70.36 -25.39 63.25 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 -179.537 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 43.6 mttp -91.05 -59.66 2.11 Favored 'General case' 0 N--CA 1.422 -1.826 0 CA-C-N 114.271 -1.331 . . . . 0.0 111.297 -171.01 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 56.1 m-85 -105.76 -0.62 25.24 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.806 -172.254 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.9 56.43 4.81 Favored Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.74 179.292 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -128.61 128.53 23.54 Favored Pre-proline 0 C--N 1.317 -0.845 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.806 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_exo -54.57 137.9 74.01 Favored 'Trans proline' 0 C--N 1.349 0.575 0 C-N-CA 122.969 2.446 . . . . 0.0 112.169 177.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 15.9 m-80 -116.04 -179.34 3.63 Favored 'General case' 0 CA--C 1.472 -2.049 0 N-CA-C 113.845 1.054 . . . . 0.0 113.845 -178.633 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . 0.451 ' HD3' ' N ' ' A' ' 73' ' ' LYS . 2.8 mppt? -93.27 1.9 56.83 Favored 'General case' 0 N--CA 1.429 -1.494 0 CA-C-N 112.921 -1.945 . . . . 0.0 108.247 -178.516 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 5.6 mmt180 -84.54 116.34 23.08 Favored 'General case' 0 N--CA 1.426 -1.645 0 CA-C-N 114.889 -1.051 . . . . 0.0 109.783 176.43 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.433 ' HD3' ' N ' ' A' ' 76' ' ' GLY . 8.7 tmtt? -56.5 125.92 24.22 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 175.632 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.556 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.03 -25.44 20.42 Favored Glycine 0 N--CA 1.434 -1.451 0 C-N-CA 121.222 -0.514 . . . . 0.0 112.081 -179.363 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.421 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 14.1 t80 -70.29 -40.28 74.39 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 122.068 0.937 . . . . 0.0 108.738 -176.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -68.47 -43.64 76.55 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 114.198 -1.364 . . . . 0.0 108.986 -176.808 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -68.49 -35.57 77.72 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 114.39 -1.277 . . . . 0.0 109.964 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . 0.402 ' HA2' ' HB3' ' A' ' 45' ' ' PHE . . . -68.45 -33.66 77.65 Favored Glycine 0 N--CA 1.438 -1.186 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.24 177.8 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.421 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 95.4 mt -62.76 -33.83 75.98 Favored 'General case' 0 C--O 1.213 -0.818 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 174.596 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 72.8 t90 -71.92 -49.54 36.84 Favored 'General case' 0 N--CA 1.441 -0.901 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.778 176.336 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . 0.441 ' CD ' ' HE2' ' A' ' 48' ' ' HIS . 46.7 mt-10 -58.25 -40.35 81.53 Favored 'General case' 0 C--O 1.204 -1.335 0 N-CA-C 112.895 0.702 . . . . 0.0 112.895 179.503 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.403 HG13 HD22 ' A' ' 10' ' ' LEU . 18.0 tt -71.18 -21.21 21.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.179 0.514 . . . . 0.0 110.583 -176.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -89.03 -42.9 11.48 Favored 'General case' 0 N--CA 1.439 -1.011 0 CA-C-N 115.47 -0.787 . . . . 0.0 110.019 -177.856 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.577 HD22 ' N ' ' A' ' 86' ' ' ASN . 0.8 OUTLIER -89.49 -48.66 7.17 Favored 'General case' 0 CA--C 1.493 -1.225 0 CA-C-N 115.92 -0.582 . . . . 0.0 112.077 -174.295 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -132.29 76.87 71.84 Favored Pre-proline 0 C--N 1.302 -1.481 0 C-N-CA 120.17 -0.612 . . . . 0.0 109.761 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.606 ' O ' ' HD3' ' A' ' 24' ' ' ARG . 28.8 Cg_endo -62.97 -16.96 57.61 Favored 'Trans proline' 0 C--O 1.218 -0.515 0 C-N-CA 122.808 2.339 . . . . 0.0 115.719 -171.399 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . 0.42 ' HA ' ' HD3' ' A' ' 24' ' ' ARG . 8.5 ptmm? . . . . . 0 C--O 1.259 1.573 0 C-N-CA 119.317 -0.953 . . . . 0.0 111.323 -179.213 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 . . . . . 0 N--CA 1.427 -1.618 0 CA-C-O 121.452 0.644 . . . . 0.0 110.152 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.36 145.98 30.7 Favored Pre-proline 0 C--N 1.304 -1.39 0 CA-C-N 114.913 -1.039 . . . . 0.0 109.326 -177.079 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -53.28 122.23 10.83 Favored 'Trans proline' 0 C--O 1.238 0.523 0 C-N-CA 122.336 2.024 . . . . 0.0 109.579 172.118 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 109.58 -9.91 32.72 Favored Glycine 0 N--CA 1.427 -1.904 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.051 -177.258 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -79.9 153.51 28.96 Favored 'General case' 0 C--O 1.251 1.166 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -179.297 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.0 mt -105.64 126.39 52.09 Favored 'General case' 0 C--N 1.291 -1.97 0 CA-C-O 121.251 0.548 . . . . 0.0 109.892 -175.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.414 ' HA ' ' H ' ' A' ' 61' ' ' TYR . 9.3 pt -140.84 -172.66 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.832 0 CA-C-O 122.256 1.027 . . . . 0.0 111.813 -174.616 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.563 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 72.8 m-85 -126.15 134.44 51.3 Favored 'General case' 0 N--CA 1.411 -2.377 0 N-CA-C 105.894 -1.891 . . . . 0.0 105.894 172.342 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . 0.581 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -113.44 141.92 46.52 Favored 'General case' 0 C--N 1.273 -2.72 0 O-C-N 123.776 0.673 . . . . 0.0 110.235 -176.28 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' LYS . . . . . 0.479 ' HD3' ' C ' ' A' ' 14' ' ' LYS . 7.5 tmtm? -113.15 117.72 32.73 Favored 'General case' 0 N--CA 1.422 -1.837 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.834 -177.441 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' MET . . . . . 0.422 ' HB2' ' HB2' ' A' ' 18' ' ' TYR . 72.1 mtm -109.54 158.48 17.96 Favored 'General case' 0 C--O 1.254 1.331 0 CA-C-O 121.26 0.552 . . . . 0.0 111.056 173.241 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 61.4 tttm -68.46 117.26 9.99 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.682 178.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.3 -1.55 76.85 Favored Glycine 0 C--O 1.238 0.361 0 C-N-CA 121.0 -0.619 . . . . 0.0 111.768 -178.746 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' TYR . . . . . 0.444 ' HA ' ' HD3' ' A' ' 19' ' ' PRO . 61.7 m-85 -120.39 150.68 52.37 Favored Pre-proline 0 C--O 1.258 1.52 0 CA-C-N 115.636 -0.282 . . . . 0.0 111.061 -179.202 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 18' ' ' TYR . 6.4 Cg_exo -74.97 171.97 17.26 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 123.286 2.657 . . . . 0.0 109.691 172.513 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -67.3 110.97 3.75 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 176.788 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 3.9 t-105 -98.78 137.48 20.57 Favored Pre-proline 0 C--N 1.297 -1.681 0 CA-C-N 114.801 -1.091 . . . . 0.0 108.542 -171.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -64.49 118.13 5.13 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 121.763 1.642 . . . . 0.0 110.148 177.72 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -135.85 166.79 22.48 Favored 'General case' 0 N--CA 1.411 -2.398 0 CA-C-O 121.519 0.676 . . . . 0.0 110.975 -175.181 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.507 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 64.4 ttt-85 -115.66 141.76 47.65 Favored 'General case' 0 C--N 1.28 -2.423 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.455 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 48.1 t -77.65 119.92 27.26 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.249 0 N-CA-C 103.957 -2.608 . . . . 0.0 103.957 169.816 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -102.33 -179.58 4.03 Favored 'General case' 0 C--N 1.283 -2.294 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.858 -170.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLU . . . . . 0.409 ' CD ' HH12 ' A' ' 24' ' ' ARG . 30.5 mp0 . . . . . 0 N--CA 1.424 -1.731 0 CA-C-O 121.622 0.725 . . . . 0.0 110.504 -178.684 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' LYS . . . . . 0.617 ' HE3' ' HA ' ' A' ' 53' ' ' LEU . 22.5 mtpp . . . . . 0 N--CA 1.415 -2.209 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 80.7 mt -103.55 154.62 37.73 Favored Pre-proline 0 C--N 1.29 -2.002 0 O-C-N 124.023 0.827 . . . . 0.0 109.772 -175.605 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -71.15 122.32 8.62 Favored 'Trans proline' 0 N--CA 1.451 -0.991 0 C-N-CA 121.521 1.481 . . . . 0.0 109.734 174.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' ILE . . . . . 0.474 HG13 ' HB2' ' A' ' 53' ' ' LEU . 44.9 mm -118.53 116.81 52.48 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.935 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -176.585 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.408 ' CZ ' ' HA ' ' A' ' 48' ' ' HIS . 79.0 t80 -93.33 122.34 35.64 Favored 'General case' 0 C--N 1.268 -2.972 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 179.718 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -88.51 124.91 34.47 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.347 0.594 . . . . 0.0 112.542 178.434 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.507 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 78.2 m-85 -74.64 152.53 39.19 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.536 176.053 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' GLY . . . . . 0.55 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 79.78 -19.97 5.79 Favored Glycine 0 C--N 1.308 -1.02 0 CA-C-N 116.289 -0.414 . . . . 0.0 113.701 178.786 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.0 p -116.62 -22.79 8.48 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 117.166 0.483 . . . . 0.0 110.149 175.48 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . 0.408 ' HA ' ' CZ ' ' A' ' 43' ' ' PHE . 49.7 m170 70.22 14.23 7.63 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 124.321 1.048 . . . . 0.0 112.017 177.123 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 57.4 mm-40 -92.4 168.15 11.49 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.873 -179.113 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.0 m -129.48 142.15 50.85 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-O 121.2 0.524 . . . . 0.0 109.908 179.606 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -137.89 -178.9 5.46 Favored 'General case' 0 C--N 1.295 -1.791 0 C-N-CA 124.096 0.958 . . . . 0.0 110.023 -177.499 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -128.53 116.0 18.99 Favored 'General case' 0 CA--C 1.5 -0.975 0 CA-C-O 120.851 0.357 . . . . 0.0 110.637 179.141 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.617 ' HA ' ' HE3' ' A' ' 39' ' ' LYS . 89.0 mt -131.59 151.32 51.7 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.793 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' GLY . . . . . 0.418 ' HA2' ' HA ' ' A' ' 39' ' ' LYS . . . -85.69 174.38 48.19 Favored Glycine 0 N--CA 1.433 -1.514 0 C-N-CA 120.564 -0.827 . . . . 0.0 111.192 -176.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 -6.87 19.67 Favored 'Trans proline' 0 C--O 1.212 -0.794 0 C-N-CA 122.591 2.194 . . . . 0.0 112.98 -176.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.54 ' NZ ' ' HB2' ' A' ' 56' ' ' LYS . 5.8 mtmp? -97.99 -15.59 20.02 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 177.317 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.51 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 9.7 m-20 -99.72 1.78 43.65 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 114.585 -1.189 . . . . 0.0 108.58 -168.121 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.2 pt -132.06 152.11 36.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 114.19 -1.368 . . . . 0.0 110.187 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -135.29 141.31 37.3 Favored Pre-proline 0 C--N 1.302 -1.457 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 179.543 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -66.11 132.23 29.28 Favored 'Trans proline' 0 C--N 1.33 -0.432 0 C-N-CA 122.801 2.334 . . . . 0.0 113.36 -177.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' TYR . . . . . 0.563 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 50.3 t80 -59.48 -41.1 89.02 Favored 'General case' 0 C--O 1.208 -1.116 0 C-N-CA 123.639 0.776 . . . . 0.0 110.209 -179.496 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.1 p -59.41 -42.67 92.36 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 115.171 -0.922 . . . . 0.0 112.99 -176.19 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -96.48 -2.88 44.38 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 112.886 0.698 . . . . 0.0 112.886 -179.094 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.4 ' OD1' ' HD2' ' A' ' 67' ' ' LYS . 36.8 m-80 -132.14 15.04 4.67 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 113.185 0.809 . . . . 0.0 113.185 -176.317 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' LYS . . . . . 0.505 ' HG2' ' OE2' ' A' ' 66' ' ' GLU . 20.5 pttm -66.02 -29.16 69.47 Favored 'General case' 0 N--CA 1.487 1.415 0 CA-C-O 121.735 0.778 . . . . 0.0 110.831 -179.18 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' GLU . . . . . 0.573 ' H ' ' CD ' ' A' ' 66' ' ' GLU . 2.9 mp0 -68.21 -36.78 80.07 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 179.476 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.4 ' HD2' ' OD1' ' A' ' 64' ' ' ASN . 40.9 mttp -84.19 -59.78 2.29 Favored 'General case' 0 N--CA 1.428 -1.542 0 CA-C-N 113.405 -1.725 . . . . 0.0 111.583 -170.42 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 36.2 m-85 -105.51 -4.91 20.71 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.386 -170.807 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -81.7 56.45 4.92 Favored Glycine 0 N--CA 1.444 -0.805 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 177.748 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.529 ' O ' ' HE1' ' A' ' 77' ' ' PHE . 0.0 OUTLIER -119.33 158.55 48.44 Favored Pre-proline 0 C--N 1.305 -1.352 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 -177.55 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -73.36 167.24 27.81 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 121.883 1.722 . . . . 0.0 111.926 175.14 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -152.65 -177.63 6.36 Favored 'General case' 0 C--N 1.308 -1.23 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.226 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 30.9 mmmt -97.08 -10.56 25.81 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 122.243 0.217 . . . . 0.0 110.795 178.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 27.4 mmt180 -67.17 124.38 22.93 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 177.456 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.61 137.22 40.62 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 176.345 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . 0.55 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 100.97 -26.14 25.77 Favored Glycine 0 N--CA 1.426 -2.013 0 N-CA-C 108.926 -1.67 . . . . 0.0 108.926 -174.53 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' PHE . . . . . 0.529 ' HE1' ' O ' ' A' ' 70' ' ' LYS . 20.6 t80 -77.04 -46.52 23.48 Favored 'General case' 0 N--CA 1.44 -0.939 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.473 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -60.37 -50.29 74.19 Favored 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 115.164 -0.925 . . . . 0.0 108.597 177.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 20.5 mp0 -61.09 -41.7 97.15 Favored 'General case' 0 N--CA 1.435 -1.207 0 CA-C-N 113.797 -1.547 . . . . 0.0 110.513 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.06 -34.55 64.76 Favored Glycine 0 CA--C 1.496 -1.11 0 CA-C-N 115.879 -0.601 . . . . 0.0 113.403 -178.445 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 32.3 tp -63.62 -30.62 71.71 Favored 'General case' 0 C--O 1.204 -1.325 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 176.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 79.1 t90 -77.04 -47.12 21.48 Favored 'General case' 0 N--CA 1.437 -1.109 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.031 175.237 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 39.0 mt-10 -58.93 -42.28 89.37 Favored 'General case' 0 C--O 1.196 -1.711 0 N-CA-C 113.202 0.816 . . . . 0.0 113.202 -178.723 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 21.1 tt -63.33 -33.18 59.63 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -175.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -81.61 -34.24 31.04 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.126 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.7 m-80 -100.52 -46.54 5.18 Favored 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 112.94 0.719 . . . . 0.0 112.94 -172.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 64.9 t30 -133.58 73.64 72.28 Favored Pre-proline 0 C--N 1.3 -1.565 0 CA-C-O 121.058 0.456 . . . . 0.0 110.686 -178.166 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -73.61 -5.61 17.37 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 122.978 2.452 . . . . 0.0 112.791 -176.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 61.5 pttt . . . . . 0 C--N 1.308 -1.2 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.874 -177.982 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.0 mmt . . . . . 0 CA--C 1.497 -1.075 0 N-CA-C 110.203 -0.295 . . . . 0.0 110.203 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -121.61 75.37 1.18 Allowed 'General case' 0 N--CA 1.429 -1.484 0 N-CA-C 108.725 -0.842 . . . . 0.0 108.725 175.324 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.412 ' HG3' ' O ' ' A' ' 4' ' ' ASP . 8.0 ptt180 -147.22 -172.91 4.12 Favored 'General case' 0 C--N 1.297 -1.674 0 N-CA-C 106.286 -1.746 . . . . 0.0 106.286 176.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . 0.412 ' O ' ' HG3' ' A' ' 3' ' ' ARG . 3.6 p-10 -89.55 155.37 19.32 Favored 'General case' 0 C--O 1.257 1.457 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 179.388 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 95.9 m-85 -133.51 118.35 18.21 Favored 'General case' 0 N--CA 1.416 -2.126 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 25.9 mttp -94.84 147.49 33.2 Favored Pre-proline 0 C--N 1.291 -1.964 0 CA-C-N 114.583 -1.19 . . . . 0.0 108.783 -173.184 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -63.19 115.64 3.1 Favored 'Trans proline' 0 N--CA 1.448 -1.157 0 N-CA-C 107.549 -1.751 . . . . 0.0 107.549 170.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 110.07 -8.47 31.3 Favored Glycine 0 N--CA 1.422 -2.253 0 C-N-CA 120.955 -0.64 . . . . 0.0 112.214 -174.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -73.1 154.92 40.19 Favored 'General case' 0 C--O 1.253 1.28 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 -178.214 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 71.1 mt -102.12 122.56 44.37 Favored 'General case' 0 C--N 1.298 -1.665 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.553 -173.064 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -139.97 178.88 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 CA-C-O 122.458 1.123 . . . . 0.0 113.206 -175.154 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.475 ' HB3' ' HB3' ' A' ' 20' ' ' HIS . 47.5 m-85 -115.89 127.87 55.35 Favored 'General case' 0 C--N 1.278 -2.516 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 170.422 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.556 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -108.43 124.68 50.78 Favored 'General case' 0 C--N 1.273 -2.757 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.579 -175.313 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.599 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -105.93 123.39 47.89 Favored 'General case' 0 N--CA 1.404 -2.768 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.34 -177.759 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 68.4 mtm -120.63 158.17 27.97 Favored 'General case' 0 C--N 1.317 -0.847 0 C-N-CA 123.344 0.657 . . . . 0.0 109.231 176.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -67.53 117.07 8.99 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.08 -5.81 57.94 Favored Glycine 0 C--O 1.251 1.195 0 N-CA-C 111.518 -0.633 . . . . 0.0 111.518 178.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -124.04 147.25 53.65 Favored Pre-proline 0 N--CA 1.426 -1.666 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 -179.37 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_endo -74.49 170.98 19.03 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 121.805 1.67 . . . . 0.0 109.273 174.249 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.575 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 65.8 m80 -59.97 110.78 1.27 Allowed 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 107.899 -1.149 . . . . 0.0 107.899 175.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -102.22 137.95 19.59 Favored Pre-proline 0 C--N 1.308 -1.22 0 C-N-CA 124.017 0.927 . . . . 0.0 109.53 -170.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -64.38 118.16 5.15 Favored 'Trans proline' 0 C--O 1.242 0.694 0 C-N-CA 121.869 1.712 . . . . 0.0 110.636 178.643 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -144.98 166.12 26.22 Favored 'General case' 0 N--CA 1.415 -2.188 0 CA-C-O 121.181 0.515 . . . . 0.0 110.403 -176.27 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.443 ' HD3' ' O ' ' A' ' 88' ' ' PRO . 11.4 ttp180 -114.63 146.25 41.06 Favored 'General case' 0 C--N 1.282 -2.351 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.496 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.6 t -73.28 117.03 16.37 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 N-CA-C 104.098 -2.556 . . . . 0.0 104.098 168.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.44 ' CG ' ' HZ1' ' A' ' 91' ' ' LYS . 4.6 t70 -92.97 -178.0 4.67 Favored 'General case' 0 C--N 1.281 -2.405 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 -170.334 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.2 pm0 -100.51 169.78 8.84 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 109.079 -0.712 . . . . 0.0 109.079 178.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 52.3 t -67.3 119.89 68.46 Favored Pre-proline 0 C--N 1.311 -1.081 0 C-N-CA 120.766 -0.374 . . . . 0.0 110.209 -177.155 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_endo -74.65 152.02 42.11 Favored 'Trans proline' 0 N--CA 1.421 -2.744 0 C-N-CA 121.877 1.718 . . . . 0.0 112.468 -179.087 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -68.45 129.21 39.24 Favored 'General case' 0 C--N 1.308 -1.232 0 CA-C-N 115.42 -0.809 . . . . 0.0 108.947 179.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 104.17 -18.57 45.38 Favored Glycine 0 N--CA 1.434 -1.454 0 CA-C-N 115.461 -0.791 . . . . 0.0 111.439 -178.452 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -79.05 94.42 5.31 Favored 'General case' 0 N--CA 1.441 -0.924 0 CA-C-O 121.406 0.622 . . . . 0.0 110.819 179.2 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.2 m -89.31 6.09 4.35 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.158 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.934 178.538 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.437 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 0.1 OUTLIER -82.43 128.23 67.85 Favored Pre-proline 0 N--CA 1.427 -1.597 0 CA-C-N 115.429 -0.805 . . . . 0.0 112.903 -179.207 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 34' ' ' LYS . 13.7 Cg_exo -70.99 170.27 18.44 Favored 'Trans proline' 0 C--O 1.265 1.833 0 C-N-CA 122.474 2.116 . . . . 0.0 110.431 175.007 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -52.24 127.89 25.38 Favored 'Trans proline' 0 C--N 1.359 1.112 0 C-N-CA 122.735 2.29 . . . . 0.0 110.787 177.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.2 m -105.94 9.0 32.79 Favored 'General case' 0 C--N 1.287 -2.121 0 CA-C-N 114.712 -1.131 . . . . 0.0 108.97 -173.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 46.9 m-80 78.92 8.53 1.95 Allowed 'General case' 0 N--CA 1.492 1.653 0 C-N-CA 125.969 1.708 . . . . 0.0 108.155 -170.478 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.501 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 47.6 mmtt -118.63 149.52 41.25 Favored 'General case' 0 N--CA 1.409 -2.504 0 CA-C-N 113.346 -1.752 . . . . 0.0 107.444 174.292 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.479 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 79.4 mt -113.25 153.28 45.54 Favored Pre-proline 0 C--N 1.263 -3.186 0 O-C-N 124.812 1.32 . . . . 0.0 108.696 -177.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 35.2 Cg_endo -69.68 123.61 10.3 Favored 'Trans proline' 0 N--CA 1.457 -0.667 0 C-N-CA 121.658 1.572 . . . . 0.0 109.667 174.794 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.402 ' O ' ' HA ' ' A' ' 50' ' ' THR . 50.7 mm -120.58 122.44 68.04 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.825 0 CA-C-O 120.879 0.371 . . . . 0.0 110.454 -176.665 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.545 ' CE1' ' HA ' ' A' ' 48' ' ' HIS . 35.0 t80 -98.05 114.84 27.11 Favored 'General case' 0 C--N 1.285 -2.196 0 C-N-CA 123.441 0.697 . . . . 0.0 109.754 178.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 81.3 m-85 -79.79 129.93 34.9 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 112.361 0.504 . . . . 0.0 112.361 177.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 73.1 m-85 -82.42 154.85 24.97 Favored 'General case' 0 C--N 1.305 -1.337 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.574 177.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.54 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 74.38 -20.65 1.6 Allowed Glycine 0 C--N 1.31 -0.883 0 CA-C-N 115.442 -0.799 . . . . 0.0 114.411 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 38.1 p -116.41 -22.64 8.68 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 117.911 0.856 . . . . 0.0 109.391 173.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . 0.545 ' HA ' ' CE1' ' A' ' 43' ' ' PHE . 12.5 m-70 68.12 22.61 8.26 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 114.959 -1.019 . . . . 0.0 112.98 177.825 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 42.2 mt-10 -79.34 172.3 13.99 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.243 -0.889 . . . . 0.0 109.975 178.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.402 ' HA ' ' O ' ' A' ' 42' ' ' ILE . 3.8 m -140.95 138.18 33.62 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 177.415 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -140.16 -179.0 5.72 Favored 'General case' 0 C--N 1.288 -2.107 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.383 -176.634 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.479 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 62.0 m-85 -129.59 109.94 11.42 Favored 'General case' 0 N--CA 1.445 -0.68 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 177.018 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.556 HD12 ' HB1' ' A' ' 13' ' ' ALA . 94.6 mt -129.08 153.57 47.51 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 -179.565 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.501 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -87.97 171.82 41.32 Favored Glycine 0 CA--C 1.49 -1.492 0 C-N-CA 120.307 -0.949 . . . . 0.0 112.191 -174.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -61.73 -19.0 63.63 Favored 'Trans proline' 0 C--O 1.239 0.532 0 C-N-CA 123.088 2.526 . . . . 0.0 111.982 -179.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -91.86 -19.95 21.97 Favored 'General case' 0 N--CA 1.433 -1.29 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.903 179.473 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.409 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 24.7 m-20 -82.07 -20.86 37.36 Favored 'General case' 0 CA--C 1.493 -1.234 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.298 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.404 ' HA ' ' O ' ' A' ' 12' ' ' PHE . 15.5 pt -110.19 151.56 12.39 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.687 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.65 -176.359 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -135.73 137.66 26.18 Favored Pre-proline 0 C--O 1.185 -2.327 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -66.32 127.36 17.27 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 122.486 2.124 . . . . 0.0 113.938 -175.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 75.3 t80 -57.8 -32.48 67.6 Favored 'General case' 0 C--O 1.205 -1.279 0 CA-C-N 114.713 -1.13 . . . . 0.0 111.694 -175.101 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -62.59 -57.45 11.04 Favored 'General case' 0 C--N 1.293 -1.889 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -69.42 -34.53 74.6 Favored 'General case' 0 C--O 1.219 -0.518 0 CA-C-O 121.506 0.669 . . . . 0.0 111.555 -177.513 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . 0.309 0.8 OUTLIER -109.81 23.74 13.98 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 115.32 1.6 . . . . 0.0 115.32 -175.715 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.429 ' HZ1' ' CG ' ' A' ' 85' ' ' ASP . 15.8 ttmm -63.27 -27.38 69.29 Favored 'General case' 0 N--CA 1.481 1.095 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.217 171.742 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.463 ' CD ' ' HG2' ' A' ' 67' ' ' LYS . 1.2 pp20? -77.41 -35.46 54.19 Favored 'General case' 0 N--CA 1.423 -1.796 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.215 176.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.463 ' HG2' ' CD ' ' A' ' 66' ' ' GLU . 0.1 OUTLIER -77.37 -59.74 2.66 Favored 'General case' 0 N--CA 1.439 -0.982 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.119 -174.381 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -105.82 -4.11 21.17 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.986 -169.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -79.7 59.86 4.41 Favored Glycine 0 N--CA 1.436 -1.347 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 176.682 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.403 ' HD3' ' HA ' ' A' ' 70' ' ' LYS . 38.7 mmtm -132.34 134.34 24.81 Favored Pre-proline 0 C--N 1.32 -0.679 0 C-N-CA 122.936 0.495 . . . . 0.0 111.259 -179.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.458 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 78.1 Cg_exo -48.31 131.3 22.45 Favored 'Trans proline' 0 C--O 1.273 2.248 0 C-N-CA 123.911 3.074 . . . . 0.0 113.75 178.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.552 ' HB2' ' CD1' ' A' ' 77' ' ' PHE . 1.2 t-20 -113.82 -178.21 3.32 Favored 'General case' 0 N--CA 1.406 -2.633 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.953 -174.146 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.614 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 7.3 mptt -110.81 10.65 22.52 Favored 'General case' 0 N--CA 1.425 -1.696 0 CA-C-O 122.485 1.136 . . . . 0.0 108.375 -178.252 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 31.2 mmt180 -96.45 129.52 43.79 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 114.204 -1.362 . . . . 0.0 108.567 173.81 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.424 ' HG3' ' OE2' ' A' ' 79' ' ' GLU . 61.9 tttp -69.7 144.35 52.85 Favored 'General case' 0 N--CA 1.446 -0.663 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 174.7 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.54 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 91.47 -25.91 13.83 Favored Glycine 0 C--O 1.208 -1.469 0 N-CA-C 111.761 -0.536 . . . . 0.0 111.761 -177.517 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.552 ' CD1' ' HB2' ' A' ' 72' ' ' ASN . 32.5 t80 -69.78 -53.63 17.42 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-O 121.85 0.834 . . . . 0.0 109.423 -178.653 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.458 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 87.5 m-20 -69.93 -32.84 71.33 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.905 -176.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . 0.424 ' OE2' ' HG3' ' A' ' 75' ' ' LYS . 28.1 mt-10 -72.09 -37.68 69.52 Favored 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 114.738 -1.119 . . . . 0.0 108.382 178.243 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.04 -31.63 66.58 Favored Glycine 0 N--CA 1.428 -1.86 0 CA-C-N 115.007 -0.997 . . . . 0.0 112.462 177.333 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 86.0 mt -55.95 -34.74 65.95 Favored 'General case' 0 N--CA 1.474 0.746 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 175.136 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.4 t90 -75.91 -50.71 14.23 Favored 'General case' 0 N--CA 1.426 -1.635 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.457 177.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 -54.98 -48.37 73.35 Favored 'General case' 0 C--O 1.2 -1.537 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -178.327 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.2 tt -67.43 -25.5 33.53 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.172 0 N-CA-C 112.205 0.446 . . . . 0.0 112.205 -175.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.429 ' CG ' ' HZ1' ' A' ' 65' ' ' LYS . 6.7 t0 -94.39 -22.59 18.22 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.261 0.553 . . . . 0.0 110.488 -174.197 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.466 HD22 ' N ' ' A' ' 86' ' ' ASN . 0.8 OUTLIER -106.96 -57.49 2.06 Favored 'General case' 0 CA--C 1.505 -0.777 0 CA-C-O 121.291 0.567 . . . . 0.0 111.366 -179.285 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 65.7 t30 -127.6 76.02 77.27 Favored Pre-proline 0 C--N 1.313 -1.015 0 C-N-CA 119.849 -0.74 . . . . 0.0 110.413 -179.072 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.443 ' O ' ' HD3' ' A' ' 24' ' ' ARG . 48.6 Cg_endo -69.73 -6.54 18.83 Favored 'Trans proline' 0 N--CA 1.483 0.857 0 C-N-CA 122.722 2.282 . . . . 0.0 113.93 -175.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.2 pttm -103.22 20.3 17.96 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 121.19 0.519 . . . . 0.0 109.699 -178.207 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 14.7 p -78.6 119.19 27.21 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.006 0 CA-C-O 122.193 0.997 . . . . 0.0 113.173 -176.263 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.44 ' HZ1' ' CG ' ' A' ' 26' ' ' ASP . 18.2 ptpt -162.1 171.97 16.62 Favored 'General case' 0 N--CA 1.419 -2.002 0 CA-C-N 114.757 -1.11 . . . . 0.0 108.275 172.582 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 57.4 m-85 -88.4 -174.61 4.68 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 123.553 0.533 . . . . 0.0 109.656 -179.106 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.9 p . . . . . 0 N--CA 1.434 -1.228 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 179.353 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.409 ' N ' ' HG2' ' A' ' 63' ' ' GLU . 98.0 mmm . . . . . 0 CA--C 1.49 -1.352 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -94.86 69.92 3.37 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 178.258 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 15.5 ptt180 -121.96 160.58 24.56 Favored 'General case' 0 C--N 1.286 -2.156 0 CA-C-N 113.61 -1.632 . . . . 0.0 109.729 -179.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -114.75 -170.12 1.68 Allowed 'General case' 0 C--O 1.261 1.673 0 N-CA-C 106.842 -1.54 . . . . 0.0 106.842 174.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.557 ' CE2' HG13 ' A' ' 58' ' ' ILE . 56.4 m-85 -109.01 145.52 35.41 Favored 'General case' 0 C--N 1.288 -2.078 0 N-CA-C 116.131 1.901 . . . . 0.0 116.131 -165.496 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.36 149.15 54.32 Favored Pre-proline 0 N--CA 1.423 -1.808 0 CA-C-N 113.166 -1.834 . . . . 0.0 106.71 179.694 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -58.56 130.44 37.31 Favored 'Trans proline' 0 C--O 1.236 0.41 0 C-N-CA 122.008 1.805 . . . . 0.0 109.97 173.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 104.72 -16.58 47.34 Favored Glycine 0 N--CA 1.433 -1.528 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.988 -179.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.0 t70 -79.59 162.31 25.4 Favored 'General case' 0 C--O 1.25 1.099 0 CA-C-N 117.216 0.508 . . . . 0.0 110.156 -175.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.512 HD21 ' HB2' ' A' ' 88' ' ' PRO . 58.0 mt -100.34 122.66 43.48 Favored 'General case' 0 CA--C 1.496 -1.116 0 C-N-CA 122.81 0.444 . . . . 0.0 110.395 -172.676 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -138.37 179.86 3.01 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.308 0 CA-C-O 122.5 1.143 . . . . 0.0 113.696 -173.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.574 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 61.0 m-85 -113.76 130.06 56.5 Favored 'General case' 0 C--N 1.283 -2.321 0 CA-C-N 113.775 -1.557 . . . . 0.0 107.684 170.671 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.434 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -107.7 118.23 36.19 Favored 'General case' 0 N--CA 1.398 -3.042 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 -176.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.603 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -105.28 122.72 46.53 Favored 'General case' 0 N--CA 1.399 -2.987 0 CA-C-N 114.981 -1.009 . . . . 0.0 110.192 -176.887 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 70.1 mtm -118.33 158.17 25.72 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-N 115.633 -0.712 . . . . 0.0 109.237 177.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 59.3 tttm -65.8 116.58 7.13 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.551 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.15 -2.45 65.81 Favored Glycine 0 C--O 1.251 1.159 0 N-CA-C 111.632 -0.587 . . . . 0.0 111.632 179.335 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.419 ' HA ' ' HD3' ' A' ' 19' ' ' PRO . 81.5 m-85 -120.9 150.94 54.09 Favored Pre-proline 0 N--CA 1.427 -1.61 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 -178.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.419 ' HD3' ' HA ' ' A' ' 18' ' ' TYR . 4.9 Cg_exo -77.61 171.09 18.08 Favored 'Trans proline' 0 N--CA 1.44 -1.622 0 C-N-CA 121.815 1.677 . . . . 0.0 109.312 174.654 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.496 ' HB3' ' HB3' ' A' ' 12' ' ' PHE . 69.7 m80 -62.01 111.18 1.82 Allowed 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 175.421 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -100.67 137.53 19.88 Favored Pre-proline 0 C--N 1.301 -1.521 0 N-CA-C 109.209 -0.664 . . . . 0.0 109.209 -172.181 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -65.99 118.05 5.17 Favored 'Trans proline' 0 C--O 1.243 0.762 0 C-N-CA 121.561 1.507 . . . . 0.0 110.932 178.234 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.34 166.85 25.09 Favored 'General case' 0 N--CA 1.419 -1.985 0 CA-C-N 116.223 -0.444 . . . . 0.0 109.815 -176.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.425 ' HB2' ' CE2' ' A' ' 45' ' ' PHE . 14.2 ttp180 -116.58 147.89 41.43 Favored 'General case' 0 C--N 1.28 -2.415 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 179.342 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 40.6 t -74.14 123.83 30.29 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.199 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 171.865 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -87.91 169.76 11.73 Favored 'General case' 0 C--N 1.289 -2.061 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 -173.054 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -113.44 132.21 55.73 Favored 'General case' 0 C--N 1.302 -1.461 0 CA-C-O 121.542 0.687 . . . . 0.0 111.511 -177.394 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.4 p -87.13 124.8 67.94 Favored Pre-proline 0 N--CA 1.432 -1.335 0 CA-C-N 115.226 -0.897 . . . . 0.0 110.313 -179.247 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -76.48 158.49 36.36 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.453 2.102 . . . . 0.0 112.474 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 20.1 t0 -70.82 149.13 47.14 Favored 'General case' 0 C--N 1.313 -1.006 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 174.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 96.97 -23.49 35.44 Favored Glycine 0 C--N 1.29 -1.995 0 N-CA-C 108.952 -1.659 . . . . 0.0 108.952 -174.143 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -93.84 38.94 1.07 Allowed 'General case' 0 C--O 1.201 -1.449 0 CA-C-O 121.819 0.819 . . . . 0.0 109.753 176.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.5 m -73.72 8.47 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 113.422 -1.717 . . . . 0.0 113.756 -175.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 3.5 mppt? -72.93 142.86 83.49 Favored Pre-proline 0 C--N 1.3 -1.576 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 176.254 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.424 ' HA ' ' HD3' ' A' ' 36' ' ' PRO . 17.8 Cg_endo -59.4 133.86 54.92 Favored 'Trans proline' 0 CA--C 1.537 0.66 0 C-N-CA 122.039 1.826 . . . . 0.0 113.111 -176.811 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 35' ' ' PRO . 89.4 Cg_endo -87.1 172.43 6.23 Favored 'Trans proline' 0 N--CA 1.439 -1.702 0 C-N-CA 122.984 2.456 . . . . 0.0 111.85 179.332 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.405 ' O ' ' HB3' ' A' ' 38' ' ' ASN . 4.8 m -60.2 8.79 0.02 OUTLIER 'General case' 0 CA--C 1.58 2.099 0 C-N-CA 126.548 1.939 . . . . 0.0 113.735 179.448 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.405 ' HB3' ' O ' ' A' ' 37' ' ' THR . 0.5 OUTLIER 74.66 9.79 4.14 Favored 'General case' 0 N--CA 1.481 1.105 0 CA-C-O 123.479 1.609 . . . . 0.0 110.05 -177.215 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.445 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 81.4 mttt -127.74 169.99 13.23 Favored 'General case' 0 N--CA 1.424 -1.747 0 CA-C-N 114.244 -1.343 . . . . 0.0 110.134 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.442 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 86.8 mt -86.04 144.76 39.43 Favored Pre-proline 0 C--N 1.313 -0.979 0 O-C-N 123.681 0.613 . . . . 0.0 109.863 -176.573 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -73.37 123.97 9.09 Favored 'Trans proline' 0 N--CA 1.454 -0.809 0 C-N-CA 122.046 1.831 . . . . 0.0 109.819 175.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 51.1 mm -118.42 125.9 74.68 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.879 0 CA-C-N 116.542 -0.299 . . . . 0.0 110.412 -176.461 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -101.34 113.9 27.4 Favored 'General case' 0 C--N 1.291 -1.971 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 178.03 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -81.02 130.57 35.08 Favored 'General case' 0 C--N 1.299 -1.617 0 CA-C-O 121.102 0.477 . . . . 0.0 111.861 178.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.429 ' CD2' ' HB ' ' A' ' 84' ' ' ILE . 74.1 m-85 -83.73 156.37 22.61 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 109.532 -0.544 . . . . 0.0 109.532 176.091 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.456 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 75.59 -20.15 2.31 Favored Glycine 0 C--N 1.314 -0.675 0 CA-C-N 115.922 -0.581 . . . . 0.0 113.957 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 24.7 p -119.08 -23.19 6.92 Favored 'General case' 0 C--N 1.308 -1.232 0 O-C-N 122.383 -0.48 . . . . 0.0 110.084 174.98 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 61.69 27.98 17.22 Favored 'General case' 0 C--N 1.354 0.788 0 CA-C-O 121.712 0.767 . . . . 0.0 111.536 -179.725 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 7.4 mm-40 -85.35 159.9 19.91 Favored 'General case' 0 CA--C 1.491 -1.317 0 CA-C-N 114.043 -1.435 . . . . 0.0 108.783 176.051 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.5 m -130.05 136.72 49.69 Favored 'General case' 0 C--N 1.268 -2.946 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 178.126 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -140.08 -179.24 5.85 Favored 'General case' 0 C--N 1.284 -2.243 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.688 -176.15 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.442 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 79.6 m-85 -132.21 110.76 10.87 Favored 'General case' 0 CA--C 1.499 -1.011 0 C-N-CA 123.351 0.66 . . . . 0.0 109.464 177.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.434 HD12 ' HB1' ' A' ' 13' ' ' ALA . 95.9 mt -126.53 151.68 47.54 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 -179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.445 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -75.9 162.67 52.99 Favored Glycine 0 N--CA 1.416 -2.648 0 C-N-CA 119.968 -1.111 . . . . 0.0 110.677 -176.192 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.438 ' O ' ' HE2' ' A' ' 5' ' ' PHE . 17.9 Cg_endo -62.42 -19.99 69.08 Favored 'Trans proline' 0 C--O 1.191 -1.874 0 C-N-CA 122.237 1.958 . . . . 0.0 111.162 179.177 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.427 ' HA ' ' HE3' ' A' ' 56' ' ' LYS . 0.0 OUTLIER -99.48 -0.4 40.8 Favored 'General case' 0 C--N 1.286 -2.166 0 O-C-N 121.441 -0.787 . . . . 0.0 111.537 178.278 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -89.57 -20.95 23.15 Favored 'General case' 0 CA--C 1.488 -1.41 0 N-CA-C 109.106 -0.701 . . . . 0.0 109.106 175.434 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.557 HG13 ' CE2' ' A' ' 5' ' ' PHE . 18.4 pt -110.59 157.24 11.41 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.75 0 CA-C-N 114.174 -1.375 . . . . 0.0 110.223 -175.872 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -139.36 147.31 52.23 Favored Pre-proline 0 C--N 1.303 -1.432 0 N-CA-C 108.431 -0.951 . . . . 0.0 108.431 -177.317 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.429 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 38.6 Cg_endo -64.89 129.68 23.94 Favored 'Trans proline' 0 C--O 1.243 0.728 0 C-N-CA 122.657 2.238 . . . . 0.0 113.081 -175.661 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.574 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 82.2 t80 -60.94 -37.12 81.22 Favored 'General case' 0 C--O 1.205 -1.264 0 CA-C-N 115.447 -0.797 . . . . 0.0 111.983 -177.077 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 22.6 t -63.63 -54.05 41.88 Favored 'General case' 0 C--N 1.307 -1.269 0 CA-C-O 120.946 0.403 . . . . 0.0 110.635 -175.332 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.429 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 4.2 mp0 -71.01 -25.84 62.86 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-O 121.376 0.608 . . . . 0.0 112.304 -178.073 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.464 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 28.0 m-80 -105.48 12.67 31.15 Favored 'General case' 0 C--N 1.293 -1.878 0 C-N-CA 120.536 -0.466 . . . . 0.0 111.917 -176.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.3 tttp -63.19 -37.87 88.94 Favored 'General case' 0 N--CA 1.479 1.001 0 CA-C-O 121.153 0.502 . . . . 0.0 110.92 -179.544 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 18.2 mm-40 -71.57 -24.01 61.84 Favored 'General case' 0 CA--C 1.488 -1.417 0 CA-C-O 121.831 0.824 . . . . 0.0 112.151 176.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.464 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 35.6 mtpt -85.79 -58.47 2.64 Favored 'General case' 0 C--N 1.266 -3.053 0 CA-C-N 114.135 -1.393 . . . . 0.0 111.426 -176.181 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 38.3 m-85 -125.17 0.75 7.84 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 115.995 -0.548 . . . . 0.0 112.006 -172.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -94.29 32.11 6.2 Favored Glycine 0 CA--C 1.496 -1.104 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.236 -175.261 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 50.0 mtmt -130.21 153.93 81.28 Favored Pre-proline 0 C--N 1.301 -1.515 0 C-N-CA 122.808 0.443 . . . . 0.0 110.138 178.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 66.9 Cg_exo -42.68 144.24 1.39 Allowed 'Trans proline' 0 C--N 1.363 1.298 0 C-N-CA 124.583 3.522 . . . . 0.0 117.328 -172.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 5.9 t-20 -137.13 -166.25 1.89 Allowed 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 105.073 -2.195 . . . . 0.0 105.073 173.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 3.5 mmmp? -116.55 2.26 13.02 Favored 'General case' 0 N--CA 1.416 -2.138 0 C-N-CA 119.019 -1.072 . . . . 0.0 113.28 174.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 14.2 mmt180 -61.39 128.92 38.68 Favored 'General case' 0 C--N 1.324 -0.539 0 O-C-N 124.167 0.917 . . . . 0.0 109.012 175.189 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.8 tmtm? -68.78 123.55 21.24 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.585 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.456 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 105.91 -25.05 25.14 Favored Glycine 0 N--CA 1.428 -1.884 0 N-CA-C 110.164 -1.175 . . . . 0.0 110.164 -177.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 29.6 t80 -76.6 -44.78 32.98 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -60.82 -50.04 75.06 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.61 178.337 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -68.16 -40.59 82.28 Favored 'General case' 0 C--N 1.302 -1.498 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.314 -178.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -72.24 -30.89 64.37 Favored Glycine 0 CA--C 1.489 -1.531 0 CA-C-N 115.646 -0.707 . . . . 0.0 112.955 -177.204 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 44.0 tp -62.39 -35.51 79.43 Favored 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.086 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.7 t90 -70.57 -48.61 54.47 Favored 'General case' 0 N--CA 1.425 -1.721 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.95 177.416 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -54.82 -51.35 66.1 Favored 'General case' 0 C--O 1.202 -1.447 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -179.382 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.429 ' HB ' ' CD2' ' A' ' 45' ' ' PHE . 17.6 tt -68.13 -24.01 29.52 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 N-CA-C 112.223 0.453 . . . . 0.0 112.223 -175.329 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 6.3 t0 -94.61 -21.21 18.97 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-O 121.252 0.549 . . . . 0.0 110.458 -175.109 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.461 HD22 ' N ' ' A' ' 86' ' ' ASN . 0.8 OUTLIER -109.83 -56.78 2.27 Favored 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 121.268 0.556 . . . . 0.0 111.603 -178.95 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -125.17 71.66 63.84 Favored Pre-proline 0 C--N 1.316 -0.886 0 C-N-CA 120.169 -0.612 . . . . 0.0 110.126 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.512 ' HB2' HD21 ' A' ' 10' ' ' LEU . 60.1 Cg_endo -73.13 -6.12 18.37 Favored 'Trans proline' 0 N--CA 1.475 0.389 0 C-N-CA 122.527 2.151 . . . . 0.0 113.46 -174.643 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.3 pttm -95.1 13.81 24.03 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.826 -0.624 . . . . 0.0 110.019 -178.451 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 9.8 p -86.3 141.79 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.328 0 CA-C-O 121.052 0.453 . . . . 0.0 110.639 -179.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 30.5 mtpp -128.25 -70.13 0.7 Allowed 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 175.436 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -97.92 115.63 28.5 Favored 'General case' 0 C--N 1.29 -2.003 0 CA-C-N 114.83 -1.077 . . . . 0.0 111.272 -178.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 25.7 p . . . . . 0 C--N 1.277 -2.585 0 N-CA-C 105.087 -2.19 . . . . 0.0 105.087 173.761 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.423 ' HB2' ' HG3' ' A' ' 3' ' ' ARG . 64.5 mtt . . . . . 0 N--CA 1.477 0.903 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -100.01 -5.49 28.04 Favored 'General case' 0 C--O 1.207 -1.16 0 CA-C-O 121.226 0.536 . . . . 0.0 110.613 176.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.423 ' HG3' ' HB2' ' A' ' 1' ' ' MET . 0.1 OUTLIER -83.87 -20.23 33.45 Favored 'General case' 0 N--CA 1.479 1.014 0 CA-C-O 122.892 1.33 . . . . 0.0 109.722 178.833 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -108.61 132.36 53.96 Favored 'General case' 0 C--N 1.258 -3.411 0 CA-C-N 112.252 -2.249 . . . . 0.0 109.783 178.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -110.2 124.95 52.52 Favored 'General case' 0 N--CA 1.413 -2.276 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.401 -174.405 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -134.65 154.67 79.68 Favored Pre-proline 0 C--N 1.283 -2.324 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.402 -176.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -49.6 123.25 10.14 Favored 'Trans proline' 0 C--N 1.35 0.63 0 C-N-CA 123.365 2.71 . . . . 0.0 111.992 179.413 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 112.85 -17.49 22.68 Favored Glycine 0 N--CA 1.424 -2.165 0 CA-C-N 115.656 -0.702 . . . . 0.0 112.24 179.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -75.44 156.84 34.88 Favored 'General case' 0 C--O 1.249 1.041 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -177.129 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 75.1 mt -106.92 120.49 42.18 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 -174.525 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.438 HG22 ' HA ' ' A' ' 60' ' ' PRO . 2.9 pp -137.01 -179.63 3.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 CA-C-O 122.528 1.156 . . . . 0.0 113.42 -174.236 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.441 ' HB3' ' HB3' ' A' ' 20' ' ' HIS . 33.2 m-85 -113.57 130.52 56.35 Favored 'General case' 0 C--N 1.275 -2.665 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 170.401 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -107.24 116.39 31.85 Favored 'General case' 0 C--N 1.268 -2.952 0 CA-C-N 115.26 -0.882 . . . . 0.0 108.839 -174.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.58 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -112.87 120.89 43.02 Favored 'General case' 0 N--CA 1.394 -3.256 0 CA-C-N 114.572 -1.194 . . . . 0.0 108.856 -178.888 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 68.1 mtm -105.64 158.48 16.67 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 179.485 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.0 tttp -65.74 116.42 6.93 Favored 'General case' 0 C--N 1.309 -1.153 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -178.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.32 -2.63 63.31 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.726 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -125.13 148.27 59.88 Favored Pre-proline 0 N--CA 1.438 -1.04 0 CA-C-O 120.595 0.236 . . . . 0.0 110.593 -178.131 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_endo -72.24 170.53 18.89 Favored 'Trans proline' 0 N--CA 1.455 -0.789 0 C-N-CA 122.444 2.096 . . . . 0.0 111.747 177.424 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.464 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 79.4 m80 -67.12 111.69 4.03 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 108.895 -0.779 . . . . 0.0 108.895 178.136 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 13.0 t-105 -109.63 136.03 20.32 Favored Pre-proline 0 C--N 1.314 -0.977 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 -176.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -62.08 120.34 7.88 Favored 'Trans proline' 0 C--O 1.244 0.799 0 C-N-CA 122.536 2.157 . . . . 0.0 112.45 -178.591 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -148.1 166.07 28.94 Favored 'General case' 0 N--CA 1.431 -1.38 0 CA-C-O 120.932 0.396 . . . . 0.0 110.806 -177.121 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.478 HH21 ' CG ' ' A' ' 26' ' ' ASP . 12.2 ttp180 -109.85 144.53 38.19 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 178.769 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 68.9 t -73.69 107.25 4.15 Favored 'Isoleucine or valine' 0 CA--C 1.488 -1.405 0 N-CA-C 102.709 -3.071 . . . . 0.0 102.709 166.489 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.478 ' CG ' HH21 ' A' ' 24' ' ' ARG . 0.4 OUTLIER -88.64 -178.22 5.75 Favored 'General case' 0 C--N 1.271 -2.808 0 C-N-CA 119.654 -0.818 . . . . 0.0 111.957 -168.241 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 33.7 mt-10 -103.69 152.06 22.26 Favored 'General case' 0 C--N 1.285 -2.205 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.956 -173.253 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 39.9 t -90.48 121.56 68.26 Favored Pre-proline 0 C--N 1.312 -1.049 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 179.604 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_endo -78.81 144.05 19.0 Favored 'Trans proline' 0 N--CA 1.438 -1.755 0 C-N-CA 121.771 1.648 . . . . 0.0 113.598 -178.041 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 4.9 m-20 -54.17 130.47 38.49 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.079 173.053 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 110.36 -27.09 11.98 Favored Glycine 0 C--N 1.295 -1.722 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 -177.399 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -78.69 80.81 5.04 Favored 'General case' 0 N--CA 1.439 -0.976 0 CA-C-O 121.988 0.899 . . . . 0.0 109.917 175.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.2 m -95.86 4.04 9.19 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.198 0 CA-C-N 114.406 -1.27 . . . . 0.0 110.532 179.315 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 31.0 mmtp -84.26 129.43 58.15 Favored Pre-proline 0 C--N 1.299 -1.62 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 178.05 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_endo -64.09 134.95 45.03 Favored 'Trans proline' 0 N--CA 1.455 -0.753 0 C-N-CA 122.029 1.819 . . . . 0.0 112.543 -178.086 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.4 ' C ' ' H ' ' A' ' 38' ' ' ASN . 69.7 Cg_endo -78.41 172.05 15.91 Favored 'Trans proline' 0 N--CA 1.443 -1.481 0 C-N-CA 122.695 2.263 . . . . 0.0 111.888 -179.656 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.6 m -70.31 8.14 0.86 Allowed 'General case' 0 CA--C 1.565 1.551 0 C-N-CA 125.178 1.391 . . . . 0.0 111.552 -179.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.4 ' H ' ' C ' ' A' ' 36' ' ' PRO . 47.9 m-80 75.8 14.11 2.74 Favored 'General case' 0 N--CA 1.481 1.119 0 C-N-CA 125.333 1.453 . . . . 0.0 110.527 -177.494 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.449 ' HE2' ' N ' ' A' ' 54' ' ' GLY . 31.6 mtpt -113.09 166.74 11.14 Favored 'General case' 0 N--CA 1.425 -1.691 0 N-CA-C 107.593 -1.262 . . . . 0.0 107.593 177.754 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 79.8 mt -85.74 144.2 39.32 Favored Pre-proline 0 C--N 1.302 -1.499 0 O-C-N 123.212 0.32 . . . . 0.0 110.175 -176.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -71.25 123.91 10.0 Favored 'Trans proline' 0 N--CA 1.457 -0.622 0 C-N-CA 122.046 1.83 . . . . 0.0 109.764 175.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.414 HG13 ' HB2' ' A' ' 53' ' ' LEU . 51.4 mm -120.49 122.7 68.77 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 O-C-N 122.165 -0.334 . . . . 0.0 110.265 -176.013 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 88.0 t80 -104.95 114.48 28.71 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 178.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -74.9 132.7 41.66 Favored 'General case' 0 C--N 1.319 -0.737 0 O-C-N 123.655 0.597 . . . . 0.0 111.335 179.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 78.8 m-85 -90.19 158.1 17.39 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.269 177.586 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.563 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 75.84 -19.9 2.54 Favored Glycine 0 C--N 1.311 -0.852 0 CA-C-N 115.631 -0.713 . . . . 0.0 113.529 -179.451 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 60.5 p -119.27 -22.68 7.02 Favored 'General case' 0 N--CA 1.431 -1.397 0 O-C-N 122.419 -0.46 . . . . 0.0 109.941 175.439 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.1 m170 66.98 25.57 9.3 Favored 'General case' 0 C--N 1.352 0.697 0 C-N-CA 124.12 0.968 . . . . 0.0 111.752 179.434 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 -84.42 178.04 7.9 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.412 -0.813 . . . . 0.0 109.329 178.239 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 8.9 m -144.01 147.42 33.85 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 178.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -147.23 -179.79 7.08 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 123.827 0.851 . . . . 0.0 109.776 -178.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -133.06 110.82 10.48 Favored 'General case' 0 C--O 1.252 1.235 0 CA-C-O 121.524 0.678 . . . . 0.0 109.353 177.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.579 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 96.2 mt -127.86 155.76 43.63 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.354 -176.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.449 ' N ' ' HE2' ' A' ' 39' ' ' LYS . . . -94.69 174.47 33.24 Favored Glycine 0 N--CA 1.425 -2.053 0 N-CA-C 110.152 -1.179 . . . . 0.0 110.152 -178.342 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -66.31 -11.04 29.73 Favored 'Trans proline' 0 C--O 1.208 -1.024 0 C-N-CA 122.797 2.332 . . . . 0.0 112.799 -177.218 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 20.7 pttp -97.62 -7.96 29.95 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 122.211 1.005 . . . . 0.0 110.245 178.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.579 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 65.5 m-20 -100.64 -10.24 21.12 Favored 'General case' 0 C--N 1.287 -2.152 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.577 -176.04 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 12.2 pt -125.23 154.97 33.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.42 -175.154 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -142.49 140.74 19.23 Favored Pre-proline 0 C--N 1.309 -1.18 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 179.424 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.438 ' HA ' HG22 ' A' ' 11' ' ' ILE . 33.8 Cg_endo -65.64 127.66 18.44 Favored 'Trans proline' 0 C--O 1.243 0.751 0 C-N-CA 122.774 2.316 . . . . 0.0 114.13 -173.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 65.2 t80 -62.48 -30.61 71.38 Favored 'General case' 0 CA--C 1.505 -0.774 0 C-N-CA 124.105 0.962 . . . . 0.0 109.437 179.321 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.8 m -55.02 -35.48 64.47 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-N 114.908 -1.042 . . . . 0.0 111.88 -179.534 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . 0.284 55.0 mt-10 -85.75 -54.11 4.72 Favored 'General case' 0 CA--C 1.483 -1.618 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 172.048 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.416 ' CG ' ' HE2' ' A' ' 67' ' ' LYS . 31.6 m-80 -67.96 9.87 0.26 Allowed 'General case' 0 CA--C 1.473 -1.991 0 C-N-CA 127.628 2.371 . . . . 0.0 113.867 -164.238 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 55.6 tttp -66.85 -33.8 76.4 Favored 'General case' 0 N--CA 1.394 -3.269 0 N-CA-C 106.895 -1.52 . . . . 0.0 106.895 174.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.727 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -80.43 -33.41 36.94 Favored 'General case' 0 N--CA 1.429 -1.525 0 CA-C-N 115.016 -0.993 . . . . 0.0 113.573 172.86 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.727 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 24.5 mtmm -77.54 -59.47 2.77 Favored 'General case' 0 CA--C 1.503 -0.843 0 N-CA-C 113.169 0.803 . . . . 0.0 113.169 -178.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -120.22 6.77 10.72 Favored 'General case' 0 C--N 1.281 -2.391 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.957 -174.333 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.5 11.99 35.96 Favored Glycine 0 CA--C 1.524 0.636 0 CA-C-N 116.29 -0.413 . . . . 0.0 114.087 -177.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -97.93 127.11 38.13 Favored Pre-proline 0 N--CA 1.441 -0.902 0 CA-C-N 117.162 0.481 . . . . 0.0 110.083 178.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -65.15 128.39 20.44 Favored 'Trans proline' 0 N--CA 1.446 -1.319 0 C-N-CA 122.42 2.08 . . . . 0.0 114.862 -176.05 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 2.8 p30 -102.35 -157.32 0.6 Allowed 'General case' 0 C--N 1.292 -1.911 0 CA-C-N 113.705 -1.589 . . . . 0.0 108.814 177.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.419 ' HA ' ' HD3' ' A' ' 73' ' ' LYS . 43.2 mmtm -108.58 15.39 23.82 Favored 'General case' 0 C--N 1.294 -1.832 0 C-N-CA 120.444 -0.503 . . . . 0.0 111.359 -179.43 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 39.5 mmt180 -80.02 121.44 25.5 Favored 'General case' 0 CA--C 1.513 -0.476 0 C-N-CA 117.95 -1.5 . . . . 0.0 108.9 171.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 11.0 tppt? -74.06 126.76 31.23 Favored 'General case' 0 N--CA 1.428 -1.551 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.563 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.32 -25.82 18.67 Favored Glycine 0 N--CA 1.424 -2.165 0 N-CA-C 109.114 -1.594 . . . . 0.0 109.114 -173.153 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 6.8 t80 -76.72 -46.97 23.37 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 108.138 -1.06 . . . . 0.0 108.138 179.586 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 11.2 m120 -56.51 -52.53 64.41 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-N 114.944 -1.025 . . . . 0.0 109.009 178.124 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 21.7 mp0 -61.37 -40.91 96.05 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-N 113.793 -1.549 . . . . 0.0 110.297 -178.704 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -67.19 -37.66 91.4 Favored Glycine 0 N--CA 1.437 -1.242 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.562 -179.558 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 90.7 mt -60.82 -34.67 74.89 Favored 'General case' 0 CA--C 1.509 -0.629 0 N-CA-C 110.224 -0.288 . . . . 0.0 110.224 176.369 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 84.9 t90 -71.7 -50.96 25.57 Favored 'General case' 0 N--CA 1.432 -1.33 0 O-C-N 123.589 0.555 . . . . 0.0 109.557 177.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 42.0 mt-10 -56.1 -50.78 70.09 Favored 'General case' 0 C--O 1.202 -1.409 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -178.528 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.3 tt -66.78 -25.87 35.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 N-CA-C 112.486 0.55 . . . . 0.0 112.486 -174.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -93.29 -19.43 21.39 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-O 121.591 0.71 . . . . 0.0 110.621 -173.896 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.9 m-80 -114.04 -56.29 2.41 Favored 'General case' 0 CA--C 1.508 -0.642 0 CA-C-N 115.792 -0.64 . . . . 0.0 111.362 -177.035 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.521 ' OD1' ' HG2' ' A' ' 89' ' ' LYS . 65.3 t30 -128.42 75.51 79.18 Favored Pre-proline 0 C--N 1.311 -1.095 0 C-N-CA 119.831 -0.748 . . . . 0.0 111.22 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -69.73 -6.3 18.25 Favored 'Trans proline' 0 N--CA 1.481 0.736 0 C-N-CA 122.704 2.269 . . . . 0.0 113.481 -176.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . 0.521 ' HG2' ' OD1' ' A' ' 87' ' ' ASN . 9.5 ptpp? -97.55 6.26 48.36 Favored 'General case' 0 C--N 1.316 -0.889 0 N-CA-C 109.841 -0.429 . . . . 0.0 109.841 -176.776 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 10.2 p -68.35 148.08 11.99 Favored 'Isoleucine or valine' 0 C--O 1.246 0.909 0 CA-C-O 121.732 0.777 . . . . 0.0 111.818 -175.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 39.1 mmtm -144.66 -49.78 0.27 Allowed 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 177.328 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 62.9 t80 -134.88 168.65 18.68 Favored 'General case' 0 C--N 1.286 -2.165 0 N-CA-C 104.757 -2.312 . . . . 0.0 104.757 176.072 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 25.0 m . . . . . 0 C--N 1.324 -0.543 0 O-C-N 124.318 1.011 . . . . 0.0 111.569 -177.934 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.8 mtt . . . . . 0 CA--C 1.5 -0.957 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -127.83 79.78 1.92 Allowed 'General case' 0 N--CA 1.436 -1.163 0 N-CA-C 106.857 -1.535 . . . . 0.0 106.857 175.258 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 11.5 ptm180 -137.69 176.31 8.82 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-N 114.442 -1.254 . . . . 0.0 110.321 -177.282 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -115.08 -176.58 2.94 Favored 'General case' 0 C--O 1.252 1.199 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 174.18 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.401 ' CE2' HG13 ' A' ' 58' ' ' ILE . 88.8 m-85 -114.27 150.41 34.45 Favored 'General case' 0 C--N 1.29 -1.998 0 N-CA-C 114.063 1.134 . . . . 0.0 114.063 -169.516 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 9.2 pttp -135.13 166.72 26.94 Favored Pre-proline 0 N--CA 1.43 -1.455 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 177.31 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -59.44 149.34 82.21 Favored 'Trans proline' 0 C--O 1.265 1.87 0 C-N-CA 122.052 1.834 . . . . 0.0 112.451 175.47 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 98.51 -14.24 62.2 Favored Glycine 0 N--CA 1.434 -1.439 0 CA-C-N 115.683 -0.689 . . . . 0.0 113.36 176.7 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -84.22 154.76 22.85 Favored 'General case' 0 C--O 1.242 0.695 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 -177.217 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.45 ' HB3' HD11 ' A' ' 84' ' ' ILE . 83.2 mt -99.54 128.68 45.66 Favored 'General case' 0 CA--C 1.498 -1.03 0 CA-C-N 114.888 -1.051 . . . . 0.0 109.163 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -141.62 -178.62 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-O 122.131 0.967 . . . . 0.0 112.418 -175.15 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 48.1 m-85 -112.84 129.77 56.33 Favored 'General case' 0 C--N 1.279 -2.464 0 N-CA-C 106.508 -1.664 . . . . 0.0 106.508 170.836 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.45 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -107.49 132.23 53.45 Favored 'General case' 0 C--N 1.275 -2.658 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -176.072 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.507 ' C ' ' HD3' ' A' ' 14' ' ' LYS . 7.3 tmtm? -113.79 117.26 30.98 Favored 'General case' 0 N--CA 1.41 -2.434 0 CA-C-N 115.779 -0.646 . . . . 0.0 109.877 -177.103 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 54.9 mtm -114.41 158.69 21.19 Favored 'General case' 0 C--N 1.308 -1.198 0 C-N-CA 120.406 -0.518 . . . . 0.0 110.724 173.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 39.5 ttpt -62.5 118.72 7.94 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 109.439 -0.578 . . . . 0.0 109.439 176.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.33 -12.86 68.64 Favored Glycine 0 C--O 1.243 0.716 0 C-N-CA 121.034 -0.603 . . . . 0.0 111.65 -178.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -106.62 151.31 40.39 Favored Pre-proline 0 C--O 1.256 1.446 0 C-N-CA 122.811 0.444 . . . . 0.0 111.137 -179.343 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_endo -82.27 172.41 11.68 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 C-N-CA 123.435 2.757 . . . . 0.0 108.91 173.499 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 78.5 m80 -65.94 110.47 2.91 Favored 'General case' 0 C--N 1.31 -1.117 0 N-CA-C 107.637 -1.246 . . . . 0.0 107.637 175.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.7 t-105 -104.37 138.24 19.46 Favored Pre-proline 0 C--N 1.303 -1.439 0 CA-C-N 115.318 -0.856 . . . . 0.0 108.909 -171.76 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -68.01 117.59 5.02 Favored 'Trans proline' 0 N--CA 1.451 -1.003 0 C-N-CA 121.484 1.456 . . . . 0.0 109.867 177.042 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -145.28 167.05 23.78 Favored 'General case' 0 N--CA 1.415 -2.2 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 -176.145 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.564 ' HB3' ' CE2' ' A' ' 45' ' ' PHE . 8.1 ptt85 -123.53 155.89 36.7 Favored 'General case' 0 C--N 1.281 -2.375 0 C-N-CA 119.149 -1.02 . . . . 0.0 109.356 179.805 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.7 t -86.32 117.7 31.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 N-CA-C 106.002 -1.851 . . . . 0.0 106.002 174.187 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -91.73 176.08 6.66 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 -175.272 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 11.8 mp0 -92.7 162.5 14.12 Favored 'General case' 0 N--CA 1.421 -1.912 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 45.3 t -77.52 123.47 86.74 Favored Pre-proline 0 C--N 1.304 -1.385 0 N-CA-C 107.93 -1.137 . . . . 0.0 107.93 175.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -76.57 148.15 29.09 Favored 'Trans proline' 0 N--CA 1.431 -2.162 0 C-N-CA 121.481 1.454 . . . . 0.0 112.611 -179.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -60.1 134.22 56.84 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 175.376 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 110.06 -31.76 7.22 Favored Glycine 0 C--N 1.278 -2.648 0 N-CA-C 109.456 -1.457 . . . . 0.0 109.456 -175.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -83.01 82.72 8.12 Favored 'General case' 0 N--CA 1.429 -1.522 0 CA-C-O 121.926 0.87 . . . . 0.0 109.551 176.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.6 m -90.24 6.83 4.42 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 CA-C-N 114.475 -1.239 . . . . 0.0 110.858 179.475 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 30.8 mmtp -86.53 130.32 49.66 Favored Pre-proline 0 C--N 1.296 -1.75 0 CA-C-N 114.943 -1.026 . . . . 0.0 108.831 179.02 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -64.43 150.18 88.71 Favored 'Trans proline' 0 C--O 1.243 0.736 0 C-N-CA 122.213 1.942 . . . . 0.0 112.105 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_endo -62.6 144.48 94.37 Favored 'Trans proline' 0 N--CA 1.452 -0.97 0 C-N-CA 122.468 2.112 . . . . 0.0 112.407 -179.289 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.8 m -71.45 8.74 0.97 Allowed 'General case' 0 CA--C 1.566 1.575 0 C-N-CA 125.69 1.596 . . . . 0.0 112.284 -178.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 85.85 7.69 0.35 Allowed 'General case' 0 N--CA 1.501 2.117 0 C-N-CA 127.551 2.341 . . . . 0.0 108.849 -173.092 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.618 ' HE3' ' HA ' ' A' ' 53' ' ' LEU . 22.0 mtpp -122.13 155.82 34.93 Favored 'General case' 0 N--CA 1.416 -2.139 0 CA-C-N 113.657 -1.611 . . . . 0.0 107.321 176.27 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 73.3 mt -99.38 155.12 36.87 Favored Pre-proline 0 C--N 1.299 -1.601 0 C-N-CA 123.189 0.596 . . . . 0.0 109.65 -174.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -74.64 121.92 7.03 Favored 'Trans proline' 0 N--CA 1.451 -0.999 0 C-N-CA 121.158 1.239 . . . . 0.0 109.399 174.804 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.51 HG13 ' HB2' ' A' ' 53' ' ' LEU . 49.8 mm -115.39 118.65 59.47 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 CA-C-O 120.898 0.38 . . . . 0.0 110.393 -176.407 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.498 ' CE1' ' HA ' ' A' ' 48' ' ' HIS . 58.3 t80 -97.74 116.27 29.63 Favored 'General case' 0 C--N 1.283 -2.303 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.342 179.147 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.421 ' CE2' ' HB2' ' A' ' 51' ' ' ALA . 73.3 m-85 -77.75 130.72 37.1 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-O 121.055 0.455 . . . . 0.0 111.669 177.775 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.564 ' CE2' ' HB3' ' A' ' 24' ' ' ARG . 59.6 m-85 -81.89 150.08 27.95 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.65 176.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.479 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 82.01 -20.59 7.94 Favored Glycine 0 C--N 1.313 -0.749 0 C-N-CA 123.875 0.75 . . . . 0.0 114.394 177.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 41.3 p -119.56 -22.49 6.93 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-N 117.521 0.661 . . . . 0.0 110.316 174.331 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . 0.498 ' HA ' ' CE1' ' A' ' 43' ' ' PHE . 11.5 m-70 69.03 19.42 8.11 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 123.655 0.782 . . . . 0.0 111.899 -178.308 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -77.29 177.15 8.15 Favored 'General case' 0 N--CA 1.446 -0.638 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.262 177.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.9 m -142.41 144.83 33.28 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 109.675 -0.491 . . . . 0.0 109.675 -179.031 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.421 ' HB2' ' CE2' ' A' ' 44' ' ' PHE . . . -137.98 171.76 13.93 Favored 'General case' 0 C--N 1.29 -1.984 0 CA-C-N 115.397 -0.819 . . . . 0.0 109.516 178.536 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -124.62 108.4 12.02 Favored 'General case' 0 CA--C 1.482 -1.659 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 174.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.618 ' HA ' ' HE3' ' A' ' 39' ' ' LYS . 94.5 mt -134.85 139.83 45.35 Favored 'General case' 0 C--N 1.285 -2.196 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 -178.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.496 ' HA2' ' HA ' ' A' ' 39' ' ' LYS . . . -87.78 177.95 46.8 Favored Glycine 0 N--CA 1.415 -2.717 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -175.245 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -67.21 -10.94 30.37 Favored 'Trans proline' 0 C--N 1.319 -0.977 0 C-N-CA 122.445 2.096 . . . . 0.0 112.589 -177.161 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 30.7 mmtm -100.07 -8.14 24.13 Favored 'General case' 0 C--N 1.305 -1.361 0 N-CA-C 112.363 0.505 . . . . 0.0 112.363 175.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.569 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 4.3 m-20 -98.15 -12.62 21.56 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-O 121.853 0.835 . . . . 0.0 108.771 -178.262 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.401 HG13 ' CE2' ' A' ' 5' ' ' PHE . 15.1 pt -112.63 157.71 13.27 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.231 0 CA-C-N 115.071 -0.968 . . . . 0.0 110.941 -177.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 -130.93 144.87 55.3 Favored Pre-proline 0 C--N 1.298 -1.647 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 -177.267 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.453 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 42.4 Cg_endo -66.04 127.93 18.64 Favored 'Trans proline' 0 CA--C 1.503 -1.034 0 C-N-CA 122.475 2.117 . . . . 0.0 112.949 -177.483 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 85.3 t80 -61.68 -36.91 82.23 Favored 'General case' 0 C--O 1.206 -1.224 0 CA-C-N 114.816 -1.084 . . . . 0.0 112.149 -176.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.418 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 14.0 m -65.85 -50.09 65.82 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-O 121.144 0.497 . . . . 0.0 110.92 -175.707 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.453 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 3.1 mp0 -79.21 -5.25 53.84 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.656 -0.702 . . . . 0.0 112.533 -177.055 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.443 ' OD1' ' HD2' ' A' ' 67' ' ' LYS . 33.3 m-80 -125.45 12.5 8.11 Favored 'General case' 0 C--N 1.301 -1.514 0 C-N-CA 120.591 -0.444 . . . . 0.0 112.089 178.364 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 62.9 tttp -70.92 -32.22 69.08 Favored 'General case' 0 N--CA 1.479 1.02 0 CA-C-O 122.03 0.919 . . . . 0.0 110.25 -179.344 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.639 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -74.82 -30.37 61.36 Favored 'General case' 0 N--CA 1.404 -2.772 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.649 175.981 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.639 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 49.3 mttp -80.14 -56.73 4.02 Favored 'General case' 0 CA--C 1.505 -0.766 0 CA-C-N 115.626 -0.715 . . . . 0.0 112.584 -178.267 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 54.5 m-85 -114.24 7.19 16.46 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-O 121.471 0.653 . . . . 0.0 111.837 -172.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -91.46 51.98 3.05 Favored Glycine 0 C--N 1.294 -1.755 0 CA-C-N 115.615 -0.72 . . . . 0.0 111.637 -176.232 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -133.64 141.94 41.98 Favored Pre-proline 0 C--N 1.293 -1.866 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 175.509 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -65.67 126.91 16.89 Favored 'Trans proline' 0 N--CA 1.445 -1.345 0 C-N-CA 121.297 1.331 . . . . 0.0 114.425 -173.311 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -83.91 -173.0 4.47 Favored 'General case' 0 CA--C 1.484 -1.589 0 CA-C-N 114.078 -1.419 . . . . 0.0 109.059 178.819 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.532 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 1.1 mptp? -107.4 20.75 18.49 Favored 'General case' 0 C--N 1.282 -2.355 0 CA-C-O 122.664 1.221 . . . . 0.0 108.003 172.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 13.7 mmt180 -87.12 121.09 29.1 Favored 'General case' 0 N--CA 1.436 -1.172 0 CA-C-N 113.504 -1.68 . . . . 0.0 107.174 173.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 28.2 tptp -60.76 124.13 19.52 Favored 'General case' 0 C--N 1.311 -1.087 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 177.307 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.479 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.21 -25.13 21.1 Favored Glycine 0 N--CA 1.437 -1.256 0 N-CA-C 111.452 -0.659 . . . . 0.0 111.452 -179.246 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 15.2 t80 -74.53 -36.02 63.14 Favored 'General case' 0 C--N 1.314 -0.946 0 CA-C-O 121.337 0.589 . . . . 0.0 109.837 -176.687 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.51 HD22 ' N ' ' A' ' 78' ' ' ASN . 0.7 OUTLIER -74.77 -41.98 59.03 Favored 'General case' 0 C--N 1.317 -0.829 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 -175.836 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -67.9 -34.69 77.13 Favored 'General case' 0 C--N 1.305 -1.368 0 CA-C-N 114.336 -1.302 . . . . 0.0 109.452 178.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -66.64 -35.0 89.22 Favored Glycine 0 CA--C 1.493 -1.285 0 CA-C-N 115.659 -0.7 . . . . 0.0 112.167 178.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 87.8 mt -63.65 -35.28 80.01 Favored 'General case' 0 C--O 1.215 -0.723 0 CA-C-O 121.035 0.445 . . . . 0.0 109.845 175.101 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 86.2 t90 -67.43 -49.06 65.36 Favored 'General case' 0 N--CA 1.429 -1.507 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 177.171 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -58.25 -45.44 87.81 Favored 'General case' 0 C--O 1.208 -1.094 0 N-CA-C 113.221 0.822 . . . . 0.0 113.221 178.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.45 HD11 ' HB3' ' A' ' 10' ' ' LEU . 19.9 tt -73.18 -29.48 28.49 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 N-CA-C 112.428 0.529 . . . . 0.0 112.428 -173.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -87.23 -18.47 30.22 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 179.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 31.8 m-80 -111.63 -54.4 2.61 Favored 'General case' 0 CA--C 1.503 -0.836 0 CA-C-O 121.273 0.559 . . . . 0.0 112.161 -176.344 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.403 ' ND2' ' HB ' ' A' ' 90' ' ' VAL . 66.5 t30 -128.56 72.47 80.73 Favored Pre-proline 0 C--N 1.306 -1.316 0 C-N-CA 119.765 -0.774 . . . . 0.0 110.724 -179.218 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -72.85 -5.82 17.89 Favored 'Trans proline' 0 N--CA 1.478 0.582 0 C-N-CA 122.597 2.198 . . . . 0.0 113.447 -175.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.2 pttm -95.87 12.65 29.47 Favored 'General case' 0 C--N 1.307 -1.256 0 CA-C-N 115.829 -0.623 . . . . 0.0 109.908 -178.602 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.403 ' HB ' ' ND2' ' A' ' 87' ' ' ASN . 9.4 p -87.55 152.32 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.26 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 178.385 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.4 ' HB3' ' HE2' ' A' ' 91' ' ' LYS . 16.9 ptpt -141.13 -165.26 1.92 Allowed 'General case' 0 N--CA 1.433 -1.311 0 N-CA-C 110.144 -0.317 . . . . 0.0 110.144 177.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 13.3 m-85 -34.99 -71.4 0.07 Allowed 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 126.602 1.961 . . . . 0.0 112.174 -175.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 50.1 m . . . . . 0 C--N 1.299 -1.618 0 N-CA-C 106.556 -1.646 . . . . 0.0 106.556 179.27 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.503 -0.833 0 N-CA-C 103.999 -2.593 . . . . 0.0 103.999 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -63.58 -30.62 71.71 Favored 'General case' 0 C--N 1.307 -1.259 0 O-C-N 123.694 0.621 . . . . 0.0 110.477 176.479 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 10.1 ptp180 -102.53 165.81 10.88 Favored 'General case' 0 C--O 1.266 1.97 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 176.435 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 9.6 p-10 -90.05 173.77 8.01 Favored 'General case' 0 C--N 1.304 -1.409 0 N-CA-C 106.976 -1.491 . . . . 0.0 106.976 175.068 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 98.4 m-85 -133.86 119.93 19.78 Favored 'General case' 0 C--N 1.303 -1.456 0 C-N-CA 120.22 -0.592 . . . . 0.0 110.945 -175.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 24.1 mtmm -119.55 155.97 53.84 Favored Pre-proline 0 C--N 1.291 -1.975 0 CA-C-N 114.703 -1.135 . . . . 0.0 108.013 -178.446 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -55.04 120.76 8.72 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 121.723 1.615 . . . . 0.0 109.497 174.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 115.94 -24.4 10.15 Favored Glycine 0 N--CA 1.432 -1.573 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.38 -175.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -62.03 123.69 18.79 Favored 'General case' 0 C--O 1.25 1.102 0 CA-C-N 117.494 0.647 . . . . 0.0 110.74 177.476 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.422 HD23 ' HG3' ' A' ' 24' ' ' ARG . 85.2 mt -79.93 124.26 28.51 Favored 'General case' 0 CA--C 1.483 -1.601 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 177.316 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 9.3 pt -141.07 -175.12 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.036 0 CA-C-O 122.592 1.187 . . . . 0.0 112.792 -172.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.523 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 60.8 m-85 -122.24 130.35 53.09 Favored 'General case' 0 N--CA 1.405 -2.686 0 CA-C-N 113.42 -1.718 . . . . 0.0 106.56 170.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.473 ' HB2' HG21 ' A' ' 42' ' ' ILE . . . -108.8 124.25 50.31 Favored 'General case' 0 C--N 1.275 -2.651 0 O-C-N 123.931 0.769 . . . . 0.0 109.494 -177.711 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.525 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.9 OUTLIER -108.46 126.69 53.18 Favored 'General case' 0 C--N 1.272 -2.781 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.228 -177.462 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 63.5 mtm -125.59 157.75 36.37 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.682 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 1.3 ttpm? -61.34 115.95 4.25 Favored 'General case' 0 C--O 1.247 0.971 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.903 179.134 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.63 -5.68 64.62 Favored Glycine 0 C--O 1.251 1.165 0 O-C-N 123.506 0.504 . . . . 0.0 112.094 178.241 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 88.8 m-85 -120.81 151.02 54.04 Favored Pre-proline 0 N--CA 1.426 -1.656 0 N-CA-C 109.101 -0.703 . . . . 0.0 109.101 -177.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -78.18 171.09 17.62 Favored 'Trans proline' 0 N--CA 1.443 -1.495 0 C-N-CA 121.676 1.584 . . . . 0.0 109.082 174.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.478 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 80.2 m80 -61.22 110.41 1.39 Allowed 'General case' 0 CA--C 1.549 0.941 0 N-CA-C 107.033 -1.469 . . . . 0.0 107.033 175.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.6 t-105 -99.34 138.39 20.51 Favored Pre-proline 0 C--N 1.31 -1.132 0 C-N-CA 123.377 0.671 . . . . 0.0 109.874 -171.071 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo -60.72 118.2 5.05 Favored 'Trans proline' 0 C--O 1.245 0.861 0 C-N-CA 121.746 1.631 . . . . 0.0 110.709 177.25 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.8 167.19 22.87 Favored 'General case' 0 N--CA 1.413 -2.309 0 CA-C-O 120.898 0.38 . . . . 0.0 110.309 -176.481 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.422 ' HG3' HD23 ' A' ' 10' ' ' LEU . 24.4 ttp-105 -125.81 147.04 49.54 Favored 'General case' 0 C--N 1.288 -2.083 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 175.346 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 48.1 t -72.78 119.04 18.85 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 N-CA-C 105.714 -1.958 . . . . 0.0 105.714 171.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -90.31 -177.5 5.12 Favored 'General case' 0 C--N 1.307 -1.247 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 -175.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -101.26 168.68 9.4 Favored 'General case' 0 C--N 1.282 -2.341 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -175.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 48.4 t -83.43 124.07 76.11 Favored Pre-proline 0 C--N 1.309 -1.178 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 177.294 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -72.18 138.0 29.77 Favored 'Trans proline' 0 N--CA 1.43 -2.229 0 C-N-CA 121.429 1.42 . . . . 0.0 112.615 -179.476 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 20.9 t70 -71.0 148.99 47.09 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 174.306 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 95.03 -16.43 61.35 Favored Glycine 0 N--CA 1.429 -1.788 0 C-N-CA 120.726 -0.749 . . . . 0.0 111.299 -176.132 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.82 92.92 1.63 Allowed 'General case' 0 N--CA 1.442 -0.848 0 CA-C-O 121.451 0.644 . . . . 0.0 110.554 177.183 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.9 m -78.2 -8.13 11.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.455 -0.793 . . . . 0.0 111.373 178.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 25.6 mmmt -108.05 119.89 48.58 Favored Pre-proline 0 N--CA 1.416 -2.157 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 174.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_exo -70.58 155.13 63.85 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 121.978 1.785 . . . . 0.0 110.639 177.146 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -71.62 168.59 23.24 Favored 'Trans proline' 0 N--CA 1.449 -1.14 0 C-N-CA 121.907 1.738 . . . . 0.0 112.545 -179.17 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.531 ' O ' ' HB3' ' A' ' 38' ' ' ASN . 4.7 m -64.62 10.23 0.07 Allowed 'General case' 0 CA--C 1.571 1.777 0 C-N-CA 126.603 1.961 . . . . 0.0 113.465 -178.469 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.531 ' HB3' ' O ' ' A' ' 37' ' ' THR . 0.7 OUTLIER 81.32 10.96 0.83 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-O 124.172 1.939 . . . . 0.0 108.701 -172.139 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 90.4 mttt -95.79 166.6 11.73 Favored 'General case' 0 N--CA 1.423 -1.81 0 CA-C-N 112.825 -1.989 . . . . 0.0 108.712 175.066 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 87.9 mt -99.96 141.23 22.38 Favored Pre-proline 0 C--N 1.291 -1.946 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.268 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 33.9 Cg_endo -71.72 123.4 9.37 Favored 'Trans proline' 0 N--CA 1.454 -0.824 0 C-N-CA 122.037 1.824 . . . . 0.0 109.852 176.607 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.473 HG21 ' HB2' ' A' ' 13' ' ' ALA . 42.4 mm -118.08 120.76 65.47 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 CA-C-N 116.196 -0.457 . . . . 0.0 109.837 -175.542 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 66.1 t80 -97.92 120.1 37.71 Favored 'General case' 0 C--N 1.281 -2.383 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 178.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -85.2 131.46 34.43 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-O 121.257 0.551 . . . . 0.0 111.972 178.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -84.96 155.04 21.79 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.712 176.394 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.571 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 79.22 -19.57 5.47 Favored Glycine 0 C--N 1.314 -0.669 0 C-N-CA 123.257 0.456 . . . . 0.0 113.418 179.11 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 16.3 p -118.61 -23.13 7.2 Favored 'General case' 0 C--N 1.307 -1.26 0 O-C-N 122.561 -0.376 . . . . 0.0 110.215 175.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.7 m170 67.46 19.19 10.06 Favored 'General case' 0 N--CA 1.476 0.862 0 C-N-CA 123.509 0.724 . . . . 0.0 111.768 -179.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 19.2 mm-40 -87.65 168.27 13.16 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.205 179.59 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.7 m -134.55 142.5 46.99 Favored 'General case' 0 C--N 1.299 -1.621 0 CA-C-O 121.067 0.46 . . . . 0.0 109.769 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -139.05 179.66 6.37 Favored 'General case' 0 C--N 1.293 -1.891 0 CA-C-N 115.527 -0.761 . . . . 0.0 110.201 -178.441 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -134.13 117.39 16.52 Favored 'General case' 0 C--O 1.262 1.726 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.679 177.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 94.8 mt -129.5 174.56 9.53 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.17 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -98.37 164.94 21.34 Favored Glycine 0 N--CA 1.417 -2.597 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -67.16 -5.4 13.62 Favored 'Trans proline' 0 C--O 1.249 1.074 0 C-N-CA 123.752 2.968 . . . . 0.0 112.905 -178.179 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 23.0 pttm -97.57 -19.78 18.12 Favored 'General case' 0 C--N 1.309 -1.188 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.009 178.366 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -96.83 0.37 49.18 Favored 'General case' 0 CA--C 1.5 -0.943 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.598 -173.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.2 pt -123.43 144.78 31.85 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.995 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.725 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 47.1 m-85 -130.55 147.13 64.74 Favored Pre-proline 0 C--N 1.289 -2.037 0 CA-C-N 114.631 -1.168 . . . . 0.0 108.006 -177.668 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -66.74 132.49 28.79 Favored 'Trans proline' 0 C--N 1.328 -0.548 0 C-N-CA 122.474 2.116 . . . . 0.0 112.558 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.523 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 53.4 t80 -64.0 -37.79 88.72 Favored 'General case' 0 C--O 1.201 -1.488 0 CA-C-N 114.939 -1.028 . . . . 0.0 112.25 -176.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -62.76 -54.35 40.49 Favored 'General case' 0 C--N 1.292 -1.92 0 N-CA-C 112.569 0.581 . . . . 0.0 112.569 -176.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 3.6 mp0 -71.58 -26.23 62.52 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-O 121.71 0.766 . . . . 0.0 111.23 -178.266 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.466 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 29.9 m-80 -106.82 10.12 30.79 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 112.903 0.705 . . . . 0.0 112.903 -175.45 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -65.44 -31.27 72.26 Favored 'General case' 0 N--CA 1.483 1.195 0 CA-C-O 121.354 0.597 . . . . 0.0 111.898 -178.117 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.525 ' HA ' ' NZ ' ' A' ' 70' ' ' LYS . 55.5 mm-40 -75.97 -28.92 58.05 Favored 'General case' 0 C--N 1.285 -2.211 0 C-N-CA 119.391 -0.924 . . . . 0.0 111.842 178.277 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.466 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 33.2 mtpt -78.04 -59.26 2.85 Favored 'General case' 0 C--N 1.281 -2.407 0 CA-C-N 113.963 -1.471 . . . . 0.0 111.052 -176.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.449 ' CD2' ' HB3' ' A' ' 64' ' ' ASN . 19.9 m-85 -109.96 -9.47 14.76 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.384 -171.229 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -86.0 47.62 3.81 Favored Glycine 0 C--N 1.311 -0.857 0 N-CA-C 111.291 -0.724 . . . . 0.0 111.291 -178.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.525 ' NZ ' ' HA ' ' A' ' 66' ' ' GLU . 47.7 mmtm -127.91 147.77 64.43 Favored Pre-proline 0 C--N 1.307 -1.263 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 179.532 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.479 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 77.4 Cg_exo -48.01 128.94 17.4 Favored 'Trans proline' 0 C--N 1.363 1.318 0 C-N-CA 123.662 2.908 . . . . 0.0 114.782 -176.225 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.46 ' HB2' ' CD1' ' A' ' 77' ' ' PHE . 1.9 t-20 -112.22 -165.48 1.0 Allowed 'General case' 0 C--N 1.279 -2.494 0 CA-C-N 114.747 -1.115 . . . . 0.0 109.559 -175.449 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 38.6 mmtm -121.53 12.68 10.82 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 178.686 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 24.2 mmt180 -93.9 128.39 40.17 Favored 'General case' 0 N--CA 1.436 -1.166 0 CA-C-N 114.874 -1.057 . . . . 0.0 109.712 174.582 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 28.1 tptp -68.89 122.5 18.75 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 177.18 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.571 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 107.14 -20.83 32.48 Favored Glycine 0 N--CA 1.438 -1.189 0 N-CA-C 111.151 -0.78 . . . . 0.0 111.151 -179.254 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.46 ' CD1' ' HB2' ' A' ' 72' ' ' ASN . 35.6 t80 -75.2 -44.1 48.28 Favored 'General case' 0 C--N 1.309 -1.195 0 CA-C-O 121.61 0.719 . . . . 0.0 109.701 -177.069 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.479 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 92.8 m-20 -76.38 -35.07 58.85 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 114.893 -1.048 . . . . 0.0 110.63 -174.112 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 3.0 mp0 -70.12 -35.5 74.15 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.183 -1.044 . . . . 0.0 108.183 174.913 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -65.75 -35.63 91.22 Favored Glycine 0 N--CA 1.435 -1.413 0 CA-C-N 115.112 -0.949 . . . . 0.0 111.968 177.697 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.439 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 95.8 mt -56.16 -38.32 70.73 Favored 'General case' 0 C--O 1.219 -0.52 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 175.589 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 73.0 t90 -74.19 -49.08 25.07 Favored 'General case' 0 N--CA 1.426 -1.635 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.417 178.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 -57.0 -46.82 82.02 Favored 'General case' 0 C--O 1.203 -1.343 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.8 tt -70.18 -24.57 26.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 C-N-CA 120.628 -0.429 . . . . 0.0 112.033 -175.219 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -93.52 -19.69 20.98 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.058 0.456 . . . . 0.0 110.141 -175.053 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.462 HD22 ' N ' ' A' ' 86' ' ' ASN . 0.8 OUTLIER -111.56 -54.34 2.62 Favored 'General case' 0 N--CA 1.483 1.198 0 CA-C-O 121.351 0.596 . . . . 0.0 111.863 -179.286 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 66.1 t30 -126.24 71.98 71.12 Favored Pre-proline 0 C--N 1.312 -1.065 0 O-C-N 121.999 -0.438 . . . . 0.0 110.93 -177.715 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -73.2 -6.49 19.0 Favored 'Trans proline' 0 CA--C 1.53 0.309 0 C-N-CA 122.242 1.961 . . . . 0.0 113.232 -175.819 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.4 pttm -95.91 12.55 29.87 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.973 -176.306 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 8.4 p -72.78 158.73 6.04 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.303 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 178.199 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 65.8 mmtt -119.36 171.52 8.27 Favored 'General case' 0 C--N 1.32 -0.686 0 N-CA-C 112.618 0.599 . . . . 0.0 112.618 -175.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 7.4 p90 -66.41 128.42 36.09 Favored 'General case' 0 N--CA 1.441 -0.89 0 CA-C-N 114.239 -1.346 . . . . 0.0 111.08 177.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 22.6 p . . . . . 0 N--CA 1.432 -1.352 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.734 -175.175 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.477 0.884 0 N-CA-C 105.462 -2.051 . . . . 0.0 105.462 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -79.21 -25.55 42.69 Favored 'General case' 0 C--N 1.313 -0.992 0 O-C-N 123.585 0.553 . . . . 0.0 110.266 177.515 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 47.2 ptt85 -93.75 170.16 9.78 Favored 'General case' 0 C--O 1.253 1.26 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 177.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -91.02 179.44 5.74 Favored 'General case' 0 N--CA 1.433 -1.317 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.464 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 97.3 m-85 -130.26 143.05 50.54 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-O 120.753 0.311 . . . . 0.0 110.438 -173.248 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.527 ' O ' ' HB2' ' A' ' 9' ' ' ASP . 47.9 mmtm -111.51 155.62 42.64 Favored Pre-proline 0 C--N 1.304 -1.392 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 -178.59 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_exo -58.33 121.46 10.02 Favored 'Trans proline' 0 C--O 1.237 0.46 0 C-N-CA 121.78 1.653 . . . . 0.0 108.448 171.105 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . 0.582 ' HA2' ' NH1' ' A' ' 24' ' ' ARG . . . 108.72 -11.95 35.31 Favored Glycine 0 N--CA 1.425 -2.034 0 C-N-CA 120.55 -0.834 . . . . 0.0 112.449 -176.505 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.527 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 0.8 OUTLIER -64.39 133.51 52.73 Favored 'General case' 0 C--O 1.252 1.202 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 -178.025 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 78.8 mt -89.27 119.97 30.22 Favored 'General case' 0 C--N 1.292 -1.91 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 179.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.419 ' HA ' ' HA ' ' A' ' 60' ' ' PRO . 7.5 pt -139.03 -173.54 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.841 0 CA-C-O 122.753 1.263 . . . . 0.0 112.956 -172.037 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.622 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 84.2 m-85 -127.48 125.41 40.42 Favored 'General case' 0 N--CA 1.403 -2.809 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 171.861 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.521 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -113.43 134.45 54.65 Favored 'General case' 0 C--N 1.266 -3.024 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.617 -176.573 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.638 ' HB2' ' CD2' ' A' ' 20' ' ' HIS . 0.0 OUTLIER -109.04 121.15 44.53 Favored 'General case' 0 N--CA 1.408 -2.532 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.396 -178.616 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 71.5 mtm -112.18 158.88 19.14 Favored 'General case' 0 C--N 1.315 -0.934 0 C-N-CA 123.587 0.755 . . . . 0.0 109.24 176.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 24.9 ttmm -66.18 117.41 8.45 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.106 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.38 -7.07 56.06 Favored Glycine 0 C--O 1.246 0.875 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -178.639 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 65.2 m-85 -123.21 148.15 54.01 Favored Pre-proline 0 N--CA 1.435 -1.222 0 C-N-CA 122.994 0.518 . . . . 0.0 110.684 179.206 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -79.34 171.6 15.81 Favored 'Trans proline' 0 N--CA 1.445 -1.333 0 C-N-CA 122.116 1.877 . . . . 0.0 108.28 170.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.638 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 78.9 m80 -58.16 111.19 1.11 Allowed 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 108.038 -1.097 . . . . 0.0 108.038 175.774 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . 0.42 ' O ' ' HA ' ' A' ' 12' ' ' PHE . 11.5 t-105 -111.74 141.69 25.2 Favored Pre-proline 0 C--N 1.302 -1.46 0 C-N-CA 123.561 0.744 . . . . 0.0 109.343 -170.526 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.424 ' HD3' ' CE2' ' A' ' 77' ' ' PHE . 26.3 Cg_exo -57.76 118.71 5.63 Favored 'Trans proline' 0 C--N 1.36 1.14 0 C-N-CA 122.274 1.983 . . . . 0.0 110.994 178.328 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -145.53 167.34 23.25 Favored 'General case' 0 N--CA 1.407 -2.584 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 -177.617 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.582 ' NH1' ' HA2' ' A' ' 8' ' ' GLY . 32.7 ttp85 -123.23 144.52 49.34 Favored 'General case' 0 C--N 1.276 -2.589 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 177.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 58.7 t -74.58 113.74 13.53 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.99 0 N-CA-C 104.793 -2.299 . . . . 0.0 104.793 170.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.58 ' OD1' ' HA ' ' A' ' 91' ' ' LYS . 1.1 t70 -86.88 -176.01 5.6 Favored 'General case' 0 C--N 1.29 -2.015 0 O-C-N 123.554 0.534 . . . . 0.0 111.084 -172.0 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 33.6 mm-40 -91.56 164.28 13.83 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 121.622 0.725 . . . . 0.0 109.81 -173.209 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.7 t -93.8 120.9 65.52 Favored Pre-proline 0 C--N 1.301 -1.522 0 N-CA-C 107.197 -1.408 . . . . 0.0 107.197 172.261 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 22.5 Cg_endo -71.99 142.88 39.49 Favored 'Trans proline' 0 N--CA 1.431 -2.155 0 C-N-CA 121.57 1.513 . . . . 0.0 113.365 -178.019 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 18.1 t0 -71.11 152.84 43.05 Favored 'General case' 0 C--O 1.251 1.161 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 170.585 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 85.48 0.39 88.19 Favored Glycine 0 N--CA 1.421 -2.31 0 C-N-CA 120.087 -1.054 . . . . 0.0 110.882 -174.363 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.29 76.36 1.84 Allowed 'General case' 0 C--O 1.208 -1.106 0 CA-C-O 122.163 0.982 . . . . 0.0 110.98 173.013 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 26.8 m -96.31 6.39 8.08 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 CA-C-N 114.154 -1.384 . . . . 0.0 109.767 177.413 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.609 ' H ' ' HD2' ' A' ' 34' ' ' LYS . 0.0 OUTLIER -107.79 141.39 22.98 Favored Pre-proline 0 N--CA 1.409 -2.499 0 N-CA-C 106.584 -1.635 . . . . 0.0 106.584 178.524 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.422 ' HA ' ' HD3' ' A' ' 36' ' ' PRO . 20.8 Cg_endo -62.19 134.13 47.37 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 121.969 1.779 . . . . 0.0 112.58 -178.096 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 35' ' ' PRO . 3.3 Cg_exo -76.64 171.76 17.44 Favored 'Trans proline' 0 N--CA 1.447 -1.208 0 C-N-CA 122.438 2.092 . . . . 0.0 111.49 176.897 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 5.9 m -71.26 6.96 1.45 Allowed 'General case' 0 C--O 1.265 1.882 0 C-N-CA 124.413 1.085 . . . . 0.0 111.92 -178.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 40.1 m-80 63.74 28.07 14.81 Favored 'General case' 0 N--CA 1.479 1.011 0 C-N-CA 124.359 1.064 . . . . 0.0 109.65 -179.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.423 ' HB3' ' O ' ' A' ' 53' ' ' LEU . 62.4 mttp -139.91 -179.55 6.01 Favored 'General case' 0 N--CA 1.433 -1.322 0 CA-C-N 114.748 -1.115 . . . . 0.0 109.237 -178.422 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.435 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 95.8 mt -90.84 139.69 26.14 Favored Pre-proline 0 C--N 1.297 -1.709 0 O-C-N 123.894 0.746 . . . . 0.0 110.134 -177.632 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -71.38 123.22 9.35 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.262 1.974 . . . . 0.0 109.779 176.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.423 HG21 ' CB ' ' A' ' 13' ' ' ALA . 39.7 mm -122.17 121.59 64.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.932 -0.48 . . . . 0.0 109.993 -176.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -106.35 118.96 38.01 Favored 'General case' 0 C--N 1.29 -2.001 0 N-CA-C 108.638 -0.875 . . . . 0.0 108.638 178.06 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 73.6 m-85 -82.32 136.07 35.08 Favored 'General case' 0 C--N 1.307 -1.266 0 N-CA-C 113.643 0.979 . . . . 0.0 113.643 -179.408 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -85.58 148.85 25.73 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.081 -0.963 . . . . 0.0 109.9 178.334 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.458 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 78.94 -21.08 4.16 Favored Glycine 0 C--N 1.308 -1.019 0 C-N-CA 123.72 0.676 . . . . 0.0 114.168 176.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 30.7 p -119.74 -22.46 6.85 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 117.523 0.662 . . . . 0.0 110.674 174.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.4 m-70 67.01 21.9 10.15 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 123.649 0.779 . . . . 0.0 111.563 -178.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.8 mt-10 -72.42 163.61 27.71 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.064 175.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.7 m -136.87 140.05 42.1 Favored 'General case' 0 C--N 1.275 -2.645 0 N-CA-C 109.07 -0.715 . . . . 0.0 109.07 179.346 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -141.05 176.07 9.11 Favored 'General case' 0 C--N 1.286 -2.18 0 CA-C-N 115.505 -0.77 . . . . 0.0 111.273 -179.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.435 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 97.7 m-85 -133.98 111.07 10.11 Favored 'General case' 0 N--CA 1.431 -1.423 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 174.52 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.521 HD12 ' HB1' ' A' ' 13' ' ' ALA . 85.9 mt -125.69 170.42 11.55 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 109.933 -0.395 . . . . 0.0 109.933 -177.527 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -95.08 167.17 26.35 Favored Glycine 0 N--CA 1.42 -2.398 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 178.166 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -66.38 -6.85 15.96 Favored 'Trans proline' 0 N--CA 1.484 0.923 0 C-N-CA 123.357 2.705 . . . . 0.0 112.743 -177.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.9 ptmm? -92.37 -19.88 21.64 Favored 'General case' 0 C--N 1.3 -1.558 0 CA-C-N 115.436 -0.802 . . . . 0.0 111.725 178.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -102.45 5.05 39.38 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-O 121.281 0.562 . . . . 0.0 111.623 -174.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.9 pt -125.22 147.53 29.87 Favored 'Isoleucine or valine' 0 C--O 1.266 1.954 0 CA-C-N 114.653 -1.158 . . . . 0.0 110.372 178.791 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.42 ' HB3' ' ND2' ' A' ' 64' ' ' ASN . 88.8 m-85 -136.37 133.11 19.17 Favored Pre-proline 0 C--N 1.289 -2.035 0 CA-C-N 114.686 -1.143 . . . . 0.0 108.355 -179.543 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.419 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 22.5 Cg_endo -68.3 144.06 60.83 Favored 'Trans proline' 0 CA--C 1.499 -1.264 0 C-N-CA 122.971 2.447 . . . . 0.0 114.04 -177.397 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.622 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 83.9 t80 -58.88 -38.26 78.42 Favored 'General case' 0 C--O 1.203 -1.377 0 CA-C-N 114.305 -1.316 . . . . 0.0 110.579 -179.737 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -62.48 -47.57 83.38 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 113.744 1.016 . . . . 0.0 113.744 -175.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -93.33 -8.27 42.46 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-O 121.357 0.599 . . . . 0.0 111.597 -177.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.445 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 24.0 m-80 -124.91 14.12 8.53 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 112.969 0.729 . . . . 0.0 112.969 -175.164 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -63.37 -37.78 88.61 Favored 'General case' 0 N--CA 1.486 1.33 0 N-CA-C 112.845 0.683 . . . . 0.0 112.845 179.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 10.4 mp0 -66.08 -34.68 78.62 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 122.796 1.284 . . . . 0.0 109.326 177.127 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.445 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 35.4 mtpt -75.48 -59.55 2.7 Favored 'General case' 0 C--N 1.292 -1.929 0 CA-C-N 113.396 -1.729 . . . . 0.0 112.008 -174.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.43 ' CD2' ' HB3' ' A' ' 64' ' ' ASN . 18.5 m-85 -115.11 -15.4 11.7 Favored 'General case' 0 C--N 1.308 -1.23 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.982 -171.068 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.77 10.77 30.19 Favored Glycine 0 N--CA 1.472 1.042 0 CA-C-O 121.213 0.341 . . . . 0.0 113.207 -175.226 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 23.2 pttm -93.04 149.9 38.32 Favored Pre-proline 0 C--N 1.298 -1.671 0 N-CA-C 107.476 -1.305 . . . . 0.0 107.476 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo -66.91 128.19 18.33 Favored 'Trans proline' 0 N--CA 1.441 -1.56 0 C-N-CA 120.845 1.03 . . . . 0.0 112.287 178.069 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 41.4 m-80 -113.19 -173.41 2.25 Favored 'General case' 0 C--N 1.295 -1.795 0 N-CA-C 108.14 -1.059 . . . . 0.0 108.14 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 47.4 mmtm -96.75 15.87 20.72 Favored 'General case' 0 C--N 1.31 -1.145 0 CA-C-O 121.238 0.542 . . . . 0.0 112.269 -176.066 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 10.1 mmt180 -87.94 120.94 29.77 Favored 'General case' 0 C--N 1.309 -1.187 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 174.352 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.4 tppt? -74.71 130.43 39.49 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 177.111 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.458 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.24 -25.78 18.96 Favored Glycine 0 N--CA 1.435 -1.381 0 N-CA-C 108.819 -1.712 . . . . 0.0 108.819 -174.053 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.424 ' CE2' ' HD3' ' A' ' 22' ' ' PRO . 11.2 t80 -76.79 -44.71 31.71 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 179.749 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 10.0 m120 -60.25 -47.89 84.07 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 22.2 mp0 -63.5 -37.06 85.85 Favored 'General case' 0 C--N 1.304 -1.391 0 CA-C-N 113.778 -1.555 . . . . 0.0 110.194 179.341 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -67.55 -34.56 84.5 Favored Glycine 0 N--CA 1.442 -0.924 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.309 177.437 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 95.5 mt -62.78 -33.95 76.24 Favored 'General case' 0 C--O 1.216 -0.694 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 175.39 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 69.8 t90 -71.62 -49.44 40.12 Favored 'General case' 0 N--CA 1.439 -0.981 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.624 175.24 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 27.4 mt-10 -60.43 -34.69 74.34 Favored 'General case' 0 C--O 1.21 -0.98 0 N-CA-C 113.882 1.067 . . . . 0.0 113.882 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.6 tt -72.77 -21.41 19.59 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-O 121.214 0.531 . . . . 0.0 110.3 -176.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -89.92 -46.74 8.33 Favored 'General case' 0 N--CA 1.435 -1.211 0 CA-C-N 115.4 -0.818 . . . . 0.0 109.719 -178.62 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.585 HD22 ' N ' ' A' ' 86' ' ' ASN . 0.8 OUTLIER -86.92 -35.88 18.67 Favored 'General case' 0 C--O 1.252 1.227 0 CA-C-O 121.63 0.728 . . . . 0.0 111.843 -173.766 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -134.08 63.6 62.6 Favored Pre-proline 0 C--N 1.298 -1.669 0 C-N-CA 118.892 -1.123 . . . . 0.0 112.873 -179.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -72.04 -5.74 17.71 Favored 'Trans proline' 0 C--N 1.369 1.61 0 C-N-CA 122.791 2.327 . . . . 0.0 110.838 177.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . 0.418 ' HG2' ' H ' ' A' ' 89' ' ' LYS . 16.5 pttp -99.09 17.08 20.69 Favored 'General case' 0 C--N 1.302 -1.478 0 C-N-CA 125.378 1.471 . . . . 0.0 110.81 -176.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 9.6 p -81.2 166.02 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.849 0 N-CA-C 107.969 -1.122 . . . . 0.0 107.969 175.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.58 ' HA ' ' OD1' ' A' ' 26' ' ' ASP . 2.4 mtmp? -147.55 -176.07 5.1 Favored 'General case' 0 C--O 1.252 1.225 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -178.335 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -43.34 -53.86 5.02 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 124.972 1.42 . . . . 0.0 108.682 175.53 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 4.1 p . . . . . 0 N--CA 1.4 -2.957 0 N-CA-C 106.908 -1.516 . . . . 0.0 106.908 173.074 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.3 mtt . . . . . 0 C--O 1.194 -1.823 0 N-CA-C 106.956 -1.498 . . . . 0.0 106.956 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -79.22 -30.2 43.16 Favored 'General case' 0 C--O 1.251 1.161 0 CA-C-N 118.639 0.654 . . . . 0.0 111.356 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.537 ' HG3' ' N ' ' A' ' 4' ' ' ASP . 23.3 ptt180 -89.02 -49.61 6.67 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.594 -177.625 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . 0.537 ' N ' ' HG3' ' A' ' 3' ' ' ARG . 5.8 p-10 -117.58 147.15 43.1 Favored 'General case' 0 C--N 1.274 -2.681 0 CA-C-N 114.273 -1.33 . . . . 0.0 109.462 -174.201 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -137.02 121.45 18.23 Favored 'General case' 0 C--N 1.298 -1.638 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 179.251 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 27.5 mtmm -124.31 156.92 66.21 Favored Pre-proline 0 C--N 1.289 -2.059 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 -176.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_exo -51.87 117.62 3.72 Favored 'Trans proline' 0 N--CA 1.461 -0.39 0 C-N-CA 122.17 1.913 . . . . 0.0 110.416 173.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.45 -23.55 10.32 Favored Glycine 0 N--CA 1.427 -1.902 0 CA-C-O 119.452 -0.638 . . . . 0.0 112.694 -176.475 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -64.98 123.68 20.08 Favored 'General case' 0 C--O 1.25 1.11 0 CA-C-N 117.573 0.686 . . . . 0.0 110.115 177.213 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.8 mt -80.05 129.48 34.53 Favored 'General case' 0 CA--C 1.49 -1.363 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 176.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 8.1 pt -143.17 -172.7 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.421 -1.884 0 CA-C-O 122.479 1.133 . . . . 0.0 112.4 -173.08 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.451 ' HB3' ' HB3' ' A' ' 20' ' ' HIS . 31.9 m-85 -128.58 129.07 45.42 Favored 'General case' 0 N--CA 1.402 -2.873 0 CA-C-N 113.288 -1.778 . . . . 0.0 106.55 172.784 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.557 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -108.78 128.92 55.31 Favored 'General case' 0 C--N 1.271 -2.834 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.446 -174.346 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.606 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -106.39 124.12 49.11 Favored 'General case' 0 N--CA 1.403 -2.782 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.039 -178.697 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 69.1 mtm -121.42 158.38 28.46 Favored 'General case' 0 CA--C 1.508 -0.667 0 C-N-CA 123.219 0.608 . . . . 0.0 109.814 176.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -64.66 116.52 6.32 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 110.058 -0.349 . . . . 0.0 110.058 178.667 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.44 -2.43 65.14 Favored Glycine 0 C--O 1.246 0.868 0 N-CA-C 111.625 -0.59 . . . . 0.0 111.625 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -121.93 146.35 45.95 Favored Pre-proline 0 N--CA 1.428 -1.567 0 C-N-CA 122.731 0.412 . . . . 0.0 110.388 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 58.7 Cg_endo -75.82 171.29 18.45 Favored 'Trans proline' 0 N--CA 1.444 -1.428 0 C-N-CA 121.798 1.665 . . . . 0.0 108.467 172.439 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.477 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 69.2 m80 -61.53 111.15 1.69 Allowed 'General case' 0 CA--C 1.548 0.883 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 175.854 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 7.8 t-105 -102.96 139.26 19.96 Favored Pre-proline 0 C--N 1.304 -1.405 0 C-N-CA 123.852 0.861 . . . . 0.0 109.31 -171.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_exo -59.08 118.66 5.59 Favored 'Trans proline' 0 C--N 1.354 0.84 0 C-N-CA 121.875 1.716 . . . . 0.0 110.869 177.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.81 167.05 23.0 Favored 'General case' 0 N--CA 1.414 -2.227 0 CA-C-O 121.227 0.537 . . . . 0.0 110.417 -177.456 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 36.6 ttt-85 -119.05 139.89 50.98 Favored 'General case' 0 C--N 1.285 -2.198 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 177.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 60.2 t -75.34 111.12 11.22 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.951 0 N-CA-C 103.817 -2.66 . . . . 0.0 103.817 168.058 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -89.37 -177.55 5.39 Favored 'General case' 0 C--N 1.289 -2.032 0 C-N-CA 119.535 -0.866 . . . . 0.0 111.451 -170.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -104.99 141.94 35.67 Favored 'General case' 0 C--N 1.293 -1.876 0 CA-C-O 121.875 0.845 . . . . 0.0 113.201 -171.131 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 60.1 t -88.86 128.56 51.75 Favored Pre-proline 0 C--N 1.312 -1.056 0 CA-C-N 114.59 -1.186 . . . . 0.0 109.828 -176.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 33.3 Cg_endo -71.93 149.08 52.74 Favored 'Trans proline' 0 N--CA 1.434 -1.983 0 C-N-CA 121.623 1.549 . . . . 0.0 112.477 178.312 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -68.08 146.78 53.15 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 174.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.43 -27.5 20.05 Favored Glycine 0 C--N 1.292 -1.865 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 -174.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -79.18 78.47 5.64 Favored 'General case' 0 N--CA 1.434 -1.233 0 CA-C-O 122.1 0.952 . . . . 0.0 110.004 175.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.0 m -94.19 6.92 6.61 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 114.383 -1.281 . . . . 0.0 111.035 -179.798 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 31.3 mmtp -81.56 126.89 74.91 Favored Pre-proline 0 C--N 1.297 -1.705 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.048 179.297 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_endo -65.54 135.21 41.36 Favored 'Trans proline' 0 N--CA 1.455 -0.745 0 C-N-CA 122.053 1.835 . . . . 0.0 112.263 -179.543 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -80.07 171.47 15.17 Favored 'Trans proline' 0 N--CA 1.443 -1.485 0 C-N-CA 122.445 2.096 . . . . 0.0 112.512 -179.07 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.3 m -72.86 8.94 1.29 Allowed 'General case' 0 CA--C 1.563 1.449 0 C-N-CA 125.576 1.55 . . . . 0.0 111.44 -179.024 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 49.0 m-80 78.42 13.41 1.48 Allowed 'General case' 0 N--CA 1.485 1.301 0 C-N-CA 125.209 1.404 . . . . 0.0 109.758 -174.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.634 ' HE3' ' HA ' ' A' ' 53' ' ' LEU . 22.5 mtpp -111.46 152.14 27.77 Favored 'General case' 0 N--CA 1.418 -2.035 0 N-CA-C 106.536 -1.653 . . . . 0.0 106.536 175.275 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 71.2 mt -98.44 153.9 37.8 Favored Pre-proline 0 C--N 1.288 -2.079 0 O-C-N 123.54 0.525 . . . . 0.0 110.356 -173.676 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -71.4 122.36 8.58 Favored 'Trans proline' 0 C--N 1.354 0.826 0 C-N-CA 121.788 1.659 . . . . 0.0 109.798 176.476 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.422 HG13 ' HB2' ' A' ' 53' ' ' LEU . 43.8 mm -117.84 119.9 62.99 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.943 0 N-CA-C 109.695 -0.483 . . . . 0.0 109.695 -176.487 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 86.2 t80 -98.27 117.68 33.2 Favored 'General case' 0 C--N 1.28 -2.437 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 178.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -81.78 129.85 34.87 Favored 'General case' 0 C--N 1.3 -1.572 0 CA-C-O 121.419 0.628 . . . . 0.0 112.672 178.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.405 ' HB3' ' HA2' ' A' ' 80' ' ' GLY . 72.1 m-85 -80.45 151.96 29.03 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.448 -0.796 . . . . 0.0 109.819 177.433 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.436 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 78.23 -20.68 3.86 Favored Glycine 0 C--N 1.315 -0.628 0 C-N-CA 123.562 0.601 . . . . 0.0 114.306 177.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 36.2 p -119.37 -22.59 6.99 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 117.533 0.666 . . . . 0.0 109.849 174.323 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.0 m-70 67.7 22.74 8.87 Favored 'General case' 0 N--CA 1.471 0.594 0 C-N-CA 123.883 0.873 . . . . 0.0 112.308 179.011 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -78.41 169.3 18.48 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 115.321 -0.854 . . . . 0.0 109.335 177.596 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 6.3 m -139.36 137.82 36.08 Favored 'General case' 0 C--N 1.289 -2.059 0 N-CA-C 108.774 -0.824 . . . . 0.0 108.774 177.04 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -138.58 -179.55 5.88 Favored 'General case' 0 C--N 1.28 -2.436 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.614 -176.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 87.3 m-85 -131.31 109.79 10.62 Favored 'General case' 0 CA--C 1.491 -1.318 0 C-N-CA 123.662 0.785 . . . . 0.0 109.294 177.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.634 ' HA ' ' HE3' ' A' ' 39' ' ' LYS . 96.2 mt -126.77 152.29 47.08 Favored 'General case' 0 C--N 1.295 -1.803 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.076 -178.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.422 ' O ' HG12 ' A' ' 58' ' ' ILE . . . -80.43 168.17 51.32 Favored Glycine 0 N--CA 1.429 -1.802 0 N-CA-C 110.564 -1.015 . . . . 0.0 110.564 -177.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_endo -65.18 -18.42 61.19 Favored 'Trans proline' 0 C--O 1.209 -0.966 0 C-N-CA 122.337 2.025 . . . . 0.0 112.13 -178.479 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 10.8 mmtm -99.56 2.05 44.34 Favored 'General case' 0 C--N 1.299 -1.593 0 N-CA-C 113.206 0.817 . . . . 0.0 113.206 173.703 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -94.04 -12.02 29.48 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 173.656 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.451 HG22 ' HA ' ' A' ' 13' ' ' ALA . 15.9 pt -125.77 151.58 32.01 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.705 0 CA-C-N 114.459 -1.246 . . . . 0.0 109.698 -176.801 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.451 ' HB3' HD21 ' A' ' 64' ' ' ASN . 96.4 m-85 -138.23 147.48 55.96 Favored Pre-proline 0 C--N 1.296 -1.754 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 -179.192 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -63.38 140.99 79.51 Favored 'Trans proline' 0 C--O 1.241 0.632 0 C-N-CA 123.19 2.593 . . . . 0.0 114.817 -174.503 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 40.5 t80 -56.03 -33.31 64.81 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 114.32 -1.309 . . . . 0.0 111.841 177.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 4.8 m -60.05 -41.9 93.3 Favored 'General case' 0 C--N 1.309 -1.178 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.527 -177.618 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . 0.301 48.8 mt-10 -75.98 -51.59 12.05 Favored 'General case' 0 CA--C 1.488 -1.426 0 CA-C-O 123.319 1.533 . . . . 0.0 108.656 176.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.451 HD21 ' HB3' ' A' ' 59' ' ' PHE . 37.0 m-80 -80.66 2.75 24.54 Favored 'General case' 0 N--CA 1.415 -2.211 0 CA-C-N 112.801 -1.999 . . . . 0.0 113.847 -161.439 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -68.92 -37.4 78.89 Favored 'General case' 0 N--CA 1.433 -1.286 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 176.424 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 56.8 mm-40 -80.83 -37.4 30.11 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.104 -0.498 . . . . 0.0 112.159 175.343 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 39.7 mtpt -70.96 -57.37 4.63 Favored 'General case' 0 C--N 1.306 -1.292 0 O-C-N 124.701 1.251 . . . . 0.0 111.171 -173.964 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 61.8 m-85 -126.97 7.24 6.63 Favored 'General case' 0 C--N 1.312 -1.055 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.213 -174.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -91.98 41.24 2.83 Favored Glycine 0 CA--C 1.496 -1.096 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 -178.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.405 ' O ' ' HE1' ' A' ' 77' ' ' PHE . 30.4 mmtp -128.77 151.02 76.52 Favored Pre-proline 0 C--N 1.299 -1.616 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 -177.595 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.472 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 52.6 Cg_exo -48.42 148.44 7.81 Favored 'Trans proline' 0 C--N 1.353 0.811 0 C-N-CA 123.642 2.895 . . . . 0.0 114.816 -176.415 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -140.17 -175.73 4.35 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-N 115.087 -0.96 . . . . 0.0 109.933 -178.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 14.2 mmmm -95.53 -3.26 46.9 Favored 'General case' 0 N--CA 1.44 -0.97 0 CA-C-O 120.804 0.335 . . . . 0.0 110.474 179.524 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 18.0 mmt180 -80.25 121.02 25.11 Favored 'General case' 0 C--N 1.309 -1.164 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.064 176.317 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 64.4 tttp -73.63 135.39 43.8 Favored 'General case' 0 C--N 1.312 -1.024 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 174.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.436 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 103.76 -25.31 27.01 Favored Glycine 0 N--CA 1.436 -1.332 0 N-CA-C 109.21 -1.556 . . . . 0.0 109.21 -177.123 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.405 ' HE1' ' O ' ' A' ' 70' ' ' LYS . 55.7 t80 -74.73 -44.93 47.4 Favored 'General case' 0 N--CA 1.437 -1.077 0 CA-C-N 114.722 -0.739 . . . . 0.0 109.08 -178.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.472 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 89.4 m-20 -76.82 -35.75 57.37 Favored 'General case' 0 C--N 1.299 -1.629 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.062 -176.2 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 8.2 mp0 -67.73 -36.55 80.78 Favored 'General case' 0 N--CA 1.433 -1.311 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 174.376 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.405 ' HA2' ' HB3' ' A' ' 45' ' ' PHE . . . -70.47 -34.38 68.08 Favored Glycine 0 CA--C 1.496 -1.155 0 CA-C-N 115.445 -0.798 . . . . 0.0 112.094 177.584 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 40.9 tp -60.62 -36.53 78.84 Favored 'General case' 0 N--CA 1.432 -1.331 0 C-N-CA 123.955 0.902 . . . . 0.0 108.947 175.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 76.1 t90 -72.14 -47.39 51.41 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 115.463 -0.789 . . . . 0.0 110.054 175.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -61.15 -36.87 80.95 Favored 'General case' 0 C--O 1.193 -1.915 0 N-CA-C 114.009 1.114 . . . . 0.0 114.009 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.4 tt -70.67 -26.51 28.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 119.282 -0.967 . . . . 0.0 111.772 -176.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -83.77 -37.06 23.1 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.176 178.238 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 30.8 m-80 -101.86 -31.35 10.76 Favored 'General case' 0 C--O 1.257 1.487 0 CA-C-O 122.063 0.935 . . . . 0.0 112.738 -173.123 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 57.3 t30 -129.06 60.2 49.18 Favored Pre-proline 0 C--N 1.29 -2.014 0 O-C-N 121.628 -0.67 . . . . 0.0 112.539 -177.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -77.77 -5.74 15.57 Favored 'Trans proline' 0 N--CA 1.486 1.076 0 C-N-CA 122.211 1.94 . . . . 0.0 110.747 178.244 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 23.1 pttm -93.09 4.31 54.22 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 113.718 -1.583 . . . . 0.0 111.063 -174.606 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 9.9 p -73.49 162.63 4.35 Favored 'Isoleucine or valine' 0 CA--C 1.551 1.008 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 179.61 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.6 mptp? -127.99 179.64 5.47 Favored 'General case' 0 C--O 1.262 1.731 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 176.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 41.4 p90 -49.93 133.22 22.59 Favored 'General case' 0 C--O 1.241 0.617 0 O-C-N 124.142 0.901 . . . . 0.0 109.097 170.416 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 41.5 m . . . . . 0 C--N 1.304 -1.382 0 N-CA-C 115.039 1.496 . . . . 0.0 115.039 -170.657 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 18.5 mmt . . . . . 0 CA--C 1.484 -1.588 0 CA-C-O 118.646 -0.692 . . . . 0.0 109.354 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -53.12 -40.59 64.31 Favored 'General case' 0 C--O 1.213 -0.868 0 O-C-N 124.603 1.19 . . . . 0.0 111.305 178.404 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.421 ' NE ' ' HB3' ' A' ' 60' ' ' PRO . 4.8 ptp180 -98.73 158.93 15.3 Favored 'General case' 0 C--O 1.262 1.713 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 175.805 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . 0.436 ' OD2' ' HE3' ' A' ' 6' ' ' LYS . 13.7 p-10 -93.21 157.51 16.23 Favored 'General case' 0 C--N 1.293 -1.87 0 N-CA-C 105.487 -2.042 . . . . 0.0 105.487 170.06 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -117.97 139.31 51.35 Favored 'General case' 0 C--N 1.304 -1.391 0 C-N-CA 119.779 -0.768 . . . . 0.0 111.645 -170.007 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.489 ' HD2' ' N ' ' A' ' 6' ' ' LYS . 7.5 mptt -121.04 147.24 46.02 Favored Pre-proline 0 C--N 1.31 -1.119 0 N-CA-C 108.172 -1.048 . . . . 0.0 108.172 -178.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -56.98 121.13 9.53 Favored 'Trans proline' 0 N--CA 1.452 -0.967 0 C-N-CA 121.456 1.438 . . . . 0.0 109.32 172.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.66 -25.33 9.11 Favored Glycine 0 N--CA 1.42 -2.41 0 CA-C-O 118.671 -1.072 . . . . 0.0 114.142 -177.14 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.354 3.7 p30 -79.37 149.71 31.6 Favored 'General case' 0 C--O 1.243 0.748 0 CA-C-N 119.453 1.626 . . . . 0.0 113.557 -179.496 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.419 HD21 ' HB2' ' A' ' 88' ' ' PRO . 78.5 mt -86.74 128.54 35.02 Favored 'General case' 0 C--O 1.253 1.268 0 CA-C-N 114.605 -1.18 . . . . 0.0 110.851 -175.812 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -141.77 -177.2 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.466 0 CA-C-O 121.785 0.803 . . . . 0.0 112.255 -175.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.431 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 49.1 m-85 -113.65 128.25 56.36 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 107.211 -1.403 . . . . 0.0 107.211 172.531 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.444 ' HB2' HG21 ' A' ' 42' ' ' ILE . . . -108.3 120.31 42.0 Favored 'General case' 0 C--N 1.274 -2.69 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.684 -175.382 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.576 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 1.1 tmmt? -109.72 126.65 53.94 Favored 'General case' 0 C--N 1.27 -2.866 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.619 -177.638 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 69.6 mtm -120.48 158.55 27.01 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.493 -0.776 . . . . 0.0 109.489 179.264 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -68.77 117.02 9.94 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 179.497 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.27 -3.07 61.54 Favored Glycine 0 N--CA 1.447 -0.567 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -179.655 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -122.94 150.3 58.74 Favored Pre-proline 0 N--CA 1.435 -1.195 0 CA-C-O 120.744 0.307 . . . . 0.0 110.855 -179.118 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -74.91 170.74 19.74 Favored 'Trans proline' 0 N--CA 1.447 -1.228 0 C-N-CA 122.134 1.889 . . . . 0.0 109.498 172.68 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.445 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 76.3 m80 -66.77 111.55 3.77 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 177.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 10.6 t-105 -97.06 138.98 21.27 Favored Pre-proline 0 C--N 1.311 -1.093 0 C-N-CA 123.541 0.737 . . . . 0.0 109.689 -174.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.438 ' HB2' HG21 ' A' ' 84' ' ' ILE . 22.7 Cg_endo -69.05 117.76 5.25 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 121.254 1.303 . . . . 0.0 110.123 175.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.5 167.1 24.52 Favored 'General case' 0 N--CA 1.426 -1.625 0 CA-C-O 121.137 0.494 . . . . 0.0 110.528 -174.619 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.427 ' NH2' ' HG2' ' A' ' 91' ' ' LYS . 12.7 ttp180 -111.75 145.21 39.76 Favored 'General case' 0 C--N 1.285 -2.218 0 N-CA-C 108.414 -0.958 . . . . 0.0 108.414 179.069 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.3 t -68.61 121.32 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.866 0 N-CA-C 104.821 -2.289 . . . . 0.0 104.821 169.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.532 ' CG ' ' HZ2' ' A' ' 91' ' ' LYS . 15.4 t70 -91.24 175.66 6.86 Favored 'General case' 0 C--N 1.281 -2.395 0 N-CA-C 109.577 -0.527 . . . . 0.0 109.577 -171.161 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.408 ' CD ' HH22 ' A' ' 24' ' ' ARG . 0.3 OUTLIER -118.22 123.83 46.41 Favored 'General case' 0 N--CA 1.425 -1.695 0 CA-C-O 121.385 0.612 . . . . 0.0 110.229 179.453 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.1 p -83.02 124.62 76.42 Favored Pre-proline 0 N--CA 1.433 -1.282 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.089 -178.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -80.89 165.05 19.99 Favored 'Trans proline' 0 C--O 1.247 0.928 0 C-N-CA 122.482 2.121 . . . . 0.0 112.276 179.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 9.6 p-10 -79.05 154.31 29.53 Favored 'General case' 0 N--CA 1.426 -1.671 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 173.078 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 92.23 -19.89 46.91 Favored Glycine 0 C--N 1.296 -1.64 0 C-N-CA 119.764 -1.208 . . . . 0.0 110.951 -177.031 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -59.58 130.63 47.78 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 174.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 26.8 m -71.14 -10.62 14.18 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 N-CA-C 113.915 1.08 . . . . 0.0 113.915 -175.687 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.467 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 0.1 OUTLIER -108.15 122.73 39.72 Favored Pre-proline 0 N--CA 1.412 -2.326 0 C-N-CA 119.86 -0.736 . . . . 0.0 112.905 179.82 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.467 ' HD3' ' HA ' ' A' ' 34' ' ' LYS . 9.8 Cg_exo -72.81 172.12 15.96 Favored 'Trans proline' 0 C--O 1.264 1.803 0 C-N-CA 122.587 2.192 . . . . 0.0 110.587 174.718 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 9.8 Cg_endo -50.5 128.04 22.29 Favored 'Trans proline' 0 C--N 1.363 1.311 0 C-N-CA 122.858 2.372 . . . . 0.0 110.431 176.232 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.6 m -102.03 8.49 40.91 Favored 'General case' 0 C--N 1.286 -2.158 0 CA-C-N 115.027 -0.988 . . . . 0.0 110.005 -172.279 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 44.7 m-80 75.52 9.98 3.55 Favored 'General case' 0 N--CA 1.493 1.697 0 C-N-CA 124.843 1.257 . . . . 0.0 109.29 -173.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.412 ' HD3' ' HA ' ' A' ' 53' ' ' LEU . 71.6 mttt -132.28 162.0 32.09 Favored 'General case' 0 N--CA 1.415 -2.192 0 CA-C-N 113.88 -1.509 . . . . 0.0 108.609 177.605 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 75.0 mt -100.19 150.42 36.88 Favored Pre-proline 0 C--N 1.291 -1.944 0 O-C-N 124.368 1.042 . . . . 0.0 109.257 -175.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -75.49 133.33 15.75 Favored 'Trans proline' 0 N--CA 1.448 -1.186 0 C-N-CA 121.684 1.589 . . . . 0.0 109.427 174.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.444 HG21 ' HB2' ' A' ' 13' ' ' ALA . 51.3 mm -124.47 126.74 72.33 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -176.692 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 65.2 t80 -105.51 115.02 29.55 Favored 'General case' 0 C--N 1.294 -1.844 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 -179.434 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.416 ' HE2' ' HB2' ' A' ' 51' ' ' ALA . 95.1 m-85 -79.23 136.18 36.99 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-O 121.245 0.545 . . . . 0.0 111.613 179.524 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -87.54 157.08 19.25 Favored 'General case' 0 C--N 1.301 -1.515 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.559 177.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 76.11 -21.27 2.25 Favored Glycine 0 CA--C 1.502 -0.775 0 C-N-CA 124.669 1.128 . . . . 0.0 114.134 179.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.404 ' CG2' ' HA3' ' A' ' 76' ' ' GLY . 40.4 p -120.01 -23.24 6.42 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 117.294 0.547 . . . . 0.0 110.199 174.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 51.7 m170 67.78 23.3 8.58 Favored 'General case' 0 C--N 1.342 0.25 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.681 178.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -73.78 162.7 28.86 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 175.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.8 m -137.5 142.33 41.48 Favored 'General case' 0 C--N 1.281 -2.371 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.416 ' HB2' ' HE2' ' A' ' 44' ' ' PHE . . . -139.65 -179.68 6.06 Favored 'General case' 0 C--N 1.293 -1.877 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.169 -178.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 80.2 m-85 -131.69 109.27 10.06 Favored 'General case' 0 N--CA 1.439 -0.989 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 175.274 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.511 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 96.0 mt -127.51 152.94 46.95 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.652 -175.171 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.97 171.72 37.71 Favored Glycine 0 N--CA 1.424 -2.164 0 C-N-CA 119.564 -1.303 . . . . 0.0 111.589 -174.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -66.12 -5.65 12.82 Favored 'Trans proline' 0 C--O 1.251 1.131 0 C-N-CA 123.235 2.624 . . . . 0.0 112.172 179.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -98.72 -16.87 18.81 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 114.961 -1.018 . . . . 0.0 111.774 175.062 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.511 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 40.9 m-20 -94.12 -8.7 38.8 Favored 'General case' 0 C--N 1.31 -1.15 0 CA-C-O 121.188 0.518 . . . . 0.0 110.118 -177.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.424 ' HA ' ' O ' ' A' ' 12' ' ' PHE . 14.3 pt -119.59 149.63 22.18 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.649 0 CA-C-N 115.48 -0.782 . . . . 0.0 111.607 -176.195 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 57.6 m-85 -132.56 148.54 70.02 Favored Pre-proline 0 C--O 1.192 -1.945 0 N-CA-C 107.428 -1.323 . . . . 0.0 107.428 -177.381 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.449 ' O ' ' HB2' ' A' ' 64' ' ' ASN . 41.4 Cg_endo -66.2 132.32 29.38 Favored 'Trans proline' 0 C--N 1.322 -0.854 0 C-N-CA 121.94 1.76 . . . . 0.0 111.956 -179.236 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.431 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 66.5 t80 -69.38 -38.48 78.05 Favored 'General case' 0 C--O 1.204 -1.327 0 N-CA-C 112.591 0.589 . . . . 0.0 112.591 -177.338 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 22.7 t -76.31 -33.63 59.03 Favored 'General case' 0 C--N 1.295 -1.8 0 C-N-CA 120.087 -0.645 . . . . 0.0 111.402 -172.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.507 ' C ' HD22 ' A' ' 64' ' ' ASN . 2.8 mp0 -95.69 -1.7 49.51 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.522 -177.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.507 HD22 ' C ' ' A' ' 63' ' ' GLU . 0.9 OUTLIER -131.17 15.34 5.12 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 112.061 0.393 . . . . 0.0 112.061 178.232 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -69.75 -32.24 70.65 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-O 121.465 0.65 . . . . 0.0 110.1 -179.535 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.603 ' H ' ' CD ' ' A' ' 66' ' ' GLU . 1.5 mp0 -66.1 -31.61 72.58 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 178.103 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.482 ' HD3' ' CG ' ' A' ' 64' ' ' ASN . 37.7 mtpt -82.22 -60.25 2.28 Favored 'General case' 0 N--CA 1.428 -1.567 0 CA-C-N 114.303 -1.317 . . . . 0.0 111.501 -175.594 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 42.6 m-85 -106.71 -1.15 23.01 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.434 -0.803 . . . . 0.0 113.057 -168.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.71 56.91 4.23 Favored Glycine 0 C--N 1.311 -0.827 0 C-N-CA 120.994 -0.622 . . . . 0.0 111.953 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 58.7 mttp -125.86 125.61 24.86 Favored Pre-proline 0 C--N 1.313 -1.021 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.27 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -53.15 128.8 30.51 Favored 'Trans proline' 0 C--O 1.263 1.763 0 C-N-CA 123.451 2.767 . . . . 0.0 114.414 -177.167 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -94.94 -172.43 2.7 Favored 'General case' 0 N--CA 1.407 -2.613 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.636 178.383 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.53 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 2.0 mptp? -106.98 -11.01 15.78 Favored 'General case' 0 N--CA 1.417 -2.118 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 -178.506 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.94 118.13 9.3 Favored 'General case' 0 N--CA 1.41 -2.429 0 N-CA-C 106.272 -1.751 . . . . 0.0 106.272 169.71 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 9.3 tptp -69.9 140.25 53.09 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 107.888 -1.152 . . . . 0.0 107.888 179.013 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.404 ' HA3' ' CG2' ' A' ' 47' ' ' THR . . . 107.93 -24.04 24.25 Favored Glycine 0 N--CA 1.413 -2.889 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 -173.15 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 11.5 t80 -75.47 -38.79 59.39 Favored 'General case' 0 N--CA 1.448 -0.533 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 179.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -68.64 -47.33 66.88 Favored 'General case' 0 CA--C 1.506 -0.739 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 -177.681 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 36.1 mp0 -61.66 -42.34 98.77 Favored 'General case' 0 N--CA 1.426 -1.661 0 CA-C-N 113.152 -1.84 . . . . 0.0 110.068 178.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.1 -37.0 72.6 Favored Glycine 0 CA--C 1.484 -1.846 0 CA-C-N 115.751 -0.659 . . . . 0.0 113.305 -179.243 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 38.3 tp -62.55 -31.1 71.84 Favored 'General case' 0 N--CA 1.431 -1.395 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 176.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.0 t90 -74.76 -51.18 14.86 Favored 'General case' 0 N--CA 1.429 -1.501 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.248 175.006 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 -55.06 -45.84 75.34 Favored 'General case' 0 C--O 1.203 -1.346 0 N-CA-C 112.815 0.672 . . . . 0.0 112.815 -178.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.438 HG21 ' HB2' ' A' ' 22' ' ' PRO . 20.2 tt -68.73 -27.89 37.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 N-CA-C 112.267 0.469 . . . . 0.0 112.267 -176.033 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -93.42 -16.96 24.03 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.252 0.549 . . . . 0.0 110.302 -173.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.435 HD22 ' N ' ' A' ' 86' ' ' ASN . 0.9 OUTLIER -109.91 -56.51 2.31 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-O 121.16 0.505 . . . . 0.0 111.527 179.605 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.501 HD22 ' HB ' ' A' ' 90' ' ' VAL . 6.8 t30 -128.27 75.19 79.2 Favored Pre-proline 0 C--N 1.313 -0.982 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.199 -177.65 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.419 ' HB2' HD21 ' A' ' 10' ' ' LEU . 56.4 Cg_endo -73.62 -5.26 16.79 Favored 'Trans proline' 0 C--N 1.332 -0.298 0 C-N-CA 122.699 2.266 . . . . 0.0 112.988 -177.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 26.1 pttm -87.46 8.73 23.46 Favored 'General case' 0 C--O 1.249 1.054 0 CA-C-O 121.38 0.609 . . . . 0.0 109.972 -176.393 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.501 ' HB ' HD22 ' A' ' 87' ' ' ASN 0.252 11.2 p -75.54 105.89 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.509 0 CA-C-O 122.475 1.131 . . . . 0.0 112.237 179.741 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.532 ' HZ2' ' CG ' ' A' ' 26' ' ' ASP . 20.2 tptm 173.13 -53.73 0.01 OUTLIER 'General case' 0 N--CA 1.431 -1.412 0 CA-C-N 112.437 -2.165 . . . . 0.0 107.326 -177.309 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 85.8 t80 -120.18 -63.23 1.39 Allowed 'General case' 0 C--N 1.299 -1.611 0 CA-C-N 114.53 -1.214 . . . . 0.0 109.719 -178.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 11.7 m . . . . . 0 C--N 1.316 -0.858 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.788 -179.813 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.0 mpp? . . . . . 0 CA--C 1.499 -1.002 0 CA-C-O 120.651 0.263 . . . . 0.0 111.03 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -99.81 70.25 1.62 Allowed 'General case' 0 N--CA 1.435 -1.182 0 N-CA-C 107.71 -1.218 . . . . 0.0 107.71 178.191 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 2.2 ptp180 -91.79 -176.05 4.34 Favored 'General case' 0 C--N 1.29 -2.021 0 CA-C-N 113.983 -1.462 . . . . 0.0 111.233 -178.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -143.42 -173.03 3.83 Favored 'General case' 0 N--CA 1.428 -1.553 0 N-CA-C 105.366 -2.087 . . . . 0.0 105.366 174.115 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.489 ' CE2' HG13 ' A' ' 58' ' ' ILE . 91.3 m-85 -125.37 149.1 48.44 Favored 'General case' 0 C--N 1.305 -1.331 0 N-CA-C 117.575 2.435 . . . . 0.0 117.575 -170.771 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.493 ' HG3' ' OD1' ' A' ' 9' ' ' ASP . 3.8 ptmm? -134.65 156.3 78.8 Favored Pre-proline 0 N--CA 1.413 -2.276 0 CA-C-N 112.076 -2.329 . . . . 0.0 107.684 177.086 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.88 141.1 95.77 Favored 'Trans proline' 0 C--O 1.253 1.234 0 C-N-CA 122.497 2.132 . . . . 0.0 112.455 178.244 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 104.81 -14.17 49.56 Favored Glycine 0 N--CA 1.44 -1.039 0 C-N-CA 121.231 -0.509 . . . . 0.0 113.033 178.18 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.493 ' OD1' ' HG3' ' A' ' 6' ' ' LYS . 1.4 m-20 -79.05 145.87 33.6 Favored 'General case' 0 C--N 1.318 -0.804 0 CA-C-O 121.087 0.47 . . . . 0.0 111.412 -179.381 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 83.6 mt -95.3 127.43 41.34 Favored 'General case' 0 C--O 1.25 1.116 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.45 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.475 HG22 ' HA ' ' A' ' 60' ' ' PRO . 2.9 pp -139.54 -178.63 1.84 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.205 0 CA-C-O 122.489 1.138 . . . . 0.0 113.761 -173.053 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.498 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 86.3 m-85 -119.43 128.59 54.17 Favored 'General case' 0 N--CA 1.408 -2.564 0 N-CA-C 105.203 -2.147 . . . . 0.0 105.203 170.766 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.501 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -108.09 140.84 40.68 Favored 'General case' 0 C--N 1.279 -2.477 0 O-C-N 123.702 0.626 . . . . 0.0 110.045 -173.569 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.483 ' HD3' ' C ' ' A' ' 14' ' ' LYS . 7.6 tmtm? -114.96 115.66 27.24 Favored 'General case' 0 N--CA 1.414 -2.273 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.834 -176.742 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.408 ' HB2' ' HB2' ' A' ' 18' ' ' TYR . 69.8 mtm -108.12 158.93 16.99 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 109.992 -0.373 . . . . 0.0 109.992 172.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 24.4 tptm -62.59 130.04 43.3 Favored 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 177.509 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 83.02 -25.5 4.73 Favored Glycine 0 C--O 1.218 -0.888 0 O-C-N 123.539 0.524 . . . . 0.0 112.568 -177.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.408 ' HB2' ' HB2' ' A' ' 15' ' ' MET . 53.5 m-85 -93.21 149.85 38.13 Favored Pre-proline 0 C--O 1.257 1.488 0 N-CA-C 112.973 0.731 . . . . 0.0 112.973 -177.225 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -75.78 171.7 17.69 Favored 'Trans proline' 0 N--CA 1.449 -1.112 0 C-N-CA 123.395 2.73 . . . . 0.0 109.646 171.251 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.453 ' HB3' ' HB3' ' A' ' 12' ' ' PHE . 79.8 m80 -69.9 111.53 5.68 Favored 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 178.461 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 8.5 t-105 -100.17 136.39 20.1 Favored Pre-proline 0 C--N 1.309 -1.175 0 CA-C-N 115.386 -0.825 . . . . 0.0 109.961 -173.27 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_endo -65.88 117.79 4.94 Favored 'Trans proline' 0 CA--C 1.542 0.9 0 C-N-CA 121.789 1.66 . . . . 0.0 110.789 176.439 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.44 167.51 23.46 Favored 'General case' 0 N--CA 1.426 -1.645 0 N-CA-C 108.91 -0.774 . . . . 0.0 108.91 -174.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.503 ' HB3' ' CE2' ' A' ' 45' ' ' PHE . 9.2 ptt180 -111.25 160.57 16.86 Favored 'General case' 0 C--N 1.291 -1.965 0 C-N-CA 119.507 -0.877 . . . . 0.0 109.182 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 42.3 t -89.47 116.05 30.24 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.163 0 N-CA-C 106.648 -1.612 . . . . 0.0 106.648 170.064 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.406 ' HB2' ' HB2' ' A' ' 41' ' ' PRO . 1.7 m-20 -87.84 173.53 8.89 Favored 'General case' 0 C--N 1.281 -2.407 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.976 -175.013 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -110.02 166.22 11.11 Favored 'General case' 0 N--CA 1.417 -2.1 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 175.613 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.2 p -98.56 115.47 65.76 Favored Pre-proline 0 C--N 1.294 -1.833 0 C-N-CA 120.05 -0.66 . . . . 0.0 110.931 -177.523 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 78.2 Cg_endo -88.59 164.3 6.45 Favored 'Trans proline' 0 N--CA 1.448 -1.156 0 C-N-CA 123.058 2.505 . . . . 0.0 113.108 -178.187 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -73.15 142.01 47.45 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 106.416 -1.698 . . . . 0.0 106.416 172.236 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 102.92 -17.88 51.33 Favored Glycine 0 C--N 1.291 -1.917 0 C-N-CA 119.797 -1.192 . . . . 0.0 111.078 -177.792 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -65.51 103.64 0.87 Allowed 'General case' 0 N--CA 1.45 -0.434 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 173.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 31.9 m -69.74 -19.91 23.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 N-CA-C 114.082 1.141 . . . . 0.0 114.082 -174.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.562 ' HD3' ' O ' ' A' ' 34' ' ' LYS . 0.0 OUTLIER -108.25 129.49 24.0 Favored Pre-proline 0 N--CA 1.41 -2.437 0 C-N-CA 119.736 -0.786 . . . . 0.0 111.515 -179.458 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -68.9 171.49 13.42 Favored 'Trans proline' 0 C--O 1.265 1.831 0 C-N-CA 123.401 2.734 . . . . 0.0 113.701 -176.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -55.83 133.28 57.08 Favored 'Trans proline' 0 C--N 1.364 1.374 0 C-N-CA 123.127 2.552 . . . . 0.0 110.757 174.546 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.7 m -110.02 8.95 24.27 Favored 'General case' 0 C--N 1.291 -1.961 0 CA-C-N 115.427 -0.806 . . . . 0.0 109.186 -174.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 45.2 m-80 78.98 8.6 1.91 Allowed 'General case' 0 N--CA 1.496 1.87 0 C-N-CA 126.027 1.731 . . . . 0.0 108.747 -172.057 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.513 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 34.3 mmtt -113.1 153.39 28.29 Favored 'General case' 0 N--CA 1.41 -2.469 0 CA-C-N 113.278 -1.783 . . . . 0.0 107.075 174.238 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.431 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 74.6 mt -96.63 154.27 38.52 Favored Pre-proline 0 C--N 1.271 -2.814 0 N-CA-C 107.913 -1.143 . . . . 0.0 107.913 -178.147 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.406 ' HB2' ' HB2' ' A' ' 26' ' ' ASP . 45.8 Cg_endo -74.96 126.48 10.02 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 C-N-CA 121.517 1.478 . . . . 0.0 109.276 173.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 50.6 mm -125.3 110.13 23.76 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 CA-C-O 121.116 0.484 . . . . 0.0 111.407 -175.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 70.2 t80 -90.26 117.52 29.06 Favored 'General case' 0 C--N 1.279 -2.497 0 C-N-CA 124.46 1.104 . . . . 0.0 109.899 176.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 88.3 m-85 -78.13 128.83 34.4 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 115.908 -0.587 . . . . 0.0 110.9 177.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.503 ' CE2' ' HB3' ' A' ' 24' ' ' ARG . 58.8 m-85 -78.14 152.04 32.99 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.254 177.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 80.96 -21.05 5.93 Favored Glycine 0 C--N 1.308 -1.027 0 C-N-CA 124.565 1.079 . . . . 0.0 114.592 177.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.457 ' CG2' ' HA3' ' A' ' 76' ' ' GLY . 32.6 p -119.88 -22.73 6.66 Favored 'General case' 0 C--N 1.299 -1.608 0 CA-C-N 117.467 0.633 . . . . 0.0 110.349 174.682 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 13.2 m-70 68.11 23.17 8.09 Favored 'General case' 0 CA--C 1.536 0.412 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.854 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -75.12 169.64 17.63 Favored 'General case' 0 C--N 1.35 0.602 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 175.076 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.4 m -141.47 145.66 35.51 Favored 'General case' 0 C--N 1.294 -1.808 0 O-C-N 121.539 -0.726 . . . . 0.0 110.005 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -139.99 -179.9 6.22 Favored 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 123.835 0.854 . . . . 0.0 109.842 178.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.431 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 93.0 m-85 -133.23 109.67 9.58 Favored 'General case' 0 CA--C 1.491 -1.29 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 174.332 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.53 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 79.5 mt -134.13 144.6 48.64 Favored 'General case' 0 C--N 1.284 -2.252 0 N-CA-C 106.761 -1.57 . . . . 0.0 106.761 -178.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.513 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -83.26 177.05 52.97 Favored Glycine 0 N--CA 1.417 -2.596 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 -174.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -66.23 -17.51 54.49 Favored 'Trans proline' 0 C--N 1.319 -0.985 0 C-N-CA 122.112 1.875 . . . . 0.0 112.481 -176.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 16.8 mmmt -98.86 -3.58 35.03 Favored 'General case' 0 C--N 1.304 -1.378 0 C-N-CA 120.204 -0.598 . . . . 0.0 110.923 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.53 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 12.8 m-20 -96.55 -9.2 30.01 Favored 'General case' 0 N--CA 1.481 1.105 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.792 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.489 HG13 ' CE2' ' A' ' 5' ' ' PHE . 12.5 pt -115.63 152.43 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.231 0 CA-C-N 115.091 -0.959 . . . . 0.0 111.428 -176.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -126.05 131.68 24.06 Favored Pre-proline 0 C--N 1.301 -1.542 0 CA-C-N 115.238 -0.892 . . . . 0.0 108.753 -177.612 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.525 ' HG2' ' HB2' ' A' ' 63' ' ' GLU . 34.1 Cg_endo -67.6 131.51 24.67 Favored 'Trans proline' 0 C--N 1.322 -0.821 0 C-N-CA 122.708 2.272 . . . . 0.0 113.202 -175.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.498 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 43.3 t80 -52.37 -42.19 63.74 Favored 'General case' 0 C--O 1.205 -1.257 0 C-N-CA 123.992 0.917 . . . . 0.0 111.337 179.62 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 23.2 t -64.94 -37.0 86.19 Favored 'General case' 0 C--N 1.301 -1.521 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.476 -175.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.525 ' HB2' ' HG2' ' A' ' 60' ' ' PRO . 29.9 mt-10 -97.03 -7.08 33.78 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-O 120.992 0.425 . . . . 0.0 111.949 -175.703 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.479 ' OD1' ' HD3' ' A' ' 67' ' ' LYS . 27.2 m-80 -133.53 17.77 3.96 Favored 'General case' 0 C--N 1.32 -0.69 0 N-CA-C 112.416 0.525 . . . . 0.0 112.416 -175.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.448 ' HG2' ' OE1' ' A' ' 66' ' ' GLU . 3.6 ptpp? -67.29 -36.13 80.91 Favored 'General case' 0 N--CA 1.498 1.968 0 C-N-CA 120.042 -0.663 . . . . 0.0 110.611 -176.149 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.448 ' OE1' ' HG2' ' A' ' 65' ' ' LYS . 28.8 mp0 -64.94 -35.45 81.21 Favored 'General case' 0 C--O 1.255 1.346 0 CA-C-O 123.241 1.496 . . . . 0.0 108.836 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.479 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 37.6 mtpt -76.38 -59.33 2.81 Favored 'General case' 0 C--N 1.294 -1.834 0 CA-C-N 112.931 -1.94 . . . . 0.0 111.912 -174.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.411 ' CD2' ' HB3' ' A' ' 64' ' ' ASN . 23.2 m-85 -112.1 -1.94 15.16 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 -169.084 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -83.85 45.69 3.52 Favored Glycine 0 C--N 1.309 -0.961 0 C-N-CA 120.654 -0.784 . . . . 0.0 113.373 -176.776 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 17.3 pttm -132.75 143.74 49.98 Favored Pre-proline 0 N--CA 1.43 -1.448 0 O-C-N 122.591 -0.358 . . . . 0.0 111.561 176.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_exo -49.42 158.13 1.83 Allowed 'Trans proline' 0 C--N 1.361 1.236 0 C-N-CA 124.577 3.518 . . . . 0.0 117.06 -173.053 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.8 t-20 -131.48 -178.42 4.85 Favored 'General case' 0 N--CA 1.416 -2.164 0 CA-C-N 113.647 -1.615 . . . . 0.0 108.31 178.317 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 12.9 mptt -90.69 -18.51 24.94 Favored 'General case' 0 C--N 1.308 -1.199 0 O-C-N 123.693 0.621 . . . . 0.0 109.659 179.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.54 115.57 5.9 Favored 'General case' 0 N--CA 1.414 -2.229 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 175.496 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.447 ' HD3' ' H ' ' A' ' 76' ' ' GLY . 14.0 tppt? -64.73 133.42 52.05 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 175.638 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.457 ' HA3' ' CG2' ' A' ' 47' ' ' THR . . . 108.46 -24.75 21.62 Favored Glycine 0 N--CA 1.414 -2.788 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -174.095 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 11.0 t80 -75.6 -37.91 59.46 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 8.9 m120 -65.96 -49.55 67.48 Favored 'General case' 0 C--N 1.322 -0.626 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 -178.487 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 23.5 mp0 -64.58 -39.07 93.07 Favored 'General case' 0 C--N 1.302 -1.489 0 CA-C-N 113.202 -1.817 . . . . 0.0 110.522 -179.687 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.64 -35.05 62.63 Favored Glycine 0 CA--C 1.48 -2.145 0 CA-C-N 116.063 -0.517 . . . . 0.0 113.011 -179.41 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 37.7 tp -62.51 -33.31 74.63 Favored 'General case' 0 N--CA 1.423 -1.802 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 176.029 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 70.5 t90 -74.34 -49.11 24.21 Favored 'General case' 0 N--CA 1.426 -1.626 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.602 175.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -55.04 -46.09 75.27 Favored 'General case' 0 C--O 1.188 -2.154 0 N-CA-C 112.644 0.609 . . . . 0.0 112.644 -179.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 17.0 tt -68.56 -23.22 27.73 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 CA-C-O 121.082 0.468 . . . . 0.0 111.629 -174.054 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -92.34 -41.93 10.09 Favored 'General case' 0 N--CA 1.423 -1.785 0 CA-C-O 121.585 0.707 . . . . 0.0 109.819 -175.443 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.584 HD22 ' N ' ' A' ' 86' ' ' ASN . 0.7 OUTLIER -97.73 -39.73 8.91 Favored 'General case' 0 N--CA 1.48 1.038 0 CA-C-O 121.713 0.768 . . . . 0.0 112.061 -173.838 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 65.2 t30 -134.99 63.33 57.24 Favored Pre-proline 0 C--N 1.296 -1.759 0 C-N-CA 119.797 -0.761 . . . . 0.0 111.673 -178.428 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -68.13 -6.57 17.58 Favored 'Trans proline' 0 C--N 1.371 1.711 0 C-N-CA 122.81 2.34 . . . . 0.0 111.742 -178.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 24.7 pttm -102.12 19.94 17.61 Favored 'General case' 0 C--N 1.311 -1.103 0 CA-C-N 114.555 -1.202 . . . . 0.0 109.828 -177.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 14.6 p -71.7 141.33 16.81 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 CA-C-O 121.447 0.641 . . . . 0.0 110.242 179.301 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.664 ' HE2' ' O ' ' A' ' 93' ' ' SER . 19.6 ptmt -74.4 146.56 42.85 Favored 'General case' 0 C--N 1.306 -1.32 0 CA-C-N 115.532 -0.758 . . . . 0.0 111.584 -178.881 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -46.6 -64.98 0.63 Allowed 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 125.425 1.49 . . . . 0.0 111.652 -178.656 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . 0.664 ' O ' ' HE2' ' A' ' 91' ' ' LYS . 46.6 t . . . . . 0 C--N 1.292 -1.931 0 N-CA-C 107.095 -1.446 . . . . 0.0 107.095 178.255 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.9 mtt . . . . . 0 CA--C 1.503 -0.85 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -97.32 72.33 2.4 Favored 'General case' 0 N--CA 1.44 -0.974 0 N-CA-C 105.846 -1.909 . . . . 0.0 105.846 175.377 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -117.55 175.86 5.44 Favored 'General case' 0 C--N 1.286 -2.156 0 CA-C-N 113.412 -1.722 . . . . 0.0 111.697 -174.161 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 8.6 t0 -127.33 162.42 26.31 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 105.8 -1.926 . . . . 0.0 105.8 176.067 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.494 ' C ' ' HD2' ' A' ' 6' ' ' LYS . 84.3 m-85 -105.37 121.24 43.5 Favored 'General case' 0 C--N 1.293 -1.857 0 CA-C-O 120.959 0.409 . . . . 0.0 110.014 -172.466 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.494 ' HD2' ' C ' ' A' ' 5' ' ' PHE . 13.4 mmmt -116.81 153.69 49.33 Favored Pre-proline 0 N--CA 1.433 -1.29 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 -178.251 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.6 Cg_exo -52.82 134.45 54.58 Favored 'Trans proline' 0 C--N 1.347 0.473 0 C-N-CA 122.755 2.303 . . . . 0.0 112.369 177.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 107.58 -25.21 21.97 Favored Glycine 0 N--CA 1.432 -1.613 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.77 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -72.24 150.23 43.85 Favored 'General case' 0 C--O 1.252 1.216 0 CA-C-O 121.582 0.706 . . . . 0.0 112.224 -177.099 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 76.5 mt -100.04 127.96 46.19 Favored 'General case' 0 N--CA 1.423 -1.794 0 CA-C-N 114.352 -1.294 . . . . 0.0 109.754 -177.116 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 8.6 pt -140.12 -173.6 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 CA-C-O 122.348 1.071 . . . . 0.0 111.897 -174.446 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.414 ' HB3' ' HB3' ' A' ' 20' ' ' HIS . 66.5 m-85 -126.31 124.31 40.02 Favored 'General case' 0 N--CA 1.412 -2.363 0 N-CA-C 106.174 -1.787 . . . . 0.0 106.174 172.162 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.439 ' CB ' HG21 ' A' ' 42' ' ' ILE . . . -108.89 131.28 55.17 Favored 'General case' 0 C--N 1.28 -2.431 0 CA-C-N 115.548 -0.751 . . . . 0.0 110.343 -174.572 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.625 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -113.54 122.18 46.46 Favored 'General case' 0 N--CA 1.401 -2.911 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.116 -177.76 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 70.2 mtm -110.43 158.03 18.93 Favored 'General case' 0 C--N 1.316 -0.886 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 175.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 60.2 tttm -67.29 116.62 8.26 Favored 'General case' 0 C--N 1.31 -1.132 0 N-CA-C 110.145 -0.317 . . . . 0.0 110.145 -179.224 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.81 -2.75 62.26 Favored Glycine 0 C--O 1.248 0.975 0 N-CA-C 111.519 -0.632 . . . . 0.0 111.519 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -121.86 151.79 58.32 Favored Pre-proline 0 N--CA 1.434 -1.268 0 C-N-CA 122.829 0.452 . . . . 0.0 109.905 -178.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -76.5 171.37 18.18 Favored 'Trans proline' 0 N--CA 1.448 -1.157 0 C-N-CA 122.296 1.997 . . . . 0.0 109.815 175.1 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.536 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 76.2 m80 -66.76 110.94 3.46 Favored 'General case' 0 C--N 1.312 -1.061 0 N-CA-C 107.594 -1.261 . . . . 0.0 107.594 176.269 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 6.0 t-105 -99.88 138.15 20.29 Favored Pre-proline 0 C--N 1.296 -1.718 0 C-N-CA 123.942 0.897 . . . . 0.0 109.324 -171.316 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -63.59 118.28 5.22 Favored 'Trans proline' 0 C--O 1.244 0.808 0 C-N-CA 121.918 1.746 . . . . 0.0 110.043 177.219 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -141.82 167.54 21.91 Favored 'General case' 0 N--CA 1.415 -2.195 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.761 -175.195 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.409 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 56.1 ttt-85 -123.73 141.15 52.29 Favored 'General case' 0 C--N 1.289 -2.03 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 178.191 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 45.6 t -77.64 125.27 37.2 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.941 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 175.029 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.458 ' OD1' ' HE3' ' A' ' 91' ' ' LYS . 5.4 t70 -94.2 171.04 9.08 Favored 'General case' 0 C--N 1.303 -1.42 0 C-N-CA 120.57 -0.452 . . . . 0.0 109.855 -175.741 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -100.88 124.43 46.56 Favored 'General case' 0 C--N 1.305 -1.367 0 CA-C-O 121.915 0.864 . . . . 0.0 113.293 -178.116 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.2 p -81.51 133.51 52.85 Favored Pre-proline 0 N--CA 1.437 -1.122 0 CA-C-N 114.357 -1.292 . . . . 0.0 108.297 177.254 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_endo -70.67 141.09 40.7 Favored 'Trans proline' 0 N--CA 1.456 -0.7 0 C-N-CA 122.051 1.834 . . . . 0.0 112.763 -179.306 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -74.25 149.31 40.83 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 172.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 89.11 -3.83 84.48 Favored Glycine 0 C--N 1.291 -1.93 0 C-N-CA 120.508 -0.854 . . . . 0.0 111.725 -175.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -57.34 116.64 3.43 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-O 121.117 0.484 . . . . 0.0 110.381 175.36 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.6 m -63.62 -21.35 28.35 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.546 0 CA-C-N 115.558 -0.746 . . . . 0.0 112.754 -178.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 44.7 mmtm -107.94 118.87 51.79 Favored Pre-proline 0 N--CA 1.424 -1.739 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 171.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -73.94 166.79 28.79 Favored 'Trans proline' 0 C--O 1.246 0.879 0 C-N-CA 122.446 2.097 . . . . 0.0 111.33 178.416 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -54.52 129.52 35.25 Favored 'Trans proline' 0 C--N 1.358 1.062 0 C-N-CA 122.679 2.253 . . . . 0.0 111.953 179.335 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.413 HG22 ' O ' ' A' ' 37' ' ' THR . 4.9 m -73.64 9.48 1.41 Allowed 'General case' 0 C--N 1.301 -1.528 0 C-N-CA 125.661 1.584 . . . . 0.0 112.722 -174.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 5.1 p30 87.44 9.16 0.17 Allowed 'General case' 0 N--CA 1.502 2.169 0 C-N-CA 126.853 2.061 . . . . 0.0 109.752 -173.554 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 62.6 mttp -126.18 162.23 25.87 Favored 'General case' 0 C--N 1.294 -1.845 0 CA-C-N 113.283 -1.78 . . . . 0.0 110.364 178.16 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 85.0 mt -112.55 147.29 36.77 Favored Pre-proline 0 C--N 1.286 -2.194 0 CA-C-N 114.8 -1.091 . . . . 0.0 109.487 -176.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -73.73 122.58 7.89 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 121.749 1.632 . . . . 0.0 109.535 176.141 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.439 HG21 ' CB ' ' A' ' 13' ' ' ALA . 45.7 mm -118.22 111.01 32.32 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.676 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.251 -174.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.461 ' CZ ' ' HA ' ' A' ' 48' ' ' HIS . 91.1 t80 -91.24 118.73 30.72 Favored 'General case' 0 C--N 1.286 -2.153 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -179.288 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -83.03 133.23 35.1 Favored 'General case' 0 C--O 1.249 1.03 0 CA-C-O 121.107 0.479 . . . . 0.0 112.163 179.449 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.409 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 72.0 m-85 -81.43 152.34 27.45 Favored 'General case' 0 N--CA 1.433 -1.31 0 CA-C-N 115.616 -0.72 . . . . 0.0 109.154 175.144 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.436 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 81.24 -19.47 8.2 Favored Glycine 0 C--N 1.309 -0.95 0 C-N-CA 123.366 0.507 . . . . 0.0 113.555 178.412 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.473 ' HB ' ' OE1' ' A' ' 49' ' ' GLU . 35.9 p -118.92 -22.78 7.17 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 122.267 -0.549 . . . . 0.0 110.578 176.426 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . 0.461 ' HA ' ' CZ ' ' A' ' 43' ' ' PHE . 13.3 m170 66.43 25.6 10.22 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 123.308 0.643 . . . . 0.0 110.879 -179.729 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.473 ' OE1' ' HB ' ' A' ' 47' ' ' THR . 45.9 mt-10 -97.45 175.47 6.22 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.454 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 10.0 m -143.76 143.85 31.56 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-O 121.172 0.511 . . . . 0.0 109.815 -179.241 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -131.37 178.26 6.85 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 114.814 -1.084 . . . . 0.0 109.675 -179.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -133.38 109.82 9.6 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 176.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.416 HD12 ' HB1' ' A' ' 13' ' ' ALA . 88.9 mt -125.65 163.7 22.2 Favored 'General case' 0 C--N 1.292 -1.911 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 -177.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -85.22 162.8 37.05 Favored Glycine 0 N--CA 1.419 -2.454 0 N-CA-C 110.077 -1.209 . . . . 0.0 110.077 178.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -63.88 -15.17 47.48 Favored 'Trans proline' 0 C--O 1.208 -0.989 0 C-N-CA 123.006 2.471 . . . . 0.0 112.257 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.08 4.96 51.1 Favored 'General case' 0 C--N 1.308 -1.202 0 CA-C-N 115.648 -0.705 . . . . 0.0 112.75 178.002 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -113.67 1.77 15.02 Favored 'General case' 0 C--N 1.292 -1.911 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.143 177.155 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 17.6 pt -127.13 150.74 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.823 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.531 ' HB3' ' ND2' ' A' ' 64' ' ' ASN . 93.3 m-85 -136.29 142.37 39.45 Favored Pre-proline 0 C--N 1.295 -1.794 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo -65.09 137.88 54.25 Favored 'Trans proline' 0 C--O 1.249 1.046 0 C-N-CA 122.835 2.357 . . . . 0.0 112.922 -177.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.404 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 25.4 t80 -56.38 -42.69 78.29 Favored 'General case' 0 C--O 1.208 -1.093 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.172 178.335 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.6 m -53.87 -43.43 69.59 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 115.677 -0.692 . . . . 0.0 112.509 -175.259 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -95.62 -17.23 21.51 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.259 0.552 . . . . 0.0 112.031 -176.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.531 ' ND2' ' HB3' ' A' ' 59' ' ' PHE . 28.0 m-80 -116.73 10.54 14.32 Favored 'General case' 0 C--N 1.309 -1.161 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -173.027 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.508 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 19.4 pttp -68.69 -35.44 77.2 Favored 'General case' 0 C--O 1.21 -0.994 0 CA-C-O 121.137 0.494 . . . . 0.0 111.032 -177.296 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.508 ' OE1' ' HG3' ' A' ' 65' ' ' LYS . 2.1 mm-40 -73.01 -22.48 60.66 Favored 'General case' 0 C--N 1.307 -1.263 0 CA-C-O 122.177 0.989 . . . . 0.0 108.819 -178.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.445 ' HD3' ' OD1' ' A' ' 64' ' ' ASN . 41.5 mtpt -83.42 -59.61 2.4 Favored 'General case' 0 N--CA 1.436 -1.148 0 CA-C-N 114.561 -1.2 . . . . 0.0 110.609 -177.606 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . 0.493 ' CD2' ' HB3' ' A' ' 64' ' ' ASN . 27.2 m-85 -105.72 -8.12 18.02 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-N 115.475 -0.784 . . . . 0.0 112.697 -169.35 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -79.25 52.12 4.01 Favored Glycine 0 C--O 1.219 -0.816 0 C-N-CA 121.583 -0.342 . . . . 0.0 112.781 -177.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 3.7 ptpp? -132.96 132.9 22.66 Favored Pre-proline 0 C--N 1.301 -1.536 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 176.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -65.49 128.89 21.17 Favored 'Trans proline' 0 N--CA 1.446 -1.316 0 C-N-CA 122.655 2.237 . . . . 0.0 115.531 -172.193 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.424 HD22 ' N ' ' A' ' 72' ' ' ASN . 0.8 OUTLIER -93.92 -170.81 2.41 Favored 'General case' 0 CA--C 1.487 -1.474 0 N-CA-C 106.205 -1.776 . . . . 0.0 106.205 173.829 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.503 ' HD3' ' HA ' ' A' ' 73' ' ' LYS 0.273 70.9 mmtt -110.09 28.93 8.12 Favored 'General case' 0 C--N 1.291 -1.977 0 CA-C-O 122.593 1.187 . . . . 0.0 110.592 171.35 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 14.7 mmt180 -82.51 125.34 31.01 Favored 'General case' 0 C--O 1.25 1.099 0 N-CA-C 106.341 -1.725 . . . . 0.0 106.341 170.511 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.401 ' HG3' ' OE2' ' A' ' 79' ' ' GLU . 61.2 tttp -66.73 139.24 57.81 Favored 'General case' 0 C--N 1.318 -0.798 0 C-N-CA 119.83 -0.748 . . . . 0.0 109.882 176.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.436 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 95.87 -25.2 26.28 Favored Glycine 0 N--CA 1.428 -1.895 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -175.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.402 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 31.7 t80 -75.87 -47.06 26.98 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-O 121.196 0.522 . . . . 0.0 109.702 -178.062 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.546 ' N ' HD22 ' A' ' 78' ' ' ASN . 0.7 OUTLIER -67.4 -37.86 83.76 Favored 'General case' 0 N--CA 1.492 1.658 0 CA-C-O 121.892 0.853 . . . . 0.0 109.142 -179.256 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . 0.401 ' OE2' ' HG3' ' A' ' 75' ' ' LYS . 26.1 mt-10 -72.44 -36.1 68.46 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 114.024 -1.444 . . . . 0.0 109.593 -179.158 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -69.66 -33.89 72.08 Favored Glycine 0 CA--C 1.494 -1.271 0 CA-C-N 115.608 -0.724 . . . . 0.0 112.641 178.455 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.402 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 94.7 mt -60.51 -38.79 85.52 Favored 'General case' 0 C--O 1.21 -0.976 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 174.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 85.4 t90 -66.66 -46.07 76.89 Favored 'General case' 0 N--CA 1.429 -1.476 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.695 177.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -61.48 -43.46 98.82 Favored 'General case' 0 C--O 1.204 -1.339 0 N-CA-C 113.076 0.769 . . . . 0.0 113.076 179.564 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.1 tt -70.8 -33.45 52.52 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.07 0 C-N-CA 120.379 -0.528 . . . . 0.0 112.056 -175.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -88.98 -5.85 57.66 Favored 'General case' 0 C--N 1.312 -1.05 0 N-CA-C 112.758 0.651 . . . . 0.0 112.758 -178.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 31.9 m-80 -123.57 -51.12 1.84 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-O 121.388 0.613 . . . . 0.0 112.089 -179.137 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.408 ' ND2' ' HB ' ' A' ' 90' ' ' VAL . 66.7 t30 -126.45 67.56 65.59 Favored Pre-proline 0 C--N 1.305 -1.341 0 O-C-N 121.94 -0.475 . . . . 0.0 110.186 -179.422 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 61.3 Cg_endo -74.78 -5.95 17.51 Favored 'Trans proline' 0 N--CA 1.48 0.698 0 C-N-CA 122.314 2.009 . . . . 0.0 112.289 -175.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.7 pttp -93.86 15.19 17.25 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.083 -178.404 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.408 ' HB ' ' ND2' ' A' ' 87' ' ' ASN . 10.0 p -89.9 147.7 5.04 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.583 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 176.172 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.458 ' HE3' ' OD1' ' A' ' 26' ' ' ASP . 18.2 ptmt -144.67 -163.17 1.64 Allowed 'General case' 0 C--N 1.309 -1.181 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 177.142 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -29.56 104.03 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 C-N-CA 125.352 1.461 . . . . 0.0 113.737 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 22.8 t . . . . . 0 N--CA 1.425 -1.696 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 178.535 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.7 mtt . . . . . 0 CA--C 1.501 -0.908 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -130.5 82.76 2.08 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 104.098 -2.556 . . . . 0.0 104.098 172.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 14.2 ptm180 -122.09 -152.14 0.5 Allowed 'General case' 0 C--N 1.293 -1.862 0 CA-C-N 114.252 -1.34 . . . . 0.0 112.251 -171.789 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -82.02 156.32 24.69 Favored 'General case' 0 N--CA 1.435 -1.202 0 C-N-CA 124.509 1.124 . . . . 0.0 109.948 -179.104 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 95.0 m-85 -134.79 131.75 37.87 Favored 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 107.121 -1.437 . . . . 0.0 107.121 178.692 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.592 ' HG2' ' OD2' ' A' ' 9' ' ' ASP . 1.6 pttm -135.22 152.49 76.96 Favored Pre-proline 0 C--N 1.289 -2.039 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 -175.277 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 82.4 Cg_exo -49.09 121.7 7.25 Favored 'Trans proline' 0 C--N 1.352 0.723 0 C-N-CA 122.657 2.238 . . . . 0.0 111.138 176.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.38 -30.48 6.45 Favored Glycine 0 N--CA 1.423 -2.206 0 CA-C-O 118.991 -0.894 . . . . 0.0 113.637 -178.51 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.592 ' OD2' ' HG2' ' A' ' 6' ' ' LYS 0.335 2.9 p30 -78.71 147.93 33.27 Favored 'General case' 0 C--O 1.248 1.009 0 CA-C-N 118.859 1.329 . . . . 0.0 113.268 -179.161 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.425 HD22 HG13 ' A' ' 84' ' ' ILE . 82.3 mt -91.42 129.1 37.45 Favored 'General case' 0 CA--C 1.488 -1.44 0 CA-C-N 114.203 -1.362 . . . . 0.0 110.312 -175.783 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 12.1 pt -140.39 -173.03 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 CA-C-O 122.374 1.083 . . . . 0.0 111.993 -174.118 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 38.4 m-85 -120.71 132.33 55.01 Favored 'General case' 0 N--CA 1.414 -2.236 0 CA-C-N 113.979 -1.464 . . . . 0.0 107.077 171.344 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.502 ' HB2' HG21 ' A' ' 42' ' ' ILE . . . -108.92 124.02 50.0 Favored 'General case' 0 C--N 1.272 -2.788 0 O-C-N 123.947 0.779 . . . . 0.0 109.337 -178.811 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.634 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -109.33 120.27 42.0 Favored 'General case' 0 N--CA 1.398 -3.043 0 CA-C-N 116.184 -0.462 . . . . 0.0 109.916 -179.145 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 66.5 mtm -114.68 157.89 22.52 Favored 'General case' 0 C--N 1.314 -0.977 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 175.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 41.7 ttmt -66.31 117.63 8.85 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 116.712 -0.222 . . . . 0.0 110.429 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.92 -3.88 65.17 Favored Glycine 0 C--O 1.251 1.206 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.651 178.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 77.5 m-85 -120.9 151.44 54.85 Favored Pre-proline 0 N--CA 1.428 -1.573 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 -179.211 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -77.58 171.27 17.81 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 122.112 1.875 . . . . 0.0 109.611 175.562 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.459 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 70.0 m80 -63.15 110.99 2.03 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 174.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 7.5 t-105 -99.4 137.68 20.37 Favored Pre-proline 0 C--N 1.303 -1.456 0 C-N-CA 123.331 0.653 . . . . 0.0 109.239 -172.535 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -63.97 117.83 4.81 Favored 'Trans proline' 0 C--O 1.245 0.863 0 C-N-CA 121.796 1.664 . . . . 0.0 110.089 176.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.21 167.83 21.21 Favored 'General case' 0 N--CA 1.413 -2.305 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.143 -175.109 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.415 HH22 ' CD ' ' A' ' 27' ' ' GLU . 10.6 ttp180 -124.7 148.06 48.23 Favored 'General case' 0 C--N 1.282 -2.33 0 N-CA-C 107.577 -1.268 . . . . 0.0 107.577 176.571 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 46.7 t -72.41 118.69 17.84 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 N-CA-C 105.275 -2.12 . . . . 0.0 105.275 170.31 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -84.76 172.43 11.49 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -171.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.415 ' CD ' HH22 ' A' ' 24' ' ' ARG . 0.5 OUTLIER -108.76 135.74 49.48 Favored 'General case' 0 C--N 1.309 -1.158 0 CA-C-O 121.669 0.747 . . . . 0.0 112.533 -175.465 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 45.6 t -86.44 124.9 69.11 Favored Pre-proline 0 C--N 1.31 -1.143 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 178.639 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -72.72 140.9 33.11 Favored 'Trans proline' 0 N--CA 1.43 -2.264 0 C-N-CA 121.356 1.371 . . . . 0.0 112.566 -179.564 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -69.6 147.88 50.12 Favored 'General case' 0 C--N 1.312 -1.064 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 174.66 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 93.38 -16.08 61.46 Favored Glycine 0 C--N 1.296 -1.677 0 C-N-CA 120.754 -0.736 . . . . 0.0 111.692 -176.119 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -67.25 118.71 11.01 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-O 121.308 0.575 . . . . 0.0 110.593 177.379 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.7 m -79.38 -0.01 3.46 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 CA-C-N 115.703 -0.681 . . . . 0.0 112.273 -179.497 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 69.7 mmtt -103.17 118.35 58.15 Favored Pre-proline 0 N--CA 1.428 -1.556 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 175.312 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -82.63 166.43 15.48 Favored 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 122.454 2.103 . . . . 0.0 111.505 178.745 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 14.2 Cg_endo -59.63 144.07 99.51 Favored 'Trans proline' 0 C--N 1.356 0.932 0 C-N-CA 122.204 1.936 . . . . 0.0 111.942 178.326 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.42 ' O ' HG22 ' A' ' 37' ' ' THR . 5.6 m -73.54 9.08 1.5 Allowed 'General case' 0 C--N 1.309 -1.173 0 C-N-CA 125.185 1.394 . . . . 0.0 112.644 -175.882 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 4.6 p30 87.11 9.43 0.18 Allowed 'General case' 0 N--CA 1.503 2.189 0 C-N-CA 126.829 2.051 . . . . 0.0 109.314 -173.489 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -131.47 170.06 15.21 Favored 'General case' 0 N--CA 1.418 -2.051 0 CA-C-N 112.74 -2.027 . . . . 0.0 109.192 178.591 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.429 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 92.8 mt -98.89 141.6 23.16 Favored Pre-proline 0 C--N 1.287 -2.148 0 O-C-N 123.977 0.798 . . . . 0.0 109.937 -176.537 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -70.65 123.27 9.65 Favored 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 122.053 1.836 . . . . 0.0 109.429 176.082 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.502 HG21 ' HB2' ' A' ' 13' ' ' ALA . 39.5 mm -116.35 117.05 54.21 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.123 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 -175.775 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 72.7 t80 -94.28 115.89 28.2 Favored 'General case' 0 C--N 1.288 -2.093 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -81.54 129.1 34.54 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 123.425 0.453 . . . . 0.0 111.387 177.821 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -80.07 150.64 30.24 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.694 176.249 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.513 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 80.78 -19.91 6.95 Favored Glycine 0 C--N 1.311 -0.827 0 CA-C-N 116.216 -0.447 . . . . 0.0 113.739 179.152 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.4 p -119.33 -23.74 6.61 Favored 'General case' 0 C--N 1.309 -1.16 0 O-C-N 122.074 -0.662 . . . . 0.0 110.556 174.974 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.7 m-70 68.02 13.66 9.17 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 123.987 0.915 . . . . 0.0 112.231 -178.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.7 mm-40 -76.52 164.11 26.27 Favored 'General case' 0 CA--C 1.493 -1.226 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.263 178.222 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.411 ' HA ' ' O ' ' A' ' 42' ' ' ILE . 4.2 m -133.2 136.85 45.9 Favored 'General case' 0 C--N 1.283 -2.298 0 CA-C-O 121.425 0.631 . . . . 0.0 109.773 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -128.53 178.02 6.6 Favored 'General case' 0 C--N 1.284 -2.256 0 CA-C-N 115.013 -0.994 . . . . 0.0 109.914 -179.302 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.429 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 95.9 m-85 -133.63 110.25 9.75 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 176.527 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 94.9 mt -124.71 160.53 28.36 Favored 'General case' 0 C--N 1.292 -1.903 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 -179.35 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -87.81 167.53 36.73 Favored Glycine 0 N--CA 1.42 -2.383 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 178.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.402 ' HA ' HD11 ' A' ' 58' ' ' ILE . 38.1 Cg_endo -66.65 -6.96 16.65 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 123.16 2.573 . . . . 0.0 112.334 -178.782 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 7.9 ptmm? -97.31 -4.32 38.89 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.415 178.411 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 19.2 m-20 -115.27 5.66 14.76 Favored 'General case' 0 C--N 1.289 -2.048 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.891 -176.587 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.402 HD11 ' HA ' ' A' ' 55' ' ' PRO . 14.3 pt -131.38 150.7 34.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.796 0 CA-C-N 114.737 -1.12 . . . . 0.0 108.981 179.885 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -141.66 147.19 44.65 Favored Pre-proline 0 C--N 1.295 -1.778 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 -179.371 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -62.06 133.24 43.06 Favored 'Trans proline' 0 CA--C 1.511 -0.667 0 C-N-CA 123.043 2.495 . . . . 0.0 113.256 -177.45 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -64.62 -36.97 85.98 Favored 'General case' 0 C--O 1.207 -1.177 0 CA-C-N 114.88 -1.055 . . . . 0.0 110.7 -177.214 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 10.6 m -63.95 -39.65 94.64 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.239 -178.22 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -89.05 -7.43 55.9 Favored 'General case' 0 C--O 1.218 -0.582 0 N-CA-C 111.879 0.326 . . . . 0.0 111.879 -177.534 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 39.0 m-80 -123.92 13.39 9.16 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -179.476 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 16.8 ttmm -67.05 -34.36 77.51 Favored 'General case' 0 N--CA 1.473 0.694 0 CA-C-O 121.667 0.746 . . . . 0.0 109.648 -179.669 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.573 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -79.16 -20.25 48.96 Favored 'General case' 0 N--CA 1.408 -2.55 0 CA-C-N 115.563 -0.744 . . . . 0.0 112.347 178.072 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.573 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 8.2 mttm -87.92 -59.28 2.29 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.979 179.529 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 66.0 m-85 -112.53 1.32 15.81 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.3 -171.789 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.6 55.97 4.15 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 111.601 -0.599 . . . . 0.0 111.601 178.229 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 58.4 mttp -129.54 123.71 21.48 Favored Pre-proline 0 C--N 1.31 -1.131 0 N-CA-C 107.742 -1.207 . . . . 0.0 107.742 -179.712 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -63.0 128.2 22.35 Favored 'Trans proline' 0 N--CA 1.444 -1.424 0 C-N-CA 121.839 1.693 . . . . 0.0 114.132 -175.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -93.24 -171.84 2.78 Favored 'General case' 0 CA--C 1.482 -1.667 0 N-CA-C 107.058 -1.46 . . . . 0.0 107.058 176.44 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.465 ' HA ' ' HD3' ' A' ' 73' ' ' LYS 0.268 71.4 mmtt -109.42 27.56 9.42 Favored 'General case' 0 C--N 1.289 -2.045 0 CA-C-O 122.613 1.197 . . . . 0.0 110.361 171.041 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 13.8 mmt180 -80.14 127.64 32.56 Favored 'General case' 0 C--O 1.25 1.11 0 N-CA-C 105.168 -2.16 . . . . 0.0 105.168 169.421 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.412 ' HG2' ' HZ3' ' A' ' 75' ' ' LYS . 42.9 tttm -67.77 141.89 56.41 Favored 'General case' 0 C--N 1.32 -0.699 0 C-N-CA 119.228 -0.989 . . . . 0.0 108.721 179.456 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.513 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 94.17 -25.31 22.83 Favored Glycine 0 N--CA 1.426 -1.985 0 C-N-CA 120.881 -0.676 . . . . 0.0 111.846 -177.08 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.423 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 20.6 t80 -72.87 -44.73 60.98 Favored 'General case' 0 C--N 1.316 -0.884 0 CA-C-O 121.336 0.588 . . . . 0.0 109.585 -177.613 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.569 HD22 ' N ' ' A' ' 78' ' ' ASN . 0.7 OUTLIER -70.34 -42.21 72.18 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 109.109 -0.7 . . . . 0.0 109.109 -178.949 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 24.4 mt-10 -65.99 -38.48 88.59 Favored 'General case' 0 C--N 1.311 -1.081 0 CA-C-N 114.447 -1.251 . . . . 0.0 109.451 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -68.51 -34.84 80.07 Favored Glycine 0 N--CA 1.433 -1.505 0 CA-C-N 115.349 -0.842 . . . . 0.0 113.057 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.423 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 94.6 mt -60.61 -35.43 76.12 Favored 'General case' 0 C--O 1.216 -0.668 0 CA-C-O 121.309 0.576 . . . . 0.0 109.782 175.701 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 83.1 t90 -70.78 -48.97 51.46 Favored 'General case' 0 N--CA 1.433 -1.284 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.724 176.53 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -58.15 -45.33 87.61 Favored 'General case' 0 C--O 1.205 -1.289 0 N-CA-C 113.042 0.756 . . . . 0.0 113.042 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.425 HG13 HD22 ' A' ' 10' ' ' LEU . 20.7 tt -68.82 -31.23 49.86 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 N-CA-C 112.341 0.497 . . . . 0.0 112.341 -174.021 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.5 m-20 -90.58 -10.34 43.77 Favored 'General case' 0 C--N 1.318 -0.793 0 N-CA-C 112.504 0.557 . . . . 0.0 112.504 -179.027 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 31.7 m-80 -117.78 -53.99 2.37 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-O 121.223 0.535 . . . . 0.0 112.215 -178.373 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 61.0 t30 -127.86 75.77 77.92 Favored Pre-proline 0 C--N 1.304 -1.396 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.189 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -70.81 -7.7 21.97 Favored 'Trans proline' 0 N--CA 1.488 1.188 0 C-N-CA 122.87 2.38 . . . . 0.0 112.688 -176.569 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.3 pttp -105.36 21.08 17.78 Favored 'General case' 0 C--N 1.302 -1.461 0 C-N-CA 123.982 0.913 . . . . 0.0 109.738 -178.344 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 11.5 p -66.61 78.42 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.558 1.275 0 N-CA-C 115.64 1.719 . . . . 0.0 115.64 -175.792 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.426 ' HA ' ' HE2' ' A' ' 91' ' ' LYS . 9.1 mmpt? -75.34 -46.64 31.97 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 103.413 -2.81 . . . . 0.0 103.413 166.303 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 94.6 m-85 -132.35 149.49 52.34 Favored 'General case' 0 N--CA 1.423 -1.781 0 N-CA-C 104.23 -2.507 . . . . 0.0 104.23 173.187 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 8.1 t . . . . . 0 C--N 1.294 -1.81 0 C-N-CA 119.229 -0.988 . . . . 0.0 109.423 -177.492 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.608 ' HB3' ' O ' ' A' ' 3' ' ' ARG . 10.2 tpt . . . . . 0 C--O 1.214 -0.797 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . 0.461 ' H ' ' HG3' ' A' ' 1' ' ' MET . . . -66.79 -13.19 61.2 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-O 121.979 0.895 . . . . 0.0 110.301 174.309 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.608 ' O ' ' HB3' ' A' ' 1' ' ' MET . 6.0 ptp180 -135.48 158.28 44.77 Favored 'General case' 0 N--CA 1.426 -1.658 0 N-CA-C 101.41 -3.552 . . . . 0.0 101.41 173.114 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . 0.326 0.2 OUTLIER -120.56 175.8 5.81 Favored 'General case' 0 C--N 1.286 -2.166 0 C-N-CA 115.105 -2.638 . . . . 0.0 114.329 179.59 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.452 ' CE2' HG13 ' A' ' 58' ' ' ILE . 88.9 m-85 -106.37 152.5 23.5 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 124.045 0.841 . . . . 0.0 113.053 -167.331 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.636 ' HG2' ' OD2' ' A' ' 9' ' ' ASP . 16.8 pttm -134.6 160.09 69.74 Favored Pre-proline 0 C--N 1.305 -1.35 0 CA-C-N 114.889 -1.05 . . . . 0.0 108.336 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -51.25 122.65 10.46 Favored 'Trans proline' 0 C--N 1.347 0.499 0 C-N-CA 122.496 2.131 . . . . 0.0 111.879 175.328 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.1 -22.59 11.25 Favored Glycine 0 N--CA 1.429 -1.77 0 CA-C-O 119.351 -0.694 . . . . 0.0 113.381 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.636 ' OD2' ' HG2' ' A' ' 6' ' ' LYS . 37.3 m-20 -66.0 128.95 38.09 Favored 'General case' 0 C--O 1.247 0.953 0 CA-C-N 117.659 0.729 . . . . 0.0 112.097 -179.456 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.4 HD21 ' HB2' ' A' ' 88' ' ' PRO . 77.2 mt -83.83 124.43 30.94 Favored 'General case' 0 CA--C 1.485 -1.545 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 176.036 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 10.3 pt -140.24 -174.3 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.283 -2.303 0 CA-C-O 122.367 1.079 . . . . 0.0 112.261 -172.137 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.493 ' HB3' ' HB3' ' A' ' 20' ' ' HIS . 45.6 m-85 -119.77 126.96 52.32 Favored 'General case' 0 N--CA 1.404 -2.741 0 CA-C-N 113.181 -1.827 . . . . 0.0 106.973 170.529 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.434 ' CB ' HG21 ' A' ' 42' ' ' ILE . . . -108.98 121.76 45.81 Favored 'General case' 0 C--N 1.27 -2.869 0 CA-C-N 115.181 -0.918 . . . . 0.0 109.312 -178.241 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.617 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -104.77 119.57 39.3 Favored 'General case' 0 N--CA 1.401 -2.887 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.939 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 72.4 mtm -104.07 159.01 16.03 Favored 'General case' 0 C--N 1.312 -1.058 0 C-N-CA 123.172 0.589 . . . . 0.0 110.215 179.406 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.4 tttp -65.37 116.22 6.45 Favored 'General case' 0 C--N 1.308 -1.237 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.553 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 97.13 -8.04 64.75 Favored Glycine 0 N--CA 1.448 -0.563 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.627 178.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 65.8 m-85 -128.72 147.85 66.09 Favored Pre-proline 0 N--CA 1.444 -0.744 0 N-CA-C 112.072 0.397 . . . . 0.0 112.072 -178.647 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -68.7 170.89 14.26 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.845 2.363 . . . . 0.0 111.909 177.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.561 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 74.6 m80 -60.83 111.64 1.73 Allowed 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.518 -0.764 . . . . 0.0 110.114 178.229 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 4.0 t-105 -101.85 136.89 19.44 Favored Pre-proline 0 C--N 1.313 -1.002 0 N-CA-C 108.712 -0.847 . . . . 0.0 108.712 -176.818 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -64.7 117.64 4.7 Favored 'Trans proline' 0 C--O 1.241 0.649 0 C-N-CA 121.779 1.653 . . . . 0.0 110.432 176.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -141.16 167.38 22.32 Favored 'General case' 0 N--CA 1.413 -2.282 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.69 -174.749 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 32.7 ttt180 -109.96 138.35 46.46 Favored 'General case' 0 C--N 1.291 -1.969 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 176.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 64.4 t -74.68 111.68 10.92 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.068 0 N-CA-C 103.501 -2.777 . . . . 0.0 103.501 166.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -86.26 -177.58 6.27 Favored 'General case' 0 C--N 1.282 -2.329 0 C-N-CA 119.543 -0.863 . . . . 0.0 112.105 -169.728 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -104.24 143.56 32.78 Favored 'General case' 0 C--N 1.294 -1.838 0 CA-C-O 121.966 0.889 . . . . 0.0 112.861 -171.776 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 58.3 t -105.09 126.92 29.77 Favored Pre-proline 0 C--N 1.31 -1.136 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 178.728 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -71.04 137.84 32.56 Favored 'Trans proline' 0 N--CA 1.433 -2.087 0 C-N-CA 121.319 1.346 . . . . 0.0 112.605 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -71.65 149.69 45.31 Favored 'General case' 0 C--N 1.31 -1.13 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 173.756 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 92.43 -10.89 73.35 Favored Glycine 0 C--N 1.294 -1.759 0 C-N-CA 120.553 -0.832 . . . . 0.0 111.793 -176.097 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -65.71 101.68 0.66 Allowed 'General case' 0 C--O 1.219 -0.537 0 CA-C-O 121.439 0.638 . . . . 0.0 110.929 176.485 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 26.0 m -85.11 7.95 1.76 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.676 0 CA-C-O 121.79 0.805 . . . . 0.0 111.804 179.741 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 26.7 mmmt -97.59 128.93 32.86 Favored Pre-proline 0 C--N 1.291 -1.969 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 176.852 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -64.18 141.98 78.24 Favored 'Trans proline' 0 CA--C 1.534 0.499 0 C-N-CA 122.012 1.808 . . . . 0.0 112.039 179.666 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -75.55 171.25 18.58 Favored 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 122.369 2.046 . . . . 0.0 112.238 -179.339 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.2 m -73.03 7.46 2.07 Favored 'General case' 0 C--O 1.262 1.745 0 C-N-CA 124.548 1.139 . . . . 0.0 111.562 -178.753 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 39.8 m-80 65.53 25.16 11.79 Favored 'General case' 0 N--CA 1.481 1.091 0 C-N-CA 124.499 1.12 . . . . 0.0 108.98 -177.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 62.5 mttp -142.99 179.72 6.87 Favored 'General case' 0 N--CA 1.429 -1.497 0 CA-C-N 114.255 -1.339 . . . . 0.0 108.644 -178.173 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 96.5 mt -97.42 139.93 21.72 Favored Pre-proline 0 C--N 1.293 -1.876 0 O-C-N 123.995 0.809 . . . . 0.0 109.87 -179.333 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -70.29 123.45 9.94 Favored 'Trans proline' 0 N--CA 1.46 -0.475 0 C-N-CA 122.484 2.123 . . . . 0.0 110.247 177.512 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.434 HG21 ' CB ' ' A' ' 13' ' ' ALA . 42.4 mm -117.8 120.52 64.9 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.788 0 N-CA-C 109.668 -0.493 . . . . 0.0 109.668 -177.072 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 93.0 t80 -105.22 117.68 34.63 Favored 'General case' 0 C--N 1.286 -2.194 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 178.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.432 ' HE2' ' HB2' ' A' ' 51' ' ' ALA . 89.6 m-85 -82.93 135.69 34.82 Favored 'General case' 0 C--N 1.308 -1.212 0 CA-C-O 121.435 0.636 . . . . 0.0 112.332 179.493 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -85.48 151.72 23.75 Favored 'General case' 0 C--N 1.303 -1.425 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.469 178.155 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.427 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 80.84 -20.91 5.96 Favored Glycine 0 C--N 1.309 -0.939 0 C-N-CA 124.553 1.073 . . . . 0.0 114.124 177.657 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.499 ' CG2' ' HA3' ' A' ' 76' ' ' GLY . 37.0 p -119.8 -23.14 6.55 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-N 117.279 0.539 . . . . 0.0 110.201 175.084 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 43.4 m170 67.96 22.37 8.6 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.282 -178.263 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.1 mt-10 -71.75 164.2 26.41 Favored 'General case' 0 C--N 1.346 0.418 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 176.254 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.4 m -138.37 140.92 39.62 Favored 'General case' 0 C--N 1.28 -2.425 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -179.806 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.432 ' HB2' ' HE2' ' A' ' 44' ' ' PHE . . . -141.41 177.68 7.95 Favored 'General case' 0 C--N 1.289 -2.034 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.183 -179.819 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 95.7 m-85 -134.36 117.57 16.49 Favored 'General case' 0 N--CA 1.434 -1.238 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 176.755 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.413 HD12 ' HB1' ' A' ' 13' ' ' ALA . 90.7 mt -127.61 169.27 13.94 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -179.257 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -90.26 162.8 29.84 Favored Glycine 0 N--CA 1.413 -2.846 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 178.861 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -66.78 -5.98 14.52 Favored 'Trans proline' 0 N--CA 1.487 1.125 0 C-N-CA 123.88 3.053 . . . . 0.0 112.578 -179.476 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.3 ptmm? -97.89 -6.98 31.2 Favored 'General case' 0 C--N 1.305 -1.339 0 CA-C-N 114.875 -1.057 . . . . 0.0 111.686 177.186 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -112.52 6.26 18.4 Favored 'General case' 0 C--N 1.294 -1.806 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.995 -175.432 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.452 HG13 ' CE2' ' A' ' 5' ' ' PHE . 14.2 pt -127.28 147.06 32.16 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 CA-C-N 114.853 -1.067 . . . . 0.0 110.396 179.39 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 89.2 m-85 -140.26 147.62 50.82 Favored Pre-proline 0 C--N 1.302 -1.474 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 -177.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -62.09 132.34 38.73 Favored 'Trans proline' 0 N--CA 1.481 0.749 0 C-N-CA 123.315 2.677 . . . . 0.0 113.955 -176.617 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.443 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 77.8 t80 -61.03 -40.7 94.59 Favored 'General case' 0 C--O 1.207 -1.136 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.652 -178.406 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 8.4 m -60.45 -40.15 90.11 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.81 -175.583 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -95.25 -4.08 46.39 Favored 'General case' 0 C--N 1.312 -1.051 0 CA-C-N 115.763 -0.653 . . . . 0.0 112.193 -174.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 29.6 m-80 -125.64 15.36 8.15 Favored 'General case' 0 N--CA 1.446 -0.645 0 CA-C-O 120.427 0.156 . . . . 0.0 111.404 178.589 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 57.2 tttp -69.58 -36.2 76.04 Favored 'General case' 0 N--CA 1.471 0.616 0 CA-C-O 121.627 0.727 . . . . 0.0 109.545 -178.355 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.561 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -75.15 -22.42 58.13 Favored 'General case' 0 N--CA 1.416 -2.131 0 CA-C-N 115.681 -0.691 . . . . 0.0 111.964 176.502 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.561 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 7.8 mtmm -84.84 -54.08 4.91 Favored 'General case' 0 N--CA 1.437 -1.09 0 CA-C-N 115.743 -0.662 . . . . 0.0 112.621 179.661 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 61.4 m-85 -122.0 -4.21 9.07 Favored 'General case' 0 C--N 1.31 -1.111 0 N-CA-C 113.275 0.843 . . . . 0.0 113.275 -173.116 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.69 52.21 4.38 Favored Glycine 0 N--CA 1.468 0.826 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.103 -179.008 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 11.2 ptpt -133.01 156.27 80.24 Favored Pre-proline 0 C--N 1.306 -1.325 0 C-N-CA 123.456 0.703 . . . . 0.0 109.676 -177.464 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_exo -49.15 153.11 4.52 Favored 'Trans proline' 0 C--N 1.355 0.897 0 C-N-CA 123.781 2.987 . . . . 0.0 115.889 -177.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.3 t-20 -136.53 -173.38 3.4 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 114.545 -1.207 . . . . 0.0 109.106 179.634 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 47.5 mmtm -100.8 -14.54 17.97 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 179.222 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 4.1 mmm180 -70.79 123.53 22.17 Favored 'General case' 0 N--CA 1.436 -1.147 0 CA-C-O 121.186 0.517 . . . . 0.0 110.697 175.031 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 16.6 tppt? -68.38 126.4 29.49 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 174.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.499 ' HA3' ' CG2' ' A' ' 47' ' ' THR . . . 108.56 -19.53 31.1 Favored Glycine 0 N--CA 1.416 -2.668 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -177.013 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.436 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 16.6 t80 -76.31 -45.49 32.14 Favored 'General case' 0 C--N 1.322 -0.61 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -179.584 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 52.7 m-80 -69.91 -39.94 75.89 Favored 'General case' 0 CA--C 1.5 -0.957 0 CA-C-O 121.942 0.877 . . . . 0.0 108.957 -179.624 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 30.4 mp0 -64.87 -36.22 83.66 Favored 'General case' 0 N--CA 1.425 -1.72 0 CA-C-N 114.06 -1.427 . . . . 0.0 109.468 177.317 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.35 -31.48 68.64 Favored Glycine 0 CA--C 1.49 -1.49 0 CA-C-N 115.385 -0.825 . . . . 0.0 112.431 178.756 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.436 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 96.0 mt -58.84 -39.98 82.89 Favored 'General case' 0 C--O 1.212 -0.913 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 174.481 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 83.1 t90 -67.97 -48.7 65.11 Favored 'General case' 0 N--CA 1.432 -1.365 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.283 177.874 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 41.3 mt-10 -59.31 -43.4 92.64 Favored 'General case' 0 C--O 1.207 -1.135 0 N-CA-C 113.5 0.926 . . . . 0.0 113.5 -179.258 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 20.1 tt -71.98 -28.44 30.0 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 C-N-CA 120.23 -0.588 . . . . 0.0 112.209 -174.354 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -86.86 -17.37 33.49 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 112.062 0.393 . . . . 0.0 112.062 179.457 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 32.1 m-80 -114.46 -51.19 2.77 Favored 'General case' 0 N--CA 1.48 1.055 0 CA-C-O 121.366 0.603 . . . . 0.0 112.471 -175.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.475 ' ND2' ' HB ' ' A' ' 90' ' ' VAL . 66.8 t30 -127.93 68.16 75.0 Favored Pre-proline 0 C--N 1.305 -1.364 0 O-C-N 121.883 -0.511 . . . . 0.0 110.678 -178.369 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.4 ' HB2' HD21 ' A' ' 10' ' ' LEU . 61.6 Cg_endo -75.77 -5.83 16.86 Favored 'Trans proline' 0 C--N 1.348 0.508 0 C-N-CA 122.025 1.817 . . . . 0.0 112.208 -177.591 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 19.8 pttp -93.4 14.67 17.82 Favored 'General case' 0 C--N 1.299 -1.592 0 CA-C-N 114.737 -1.119 . . . . 0.0 110.429 -178.779 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.475 ' HB ' ' ND2' ' A' ' 87' ' ' ASN . 13.4 p -80.8 83.48 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.117 0 CA-C-O 122.581 1.181 . . . . 0.0 111.896 178.869 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -109.28 21.53 16.99 Favored 'General case' 0 C--N 1.304 -1.385 0 CA-C-O 122.475 1.131 . . . . 0.0 111.465 -178.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 77.7 m-85 -93.45 -0.13 56.55 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 114.617 -1.174 . . . . 0.0 109.028 179.005 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 14.3 m . . . . . 0 N--CA 1.444 -0.751 0 C-N-CA 124.948 1.299 . . . . 0.0 111.522 -177.176 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.7 mmm . . . . . 0 C--O 1.21 -1.017 0 CA-C-O 119.44 -0.314 . . . . 0.0 110.28 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -81.23 -7.17 59.52 Favored 'General case' 0 C--O 1.218 -0.595 0 O-C-N 124.203 0.939 . . . . 0.0 113.404 -176.387 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 47.7 ptt85 -95.77 177.29 5.83 Favored 'General case' 0 CA--C 1.511 -0.542 0 C-N-CA 118.954 -1.098 . . . . 0.0 109.587 177.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -84.45 165.75 17.87 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -177.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -131.35 125.73 33.45 Favored 'General case' 0 N--CA 1.42 -1.965 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 179.73 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 33.1 mttp -105.45 153.53 39.69 Favored Pre-proline 0 C--N 1.298 -1.656 0 CA-C-N 115.688 -0.687 . . . . 0.0 109.638 -172.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -62.44 116.51 3.56 Favored 'Trans proline' 0 N--CA 1.457 -0.667 0 N-CA-C 107.921 -1.607 . . . . 0.0 107.921 170.397 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 108.62 -10.34 35.35 Favored Glycine 0 N--CA 1.426 -1.974 0 C-N-CA 120.833 -0.698 . . . . 0.0 112.172 -175.426 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -73.09 154.96 40.18 Favored 'General case' 0 C--O 1.253 1.245 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 -178.397 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.493 HD21 ' HB2' ' A' ' 88' ' ' PRO . 79.9 mt -105.36 123.67 48.26 Favored 'General case' 0 C--N 1.294 -1.845 0 N-CA-C 110.214 -0.291 . . . . 0.0 110.214 -173.439 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.9 pp -140.28 177.56 4.05 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 CA-C-O 122.058 0.932 . . . . 0.0 112.934 -174.14 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.527 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 74.6 m-85 -110.31 129.54 55.72 Favored 'General case' 0 C--N 1.284 -2.263 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 170.662 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.404 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -108.0 118.49 36.88 Favored 'General case' 0 C--N 1.277 -2.569 0 CA-C-N 115.411 -0.813 . . . . 0.0 109.136 -176.345 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.614 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -107.14 122.64 46.91 Favored 'General case' 0 N--CA 1.4 -2.957 0 CA-C-N 115.383 -0.826 . . . . 0.0 109.384 -179.092 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.47 ' HG2' HD21 ' A' ' 53' ' ' LEU . 30.2 mtm -127.08 158.25 37.49 Favored 'General case' 0 CA--C 1.493 -1.22 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 176.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -64.17 117.23 6.84 Favored 'General case' 0 C--N 1.307 -1.255 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 178.44 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.05 -16.11 57.47 Favored Glycine 0 C--O 1.249 1.034 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 -178.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -105.47 151.04 39.65 Favored Pre-proline 0 N--CA 1.43 -1.466 0 C-N-CA 123.175 0.59 . . . . 0.0 109.623 178.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -83.12 171.69 11.3 Favored 'Trans proline' 0 N--CA 1.439 -1.685 0 C-N-CA 122.122 1.882 . . . . 0.0 107.416 169.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.489 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 70.6 m80 -61.83 109.97 1.4 Allowed 'General case' 0 CA--C 1.542 0.648 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 174.023 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 4.6 t-105 -105.15 136.79 19.14 Favored Pre-proline 0 C--N 1.305 -1.342 0 C-N-CA 123.131 0.572 . . . . 0.0 109.53 -170.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -65.02 117.84 4.9 Favored 'Trans proline' 0 N--CA 1.455 -0.754 0 C-N-CA 121.321 1.347 . . . . 0.0 110.433 177.497 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.92 166.61 24.15 Favored 'General case' 0 N--CA 1.413 -2.292 0 CA-C-O 121.279 0.561 . . . . 0.0 110.157 -175.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.473 ' HB2' ' CE2' ' A' ' 45' ' ' PHE . 31.7 ttp85 -116.68 145.83 43.17 Favored 'General case' 0 C--N 1.283 -2.303 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.554 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.6 t -76.49 123.88 33.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 105.302 -2.11 . . . . 0.0 105.302 171.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -90.93 -177.1 4.85 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -173.478 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.404 ' CD ' HH22 ' A' ' 24' ' ' ARG . 15.0 mp0 -91.09 156.68 17.72 Favored 'General case' 0 N--CA 1.423 -1.809 0 CA-C-O 121.87 0.843 . . . . 0.0 111.499 -176.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 61.5 t -112.26 126.74 27.89 Favored Pre-proline 0 C--N 1.313 -1.012 0 N-CA-C 107.038 -1.467 . . . . 0.0 107.038 175.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_endo -73.0 136.34 24.71 Favored 'Trans proline' 0 N--CA 1.431 -2.201 0 C-N-CA 121.131 1.221 . . . . 0.0 112.182 178.293 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 20.2 t70 -74.83 150.24 39.33 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 174.178 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 88.15 -4.71 85.41 Favored Glycine 0 N--CA 1.428 -1.869 0 C-N-CA 120.452 -0.88 . . . . 0.0 111.909 -175.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -67.36 94.66 0.4 Allowed 'General case' 0 N--CA 1.448 -0.528 0 CA-C-O 121.409 0.624 . . . . 0.0 111.074 176.511 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 31.3 m -83.82 1.87 3.97 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.691 178.554 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 31.1 mmtp -86.41 124.83 69.28 Favored Pre-proline 0 C--N 1.304 -1.408 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 177.086 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -65.07 134.5 39.89 Favored 'Trans proline' 0 N--CA 1.453 -0.88 0 C-N-CA 121.862 1.708 . . . . 0.0 111.976 -179.091 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -82.43 171.17 12.58 Favored 'Trans proline' 0 N--CA 1.441 -1.573 0 C-N-CA 122.176 1.917 . . . . 0.0 111.638 -179.702 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 4.4 m -78.12 7.23 6.51 Favored 'General case' 0 C--N 1.305 -1.353 0 C-N-CA 123.316 0.646 . . . . 0.0 110.511 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 41.8 m-80 70.69 18.06 6.42 Favored 'General case' 0 N--CA 1.486 1.334 0 C-N-CA 124.819 1.248 . . . . 0.0 110.213 -177.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.557 ' HE2' ' N ' ' A' ' 54' ' ' GLY . 30.3 mtpt -122.87 166.67 14.64 Favored 'General case' 0 N--CA 1.429 -1.475 0 N-CA-C 107.68 -1.23 . . . . 0.0 107.68 -179.746 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.401 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 91.8 mt -88.16 147.05 39.54 Favored Pre-proline 0 C--N 1.304 -1.388 0 C-N-CA 122.721 0.408 . . . . 0.0 110.369 -176.033 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -71.54 123.87 9.84 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.438 2.092 . . . . 0.0 110.295 177.419 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 49.3 mm -119.02 125.17 74.27 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 O-C-N 122.064 -0.398 . . . . 0.0 110.613 -176.344 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -104.77 114.52 28.79 Favored 'General case' 0 C--N 1.288 -2.104 0 C-N-CA 123.431 0.692 . . . . 0.0 109.144 177.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.417 ' HE2' ' HB2' ' A' ' 51' ' ' ALA . 96.9 m-85 -77.97 137.27 38.22 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.014 0.435 . . . . 0.0 111.681 178.035 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.473 ' CE2' ' HB2' ' A' ' 24' ' ' ARG . 70.5 m-85 -89.16 156.44 18.79 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.492 177.168 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.442 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 74.02 -20.78 1.44 Allowed Glycine 0 N--CA 1.469 0.878 0 C-N-CA 124.578 1.085 . . . . 0.0 114.454 178.734 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.2 p -119.15 -22.67 7.08 Favored 'General case' 0 C--N 1.301 -1.524 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 173.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 11.2 m170 65.87 24.7 11.27 Favored 'General case' 0 C--N 1.348 0.519 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.107 179.06 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -73.34 167.39 21.33 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 115.388 -0.824 . . . . 0.0 108.904 176.794 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.6 m -137.82 140.81 40.71 Favored 'General case' 0 C--N 1.287 -2.122 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.417 ' HB2' ' HE2' ' A' ' 44' ' ' PHE . . . -145.37 -179.32 6.58 Favored 'General case' 0 C--N 1.293 -1.859 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.131 -178.202 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.401 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 83.4 m-85 -132.2 110.71 10.84 Favored 'General case' 0 C--O 1.246 0.886 0 CA-C-N 115.217 -0.902 . . . . 0.0 109.427 177.193 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.532 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 93.8 mt -129.48 154.64 46.8 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.656 -177.415 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.557 ' N ' ' HE2' ' A' ' 39' ' ' LYS . . . -95.87 176.34 33.32 Favored Glycine 0 N--CA 1.432 -1.585 0 C-N-CA 120.016 -1.088 . . . . 0.0 111.301 -174.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -66.22 -7.53 17.63 Favored 'Trans proline' 0 C--O 1.239 0.566 0 C-N-CA 122.966 2.444 . . . . 0.0 112.311 -178.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 26.7 mtpp -97.3 -15.16 20.9 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.238 177.054 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.532 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 40.9 m-20 -93.39 -14.38 26.89 Favored 'General case' 0 CA--C 1.49 -1.346 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.084 -178.488 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.446 ' HA ' ' O ' ' A' ' 12' ' ' PHE . 17.9 pt -119.12 148.58 21.96 Favored 'Isoleucine or valine' 0 C--O 1.268 2.04 0 CA-C-O 122.482 1.134 . . . . 0.0 112.849 -171.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 80.8 m-85 -136.08 133.25 19.56 Favored Pre-proline 0 C--N 1.292 -1.895 0 CA-C-N 113.885 -1.507 . . . . 0.0 106.951 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.49 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 35.8 Cg_endo -64.12 127.91 20.45 Favored 'Trans proline' 0 C--N 1.31 -1.469 0 C-N-CA 122.881 2.388 . . . . 0.0 113.147 -177.2 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.527 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 72.0 t80 -58.86 -35.38 72.85 Favored 'General case' 0 C--O 1.197 -1.674 0 CA-C-N 114.062 -1.426 . . . . 0.0 112.915 -174.78 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.427 ' HB3' ' OE1' ' A' ' 63' ' ' GLU . 28.2 t -67.63 -52.19 41.15 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.191 0.52 . . . . 0.0 110.478 -177.808 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.49 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 2.6 mp0 -81.32 -5.67 58.07 Favored 'General case' 0 C--N 1.315 -0.923 0 CA-C-N 115.906 -0.588 . . . . 0.0 112.128 -175.58 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.409 ' OD1' ' HE2' ' A' ' 67' ' ' LYS . 24.2 m-80 -126.59 15.12 7.61 Favored 'General case' 0 C--N 1.311 -1.079 0 C-N-CA 122.893 0.477 . . . . 0.0 111.557 -179.558 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -67.85 -35.89 79.36 Favored 'General case' 0 N--CA 1.476 0.869 0 CA-C-O 121.722 0.772 . . . . 0.0 110.093 -179.488 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.606 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -72.01 -28.31 63.31 Favored 'General case' 0 N--CA 1.408 -2.566 0 CA-C-N 115.648 -0.705 . . . . 0.0 111.99 176.864 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.606 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 7.0 mtmm -80.2 -58.17 3.27 Favored 'General case' 0 N--CA 1.439 -0.979 0 CA-C-N 115.729 -0.668 . . . . 0.0 112.452 179.759 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 76.4 m-85 -113.67 -10.98 13.02 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -172.368 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -78.4 56.22 4.09 Favored Glycine 0 C--N 1.314 -0.648 0 C-N-CA 121.332 -0.461 . . . . 0.0 112.834 -177.556 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.419 ' O ' ' HE1' ' A' ' 77' ' ' PHE . 4.5 ptpp? -132.54 147.42 65.53 Favored Pre-proline 0 C--N 1.303 -1.416 0 CA-C-O 119.244 -0.408 . . . . 0.0 110.084 178.702 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.445 ' HA ' ' OD1' ' A' ' 78' ' ' ASN . 87.0 Cg_exo -50.2 156.92 3.36 Favored 'Trans proline' 0 C--N 1.355 0.914 0 C-N-CA 124.031 3.154 . . . . 0.0 114.803 -179.413 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -143.04 -173.34 3.88 Favored 'General case' 0 N--CA 1.433 -1.29 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.532 179.189 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.411 ' HD3' ' N ' ' A' ' 73' ' ' LYS . 0.1 OUTLIER -93.79 1.11 56.55 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.047 -179.809 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 30.9 mmt180 -82.79 120.6 25.83 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.687 176.72 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.441 ' HD3' ' N ' ' A' ' 76' ' ' GLY . 8.1 tmtt? -70.03 127.15 31.85 Favored 'General case' 0 C--N 1.311 -1.084 0 N-CA-C 106.744 -1.576 . . . . 0.0 106.744 175.316 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.442 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 106.8 -25.41 22.7 Favored Glycine 0 CA--C 1.501 -0.817 0 N-CA-C 110.598 -1.001 . . . . 0.0 110.598 -178.821 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.419 ' HE1' ' O ' ' A' ' 70' ' ' LYS . 54.1 t80 -72.11 -42.06 66.51 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-O 121.74 0.781 . . . . 0.0 109.557 -177.432 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.445 ' OD1' ' HA ' ' A' ' 71' ' ' PRO . 87.2 m-20 -79.07 -33.81 44.24 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.668 -173.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -71.55 -33.37 69.06 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 108.819 -0.808 . . . . 0.0 108.819 175.111 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -70.34 -37.26 70.52 Favored Glycine 0 N--CA 1.432 -1.601 0 CA-C-N 115.561 -0.745 . . . . 0.0 111.432 177.395 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 43.9 tp -59.74 -33.58 71.83 Favored 'General case' 0 N--CA 1.434 -1.249 0 C-N-CA 124.007 0.923 . . . . 0.0 108.855 175.03 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 82.0 t90 -72.46 -51.02 21.98 Favored 'General case' 0 N--CA 1.434 -1.236 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.022 175.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 35.6 mt-10 -53.8 -49.76 67.63 Favored 'General case' 0 C--O 1.206 -1.189 0 N-CA-C 112.797 0.666 . . . . 0.0 112.797 179.746 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 19.3 tt -67.94 -23.87 29.69 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.242 0 N-CA-C 112.573 0.583 . . . . 0.0 112.573 -173.782 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -94.31 -22.67 18.21 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-O 121.409 0.623 . . . . 0.0 110.686 -176.417 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 28.4 m-80 -105.97 -55.17 2.37 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-O 121.435 0.636 . . . . 0.0 111.785 -176.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 67.4 t30 -127.62 72.61 78.13 Favored Pre-proline 0 C--N 1.312 -1.032 0 C-N-CA 119.969 -0.693 . . . . 0.0 110.228 179.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.493 ' HB2' HD21 ' A' ' 10' ' ' LEU . 57.0 Cg_endo -74.81 -6.76 18.57 Favored 'Trans proline' 0 C--O 1.221 -0.326 0 C-N-CA 122.128 1.886 . . . . 0.0 112.815 -176.223 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 25.4 pttm -97.6 17.75 17.06 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.986 -178.085 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 14.9 p -75.52 113.68 14.66 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.996 0 CA-C-O 122.575 1.179 . . . . 0.0 112.947 -178.296 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -113.5 143.89 43.77 Favored 'General case' 0 N--CA 1.423 -1.817 0 N-CA-C 105.082 -2.192 . . . . 0.0 105.082 174.019 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 24.5 p90 -114.76 161.48 18.12 Favored 'General case' 0 C--N 1.302 -1.458 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.007 -177.689 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 20.4 m . . . . . 0 N--CA 1.471 0.625 0 C-N-CA 125.767 1.627 . . . . 0.0 110.902 -179.612 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.3 mtt . . . . . 0 CA--C 1.506 -0.746 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -68.31 -15.66 63.65 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 112.767 0.655 . . . . 0.0 112.767 -179.08 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.554 ' HG3' ' OD1' ' A' ' 4' ' ' ASP . 8.2 ptm180 -95.86 -39.67 9.7 Favored 'General case' 0 C--N 1.312 -1.022 0 N-CA-C 113.037 0.754 . . . . 0.0 113.037 -179.344 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . 0.554 ' OD1' ' HG3' ' A' ' 3' ' ' ARG . 4.9 p-10 -152.69 162.4 41.3 Favored 'General case' 0 C--N 1.275 -2.673 0 CA-C-N 114.677 -1.147 . . . . 0.0 110.383 -177.46 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 90.9 m-85 -125.76 120.37 30.43 Favored 'General case' 0 N--CA 1.425 -1.717 0 N-CA-C 107.753 -1.202 . . . . 0.0 107.753 178.23 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.506 ' H ' ' HB2' ' A' ' 9' ' ' ASP . 32.3 mttp -104.76 158.36 32.18 Favored Pre-proline 0 C--N 1.298 -1.661 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -174.793 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.484 ' HB3' ' HA ' ' A' ' 27' ' ' GLU . 37.1 Cg_exo -63.46 117.02 3.99 Favored 'Trans proline' 0 N--CA 1.451 -0.986 0 N-CA-C 107.385 -1.813 . . . . 0.0 107.385 167.296 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 101.66 -1.42 52.72 Favored Glycine 0 N--CA 1.435 -1.421 0 C-N-CA 121.045 -0.598 . . . . 0.0 112.458 -175.602 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.506 ' HB2' ' H ' ' A' ' 6' ' ' LYS . 4.9 t70 -78.11 154.94 30.82 Favored 'General case' 0 C--O 1.254 1.339 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 64.3 mt -102.54 124.83 48.82 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.44 -172.542 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.41 HD11 HD12 ' A' ' 42' ' ' ILE . 7.9 pt -141.39 -177.11 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.825 0 CA-C-O 122.295 1.045 . . . . 0.0 112.82 -174.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.509 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 76.4 m-85 -120.83 126.49 50.2 Favored 'General case' 0 N--CA 1.417 -2.099 0 C-N-CA 126.232 1.813 . . . . 0.0 106.241 170.771 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.479 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -108.96 128.85 55.3 Favored 'General case' 0 C--N 1.27 -2.859 0 O-C-N 123.625 0.578 . . . . 0.0 109.632 -178.022 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.622 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -114.36 122.13 45.74 Favored 'General case' 0 N--CA 1.407 -2.596 0 CA-C-N 116.136 -0.484 . . . . 0.0 109.707 -179.593 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 63.4 mtm -116.31 158.83 22.8 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 109.417 -0.586 . . . . 0.0 109.417 177.218 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.1 tttt -63.94 117.13 6.56 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 174.454 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.54 -5.52 54.73 Favored Glycine 0 C--N 1.315 -0.622 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -176.858 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.429 ' HA ' ' HD3' ' A' ' 19' ' ' PRO . 21.8 m-85 -126.51 136.57 28.85 Favored Pre-proline 0 N--CA 1.436 -1.164 0 N-CA-C 112.326 0.491 . . . . 0.0 112.326 -179.782 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 18' ' ' TYR . 14.3 Cg_exo -70.21 171.12 15.54 Favored 'Trans proline' 0 N--CA 1.444 -1.399 0 C-N-CA 122.212 1.941 . . . . 0.0 108.628 169.427 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.512 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 80.2 m80 -63.55 110.75 2.09 Favored 'General case' 0 C--N 1.312 -1.049 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.722 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 10.4 t-105 -107.88 136.65 19.7 Favored Pre-proline 0 C--N 1.306 -1.304 0 C-N-CA 123.316 0.646 . . . . 0.0 109.885 -171.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -62.97 118.14 5.04 Favored 'Trans proline' 0 C--O 1.244 0.782 0 C-N-CA 122.214 1.943 . . . . 0.0 111.137 178.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -139.7 166.2 25.24 Favored 'General case' 0 N--CA 1.409 -2.5 0 CA-C-O 121.525 0.679 . . . . 0.0 111.285 -176.145 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.526 HH21 ' CD ' ' A' ' 27' ' ' GLU . 17.2 ttt-85 -111.49 139.01 47.27 Favored 'General case' 0 C--N 1.285 -2.204 0 C-N-CA 124.179 0.992 . . . . 0.0 108.404 177.729 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 58.9 t -75.84 121.86 28.6 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 N-CA-C 104.986 -2.228 . . . . 0.0 104.986 170.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.401 ' HB3' ' HB2' ' A' ' 41' ' ' PRO . 3.9 t0 -84.02 172.61 11.86 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 -173.275 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.526 ' CD ' HH21 ' A' ' 24' ' ' ARG . 4.4 mp0 -92.62 123.23 35.76 Favored 'General case' 0 N--CA 1.411 -2.398 0 CA-C-O 122.256 1.026 . . . . 0.0 112.522 -177.555 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.7 p -106.1 126.67 30.01 Favored Pre-proline 0 N--CA 1.425 -1.71 0 N-CA-C 107.797 -1.186 . . . . 0.0 107.797 174.105 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_endo -73.67 136.11 22.85 Favored 'Trans proline' 0 N--CA 1.445 -1.35 0 C-N-CA 121.481 1.454 . . . . 0.0 111.718 178.478 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.3 t0 -77.83 147.82 35.0 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 107.508 -1.293 . . . . 0.0 107.508 174.369 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 83.49 5.5 88.45 Favored Glycine 0 N--CA 1.427 -1.924 0 C-N-CA 120.557 -0.83 . . . . 0.0 111.678 -175.32 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -60.67 138.32 58.09 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-O 121.117 0.484 . . . . 0.0 110.59 176.263 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.7 m -62.91 -22.09 29.6 Favored 'Isoleucine or valine' 0 C--O 1.243 0.725 0 CA-C-N 115.476 -0.784 . . . . 0.0 111.986 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 23.5 mmmt -108.48 118.06 52.99 Favored Pre-proline 0 N--CA 1.416 -2.167 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 172.142 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -78.58 155.98 28.04 Favored 'Trans proline' 0 N--CA 1.453 -0.887 0 C-N-CA 121.785 1.657 . . . . 0.0 111.957 -179.732 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -64.82 136.9 51.17 Favored 'Trans proline' 0 N--CA 1.451 -1.022 0 C-N-CA 122.18 1.92 . . . . 0.0 111.857 179.239 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.0 m -72.34 9.05 1.11 Allowed 'General case' 0 CA--C 1.567 1.6 0 C-N-CA 125.399 1.479 . . . . 0.0 112.392 -177.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER 84.27 8.12 0.53 Allowed 'General case' 0 N--CA 1.503 2.211 0 C-N-CA 126.986 2.114 . . . . 0.0 108.221 -171.814 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 86.5 mttt -109.08 162.24 14.43 Favored 'General case' 0 N--CA 1.414 -2.266 0 CA-C-N 113.036 -1.893 . . . . 0.0 109.637 176.268 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 84.4 mt -106.81 146.29 32.79 Favored Pre-proline 0 C--N 1.282 -2.329 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 178.654 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.401 ' HB2' ' HB3' ' A' ' 26' ' ' ASP . 60.1 Cg_endo -73.62 128.95 13.1 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 121.888 1.725 . . . . 0.0 109.395 176.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.429 HG21 ' CB ' ' A' ' 13' ' ' ALA . 37.0 mm -118.41 125.73 74.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 O-C-N 121.987 -0.446 . . . . 0.0 110.799 -174.166 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -109.71 115.34 29.68 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 176.726 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -79.04 139.09 38.22 Favored 'General case' 0 C--N 1.311 -1.088 0 CA-C-O 121.0 0.429 . . . . 0.0 111.794 179.003 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 -90.26 160.4 16.19 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.385 177.141 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.529 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 73.06 -21.53 1.01 Allowed Glycine 0 C--N 1.311 -0.828 0 C-N-CA 124.932 1.253 . . . . 0.0 114.315 179.228 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.435 HG23 ' HA3' ' A' ' 76' ' ' GLY . 37.1 p -119.98 -22.3 6.78 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-N 117.559 0.68 . . . . 0.0 109.685 173.037 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.1 m170 66.88 24.87 9.62 Favored 'General case' 0 C--N 1.35 0.629 0 CA-C-N 115.406 -0.815 . . . . 0.0 111.153 -179.517 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -71.94 167.17 20.65 Favored 'General case' 0 C--N 1.347 0.462 0 CA-C-N 115.179 -0.919 . . . . 0.0 108.728 175.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 3.9 m -137.45 145.95 43.74 Favored 'General case' 0 C--N 1.289 -2.034 0 O-C-N 121.576 -0.702 . . . . 0.0 109.581 -178.678 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -150.57 178.43 9.08 Favored 'General case' 0 C--N 1.308 -1.197 0 O-C-N 123.533 0.521 . . . . 0.0 111.404 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.2 m-85 -134.26 114.74 13.35 Favored 'General case' 0 C--O 1.262 1.745 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.575 175.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.479 HD12 ' HB1' ' A' ' 13' ' ' ALA . 94.6 mt -130.99 158.75 39.45 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 109.19 -0.67 . . . . 0.0 109.19 -179.159 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -91.0 172.55 36.92 Favored Glycine 0 N--CA 1.429 -1.796 0 N-CA-C 110.202 -1.159 . . . . 0.0 110.202 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.414 ' HA ' HD11 ' A' ' 58' ' ' ILE . 36.4 Cg_endo -65.89 -6.84 15.14 Favored 'Trans proline' 0 C--O 1.21 -0.91 0 C-N-CA 123.046 2.497 . . . . 0.0 112.438 -178.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 8.2 ptmm? -97.52 -5.02 36.76 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 115.333 -0.849 . . . . 0.0 111.764 179.518 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -115.86 5.8 14.14 Favored 'General case' 0 C--N 1.293 -1.888 0 N-CA-C 112.511 0.56 . . . . 0.0 112.511 -177.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.414 HD11 ' HA ' ' A' ' 55' ' ' PRO . 16.8 pt -126.53 150.63 32.37 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 CA-C-N 115.073 -0.967 . . . . 0.0 110.487 -178.639 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 -131.94 135.32 26.45 Favored Pre-proline 0 C--O 1.188 -2.167 0 N-CA-C 107.596 -1.261 . . . . 0.0 107.596 177.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.545 ' HB2' ' OE1' ' A' ' 63' ' ' GLU . 37.8 Cg_endo -66.82 131.01 24.53 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 C-N-CA 122.841 2.361 . . . . 0.0 114.007 -177.791 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.509 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 65.4 t80 -63.54 -33.79 76.36 Favored 'General case' 0 C--O 1.204 -1.328 0 CA-C-N 114.889 -1.05 . . . . 0.0 112.159 -174.331 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.15 -54.31 35.81 Favored 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -177.121 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.545 ' OE1' ' HB2' ' A' ' 60' ' ' PRO . 2.1 pm0 -89.68 1.32 56.2 Favored 'General case' 0 N--CA 1.433 -1.298 0 N-CA-C 114.276 1.213 . . . . 0.0 114.276 -178.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 26.8 m-80 -122.8 15.18 10.11 Favored 'General case' 0 C--N 1.314 -0.935 0 C-N-CA 123.327 0.651 . . . . 0.0 111.132 175.613 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.46 ' HZ1' ' CG ' ' A' ' 85' ' ' ASP . 16.5 ttmm -65.13 -33.32 75.75 Favored 'General case' 0 N--CA 1.476 0.855 0 CA-C-O 121.579 0.704 . . . . 0.0 110.189 179.473 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.599 ' OE1' ' HG3' ' A' ' 67' ' ' LYS . 0.0 OUTLIER -80.25 -28.95 38.35 Favored 'General case' 0 N--CA 1.403 -2.819 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.098 177.33 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.599 ' HG3' ' OE1' ' A' ' 66' ' ' GLU . 8.3 mttm -76.71 -59.09 2.92 Favored 'General case' 0 CA--C 1.505 -0.778 0 CA-C-N 115.721 -0.672 . . . . 0.0 112.253 -179.24 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 -112.1 -4.28 14.49 Favored 'General case' 0 C--N 1.301 -1.507 0 N-CA-C 112.136 0.421 . . . . 0.0 112.136 -173.443 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -75.64 51.76 2.68 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 121.715 -0.279 . . . . 0.0 113.11 -179.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 4.3 ptpp? -132.44 135.71 26.75 Favored Pre-proline 0 C--N 1.311 -1.09 0 O-C-N 122.459 -0.436 . . . . 0.0 110.161 179.144 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -66.91 128.24 18.42 Favored 'Trans proline' 0 C--O 1.25 1.111 0 C-N-CA 122.787 2.325 . . . . 0.0 116.316 -171.178 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -84.69 -168.93 2.39 Favored 'General case' 0 CA--C 1.483 -1.633 0 CA-C-N 113.784 -1.553 . . . . 0.0 108.165 175.311 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.438 ' HD3' ' HA ' ' A' ' 73' ' ' LYS . 39.4 mmtm -108.53 10.49 27.19 Favored 'General case' 0 C--N 1.287 -2.146 0 CA-C-O 121.842 0.829 . . . . 0.0 109.475 175.36 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . 0.427 HH21 HG21 ' A' ' 47' ' ' THR . 4.5 mmm-85 -77.45 122.8 25.69 Favored 'General case' 0 N--CA 1.417 -2.099 0 CA-C-N 115.04 -0.982 . . . . 0.0 109.199 170.664 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 15.6 tppt? -65.17 129.54 40.1 Favored 'General case' 0 N--CA 1.429 -1.523 0 N-CA-C 107.551 -1.278 . . . . 0.0 107.551 173.58 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.529 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.21 -25.19 20.9 Favored Glycine 0 N--CA 1.415 -2.742 0 N-CA-C 110.271 -1.132 . . . . 0.0 110.271 -176.142 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . . . . . . . . . 22.3 t80 -76.63 -41.13 47.03 Favored 'General case' 0 N--CA 1.448 -0.561 0 CA-C-O 121.356 0.598 . . . . 0.0 109.39 -178.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.484 ' N ' HD22 ' A' ' 78' ' ' ASN . 0.7 OUTLIER -71.31 -43.85 66.28 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 -176.289 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 25.2 mp0 -63.11 -41.77 99.42 Favored 'General case' 0 N--CA 1.428 -1.554 0 CA-C-N 113.577 -1.647 . . . . 0.0 109.634 177.712 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -65.38 -37.6 94.02 Favored Glycine 0 N--CA 1.44 -1.052 0 CA-C-N 115.449 -0.796 . . . . 0.0 112.804 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 87.9 mt -59.56 -35.12 73.62 Favored 'General case' 0 CA--C 1.506 -0.723 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 176.094 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 74.3 t90 -74.29 -50.32 19.38 Favored 'General case' 0 N--CA 1.425 -1.712 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.295 177.501 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 26.8 mt-10 -53.74 -49.94 67.06 Favored 'General case' 0 C--O 1.188 -2.175 0 N-CA-C 112.293 0.479 . . . . 0.0 112.293 -179.512 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.8 tt -67.99 -23.48 29.09 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.669 0 N-CA-C 112.256 0.465 . . . . 0.0 112.256 -173.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . 0.46 ' CG ' ' HZ1' ' A' ' 65' ' ' LYS . 15.2 t70 -94.21 -32.52 13.66 Favored 'General case' 0 C--N 1.305 -1.36 0 CA-C-O 121.497 0.665 . . . . 0.0 110.05 -175.053 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.516 HD22 ' N ' ' A' ' 86' ' ' ASN . 0.8 OUTLIER -103.43 -44.89 5.02 Favored 'General case' 0 C--O 1.257 1.456 0 CA-C-O 121.911 0.862 . . . . 0.0 111.504 -176.679 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 60.7 t30 -131.76 61.32 57.65 Favored Pre-proline 0 C--N 1.296 -1.73 0 C-N-CA 119.983 -0.687 . . . . 0.0 112.329 -176.595 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -71.12 -7.68 21.91 Favored 'Trans proline' 0 C--N 1.372 1.789 0 C-N-CA 122.19 1.926 . . . . 0.0 110.465 179.078 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . 0.409 ' H ' ' HG2' ' A' ' 89' ' ' LYS . 22.7 pttm -102.88 20.52 17.27 Favored 'General case' 0 C--N 1.307 -1.249 0 CA-C-N 113.159 -1.837 . . . . 0.0 109.197 -175.49 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 7.4 p -53.56 108.17 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.847 0 CA-C-O 122.15 0.976 . . . . 0.0 112.452 -179.107 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.9 mmmp? 74.65 -66.87 0.28 Allowed 'General case' 0 CA--C 1.492 -1.282 0 CA-C-N 114.218 -1.356 . . . . 0.0 114.418 -179.089 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 46.2 t80 61.68 177.65 0.12 Allowed 'General case' 0 C--O 1.265 1.869 0 O-C-N 124.382 1.051 . . . . 0.0 110.02 -174.664 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 23.0 m . . . . . 0 C--N 1.309 -1.156 0 N-CA-C 112.241 0.46 . . . . 0.0 112.241 -177.865 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.0 mmt . . . . . 0 CA--C 1.495 -1.158 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -84.32 55.39 3.34 Favored 'General case' 0 C--O 1.248 1.012 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 173.2 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 14.0 ptp180 168.71 -164.92 0.01 OUTLIER 'General case' 0 N--CA 1.429 -1.496 0 C-N-CA 130.398 3.479 . . . . 0.0 104.451 -178.566 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . 0.291 3.6 p30 58.55 105.04 0.02 OUTLIER 'General case' 0 CA--C 1.495 -1.136 0 C-N-CA 125.061 1.344 . . . . 0.0 112.786 -178.46 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -113.45 123.46 50.1 Favored 'General case' 0 N--CA 1.397 -3.124 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.399 -172.113 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 25.9 mtmm -120.67 156.65 55.82 Favored Pre-proline 0 C--N 1.274 -2.677 0 CA-C-N 113.886 -1.506 . . . . 0.0 107.695 -172.287 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.444 ' HB3' ' HA ' ' A' ' 27' ' ' GLU . 52.5 Cg_exo -57.4 120.94 9.19 Favored 'Trans proline' 0 N--CA 1.461 -0.436 0 C-N-CA 121.825 1.683 . . . . 0.0 110.566 176.311 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 116.22 -24.28 10.03 Favored Glycine 0 N--CA 1.426 -2.029 0 CA-C-O 119.138 -0.812 . . . . 0.0 113.452 -178.426 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 32.8 m-20 -63.3 137.31 58.14 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 117.769 0.784 . . . . 0.0 111.725 -179.181 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 95.6 mt -90.18 126.58 35.86 Favored 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 176.64 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.8 pp -142.08 -174.97 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 CA-C-O 122.197 0.998 . . . . 0.0 112.899 -174.497 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 34.3 m-85 -115.71 130.0 56.69 Favored 'General case' 0 C--N 1.28 -2.431 0 CA-C-N 114.083 -1.417 . . . . 0.0 107.416 170.335 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.621 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -107.43 114.36 28.31 Favored 'General case' 0 C--N 1.275 -2.654 0 CA-C-N 114.866 -1.061 . . . . 0.0 109.426 -173.372 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.616 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.9 OUTLIER -103.76 128.24 51.16 Favored 'General case' 0 C--N 1.264 -3.129 0 CA-C-N 114.343 -1.299 . . . . 0.0 109.54 -178.597 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.402 ' HB2' ' HB2' ' A' ' 18' ' ' TYR . 68.2 mtm -113.84 158.25 21.27 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 108.567 -0.901 . . . . 0.0 108.567 178.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -70.26 116.77 11.0 Favored 'General case' 0 C--N 1.308 -1.208 0 C-N-CA 120.607 -0.437 . . . . 0.0 109.879 -178.626 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 93.99 0.11 66.36 Favored Glycine 0 N--CA 1.448 -0.518 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.97 178.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.402 ' HB2' ' HB2' ' A' ' 15' ' ' MET . 99.5 m-85 -129.75 152.23 79.47 Favored Pre-proline 0 N--CA 1.439 -0.996 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 -177.825 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -68.97 170.33 15.87 Favored 'Trans proline' 0 N--CA 1.457 -0.652 0 C-N-CA 122.4 2.067 . . . . 0.0 112.197 177.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 57.5 m80 -71.5 114.26 9.4 Favored 'General case' 0 CA--C 1.552 1.02 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.605 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 11.1 t-105 -101.35 136.91 19.55 Favored Pre-proline 0 C--N 1.31 -1.127 0 C-N-CA 123.142 0.577 . . . . 0.0 109.468 -176.604 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -64.77 117.87 4.91 Favored 'Trans proline' 0 CA--C 1.542 0.911 0 C-N-CA 121.978 1.786 . . . . 0.0 110.741 177.624 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -146.55 167.12 24.5 Favored 'General case' 0 N--CA 1.426 -1.66 0 CA-C-O 121.242 0.544 . . . . 0.0 111.214 -174.512 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.411 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 41.9 ttt-85 -115.4 143.52 45.17 Favored 'General case' 0 C--N 1.291 -1.965 0 N-CA-C 109.582 -0.525 . . . . 0.0 109.582 179.552 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 64.9 t -79.21 114.2 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.744 0 N-CA-C 104.385 -2.45 . . . . 0.0 104.385 168.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.439 ' CG ' ' HZ2' ' A' ' 91' ' ' LYS . 4.3 t70 -90.74 -179.55 5.55 Favored 'General case' 0 C--N 1.29 -1.985 0 C-N-CA 120.117 -0.633 . . . . 0.0 110.878 -171.45 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.444 ' HA ' ' HB3' ' A' ' 7' ' ' PRO . 32.2 mp0 -92.61 151.23 20.24 Favored 'General case' 0 N--CA 1.439 -0.993 0 CA-C-O 121.948 0.88 . . . . 0.0 112.593 -175.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 8.1 p -113.74 130.74 23.52 Favored Pre-proline 0 N--CA 1.43 -1.454 0 N-CA-C 107.324 -1.362 . . . . 0.0 107.324 176.209 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -66.2 139.12 54.07 Favored 'Trans proline' 0 C--O 1.248 0.996 0 C-N-CA 122.41 2.073 . . . . 0.0 114.108 -177.167 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.5 m-20 -59.17 129.87 44.19 Favored 'General case' 0 CA--C 1.505 -0.762 0 CA-C-N 115.3 -0.864 . . . . 0.0 108.86 174.2 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 110.4 -17.33 28.75 Favored Glycine 0 C--N 1.297 -1.612 0 C-N-CA 120.364 -0.922 . . . . 0.0 111.181 -178.235 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -66.3 108.54 2.36 Favored 'General case' 0 N--CA 1.446 -0.673 0 CA-C-O 121.087 0.47 . . . . 0.0 109.766 175.011 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.9 m -79.01 6.42 1.07 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 115.51 -0.768 . . . . 0.0 113.005 -178.323 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 31.5 mmtp -83.59 118.32 71.15 Favored Pre-proline 0 C--N 1.301 -1.507 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.203 178.51 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -80.58 163.71 21.35 Favored 'Trans proline' 0 C--O 1.249 1.065 0 C-N-CA 122.186 1.924 . . . . 0.0 111.146 177.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -59.88 127.56 23.82 Favored 'Trans proline' 0 N--CA 1.452 -0.96 0 C-N-CA 121.825 1.683 . . . . 0.0 111.193 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.494 ' O ' ' HB2' ' A' ' 38' ' ' ASN . 3.2 m -95.53 8.94 41.86 Favored 'General case' 0 C--N 1.293 -1.857 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.424 -175.12 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . 0.494 ' HB2' ' O ' ' A' ' 37' ' ' THR . 25.4 m-80 86.33 8.98 0.26 Allowed 'General case' 0 N--CA 1.493 1.725 0 C-N-CA 125.57 1.548 . . . . 0.0 109.065 -169.54 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.435 ' HE2' ' N ' ' A' ' 54' ' ' GLY . 8.9 mmpt? -124.12 155.94 37.54 Favored 'General case' 0 N--CA 1.429 -1.518 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 175.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 87.8 mt -128.41 155.59 78.32 Favored Pre-proline 0 C--N 1.283 -2.298 0 C-N-CA 125.306 1.442 . . . . 0.0 107.253 178.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -71.22 122.8 9.05 Favored 'Trans proline' 0 CA--C 1.536 0.617 0 C-N-CA 121.697 1.598 . . . . 0.0 110.679 177.552 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.462 HG13 ' HB2' ' A' ' 53' ' ' LEU . 49.2 mm -122.51 124.68 71.3 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.083 0 CA-C-O 120.753 0.311 . . . . 0.0 110.355 -176.377 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 80.9 t80 -106.96 116.41 31.87 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 178.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 62.2 m-85 -79.27 132.09 36.36 Favored 'General case' 0 C--O 1.244 0.805 0 CA-C-O 121.016 0.436 . . . . 0.0 110.923 179.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.411 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 66.9 m-85 -82.81 158.6 22.71 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.029 178.829 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.51 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 74.99 -20.11 1.97 Allowed Glycine 0 C--O 1.256 1.473 0 C-N-CA 124.513 1.054 . . . . 0.0 114.454 178.787 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.537 HG23 ' HA3' ' A' ' 76' ' ' GLY . 31.2 p -119.32 -23.88 6.57 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 122.237 -0.566 . . . . 0.0 109.957 175.273 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 44.8 m170 67.74 23.09 8.71 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.432 -179.519 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -74.98 166.43 23.67 Favored 'General case' 0 N--CA 1.452 -0.336 0 N-CA-C 108.197 -1.038 . . . . 0.0 108.197 176.352 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.5 m -137.11 145.71 44.21 Favored 'General case' 0 C--N 1.286 -2.192 0 N-CA-C 109.195 -0.668 . . . . 0.0 109.195 -179.758 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -146.76 179.52 7.51 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 123.136 0.575 . . . . 0.0 109.71 -179.526 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -131.75 109.29 10.05 Favored 'General case' 0 N--CA 1.432 -1.339 0 N-CA-C 109.003 -0.739 . . . . 0.0 109.003 176.488 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.621 HD12 ' HB1' ' A' ' 13' ' ' ALA . 88.7 mt -130.26 149.29 52.02 Favored 'General case' 0 C--N 1.287 -2.145 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 -178.826 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.483 ' HA3' ' O ' ' A' ' 38' ' ' ASN . . . -95.37 178.07 35.29 Favored Glycine 0 N--CA 1.417 -2.57 0 C-N-CA 119.707 -1.235 . . . . 0.0 112.104 -174.059 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.1 -9.3 16.6 Favored 'Trans proline' 0 N--CA 1.479 0.667 0 C-N-CA 123.224 2.616 . . . . 0.0 111.831 179.163 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 42.6 mtmt -98.29 -1.57 41.5 Favored 'General case' 0 N--CA 1.431 -1.385 0 CA-C-N 114.879 -1.055 . . . . 0.0 110.705 -179.653 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.54 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 36.8 m-20 -115.22 -9.65 12.22 Favored 'General case' 0 CA--C 1.5 -0.957 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.484 -179.436 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 9.5 pt -119.91 152.71 22.65 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.127 0 CA-C-N 115.731 -0.668 . . . . 0.0 111.751 -173.562 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -138.99 147.59 54.42 Favored Pre-proline 0 C--N 1.297 -1.68 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 -178.416 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.533 ' HG2' ' OE2' ' A' ' 63' ' ' GLU . 11.7 Cg_endo -58.11 139.61 91.1 Favored 'Trans proline' 0 CA--C 1.516 -0.383 0 C-N-CA 122.758 2.305 . . . . 0.0 114.432 -175.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.403 ' O ' ' HB3' ' A' ' 65' ' ' LYS . 16.3 t80 -65.18 -35.84 82.33 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 115.214 -0.903 . . . . 0.0 111.451 177.151 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 10.5 m -48.91 -57.19 6.84 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 112.953 0.723 . . . . 0.0 112.953 -175.319 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.533 ' OE2' ' HG2' ' A' ' 60' ' ' PRO . 0.0 OUTLIER -95.79 -14.43 23.29 Favored 'General case' 0 N--CA 1.432 -1.352 0 N-CA-C 114.903 1.446 . . . . 0.0 114.903 178.867 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.454 ' HB2' ' O ' ' A' ' 60' ' ' PRO . 22.6 m-80 -88.85 -8.0 55.12 Favored 'General case' 0 C--N 1.304 -1.373 0 O-C-N 121.681 -0.637 . . . . 0.0 112.648 179.221 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.418 ' O ' ' HA3' ' A' ' 69' ' ' GLY . 11.6 ptmm? -60.52 -38.28 83.88 Favored 'General case' 0 C--O 1.201 -1.466 0 CA-C-O 121.182 0.515 . . . . 0.0 111.308 -176.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 55.9 mm-40 -82.3 -33.85 28.89 Favored 'General case' 0 CA--C 1.477 -1.832 0 C-N-CA 119.453 -0.899 . . . . 0.0 112.426 177.494 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 29.9 mtmm -67.52 -58.92 3.87 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 124.725 1.265 . . . . 0.0 111.526 -176.118 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 84.4 m-85 -111.66 -1.87 15.57 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-O 121.551 0.691 . . . . 0.0 111.447 -175.632 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . 0.418 ' HA3' ' O ' ' A' ' 65' ' ' LYS . . . -91.46 54.68 3.13 Favored Glycine 0 N--CA 1.429 -1.775 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 177.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.497 ' HA ' ' HE3' ' A' ' 70' ' ' LYS . 0.0 OUTLIER -117.93 149.06 44.68 Favored Pre-proline 0 C--N 1.299 -1.623 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 177.709 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.501 ' HB3' ' OD1' ' A' ' 78' ' ' ASN . 70.2 Cg_exo -49.43 146.65 13.8 Favored 'Trans proline' 0 C--O 1.243 0.727 0 C-N-CA 123.338 2.692 . . . . 0.0 114.868 -176.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -131.0 -171.06 2.48 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 114.965 -1.016 . . . . 0.0 109.829 -178.617 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 45.9 mmtm -104.9 -11.05 16.91 Favored 'General case' 0 C--N 1.308 -1.203 0 CA-C-O 121.235 0.541 . . . . 0.0 109.618 179.538 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 3.2 mmm180 -73.57 121.64 20.96 Favored 'General case' 0 N--CA 1.43 -1.465 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.039 173.176 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.94 127.47 31.54 Favored 'General case' 0 N--CA 1.435 -1.189 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 174.226 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.537 ' HA3' HG23 ' A' ' 47' ' ' THR . . . 108.86 -21.12 28.15 Favored Glycine 0 N--CA 1.409 -3.132 0 C-N-CA 120.763 -0.732 . . . . 0.0 111.854 -177.61 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.563 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 12.6 t80 -76.26 -43.2 42.91 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 -179.435 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.501 ' OD1' ' HB3' ' A' ' 71' ' ' PRO . 52.5 m-80 -70.66 -43.25 69.51 Favored 'General case' 0 CA--C 1.508 -0.671 0 CA-C-N 115.579 -0.737 . . . . 0.0 109.739 -178.808 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -68.36 -33.3 74.04 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 115.362 -0.836 . . . . 0.0 109.771 179.011 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -66.73 -34.94 88.91 Favored Glycine 0 CA--C 1.491 -1.423 0 CA-C-N 115.764 -0.653 . . . . 0.0 111.797 178.64 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.563 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 98.2 mt -62.26 -41.57 98.56 Favored 'General case' 0 C--O 1.212 -0.915 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 174.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 85.7 t90 -65.5 -45.85 81.97 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-N 115.807 -0.633 . . . . 0.0 109.647 178.564 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 54.9 mt-10 -59.72 -47.46 85.56 Favored 'General case' 0 C--N 1.312 -1.04 0 N-CA-C 112.837 0.68 . . . . 0.0 112.837 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 18.8 tt -74.85 -27.48 20.4 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 C-N-CA 120.248 -0.581 . . . . 0.0 111.959 -175.174 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -84.39 -10.89 57.17 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 122.647 0.379 . . . . 0.0 111.83 178.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 32.3 m-80 -125.32 -56.29 1.53 Allowed 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -175.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 42.5 t30 -123.62 79.69 55.29 Favored Pre-proline 0 C--N 1.315 -0.932 0 CA-C-O 121.17 0.51 . . . . 0.0 110.479 -177.23 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -68.62 -6.96 19.07 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 123.129 2.552 . . . . 0.0 115.01 -175.155 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 7.3 ptmm? -103.69 18.67 21.41 Favored 'General case' 0 C--O 1.263 1.77 0 N-CA-C 109.272 -0.64 . . . . 0.0 109.272 177.279 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 7.3 p -72.87 121.89 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.866 0 CA-C-O 122.726 1.251 . . . . 0.0 112.244 -177.343 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.439 ' HZ2' ' CG ' ' A' ' 26' ' ' ASP . 60.8 pttt -173.36 172.25 3.8 Favored 'General case' 0 N--CA 1.405 -2.717 0 N-CA-C 103.511 -2.774 . . . . 0.0 103.511 174.862 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 89.7 m-85 -44.91 -51.3 9.84 Favored 'General case' 0 C--N 1.312 -1.057 0 O-C-N 124.803 1.315 . . . . 0.0 112.779 -174.326 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 17.1 m . . . . . 0 N--CA 1.478 0.974 0 C-N-CA 124.651 1.181 . . . . 0.0 110.539 179.41 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.8 mtt . . . . . 0 CA--C 1.507 -0.711 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -65.91 -36.68 84.07 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 107.816 -1.179 . . . . 0.0 107.816 172.06 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 19.1 ptt180 -92.09 -175.31 4.04 Favored 'General case' 0 C--N 1.315 -0.894 0 N-CA-C 105.634 -1.988 . . . . 0.0 105.634 172.015 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . 0.431 2.6 p30 58.73 -105.35 0.25 Allowed 'General case' 0 N--CA 1.412 -2.328 0 N-CA-C 114.377 1.251 . . . . 0.0 114.377 174.733 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -109.38 119.34 39.17 Favored 'General case' 1 C--N 1.209 -5.524 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.628 -178.987 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.8 mppt? -101.01 151.42 37.62 Favored Pre-proline 0 C--N 1.303 -1.454 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 -174.117 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 31.9 Cg_exo -59.13 121.85 10.6 Favored 'Trans proline' 0 C--O 1.235 0.328 0 C-N-CA 122.145 1.896 . . . . 0.0 110.278 174.613 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 111.43 -11.37 28.38 Favored Glycine 0 N--CA 1.43 -1.721 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.889 -177.963 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 9.0 t0 -79.13 162.41 25.83 Favored 'General case' 0 C--O 1.258 1.532 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 -177.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.425 HD21 ' HB2' ' A' ' 88' ' ' PRO . 99.0 mt -114.56 129.22 56.65 Favored 'General case' 0 C--N 1.292 -1.902 0 C-N-CA 123.442 0.697 . . . . 0.0 109.127 -175.779 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 2.9 pp -142.75 -177.87 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 CA-C-O 121.856 0.836 . . . . 0.0 112.672 -172.566 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.487 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 66.0 m-85 -119.91 118.86 31.86 Favored 'General case' 0 C--N 1.289 -2.048 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 172.738 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.504 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -112.67 143.11 44.43 Favored 'General case' 0 C--N 1.283 -2.304 0 CA-C-N 115.482 -0.781 . . . . 0.0 110.46 -173.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.617 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -119.74 123.53 43.97 Favored 'General case' 0 N--CA 1.4 -2.947 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.348 -178.206 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . . . . . . . . . 71.2 mtm -113.77 158.53 20.84 Favored 'General case' 0 CA--C 1.5 -0.981 0 N-CA-C 108.52 -0.918 . . . . 0.0 108.52 175.315 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 29.1 tptp -69.61 124.07 22.99 Favored 'General case' 0 C--N 1.306 -1.315 0 C-N-CA 120.41 -0.516 . . . . 0.0 109.828 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.97 -12.55 60.7 Favored Glycine 0 C--N 1.303 -1.303 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.086 -176.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 72.3 m-85 -117.99 148.87 44.37 Favored Pre-proline 0 N--CA 1.433 -1.315 0 C-N-CA 123.088 0.555 . . . . 0.0 110.501 179.602 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -79.52 171.84 15.27 Favored 'Trans proline' 0 N--CA 1.449 -1.104 0 C-N-CA 122.315 2.01 . . . . 0.0 108.483 170.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.535 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 79.7 m80 -57.95 111.86 1.31 Allowed 'General case' 0 CA--C 1.537 0.472 0 N-CA-C 108.248 -1.019 . . . . 0.0 108.248 175.21 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 10.2 t-105 -112.33 142.27 26.64 Favored Pre-proline 0 C--N 1.294 -1.807 0 C-N-CA 123.983 0.913 . . . . 0.0 108.872 -169.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -62.63 118.49 5.38 Favored 'Trans proline' 0 C--O 1.245 0.847 0 C-N-CA 122.326 2.018 . . . . 0.0 110.57 178.054 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.45 166.98 23.2 Favored 'General case' 0 N--CA 1.41 -2.46 0 CA-C-O 121.702 0.763 . . . . 0.0 111.481 -175.874 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.417 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 36.3 ttt85 -114.38 139.42 49.49 Favored 'General case' 0 C--N 1.276 -2.63 0 C-N-CA 124.255 1.022 . . . . 0.0 110.604 -177.358 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 50.3 t -82.19 110.15 17.06 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.991 0 N-CA-C 104.025 -2.583 . . . . 0.0 104.025 169.77 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -91.45 168.12 11.77 Favored 'General case' 0 C--N 1.274 -2.707 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.107 -169.387 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -102.16 138.17 39.46 Favored 'General case' 0 C--N 1.305 -1.361 0 N-CA-C 109.757 -0.46 . . . . 0.0 109.757 177.509 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 47.4 t -71.03 125.07 91.97 Favored Pre-proline 0 C--N 1.316 -0.868 0 CA-C-N 115.526 -0.761 . . . . 0.0 111.002 -175.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -83.19 161.54 15.38 Favored 'Trans proline' 0 N--CA 1.431 -2.17 0 C-N-CA 122.023 1.815 . . . . 0.0 111.8 177.27 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -69.54 145.85 52.29 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.936 -0.764 . . . . 0.0 108.936 175.402 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 101.92 -34.15 5.93 Favored Glycine 0 C--N 1.291 -1.946 0 N-CA-C 108.57 -1.812 . . . . 0.0 108.57 -174.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -95.22 43.82 1.09 Allowed 'General case' 0 N--CA 1.442 -0.857 0 N-CA-C 108.576 -0.898 . . . . 0.0 108.576 177.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 33.7 m -64.8 15.68 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.218 0 C-N-CA 127.475 2.31 . . . . 0.0 115.617 -172.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.401 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 0.1 OUTLIER -64.1 135.45 96.32 Favored Pre-proline 0 C--N 1.292 -1.927 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 178.258 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 34' ' ' LYS . 14.8 Cg_exo -67.24 164.56 29.91 Favored 'Trans proline' 0 C--O 1.262 1.708 0 C-N-CA 122.235 1.956 . . . . 0.0 111.822 179.792 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 14.6 Cg_endo -55.48 128.22 29.51 Favored 'Trans proline' 0 C--N 1.36 1.149 0 C-N-CA 122.678 2.252 . . . . 0.0 111.391 -179.552 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 7.5 m -101.45 8.8 41.94 Favored 'General case' 0 C--N 1.291 -1.944 0 CA-C-N 114.927 -1.033 . . . . 0.0 109.605 -175.134 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 73.59 8.97 5.01 Favored 'General case' 0 N--CA 1.482 1.156 0 CA-C-O 123.726 1.727 . . . . 0.0 109.202 -173.841 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 84.1 mttt -124.37 163.04 22.57 Favored 'General case' 0 N--CA 1.417 -2.102 0 CA-C-N 113.296 -1.775 . . . . 0.0 108.832 177.349 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 72.8 mt -118.15 146.98 40.53 Favored Pre-proline 0 C--N 1.285 -2.2 0 O-C-N 124.364 1.04 . . . . 0.0 108.79 -178.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -72.95 123.3 8.8 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 C-N-CA 121.724 1.616 . . . . 0.0 109.524 175.382 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 48.7 mm -115.84 115.6 49.76 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.121 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.21 -175.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 74.3 t80 -95.63 115.95 28.16 Favored 'General case' 0 C--N 1.286 -2.181 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 178.58 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.425 ' HE1' ' HB3' ' A' ' 51' ' ' ALA . 74.2 m-85 -82.66 133.67 35.16 Favored 'General case' 0 C--N 1.293 -1.86 0 N-CA-C 112.686 0.625 . . . . 0.0 112.686 179.82 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.417 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 71.6 m-85 -84.21 151.0 25.1 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.641 179.523 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.538 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 78.14 -20.45 3.92 Favored Glycine 0 C--N 1.305 -1.188 0 C-N-CA 123.816 0.722 . . . . 0.0 114.109 178.835 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 32.0 p -119.07 -22.66 7.13 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 117.412 0.606 . . . . 0.0 109.939 175.085 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.8 m-70 66.43 22.49 10.71 Favored 'General case' 0 C--N 1.35 0.607 0 C-N-CA 123.667 0.787 . . . . 0.0 112.024 179.393 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -74.31 161.88 29.44 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 176.344 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.3 m -136.04 135.96 39.85 Favored 'General case' 0 C--N 1.278 -2.503 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 176.749 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . 0.425 ' HB3' ' HE1' ' A' ' 44' ' ' PHE . . . -136.28 178.92 6.68 Favored 'General case' 0 C--N 1.277 -2.572 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.151 -177.046 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -133.49 109.65 9.42 Favored 'General case' 0 C--O 1.262 1.761 0 CA-C-N 115.326 -0.852 . . . . 0.0 108.713 175.066 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.504 HD12 ' HB1' ' A' ' 13' ' ' ALA . 64.8 mt -125.49 161.94 26.01 Favored 'General case' 0 C--N 1.29 -1.999 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 -178.612 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -89.53 169.58 35.95 Favored Glycine 0 N--CA 1.422 -2.25 0 C-N-CA 119.878 -1.153 . . . . 0.0 110.296 -179.451 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -65.85 -6.59 14.51 Favored 'Trans proline' 0 C--O 1.212 -0.818 0 C-N-CA 123.087 2.525 . . . . 0.0 112.223 -179.503 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 5.9 ptmm? -97.73 -2.06 42.07 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-N 115.358 -0.837 . . . . 0.0 111.768 178.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -116.13 6.37 13.96 Favored 'General case' 0 C--N 1.293 -1.875 0 CA-C-O 121.134 0.492 . . . . 0.0 112.158 -179.069 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 11.5 pt -130.55 152.42 37.47 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.599 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 93.7 m-85 -139.28 147.47 53.1 Favored Pre-proline 0 C--N 1.303 -1.434 0 N-CA-C 108.771 -0.826 . . . . 0.0 108.771 -178.84 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -60.55 129.82 31.05 Favored 'Trans proline' 0 N--CA 1.481 0.786 0 C-N-CA 123.2 2.6 . . . . 0.0 112.919 -177.003 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.487 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 3.4 t80 -58.67 -34.28 71.06 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 113.819 1.044 . . . . 0.0 113.819 -177.526 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 30.4 t -60.62 -57.96 10.5 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 123.427 0.455 . . . . 0.0 111.226 -177.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 15.9 mp0 -75.72 -27.36 58.14 Favored 'General case' 0 C--N 1.311 -1.079 0 CA-C-O 122.059 0.933 . . . . 0.0 110.988 -175.434 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 37.5 m-80 -95.54 5.09 52.42 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 113.484 0.92 . . . . 0.0 113.484 -176.023 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.444 ' HE2' ' CE1' ' A' ' 61' ' ' TYR . 17.6 ttmm -62.69 -39.09 92.9 Favored 'General case' 0 C--O 1.21 -1.024 0 CA-C-O 120.986 0.422 . . . . 0.0 111.295 177.55 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.465 ' HA ' ' HD3' ' A' ' 70' ' ' LYS . 38.8 mm-40 -80.91 -16.81 52.58 Favored 'General case' 0 C--N 1.299 -1.588 0 CA-C-O 122.008 0.908 . . . . 0.0 112.205 177.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 19.3 mtpp -85.2 -56.7 3.41 Favored 'General case' 0 C--N 1.268 -2.941 0 CA-C-N 114.462 -1.244 . . . . 0.0 111.733 -178.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 35.1 m-85 -125.4 5.25 7.67 Favored 'General case' 0 C--N 1.306 -1.298 0 CA-C-N 116.029 -0.532 . . . . 0.0 111.08 -174.023 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -99.98 25.41 28.38 Favored Glycine 0 C--N 1.304 -1.201 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 -178.416 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.465 ' HD3' ' HA ' ' A' ' 66' ' ' GLU . 27.7 mmmt -96.8 153.33 38.69 Favored Pre-proline 0 C--N 1.307 -1.281 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 -179.173 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_exo -58.31 128.2 27.67 Favored 'Trans proline' 0 C--O 1.252 1.18 0 C-N-CA 121.981 1.787 . . . . 0.0 112.974 -179.517 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 16.2 m-80 -114.82 177.64 4.57 Favored 'General case' 0 CA--C 1.47 -2.113 0 CA-C-N 114.955 -1.02 . . . . 0.0 112.226 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.558 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 9.5 mptt -96.03 7.45 46.34 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 113.84 -1.527 . . . . 0.0 108.385 -178.37 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 11.1 mmt180 -88.27 122.79 32.2 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 175.177 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 10.2 tptp -77.04 144.38 38.65 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 177.278 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.538 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 95.13 -26.47 19.0 Favored Glycine 0 C--O 1.21 -1.367 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 -173.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.466 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 27.0 t80 -76.61 -41.36 46.29 Favored 'General case' 0 N--CA 1.444 -0.751 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 178.153 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 11.6 m120 -61.4 -49.22 77.77 Favored 'General case' 0 N--CA 1.472 0.648 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 177.886 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 6.1 mp0 -60.85 -40.73 94.0 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-N 113.711 -1.586 . . . . 0.0 110.352 179.309 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -67.54 -35.75 87.1 Favored Glycine 0 N--CA 1.44 -1.034 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.821 179.432 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.466 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 94.8 mt -61.92 -37.18 83.72 Favored 'General case' 0 C--O 1.218 -0.574 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 175.386 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 85.3 t90 -67.98 -48.34 66.06 Favored 'General case' 0 N--CA 1.427 -1.597 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.46 177.605 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -59.14 -46.7 87.67 Favored 'General case' 0 C--O 1.206 -1.196 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 179.719 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.402 HD11 ' HB3' ' A' ' 10' ' ' LEU . 19.0 tt -71.79 -27.83 28.95 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.05 0 C-N-CA 120.619 -0.432 . . . . 0.0 112.164 -174.842 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -89.57 -11.51 42.53 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 112.262 0.468 . . . . 0.0 112.262 -179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 32.4 m-80 -120.81 -57.55 1.88 Allowed 'General case' 0 N--CA 1.477 0.912 0 CA-C-O 121.16 0.505 . . . . 0.0 112.052 -176.813 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -128.59 73.64 80.63 Favored Pre-proline 0 C--N 1.308 -1.214 0 C-N-CA 120.418 -0.513 . . . . 0.0 110.305 -179.386 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.425 ' HB2' HD21 ' A' ' 10' ' ' LEU . 41.3 Cg_endo -70.13 -6.13 18.06 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 C-N-CA 123.178 2.585 . . . . 0.0 112.431 -176.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 20.9 pttp -106.52 21.69 17.04 Favored 'General case' 0 C--N 1.291 -1.969 0 CA-C-N 114.261 -1.336 . . . . 0.0 110.152 -179.651 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 8.4 p -61.51 81.32 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.55 0.952 0 CA-C-O 123.753 1.739 . . . . 0.0 113.802 -178.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 59.9 mtpt -155.87 -38.75 0.08 Allowed 'General case' 0 C--N 1.281 -2.398 0 N-CA-C 102.541 -3.133 . . . . 0.0 102.541 179.044 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -78.16 141.77 38.46 Favored 'General case' 0 N--CA 1.428 -1.549 0 CA-C-N 112.714 -2.039 . . . . 0.0 106.363 168.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 14.6 m . . . . . 0 C--N 1.303 -1.438 0 N-CA-C 112.461 0.541 . . . . 0.0 112.461 -176.48 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.3 mtt . . . . . 0 CA--C 1.498 -1.057 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -129.71 80.91 1.99 Allowed 'General case' 0 N--CA 1.434 -1.262 0 N-CA-C 105.202 -2.147 . . . . 0.0 105.202 173.501 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -123.55 -175.06 3.11 Favored 'General case' 0 C--N 1.296 -1.757 0 CA-C-N 114.48 -1.236 . . . . 0.0 112.661 -173.232 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . 0.417 ' OD1' ' HG3' ' A' ' 6' ' ' LYS . 15.3 t70 -96.95 152.82 18.34 Favored 'General case' 0 C--N 1.287 -2.123 0 CA-C-N 113.508 -1.678 . . . . 0.0 109.982 -173.568 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -134.65 122.76 22.71 Favored 'General case' 0 C--N 1.296 -1.72 0 N-CA-C 109.138 -0.689 . . . . 0.0 109.138 -178.204 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.417 ' HG3' ' OD1' ' A' ' 4' ' ' ASP . 63.0 mttp -134.07 155.77 79.79 Favored Pre-proline 0 C--N 1.301 -1.538 0 CA-C-N 116.452 -0.34 . . . . 0.0 110.298 179.587 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 94.7 Cg_exo -45.43 125.52 7.53 Favored 'Trans proline' 0 C--N 1.359 1.086 0 C-N-CA 123.554 2.836 . . . . 0.0 113.05 177.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 115.33 -25.44 9.82 Favored Glycine 0 N--CA 1.428 -1.837 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.871 -179.352 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 31.9 t70 -74.66 151.57 39.27 Favored 'General case' 0 C--O 1.257 1.466 0 CA-C-O 121.501 0.667 . . . . 0.0 111.564 -177.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.421 HD22 HG13 ' A' ' 84' ' ' ILE . 79.3 mt -103.38 124.38 48.58 Favored 'General case' 0 N--CA 1.424 -1.731 0 CA-C-N 114.707 -1.133 . . . . 0.0 110.134 -175.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 8.1 pt -137.11 -173.89 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.292 -1.896 0 CA-C-O 122.752 1.263 . . . . 0.0 112.2 -173.344 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.448 ' CD1' ' HB2' ' A' ' 64' ' ' ASN . 22.0 m-85 -125.49 131.26 52.87 Favored 'General case' 0 N--CA 1.399 -2.99 0 N-CA-C 105.277 -2.12 . . . . 0.0 105.277 170.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.554 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -107.47 128.39 54.45 Favored 'General case' 0 C--N 1.265 -3.081 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.011 -174.027 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.593 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -120.02 117.85 29.09 Favored 'General case' 0 N--CA 1.389 -3.524 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 -179.03 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.477 ' HB2' ' HB2' ' A' ' 18' ' ' TYR . 82.1 mtp -97.08 158.39 15.46 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.053 -177.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.6 tttp -67.23 115.8 7.3 Favored 'General case' 0 C--N 1.307 -1.267 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 176.38 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 100.56 -18.53 55.05 Favored Glycine 0 N--CA 1.446 -0.681 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.429 179.729 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.477 ' HB2' ' HB2' ' A' ' 15' ' ' MET . 88.1 m-85 -119.96 143.86 36.24 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 117.117 0.459 . . . . 0.0 111.173 -177.744 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -68.85 170.95 14.31 Favored 'Trans proline' 0 CA--C 1.539 0.73 0 C-N-CA 123.115 2.543 . . . . 0.0 112.853 179.445 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.543 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 77.3 m80 -60.86 122.16 14.17 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.97 179.64 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 15.1 t-105 -121.58 137.48 27.11 Favored Pre-proline 0 C--N 1.304 -1.401 0 N-CA-C 107.497 -1.298 . . . . 0.0 107.497 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -61.09 123.62 13.24 Favored 'Trans proline' 0 C--O 1.243 0.736 0 C-N-CA 122.426 2.084 . . . . 0.0 111.507 -179.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.9 166.71 24.16 Favored 'General case' 0 N--CA 1.422 -1.864 0 CA-C-O 121.39 0.614 . . . . 0.0 111.806 -176.764 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 46.7 ttt85 -114.02 139.94 48.85 Favored 'General case' 0 C--N 1.296 -1.745 0 CA-C-N 115.307 -0.86 . . . . 0.0 109.762 178.76 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 57.5 t -85.98 115.53 27.45 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 104.678 -2.342 . . . . 0.0 104.678 169.801 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.416 ' O ' ' HG2' ' A' ' 41' ' ' PRO . 3.6 t70 -99.71 -178.0 3.74 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 119.356 -0.937 . . . . 0.0 110.533 -173.592 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.424 ' CD ' ' HZ1' ' A' ' 91' ' ' LYS . 1.7 mp0 -92.16 126.38 37.22 Favored 'General case' 0 N--CA 1.43 -1.441 0 CA-C-O 121.593 0.711 . . . . 0.0 112.017 -174.102 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 7.0 p -100.57 117.06 63.53 Favored Pre-proline 0 N--CA 1.426 -1.644 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 174.201 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_endo -84.7 151.58 11.5 Favored 'Trans proline' 0 C--O 1.252 1.217 0 C-N-CA 122.541 2.16 . . . . 0.0 113.467 -178.27 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -59.2 122.4 13.74 Favored 'General case' 0 C--N 1.314 -0.963 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 172.793 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.446 ' C ' ' H ' ' A' ' 33' ' ' VAL . . . 110.72 -8.88 30.03 Favored Glycine 0 N--CA 1.431 -1.677 0 C-N-CA 119.803 -1.189 . . . . 0.0 112.267 -179.021 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -75.0 41.39 0.16 Allowed 'General case' 0 N--CA 1.489 1.48 0 CA-C-N 117.377 0.589 . . . . 0.0 111.91 176.203 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.446 ' H ' ' C ' ' A' ' 31' ' ' GLY 0.344 30.1 m 44.19 -41.82 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 C-N-CA 131.042 3.737 . . . . 0.0 118.958 -177.752 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 18.6 ptmt -86.1 138.35 34.78 Favored Pre-proline 0 C--N 1.288 -2.067 0 N-CA-C 113.314 0.857 . . . . 0.0 113.314 -176.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 59.2 Cg_endo -81.71 171.48 13.2 Favored 'Trans proline' 0 C--O 1.26 1.587 0 C-N-CA 122.325 2.017 . . . . 0.0 108.359 168.702 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_endo -56.89 126.81 23.44 Favored 'Trans proline' 0 N--CA 1.451 -0.991 0 C-N-CA 121.366 1.377 . . . . 0.0 109.796 177.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 2.3 m -104.63 8.48 35.27 Favored 'General case' 0 C--N 1.293 -1.882 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.212 -172.008 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 82.88 8.03 0.74 Allowed 'General case' 0 N--CA 1.506 2.35 0 C-N-CA 126.654 1.981 . . . . 0.0 107.654 -170.326 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.522 ' HA ' ' HA2' ' A' ' 54' ' ' GLY . 56.5 mttm -124.32 160.72 27.42 Favored 'General case' 0 N--CA 1.412 -2.333 0 CA-C-N 113.255 -1.793 . . . . 0.0 111.274 178.23 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 71.0 mt -122.05 157.03 59.03 Favored Pre-proline 0 C--N 1.279 -2.467 0 CA-C-N 113.615 -1.629 . . . . 0.0 108.491 -176.646 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.416 ' HG2' ' O ' ' A' ' 26' ' ' ASP . 47.5 Cg_endo -75.4 122.59 7.11 Favored 'Trans proline' 0 N--CA 1.456 -0.682 0 C-N-CA 121.796 1.664 . . . . 0.0 109.978 174.369 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.432 HG13 ' HB2' ' A' ' 53' ' ' LEU . 41.2 mm -116.8 122.72 70.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -175.73 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 86.0 t80 -103.45 116.05 31.67 Favored 'General case' 0 C--N 1.282 -2.347 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 178.627 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 57.5 m-85 -76.71 129.66 36.65 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-O 121.047 0.451 . . . . 0.0 112.022 179.448 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.473 ' HB3' ' HA2' ' A' ' 80' ' ' GLY . 60.3 m-85 -78.96 151.33 31.7 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.258 177.581 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.523 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 77.28 -19.7 3.59 Favored Glycine 0 C--O 1.254 1.38 0 N-CA-C 114.534 0.573 . . . . 0.0 114.534 177.008 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 46.4 p -119.23 -23.04 6.89 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 117.43 0.615 . . . . 0.0 110.248 174.708 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 12.0 m-70 68.76 21.68 7.67 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 123.975 0.91 . . . . 0.0 112.546 179.176 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -80.28 164.89 22.85 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.838 178.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 2.2 m -130.29 140.16 50.68 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 178.241 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -141.24 -179.72 6.28 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 123.641 0.776 . . . . 0.0 109.843 -178.358 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -133.19 112.32 11.62 Favored 'General case' 0 C--O 1.249 1.038 0 CA-C-O 121.605 0.717 . . . . 0.0 110.464 178.751 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.554 HD12 ' HB1' ' A' ' 13' ' ' ALA . 82.0 mt -135.84 147.4 48.24 Favored 'General case' 0 C--N 1.29 -1.993 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.522 ' HA2' ' HA ' ' A' ' 39' ' ' LYS . . . -94.77 177.23 35.54 Favored Glycine 0 CA--C 1.479 -2.169 0 C-N-CA 119.908 -1.139 . . . . 0.0 111.554 -177.196 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 29.6 Cg_endo -62.25 -17.47 57.19 Favored 'Trans proline' 0 C--O 1.212 -0.821 0 C-N-CA 123.249 2.632 . . . . 0.0 112.096 -177.535 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.55 1.47 48.97 Favored 'General case' 0 N--CA 1.425 -1.708 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.964 178.111 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.538 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 71.9 m-20 -107.92 -16.25 14.35 Favored 'General case' 0 C--N 1.29 -2.021 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.209 176.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.438 HG12 ' O ' ' A' ' 54' ' ' GLY . 12.0 pt -117.55 157.28 18.79 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.057 -174.059 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.568 ' HB3' HD21 ' A' ' 64' ' ' ASN . 98.0 m-85 -137.92 143.31 39.35 Favored Pre-proline 0 C--N 1.297 -1.711 0 N-CA-C 107.432 -1.322 . . . . 0.0 107.432 179.847 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -69.29 148.44 68.13 Favored 'Trans proline' 0 C--O 1.245 0.873 0 C-N-CA 122.975 2.45 . . . . 0.0 114.934 -172.516 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 54.4 t80 -55.82 -34.71 65.6 Favored 'General case' 0 C--O 1.221 -0.434 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.078 177.002 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 7.1 m -52.86 -44.24 66.67 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.169 -0.923 . . . . 0.0 112.224 -179.028 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 40.8 mt-10 -93.3 -26.55 17.26 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 121.644 0.735 . . . . 0.0 111.497 -177.089 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.568 HD21 ' HB3' ' A' ' 59' ' ' PHE . 40.8 m-80 -91.21 0.57 57.5 Favored 'General case' 0 C--O 1.203 -1.377 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -174.446 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.555 ' HZ3' ' CD ' ' A' ' 66' ' ' GLU . 4.5 ttpm? -65.95 -47.68 73.83 Favored 'General case' 0 C--N 1.29 -2.006 0 CA-C-O 121.446 0.641 . . . . 0.0 110.079 179.292 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.555 ' CD ' ' HZ3' ' A' ' 65' ' ' LYS . 12.1 mp0 -68.7 -36.34 78.35 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-O 122.331 1.062 . . . . 0.0 109.65 178.306 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 47.4 mtmt -79.16 -59.75 2.64 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 114.264 -1.335 . . . . 0.0 112.764 -174.34 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 47.8 m-85 -121.73 4.43 10.04 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 112.394 0.516 . . . . 0.0 112.394 -172.23 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -82.35 34.11 2.69 Favored Glycine 0 CA--C 1.524 0.649 0 C-N-CA 121.28 -0.486 . . . . 0.0 113.211 -177.454 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 2.6 mppt? -122.92 144.37 42.85 Favored Pre-proline 0 N--CA 1.439 -1.017 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 -179.318 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.48 ' HB3' ' OD1' ' A' ' 78' ' ' ASN . 82.8 Cg_exo -46.19 128.67 12.18 Favored 'Trans proline' 0 C--O 1.263 1.772 0 C-N-CA 123.984 3.123 . . . . 0.0 115.142 -176.248 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . 0.52 ' HB2' ' CD1' ' A' ' 77' ' ' PHE . 1.7 t-20 -102.73 -166.96 1.33 Allowed 'General case' 0 C--N 1.269 -2.9 0 CA-C-N 114.516 -1.22 . . . . 0.0 109.356 -178.208 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.458 ' HD2' ' N ' ' A' ' 73' ' ' LYS . 1.9 mptp? -120.61 18.39 12.0 Favored 'General case' 0 C--N 1.288 -2.091 0 N-CA-C 107.647 -1.242 . . . . 0.0 107.647 178.332 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 37.1 mmt180 -102.75 132.46 48.89 Favored 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 114.343 -1.298 . . . . 0.0 109.269 176.543 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 6.8 tmtm? -68.37 127.66 33.76 Favored 'General case' 0 CA--C 1.506 -0.737 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 175.477 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.523 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 107.17 -25.67 21.29 Favored Glycine 0 N--CA 1.416 -2.637 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.29 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.557 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 16.0 t80 -76.56 -45.4 30.69 Favored 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 -178.088 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.48 ' OD1' ' HB3' ' A' ' 71' ' ' PRO . 53.6 m-80 -71.61 -41.8 68.46 Favored 'General case' 0 CA--C 1.498 -1.045 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.45 -178.459 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -67.76 -33.64 75.23 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.18 179.487 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.473 ' HA2' ' HB3' ' A' ' 45' ' ' PHE . . . -70.97 -34.71 65.05 Favored Glycine 0 N--CA 1.43 -1.741 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.984 178.342 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.557 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 95.3 mt -61.97 -35.23 77.85 Favored 'General case' 0 C--O 1.215 -0.727 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 174.483 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 71.3 t90 -71.37 -48.78 47.89 Favored 'General case' 0 N--CA 1.431 -1.397 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.326 176.598 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -58.87 -40.53 84.64 Favored 'General case' 0 C--O 1.2 -1.537 0 N-CA-C 112.944 0.72 . . . . 0.0 112.944 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.421 HG13 HD22 ' A' ' 10' ' ' LEU . 19.0 tt -71.27 -21.36 21.8 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.071 0 CA-C-O 121.128 0.489 . . . . 0.0 110.795 -175.506 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -92.1 -43.78 9.18 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.066 -177.359 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.568 HD22 ' N ' ' A' ' 86' ' ' ASN . 0.8 OUTLIER -92.52 -44.27 8.72 Favored 'General case' 0 N--CA 1.481 1.115 0 CA-C-O 121.327 0.584 . . . . 0.0 112.182 -173.528 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.506 ' OD1' ' HG3' ' A' ' 89' ' ' LYS . 61.5 t30 -133.36 67.91 76.68 Favored Pre-proline 0 C--N 1.299 -1.614 0 C-N-CA 119.809 -0.756 . . . . 0.0 110.786 -178.698 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -68.09 -6.75 17.96 Favored 'Trans proline' 0 C--N 1.369 1.637 0 C-N-CA 123.193 2.595 . . . . 0.0 111.65 -178.227 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . 0.506 ' HG3' ' OD1' ' A' ' 87' ' ' ASN . 5.5 ptmm? -102.53 20.75 16.49 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-N 113.941 -1.481 . . . . 0.0 110.825 179.812 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 7.9 p -79.24 153.25 4.77 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.697 0 N-CA-C 108.602 -0.888 . . . . 0.0 108.602 176.166 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.424 ' HZ1' ' CD ' ' A' ' 27' ' ' GLU . 68.0 mttm -138.23 -168.12 2.31 Favored 'General case' 0 C--O 1.251 1.14 0 CA-C-O 122.012 0.91 . . . . 0.0 111.502 -178.194 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 3.6 p90 -75.04 -167.55 0.62 Allowed 'General case' 0 C--N 1.308 -1.22 0 C-N-CA 126.125 1.77 . . . . 0.0 111.012 176.444 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 4.9 m . . . . . 0 CA--C 1.546 0.82 0 C-N-CA 124.09 0.956 . . . . 0.0 113.492 -175.574 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.518 ' SD ' ' HD1' ' A' ' 59' ' ' PHE . 1.5 mpt? . . . . . 0 N--CA 1.494 1.73 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -95.23 70.88 3.24 Favored 'General case' 0 N--CA 1.433 -1.316 0 CA-C-O 121.925 0.869 . . . . 0.0 109.917 179.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . 0.478 HH21 ' HB3' ' A' ' 60' ' ' PRO . 18.4 ptt85 -130.09 178.85 6.24 Favored 'General case' 0 C--N 1.286 -2.161 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 173.288 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -89.74 145.33 25.27 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 175.643 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . 0.45 ' HB3' HG21 ' A' ' 25' ' ' VAL . 67.6 m-85 -115.67 122.12 44.6 Favored 'General case' 0 C--N 1.283 -2.296 0 N-CA-C 108.047 -1.094 . . . . 0.0 108.047 -179.418 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.419 ' O ' ' HB2' ' A' ' 9' ' ' ASP . 48.4 mttm -96.35 144.3 27.61 Favored Pre-proline 0 C--N 1.294 -1.831 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.918 -170.364 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -58.0 116.02 2.94 Favored 'Trans proline' 0 N--CA 1.462 -0.369 0 C-N-CA 121.731 1.621 . . . . 0.0 110.002 175.133 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 109.52 -7.4 32.04 Favored Glycine 0 N--CA 1.433 -1.543 0 C-N-CA 120.81 -0.709 . . . . 0.0 112.335 -176.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . 0.419 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 5.2 t70 -69.57 152.57 44.62 Favored 'General case' 0 C--O 1.251 1.175 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 -177.86 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 80.4 mt -104.91 120.91 42.57 Favored 'General case' 0 C--N 1.298 -1.633 0 CA-C-O 121.375 0.607 . . . . 0.0 109.85 -175.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.0 pt -140.45 -175.49 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.416 -2.165 0 CA-C-O 122.25 1.024 . . . . 0.0 112.024 -174.734 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -124.62 128.95 49.65 Favored 'General case' 0 N--CA 1.409 -2.497 0 N-CA-C 105.64 -1.985 . . . . 0.0 105.64 171.068 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.497 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -117.02 141.41 48.29 Favored 'General case' 0 C--N 1.278 -2.513 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.798 -176.62 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.626 ' C ' ' HD2' ' A' ' 14' ' ' LYS . 0.0 OUTLIER -123.24 124.46 43.07 Favored 'General case' 0 N--CA 1.405 -2.72 0 CA-C-N 116.009 -0.541 . . . . 0.0 109.693 -177.437 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.496 ' HG2' HD21 ' A' ' 53' ' ' LEU . 44.6 mtm -115.87 158.2 23.32 Favored 'General case' 0 CA--C 1.499 -1.017 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 175.574 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 63.3 tttp -65.45 116.91 7.23 Favored 'General case' 0 C--N 1.311 -1.095 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 178.305 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 101.33 -12.38 58.49 Favored Glycine 0 C--O 1.247 0.93 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -178.058 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . . . . . . . . . 7.8 m-85 -110.59 149.46 40.32 Favored Pre-proline 0 C--N 1.307 -1.279 0 C-N-CA 123.196 0.598 . . . . 0.0 109.872 178.528 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -81.41 171.45 13.61 Favored 'Trans proline' 0 N--CA 1.442 -1.512 0 C-N-CA 122.118 1.879 . . . . 0.0 108.173 171.323 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . 0.474 ' CD2' ' HB2' ' A' ' 14' ' ' LYS . 80.8 m80 -64.46 111.28 2.61 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 174.829 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 9.6 t-105 -110.85 141.03 23.29 Favored Pre-proline 0 C--N 1.292 -1.925 0 C-N-CA 123.585 0.754 . . . . 0.0 109.12 -170.001 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_endo -64.49 118.2 5.19 Favored 'Trans proline' 0 C--O 1.245 0.845 0 C-N-CA 122.147 1.898 . . . . 0.0 110.359 177.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -139.92 166.51 24.44 Favored 'General case' 0 N--CA 1.408 -2.526 0 CA-C-O 121.118 0.485 . . . . 0.0 110.311 -175.537 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.494 ' HD3' ' O ' ' A' ' 88' ' ' PRO . 10.7 ttp180 -115.3 145.35 42.56 Favored 'General case' 0 C--N 1.285 -2.237 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 178.135 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.45 HG21 ' HB3' ' A' ' 5' ' ' PHE . 52.4 t -74.63 119.91 23.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 N-CA-C 104.728 -2.323 . . . . 0.0 104.728 170.099 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.442 ' HB3' ' HB2' ' A' ' 41' ' ' PRO . 4.1 t70 -84.78 179.0 7.43 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -172.219 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 2.4 pm0 -106.0 150.36 25.79 Favored 'General case' 0 N--CA 1.429 -1.507 0 C-N-CA 119.278 -0.969 . . . . 0.0 111.72 -175.276 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 47.8 t -69.36 119.38 70.14 Favored Pre-proline 0 CA--C 1.505 -0.775 0 CA-C-N 115.448 -0.796 . . . . 0.0 108.902 178.491 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -75.6 143.62 27.44 Favored 'Trans proline' 0 N--CA 1.423 -2.649 0 C-N-CA 121.805 1.67 . . . . 0.0 113.215 -177.756 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 6.8 p-10 -61.84 136.38 57.96 Favored 'General case' 0 C--O 1.259 1.56 0 N-CA-C 107.065 -1.457 . . . . 0.0 107.065 171.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 103.21 -13.05 55.4 Favored Glycine 0 N--CA 1.43 -1.718 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 -175.283 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -82.79 84.96 7.17 Favored 'General case' 0 C--O 1.207 -1.178 0 CA-C-O 121.809 0.814 . . . . 0.0 110.542 175.112 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 29.4 m -99.96 8.3 8.54 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-N 114.33 -1.304 . . . . 0.0 109.217 176.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 9.4 mptt -81.69 139.43 47.2 Favored Pre-proline 0 N--CA 1.426 -1.635 0 CA-C-N 114.191 -1.368 . . . . 0.0 108.542 -179.572 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -62.57 147.28 95.04 Favored 'Trans proline' 0 C--O 1.244 0.789 0 C-N-CA 122.246 1.964 . . . . 0.0 112.103 179.654 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo -62.98 128.76 23.86 Favored 'Trans proline' 0 N--CA 1.451 -0.975 0 C-N-CA 122.405 2.07 . . . . 0.0 111.697 -178.523 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . 0.437 HG22 ' O ' ' A' ' 37' ' ' THR . 4.2 m -78.66 9.51 4.04 Favored 'General case' 0 C--N 1.301 -1.515 0 C-N-CA 123.885 0.874 . . . . 0.0 112.241 -177.037 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 5.0 p30 80.91 9.94 1.02 Allowed 'General case' 0 N--CA 1.499 2.006 0 C-N-CA 125.784 1.633 . . . . 0.0 110.691 -178.401 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 62.1 mttp -125.3 164.9 19.36 Favored 'General case' 0 C--N 1.293 -1.866 0 CA-C-N 113.367 -1.742 . . . . 0.0 111.12 -179.331 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' A' ' 52' ' ' PHE . 88.8 mt -116.99 147.17 39.57 Favored Pre-proline 0 C--N 1.287 -2.151 0 CA-C-N 114.33 -1.304 . . . . 0.0 109.246 -178.07 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . 0.442 ' HB2' ' HB3' ' A' ' 26' ' ' ASP . 68.9 Cg_endo -73.06 123.86 9.16 Favored 'Trans proline' 0 N--CA 1.459 -0.539 0 C-N-CA 122.33 2.02 . . . . 0.0 110.523 177.565 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.412 HG21 ' CB ' ' A' ' 13' ' ' ALA . 43.4 mm -120.86 127.56 75.95 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 -176.753 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.655 ' CZ ' ' HA ' ' A' ' 91' ' ' LYS . 87.7 t80 -107.14 120.69 42.8 Favored 'General case' 0 C--N 1.29 -1.979 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 178.846 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 93.0 m-85 -86.66 131.7 34.08 Favored 'General case' 0 C--N 1.306 -1.325 0 CA-C-O 121.254 0.55 . . . . 0.0 112.247 179.028 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.494 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 67.6 m-85 -85.83 158.44 19.97 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.694 179.326 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.533 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 75.31 -20.32 2.1 Favored Glycine 0 C--O 1.248 1.015 0 C-N-CA 123.526 0.584 . . . . 0.0 114.538 179.139 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 18.3 p -119.38 -23.04 6.81 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 122.305 -0.527 . . . . 0.0 109.73 173.005 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . 0.441 ' HA ' ' CZ ' ' A' ' 43' ' ' PHE . 11.5 m-70 67.67 26.18 7.98 Favored 'General case' 0 C--N 1.348 0.507 0 CA-C-N 115.287 -0.869 . . . . 0.0 111.818 179.507 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -79.4 161.89 25.87 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 108.698 -0.852 . . . . 0.0 108.698 177.373 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 6.9 m -136.12 140.43 43.68 Favored 'General case' 0 C--N 1.284 -2.25 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 176.794 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -142.74 179.35 7.05 Favored 'General case' 0 C--N 1.287 -2.124 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.289 -175.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.409 ' HA ' ' O ' ' A' ' 40' ' ' LEU . 84.8 m-85 -134.0 115.07 13.91 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 178.305 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.497 HD12 ' HB1' ' A' ' 13' ' ' ALA . 87.4 mt -129.44 166.49 19.49 Favored 'General case' 0 C--N 1.3 -1.566 0 N-CA-C 110.156 -0.313 . . . . 0.0 110.156 -177.67 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -93.03 167.7 29.49 Favored Glycine 0 N--CA 1.423 -2.18 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 179.454 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -67.03 -6.89 17.11 Favored 'Trans proline' 0 N--CA 1.481 0.747 0 C-N-CA 123.303 2.669 . . . . 0.0 112.828 -176.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 20.8 pttp -93.05 -18.17 22.97 Favored 'General case' 0 C--N 1.298 -1.64 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.366 178.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 24.2 m-20 -99.98 1.25 42.41 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.585 -0.734 . . . . 0.0 111.188 -175.226 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 16.3 pt -125.94 145.84 32.71 Favored 'Isoleucine or valine' 0 C--O 1.258 1.551 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.754 179.359 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.518 ' HD1' ' SD ' ' A' ' 1' ' ' MET . 83.0 m-85 -136.32 144.82 49.3 Favored Pre-proline 0 C--N 1.288 -2.087 0 CA-C-N 114.823 -1.081 . . . . 0.0 108.554 -177.131 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.478 ' HB3' HH21 ' A' ' 3' ' ' ARG . 35.0 Cg_endo -68.34 127.82 16.37 Favored 'Trans proline' 0 N--CA 1.483 0.857 0 C-N-CA 122.746 2.298 . . . . 0.0 113.956 -179.121 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -51.97 -39.34 59.17 Favored 'General case' 0 C--O 1.217 -0.626 0 C-N-CA 123.87 0.868 . . . . 0.0 111.043 -179.536 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 6.5 m -57.28 -40.33 77.54 Favored 'General case' 0 C--N 1.307 -1.27 0 CA-C-N 115.443 -0.799 . . . . 0.0 112.185 -178.072 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 12.2 mm-40 -95.75 -19.19 19.85 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.278 0.561 . . . . 0.0 112.21 -172.792 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.469 ' ND2' ' HB3' ' A' ' 59' ' ' PHE . 0.5 OUTLIER -124.19 26.88 7.29 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 114.703 1.371 . . . . 0.0 114.703 -178.214 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.43 ' HZ3' ' CD ' ' A' ' 66' ' ' GLU . 17.0 pttm -70.1 -30.91 68.24 Favored 'General case' 0 C--N 1.308 -1.236 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 174.698 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.43 ' CD ' ' HZ3' ' A' ' 65' ' ' LYS . 19.8 mp0 -65.25 -39.06 92.17 Favored 'General case' 0 C--O 1.251 1.151 0 CA-C-O 122.557 1.17 . . . . 0.0 108.617 175.091 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.443 ' HB3' ' HE2' ' A' ' 67' ' ' LYS . 35.8 mtpt -76.44 -59.96 2.55 Favored 'General case' 0 N--CA 1.427 -1.618 0 CA-C-N 113.918 -1.492 . . . . 0.0 112.029 -175.07 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 21.0 m-85 -107.67 -9.75 15.78 Favored 'General case' 0 C--N 1.296 -1.719 0 CA-C-N 115.482 -0.781 . . . . 0.0 112.428 -168.297 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -82.3 41.55 2.8 Favored Glycine 0 C--O 1.22 -0.726 0 C-N-CA 121.245 -0.503 . . . . 0.0 113.21 -176.826 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 38.4 mtmm -122.96 124.95 26.44 Favored Pre-proline 0 C--N 1.308 -1.202 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 177.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 16.5 Cg_exo -56.96 127.17 24.72 Favored 'Trans proline' 0 C--O 1.251 1.167 0 C-N-CA 122.23 1.954 . . . . 0.0 114.686 -172.239 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -84.76 -170.46 3.13 Favored 'General case' 0 CA--C 1.484 -1.594 0 CA-C-N 113.875 -1.511 . . . . 0.0 108.304 176.608 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 40.0 mmtm -111.46 22.0 15.57 Favored 'General case' 0 C--N 1.285 -2.201 0 CA-C-O 122.592 1.187 . . . . 0.0 107.821 173.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 12.0 mmt180 -87.06 127.89 35.11 Favored 'General case' 0 C--O 1.251 1.162 0 CA-C-N 113.548 -1.66 . . . . 0.0 107.547 173.279 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -65.29 134.79 54.38 Favored 'General case' 0 N--CA 1.439 -0.997 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 176.47 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.533 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 100.2 -25.73 27.18 Favored Glycine 0 N--CA 1.42 -2.374 0 C-N-CA 121.405 -0.426 . . . . 0.0 112.363 -178.242 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.405 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 23.2 t80 -73.36 -42.61 62.0 Favored 'General case' 0 C--N 1.312 -1.063 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 -177.709 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.491 ' N ' HD22 ' A' ' 78' ' ' ASN . 0.7 OUTLIER -72.87 -41.37 64.79 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 -177.323 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 16.3 mt-10 -65.06 -39.89 93.91 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 114.411 -1.268 . . . . 0.0 109.857 178.464 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -68.63 -32.29 74.47 Favored Glycine 0 CA--C 1.499 -0.936 0 CA-C-N 115.741 -0.663 . . . . 0.0 112.636 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.405 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 90.8 mt -62.9 -32.86 74.22 Favored 'General case' 0 C--O 1.214 -0.798 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 174.764 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 73.6 t90 -73.48 -48.27 34.72 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-N 115.837 -0.619 . . . . 0.0 110.382 176.541 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -58.3 -41.32 84.19 Favored 'General case' 0 C--O 1.203 -1.384 0 N-CA-C 112.87 0.693 . . . . 0.0 112.87 179.669 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 16.3 tt -71.29 -21.24 21.7 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 CA-C-O 121.145 0.497 . . . . 0.0 110.619 -175.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 29.9 t70 -90.36 -42.42 10.95 Favored 'General case' 0 N--CA 1.437 -1.112 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.108 -177.196 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.567 HD22 ' N ' ' A' ' 86' ' ' ASN . 0.8 OUTLIER -92.22 -50.16 5.81 Favored 'General case' 0 CA--C 1.494 -1.188 0 CA-C-N 116.06 -0.518 . . . . 0.0 112.136 -174.154 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 64.6 t30 -132.72 75.9 72.17 Favored Pre-proline 0 C--N 1.303 -1.442 0 C-N-CA 119.725 -0.79 . . . . 0.0 110.152 -179.048 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.494 ' O ' ' HD3' ' A' ' 24' ' ' ARG . 42.5 Cg_endo -68.52 -6.51 17.86 Favored 'Trans proline' 0 N--CA 1.477 0.542 0 C-N-CA 122.795 2.33 . . . . 0.0 114.143 -174.211 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 61.5 pttt -102.96 15.94 28.02 Favored 'General case' 0 C--N 1.304 -1.393 0 CA-C-O 120.85 0.357 . . . . 0.0 110.182 -179.053 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 9.8 p -82.92 148.63 5.02 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-O 121.473 0.654 . . . . 0.0 111.376 -176.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.655 ' HA ' ' CZ ' ' A' ' 43' ' ' PHE . 16.2 ptpt -151.0 -175.33 5.1 Favored 'General case' 0 N--CA 1.424 -1.74 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 173.522 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 79.2 t80 -75.91 -44.19 41.5 Favored 'General case' 0 C--N 1.321 -0.67 0 C-N-CA 119.513 -0.875 . . . . 0.0 111.221 -178.299 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . 0.479 ' O ' ' HG3' ' A' ' 91' ' ' LYS . 33.2 p . . . . . 0 N--CA 1.422 -1.849 0 N-CA-C 109.224 -0.658 . . . . 0.0 109.224 178.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 92.9 mtp . . . . . 0 CA--C 1.492 -1.283 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -129.85 82.04 2.05 Favored 'General case' 0 N--CA 1.421 -1.909 0 N-CA-C 103.901 -2.629 . . . . 0.0 103.901 172.302 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 11.6 ptp180 -105.7 162.55 13.43 Favored 'General case' 0 C--N 1.294 -1.81 0 CA-C-N 114.597 -1.183 . . . . 0.0 111.51 -174.046 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . . . . . . . . . 9.6 p-10 -95.09 -174.0 3.11 Favored 'General case' 0 C--N 1.28 -2.415 0 C-N-CA 126.107 1.763 . . . . 0.0 108.86 175.241 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 76.4 m-85 -118.94 112.99 20.31 Favored 'General case' 0 N--CA 1.427 -1.575 0 CA-C-O 120.958 0.408 . . . . 0.0 109.987 -177.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.403 ' O ' ' HB ' ' A' ' 25' ' ' VAL . 29.6 mttp -110.27 153.53 43.31 Favored Pre-proline 0 C--N 1.307 -1.281 0 N-CA-C 107.731 -1.211 . . . . 0.0 107.731 -177.405 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_exo -62.15 115.4 2.82 Favored 'Trans proline' 0 N--CA 1.448 -1.193 0 N-CA-C 107.08 -1.931 . . . . 0.0 107.08 169.02 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 114.93 -19.05 15.94 Favored Glycine 0 N--CA 1.424 -2.152 0 C-N-CA 120.411 -0.899 . . . . 0.0 112.391 -174.835 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -78.45 152.19 32.26 Favored 'General case' 0 C--O 1.253 1.268 0 CA-C-N 117.397 0.599 . . . . 0.0 109.446 -177.065 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.403 HD22 HG13 ' A' ' 84' ' ' ILE . 82.5 mt -98.03 127.32 43.91 Favored 'General case' 0 C--N 1.306 -1.31 0 C-N-CA 122.917 0.487 . . . . 0.0 111.211 -171.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.458 HG22 ' HA ' ' A' ' 60' ' ' PRO . 2.8 pp -140.08 -178.78 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.438 -1.046 0 CA-C-O 121.956 0.884 . . . . 0.0 112.555 -174.718 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.43 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 69.0 m-85 -120.98 125.4 47.26 Favored 'General case' 0 C--N 1.291 -1.971 0 N-CA-C 105.429 -2.063 . . . . 0.0 105.429 172.47 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.487 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -111.22 146.35 37.08 Favored 'General case' 0 C--N 1.277 -2.545 0 O-C-N 123.531 0.519 . . . . 0.0 111.035 -174.54 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.481 ' HD3' ' C ' ' A' ' 14' ' ' LYS . 7.5 tmtm? -117.9 117.66 29.87 Favored 'General case' 0 N--CA 1.419 -1.998 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.707 -177.746 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.447 ' HB2' ' HB2' ' A' ' 18' ' ' TYR . 70.1 mtm -112.28 159.38 18.69 Favored 'General case' 0 C--O 1.248 0.999 0 CA-C-O 120.962 0.41 . . . . 0.0 111.364 173.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 26.2 ttpp -67.71 116.82 8.83 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 108.631 -0.878 . . . . 0.0 108.631 176.025 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.52 -4.91 64.43 Favored Glycine 0 C--O 1.239 0.432 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 -176.305 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.447 ' HB2' ' HB2' ' A' ' 15' ' ' MET . 35.3 m-85 -118.13 145.39 36.85 Favored Pre-proline 0 C--O 1.254 1.335 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 179.325 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 72.2 Cg_endo -79.79 171.93 14.86 Favored 'Trans proline' 0 N--CA 1.445 -1.324 0 C-N-CA 123.16 2.573 . . . . 0.0 108.281 170.093 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 79.1 m80 -63.93 111.51 2.52 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 108.229 -1.026 . . . . 0.0 108.229 177.063 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 10.2 t-105 -110.18 140.51 22.47 Favored Pre-proline 0 C--N 1.295 -1.767 0 CA-C-N 114.866 -1.061 . . . . 0.0 109.369 -170.188 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_endo -65.85 118.15 5.24 Favored 'Trans proline' 0 C--O 1.243 0.744 0 C-N-CA 122.008 1.805 . . . . 0.0 110.184 177.233 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -145.94 167.19 23.91 Favored 'General case' 0 N--CA 1.413 -2.307 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 -175.632 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.606 ' HD3' ' O ' ' A' ' 88' ' ' PRO . 10.0 ttp180 -122.29 149.06 44.25 Favored 'General case' 0 C--N 1.272 -2.782 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.403 ' HB ' ' O ' ' A' ' 6' ' ' LYS . 51.5 t -72.34 121.07 21.98 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.452 0 N-CA-C 104.647 -2.353 . . . . 0.0 104.647 169.135 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -84.0 172.44 12.03 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 -170.656 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -105.48 127.11 52.83 Favored 'General case' 0 N--CA 1.431 -1.386 0 CA-C-O 121.506 0.669 . . . . 0.0 111.772 -176.872 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 62.1 t -77.06 127.89 82.48 Favored Pre-proline 0 C--N 1.315 -0.904 0 CA-C-N 114.585 -1.189 . . . . 0.0 110.502 -176.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_endo -72.8 151.77 51.79 Favored 'Trans proline' 0 N--CA 1.433 -2.037 0 C-N-CA 121.7 1.6 . . . . 0.0 112.767 178.201 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -71.03 151.49 44.53 Favored 'General case' 0 C--N 1.31 -1.116 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 172.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 88.04 -7.08 82.49 Favored Glycine 0 N--CA 1.425 -2.097 0 C-N-CA 120.533 -0.841 . . . . 0.0 111.083 -175.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -76.41 80.44 3.14 Favored 'General case' 0 C--O 1.207 -1.165 0 CA-C-O 122.037 0.922 . . . . 0.0 110.985 173.845 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.3 m -98.55 8.74 7.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.258 0 CA-C-N 114.246 -1.343 . . . . 0.0 109.504 176.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 9.6 mptt -79.26 140.36 56.69 Favored Pre-proline 0 C--N 1.3 -1.568 0 CA-C-N 114.1 -1.409 . . . . 0.0 107.723 179.621 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.443 ' HA ' ' HD3' ' A' ' 36' ' ' PRO . 29.4 Cg_endo -63.53 133.49 40.09 Favored 'Trans proline' 0 CA--C 1.537 0.651 0 C-N-CA 121.775 1.65 . . . . 0.0 112.458 -177.628 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 35' ' ' PRO . 86.4 Cg_endo -90.77 171.64 3.33 Favored 'Trans proline' 0 N--CA 1.437 -1.799 0 C-N-CA 122.533 2.156 . . . . 0.0 111.836 179.086 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 5.5 m -77.1 7.39 5.06 Favored 'General case' 0 CA--C 1.561 1.384 0 C-N-CA 123.4 0.68 . . . . 0.0 110.568 178.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 41.8 m-80 69.72 19.61 7.18 Favored 'General case' 0 N--CA 1.482 1.164 0 C-N-CA 124.804 1.241 . . . . 0.0 110.777 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.462 ' HD3' ' N ' ' A' ' 54' ' ' GLY . 88.6 mttt -129.35 177.01 7.49 Favored 'General case' 0 N--CA 1.431 -1.407 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.179 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 66.6 mt -84.16 140.8 39.71 Favored Pre-proline 0 C--N 1.314 -0.97 0 O-C-N 123.609 0.568 . . . . 0.0 109.574 -177.488 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 63.7 Cg_endo -72.74 123.93 9.36 Favored 'Trans proline' 0 C--O 1.222 -0.276 0 C-N-CA 122.395 2.064 . . . . 0.0 110.186 178.767 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . . . . . . . . . 47.6 mm -120.85 123.43 70.2 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 0 O-C-N 121.924 -0.485 . . . . 0.0 110.401 -176.495 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.477 ' CZ ' ' HA ' ' A' ' 91' ' ' LYS . 77.4 t80 -106.09 119.13 38.4 Favored 'General case' 0 C--N 1.291 -1.974 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 177.889 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.415 ' CE2' ' HB3' ' A' ' 13' ' ' ALA . 80.4 m-85 -83.39 131.91 35.02 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-O 121.314 0.578 . . . . 0.0 112.141 179.591 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.433 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 46.1 m-85 -85.01 154.5 22.07 Favored 'General case' 0 C--N 1.303 -1.449 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.406 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.556 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 73.44 -21.16 1.17 Allowed Glycine 0 C--N 1.308 -0.981 0 C-N-CA 124.184 0.897 . . . . 0.0 114.977 179.679 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 22.4 p -115.98 -22.92 8.78 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 117.942 0.871 . . . . 0.0 109.668 173.409 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . 0.441 ' HE2' ' CD ' ' A' ' 83' ' ' GLU . 55.9 m170 69.73 23.17 5.83 Favored 'General case' 0 CA--C 1.518 -0.285 0 CA-C-N 114.887 -1.051 . . . . 0.0 111.595 176.319 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -76.51 160.79 29.17 Favored 'General case' 0 N--CA 1.443 -0.785 0 CA-C-N 115.261 -0.881 . . . . 0.0 108.745 177.035 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 5.2 m -136.3 138.31 41.6 Favored 'General case' 0 C--N 1.279 -2.473 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.093 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -140.2 -179.62 6.09 Favored 'General case' 0 C--N 1.282 -2.343 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.0 -177.267 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -133.03 111.21 10.8 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 175.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.546 ' HB3' ' HB2' ' A' ' 57' ' ' ASP . 87.2 mt -129.25 150.9 50.43 Favored 'General case' 0 C--N 1.288 -2.094 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.293 -176.227 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.462 ' N ' ' HD3' ' A' ' 39' ' ' LYS . . . -85.17 172.84 47.87 Favored Glycine 0 N--CA 1.424 -2.156 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 -176.54 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -65.04 -16.65 56.35 Favored 'Trans proline' 0 C--O 1.208 -0.992 0 C-N-CA 122.266 1.977 . . . . 0.0 112.407 -177.478 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -97.75 -1.14 44.04 Favored 'General case' 0 N--CA 1.436 -1.153 0 CA-C-O 121.301 0.572 . . . . 0.0 112.197 177.205 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.546 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 69.4 m-20 -104.22 -4.83 22.54 Favored 'General case' 0 C--N 1.295 -1.791 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 179.513 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.7 pt -128.2 156.58 40.41 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.707 0 CA-C-N 114.898 -1.046 . . . . 0.0 109.1 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . 0.425 ' HB3' ' ND2' ' A' ' 64' ' ' ASN . 88.6 m-85 -136.72 136.76 22.08 Favored Pre-proline 0 C--N 1.287 -2.115 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 -179.625 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . 0.485 ' HG2' ' HB2' ' A' ' 63' ' ' GLU . 20.5 Cg_endo -64.43 132.92 35.19 Favored 'Trans proline' 0 C--N 1.318 -1.079 0 C-N-CA 122.273 1.982 . . . . 0.0 112.416 -177.621 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.43 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 60.7 t80 -58.63 -39.76 81.41 Favored 'General case' 0 C--O 1.206 -1.214 0 C-N-CA 123.695 0.798 . . . . 0.0 110.839 -178.331 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 29.5 t -62.06 -36.09 80.58 Favored 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.608 -0.724 . . . . 0.0 111.484 -176.009 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.485 ' HB2' ' HG2' ' A' ' 60' ' ' PRO . 1.3 mp0 -95.05 -18.0 21.39 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 113.172 0.805 . . . . 0.0 113.172 -175.2 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.425 ' ND2' ' HB3' ' A' ' 59' ' ' PHE . 37.3 m-80 -123.55 16.07 9.6 Favored 'General case' 0 C--N 1.285 -2.227 0 N-CA-C 112.778 0.658 . . . . 0.0 112.778 -175.814 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.499 ' HG2' ' OE2' ' A' ' 66' ' ' GLU . 21.4 pttm -66.8 -32.19 73.3 Favored 'General case' 0 N--CA 1.484 1.268 0 CA-C-O 121.273 0.559 . . . . 0.0 110.703 -178.062 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.561 ' H ' ' CD ' ' A' ' 66' ' ' GLU . 2.7 mp0 -70.36 -25.39 63.25 Favored 'General case' 0 C--N 1.321 -0.669 0 N-CA-C 108.19 -1.041 . . . . 0.0 108.19 -179.537 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 43.6 mttp -91.05 -59.66 2.11 Favored 'General case' 0 N--CA 1.422 -1.826 0 CA-C-N 114.271 -1.331 . . . . 0.0 111.297 -171.01 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 56.1 m-85 -105.76 -0.62 25.24 Favored 'General case' 0 C--N 1.309 -1.187 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.806 -172.254 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -80.9 56.43 4.81 Favored Glycine 0 N--CA 1.444 -0.783 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.74 179.292 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 59.2 mttp -128.61 128.53 23.54 Favored Pre-proline 0 C--N 1.317 -0.845 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 179.806 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_exo -54.57 137.9 74.01 Favored 'Trans proline' 0 C--N 1.349 0.575 0 C-N-CA 122.969 2.446 . . . . 0.0 112.169 177.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 15.9 m-80 -116.04 -179.34 3.63 Favored 'General case' 0 CA--C 1.472 -2.049 0 N-CA-C 113.845 1.054 . . . . 0.0 113.845 -178.633 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . 0.451 ' HD3' ' N ' ' A' ' 73' ' ' LYS . 2.8 mppt? -93.27 1.9 56.83 Favored 'General case' 0 N--CA 1.429 -1.494 0 CA-C-N 112.921 -1.945 . . . . 0.0 108.247 -178.516 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 5.6 mmt180 -84.54 116.34 23.08 Favored 'General case' 0 N--CA 1.426 -1.645 0 CA-C-N 114.889 -1.051 . . . . 0.0 109.783 176.43 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.433 ' HD3' ' N ' ' A' ' 76' ' ' GLY . 8.7 tmtt? -56.5 125.92 24.22 Favored 'General case' 0 C--N 1.322 -0.593 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 175.632 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.556 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 108.03 -25.44 20.42 Favored Glycine 0 N--CA 1.434 -1.451 0 C-N-CA 121.222 -0.514 . . . . 0.0 112.081 -179.363 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.421 ' O ' ' HG ' ' A' ' 81' ' ' LEU . 14.1 t80 -70.29 -40.28 74.39 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 122.068 0.937 . . . . 0.0 108.738 -176.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 2.3 m120 -68.47 -43.64 76.55 Favored 'General case' 0 C--N 1.306 -1.299 0 CA-C-N 114.198 -1.364 . . . . 0.0 108.986 -176.808 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 -68.49 -35.57 77.72 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 114.39 -1.277 . . . . 0.0 109.964 179.765 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . 0.402 ' HA2' ' HB3' ' A' ' 45' ' ' PHE . . . -68.45 -33.66 77.65 Favored Glycine 0 N--CA 1.438 -1.186 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.24 177.8 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.421 ' HG ' ' O ' ' A' ' 77' ' ' PHE . 95.4 mt -62.76 -33.83 75.98 Favored 'General case' 0 C--O 1.213 -0.818 0 N-CA-C 109.471 -0.566 . . . . 0.0 109.471 174.596 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 72.8 t90 -71.92 -49.54 36.84 Favored 'General case' 0 N--CA 1.441 -0.901 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.778 176.336 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.441 ' CD ' ' HE2' ' A' ' 48' ' ' HIS . 46.7 mt-10 -58.25 -40.35 81.53 Favored 'General case' 0 C--O 1.204 -1.335 0 N-CA-C 112.895 0.702 . . . . 0.0 112.895 179.503 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.403 HG13 HD22 ' A' ' 10' ' ' LEU . 18.0 tt -71.18 -21.21 21.86 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.753 0 CA-C-O 121.179 0.514 . . . . 0.0 110.583 -176.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 28.1 t70 -89.03 -42.9 11.48 Favored 'General case' 0 N--CA 1.439 -1.011 0 CA-C-N 115.47 -0.787 . . . . 0.0 110.019 -177.856 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.577 HD22 ' N ' ' A' ' 86' ' ' ASN . 0.8 OUTLIER -89.49 -48.66 7.17 Favored 'General case' 0 CA--C 1.493 -1.225 0 CA-C-N 115.92 -0.582 . . . . 0.0 112.077 -174.295 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 57.4 t30 -132.29 76.87 71.84 Favored Pre-proline 0 C--N 1.302 -1.481 0 C-N-CA 120.17 -0.612 . . . . 0.0 109.761 179.525 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.606 ' O ' ' HD3' ' A' ' 24' ' ' ARG . 28.8 Cg_endo -62.97 -16.96 57.61 Favored 'Trans proline' 0 C--O 1.218 -0.515 0 C-N-CA 122.808 2.339 . . . . 0.0 115.719 -171.399 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . 0.42 ' HA ' ' HD3' ' A' ' 24' ' ' ARG . 8.5 ptmm? -106.58 20.64 18.71 Favored 'General case' 0 C--O 1.259 1.573 0 C-N-CA 119.317 -0.953 . . . . 0.0 111.323 -179.213 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 9.0 p -70.06 146.4 12.33 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-O 122.168 0.985 . . . . 0.0 113.283 -174.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.477 ' HA ' ' CZ ' ' A' ' 43' ' ' PHE . 0.2 OUTLIER -145.39 146.23 31.47 Favored 'General case' 0 N--CA 1.417 -2.113 0 N-CA-C 104.422 -2.436 . . . . 0.0 104.422 169.661 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 54.2 t80 -75.78 106.07 7.15 Favored 'General case' 0 C--N 1.3 -1.547 0 C-N-CA 119.817 -0.753 . . . . 0.0 110.107 -175.259 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 14.0 m . . . . . 0 C--N 1.29 -2.015 0 CA-C-N 114.404 -1.271 . . . . 0.0 109.975 -177.505 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 22.4 mmt . . . . . 0 CA--C 1.487 -1.442 0 N-CA-C 107.853 -1.166 . . . . 0.0 107.853 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -120.92 77.99 1.35 Allowed 'General case' 0 N--CA 1.426 -1.633 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 176.677 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ARG . . . . . . . . . . . . . 31.4 ptt-85 -117.75 171.88 7.74 Favored 'General case' 0 C--N 1.296 -1.727 0 CA-C-N 114.583 -1.19 . . . . 0.0 109.004 179.296 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ASP . . . . . 0.406 ' OD1' ' HD2' ' A' ' 6' ' ' LYS . 12.0 p-10 -91.93 -179.4 5.29 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 177.075 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -111.13 101.34 9.87 Favored 'General case' 0 N--CA 1.427 -1.618 0 CA-C-O 121.452 0.644 . . . . 0.0 110.152 -176.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.406 ' HD2' ' OD1' ' A' ' 4' ' ' ASP . 0.1 OUTLIER -94.36 145.98 30.7 Favored Pre-proline 0 C--N 1.304 -1.39 0 CA-C-N 114.913 -1.039 . . . . 0.0 109.326 -177.079 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -53.28 122.23 10.83 Favored 'Trans proline' 0 C--O 1.238 0.523 0 C-N-CA 122.336 2.024 . . . . 0.0 109.579 172.118 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 109.58 -9.91 32.72 Favored Glycine 0 N--CA 1.427 -1.904 0 C-N-CA 120.982 -0.628 . . . . 0.0 112.051 -177.258 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -79.9 153.51 28.96 Favored 'General case' 0 C--O 1.251 1.166 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 -179.297 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 86.0 mt -105.64 126.39 52.09 Favored 'General case' 0 C--N 1.291 -1.97 0 CA-C-O 121.251 0.548 . . . . 0.0 109.892 -175.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.414 ' HA ' ' H ' ' A' ' 61' ' ' TYR . 9.3 pt -140.84 -172.66 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.832 0 CA-C-O 122.256 1.027 . . . . 0.0 111.813 -174.616 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.563 ' CE2' ' HA ' ' A' ' 61' ' ' TYR . 72.8 m-85 -126.15 134.44 51.3 Favored 'General case' 0 N--CA 1.411 -2.377 0 N-CA-C 105.894 -1.891 . . . . 0.0 105.894 172.342 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.581 ' HB1' HD12 ' A' ' 53' ' ' LEU . . . -113.44 141.92 46.52 Favored 'General case' 0 C--N 1.273 -2.72 0 O-C-N 123.776 0.673 . . . . 0.0 110.235 -176.28 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' LYS . . . . . 0.479 ' HD3' ' C ' ' A' ' 14' ' ' LYS . 7.5 tmtm? -113.15 117.72 32.73 Favored 'General case' 0 N--CA 1.422 -1.837 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.834 -177.441 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' MET . . . . . 0.422 ' HB2' ' HB2' ' A' ' 18' ' ' TYR . 72.1 mtm -109.54 158.48 17.96 Favored 'General case' 0 C--O 1.254 1.331 0 CA-C-O 121.26 0.552 . . . . 0.0 111.056 173.241 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 61.4 tttm -68.46 117.26 9.99 Favored 'General case' 0 C--N 1.311 -1.067 0 CA-C-N 115.782 -0.644 . . . . 0.0 109.682 178.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 91.3 -1.55 76.85 Favored Glycine 0 C--O 1.238 0.361 0 C-N-CA 121.0 -0.619 . . . . 0.0 111.768 -178.746 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' TYR . . . . . 0.444 ' HA ' ' HD3' ' A' ' 19' ' ' PRO . 61.7 m-85 -120.39 150.68 52.37 Favored Pre-proline 0 C--O 1.258 1.52 0 CA-C-N 115.636 -0.282 . . . . 0.0 111.061 -179.202 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 18' ' ' TYR . 6.4 Cg_exo -74.97 171.97 17.26 Favored 'Trans proline' 0 N--CA 1.458 -0.571 0 C-N-CA 123.286 2.657 . . . . 0.0 109.691 172.513 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -67.3 110.97 3.75 Favored 'General case' 0 C--N 1.315 -0.896 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 176.788 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' TRP . . . . . . . . . . . . . 3.9 t-105 -98.78 137.48 20.57 Favored Pre-proline 0 C--N 1.297 -1.681 0 CA-C-N 114.801 -1.091 . . . . 0.0 108.542 -171.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -64.49 118.13 5.13 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 121.763 1.642 . . . . 0.0 110.148 177.72 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -135.85 166.79 22.48 Favored 'General case' 0 N--CA 1.411 -2.398 0 CA-C-O 121.519 0.676 . . . . 0.0 110.975 -175.181 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.507 ' HB2' ' CZ ' ' A' ' 45' ' ' PHE . 64.4 ttt-85 -115.66 141.76 47.65 Favored 'General case' 0 C--N 1.28 -2.423 0 N-CA-C 108.127 -1.064 . . . . 0.0 108.127 179.455 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 48.1 t -77.65 119.92 27.26 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.249 0 N-CA-C 103.957 -2.608 . . . . 0.0 103.957 169.816 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -102.33 -179.58 4.03 Favored 'General case' 0 C--N 1.283 -2.294 0 C-N-CA 119.42 -0.912 . . . . 0.0 110.858 -170.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLU . . . . . 0.409 ' CD ' HH12 ' A' ' 24' ' ' ARG . 30.5 mp0 -91.47 168.39 11.57 Favored 'General case' 0 N--CA 1.424 -1.731 0 CA-C-O 121.622 0.725 . . . . 0.0 110.504 -178.684 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 75.4 t -92.83 124.08 59.62 Favored Pre-proline 0 C--N 1.304 -1.402 0 N-CA-C 107.619 -1.252 . . . . 0.0 107.619 175.361 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -71.0 149.26 58.65 Favored 'Trans proline' 0 N--CA 1.435 -1.953 0 C-N-CA 121.512 1.474 . . . . 0.0 112.085 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -68.13 141.51 56.04 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.617 -0.882 . . . . 0.0 108.617 177.172 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 106.62 -33.61 6.32 Favored Glycine 0 C--N 1.293 -1.843 0 N-CA-C 109.059 -1.616 . . . . 0.0 109.059 -175.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -80.87 85.97 6.1 Favored 'General case' 0 N--CA 1.433 -1.301 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 176.071 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.3 m -90.47 6.09 5.0 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.267 0 CA-C-N 114.95 -1.023 . . . . 0.0 112.105 -177.689 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . . . . . . . . . 14.0 ptmm? -71.09 152.58 94.73 Favored Pre-proline 0 N--CA 1.424 -1.728 0 CA-C-N 115.618 -0.719 . . . . 0.0 111.688 179.426 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -69.41 167.95 22.51 Favored 'Trans proline' 0 C--O 1.274 2.303 0 C-N-CA 121.855 1.703 . . . . 0.0 110.058 173.005 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -56.4 143.16 87.85 Favored 'Trans proline' 0 N--CA 1.455 -0.764 0 C-N-CA 122.599 2.199 . . . . 0.0 111.374 177.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' THR . . . . . . . . . . . . . 3.0 m -85.17 8.42 18.32 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.748 -176.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ASN . . . . . . . . . . . . . 44.8 m-80 74.05 11.48 4.36 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 125.096 1.359 . . . . 0.0 108.354 -172.07 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . 0.617 ' HE3' ' HA ' ' A' ' 53' ' ' LEU . 22.5 mtpp -139.76 153.24 47.11 Favored 'General case' 0 N--CA 1.415 -2.209 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 179.801 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' LEU . . . . . . . . . . . . . 80.7 mt -103.55 154.62 37.73 Favored Pre-proline 0 C--N 1.29 -2.002 0 O-C-N 124.023 0.827 . . . . 0.0 109.772 -175.605 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -71.15 122.32 8.62 Favored 'Trans proline' 0 N--CA 1.451 -0.991 0 C-N-CA 121.521 1.481 . . . . 0.0 109.734 174.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ILE . . . . . 0.474 HG13 ' HB2' ' A' ' 53' ' ' LEU . 44.9 mm -118.53 116.81 52.48 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.935 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -176.585 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.408 ' CZ ' ' HA ' ' A' ' 48' ' ' HIS . 79.0 t80 -93.33 122.34 35.64 Favored 'General case' 0 C--N 1.268 -2.972 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 179.718 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -88.51 124.91 34.47 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.347 0.594 . . . . 0.0 112.542 178.434 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.507 ' CZ ' ' HB2' ' A' ' 24' ' ' ARG . 78.2 m-85 -74.64 152.53 39.19 Favored 'General case' 0 C--N 1.31 -1.148 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.536 176.053 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.55 ' HA3' ' O ' ' A' ' 76' ' ' GLY . . . 79.78 -19.97 5.79 Favored Glycine 0 C--N 1.308 -1.02 0 CA-C-N 116.289 -0.414 . . . . 0.0 113.701 178.786 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 17.0 p -116.62 -22.79 8.48 Favored 'General case' 0 C--N 1.304 -1.396 0 CA-C-N 117.166 0.483 . . . . 0.0 110.149 175.48 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . 0.575 ' O ' ' HA ' ' A' ' 92' ' ' PHE . 49.7 m170 70.22 14.23 7.63 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 124.321 1.048 . . . . 0.0 112.017 177.123 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 57.4 mm-40 -92.4 168.15 11.49 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.873 -179.113 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . . . . . . . . . 4.0 m -129.48 142.15 50.85 Favored 'General case' 0 C--N 1.306 -1.302 0 CA-C-O 121.2 0.524 . . . . 0.0 109.908 179.606 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ALA . . . . . . . . . . . . . . . -137.89 -178.9 5.46 Favored 'General case' 0 C--N 1.295 -1.791 0 C-N-CA 124.096 0.958 . . . . 0.0 110.023 -177.499 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -128.53 116.0 18.99 Favored 'General case' 0 CA--C 1.5 -0.975 0 CA-C-O 120.851 0.357 . . . . 0.0 110.637 179.141 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.617 ' HA ' ' HE3' ' A' ' 39' ' ' LYS . 89.0 mt -131.59 151.32 51.7 Favored 'General case' 0 C--N 1.305 -1.346 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 177.793 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . 0.418 ' HA2' ' HA ' ' A' ' 39' ' ' LYS . . . -85.69 174.38 48.19 Favored Glycine 0 N--CA 1.433 -1.514 0 C-N-CA 120.564 -0.827 . . . . 0.0 111.192 -176.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 -6.87 19.67 Favored 'Trans proline' 0 C--O 1.212 -0.794 0 C-N-CA 122.591 2.194 . . . . 0.0 112.98 -176.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.54 ' NZ ' ' HB2' ' A' ' 56' ' ' LYS . 5.8 mtmp? -97.99 -15.59 20.02 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 177.317 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.51 ' HB2' ' HB3' ' A' ' 53' ' ' LEU . 9.7 m-20 -99.72 1.78 43.65 Favored 'General case' 0 C--N 1.307 -1.271 0 CA-C-N 114.585 -1.189 . . . . 0.0 108.58 -168.121 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . . . . . . . . . 13.2 pt -132.06 152.11 36.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 CA-C-N 114.19 -1.368 . . . . 0.0 110.187 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -135.29 141.31 37.3 Favored Pre-proline 0 C--N 1.302 -1.457 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 179.543 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -66.11 132.23 29.28 Favored 'Trans proline' 0 C--N 1.33 -0.432 0 C-N-CA 122.801 2.334 . . . . 0.0 113.36 -177.884 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' TYR . . . . . 0.563 ' HA ' ' CE2' ' A' ' 12' ' ' PHE . 50.3 t80 -59.48 -41.1 89.02 Favored 'General case' 0 C--O 1.208 -1.116 0 C-N-CA 123.639 0.776 . . . . 0.0 110.209 -179.496 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.1 p -59.41 -42.67 92.36 Favored 'General case' 0 C--N 1.288 -2.086 0 CA-C-N 115.171 -0.922 . . . . 0.0 112.99 -176.19 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -96.48 -2.88 44.38 Favored 'General case' 0 C--N 1.314 -0.944 0 N-CA-C 112.886 0.698 . . . . 0.0 112.886 -179.094 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.4 ' OD1' ' HD2' ' A' ' 67' ' ' LYS . 36.8 m-80 -132.14 15.04 4.67 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 113.185 0.809 . . . . 0.0 113.185 -176.317 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.505 ' HG2' ' OE2' ' A' ' 66' ' ' GLU . 20.5 pttm -66.02 -29.16 69.47 Favored 'General case' 0 N--CA 1.487 1.415 0 CA-C-O 121.735 0.778 . . . . 0.0 110.831 -179.18 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . 0.573 ' H ' ' CD ' ' A' ' 66' ' ' GLU . 2.9 mp0 -68.21 -36.78 80.07 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 179.476 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.4 ' HD2' ' OD1' ' A' ' 64' ' ' ASN . 40.9 mttp -84.19 -59.78 2.29 Favored 'General case' 0 N--CA 1.428 -1.542 0 CA-C-N 113.405 -1.725 . . . . 0.0 111.583 -170.42 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' TYR . . . . . . . . . . . . . 36.2 m-85 -105.51 -4.91 20.71 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 116.075 -0.511 . . . . 0.0 111.386 -170.807 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . -81.7 56.45 4.92 Favored Glycine 0 N--CA 1.444 -0.805 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 177.748 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.529 ' O ' ' HE1' ' A' ' 77' ' ' PHE . 0.0 OUTLIER -119.33 158.55 48.44 Favored Pre-proline 0 C--N 1.305 -1.352 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 -177.55 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -73.36 167.24 27.81 Favored 'Trans proline' 0 N--CA 1.454 -0.823 0 C-N-CA 121.883 1.722 . . . . 0.0 111.926 175.14 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ASN . . . . . . . . . . . . . 3.6 t-20 -152.65 -177.63 6.36 Favored 'General case' 0 C--N 1.308 -1.23 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 179.226 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' LYS . . . . . . . . . . . . . 30.9 mmmt -97.08 -10.56 25.81 Favored 'General case' 0 C--N 1.306 -1.309 0 C-N-CA 122.243 0.217 . . . . 0.0 110.795 178.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ARG . . . . . . . . . . . . . 27.4 mmt180 -67.17 124.38 22.93 Favored 'General case' 0 N--CA 1.448 -0.575 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 177.456 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.61 137.22 40.62 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 176.345 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . 0.55 ' O ' ' HA3' ' A' ' 46' ' ' GLY . . . 100.97 -26.14 25.77 Favored Glycine 0 N--CA 1.426 -2.013 0 N-CA-C 108.926 -1.67 . . . . 0.0 108.926 -174.53 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' PHE . . . . . 0.529 ' HE1' ' O ' ' A' ' 70' ' ' LYS . 20.6 t80 -77.04 -46.52 23.48 Favored 'General case' 0 N--CA 1.44 -0.939 0 N-CA-C 108.17 -1.048 . . . . 0.0 108.17 178.473 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 14.1 m120 -60.37 -50.29 74.19 Favored 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 115.164 -0.925 . . . . 0.0 108.597 177.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 20.5 mp0 -61.09 -41.7 97.15 Favored 'General case' 0 N--CA 1.435 -1.207 0 CA-C-N 113.797 -1.547 . . . . 0.0 110.513 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' GLY . . . . . . . . . . . . . . . -71.06 -34.55 64.76 Favored Glycine 0 CA--C 1.496 -1.11 0 CA-C-N 115.879 -0.601 . . . . 0.0 113.403 -178.445 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 32.3 tp -63.62 -30.62 71.71 Favored 'General case' 0 C--O 1.204 -1.325 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 176.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' TRP . . . . . . . . . . . . . 79.1 t90 -77.04 -47.12 21.48 Favored 'General case' 0 N--CA 1.437 -1.109 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.031 175.237 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 39.0 mt-10 -58.93 -42.28 89.37 Favored 'General case' 0 C--O 1.196 -1.711 0 N-CA-C 113.202 0.816 . . . . 0.0 113.202 -178.723 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 21.1 tt -63.33 -33.18 59.63 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.937 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 -175.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -81.61 -34.24 31.04 Favored 'General case' 0 C--N 1.311 -1.076 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.126 -179.882 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 29.7 m-80 -100.52 -46.54 5.18 Favored 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 112.94 0.719 . . . . 0.0 112.94 -172.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . . . . . . . . . 64.9 t30 -133.58 73.64 72.28 Favored Pre-proline 0 C--N 1.3 -1.565 0 CA-C-O 121.058 0.456 . . . . 0.0 110.686 -178.166 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -73.61 -5.61 17.37 Favored 'Trans proline' 0 C--N 1.35 0.616 0 C-N-CA 122.978 2.452 . . . . 0.0 112.791 -176.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' LYS . . . . . . . . . . . . . 61.5 pttt -100.3 12.84 36.19 Favored 'General case' 0 C--N 1.308 -1.2 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.874 -177.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 10.0 p -72.55 154.61 7.35 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.704 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 -179.631 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.4 mptp? -126.99 -172.37 2.63 Favored 'General case' 0 C--N 1.319 -0.757 0 C-N-CA 122.743 0.417 . . . . 0.0 111.655 -176.118 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.575 ' HA ' ' O ' ' A' ' 48' ' ' HIS . 63.9 t80 -45.86 158.49 0.09 Allowed 'General case' 0 CA--C 1.559 1.299 0 C-N-CA 126.802 2.041 . . . . 0.0 115.132 -174.324 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 16.4 m . . . . . 0 CA--C 1.559 1.322 0 C-N-CA 127.762 2.425 . . . . 0.0 115.585 -176.999 . . . . . . . . 0 0 . 1 stop_ save_